Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,7742156,"AUC(0,12 h)","The AUC(0,12 h) values of cyclosporin A were significantly greater after NEO than SGC (2873 +/- 848 ng ml-1 h (mean +/- s.d.) vs 2355 +/- 1128 ng ml-1 h; P = 0.02, 95% CI (confidence interval of the difference: 81 to 955 ng ml-1 h).",Relative bioavailability of a new oral form of cyclosporin A in patients with rheumatoid arthritis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7742156/),[h·ng] / [ml],2873,34,DB00091,Cyclosporine
,7742156,"AUC(0,12 h)","The AUC(0,12 h) values of cyclosporin A were significantly greater after NEO than SGC (2873 +/- 848 ng ml-1 h (mean +/- s.d.) vs 2355 +/- 1128 ng ml-1 h; P = 0.02, 95% CI (confidence interval of the difference: 81 to 955 ng ml-1 h).",Relative bioavailability of a new oral form of cyclosporin A in patients with rheumatoid arthritis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7742156/),[h·ng] / [ml],2355,35,DB00091,Cyclosporine
,7742156,Cmax,"Cmax values were significantly higher after NEO than after SGC (811 +/- 244 ng ml-1 vs 495 +/- 291 ng ml-1, P < 0.0001, 95% CI of the difference: 209 to 422 ng ml-1).",Relative bioavailability of a new oral form of cyclosporin A in patients with rheumatoid arthritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7742156/),[ng] / [ml],811,36,DB00091,Cyclosporine
,7742156,Cmax,"Cmax values were significantly higher after NEO than after SGC (811 +/- 244 ng ml-1 vs 495 +/- 291 ng ml-1, P < 0.0001, 95% CI of the difference: 209 to 422 ng ml-1).",Relative bioavailability of a new oral form of cyclosporin A in patients with rheumatoid arthritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7742156/),[ng] / [ml],495,37,DB00091,Cyclosporine
,15049800,C(0),"The mean C(0) and C(2) levels were as follows: day 1: C(0) 77.0 +/- 39.6, C(2) 340.5 +/- 140.0 ng/mL; day 2: C(0) 135.5 +/- 53.2, C(2) 467.0 +/- 168.2 ng/mL; day 3: C(0) 146.5 +/- 70.8, C(2) 519.0 +/- 219.1 ng/mL; day 4: C(0) 168.5 +/- 55.1, C(2) 570.0 +/- 163.7 ng/mL; day 5: C(0) 156.5 +/- 38.0, C(2) 612.0 +/- 132.4 ng/mL; day 6: C(0) 177.0 +/- 41.1, C(2) 606.0 +/- 149.2 ng/mL; day 7: C(0) 174.0 +/- 27.2, C(2) 622.0 +/- 98.8 ng/mL (r = 0.82, p < 0.05).",C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049800/),,77.0,45,DB00091,Cyclosporine
,15049800,C(2),"The mean C(0) and C(2) levels were as follows: day 1: C(0) 77.0 +/- 39.6, C(2) 340.5 +/- 140.0 ng/mL; day 2: C(0) 135.5 +/- 53.2, C(2) 467.0 +/- 168.2 ng/mL; day 3: C(0) 146.5 +/- 70.8, C(2) 519.0 +/- 219.1 ng/mL; day 4: C(0) 168.5 +/- 55.1, C(2) 570.0 +/- 163.7 ng/mL; day 5: C(0) 156.5 +/- 38.0, C(2) 612.0 +/- 132.4 ng/mL; day 6: C(0) 177.0 +/- 41.1, C(2) 606.0 +/- 149.2 ng/mL; day 7: C(0) 174.0 +/- 27.2, C(2) 622.0 +/- 98.8 ng/mL (r = 0.82, p < 0.05).",C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049800/),[ng] / [ml],340.5,46,DB00091,Cyclosporine
,15049800,C(0),"The mean C(0) and C(2) levels were as follows: day 1: C(0) 77.0 +/- 39.6, C(2) 340.5 +/- 140.0 ng/mL; day 2: C(0) 135.5 +/- 53.2, C(2) 467.0 +/- 168.2 ng/mL; day 3: C(0) 146.5 +/- 70.8, C(2) 519.0 +/- 219.1 ng/mL; day 4: C(0) 168.5 +/- 55.1, C(2) 570.0 +/- 163.7 ng/mL; day 5: C(0) 156.5 +/- 38.0, C(2) 612.0 +/- 132.4 ng/mL; day 6: C(0) 177.0 +/- 41.1, C(2) 606.0 +/- 149.2 ng/mL; day 7: C(0) 174.0 +/- 27.2, C(2) 622.0 +/- 98.8 ng/mL (r = 0.82, p < 0.05).",C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049800/),,135.5,47,DB00091,Cyclosporine
,15049800,C(2),"The mean C(0) and C(2) levels were as follows: day 1: C(0) 77.0 +/- 39.6, C(2) 340.5 +/- 140.0 ng/mL; day 2: C(0) 135.5 +/- 53.2, C(2) 467.0 +/- 168.2 ng/mL; day 3: C(0) 146.5 +/- 70.8, C(2) 519.0 +/- 219.1 ng/mL; day 4: C(0) 168.5 +/- 55.1, C(2) 570.0 +/- 163.7 ng/mL; day 5: C(0) 156.5 +/- 38.0, C(2) 612.0 +/- 132.4 ng/mL; day 6: C(0) 177.0 +/- 41.1, C(2) 606.0 +/- 149.2 ng/mL; day 7: C(0) 174.0 +/- 27.2, C(2) 622.0 +/- 98.8 ng/mL (r = 0.82, p < 0.05).",C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049800/),[ng] / [ml],467.0,48,DB00091,Cyclosporine
,15049800,C(0),"The mean C(0) and C(2) levels were as follows: day 1: C(0) 77.0 +/- 39.6, C(2) 340.5 +/- 140.0 ng/mL; day 2: C(0) 135.5 +/- 53.2, C(2) 467.0 +/- 168.2 ng/mL; day 3: C(0) 146.5 +/- 70.8, C(2) 519.0 +/- 219.1 ng/mL; day 4: C(0) 168.5 +/- 55.1, C(2) 570.0 +/- 163.7 ng/mL; day 5: C(0) 156.5 +/- 38.0, C(2) 612.0 +/- 132.4 ng/mL; day 6: C(0) 177.0 +/- 41.1, C(2) 606.0 +/- 149.2 ng/mL; day 7: C(0) 174.0 +/- 27.2, C(2) 622.0 +/- 98.8 ng/mL (r = 0.82, p < 0.05).",C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049800/),,146.5,49,DB00091,Cyclosporine
,15049800,C(2),"The mean C(0) and C(2) levels were as follows: day 1: C(0) 77.0 +/- 39.6, C(2) 340.5 +/- 140.0 ng/mL; day 2: C(0) 135.5 +/- 53.2, C(2) 467.0 +/- 168.2 ng/mL; day 3: C(0) 146.5 +/- 70.8, C(2) 519.0 +/- 219.1 ng/mL; day 4: C(0) 168.5 +/- 55.1, C(2) 570.0 +/- 163.7 ng/mL; day 5: C(0) 156.5 +/- 38.0, C(2) 612.0 +/- 132.4 ng/mL; day 6: C(0) 177.0 +/- 41.1, C(2) 606.0 +/- 149.2 ng/mL; day 7: C(0) 174.0 +/- 27.2, C(2) 622.0 +/- 98.8 ng/mL (r = 0.82, p < 0.05).",C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049800/),[ng] / [ml],519.0,50,DB00091,Cyclosporine
,15049800,C(0),"The mean C(0) and C(2) levels were as follows: day 1: C(0) 77.0 +/- 39.6, C(2) 340.5 +/- 140.0 ng/mL; day 2: C(0) 135.5 +/- 53.2, C(2) 467.0 +/- 168.2 ng/mL; day 3: C(0) 146.5 +/- 70.8, C(2) 519.0 +/- 219.1 ng/mL; day 4: C(0) 168.5 +/- 55.1, C(2) 570.0 +/- 163.7 ng/mL; day 5: C(0) 156.5 +/- 38.0, C(2) 612.0 +/- 132.4 ng/mL; day 6: C(0) 177.0 +/- 41.1, C(2) 606.0 +/- 149.2 ng/mL; day 7: C(0) 174.0 +/- 27.2, C(2) 622.0 +/- 98.8 ng/mL (r = 0.82, p < 0.05).",C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049800/),,168.5,51,DB00091,Cyclosporine
,15049800,C(2),"The mean C(0) and C(2) levels were as follows: day 1: C(0) 77.0 +/- 39.6, C(2) 340.5 +/- 140.0 ng/mL; day 2: C(0) 135.5 +/- 53.2, C(2) 467.0 +/- 168.2 ng/mL; day 3: C(0) 146.5 +/- 70.8, C(2) 519.0 +/- 219.1 ng/mL; day 4: C(0) 168.5 +/- 55.1, C(2) 570.0 +/- 163.7 ng/mL; day 5: C(0) 156.5 +/- 38.0, C(2) 612.0 +/- 132.4 ng/mL; day 6: C(0) 177.0 +/- 41.1, C(2) 606.0 +/- 149.2 ng/mL; day 7: C(0) 174.0 +/- 27.2, C(2) 622.0 +/- 98.8 ng/mL (r = 0.82, p < 0.05).",C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049800/),[ng] / [ml],570.0,52,DB00091,Cyclosporine
,15049800,C(0),"The mean C(0) and C(2) levels were as follows: day 1: C(0) 77.0 +/- 39.6, C(2) 340.5 +/- 140.0 ng/mL; day 2: C(0) 135.5 +/- 53.2, C(2) 467.0 +/- 168.2 ng/mL; day 3: C(0) 146.5 +/- 70.8, C(2) 519.0 +/- 219.1 ng/mL; day 4: C(0) 168.5 +/- 55.1, C(2) 570.0 +/- 163.7 ng/mL; day 5: C(0) 156.5 +/- 38.0, C(2) 612.0 +/- 132.4 ng/mL; day 6: C(0) 177.0 +/- 41.1, C(2) 606.0 +/- 149.2 ng/mL; day 7: C(0) 174.0 +/- 27.2, C(2) 622.0 +/- 98.8 ng/mL (r = 0.82, p < 0.05).",C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049800/),,156.5,53,DB00091,Cyclosporine
,15049800,C(2),"The mean C(0) and C(2) levels were as follows: day 1: C(0) 77.0 +/- 39.6, C(2) 340.5 +/- 140.0 ng/mL; day 2: C(0) 135.5 +/- 53.2, C(2) 467.0 +/- 168.2 ng/mL; day 3: C(0) 146.5 +/- 70.8, C(2) 519.0 +/- 219.1 ng/mL; day 4: C(0) 168.5 +/- 55.1, C(2) 570.0 +/- 163.7 ng/mL; day 5: C(0) 156.5 +/- 38.0, C(2) 612.0 +/- 132.4 ng/mL; day 6: C(0) 177.0 +/- 41.1, C(2) 606.0 +/- 149.2 ng/mL; day 7: C(0) 174.0 +/- 27.2, C(2) 622.0 +/- 98.8 ng/mL (r = 0.82, p < 0.05).",C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049800/),[ng] / [ml],612.0,54,DB00091,Cyclosporine
,15049800,C(0),"The mean C(0) and C(2) levels were as follows: day 1: C(0) 77.0 +/- 39.6, C(2) 340.5 +/- 140.0 ng/mL; day 2: C(0) 135.5 +/- 53.2, C(2) 467.0 +/- 168.2 ng/mL; day 3: C(0) 146.5 +/- 70.8, C(2) 519.0 +/- 219.1 ng/mL; day 4: C(0) 168.5 +/- 55.1, C(2) 570.0 +/- 163.7 ng/mL; day 5: C(0) 156.5 +/- 38.0, C(2) 612.0 +/- 132.4 ng/mL; day 6: C(0) 177.0 +/- 41.1, C(2) 606.0 +/- 149.2 ng/mL; day 7: C(0) 174.0 +/- 27.2, C(2) 622.0 +/- 98.8 ng/mL (r = 0.82, p < 0.05).",C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049800/),,177.0,55,DB00091,Cyclosporine
,15049800,C(2),"The mean C(0) and C(2) levels were as follows: day 1: C(0) 77.0 +/- 39.6, C(2) 340.5 +/- 140.0 ng/mL; day 2: C(0) 135.5 +/- 53.2, C(2) 467.0 +/- 168.2 ng/mL; day 3: C(0) 146.5 +/- 70.8, C(2) 519.0 +/- 219.1 ng/mL; day 4: C(0) 168.5 +/- 55.1, C(2) 570.0 +/- 163.7 ng/mL; day 5: C(0) 156.5 +/- 38.0, C(2) 612.0 +/- 132.4 ng/mL; day 6: C(0) 177.0 +/- 41.1, C(2) 606.0 +/- 149.2 ng/mL; day 7: C(0) 174.0 +/- 27.2, C(2) 622.0 +/- 98.8 ng/mL (r = 0.82, p < 0.05).",C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049800/),[ng] / [ml],606.0,56,DB00091,Cyclosporine
,15049800,C(0),"The mean C(0) and C(2) levels were as follows: day 1: C(0) 77.0 +/- 39.6, C(2) 340.5 +/- 140.0 ng/mL; day 2: C(0) 135.5 +/- 53.2, C(2) 467.0 +/- 168.2 ng/mL; day 3: C(0) 146.5 +/- 70.8, C(2) 519.0 +/- 219.1 ng/mL; day 4: C(0) 168.5 +/- 55.1, C(2) 570.0 +/- 163.7 ng/mL; day 5: C(0) 156.5 +/- 38.0, C(2) 612.0 +/- 132.4 ng/mL; day 6: C(0) 177.0 +/- 41.1, C(2) 606.0 +/- 149.2 ng/mL; day 7: C(0) 174.0 +/- 27.2, C(2) 622.0 +/- 98.8 ng/mL (r = 0.82, p < 0.05).",C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049800/),,174.0,57,DB00091,Cyclosporine
,15049800,C(2),"The mean C(0) and C(2) levels were as follows: day 1: C(0) 77.0 +/- 39.6, C(2) 340.5 +/- 140.0 ng/mL; day 2: C(0) 135.5 +/- 53.2, C(2) 467.0 +/- 168.2 ng/mL; day 3: C(0) 146.5 +/- 70.8, C(2) 519.0 +/- 219.1 ng/mL; day 4: C(0) 168.5 +/- 55.1, C(2) 570.0 +/- 163.7 ng/mL; day 5: C(0) 156.5 +/- 38.0, C(2) 612.0 +/- 132.4 ng/mL; day 6: C(0) 177.0 +/- 41.1, C(2) 606.0 +/- 149.2 ng/mL; day 7: C(0) 174.0 +/- 27.2, C(2) 622.0 +/- 98.8 ng/mL (r = 0.82, p < 0.05).",C2 blood concentrations of orally administered cyclosporine in pediatric liver graft recipients with a body weight below 10 kg. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049800/),,622,58,DB00091,Cyclosporine
,9210502,steady state concentration,"They had a significantly higher increase in average steady state concentration between baseline and 6 months than the six patients with the best outcome in GFR during the same time period (164 ng/ml vs. 53 ng/ml, P<0.05).",Kidney function after 1:1 conversion to the cyclosporine microemulsion formulation in children with liver allografts. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210502/),[ng] / [ml],164,258,DB00091,Cyclosporine
,9210502,steady state concentration,"They had a significantly higher increase in average steady state concentration between baseline and 6 months than the six patients with the best outcome in GFR during the same time period (164 ng/ml vs. 53 ng/ml, P<0.05).",Kidney function after 1:1 conversion to the cyclosporine microemulsion formulation in children with liver allografts. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210502/),[ng] / [ml],53,259,DB00091,Cyclosporine
,8892677,trough,"The median trough and peak blood levels of SDZ PSC 833 ranged from 461/1134 ng/ml at 5 mg/kg/day to 821/2663 ng/ml at 15 mg/kg, respectively.","Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8892677/),[ng] / [ml],461,275,DB00091,Cyclosporine
,8892677,peak blood levels,"The median trough and peak blood levels of SDZ PSC 833 ranged from 461/1134 ng/ml at 5 mg/kg/day to 821/2663 ng/ml at 15 mg/kg, respectively.","Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8892677/),[ng] / [ml],1134,276,DB00091,Cyclosporine
,8892677,peak blood levels,"The median trough and peak blood levels of SDZ PSC 833 ranged from 461/1134 ng/ml at 5 mg/kg/day to 821/2663 ng/ml at 15 mg/kg, respectively.","Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8892677/),[ng] / [ml],821,277,DB00091,Cyclosporine
,8892677,peak blood levels,"The median trough and peak blood levels of SDZ PSC 833 ranged from 461/1134 ng/ml at 5 mg/kg/day to 821/2663 ng/ml at 15 mg/kg, respectively.","Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8892677/),[ng] / [ml],2663,278,DB00091,Cyclosporine
,8892677,plasma AUC 0-->96 h,"With addition of SDZ PSC 833 (5 mg/kg) the mean plasma AUC 0-->96 h of doxorubicin as compared with control patients treated with VAD increased from 779 to 1510 ng/ml/h (P=0.0071), while the doxorubicin clearance was reduced from 47.6 to 27.8 l/h/m2 (P=0.0002).","Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8892677/),[ng] / [h·ml],77,279,DB00091,Cyclosporine
,8892677,clearance,"With addition of SDZ PSC 833 (5 mg/kg) the mean plasma AUC 0-->96 h of doxorubicin as compared with control patients treated with VAD increased from 779 to 1510 ng/ml/h (P=0.0071), while the doxorubicin clearance was reduced from 47.6 to 27.8 l/h/m2 (P=0.0002).","Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8892677/),[l] / [h·m2],47.6,280,DB00091,Cyclosporine
,12562644,time to progression,The median time to progression was 16 weeks (95% CI 9-22).,Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12562644/),weeks,16,501,DB00091,Cyclosporine
,12562644,area under the plasma concentration-time curve (AUC),Pharmacokinetic analyses revealed that the mean area under the plasma concentration-time curve (AUC) of orally administered paclitaxel (+/- standard deviation) was 3757.6 +/- 939.4 ng.h/ml in week 1 and 3928.4 +/- 1281 ng.h/ml in week 2.,Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12562644/),[h·ng] / [ml],3757.6,502,DB00091,Cyclosporine
,12562644,area under the plasma concentration-time curve (AUC),Pharmacokinetic analyses revealed that the mean area under the plasma concentration-time curve (AUC) of orally administered paclitaxel (+/- standard deviation) was 3757.6 +/- 939.4 ng.h/ml in week 1 and 3928.4 +/- 1281 ng.h/ml in week 2.,Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12562644/),[h·ng] / [ml],3928.4,503,DB00091,Cyclosporine
,11215860,12-h,The mean values of 12-h AUC (area under the concentration-blood curve) were 4603.63 +/- 344.61 ng x h/ml.,Pharmacokinetic studies of cyclosporin in Thai kidney transplantation patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11215860/),[h·ng] / [ml],4603.63,632,DB00091,Cyclosporine
,11215860,AUC (area under the concentration-blood curve),The mean values of 12-h AUC (area under the concentration-blood curve) were 4603.63 +/- 344.61 ng x h/ml.,Pharmacokinetic studies of cyclosporin in Thai kidney transplantation patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11215860/),[h·ng] / [ml],4603.63,633,DB00091,Cyclosporine
,11435743,plasma levels,"Nitric oxide plasma levels decreased in nearly all patients from 21.0 +/- 2.8 to 19.1 +/- 2.6 (p = 0.003) and then rose slightly to 19.5 +/- 2.5 micromol/l (p = 0.1) 3 and 6 h after CsA ingestion, respectively.",Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),,21.0,816,DB00091,Cyclosporine
,11435743,plasma levels,"Nitric oxide plasma levels decreased in nearly all patients from 21.0 +/- 2.8 to 19.1 +/- 2.6 (p = 0.003) and then rose slightly to 19.5 +/- 2.5 micromol/l (p = 0.1) 3 and 6 h after CsA ingestion, respectively.",Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),,19.1,817,DB00091,Cyclosporine
,11435743,plasma levels,"Nitric oxide plasma levels decreased in nearly all patients from 21.0 +/- 2.8 to 19.1 +/- 2.6 (p = 0.003) and then rose slightly to 19.5 +/- 2.5 micromol/l (p = 0.1) 3 and 6 h after CsA ingestion, respectively.",Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),,19,818,DB00091,Cyclosporine
,11435743,Urinary excretion,Urinary excretion of NO2/NO3 decreased nonsignificantly from 269 +/- 38.8 to 259 +/- 27.7 and 254 +/- 41.6 micromol/min (p = 0.5 and 0.5).,Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),[μM] / [min],269,819,DB00091,Cyclosporine
,11435743,Urinary excretion,Urinary excretion of NO2/NO3 decreased nonsignificantly from 269 +/- 38.8 to 259 +/- 27.7 and 254 +/- 41.6 micromol/min (p = 0.5 and 0.5).,Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),[μM] / [min],259,820,DB00091,Cyclosporine
,11435743,Urinary excretion,Urinary excretion of NO2/NO3 decreased nonsignificantly from 269 +/- 38.8 to 259 +/- 27.7 and 254 +/- 41.6 micromol/min (p = 0.5 and 0.5).,Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),[μM] / [min],254,821,DB00091,Cyclosporine
,11435743,excretion rate,"At the same time, urinary prostaglandin E2 and 6-keto-prostaglandin F(1 alpha) excretion rate declined significantly [from 1,187 +/- 254 to 1,186 +/- 351 and 730 +/- 148 pg/min (p = 0.27 and 0.02) and from 697 +/- 115 to 645 +/- 134 and 508 +/- 58.2 pg/min (p = 0.34 and 0.05)].",Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),[pg] / [min],"1,187",822,DB00091,Cyclosporine
,11435743,excretion rate,"At the same time, urinary prostaglandin E2 and 6-keto-prostaglandin F(1 alpha) excretion rate declined significantly [from 1,187 +/- 254 to 1,186 +/- 351 and 730 +/- 148 pg/min (p = 0.27 and 0.02) and from 697 +/- 115 to 645 +/- 134 and 508 +/- 58.2 pg/min (p = 0.34 and 0.05)].",Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),[pg] / [min],"1,186",823,DB00091,Cyclosporine
,11435743,excretion rate,"At the same time, urinary prostaglandin E2 and 6-keto-prostaglandin F(1 alpha) excretion rate declined significantly [from 1,187 +/- 254 to 1,186 +/- 351 and 730 +/- 148 pg/min (p = 0.27 and 0.02) and from 697 +/- 115 to 645 +/- 134 and 508 +/- 58.2 pg/min (p = 0.34 and 0.05)].",Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),[pg] / [min],730,824,DB00091,Cyclosporine
,11435743,excretion rate,"At the same time, urinary prostaglandin E2 and 6-keto-prostaglandin F(1 alpha) excretion rate declined significantly [from 1,187 +/- 254 to 1,186 +/- 351 and 730 +/- 148 pg/min (p = 0.27 and 0.02) and from 697 +/- 115 to 645 +/- 134 and 508 +/- 58.2 pg/min (p = 0.34 and 0.05)].",Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),[pg] / [min],697,825,DB00091,Cyclosporine
,11435743,excretion rate,"At the same time, urinary prostaglandin E2 and 6-keto-prostaglandin F(1 alpha) excretion rate declined significantly [from 1,187 +/- 254 to 1,186 +/- 351 and 730 +/- 148 pg/min (p = 0.27 and 0.02) and from 697 +/- 115 to 645 +/- 134 and 508 +/- 58.2 pg/min (p = 0.34 and 0.05)].",Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),[pg] / [min],645,826,DB00091,Cyclosporine
,11435743,excretion rate,"At the same time, urinary prostaglandin E2 and 6-keto-prostaglandin F(1 alpha) excretion rate declined significantly [from 1,187 +/- 254 to 1,186 +/- 351 and 730 +/- 148 pg/min (p = 0.27 and 0.02) and from 697 +/- 115 to 645 +/- 134 and 508 +/- 58.2 pg/min (p = 0.34 and 0.05)].",Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide? ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11435743/),[pg] / [min],508,827,DB00091,Cyclosporine
,17631022,C0,"Mean C0 levels of 119, 310, and 337 ng/mL and mean C2 levels of 213, 753, and 888 ng/mL were obtained.",Cyclosporine monitoring in the early post-transplant period in pediatric liver transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17631022/),[ng] / [ml],119,873,DB00091,Cyclosporine
,17631022,C0,"Mean C0 levels of 119, 310, and 337 ng/mL and mean C2 levels of 213, 753, and 888 ng/mL were obtained.",Cyclosporine monitoring in the early post-transplant period in pediatric liver transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17631022/),[ng] / [ml],310,874,DB00091,Cyclosporine
,17631022,C0,"Mean C0 levels of 119, 310, and 337 ng/mL and mean C2 levels of 213, 753, and 888 ng/mL were obtained.",Cyclosporine monitoring in the early post-transplant period in pediatric liver transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17631022/),[ng] / [ml],337,875,DB00091,Cyclosporine
,17631022,C2,"Mean C0 levels of 119, 310, and 337 ng/mL and mean C2 levels of 213, 753, and 888 ng/mL were obtained.",Cyclosporine monitoring in the early post-transplant period in pediatric liver transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17631022/),[ng] / [ml],213,876,DB00091,Cyclosporine
,17631022,C2,"Mean C0 levels of 119, 310, and 337 ng/mL and mean C2 levels of 213, 753, and 888 ng/mL were obtained.",Cyclosporine monitoring in the early post-transplant period in pediatric liver transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17631022/),[ng] / [ml],753,877,DB00091,Cyclosporine
,17631022,C2,"Mean C0 levels of 119, 310, and 337 ng/mL and mean C2 levels of 213, 753, and 888 ng/mL were obtained.",Cyclosporine monitoring in the early post-transplant period in pediatric liver transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17631022/),[ng] / [ml],888,878,DB00091,Cyclosporine
,8610371,relative,"Comparative pharmacokinetic studies were performed in both cases, and the relative Neoral/Sandimmun bioavailabilities were 32.9 and 5.4, respectively.",Microemulsion formulation of cyclosporine in pediatric liver transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610371/),,32.9,1515,DB00091,Cyclosporine
,8610371,bioavailabilities,"Comparative pharmacokinetic studies were performed in both cases, and the relative Neoral/Sandimmun bioavailabilities were 32.9 and 5.4, respectively.",Microemulsion formulation of cyclosporine in pediatric liver transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610371/),,32.9,1516,DB00091,Cyclosporine
,8610371,bioavailabilities,"Comparative pharmacokinetic studies were performed in both cases, and the relative Neoral/Sandimmun bioavailabilities were 32.9 and 5.4, respectively.",Microemulsion formulation of cyclosporine in pediatric liver transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610371/),,5.4,1517,DB00091,Cyclosporine
,25707517,oral clearance,"Typical mean value of MPA oral clearance, estimated by base model (without covariates) was 0.741 L h(-1).",Variability of mycophenolic acid elimination in the renal transplant recipients – population pharmacokinetic approach. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25707517/),[l] / [h],0.741,1786,DB00091,Cyclosporine
,9428122,half-lives,"The mean half-lives obtained were 8.1, 7.7, and 6.9 h, respectively, and the bioavailabilities were 22% and 21% for the first and last NEO doses.",Clinical pharmacokinetics of Neoral in pediatric recipients of primary liver transplants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9428122/),h,8.1,1978,DB00091,Cyclosporine
,9428122,half-lives,"The mean half-lives obtained were 8.1, 7.7, and 6.9 h, respectively, and the bioavailabilities were 22% and 21% for the first and last NEO doses.",Clinical pharmacokinetics of Neoral in pediatric recipients of primary liver transplants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9428122/),h,7.7,1979,DB00091,Cyclosporine
,9428122,half-lives,"The mean half-lives obtained were 8.1, 7.7, and 6.9 h, respectively, and the bioavailabilities were 22% and 21% for the first and last NEO doses.",Clinical pharmacokinetics of Neoral in pediatric recipients of primary liver transplants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9428122/),h,6.9,1980,DB00091,Cyclosporine
,9428122,bioavailabilities,"The mean half-lives obtained were 8.1, 7.7, and 6.9 h, respectively, and the bioavailabilities were 22% and 21% for the first and last NEO doses.",Clinical pharmacokinetics of Neoral in pediatric recipients of primary liver transplants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9428122/),%,22,1981,DB00091,Cyclosporine
,9428122,bioavailabilities,"The mean half-lives obtained were 8.1, 7.7, and 6.9 h, respectively, and the bioavailabilities were 22% and 21% for the first and last NEO doses.",Clinical pharmacokinetics of Neoral in pediatric recipients of primary liver transplants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9428122/),%,21,1982,DB00091,Cyclosporine
,10496299,absolute bioavailability,It is rapidly absorbed with an absolute bioavailability of between 40 and 50%.,Clinical pharmacokinetics of troglitazone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496299/),%,40 and 50,2272,DB00091,Cyclosporine
,10496299,elimination half-life,"The mean elimination half-life ranges from 7.6 to 24 hours, which facilitates a once daily administration regimen.",Clinical pharmacokinetics of troglitazone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496299/),h,7.6 to 24,2273,DB00091,Cyclosporine
>,8685946,maximal concentration,"Pharmacokinetics demonstrated that, when taking SIM, only 5 patients had ""good absorption"" (maximal concentration >500 ng/ml and time to maximal concentration < / = 2 hr), but after conversion to NEO, 14 at week +2, and 13 at week +4 were good absorbers (P<0.02 and <0.01, respectively).",Reversal of cyclosporine malabsorption in diabetic recipients of simultaneous pancreas and kidney transplant using a microemulsion formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685946/),[ng] / [ml],500,2701,DB00091,Cyclosporine
<,8685946,time to maximal concentration,"Pharmacokinetics demonstrated that, when taking SIM, only 5 patients had ""good absorption"" (maximal concentration >500 ng/ml and time to maximal concentration < / = 2 hr), but after conversion to NEO, 14 at week +2, and 13 at week +4 were good absorbers (P<0.02 and <0.01, respectively).",Reversal of cyclosporine malabsorption in diabetic recipients of simultaneous pancreas and kidney transplant using a microemulsion formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685946/),h,2,2702,DB00091,Cyclosporine
,8685946,time to maximal blood concentration,"There was a 50% reduction in the time to maximal blood concentration (from 3.2 +/- 1.9 hr with SIM, to 1.8 +/- 1.3 hr on NEO [P<0.007]) and a 36% increase in trough and a 143% increase (P<0.01) in maximal blood concentrations, although the 9-hr cyclosporine AUC showed an 89% increase (P<0.01).",Reversal of cyclosporine malabsorption in diabetic recipients of simultaneous pancreas and kidney transplant using a microemulsion formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685946/),h,3.2,2703,DB00091,Cyclosporine
,8685946,time to maximal blood concentration,"There was a 50% reduction in the time to maximal blood concentration (from 3.2 +/- 1.9 hr with SIM, to 1.8 +/- 1.3 hr on NEO [P<0.007]) and a 36% increase in trough and a 143% increase (P<0.01) in maximal blood concentrations, although the 9-hr cyclosporine AUC showed an 89% increase (P<0.01).",Reversal of cyclosporine malabsorption in diabetic recipients of simultaneous pancreas and kidney transplant using a microemulsion formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8685946/),h,1.8,2704,DB00091,Cyclosporine
,17053886,AUC,"There was a statistically significant difference of the AUC, trough levels, and t (max) between weeks 1 and 24, with a decrease of AUC from 5,211 ng*h/ml in week 1 to 3,289 ng*h/ml in week 24, the trough levels decreased from 157 ng/ml to 96 ng/ml, and the t (max) decreased from 1.85 h to 1.00 h.",Decreased cyclosporine exposure during the remission of nephrotic syndrome. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17053886/),[h·ng] / [ml],"5,211",2907,DB00091,Cyclosporine
,17053886,AUC,"There was a statistically significant difference of the AUC, trough levels, and t (max) between weeks 1 and 24, with a decrease of AUC from 5,211 ng*h/ml in week 1 to 3,289 ng*h/ml in week 24, the trough levels decreased from 157 ng/ml to 96 ng/ml, and the t (max) decreased from 1.85 h to 1.00 h.",Decreased cyclosporine exposure during the remission of nephrotic syndrome. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17053886/),[h·ng] / [ml],"3,289",2908,DB00091,Cyclosporine
,17053886,trough levels,"There was a statistically significant difference of the AUC, trough levels, and t (max) between weeks 1 and 24, with a decrease of AUC from 5,211 ng*h/ml in week 1 to 3,289 ng*h/ml in week 24, the trough levels decreased from 157 ng/ml to 96 ng/ml, and the t (max) decreased from 1.85 h to 1.00 h.",Decreased cyclosporine exposure during the remission of nephrotic syndrome. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17053886/),[ng] / [ml],157,2909,DB00091,Cyclosporine
,17053886,trough levels,"There was a statistically significant difference of the AUC, trough levels, and t (max) between weeks 1 and 24, with a decrease of AUC from 5,211 ng*h/ml in week 1 to 3,289 ng*h/ml in week 24, the trough levels decreased from 157 ng/ml to 96 ng/ml, and the t (max) decreased from 1.85 h to 1.00 h.",Decreased cyclosporine exposure during the remission of nephrotic syndrome. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17053886/),[ng] / [ml],96,2910,DB00091,Cyclosporine
,17053886,t (max),"There was a statistically significant difference of the AUC, trough levels, and t (max) between weeks 1 and 24, with a decrease of AUC from 5,211 ng*h/ml in week 1 to 3,289 ng*h/ml in week 24, the trough levels decreased from 157 ng/ml to 96 ng/ml, and the t (max) decreased from 1.85 h to 1.00 h.",Decreased cyclosporine exposure during the remission of nephrotic syndrome. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17053886/),h,1.85,2911,DB00091,Cyclosporine
,17053886,t (max),"There was a statistically significant difference of the AUC, trough levels, and t (max) between weeks 1 and 24, with a decrease of AUC from 5,211 ng*h/ml in week 1 to 3,289 ng*h/ml in week 24, the trough levels decreased from 157 ng/ml to 96 ng/ml, and the t (max) decreased from 1.85 h to 1.00 h.",Decreased cyclosporine exposure during the remission of nephrotic syndrome. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17053886/),h,1.00,2912,DB00091,Cyclosporine
,12780669,area under the concentration-time curve (AUC0-12),"The am and pm doses were independently adjusted to achieve a 12-h area under the concentration-time curve (AUC0-12) of 6600-7200 nghr/mL and morning trough level (C0) of 250-325 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[nghr] / [ml],6600-7200,3025,DB00091,Cyclosporine
,12780669,trough level (C0),"The am and pm doses were independently adjusted to achieve a 12-h area under the concentration-time curve (AUC0-12) of 6600-7200 nghr/mL and morning trough level (C0) of 250-325 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[ng] / [ml],250-325,3026,DB00091,Cyclosporine
,12780669,AUC0-12,"Mean AUC0-12 in 1 wk, 1, 3, 6, and 12 months were 7810 +/- 1880 nghr/mL, 9057 +/- 2097 nghr/mL, 7674 +/- 1912 nghr/mL, 7132 +/- 2040 nghr/mL, and 6503 +/- 1410 ngl/h with corresponding C0 of 301 +/- 79 ng/mL, 316 +/- 66 ng/mL, 275 +/- 59 ng/mL, 273 +/- 66 ng/mL, and 224 +/- 49 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[nghr] / [ml],7810,3027,DB00091,Cyclosporine
,12780669,AUC0-12,"Mean AUC0-12 in 1 wk, 1, 3, 6, and 12 months were 7810 +/- 1880 nghr/mL, 9057 +/- 2097 nghr/mL, 7674 +/- 1912 nghr/mL, 7132 +/- 2040 nghr/mL, and 6503 +/- 1410 ngl/h with corresponding C0 of 301 +/- 79 ng/mL, 316 +/- 66 ng/mL, 275 +/- 59 ng/mL, 273 +/- 66 ng/mL, and 224 +/- 49 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[nghr] / [ml],9057,3028,DB00091,Cyclosporine
,12780669,AUC0-12,"Mean AUC0-12 in 1 wk, 1, 3, 6, and 12 months were 7810 +/- 1880 nghr/mL, 9057 +/- 2097 nghr/mL, 7674 +/- 1912 nghr/mL, 7132 +/- 2040 nghr/mL, and 6503 +/- 1410 ngl/h with corresponding C0 of 301 +/- 79 ng/mL, 316 +/- 66 ng/mL, 275 +/- 59 ng/mL, 273 +/- 66 ng/mL, and 224 +/- 49 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[nghr] / [ml],7674,3029,DB00091,Cyclosporine
,12780669,AUC0-12,"Mean AUC0-12 in 1 wk, 1, 3, 6, and 12 months were 7810 +/- 1880 nghr/mL, 9057 +/- 2097 nghr/mL, 7674 +/- 1912 nghr/mL, 7132 +/- 2040 nghr/mL, and 6503 +/- 1410 ngl/h with corresponding C0 of 301 +/- 79 ng/mL, 316 +/- 66 ng/mL, 275 +/- 59 ng/mL, 273 +/- 66 ng/mL, and 224 +/- 49 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[nghr] / [ml],7132,3030,DB00091,Cyclosporine
,12780669,AUC0-12,"Mean AUC0-12 in 1 wk, 1, 3, 6, and 12 months were 7810 +/- 1880 nghr/mL, 9057 +/- 2097 nghr/mL, 7674 +/- 1912 nghr/mL, 7132 +/- 2040 nghr/mL, and 6503 +/- 1410 ngl/h with corresponding C0 of 301 +/- 79 ng/mL, 316 +/- 66 ng/mL, 275 +/- 59 ng/mL, 273 +/- 66 ng/mL, and 224 +/- 49 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[ngl] / [h],6503,3031,DB00091,Cyclosporine
,12780669,C0,"Mean AUC0-12 in 1 wk, 1, 3, 6, and 12 months were 7810 +/- 1880 nghr/mL, 9057 +/- 2097 nghr/mL, 7674 +/- 1912 nghr/mL, 7132 +/- 2040 nghr/mL, and 6503 +/- 1410 ngl/h with corresponding C0 of 301 +/- 79 ng/mL, 316 +/- 66 ng/mL, 275 +/- 59 ng/mL, 273 +/- 66 ng/mL, and 224 +/- 49 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[ng] / [ml],301,3032,DB00091,Cyclosporine
,12780669,C0,"Mean AUC0-12 in 1 wk, 1, 3, 6, and 12 months were 7810 +/- 1880 nghr/mL, 9057 +/- 2097 nghr/mL, 7674 +/- 1912 nghr/mL, 7132 +/- 2040 nghr/mL, and 6503 +/- 1410 ngl/h with corresponding C0 of 301 +/- 79 ng/mL, 316 +/- 66 ng/mL, 275 +/- 59 ng/mL, 273 +/- 66 ng/mL, and 224 +/- 49 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[ng] / [ml],316,3033,DB00091,Cyclosporine
,12780669,C0,"Mean AUC0-12 in 1 wk, 1, 3, 6, and 12 months were 7810 +/- 1880 nghr/mL, 9057 +/- 2097 nghr/mL, 7674 +/- 1912 nghr/mL, 7132 +/- 2040 nghr/mL, and 6503 +/- 1410 ngl/h with corresponding C0 of 301 +/- 79 ng/mL, 316 +/- 66 ng/mL, 275 +/- 59 ng/mL, 273 +/- 66 ng/mL, and 224 +/- 49 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[ng] / [ml],275,3034,DB00091,Cyclosporine
,12780669,C0,"Mean AUC0-12 in 1 wk, 1, 3, 6, and 12 months were 7810 +/- 1880 nghr/mL, 9057 +/- 2097 nghr/mL, 7674 +/- 1912 nghr/mL, 7132 +/- 2040 nghr/mL, and 6503 +/- 1410 ngl/h with corresponding C0 of 301 +/- 79 ng/mL, 316 +/- 66 ng/mL, 275 +/- 59 ng/mL, 273 +/- 66 ng/mL, and 224 +/- 49 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[ng] / [ml],273,3035,DB00091,Cyclosporine
,12780669,C0,"Mean AUC0-12 in 1 wk, 1, 3, 6, and 12 months were 7810 +/- 1880 nghr/mL, 9057 +/- 2097 nghr/mL, 7674 +/- 1912 nghr/mL, 7132 +/- 2040 nghr/mL, and 6503 +/- 1410 ngl/h with corresponding C0 of 301 +/- 79 ng/mL, 316 +/- 66 ng/mL, 275 +/- 59 ng/mL, 273 +/- 66 ng/mL, and 224 +/- 49 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[ng] / [ml],224,3036,DB00091,Cyclosporine
,9846420,trough CsA level (C0),"Dose adjustments were made daily, or as needed, to reach a target trough CsA level (C0) of 350 ng/mL in both groups.",[A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation]. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9846420/),[ng] / [ml],350,3367,DB00091,Cyclosporine
,32858576,flow rate,"PBMCs were isolated from the whole blood of 27 Chinese renal transplant patients using Ficoll-Paque Plus solution, and cell number was determined; acetonitrile treatment for protein precipitation, and gradient elution was performed on an Agilent Eclipse XDB-C18 column (3.5 μm, 2.1 × 100 mm) with mobile phase: water and methanol (containing 2 mM ammonium formate); flow rate: 0.3 mL·min.",Establishment of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Immunosuppressant Levels in the Peripheral Blood Mononuclear Cells of Chinese Renal Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32858576/),min·ml,0.3,3532,DB00091,Cyclosporine
,32858576,extraction effects,"The extraction effects, matrix effects, and mean relative recovery of these immunosuppressants were 70.4%-93.2%, 72.7%-96.5%, and 90.1%-112.4%, respectively.",Establishment of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Immunosuppressant Levels in the Peripheral Blood Mononuclear Cells of Chinese Renal Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32858576/),%,70.4,3533,DB00091,Cyclosporine
,32858576,matrix effects,"The extraction effects, matrix effects, and mean relative recovery of these immunosuppressants were 70.4%-93.2%, 72.7%-96.5%, and 90.1%-112.4%, respectively.",Establishment of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Immunosuppressant Levels in the Peripheral Blood Mononuclear Cells of Chinese Renal Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32858576/),%,93,3534,DB00091,Cyclosporine
,32858576,matrix effects,"The extraction effects, matrix effects, and mean relative recovery of these immunosuppressants were 70.4%-93.2%, 72.7%-96.5%, and 90.1%-112.4%, respectively.",Establishment of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Immunosuppressant Levels in the Peripheral Blood Mononuclear Cells of Chinese Renal Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32858576/),%,72.7,3535,DB00091,Cyclosporine
,32858576,matrix effects,"The extraction effects, matrix effects, and mean relative recovery of these immunosuppressants were 70.4%-93.2%, 72.7%-96.5%, and 90.1%-112.4%, respectively.",Establishment of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Immunosuppressant Levels in the Peripheral Blood Mononuclear Cells of Chinese Renal Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32858576/),%,90.1,3536,DB00091,Cyclosporine
,32858576,relative recovery,"The extraction effects, matrix effects, and mean relative recovery of these immunosuppressants were 70.4%-93.2%, 72.7%-96.5%, and 90.1%-112.4%, respectively.",Establishment of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Immunosuppressant Levels in the Peripheral Blood Mononuclear Cells of Chinese Renal Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32858576/),%,90.1,3537,DB00091,Cyclosporine
,15212874,bioavailability,"The bioavailability of CyA-HP50 and CyA-HP55 nanoparticle colloids calculated by the AUC(0-72) were 82.3% and 119.6%, similar to the reference of Neoral, while the bioavailability of CyA-HP55 nanoparticle colloids was found to be higher than that of CyA-HP50 nanoparticle colloids.",Bioavailability and pharmacokinetics of cyclosporine A-loaded pH-sensitive nanoparticles for oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15212874/),%,82.3,3611,DB00091,Cyclosporine
,15212874,bioavailability,"The bioavailability of CyA-HP50 and CyA-HP55 nanoparticle colloids calculated by the AUC(0-72) were 82.3% and 119.6%, similar to the reference of Neoral, while the bioavailability of CyA-HP55 nanoparticle colloids was found to be higher than that of CyA-HP50 nanoparticle colloids.",Bioavailability and pharmacokinetics of cyclosporine A-loaded pH-sensitive nanoparticles for oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15212874/),%,119.6,3612,DB00091,Cyclosporine
,21193152,bioavailability,"The bioavailability of pitavastatin is, at 60%, higher than that of any other statin and the majority of the bioavailable fraction of an oral dose is excreted unchanged in the bile.",Pitavastatin - pharmacological profile from early phase studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21193152/),%,60,4646,DB00091,Cyclosporine
,18510173,AUCs,"After oral administration of Genetaxyl at doses of 60, 120, and 180 mg/m2, the median total paclitaxel AUCs were 1.29, 1.60, and 1.85 microg x h/ml, respectively, suggesting a less than proportional increase in systemic exposure with increasing doses.",Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18510173/),[h·μg] / [ml],1.29,4730,DB00091,Cyclosporine
,18510173,AUCs,"After oral administration of Genetaxyl at doses of 60, 120, and 180 mg/m2, the median total paclitaxel AUCs were 1.29, 1.60, and 1.85 microg x h/ml, respectively, suggesting a less than proportional increase in systemic exposure with increasing doses.",Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18510173/),[h·μg] / [ml],1.60,4731,DB00091,Cyclosporine
,18510173,AUCs,"After oral administration of Genetaxyl at doses of 60, 120, and 180 mg/m2, the median total paclitaxel AUCs were 1.29, 1.60, and 1.85 microg x h/ml, respectively, suggesting a less than proportional increase in systemic exposure with increasing doses.",Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18510173/),[h·μg] / [ml],1.85,4732,DB00091,Cyclosporine
,2328306,areas under the whole blood concentration-time profiles,"Similarly, mean areas under the whole blood concentration-time profiles were not significantly different with or without concomitant lovastatin (61823 +/- 27295 vs 41470 +/- 10312 ng h ml-1; p = 0.13).","Influence of lovastatin on the pharmacokinetics, toxicity and immunologic response of cyclosporine in the obese Zucker rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328306/),[h·ng] / [ml],61823,5028,DB00091,Cyclosporine
,2328306,areas under the whole blood concentration-time profiles,"Similarly, mean areas under the whole blood concentration-time profiles were not significantly different with or without concomitant lovastatin (61823 +/- 27295 vs 41470 +/- 10312 ng h ml-1; p = 0.13).","Influence of lovastatin on the pharmacokinetics, toxicity and immunologic response of cyclosporine in the obese Zucker rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2328306/),[h·ng] / [ml],41470,5029,DB00091,Cyclosporine
,15606436,apparent clearance,"Mean population pharmacokinetic parameters were apparent clearance 30 l h(-1), apparent volume of distribution 79.8 l, duration of absorption 52 min, absorption lag time 7 min.",Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606436/),[l] / [h],30,5036,DB00091,Cyclosporine
,15606436,apparent volume of distribution,"Mean population pharmacokinetic parameters were apparent clearance 30 l h(-1), apparent volume of distribution 79.8 l, duration of absorption 52 min, absorption lag time 7 min.",Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606436/),l,79.8,5037,DB00091,Cyclosporine
,15606436,duration of absorption,"Mean population pharmacokinetic parameters were apparent clearance 30 l h(-1), apparent volume of distribution 79.8 l, duration of absorption 52 min, absorption lag time 7 min.",Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606436/),min,52,5038,DB00091,Cyclosporine
,15606436,absorption lag time,"Mean population pharmacokinetic parameters were apparent clearance 30 l h(-1), apparent volume of distribution 79.8 l, duration of absorption 52 min, absorption lag time 7 min.",Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606436/),min,7,5039,DB00091,Cyclosporine
,15561257,AUC,"Comparing the AUC per milligram dose, there was no significant difference between PK-1 and PK-S among TAC (46.0 +/- 24.3 ng x h/mg x mL versus 69.0 +/- 43.9 ng x h/mg x mL, P = .15 by paired t-test), but a significant difference in CsA (25.2 +/- 11.4 ng x h/mg x mL versus 45.4 +/- 12.9 ng x h/mg x mL, P = .0005 by paired t-test).",Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561257/),[h·ng] / [mg·ml],46.0,5067,DB00091,Cyclosporine
,15561257,AUC,"Comparing the AUC per milligram dose, there was no significant difference between PK-1 and PK-S among TAC (46.0 +/- 24.3 ng x h/mg x mL versus 69.0 +/- 43.9 ng x h/mg x mL, P = .15 by paired t-test), but a significant difference in CsA (25.2 +/- 11.4 ng x h/mg x mL versus 45.4 +/- 12.9 ng x h/mg x mL, P = .0005 by paired t-test).",Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561257/),[h·ng] / [mg·ml],69.0,5068,DB00091,Cyclosporine
,15561257,AUC,"Comparing the AUC per milligram dose, there was no significant difference between PK-1 and PK-S among TAC (46.0 +/- 24.3 ng x h/mg x mL versus 69.0 +/- 43.9 ng x h/mg x mL, P = .15 by paired t-test), but a significant difference in CsA (25.2 +/- 11.4 ng x h/mg x mL versus 45.4 +/- 12.9 ng x h/mg x mL, P = .0005 by paired t-test).",Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561257/),[h·ng] / [mg·ml],25.2,5069,DB00091,Cyclosporine
,15561257,AUC,"Comparing the AUC per milligram dose, there was no significant difference between PK-1 and PK-S among TAC (46.0 +/- 24.3 ng x h/mg x mL versus 69.0 +/- 43.9 ng x h/mg x mL, P = .15 by paired t-test), but a significant difference in CsA (25.2 +/- 11.4 ng x h/mg x mL versus 45.4 +/- 12.9 ng x h/mg x mL, P = .0005 by paired t-test).",Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561257/),[h·ng] / [mg·ml],45.4,5070,DB00091,Cyclosporine
,31539095,AUC0-12h,The median AUC0-12h was 4.76 mg*h/L.,Therapeutic durg monitoring of cyclosporin using area under the curve in nephrotic syndrome. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31539095/),[h·mg] / [l],4.76,5076,DB00091,Cyclosporine
,31539095,C2h,The median C2h found in our work was 878 ng / mL during the first six months versus 1039 ng / mL in the following months.,Therapeutic durg monitoring of cyclosporin using area under the curve in nephrotic syndrome. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31539095/),[ng] / [ml],878,5077,DB00091,Cyclosporine
,31539095,C2h,The median C2h found in our work was 878 ng / mL during the first six months versus 1039 ng / mL in the following months.,Therapeutic durg monitoring of cyclosporin using area under the curve in nephrotic syndrome. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31539095/),[ng] / [ml],1039,5078,DB00091,Cyclosporine
,27283486,area-under the time-activity curve,Lop kinetics and radiometabolites in arterial plasma were measured to calculate [(11)C]dLop area-under the time-activity curve from 10 to 30min in the brain (AUCbrain) and in plasma (AUCplasma).,Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27283486/),min,10 to 30,5092,DB00091,Cyclosporine
,27283486,AUCR,Baseline AUCR (0.85±0.29) was significantly enhanced in the presence of CsA (AUCR=10.8±3.6).,Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27283486/),,0.85,5093,DB00091,Cyclosporine
,27283486,AUCR,Baseline AUCR (0.85±0.29) was significantly enhanced in the presence of CsA (AUCR=10.8±3.6).,Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27283486/),,10.8,5094,DB00091,Cyclosporine
,27283486,AUCR,"Injection of pharmacologic dose of DPy did not enhance [(11)C]dLop brain distribution with AUCR being 1.2, 0.9 and 1.1 after administration of 0.56, 0.96 and 2mg/kg DPy doses, respectively.",Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27283486/),,1.2,5095,DB00091,Cyclosporine
,27283486,AUCR,"Injection of pharmacologic dose of DPy did not enhance [(11)C]dLop brain distribution with AUCR being 1.2, 0.9 and 1.1 after administration of 0.56, 0.96 and 2mg/kg DPy doses, respectively.",Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27283486/),,0.9,5096,DB00091,Cyclosporine
,27283486,AUCR,"Injection of pharmacologic dose of DPy did not enhance [(11)C]dLop brain distribution with AUCR being 1.2, 0.9 and 1.1 after administration of 0.56, 0.96 and 2mg/kg DPy doses, respectively.",Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27283486/),,1.1,5097,DB00091,Cyclosporine
,11856782,AUC(0-12),"There was an association between the risk of acute rejection episodes and MPA-AUC(0-12) values or MPA predose levels; by receiver operating characteristic analysis, an AUC(0-12) of 33.8 mg x h/L in the initial phase posttransplant had a diagnostic sensitivity of 75% and a diagnostic specificity of 64% for discrimination of patients with acute rejections.",The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11856782/),[h·mg] / [l],33.8,5527,DB00091,Cyclosporine
,21942970,t(max),"The main pharmacokinetic parameters of CsA were as follows: t(max) (1.60 ± 0.55) h, ρmax(951.60 ± 229.20) μg.L-1, t1/2(6.53 ± 2.40) h, and AUC0 -t(5162.10 ± 1355.01) μg.h.L-1.",Pharmacokinetics of Cyclosporine A in Chinese heart transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21942970/),h,1.60,5554,DB00091,Cyclosporine
,21942970,ρmax,"The main pharmacokinetic parameters of CsA were as follows: t(max) (1.60 ± 0.55) h, ρmax(951.60 ± 229.20) μg.L-1, t1/2(6.53 ± 2.40) h, and AUC0 -t(5162.10 ± 1355.01) μg.h.L-1.",Pharmacokinetics of Cyclosporine A in Chinese heart transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21942970/),[μg] / [l],951.60,5555,DB00091,Cyclosporine
,21942970,t1/2,"The main pharmacokinetic parameters of CsA were as follows: t(max) (1.60 ± 0.55) h, ρmax(951.60 ± 229.20) μg.L-1, t1/2(6.53 ± 2.40) h, and AUC0 -t(5162.10 ± 1355.01) μg.h.L-1.",Pharmacokinetics of Cyclosporine A in Chinese heart transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21942970/),h,6.53,5556,DB00091,Cyclosporine
,21942970,AUC0 -t,"The main pharmacokinetic parameters of CsA were as follows: t(max) (1.60 ± 0.55) h, ρmax(951.60 ± 229.20) μg.L-1, t1/2(6.53 ± 2.40) h, and AUC0 -t(5162.10 ± 1355.01) μg.h.L-1.",Pharmacokinetics of Cyclosporine A in Chinese heart transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21942970/),[h·μg] / [l],5162.10,5557,DB00091,Cyclosporine
,17651179,area under the drug concentration-time curve from 0 to 4 h after treatment (AUC0-4),"After the postprandial administration of cyclosporine, the mean area under the drug concentration-time curve from 0 to 4 h after treatment (AUC0-4) was 1393.5 ng h/mL and the mean maximum drug concentration (Cmax) was 604.1 ng/mL.",Preprandial vs. postprandial pharmacokinetics of cyclosporine in patients with psoriasis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17651179/),[h·ng] / [ml],1393.5,5921,DB00091,Cyclosporine
,17651179,maximum drug concentration (Cmax),"After the postprandial administration of cyclosporine, the mean area under the drug concentration-time curve from 0 to 4 h after treatment (AUC0-4) was 1393.5 ng h/mL and the mean maximum drug concentration (Cmax) was 604.1 ng/mL.",Preprandial vs. postprandial pharmacokinetics of cyclosporine in patients with psoriasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17651179/),[ng] / [ml],604.1,5922,DB00091,Cyclosporine
,17651179,AUC0-4,"After preprandial administration, the mean AUC0-4 was 2195.2 ng h/mL and the mean Cmax was 1054.9 ng/mL.",Preprandial vs. postprandial pharmacokinetics of cyclosporine in patients with psoriasis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17651179/),[h·ng] / [ml],2195.2,5923,DB00091,Cyclosporine
,17651179,Cmax,"After preprandial administration, the mean AUC0-4 was 2195.2 ng h/mL and the mean Cmax was 1054.9 ng/mL.",Preprandial vs. postprandial pharmacokinetics of cyclosporine in patients with psoriasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17651179/),[ng] / [ml],1054.9,5924,DB00091,Cyclosporine
,8649628,drug through levels,"Acutely, i.e. by day 8, 1:1 dose conversion resulted in a modest increase of mean drug through levels (from 114 ng/ml at baseline to 120 ng/ml, P < 0.01).",Substitution of conventional cyclosporin with a new microemulsion formulation in renal transplant patients: results after 1 year. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8649628/),[ng] / [ml],114,6014,DB00091,Cyclosporine
,8649628,drug through levels,"Acutely, i.e. by day 8, 1:1 dose conversion resulted in a modest increase of mean drug through levels (from 114 ng/ml at baseline to 120 ng/ml, P < 0.01).",Substitution of conventional cyclosporin with a new microemulsion formulation in renal transplant patients: results after 1 year. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8649628/),[ng] / [ml],120,6015,DB00091,Cyclosporine
,8649628,drug through levels,"After 1 month, drug through levels had decreased to baseline (112 ng/ml) and remained there until month 6.",Substitution of conventional cyclosporin with a new microemulsion formulation in renal transplant patients: results after 1 year. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8649628/),[ng] / [ml],112,6016,DB00091,Cyclosporine
,11441909,mean residence time,"After addition of cyclosporine, the mean residence time was increased from 34.9 min to 48.6 min (p<0.05, n=6), and the area under the concentration versus time curve (AUC) increased from 4775 min microg/ml to 6960 min microg/ml (p<0.01, n=6).","Effect of cyclosporine, a P-glycoprotein inhibitor, on the pharmacokinetics of cefepime in rat blood and brain: a microdialysis study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11441909/),min,34.9,6357,DB00091,Cyclosporine
,11441909,mean residence time,"After addition of cyclosporine, the mean residence time was increased from 34.9 min to 48.6 min (p<0.05, n=6), and the area under the concentration versus time curve (AUC) increased from 4775 min microg/ml to 6960 min microg/ml (p<0.01, n=6).","Effect of cyclosporine, a P-glycoprotein inhibitor, on the pharmacokinetics of cefepime in rat blood and brain: a microdialysis study. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11441909/),min,48.6,6358,DB00091,Cyclosporine
,11441909,area under the concentration versus time curve (AUC),"After addition of cyclosporine, the mean residence time was increased from 34.9 min to 48.6 min (p<0.05, n=6), and the area under the concentration versus time curve (AUC) increased from 4775 min microg/ml to 6960 min microg/ml (p<0.01, n=6).","Effect of cyclosporine, a P-glycoprotein inhibitor, on the pharmacokinetics of cefepime in rat blood and brain: a microdialysis study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11441909/),[min·μg] / [ml],4775,6359,DB00091,Cyclosporine
,11441909,area under the concentration versus time curve (AUC),"After addition of cyclosporine, the mean residence time was increased from 34.9 min to 48.6 min (p<0.05, n=6), and the area under the concentration versus time curve (AUC) increased from 4775 min microg/ml to 6960 min microg/ml (p<0.01, n=6).","Effect of cyclosporine, a P-glycoprotein inhibitor, on the pharmacokinetics of cefepime in rat blood and brain: a microdialysis study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11441909/),[min·μg] / [ml],6960,6360,DB00091,Cyclosporine
,11441909,AUC,"While in the brain, AUC increased from 64.3 min microg/ml to 110.2 min microg/ml.","Effect of cyclosporine, a P-glycoprotein inhibitor, on the pharmacokinetics of cefepime in rat blood and brain: a microdialysis study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11441909/),[min·μg] / [ml],64.3,6361,DB00091,Cyclosporine
,11441909,AUC,"While in the brain, AUC increased from 64.3 min microg/ml to 110.2 min microg/ml.","Effect of cyclosporine, a P-glycoprotein inhibitor, on the pharmacokinetics of cefepime in rat blood and brain: a microdialysis study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11441909/),[min·μg] / [ml],110.2,6362,DB00091,Cyclosporine
,12457304,serum trough levels,"Beside cyclosporine A at serum trough levels of 240 (195-273) microg/l, five patients additionally received aminoglycosides for at least 2 weeks, and 4 were treated with ganciclovir.","Tolerability, safety and efficacy of conventional amphotericin B administered by 24-hour infusion to lung transplant recipients. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12457304/),[μg] / [l],240,6900,DB00091,Cyclosporine
,26740371,AUC(0-24),"Based on steady-state pharmacokinetics, MMF was converted to CI to target a total MPA AUC(0-24) of 40 to 80 μg·hour/mL.",A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26740371/),[h·μg] / [ml],40 to 80,8124,DB00091,Cyclosporine
,26740371,steady-state concentration (Css),The MMF dose was adjusted to maintain a total MPA steady-state concentration (Css) of 1.7 to 3.3 μg/mL.,A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26740371/),[μg] / [ml],1.7 to 3.3,8125,DB00091,Cyclosporine
,26740371,AUC(0-24),"During the CI schedule, MPA AUC(0-24) was maintained at a mean of 40.1 μg·hour/mL (range, 20.6 to 63.8), and 17 of 19 patients (89%) achieved MPA Css within target of 1.7 to 3.3 μg/mL.",A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26740371/),[h·μg] / [ml],40.1,8126,DB00091,Cyclosporine
,26740371,Css,"During the CI schedule, MPA AUC(0-24) was maintained at a mean of 40.1 μg·hour/mL (range, 20.6 to 63.8), and 17 of 19 patients (89%) achieved MPA Css within target of 1.7 to 3.3 μg/mL.",A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26740371/),[μg] / [ml],1.7 to 3.3,8127,DB00091,Cyclosporine
,3363220,volume of distribution at steady-state,"However, Zucker obese rats demonstrated a significantly smaller volume of distribution at steady-state (2.8 +/- 1.1 L/kg; p less than 0.01) versus the Zucker lean (5.4 +/- .9 L/kg) and Sprague-Dawley rats (5.6 +/- .7 L/kg).",Cyclosporine disposition in the hyperlipidemic rat model. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3363220/),[l] / [kg],2.8,8858,DB00091,Cyclosporine
,3363220,volume of distribution at steady-state,"However, Zucker obese rats demonstrated a significantly smaller volume of distribution at steady-state (2.8 +/- 1.1 L/kg; p less than 0.01) versus the Zucker lean (5.4 +/- .9 L/kg) and Sprague-Dawley rats (5.6 +/- .7 L/kg).",Cyclosporine disposition in the hyperlipidemic rat model. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3363220/),[l] / [kg],5.4,8859,DB00091,Cyclosporine
,3363220,volume of distribution at steady-state,"However, Zucker obese rats demonstrated a significantly smaller volume of distribution at steady-state (2.8 +/- 1.1 L/kg; p less than 0.01) versus the Zucker lean (5.4 +/- .9 L/kg) and Sprague-Dawley rats (5.6 +/- .7 L/kg).",Cyclosporine disposition in the hyperlipidemic rat model. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3363220/),[l] / [kg],5.6,8860,DB00091,Cyclosporine
,3363220,total body clearance,"Likewise, the total body clearance was markedly reduced in the obese (0.24 +/- .09 L/h/kg; p less than 0.01) versus lean (0.51 +/- .04 L/h/kg) and Sprague-Dawley (0.52 +/- .06 L/h/kg) rat models.",Cyclosporine disposition in the hyperlipidemic rat model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3363220/),[l] / [h·kg],0.24,8861,DB00091,Cyclosporine
,3363220,total body clearance,"Likewise, the total body clearance was markedly reduced in the obese (0.24 +/- .09 L/h/kg; p less than 0.01) versus lean (0.51 +/- .04 L/h/kg) and Sprague-Dawley (0.52 +/- .06 L/h/kg) rat models.",Cyclosporine disposition in the hyperlipidemic rat model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3363220/),[l] / [h·kg],0.51,8862,DB00091,Cyclosporine
,3363220,total body clearance,"Likewise, the total body clearance was markedly reduced in the obese (0.24 +/- .09 L/h/kg; p less than 0.01) versus lean (0.51 +/- .04 L/h/kg) and Sprague-Dawley (0.52 +/- .06 L/h/kg) rat models.",Cyclosporine disposition in the hyperlipidemic rat model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3363220/),[l] / [h·kg],0.52,8863,DB00091,Cyclosporine
,7895604,Maximum blood concentrations,"Maximum blood concentrations of CsG at 2- to 3-hr postdose averaged 342 and 1170 ng/ml after doses of 150 and 600 mg, respectively, each accounting for approximately 50% of the blood radioactivity level.",Pharmacokinetics and metabolism of cyclosporin G in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7895604/),[ng] / [ml],342,9044,DB00091,Cyclosporine
,7895604,Maximum blood concentrations,"Maximum blood concentrations of CsG at 2- to 3-hr postdose averaged 342 and 1170 ng/ml after doses of 150 and 600 mg, respectively, each accounting for approximately 50% of the blood radioactivity level.",Pharmacokinetics and metabolism of cyclosporin G in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7895604/),[ng] / [ml],1170,9045,DB00091,Cyclosporine
,7895604,plasma:blood concentration ratio,The plasma:blood concentration ratio for both CsG and total radioactivity averaged approximately 0.8.,Pharmacokinetics and metabolism of cyclosporin G in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7895604/),,0.8,9046,DB00091,Cyclosporine
,7895604,Total recovery,Total recovery in urine was only approximately 3% of the dose.,Pharmacokinetics and metabolism of cyclosporin G in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7895604/),%,3,9047,DB00091,Cyclosporine
,7895604,terminal half-life,"In blood, the terminal half-life of CsG and total radioactivity averaged 9-11 hr following both the 150 and 600 mg doses.",Pharmacokinetics and metabolism of cyclosporin G in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7895604/),h,9-11,9048,DB00091,Cyclosporine
,7895604,half-life,"In plasma, the half-life of CsG was 2-4 hr and that of total radioactivity was 27-29 hr.",Pharmacokinetics and metabolism of cyclosporin G in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7895604/),h,2-4,9049,DB00091,Cyclosporine
,7895604,half-life,"In plasma, the half-life of CsG was 2-4 hr and that of total radioactivity was 27-29 hr.",Pharmacokinetics and metabolism of cyclosporin G in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7895604/),h,27-29,9050,DB00091,Cyclosporine
,22329639,k(a),"k(a), estimated at 1.7 h(-1) at age 8.7 years, exhibited large interindividual variability (308%).",Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22329639/),1/[h],1.7,9194,DB00091,Cyclosporine
,22329639,V/F,"V/F, estimated at 64.7 l, increased about 2.3 times in children during the immediate post transplantation period.",Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22329639/),l,64.7,9195,DB00091,Cyclosporine
,22329639,CL/F,CL/F was estimated at 12.7 l h(-1).,Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22329639/),[l] / [h],12.7,9196,DB00091,Cyclosporine
,12826142,C(0),The C(0) (mean +/- SE) was 175 +/- 15 ng.,Neoral monitoring by limited sampling area under the concentration time curve in stable indian renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12826142/),ng,175,9300,DB00091,Cyclosporine
,12826142,C(max),mL(-1); C(max) 970 +/- 101 ng.,Neoral monitoring by limited sampling area under the concentration time curve in stable indian renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12826142/),ng,970,9301,DB00091,Cyclosporine
,12826142,AUC (0-4),"mL(-1), and the AUC (0-4) 2734 +/- 258 ng. h. mL(-1).",Neoral monitoring by limited sampling area under the concentration time curve in stable indian renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12826142/),[h·ng] / [ml],2734,9302,DB00091,Cyclosporine
,12433438,C(max),"The in vivo results showed that, chitosan-nanoparticles gave the highest C(max) (2762.8 ng/ml) of Cy-A after 2.17 h (T(max)), while SGC-nanoparticles gave the lowest one (1202.4 ng/ml after 4.0 h).",Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12433438/),[ng] / [ml],2762.8,9311,DB00091,Cyclosporine
,12433438,T(max),"The in vivo results showed that, chitosan-nanoparticles gave the highest C(max) (2762.8 ng/ml) of Cy-A after 2.17 h (T(max)), while SGC-nanoparticles gave the lowest one (1202.4 ng/ml after 4.0 h).",Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12433438/),h,2.17,9312,DB00091,Cyclosporine
,12433438,T(max),"The in vivo results showed that, chitosan-nanoparticles gave the highest C(max) (2762.8 ng/ml) of Cy-A after 2.17 h (T(max)), while SGC-nanoparticles gave the lowest one (1202.4 ng/ml after 4.0 h).",Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12433438/),[ng] / [ml],1202.4,9313,DB00091,Cyclosporine
,17488394,apparent half-life,"The mean apparent half-life of MPA was 5.3 +/- 4.3 h, (1.0-15.7).",Pharmacokinetics of enteric-coated mycophenolate sodium in stable liver transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17488394/),h,5.3,9641,DB00091,Cyclosporine
,17488394,t(max),Mean t(max) was 2.4 +/- 1.1 h (1.0-5.0).,Pharmacokinetics of enteric-coated mycophenolate sodium in stable liver transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17488394/),h,2.4,9642,DB00091,Cyclosporine
,17488394,area-under-curve,The mean area-under-curve was 45.3 +/- 23.1 microg-h/mL (17.3-90.0).,Pharmacokinetics of enteric-coated mycophenolate sodium in stable liver transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17488394/),[μg-h] / [ml],45.3,9643,DB00091,Cyclosporine
,17488394,Trough level concentrations (C(12 h)),Trough level concentrations (C(12 h)) showed large inter-individual variability (0-9.2 microg/mL).,Pharmacokinetics of enteric-coated mycophenolate sodium in stable liver transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17488394/),[μg] / [ml],0-9.2,9644,DB00091,Cyclosporine
,11996501,flow-rate,"Samples were eluted with a mobile phase containing 100 mM sodium dihydrogenphosphate (pH 3.1)-acetonitrile (30:70, v/v), and the flow-rate of the mobile phase was 0.05 ml/min.",Determination of diclofenac in rat bile and its interaction with cyclosporin A using on-line microdialysis coupled to liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996501/),[ml] / [min],0.05,9819,DB00091,Cyclosporine
,17445553,C(0),"The mean values for C(0) and AUC(0-6h) were 1.8 +/- 1.2 mg/L and 31.1 +/- 14.8 mg*h/L, respectively.",Therapeutic drug monitoring of mycophenolic acid in kidney transplant patients: a abbreviated sampling strategy. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17445553/),[mg] / [l],1.8,9878,DB00091,Cyclosporine
,17445553,AUC(0-6h),"The mean values for C(0) and AUC(0-6h) were 1.8 +/- 1.2 mg/L and 31.1 +/- 14.8 mg*h/L, respectively.",Therapeutic drug monitoring of mycophenolic acid in kidney transplant patients: a abbreviated sampling strategy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17445553/),[h·mg] / [l],31.1,9879,DB00091,Cyclosporine
,17445553,dose-corrected AUC(0-6h),The dose-corrected AUC(0-6h) was 35.4 +/- 17.9 mg*h/L.,Therapeutic drug monitoring of mycophenolic acid in kidney transplant patients: a abbreviated sampling strategy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17445553/),[h·mg] / [l],35.4,9880,DB00091,Cyclosporine
,24219005,overall response rate,The overall response rate in evaluable patients was 42% (95% CI: 23 - 63) and the median overall survival was 12.2 months (8.4 - 23.1).,Phase II and pharmacological study of oral docetaxel plus cyclosporin A in anthracycline pre-treated metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24219005/),%,42,9892,DB00091,Cyclosporine
,24219005,overall survival,The overall response rate in evaluable patients was 42% (95% CI: 23 - 63) and the median overall survival was 12.2 months (8.4 - 23.1).,Phase II and pharmacological study of oral docetaxel plus cyclosporin A in anthracycline pre-treated metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24219005/),month,12.2,9893,DB00091,Cyclosporine
,11180020,peak concentration,"We found no significant differences before or after the administration of St John's Wort in carbamazepine peak concentration (7.2 +/- 1 mg/L before versus 7.6 +/- 1.3 mg/L after), trough concentration (4.8 +/- 0.5 mg/L before versus 4.3 +/- 0.8 mg/L after), area under the plasma concentration-time curve (142.4 +/- 12.9 mg x h/L before versus 143.8 +/- 27.2 mg x h/L after), or oral clearance (2.8 +/- 0.3 L/h before versus 2.9 +/- 0.6 L/h after).",Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180020/),[mg] / [l],7.2,10046,DB00091,Cyclosporine
,11180020,peak concentration,"We found no significant differences before or after the administration of St John's Wort in carbamazepine peak concentration (7.2 +/- 1 mg/L before versus 7.6 +/- 1.3 mg/L after), trough concentration (4.8 +/- 0.5 mg/L before versus 4.3 +/- 0.8 mg/L after), area under the plasma concentration-time curve (142.4 +/- 12.9 mg x h/L before versus 143.8 +/- 27.2 mg x h/L after), or oral clearance (2.8 +/- 0.3 L/h before versus 2.9 +/- 0.6 L/h after).",Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180020/),[mg] / [l],7.6,10047,DB00091,Cyclosporine
,11180020,trough concentration,"We found no significant differences before or after the administration of St John's Wort in carbamazepine peak concentration (7.2 +/- 1 mg/L before versus 7.6 +/- 1.3 mg/L after), trough concentration (4.8 +/- 0.5 mg/L before versus 4.3 +/- 0.8 mg/L after), area under the plasma concentration-time curve (142.4 +/- 12.9 mg x h/L before versus 143.8 +/- 27.2 mg x h/L after), or oral clearance (2.8 +/- 0.3 L/h before versus 2.9 +/- 0.6 L/h after).",Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180020/),[mg] / [l],4.8,10048,DB00091,Cyclosporine
,11180020,trough concentration,"We found no significant differences before or after the administration of St John's Wort in carbamazepine peak concentration (7.2 +/- 1 mg/L before versus 7.6 +/- 1.3 mg/L after), trough concentration (4.8 +/- 0.5 mg/L before versus 4.3 +/- 0.8 mg/L after), area under the plasma concentration-time curve (142.4 +/- 12.9 mg x h/L before versus 143.8 +/- 27.2 mg x h/L after), or oral clearance (2.8 +/- 0.3 L/h before versus 2.9 +/- 0.6 L/h after).",Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180020/),[mg] / [l],4.3,10049,DB00091,Cyclosporine
,11180020,area under the plasma concentration-time curve,"We found no significant differences before or after the administration of St John's Wort in carbamazepine peak concentration (7.2 +/- 1 mg/L before versus 7.6 +/- 1.3 mg/L after), trough concentration (4.8 +/- 0.5 mg/L before versus 4.3 +/- 0.8 mg/L after), area under the plasma concentration-time curve (142.4 +/- 12.9 mg x h/L before versus 143.8 +/- 27.2 mg x h/L after), or oral clearance (2.8 +/- 0.3 L/h before versus 2.9 +/- 0.6 L/h after).",Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180020/),[h·mg] / [l],142.4,10050,DB00091,Cyclosporine
,11180020,area under the plasma concentration-time curve,"We found no significant differences before or after the administration of St John's Wort in carbamazepine peak concentration (7.2 +/- 1 mg/L before versus 7.6 +/- 1.3 mg/L after), trough concentration (4.8 +/- 0.5 mg/L before versus 4.3 +/- 0.8 mg/L after), area under the plasma concentration-time curve (142.4 +/- 12.9 mg x h/L before versus 143.8 +/- 27.2 mg x h/L after), or oral clearance (2.8 +/- 0.3 L/h before versus 2.9 +/- 0.6 L/h after).",Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180020/),[h·mg] / [l],143.8,10051,DB00091,Cyclosporine
,11180020,oral clearance,"We found no significant differences before or after the administration of St John's Wort in carbamazepine peak concentration (7.2 +/- 1 mg/L before versus 7.6 +/- 1.3 mg/L after), trough concentration (4.8 +/- 0.5 mg/L before versus 4.3 +/- 0.8 mg/L after), area under the plasma concentration-time curve (142.4 +/- 12.9 mg x h/L before versus 143.8 +/- 27.2 mg x h/L after), or oral clearance (2.8 +/- 0.3 L/h before versus 2.9 +/- 0.6 L/h after).",Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180020/),[l] / [h],2.8,10052,DB00091,Cyclosporine
,11180020,oral clearance,"We found no significant differences before or after the administration of St John's Wort in carbamazepine peak concentration (7.2 +/- 1 mg/L before versus 7.6 +/- 1.3 mg/L after), trough concentration (4.8 +/- 0.5 mg/L before versus 4.3 +/- 0.8 mg/L after), area under the plasma concentration-time curve (142.4 +/- 12.9 mg x h/L before versus 143.8 +/- 27.2 mg x h/L after), or oral clearance (2.8 +/- 0.3 L/h before versus 2.9 +/- 0.6 L/h after).",Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180020/),[l] / [h],2.9,10053,DB00091,Cyclosporine
,11180020,peak concentration,"Similarly, no differences were found in peak concentration (2 +/- 0.5 mg/L before versus 2.1 +/- 0.4 mg/L after), trough concentration (1.3 +/- 0.3 mg/L before versus 1.4 +/- 0.3 mg/L after), and area under the plasma concentration-time curve (37.5 +/- 7.4 mg x h/L before versus 41.9 +/- 10.3 mg x h/L after) of carbamazepine-10,11-epoxide.",Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180020/),[mg] / [l],2,10054,DB00091,Cyclosporine
,11180020,peak concentration,"Similarly, no differences were found in peak concentration (2 +/- 0.5 mg/L before versus 2.1 +/- 0.4 mg/L after), trough concentration (1.3 +/- 0.3 mg/L before versus 1.4 +/- 0.3 mg/L after), and area under the plasma concentration-time curve (37.5 +/- 7.4 mg x h/L before versus 41.9 +/- 10.3 mg x h/L after) of carbamazepine-10,11-epoxide.",Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180020/),[mg] / [l],2.1,10055,DB00091,Cyclosporine
,11180020,trough concentration,"Similarly, no differences were found in peak concentration (2 +/- 0.5 mg/L before versus 2.1 +/- 0.4 mg/L after), trough concentration (1.3 +/- 0.3 mg/L before versus 1.4 +/- 0.3 mg/L after), and area under the plasma concentration-time curve (37.5 +/- 7.4 mg x h/L before versus 41.9 +/- 10.3 mg x h/L after) of carbamazepine-10,11-epoxide.",Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180020/),[mg] / [l],1.3,10056,DB00091,Cyclosporine
,11180020,trough concentration,"Similarly, no differences were found in peak concentration (2 +/- 0.5 mg/L before versus 2.1 +/- 0.4 mg/L after), trough concentration (1.3 +/- 0.3 mg/L before versus 1.4 +/- 0.3 mg/L after), and area under the plasma concentration-time curve (37.5 +/- 7.4 mg x h/L before versus 41.9 +/- 10.3 mg x h/L after) of carbamazepine-10,11-epoxide.",Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180020/),[mg] / [l],1.4,10057,DB00091,Cyclosporine
,11180020,area under the plasma concentration-time curve,"Similarly, no differences were found in peak concentration (2 +/- 0.5 mg/L before versus 2.1 +/- 0.4 mg/L after), trough concentration (1.3 +/- 0.3 mg/L before versus 1.4 +/- 0.3 mg/L after), and area under the plasma concentration-time curve (37.5 +/- 7.4 mg x h/L before versus 41.9 +/- 10.3 mg x h/L after) of carbamazepine-10,11-epoxide.",Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180020/),[h·mg] / [l],37.5,10058,DB00091,Cyclosporine
,11180020,area under the plasma concentration-time curve,"Similarly, no differences were found in peak concentration (2 +/- 0.5 mg/L before versus 2.1 +/- 0.4 mg/L after), trough concentration (1.3 +/- 0.3 mg/L before versus 1.4 +/- 0.3 mg/L after), and area under the plasma concentration-time curve (37.5 +/- 7.4 mg x h/L before versus 41.9 +/- 10.3 mg x h/L after) of carbamazepine-10,11-epoxide.",Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180020/),[h·mg] / [l],41.9,10059,DB00091,Cyclosporine
,12563620,area under the curve (AUC),"Each patient in the study had a consistent decrease in area under the curve (AUC) when given olestra along with their usual dose of Neoral, compared with giving Neoral alone (5,018 ng*hr/mL versus 4,086 ng*hr/mL; P <.001).",Modifications in cyclosporine (CsA) microemulsion blood concentrations by olestra. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12563620/),[h·ng] / [ml],"5,018",10246,DB00091,Cyclosporine
,12563620,area under the curve (AUC),"Each patient in the study had a consistent decrease in area under the curve (AUC) when given olestra along with their usual dose of Neoral, compared with giving Neoral alone (5,018 ng*hr/mL versus 4,086 ng*hr/mL; P <.001).",Modifications in cyclosporine (CsA) microemulsion blood concentrations by olestra. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12563620/),[h·ng] / [ml],"4,086",10247,DB00091,Cyclosporine
,12563620,maximum concentration (Cmax),"There also was a decrease in maximum concentration (Cmax) when Neoral was given with olestra compared with giving Neoral alone (1,202 ng/mL versus 876 ng/mL; P =.015).",Modifications in cyclosporine (CsA) microemulsion blood concentrations by olestra. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12563620/),[ng] / [ml],"1,202",10248,DB00091,Cyclosporine
,12563620,maximum concentration (Cmax),"There also was a decrease in maximum concentration (Cmax) when Neoral was given with olestra compared with giving Neoral alone (1,202 ng/mL versus 876 ng/mL; P =.015).",Modifications in cyclosporine (CsA) microemulsion blood concentrations by olestra. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12563620/),[ng] / [ml],876,10249,DB00091,Cyclosporine
,12563620,half-life,There was no statistical difference in the mean elimination rate or the trough values for both regimens (half-life 4.767 hours versus 4.771 hours and trough levels of 143 ng/mL versus 124 ng/mL).,Modifications in cyclosporine (CsA) microemulsion blood concentrations by olestra. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12563620/),h,4.767,10250,DB00091,Cyclosporine
,12563620,half-life,There was no statistical difference in the mean elimination rate or the trough values for both regimens (half-life 4.767 hours versus 4.771 hours and trough levels of 143 ng/mL versus 124 ng/mL).,Modifications in cyclosporine (CsA) microemulsion blood concentrations by olestra. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12563620/),h,4.771,10251,DB00091,Cyclosporine
,12563620,trough levels,There was no statistical difference in the mean elimination rate or the trough values for both regimens (half-life 4.767 hours versus 4.771 hours and trough levels of 143 ng/mL versus 124 ng/mL).,Modifications in cyclosporine (CsA) microemulsion blood concentrations by olestra. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12563620/),[ng] / [ml],143,10252,DB00091,Cyclosporine
,12563620,trough levels,There was no statistical difference in the mean elimination rate or the trough values for both regimens (half-life 4.767 hours versus 4.771 hours and trough levels of 143 ng/mL versus 124 ng/mL).,Modifications in cyclosporine (CsA) microemulsion blood concentrations by olestra. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12563620/),[ng] / [ml],124,10253,DB00091,Cyclosporine
,12814453,area under the plasma nifedipine concentration-time curve (AUC0-alpha),The area under the plasma nifedipine concentration-time curve (AUC0-alpha) in nafcillin-pretreated subjects (80.9 +/- 32.9 micro g l-1 h-1) was significantly decreased compared with subjects who received only nifedipine (216.4 +/- 93.2 micro g l-1 h-1) (P < 0.001).,Evidence of an interaction between nifedipine and nafcillin in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12814453/),[μg] / [h·l],80.9,10400,DB00091,Cyclosporine
,12814453,area under the plasma nifedipine concentration-time curve (AUC0-alpha),The area under the plasma nifedipine concentration-time curve (AUC0-alpha) in nafcillin-pretreated subjects (80.9 +/- 32.9 micro g l-1 h-1) was significantly decreased compared with subjects who received only nifedipine (216.4 +/- 93.2 micro g l-1 h-1) (P < 0.001).,Evidence of an interaction between nifedipine and nafcillin in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12814453/),[μg] / [h·l],216.4,10401,DB00091,Cyclosporine
,12814453,Total plasma clearance of nifedipine (CL/F),Total plasma clearance of nifedipine (CL/F) was significantly increased with nafcillin pretreatment (138.5 +/- 42.0 l h-1 vs 56.5 +/- 32.0 l h-1) (P < 0.002).,Evidence of an interaction between nifedipine and nafcillin in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12814453/),[l] / [h],138.5,10402,DB00091,Cyclosporine
,12814453,Total plasma clearance of nifedipine (CL/F),Total plasma clearance of nifedipine (CL/F) was significantly increased with nafcillin pretreatment (138.5 +/- 42.0 l h-1 vs 56.5 +/- 32.0 l h-1) (P < 0.002).,Evidence of an interaction between nifedipine and nafcillin in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12814453/),[l] / [h],56.5,10403,DB00091,Cyclosporine
,15752379,first order rate constant,The concentration of CrEL in the gastrointestinal tract decreased with time with a first order rate constant of 1.73 h(-1).,Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752379/),1/[h],1.73,10866,DB00091,Cyclosporine
,15752379,apparent paclitaxel clearance,"Estimated apparent paclitaxel clearance and volume of distribution were 127 l h(-1) and 409 l, respectively.",Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752379/),[l] / [h],127,10867,DB00091,Cyclosporine
,15752379,volume of distribution,"Estimated apparent paclitaxel clearance and volume of distribution were 127 l h(-1) and 409 l, respectively.",Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752379/),l,409,10868,DB00091,Cyclosporine
,10375179,assay time,"The reproducibility (coefficient of variation), detection limit, and assay time for FE-FPIA were below 2%, 25 ng/ml, and about 24 min/24 samples, respectively, and were comparable with those for the whole blood samples determined by the conventional FPIA.",A modified fluorescence polarization immunoassay method incorporating fat emulsion (FE-FPIA) to determine cyclosporin A concentrations in rat skin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10375179/),[min] / [24],24,11066,DB00091,Cyclosporine
,3576671,ED50,"The dose that produced 50% of the maximal immunosuppression (ED50) for cyclosporine alone was 89 mg/kg/day, whereas the ED50 for cyclosporine, when combined with ketoconazole, was 33 mg/kg/day.",Pharmacodynamics of cyclosporine-ketoconazole interaction in mice. Combined therapy potentiates cyclosporine immunosuppression and toxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3576671/),[mg] / [d·kg],33,11465,DB00091,Cyclosporine
,22283648,fEO,Three PEO-b-PBCL block copolymers having fEO ranging from 0.18-0.40 were synthesized.,Characterization of the self assembly of methoxy poly(ethylene oxide)-block-poly(α-benzyl carboxylate-ε-caprolactone) for the solubilization and in vivo delivery of valspodar. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22283648/),,0.18-0.40,11772,DB00091,Cyclosporine
,22283648,critical aggregation concentration (CAC),"The average critical aggregation concentration (CAC) for PEO114-b-PBCL₃₀, PEO₁₁₄-b-PBCL₆₀, and PEO₁₁₄-b-PBCL₉₅ was found to be 62, 41, and 23 nM, respectively.",Characterization of the self assembly of methoxy poly(ethylene oxide)-block-poly(α-benzyl carboxylate-ε-caprolactone) for the solubilization and in vivo delivery of valspodar. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22283648/),nM,62,11773,DB00091,Cyclosporine
,22283648,critical aggregation concentration (CAC),"The average critical aggregation concentration (CAC) for PEO114-b-PBCL₃₀, PEO₁₁₄-b-PBCL₆₀, and PEO₁₁₄-b-PBCL₉₅ was found to be 62, 41, and 23 nM, respectively.",Characterization of the self assembly of methoxy poly(ethylene oxide)-block-poly(α-benzyl carboxylate-ε-caprolactone) for the solubilization and in vivo delivery of valspodar. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22283648/),nM,41,11774,DB00091,Cyclosporine
,22283648,critical aggregation concentration (CAC),"The average critical aggregation concentration (CAC) for PEO114-b-PBCL₃₀, PEO₁₁₄-b-PBCL₆₀, and PEO₁₁₄-b-PBCL₉₅ was found to be 62, 41, and 23 nM, respectively.",Characterization of the self assembly of methoxy poly(ethylene oxide)-block-poly(α-benzyl carboxylate-ε-caprolactone) for the solubilization and in vivo delivery of valspodar. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22283648/),nM,23,11775,DB00091,Cyclosporine
,22283648,solubility,Valspodar achieved high loading in all the three PEO-b-PBCL nanocarriers reaching aqueous solubility of nearly 2 mg/mL.,Characterization of the self assembly of methoxy poly(ethylene oxide)-block-poly(α-benzyl carboxylate-ε-caprolactone) for the solubilization and in vivo delivery of valspodar. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22283648/),[mg] / [ml],2,11776,DB00091,Cyclosporine
,14762854,C-0,"With C-0 between 90 and 150 ng/mL we collected 24-hour urine, while blood samples were taken at t = 0, 1, 2, 3, 4, 6, and 8 hours after dosing to measure cyclosporine, creatinine, liver tests, and blood pressure and calculated AUC and CrCl.",Switching monitoring of emulsified cyclosporine from trough level to 2-hour level in stable liver transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14762854/),[ng] / [ml],90 and 150,11993,DB00091,Cyclosporine
,14762854,C-2,"Then the dose was adjusted to two subsequent C-2 values of 600 ng/mL +/- 15%, the above was repeated, and the differences were assessed.",Switching monitoring of emulsified cyclosporine from trough level to 2-hour level in stable liver transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14762854/),[ng] / [ml],600,11994,DB00091,Cyclosporine
,9521566,Total imprecision,Total imprecision was 11.1% at 10 microg/l and 2.8% at 800 microg/l.,Microscale high-performance liquid chromatography-electrospray tandem mass spectrometry assay for cyclosporin A in blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9521566/),%,11.1,12119,DB00091,Cyclosporine
,9521566,Total imprecision,Total imprecision was 11.1% at 10 microg/l and 2.8% at 800 microg/l.,Microscale high-performance liquid chromatography-electrospray tandem mass spectrometry assay for cyclosporin A in blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9521566/),%,2.8,12120,DB00091,Cyclosporine
,9521566,Absolute recovery,"Absolute recovery of cyclosporin A and internal standard was 72.5 and 73.3%, respectively.",Microscale high-performance liquid chromatography-electrospray tandem mass spectrometry assay for cyclosporin A in blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9521566/),%,72.5,12121,DB00091,Cyclosporine
,9521566,Absolute recovery,"Absolute recovery of cyclosporin A and internal standard was 72.5 and 73.3%, respectively.",Microscale high-performance liquid chromatography-electrospray tandem mass spectrometry assay for cyclosporin A in blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9521566/),%,73.3,12122,DB00091,Cyclosporine
,18708992,peak concentration,"Switching to TRL had minimal impact on peak concentration of MPA (15.0 +/- 6.9 mg/L with CsA versus 16.1 +/- 9.7 mg/L with TRL, P = 0.773) and time to reach the peak concentration (1.0 +/- 0.4 hours with CsA versus 1.2 +/- 0.8 hours with TRL, P = 0.461).",Impact of changing from cyclosporine to tacrolimus on pharmacokinetics of mycophenolic acid in renal transplant recipients with diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18708992/),[mg] / [l],15.0,12414,DB00091,Cyclosporine
,18708992,peak concentration,"Switching to TRL had minimal impact on peak concentration of MPA (15.0 +/- 6.9 mg/L with CsA versus 16.1 +/- 9.7 mg/L with TRL, P = 0.773) and time to reach the peak concentration (1.0 +/- 0.4 hours with CsA versus 1.2 +/- 0.8 hours with TRL, P = 0.461).",Impact of changing from cyclosporine to tacrolimus on pharmacokinetics of mycophenolic acid in renal transplant recipients with diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18708992/),[mg] / [l],16.1,12415,DB00091,Cyclosporine
,18708992,time to reach the peak concentration,"Switching to TRL had minimal impact on peak concentration of MPA (15.0 +/- 6.9 mg/L with CsA versus 16.1 +/- 9.7 mg/L with TRL, P = 0.773) and time to reach the peak concentration (1.0 +/- 0.4 hours with CsA versus 1.2 +/- 0.8 hours with TRL, P = 0.461).",Impact of changing from cyclosporine to tacrolimus on pharmacokinetics of mycophenolic acid in renal transplant recipients with diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18708992/),h,1.0,12416,DB00091,Cyclosporine
,18708992,time to reach the peak concentration,"Switching to TRL had minimal impact on peak concentration of MPA (15.0 +/- 6.9 mg/L with CsA versus 16.1 +/- 9.7 mg/L with TRL, P = 0.773) and time to reach the peak concentration (1.0 +/- 0.4 hours with CsA versus 1.2 +/- 0.8 hours with TRL, P = 0.461).",Impact of changing from cyclosporine to tacrolimus on pharmacokinetics of mycophenolic acid in renal transplant recipients with diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18708992/),h,1.2,12417,DB00091,Cyclosporine
,19591121,flow-rate,The analysis was performed on a C(8) column 3.5 microm (2.1 x 50 mm) heated to 60 degrees C with a mobile phase consisting of acetonitrile:methanol:0.2% NH(4)OH (60:20:20) at an isocratic flow-rate of 0.2 mL/min.,An analytical method for cyclosporine using liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19591121/),[ml] / [min],0.2,12523,DB00091,Cyclosporine
,19591121,m/,"The ions used for quantitation of CyA and IS were m/z 1202.8 and 645.9, with retention times of 3.35 and 4.72 min, respectively.",An analytical method for cyclosporine using liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19591121/),,1202.8,12524,DB00091,Cyclosporine
,19591121,m/,"The ions used for quantitation of CyA and IS were m/z 1202.8 and 645.9, with retention times of 3.35 and 4.72 min, respectively.",An analytical method for cyclosporine using liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19591121/),,645.9,12525,DB00091,Cyclosporine
,19591121,retention times,"The ions used for quantitation of CyA and IS were m/z 1202.8 and 645.9, with retention times of 3.35 and 4.72 min, respectively.",An analytical method for cyclosporine using liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19591121/),min,3.35,12526,DB00091,Cyclosporine
,19591121,retention times,"The ions used for quantitation of CyA and IS were m/z 1202.8 and 645.9, with retention times of 3.35 and 4.72 min, respectively.",An analytical method for cyclosporine using liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19591121/),min,4.72,12527,DB00091,Cyclosporine
,7903372,clearance,"Whole blood concentrations of cyclosporin A were measured by HPLC and mean clearance (0.45 +/- 0.05 L h-1 kg-1), distribution volume (4.4 +/- 2.0 L kg-1), mean residence time (9.6 +/- 4.1 h) and half-life (12.1 +/- 3.1 h) were calculated cyclosporin A was excreted in urine or bile.",Pharmacokinetics and absolute bioavailability of cyclosporin following intravenous and abomasal administration to sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7903372/),[l] / [h·kg],0.45,12827,DB00091,Cyclosporine
,7903372,distribution volume,"Whole blood concentrations of cyclosporin A were measured by HPLC and mean clearance (0.45 +/- 0.05 L h-1 kg-1), distribution volume (4.4 +/- 2.0 L kg-1), mean residence time (9.6 +/- 4.1 h) and half-life (12.1 +/- 3.1 h) were calculated cyclosporin A was excreted in urine or bile.",Pharmacokinetics and absolute bioavailability of cyclosporin following intravenous and abomasal administration to sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7903372/),[l] / [kg],4.4,12828,DB00091,Cyclosporine
,7903372,mean residence time,"Whole blood concentrations of cyclosporin A were measured by HPLC and mean clearance (0.45 +/- 0.05 L h-1 kg-1), distribution volume (4.4 +/- 2.0 L kg-1), mean residence time (9.6 +/- 4.1 h) and half-life (12.1 +/- 3.1 h) were calculated cyclosporin A was excreted in urine or bile.",Pharmacokinetics and absolute bioavailability of cyclosporin following intravenous and abomasal administration to sheep. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7903372/),h,9.6,12829,DB00091,Cyclosporine
,7903372,half-life,"Whole blood concentrations of cyclosporin A were measured by HPLC and mean clearance (0.45 +/- 0.05 L h-1 kg-1), distribution volume (4.4 +/- 2.0 L kg-1), mean residence time (9.6 +/- 4.1 h) and half-life (12.1 +/- 3.1 h) were calculated cyclosporin A was excreted in urine or bile.",Pharmacokinetics and absolute bioavailability of cyclosporin following intravenous and abomasal administration to sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7903372/),h,12.1,12830,DB00091,Cyclosporine
,7903372,Abomasal bioavailability,"Abomasal bioavailability at 6.4 mg kg-1 was 0.26 +/- 0.09, and mean absorption time was 4.7 +/- 11.1 h.",Pharmacokinetics and absolute bioavailability of cyclosporin following intravenous and abomasal administration to sheep. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7903372/),,0.26,12831,DB00091,Cyclosporine
,7903372,mean absorption time,"Abomasal bioavailability at 6.4 mg kg-1 was 0.26 +/- 0.09, and mean absorption time was 4.7 +/- 11.1 h.",Pharmacokinetics and absolute bioavailability of cyclosporin following intravenous and abomasal administration to sheep. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7903372/),h,4.7,12832,DB00091,Cyclosporine
,12235265,C(max),Sirolimus C(max) (6.6 +/- 1.6 versus 26 +/- 7 ng/ml) and area under the concentration versus time curve from 0 to 6 h (AUC(0-6)) (22 +/- 7 versus 105 +/- 27 ng.,Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235265/),[ng] / [ml],6.6,12867,DB00091,Cyclosporine
,12235265,C(max),Sirolimus C(max) (6.6 +/- 1.6 versus 26 +/- 7 ng/ml) and area under the concentration versus time curve from 0 to 6 h (AUC(0-6)) (22 +/- 7 versus 105 +/- 27 ng.,Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235265/),[ng] / [ml],26,12868,DB00091,Cyclosporine
,12235265,area under the concentration versus time curve from 0 to 6 h (AUC(0-6)),Sirolimus C(max) (6.6 +/- 1.6 versus 26 +/- 7 ng/ml) and area under the concentration versus time curve from 0 to 6 h (AUC(0-6)) (22 +/- 7 versus 105 +/- 27 ng.,Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235265/),ng,22,12869,DB00091,Cyclosporine
,12235265,area under the concentration versus time curve from 0 to 6 h (AUC(0-6)),Sirolimus C(max) (6.6 +/- 1.6 versus 26 +/- 7 ng/ml) and area under the concentration versus time curve from 0 to 6 h (AUC(0-6)) (22 +/- 7 versus 105 +/- 27 ng.,Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235265/),ng,105,12870,DB00091,Cyclosporine
,12235265,T(max),Median T(max) (1.5-2 h) was unchanged.,Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235265/),h,1.5-2,12871,DB00091,Cyclosporine
,12235265,IC(50),"Consistent with published reports, sirolimus was a good inhibitor of P-glycoprotein, inhibiting polarized basolateral-to-apical flux of rhodamine 123 with an IC(50) of 0.625 to 1.25 microM (cyclosporine caused >80% inhibition at 5 microM).",Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12235265/),μM,0.625 to 1.25,12872,DB00091,Cyclosporine
,15917949,FTY720,"Mean FTY720 concentrations were 0.36 +/- 0.05 (0.25 mg), 0.73 +/- 0.12 (0.5 mg), 3.26 +/- 0.51 (1 mg), and 7.15 +/- 1.41 ng/ml (2.5 mg) between 4 and 12 weeks after transplantation.",Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917949/),[ng] / [ml],0.36,12974,DB00091,Cyclosporine
,15917949,FTY720,"Mean FTY720 concentrations were 0.36 +/- 0.05 (0.25 mg), 0.73 +/- 0.12 (0.5 mg), 3.26 +/- 0.51 (1 mg), and 7.15 +/- 1.41 ng/ml (2.5 mg) between 4 and 12 weeks after transplantation.",Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917949/),[ng] / [ml],0.73,12975,DB00091,Cyclosporine
,15917949,FTY720,"Mean FTY720 concentrations were 0.36 +/- 0.05 (0.25 mg), 0.73 +/- 0.12 (0.5 mg), 3.26 +/- 0.51 (1 mg), and 7.15 +/- 1.41 ng/ml (2.5 mg) between 4 and 12 weeks after transplantation.",Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917949/),[ng] / [ml],3.26,12976,DB00091,Cyclosporine
,15917949,FTY720,"Mean FTY720 concentrations were 0.36 +/- 0.05 (0.25 mg), 0.73 +/- 0.12 (0.5 mg), 3.26 +/- 0.51 (1 mg), and 7.15 +/- 1.41 ng/ml (2.5 mg) between 4 and 12 weeks after transplantation.",Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917949/),[ng] / [ml],7.15,12977,DB00091,Cyclosporine
,15917949,concentrations,"Mean FTY720 concentrations were 0.36 +/- 0.05 (0.25 mg), 0.73 +/- 0.12 (0.5 mg), 3.26 +/- 0.51 (1 mg), and 7.15 +/- 1.41 ng/ml (2.5 mg) between 4 and 12 weeks after transplantation.",Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917949/),[ng] / [ml],0.36,12978,DB00091,Cyclosporine
,15917949,concentrations,"Mean FTY720 concentrations were 0.36 +/- 0.05 (0.25 mg), 0.73 +/- 0.12 (0.5 mg), 3.26 +/- 0.51 (1 mg), and 7.15 +/- 1.41 ng/ml (2.5 mg) between 4 and 12 weeks after transplantation.",Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917949/),[ng] / [ml],0.73,12979,DB00091,Cyclosporine
,15917949,concentrations,"Mean FTY720 concentrations were 0.36 +/- 0.05 (0.25 mg), 0.73 +/- 0.12 (0.5 mg), 3.26 +/- 0.51 (1 mg), and 7.15 +/- 1.41 ng/ml (2.5 mg) between 4 and 12 weeks after transplantation.",Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917949/),[ng] / [ml],3.26,12980,DB00091,Cyclosporine
,15917949,concentrations,"Mean FTY720 concentrations were 0.36 +/- 0.05 (0.25 mg), 0.73 +/- 0.12 (0.5 mg), 3.26 +/- 0.51 (1 mg), and 7.15 +/- 1.41 ng/ml (2.5 mg) between 4 and 12 weeks after transplantation.",Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917949/),[ng] / [ml],7.15,12981,DB00091,Cyclosporine
,15917949,Emax,"The simple Emax model [E = (Emax * C)/(C + EC50)] was the best-fit PK/PD modeling for FTY720 dose (Emax = 87.8 +/- 5.3% and ED50 = 0.48 +/- 0.08 mg, r(2) = 0.94) or concentration (Emax = 78.3 +/- 2.9% and EC50 = 0.59 +/- 0.09 ng/ml, r(2) = 0.89) vs effect (% reduction in peripheral lymphocytes).",Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917949/),%,87.8,12982,DB00091,Cyclosporine
,15917949,ED50,"The simple Emax model [E = (Emax * C)/(C + EC50)] was the best-fit PK/PD modeling for FTY720 dose (Emax = 87.8 +/- 5.3% and ED50 = 0.48 +/- 0.08 mg, r(2) = 0.94) or concentration (Emax = 78.3 +/- 2.9% and EC50 = 0.59 +/- 0.09 ng/ml, r(2) = 0.89) vs effect (% reduction in peripheral lymphocytes).",Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917949/),mg,0.48,12983,DB00091,Cyclosporine
,15917949,Emax,"The simple Emax model [E = (Emax * C)/(C + EC50)] was the best-fit PK/PD modeling for FTY720 dose (Emax = 87.8 +/- 5.3% and ED50 = 0.48 +/- 0.08 mg, r(2) = 0.94) or concentration (Emax = 78.3 +/- 2.9% and EC50 = 0.59 +/- 0.09 ng/ml, r(2) = 0.89) vs effect (% reduction in peripheral lymphocytes).",Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917949/),%,78.3,12984,DB00091,Cyclosporine
,15917949,EC50,"The simple Emax model [E = (Emax * C)/(C + EC50)] was the best-fit PK/PD modeling for FTY720 dose (Emax = 87.8 +/- 5.3% and ED50 = 0.48 +/- 0.08 mg, r(2) = 0.94) or concentration (Emax = 78.3 +/- 2.9% and EC50 = 0.59 +/- 0.09 ng/ml, r(2) = 0.89) vs effect (% reduction in peripheral lymphocytes).",Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917949/),[ng] / [ml],0.59,12985,DB00091,Cyclosporine
,15917949,EC50,FTY720 PK/PD is dose dependent and follows an Emax model (EC50 = 0.5 mg or 0.6 ng/ml).,Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917949/),mg,0.5,12986,DB00091,Cyclosporine
,15917949,EC50,FTY720 PK/PD is dose dependent and follows an Emax model (EC50 = 0.5 mg or 0.6 ng/ml).,Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917949/),[ng] / [ml],0.6,12987,DB00091,Cyclosporine
,3547879,maximum blood concentration,"Coadministration of cyclosporine with metoclopramide resulted in a significant increase in mean maximum blood concentration (567 ng/mL nu 388 ng/mL) and mean area under the blood concentration nu time curve (4120 ng X h/mL nu 3370 ng X h/mL), and a significant decrease in mean time to reach maximum concentration: The mean increase in area under the blood concentration versus time curve was 29%.",The effect of oral metoclopramide on the absorption of cyclosporine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3547879/),[ng] / [ml],567,12990,DB00091,Cyclosporine
,3547879,area under the blood concentration nu time curve,"Coadministration of cyclosporine with metoclopramide resulted in a significant increase in mean maximum blood concentration (567 ng/mL nu 388 ng/mL) and mean area under the blood concentration nu time curve (4120 ng X h/mL nu 3370 ng X h/mL), and a significant decrease in mean time to reach maximum concentration: The mean increase in area under the blood concentration versus time curve was 29%.",The effect of oral metoclopramide on the absorption of cyclosporine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3547879/),[h·ng] / [ml],4120,12991,DB00091,Cyclosporine
,8603456,AUC,"High-dose Cremophor increased the AUC (from 334 +/- 23 to 1540 +/- 490 microgram min ml(-1), P<0.05) and decreased the total clearance (from 4.8 +/- 0.3 to 1.1 +/- 0.3 ml/min, P<0.05) and biliary clearance (from 2.6 +/- 1.1 to 0.5 +/- 0.2 ml/min, p<0.05) but decreased the elimination half-life (from 62 +/- 17 to 40 +/- 5 min, P<0.05) and volume of distribution (from 424 +/- 85 to 65 +/- 19 ml, P<0.05).",Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603456/),[min·μg] / [ml],334,13160,DB00091,Cyclosporine
,8603456,AUC,"High-dose Cremophor increased the AUC (from 334 +/- 23 to 1540 +/- 490 microgram min ml(-1), P<0.05) and decreased the total clearance (from 4.8 +/- 0.3 to 1.1 +/- 0.3 ml/min, P<0.05) and biliary clearance (from 2.6 +/- 1.1 to 0.5 +/- 0.2 ml/min, p<0.05) but decreased the elimination half-life (from 62 +/- 17 to 40 +/- 5 min, P<0.05) and volume of distribution (from 424 +/- 85 to 65 +/- 19 ml, P<0.05).",Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603456/),[min·μg] / [ml],1540,13161,DB00091,Cyclosporine
,8603456,total clearance,"High-dose Cremophor increased the AUC (from 334 +/- 23 to 1540 +/- 490 microgram min ml(-1), P<0.05) and decreased the total clearance (from 4.8 +/- 0.3 to 1.1 +/- 0.3 ml/min, P<0.05) and biliary clearance (from 2.6 +/- 1.1 to 0.5 +/- 0.2 ml/min, p<0.05) but decreased the elimination half-life (from 62 +/- 17 to 40 +/- 5 min, P<0.05) and volume of distribution (from 424 +/- 85 to 65 +/- 19 ml, P<0.05).",Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603456/),[ml] / [min],4.8,13162,DB00091,Cyclosporine
,8603456,total clearance,"High-dose Cremophor increased the AUC (from 334 +/- 23 to 1540 +/- 490 microgram min ml(-1), P<0.05) and decreased the total clearance (from 4.8 +/- 0.3 to 1.1 +/- 0.3 ml/min, P<0.05) and biliary clearance (from 2.6 +/- 1.1 to 0.5 +/- 0.2 ml/min, p<0.05) but decreased the elimination half-life (from 62 +/- 17 to 40 +/- 5 min, P<0.05) and volume of distribution (from 424 +/- 85 to 65 +/- 19 ml, P<0.05).",Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603456/),[ml] / [min],1.1,13163,DB00091,Cyclosporine
,8603456,biliary clearance,"High-dose Cremophor increased the AUC (from 334 +/- 23 to 1540 +/- 490 microgram min ml(-1), P<0.05) and decreased the total clearance (from 4.8 +/- 0.3 to 1.1 +/- 0.3 ml/min, P<0.05) and biliary clearance (from 2.6 +/- 1.1 to 0.5 +/- 0.2 ml/min, p<0.05) but decreased the elimination half-life (from 62 +/- 17 to 40 +/- 5 min, P<0.05) and volume of distribution (from 424 +/- 85 to 65 +/- 19 ml, P<0.05).",Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603456/),[ml] / [min],2.6,13164,DB00091,Cyclosporine
,8603456,biliary clearance,"High-dose Cremophor increased the AUC (from 334 +/- 23 to 1540 +/- 490 microgram min ml(-1), P<0.05) and decreased the total clearance (from 4.8 +/- 0.3 to 1.1 +/- 0.3 ml/min, P<0.05) and biliary clearance (from 2.6 +/- 1.1 to 0.5 +/- 0.2 ml/min, p<0.05) but decreased the elimination half-life (from 62 +/- 17 to 40 +/- 5 min, P<0.05) and volume of distribution (from 424 +/- 85 to 65 +/- 19 ml, P<0.05).",Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603456/),[ml] / [min],0.5,13165,DB00091,Cyclosporine
,8603456,elimination half-life,"High-dose Cremophor increased the AUC (from 334 +/- 23 to 1540 +/- 490 microgram min ml(-1), P<0.05) and decreased the total clearance (from 4.8 +/- 0.3 to 1.1 +/- 0.3 ml/min, P<0.05) and biliary clearance (from 2.6 +/- 1.1 to 0.5 +/- 0.2 ml/min, p<0.05) but decreased the elimination half-life (from 62 +/- 17 to 40 +/- 5 min, P<0.05) and volume of distribution (from 424 +/- 85 to 65 +/- 19 ml, P<0.05).",Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603456/),min,62,13166,DB00091,Cyclosporine
,8603456,elimination half-life,"High-dose Cremophor increased the AUC (from 334 +/- 23 to 1540 +/- 490 microgram min ml(-1), P<0.05) and decreased the total clearance (from 4.8 +/- 0.3 to 1.1 +/- 0.3 ml/min, P<0.05) and biliary clearance (from 2.6 +/- 1.1 to 0.5 +/- 0.2 ml/min, p<0.05) but decreased the elimination half-life (from 62 +/- 17 to 40 +/- 5 min, P<0.05) and volume of distribution (from 424 +/- 85 to 65 +/- 19 ml, P<0.05).",Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603456/),min,40,13167,DB00091,Cyclosporine
,8603456,volume of distribution,"High-dose Cremophor increased the AUC (from 334 +/- 23 to 1540 +/- 490 microgram min ml(-1), P<0.05) and decreased the total clearance (from 4.8 +/- 0.3 to 1.1 +/- 0.3 ml/min, P<0.05) and biliary clearance (from 2.6 +/- 1.1 to 0.5 +/- 0.2 ml/min, p<0.05) but decreased the elimination half-life (from 62 +/- 17 to 40 +/- 5 min, P<0.05) and volume of distribution (from 424 +/- 85 to 65 +/- 19 ml, P<0.05).",Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603456/),ml,424,13168,DB00091,Cyclosporine
,8603456,volume of distribution,"High-dose Cremophor increased the AUC (from 334 +/- 23 to 1540 +/- 490 microgram min ml(-1), P<0.05) and decreased the total clearance (from 4.8 +/- 0.3 to 1.1 +/- 0.3 ml/min, P<0.05) and biliary clearance (from 2.6 +/- 1.1 to 0.5 +/- 0.2 ml/min, p<0.05) but decreased the elimination half-life (from 62 +/- 17 to 40 +/- 5 min, P<0.05) and volume of distribution (from 424 +/- 85 to 65 +/- 19 ml, P<0.05).",Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8603456/),ml,65,13169,DB00091,Cyclosporine
,3950868,clearance,"In the presence of ketoconazole, cyclosporine clearance decreased from 15.4 to 7.6 ml/hr; terminal half-life increased from 4.1 to 11.2 hr; and steady-state volume of distribution did not change significantly.",Ketoconazole inhibits cyclosporine metabolism in vivo in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950868/),[ml] / [h],15.4 to 7.6,13193,DB00091,Cyclosporine
,3950868,terminal half-life,"In the presence of ketoconazole, cyclosporine clearance decreased from 15.4 to 7.6 ml/hr; terminal half-life increased from 4.1 to 11.2 hr; and steady-state volume of distribution did not change significantly.",Ketoconazole inhibits cyclosporine metabolism in vivo in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3950868/),h,4.1 to 11.2,13194,DB00091,Cyclosporine
,9043030,nadir,"The nadir neutrophil count after VM26 plus CSA (median 700 microl(-1), range <100 to 2860 microl(-1)) was lower than after VM26 alone (median 1900 microl(-1), range 200 to 6000 microl(-1)).",Cyclosporin A as a multidrug-resistant modulator in patients with renal cell carcinoma treated with teniposide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9043030/),1/[μl],700,13274,DB00091,Cyclosporine
,9043030,neutrophil count,"The nadir neutrophil count after VM26 plus CSA (median 700 microl(-1), range <100 to 2860 microl(-1)) was lower than after VM26 alone (median 1900 microl(-1), range 200 to 6000 microl(-1)).",Cyclosporin A as a multidrug-resistant modulator in patients with renal cell carcinoma treated with teniposide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9043030/),1/[μl],700,13275,DB00091,Cyclosporine
,9043030,neutrophil count,"The nadir neutrophil count after VM26 plus CSA (median 700 microl(-1), range <100 to 2860 microl(-1)) was lower than after VM26 alone (median 1900 microl(-1), range 200 to 6000 microl(-1)).",Cyclosporin A as a multidrug-resistant modulator in patients with renal cell carcinoma treated with teniposide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9043030/),1/[μl],1900,13276,DB00091,Cyclosporine
> or =,15659129,Cmax,A Cmax> or =10 microg/mL was seen in 20 (57%) of the patients.,The need of mycophenolic acid monitoring in long-term renal transplants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15659129/),[μg] / [ml],10,14142,DB00091,Cyclosporine
,2611359,Bioavailability,Bioavailability of cyclosporine was observed to be 20.8 +/- 5.5 per cent.,Absorption kinetics of cyclosporine in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611359/),%,20.8,14408,DB00091,Cyclosporine
,31040639,Cmax,"Blood sample analysis indicated limited systemic exposure to CsA; three subjects had a CsA concentration greater than or equal to the lower limit of quantitation (LLOQ) on day 1; only four subjects had three consecutive CsA concentration measurements ≥LLOQ on day 8; the mean±SD for Cmax was 0.17±0.02 ng/mL, Tmax was 1.5±0.58 hours, and AUC(0-t) was 0.53±0.06 h·ng/mL.","A phase 1, open-label, single-arm study evaluating the ocular safety of OTX-101 and systemic absorption of cyclosporine in healthy human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31040639/),[ng] / [ml],0.17,14460,DB00091,Cyclosporine
,31040639,Tmax,"Blood sample analysis indicated limited systemic exposure to CsA; three subjects had a CsA concentration greater than or equal to the lower limit of quantitation (LLOQ) on day 1; only four subjects had three consecutive CsA concentration measurements ≥LLOQ on day 8; the mean±SD for Cmax was 0.17±0.02 ng/mL, Tmax was 1.5±0.58 hours, and AUC(0-t) was 0.53±0.06 h·ng/mL.","A phase 1, open-label, single-arm study evaluating the ocular safety of OTX-101 and systemic absorption of cyclosporine in healthy human volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31040639/),h,1.5,14461,DB00091,Cyclosporine
,31040639,AUC(0-t),"Blood sample analysis indicated limited systemic exposure to CsA; three subjects had a CsA concentration greater than or equal to the lower limit of quantitation (LLOQ) on day 1; only four subjects had three consecutive CsA concentration measurements ≥LLOQ on day 8; the mean±SD for Cmax was 0.17±0.02 ng/mL, Tmax was 1.5±0.58 hours, and AUC(0-t) was 0.53±0.06 h·ng/mL.","A phase 1, open-label, single-arm study evaluating the ocular safety of OTX-101 and systemic absorption of cyclosporine in healthy human volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31040639/),[h·ng] / [ml],0.53,14462,DB00091,Cyclosporine
>,19057979,peak concentration,"Only three of 10 patients with postprandial administration showed a peak concentration> 500 ng/ml within 1-2 h after administration, while with preprandial administration, nine of 10 patients showed this good absorption profiles.",Preprandial microemulsion cyclosporine administration is effective for patients with refractory nephrotic syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19057979/),[ng] / [ml],500,14841,DB00091,Cyclosporine
,17318074,area under the curve,MPA concentration-time profiles in 21 patients showed that MPA exposure was similar with MMF or EC-MPS (mean area under the curve 39.9+/-11.6 microg x h/mL versus 43.7+/-17.4 microg x h/mL at day 14 post-conversion).,"Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17318074/),[h·μg] / [ml],39.9,14993,DB00091,Cyclosporine
,17318074,area under the curve,MPA concentration-time profiles in 21 patients showed that MPA exposure was similar with MMF or EC-MPS (mean area under the curve 39.9+/-11.6 microg x h/mL versus 43.7+/-17.4 microg x h/mL at day 14 post-conversion).,"Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17318074/),[h·μg] / [ml],43.7,14994,DB00091,Cyclosporine
,17318074,time to peak concentration,Median time to peak concentration was 0.5 hr with MMF and 1.5 hr with EC-MPS.,"Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17318074/),h,0.5,14995,DB00091,Cyclosporine
,17318074,time to peak concentration,Median time to peak concentration was 0.5 hr with MMF and 1.5 hr with EC-MPS.,"Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17318074/),h,1.5,14996,DB00091,Cyclosporine
,17318074,area under the enzyme activity time curve (AEC),"Inosine monophosphate dehydrogenase (IMPDH) activity was almost identical: area under the enzyme activity time curve (AEC) was 124.2+/-32.0 nmol x h/mg prot/h with MMF and 130.3+/-36.6 nmol x h/mg prot/h with EC-MPS at 14 days post-conversion; average daytime IMPDH activity was 10.3+/-2.7 nmol/h/mg protein and 10.9+/-2.7 nmol/h/mg protein, respectively.","Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17318074/),[h·nM] / [h·mg·prot],124.2,14997,DB00091,Cyclosporine
,17318074,area under the enzyme activity time curve (AEC),"Inosine monophosphate dehydrogenase (IMPDH) activity was almost identical: area under the enzyme activity time curve (AEC) was 124.2+/-32.0 nmol x h/mg prot/h with MMF and 130.3+/-36.6 nmol x h/mg prot/h with EC-MPS at 14 days post-conversion; average daytime IMPDH activity was 10.3+/-2.7 nmol/h/mg protein and 10.9+/-2.7 nmol/h/mg protein, respectively.","Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17318074/),[h·nM] / [h·mg·prot],130.3,14998,DB00091,Cyclosporine
,17318074,activity,"Inosine monophosphate dehydrogenase (IMPDH) activity was almost identical: area under the enzyme activity time curve (AEC) was 124.2+/-32.0 nmol x h/mg prot/h with MMF and 130.3+/-36.6 nmol x h/mg prot/h with EC-MPS at 14 days post-conversion; average daytime IMPDH activity was 10.3+/-2.7 nmol/h/mg protein and 10.9+/-2.7 nmol/h/mg protein, respectively.","Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17318074/),[nM] / [h·mg],10.3,14999,DB00091,Cyclosporine
,17318074,activity,"Inosine monophosphate dehydrogenase (IMPDH) activity was almost identical: area under the enzyme activity time curve (AEC) was 124.2+/-32.0 nmol x h/mg prot/h with MMF and 130.3+/-36.6 nmol x h/mg prot/h with EC-MPS at 14 days post-conversion; average daytime IMPDH activity was 10.3+/-2.7 nmol/h/mg protein and 10.9+/-2.7 nmol/h/mg protein, respectively.","Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17318074/),[nM] / [h·mg],10.9,15000,DB00091,Cyclosporine
,21191769,area under the plasma concentration-time curve (AUC,"In contrast to previous in vitro results, in this study, we found that the HT-treated and control groups did not show any significant difference in the plasma PSP concentration and pharmacokinetic parameters, including area under the plasma concentration-time curve (AUC; control: 118 ± 19, single dose: 116 ± 40, and multiple dose: 137 ± 4, in mg/(min·mL)) and biliary clearance (control: 3.15 ± 0.69, single dose: 2.59 ± 1.11, and multiple dose: 2.53 ± 0.65, in mL/(min·kg)).",Absence of drug interaction between Hwang-Ryun-Hae-Dok-Tang and phenolsulfonphthalein. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21191769/),-1·mg,118,15310,DB00091,Cyclosporine
,21191769,area under the plasma concentration-time curve (AUC,"In contrast to previous in vitro results, in this study, we found that the HT-treated and control groups did not show any significant difference in the plasma PSP concentration and pharmacokinetic parameters, including area under the plasma concentration-time curve (AUC; control: 118 ± 19, single dose: 116 ± 40, and multiple dose: 137 ± 4, in mg/(min·mL)) and biliary clearance (control: 3.15 ± 0.69, single dose: 2.59 ± 1.11, and multiple dose: 2.53 ± 0.65, in mL/(min·kg)).",Absence of drug interaction between Hwang-Ryun-Hae-Dok-Tang and phenolsulfonphthalein. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21191769/),-1·mg,116,15311,DB00091,Cyclosporine
,21191769,area under the plasma concentration-time curve (AUC,"In contrast to previous in vitro results, in this study, we found that the HT-treated and control groups did not show any significant difference in the plasma PSP concentration and pharmacokinetic parameters, including area under the plasma concentration-time curve (AUC; control: 118 ± 19, single dose: 116 ± 40, and multiple dose: 137 ± 4, in mg/(min·mL)) and biliary clearance (control: 3.15 ± 0.69, single dose: 2.59 ± 1.11, and multiple dose: 2.53 ± 0.65, in mL/(min·kg)).",Absence of drug interaction between Hwang-Ryun-Hae-Dok-Tang and phenolsulfonphthalein. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21191769/),min·ml),137,15312,DB00091,Cyclosporine
,21191769,biliary clearance,"In contrast to previous in vitro results, in this study, we found that the HT-treated and control groups did not show any significant difference in the plasma PSP concentration and pharmacokinetic parameters, including area under the plasma concentration-time curve (AUC; control: 118 ± 19, single dose: 116 ± 40, and multiple dose: 137 ± 4, in mg/(min·mL)) and biliary clearance (control: 3.15 ± 0.69, single dose: 2.59 ± 1.11, and multiple dose: 2.53 ± 0.65, in mL/(min·kg)).",Absence of drug interaction between Hwang-Ryun-Hae-Dok-Tang and phenolsulfonphthalein. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21191769/),[ml] / [kg·min],3.15,15313,DB00091,Cyclosporine
,21191769,biliary clearance,"In contrast to previous in vitro results, in this study, we found that the HT-treated and control groups did not show any significant difference in the plasma PSP concentration and pharmacokinetic parameters, including area under the plasma concentration-time curve (AUC; control: 118 ± 19, single dose: 116 ± 40, and multiple dose: 137 ± 4, in mg/(min·mL)) and biliary clearance (control: 3.15 ± 0.69, single dose: 2.59 ± 1.11, and multiple dose: 2.53 ± 0.65, in mL/(min·kg)).",Absence of drug interaction between Hwang-Ryun-Hae-Dok-Tang and phenolsulfonphthalein. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21191769/),[ml] / [kg·min],2.59,15314,DB00091,Cyclosporine
,21191769,biliary clearance,"In contrast to previous in vitro results, in this study, we found that the HT-treated and control groups did not show any significant difference in the plasma PSP concentration and pharmacokinetic parameters, including area under the plasma concentration-time curve (AUC; control: 118 ± 19, single dose: 116 ± 40, and multiple dose: 137 ± 4, in mg/(min·mL)) and biliary clearance (control: 3.15 ± 0.69, single dose: 2.59 ± 1.11, and multiple dose: 2.53 ± 0.65, in mL/(min·kg)).",Absence of drug interaction between Hwang-Ryun-Hae-Dok-Tang and phenolsulfonphthalein. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21191769/),[ml] / [kg·min],2.53,15315,DB00091,Cyclosporine
outside,19817503,AUC(12),Fifty-two percent of the observed AUC(12) values (three periods) in the 40 patients receiving a fixed dose of mycophenolate mofetil 750 mg twice daily were outside the recommended therapeutic range (30-60 microg x h/mL).,Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19817503/),[h·μg] / [ml],30-60,15549,DB00091,Cyclosporine
,2376427,biological half-life (beta-phase),"The biological half-life (beta-phase) of roxithromycin in cyclosporin patients was 34.4 (+/- 12.25) h (mean +/- SD), in azathioprine patients 23.4 (+/- 8.18) h and in healthy volunteers 17.0 (+/- 3.8) h.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),h,34.4,16171,DB00091,Cyclosporine
,2376427,biological half-life (beta-phase),"The biological half-life (beta-phase) of roxithromycin in cyclosporin patients was 34.4 (+/- 12.25) h (mean +/- SD), in azathioprine patients 23.4 (+/- 8.18) h and in healthy volunteers 17.0 (+/- 3.8) h.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),h,23.4,16172,DB00091,Cyclosporine
,2376427,biological half-life (beta-phase),"The biological half-life (beta-phase) of roxithromycin in cyclosporin patients was 34.4 (+/- 12.25) h (mean +/- SD), in azathioprine patients 23.4 (+/- 8.18) h and in healthy volunteers 17.0 (+/- 3.8) h.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),h,17.0,16173,DB00091,Cyclosporine
,2376427,total elimination constant (k10),"The total elimination constant (k10) was 0.046 (+/- 0.014), 0.068 (+/- 0.019) and 0.084 (+/- 0.036) h, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),h,0.046,16174,DB00091,Cyclosporine
,2376427,total elimination constant (k10),"The total elimination constant (k10) was 0.046 (+/- 0.014), 0.068 (+/- 0.019) and 0.084 (+/- 0.036) h, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),h,0.068,16175,DB00091,Cyclosporine
,2376427,total elimination constant (k10),"The total elimination constant (k10) was 0.046 (+/- 0.014), 0.068 (+/- 0.019) and 0.084 (+/- 0.036) h, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),h,0.084,16176,DB00091,Cyclosporine
,2376427,total clearance,"The total clearance was 0.79 (+/- 0.21), 1.45 (+/- 0.66) and 1.84 (+/- 0.56) l/h, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),[l] / [h],0.79,16177,DB00091,Cyclosporine
,2376427,total clearance,"The total clearance was 0.79 (+/- 0.21), 1.45 (+/- 0.66) and 1.84 (+/- 0.56) l/h, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),[l] / [h],1.45,16178,DB00091,Cyclosporine
,2376427,total clearance,"The total clearance was 0.79 (+/- 0.21), 1.45 (+/- 0.66) and 1.84 (+/- 0.56) l/h, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),[l] / [h],1.84,16179,DB00091,Cyclosporine
,2376427,areas under the serum level curves,"The areas under the serum level curves were 407.6 (+/- 118.3), 251.0 (+/- 106.6) and 180.7 (+/- 73.2) mg.h/l, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),[h·mg] / [l],407.6,16180,DB00091,Cyclosporine
,2376427,areas under the serum level curves,"The areas under the serum level curves were 407.6 (+/- 118.3), 251.0 (+/- 106.6) and 180.7 (+/- 73.2) mg.h/l, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),[h·mg] / [l],251.0,16181,DB00091,Cyclosporine
,2376427,areas under the serum level curves,"The areas under the serum level curves were 407.6 (+/- 118.3), 251.0 (+/- 106.6) and 180.7 (+/- 73.2) mg.h/l, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),[h·mg] / [l],180.7,16182,DB00091,Cyclosporine
,17660840,C0,"Median (range) C0 and C2 were 254 (145-332) and 898 (419-1466) ng/ml in MUD patients, and 130 (93-265) and 554 (196-988) ng/ml in Sib patients.",Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17660840/),[ng] / [ml],254,16186,DB00091,Cyclosporine
,17660840,C0,"Median (range) C0 and C2 were 254 (145-332) and 898 (419-1466) ng/ml in MUD patients, and 130 (93-265) and 554 (196-988) ng/ml in Sib patients.",Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17660840/),[ng] / [ml],898,16187,DB00091,Cyclosporine
,17660840,C2,"Median (range) C0 and C2 were 254 (145-332) and 898 (419-1466) ng/ml in MUD patients, and 130 (93-265) and 554 (196-988) ng/ml in Sib patients.",Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17660840/),[ng] / [ml],898,16188,DB00091,Cyclosporine
,17660840,C2,"Median (range) C0 and C2 were 254 (145-332) and 898 (419-1466) ng/ml in MUD patients, and 130 (93-265) and 554 (196-988) ng/ml in Sib patients.",Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17660840/),[ng] / [ml],130,16189,DB00091,Cyclosporine
,17660840,C2,"Median (range) C0 and C2 were 254 (145-332) and 898 (419-1466) ng/ml in MUD patients, and 130 (93-265) and 554 (196-988) ng/ml in Sib patients.",Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17660840/),[ng] / [ml],554,16190,DB00091,Cyclosporine
,17660840,C2,"In MUD patients with either aGVHD grade < II or > or = II, the median C2 were 915 (419-1466) and 890 (519-1399) ng/ml, respectively.",Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17660840/),[ng] / [ml],915,16191,DB00091,Cyclosporine
,17660840,C2,"In MUD patients with either aGVHD grade < II or > or = II, the median C2 were 915 (419-1466) and 890 (519-1399) ng/ml, respectively.",Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17660840/),[ng] / [ml],890,16192,DB00091,Cyclosporine
,17660840,C2,"In Sib patients with aGVHD grade < II or grade > or = II, the median C2 were 552 (404-718) and 539 (196-988) ng/ml, respectively.",Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17660840/),[ng] / [ml],552,16193,DB00091,Cyclosporine
,17660840,C2,"In Sib patients with aGVHD grade < II or grade > or = II, the median C2 were 552 (404-718) and 539 (196-988) ng/ml, respectively.",Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17660840/),[ng] / [ml],539,16194,DB00091,Cyclosporine
,8680052,Cmax,"The Cmax and Tmax for mycophenolic acid (MPA) were 3.6-35.2 micrograms/mL and 0.5-4 h, respectively, and did not significantly change over 6 months.",Mycophenolate mofetil in liver transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8680052/),[μg] / [ml],3.6-35.2,16245,DB00091,Cyclosporine
,8680052,Tmax,"The Cmax and Tmax for mycophenolic acid (MPA) were 3.6-35.2 micrograms/mL and 0.5-4 h, respectively, and did not significantly change over 6 months.",Mycophenolate mofetil in liver transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8680052/),h,0.5-4,16246,DB00091,Cyclosporine
,9342502,oral bioavailability,Nefazodone undergoes significant first-pass metabolism resulting in an oral bioavailability of approximately 20%.,Clinical pharmacokinetics of nefazodone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342502/),%,20,16638,DB00091,Cyclosporine
,14529944,C(0) MPA level,C(0) MPA level among the tacrolimus group were significantly higher than those in CsA group: 3.18 +/- 2.21 microg/mL versus 1.68 +/- 1.03 microg/mL (P </=.001).,The influence of calcineurin inhibitors on mycophenolic acid pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14529944/),[μg] / [ml],3.18,17449,DB00091,Cyclosporine
,14529944,C(0) MPA level,C(0) MPA level among the tacrolimus group were significantly higher than those in CsA group: 3.18 +/- 2.21 microg/mL versus 1.68 +/- 1.03 microg/mL (P </=.001).,The influence of calcineurin inhibitors on mycophenolic acid pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14529944/),[μg] / [ml],1.68,17450,DB00091,Cyclosporine
,15813034,relative bioavailability,"Compared with the Neoral microemulsion, the relative bioavailability of CyA was 94.8%, 115.2%, 113.6% and 132.5% for CyA-E100, CyA-L100, CyA-L100-55 and CyA-S100 nanoparticles respectively.",[Preparation of cyclosporine A pH sensitive nanoparticles and oral pharmacokinetics in rats]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15813034/),%,94.8,17684,DB00091,Cyclosporine
,15813034,relative bioavailability,"Compared with the Neoral microemulsion, the relative bioavailability of CyA was 94.8%, 115.2%, 113.6% and 132.5% for CyA-E100, CyA-L100, CyA-L100-55 and CyA-S100 nanoparticles respectively.",[Preparation of cyclosporine A pH sensitive nanoparticles and oral pharmacokinetics in rats]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15813034/),%,115.2,17685,DB00091,Cyclosporine
,15813034,relative bioavailability,"Compared with the Neoral microemulsion, the relative bioavailability of CyA was 94.8%, 115.2%, 113.6% and 132.5% for CyA-E100, CyA-L100, CyA-L100-55 and CyA-S100 nanoparticles respectively.",[Preparation of cyclosporine A pH sensitive nanoparticles and oral pharmacokinetics in rats]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15813034/),%,113.6,17686,DB00091,Cyclosporine
,15813034,relative bioavailability,"Compared with the Neoral microemulsion, the relative bioavailability of CyA was 94.8%, 115.2%, 113.6% and 132.5% for CyA-E100, CyA-L100, CyA-L100-55 and CyA-S100 nanoparticles respectively.",[Preparation of cyclosporine A pH sensitive nanoparticles and oral pharmacokinetics in rats]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15813034/),%,132.5,17687,DB00091,Cyclosporine
,25590941,oral bioavailability,"Then the pharmacokinetics of PPI in rats was studied and the result revealed that PPI was slowly eliminated with low oral bioavailability (about 0.62%) at a dose of 50 mg/kg, and when co-administrated with verapamil (VPL) and cyclosporine A (CYA), the oral bioavailability of PPI could increase from 0.62% to 3.52% and 3.79% respectively.",Study on the pharmacokinetics profiles of polyphyllin I and its bioavailability enhancement through co-administration with P-glycoprotein inhibitors by LC-MS/MS method. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25590941/),%,0.62,18150,DB00091,Cyclosporine
,25590941,oral bioavailability,"Then the pharmacokinetics of PPI in rats was studied and the result revealed that PPI was slowly eliminated with low oral bioavailability (about 0.62%) at a dose of 50 mg/kg, and when co-administrated with verapamil (VPL) and cyclosporine A (CYA), the oral bioavailability of PPI could increase from 0.62% to 3.52% and 3.79% respectively.",Study on the pharmacokinetics profiles of polyphyllin I and its bioavailability enhancement through co-administration with P-glycoprotein inhibitors by LC-MS/MS method. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25590941/),%,3.52,18151,DB00091,Cyclosporine
,25590941,oral bioavailability,"Then the pharmacokinetics of PPI in rats was studied and the result revealed that PPI was slowly eliminated with low oral bioavailability (about 0.62%) at a dose of 50 mg/kg, and when co-administrated with verapamil (VPL) and cyclosporine A (CYA), the oral bioavailability of PPI could increase from 0.62% to 3.52% and 3.79% respectively.",Study on the pharmacokinetics profiles of polyphyllin I and its bioavailability enhancement through co-administration with P-glycoprotein inhibitors by LC-MS/MS method. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25590941/),%,3.79,18152,DB00091,Cyclosporine
,25590941,efflux ratio,"In addition, in vitro studies showed that with the presence of VPL and CYA in Caco-2 cells, the efflux ratio of PPI decreased from 12.5 to 2.96 and 2.22, and the intracellular concentrations increased 5.8- and 5.0-fold respectively.",Study on the pharmacokinetics profiles of polyphyllin I and its bioavailability enhancement through co-administration with P-glycoprotein inhibitors by LC-MS/MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25590941/),,12.5,18153,DB00091,Cyclosporine
,25590941,efflux ratio,"In addition, in vitro studies showed that with the presence of VPL and CYA in Caco-2 cells, the efflux ratio of PPI decreased from 12.5 to 2.96 and 2.22, and the intracellular concentrations increased 5.8- and 5.0-fold respectively.",Study on the pharmacokinetics profiles of polyphyllin I and its bioavailability enhancement through co-administration with P-glycoprotein inhibitors by LC-MS/MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25590941/),,2.96,18154,DB00091,Cyclosporine
,25590941,efflux ratio,"In addition, in vitro studies showed that with the presence of VPL and CYA in Caco-2 cells, the efflux ratio of PPI decreased from 12.5 to 2.96 and 2.22, and the intracellular concentrations increased 5.8- and 5.0-fold respectively.",Study on the pharmacokinetics profiles of polyphyllin I and its bioavailability enhancement through co-administration with P-glycoprotein inhibitors by LC-MS/MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25590941/),,2.22,18155,DB00091,Cyclosporine
,23179005,blood flow rate,"The calculated teriflunomide clearances during a standardized dialysis session of 3-4.5 h at a blood flow rate of 160-300 ml/min were between 0 and 4.3 ml/min, the mean clearances of the total dialysis ranged between 1.1 and 3.4 ml/min.",Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179005/),[ml] / [min],160-300,18219,DB00091,Cyclosporine
,23179005,blood flow rate,"The calculated teriflunomide clearances during a standardized dialysis session of 3-4.5 h at a blood flow rate of 160-300 ml/min were between 0 and 4.3 ml/min, the mean clearances of the total dialysis ranged between 1.1 and 3.4 ml/min.",Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179005/),[ml] / [min],0 and 4.3,18220,DB00091,Cyclosporine
,23179005,clearances,"The calculated teriflunomide clearances during a standardized dialysis session of 3-4.5 h at a blood flow rate of 160-300 ml/min were between 0 and 4.3 ml/min, the mean clearances of the total dialysis ranged between 1.1 and 3.4 ml/min.",Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179005/),[ml] / [min],1.1 and 3.4,18221,DB00091,Cyclosporine
,23179005,Total amount of teriflunomide removed,Total amount of teriflunomide removed was 5.8-8.8 μg per dialysis session.,Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23179005/),μg,5.8-8.8,18222,DB00091,Cyclosporine
,3538564,Serum trough levels,"Serum trough levels in the early post-renal transplant course were set at 175 to 200 ng/mL in spite of a standard drug administration regimen by selecting once- v twice-daily dosing intervals, in order to attempt to compensate for differences in drug clearance rates, which might determine trough values.",Relationship of cyclosporine pharmacokinetic parameters to clinical events in human renal transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3538564/),[ng] / [ml],175 to 200,18809,DB00091,Cyclosporine
,22913907,oral clearance,"Coadministration of cyclosporine increased colchicine maximum observed plasma concentration, area under the plasma concentration-time curve to the last measurable time point, and area under the plasma concentration-time curve to time infinity on average by 224%, 216%, and 215% (ie, almost doubled), respectively, and decreased colchicine oral clearance on average by 72% (from 48.24 to 13.42 L/h), indicating substantially higher colchicine exposures when combined with cyclosporine, compared with colchicine alone.",Effect of cyclosporine on the pharmacokinetics of colchicine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913907/),[l] / [h],48,18899,DB00091,Cyclosporine
,22913907,oral clearance,"Coadministration of cyclosporine increased colchicine maximum observed plasma concentration, area under the plasma concentration-time curve to the last measurable time point, and area under the plasma concentration-time curve to time infinity on average by 224%, 216%, and 215% (ie, almost doubled), respectively, and decreased colchicine oral clearance on average by 72% (from 48.24 to 13.42 L/h), indicating substantially higher colchicine exposures when combined with cyclosporine, compared with colchicine alone.",Effect of cyclosporine on the pharmacokinetics of colchicine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913907/),[l] / [h],13,18900,DB00091,Cyclosporine
,12403074,solubility,The solubility of cyclosporin A or tacrolimus in water dropped to 49% or 16% of the respective control in the presence of probucol.,Evaluation of pharmacokinetic interaction between cyclosporin A and probucol in rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12403074/),%,49,18942,DB00091,Cyclosporine
,12403074,solubility,The solubility of cyclosporin A or tacrolimus in water dropped to 49% or 16% of the respective control in the presence of probucol.,Evaluation of pharmacokinetic interaction between cyclosporin A and probucol in rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12403074/),%,16,18943,DB00091,Cyclosporine
,3203704,half-times,"Steady-state was reached within 18 h of starting the i.v. infusion; the plasma data were best fitted by a biexponential equation with half-times of 0.13-1.02 h and 4.3-13.9 h, associated with the two phases.",Cyclosporin: pharmacokinetics and detailed studies of plasma and erythrocyte binding during intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203704/),h,0.13-1.02,19252,DB00091,Cyclosporine
,3203704,half-times,"Steady-state was reached within 18 h of starting the i.v. infusion; the plasma data were best fitted by a biexponential equation with half-times of 0.13-1.02 h and 4.3-13.9 h, associated with the two phases.",Cyclosporin: pharmacokinetics and detailed studies of plasma and erythrocyte binding during intravenous and oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203704/),h,4.3-13.9,19253,DB00091,Cyclosporine
,3203704,plasma clearance,The mean plasma clearance was 700 ml/min.,Cyclosporin: pharmacokinetics and detailed studies of plasma and erythrocyte binding during intravenous and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203704/),[ml] / [min],700,19254,DB00091,Cyclosporine
,3203704,peak plasma concentrations,"The peak plasma concentrations were 1460-1880 micrograms.l-1 and occurred 2-4 h after dosing, with bioavailability estimates of 41-113%.",Cyclosporin: pharmacokinetics and detailed studies of plasma and erythrocyte binding during intravenous and oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203704/),[μg] / [l],1460-1880,19255,DB00091,Cyclosporine
,3203704,bioavailability,"The peak plasma concentrations were 1460-1880 micrograms.l-1 and occurred 2-4 h after dosing, with bioavailability estimates of 41-113%.",Cyclosporin: pharmacokinetics and detailed studies of plasma and erythrocyte binding during intravenous and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203704/),%,41-113,19256,DB00091,Cyclosporine
,3203704,Fraction unbound,"Fraction unbound, measured by ultra-centrifugation, was in the range 0.042-0.122 with an average of 0.068, and varied little in some patients but showed systematic changes with time in others.",Cyclosporin: pharmacokinetics and detailed studies of plasma and erythrocyte binding during intravenous and oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203704/),,0.042-0.122,19257,DB00091,Cyclosporine
,3203704,Fraction unbound,"Fraction unbound, measured by ultra-centrifugation, was in the range 0.042-0.122 with an average of 0.068, and varied little in some patients but showed systematic changes with time in others.",Cyclosporin: pharmacokinetics and detailed studies of plasma and erythrocyte binding during intravenous and oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3203704/),,0.068,19258,DB00091,Cyclosporine
,22427552,AUC,"The evaluation of the tear fluid gave similar CyA kinetics values: AUC = 2339 ± 1032 min*μg/mL and 2321 ± 881.63; Cmax = 478 ± 111 μg/mL and 451 ± 74; half-life = 36 ± 9 min and 28 ± 9 for the micelle formulation and Restasis, respectively.",A novel cyclosporin a aqueous formulation for dry eye treatment: in vitro and in vivo evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22427552/),[min·μg] / [ml],2339,19374,DB00091,Cyclosporine
,22427552,AUC,"The evaluation of the tear fluid gave similar CyA kinetics values: AUC = 2339 ± 1032 min*μg/mL and 2321 ± 881.63; Cmax = 478 ± 111 μg/mL and 451 ± 74; half-life = 36 ± 9 min and 28 ± 9 for the micelle formulation and Restasis, respectively.",A novel cyclosporin a aqueous formulation for dry eye treatment: in vitro and in vivo evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22427552/),[min·μg] / [ml],2321,19375,DB00091,Cyclosporine
,22427552,Cmax,"The evaluation of the tear fluid gave similar CyA kinetics values: AUC = 2339 ± 1032 min*μg/mL and 2321 ± 881.63; Cmax = 478 ± 111 μg/mL and 451 ± 74; half-life = 36 ± 9 min and 28 ± 9 for the micelle formulation and Restasis, respectively.",A novel cyclosporin a aqueous formulation for dry eye treatment: in vitro and in vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22427552/),[μg] / [ml],478,19376,DB00091,Cyclosporine
,22427552,Cmax,"The evaluation of the tear fluid gave similar CyA kinetics values: AUC = 2339 ± 1032 min*μg/mL and 2321 ± 881.63; Cmax = 478 ± 111 μg/mL and 451 ± 74; half-life = 36 ± 9 min and 28 ± 9 for the micelle formulation and Restasis, respectively.",A novel cyclosporin a aqueous formulation for dry eye treatment: in vitro and in vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22427552/),,451,19377,DB00091,Cyclosporine
,22427552,half-life,"The evaluation of the tear fluid gave similar CyA kinetics values: AUC = 2339 ± 1032 min*μg/mL and 2321 ± 881.63; Cmax = 478 ± 111 μg/mL and 451 ± 74; half-life = 36 ± 9 min and 28 ± 9 for the micelle formulation and Restasis, respectively.",A novel cyclosporin a aqueous formulation for dry eye treatment: in vitro and in vivo evaluation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22427552/),min,36,19378,DB00091,Cyclosporine
,22427552,half-life,"The evaluation of the tear fluid gave similar CyA kinetics values: AUC = 2339 ± 1032 min*μg/mL and 2321 ± 881.63; Cmax = 478 ± 111 μg/mL and 451 ± 74; half-life = 36 ± 9 min and 28 ± 9 for the micelle formulation and Restasis, respectively.",A novel cyclosporin a aqueous formulation for dry eye treatment: in vitro and in vivo evaluation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22427552/),,28,19379,DB00091,Cyclosporine
,27105859,AUC0-12,The median AUC0-12 was 44.3 ng h/mL.,Pharmacokinetics of mycophenolic acid in children with clinically stable idiopathic nephrotic syndrome receiving cyclosporine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27105859/),[h·ng] / [ml],44.3,19446,DB00091,Cyclosporine
,16239360,terminal phase half-life,"The pharmacokinetics of FTY720 in de novo renal transplant patients were characterized by the long terminal phase half-life of approximately 200 hours across doses, high volume of distribution (>3000 L), and low clearance (10.8 L/h).","FTY720, a novel immunomodulator in de novo kidney transplant patients: pharmacokinetics and exposure-response relationship. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16239360/),h,200,20092,DB00091,Cyclosporine
>,16239360,volume of distribution,"The pharmacokinetics of FTY720 in de novo renal transplant patients were characterized by the long terminal phase half-life of approximately 200 hours across doses, high volume of distribution (>3000 L), and low clearance (10.8 L/h).","FTY720, a novel immunomodulator in de novo kidney transplant patients: pharmacokinetics and exposure-response relationship. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16239360/),l,3000,20093,DB00091,Cyclosporine
,16239360,clearance,"The pharmacokinetics of FTY720 in de novo renal transplant patients were characterized by the long terminal phase half-life of approximately 200 hours across doses, high volume of distribution (>3000 L), and low clearance (10.8 L/h).","FTY720, a novel immunomodulator in de novo kidney transplant patients: pharmacokinetics and exposure-response relationship. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16239360/),[l] / [h],10.8,20094,DB00091,Cyclosporine
,11523724,trough concentration,"Target trough concentration ranges depend on the concomitant immunosuppressive regimen, but a range of 5 to 15 microg/L is appropriate if cyclosporin is being used at trough concentrations of 75 to 150 microg/L.",Clinical pharmacokinetics of sirolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11523724/),[μg] / [l],5 to 15,20590,DB00091,Cyclosporine
,11523724,trough concentrations,"Target trough concentration ranges depend on the concomitant immunosuppressive regimen, but a range of 5 to 15 microg/L is appropriate if cyclosporin is being used at trough concentrations of 75 to 150 microg/L.",Clinical pharmacokinetics of sirolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11523724/),[μg] / [l],75 to 150,20591,DB00091,Cyclosporine
,21094848,AUC(0-12h),The mean pharmacokinetic features were: AUC(0-12h): Equoral 4162 ± 1231 ng·mL/h vs Neoral 4370 ± 1059 ng·mL/h (P = .50); Cmax: Equoral 821 ± 244 ng/mL vs Neoral 834 ± 298 ng/mL (P = .86); and tmax: 105 minutes for both formulations.,Assessment of bioequivalence of a generic cyclosporine (Equoral) by a prospective randomized controlled trial on allogeneic stem cell transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21094848/),[ml·ng] / [h],4162,20604,DB00091,Cyclosporine
,21094848,AUC(0-12h),The mean pharmacokinetic features were: AUC(0-12h): Equoral 4162 ± 1231 ng·mL/h vs Neoral 4370 ± 1059 ng·mL/h (P = .50); Cmax: Equoral 821 ± 244 ng/mL vs Neoral 834 ± 298 ng/mL (P = .86); and tmax: 105 minutes for both formulations.,Assessment of bioequivalence of a generic cyclosporine (Equoral) by a prospective randomized controlled trial on allogeneic stem cell transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21094848/),[ml·ng] / [h],4370,20605,DB00091,Cyclosporine
,21094848,Cmax,The mean pharmacokinetic features were: AUC(0-12h): Equoral 4162 ± 1231 ng·mL/h vs Neoral 4370 ± 1059 ng·mL/h (P = .50); Cmax: Equoral 821 ± 244 ng/mL vs Neoral 834 ± 298 ng/mL (P = .86); and tmax: 105 minutes for both formulations.,Assessment of bioequivalence of a generic cyclosporine (Equoral) by a prospective randomized controlled trial on allogeneic stem cell transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21094848/),[ng] / [ml],821,20606,DB00091,Cyclosporine
,21094848,Cmax,The mean pharmacokinetic features were: AUC(0-12h): Equoral 4162 ± 1231 ng·mL/h vs Neoral 4370 ± 1059 ng·mL/h (P = .50); Cmax: Equoral 821 ± 244 ng/mL vs Neoral 834 ± 298 ng/mL (P = .86); and tmax: 105 minutes for both formulations.,Assessment of bioequivalence of a generic cyclosporine (Equoral) by a prospective randomized controlled trial on allogeneic stem cell transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21094848/),[ng] / [ml],834,20607,DB00091,Cyclosporine
,21094848,tmax,The mean pharmacokinetic features were: AUC(0-12h): Equoral 4162 ± 1231 ng·mL/h vs Neoral 4370 ± 1059 ng·mL/h (P = .50); Cmax: Equoral 821 ± 244 ng/mL vs Neoral 834 ± 298 ng/mL (P = .86); and tmax: 105 minutes for both formulations.,Assessment of bioequivalence of a generic cyclosporine (Equoral) by a prospective randomized controlled trial on allogeneic stem cell transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21094848/),min,105,20608,DB00091,Cyclosporine
,1554925,Tmax,"For CSA blood concentrations measured by HPLC assay, the Tmax, Cmax, and AUC were 3.4 +/- 1.3 h, 569 +/- 240 nmol/L, and 4659 +/- 2144 h.nmol/L (mean +/- SD), respectively, with solution and 4.2 +/- 2.1 h, 560 +/- 257 nmol/L, and 4765 +/- 1799 h.nmol/L (mean +/- SD), respectively, with capsules.",Bioavailability and patient acceptance of cyclosporine soft gelatin capsules in renal allograft recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1554925/),h,3.4,21103,DB00091,Cyclosporine
,1554925,Cmax,"For CSA blood concentrations measured by HPLC assay, the Tmax, Cmax, and AUC were 3.4 +/- 1.3 h, 569 +/- 240 nmol/L, and 4659 +/- 2144 h.nmol/L (mean +/- SD), respectively, with solution and 4.2 +/- 2.1 h, 560 +/- 257 nmol/L, and 4765 +/- 1799 h.nmol/L (mean +/- SD), respectively, with capsules.",Bioavailability and patient acceptance of cyclosporine soft gelatin capsules in renal allograft recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1554925/),[nM] / [l],569,21104,DB00091,Cyclosporine
,1554925,Cmax,"For CSA blood concentrations measured by HPLC assay, the Tmax, Cmax, and AUC were 3.4 +/- 1.3 h, 569 +/- 240 nmol/L, and 4659 +/- 2144 h.nmol/L (mean +/- SD), respectively, with solution and 4.2 +/- 2.1 h, 560 +/- 257 nmol/L, and 4765 +/- 1799 h.nmol/L (mean +/- SD), respectively, with capsules.",Bioavailability and patient acceptance of cyclosporine soft gelatin capsules in renal allograft recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1554925/),h,4.2,21105,DB00091,Cyclosporine
,1554925,Cmax,"For CSA blood concentrations measured by HPLC assay, the Tmax, Cmax, and AUC were 3.4 +/- 1.3 h, 569 +/- 240 nmol/L, and 4659 +/- 2144 h.nmol/L (mean +/- SD), respectively, with solution and 4.2 +/- 2.1 h, 560 +/- 257 nmol/L, and 4765 +/- 1799 h.nmol/L (mean +/- SD), respectively, with capsules.",Bioavailability and patient acceptance of cyclosporine soft gelatin capsules in renal allograft recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1554925/),[nM] / [l],560,21106,DB00091,Cyclosporine
,1554925,AUC,"For CSA blood concentrations measured by HPLC assay, the Tmax, Cmax, and AUC were 3.4 +/- 1.3 h, 569 +/- 240 nmol/L, and 4659 +/- 2144 h.nmol/L (mean +/- SD), respectively, with solution and 4.2 +/- 2.1 h, 560 +/- 257 nmol/L, and 4765 +/- 1799 h.nmol/L (mean +/- SD), respectively, with capsules.",Bioavailability and patient acceptance of cyclosporine soft gelatin capsules in renal allograft recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1554925/),[h·nM] / [l],4659,21107,DB00091,Cyclosporine
,1554925,AUC,"For CSA blood concentrations measured by HPLC assay, the Tmax, Cmax, and AUC were 3.4 +/- 1.3 h, 569 +/- 240 nmol/L, and 4659 +/- 2144 h.nmol/L (mean +/- SD), respectively, with solution and 4.2 +/- 2.1 h, 560 +/- 257 nmol/L, and 4765 +/- 1799 h.nmol/L (mean +/- SD), respectively, with capsules.",Bioavailability and patient acceptance of cyclosporine soft gelatin capsules in renal allograft recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1554925/),[h·nM] / [l],4765,21108,DB00091,Cyclosporine
,1554925,relative bioavailability,The mean (+/- SD) relative bioavailability of capsules compared with solution was 109 +/- 29 percent AUC (0-12 h) measured by HPLC and 111 +/- 27 percent AUC (0-12 h) measured by FPIA.,Bioavailability and patient acceptance of cyclosporine soft gelatin capsules in renal allograft recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1554925/),%,109,21109,DB00091,Cyclosporine
,1554925,relative bioavailability,The mean (+/- SD) relative bioavailability of capsules compared with solution was 109 +/- 29 percent AUC (0-12 h) measured by HPLC and 111 +/- 27 percent AUC (0-12 h) measured by FPIA.,Bioavailability and patient acceptance of cyclosporine soft gelatin capsules in renal allograft recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1554925/),%,111,21110,DB00091,Cyclosporine
,7937285,blood clearance,Cyclosporine blood clearance decreased significantly after treatment with diltiazem (18.0-11.0 ml/min.kg; p = 0.008).,Clinical and medicoeconomic impact of the cyclosporine-diltiazem interaction in renal transplant recipients. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937285/),[ml] / [kg·min],18.0-11.0,21465,DB00091,Cyclosporine
,7937285,apparent volume of,The apparent volume of cyclosporine distribution also decreased significantly (4.26-2.62 L/kg; p < 0.05).,Clinical and medicoeconomic impact of the cyclosporine-diltiazem interaction in renal transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7937285/),[l] / [kg],4.26-2.62,21466,DB00091,Cyclosporine
,12644921,C(0),"Mean C(0), C(max), AUC (0-12), and T(max )were 3.46+/-1.32, 13.5+/-0.58 microg/ml, 63.2+/-24.4 microg x h/ml, and 1.3+/-0.6 h, respectively.",Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),[μg] / [ml],3.46,21628,DB00091,Cyclosporine
,12644921,C(max),"Mean C(0), C(max), AUC (0-12), and T(max )were 3.46+/-1.32, 13.5+/-0.58 microg/ml, 63.2+/-24.4 microg x h/ml, and 1.3+/-0.6 h, respectively.",Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),[μg] / [ml],13.5,21629,DB00091,Cyclosporine
,12644921,C(max),"Mean C(0), C(max), AUC (0-12), and T(max )were 3.46+/-1.32, 13.5+/-0.58 microg/ml, 63.2+/-24.4 microg x h/ml, and 1.3+/-0.6 h, respectively.",Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),[h·μg] / [ml],63.2,21630,DB00091,Cyclosporine
,12644921,AUC (0-12),"Mean C(0), C(max), AUC (0-12), and T(max )were 3.46+/-1.32, 13.5+/-0.58 microg/ml, 63.2+/-24.4 microg x h/ml, and 1.3+/-0.6 h, respectively.",Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),[μg] / [ml],13.5,21631,DB00091,Cyclosporine
,12644921,AUC (0-12),"Mean C(0), C(max), AUC (0-12), and T(max )were 3.46+/-1.32, 13.5+/-0.58 microg/ml, 63.2+/-24.4 microg x h/ml, and 1.3+/-0.6 h, respectively.",Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),[h·μg] / [ml],63.2,21632,DB00091,Cyclosporine
,12644921,T(max ),"Mean C(0), C(max), AUC (0-12), and T(max )were 3.46+/-1.32, 13.5+/-0.58 microg/ml, 63.2+/-24.4 microg x h/ml, and 1.3+/-0.6 h, respectively.",Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),h,1.3,21633,DB00091,Cyclosporine
>,12644921,AUC(0-12 ),"Six (30%) children were considered to have an adequate exposure (36-54 microg x h/ml) to MPA, 11 (55%) showed an AUC(0-12 )>54 microg.h/ml, and 3 (15%) showed an AUC(0-12 )<36 microg x h/ml.",Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),[h·μg] / [ml],54,21634,DB00091,Cyclosporine
<,12644921,AUC(0-12 ),"Six (30%) children were considered to have an adequate exposure (36-54 microg x h/ml) to MPA, 11 (55%) showed an AUC(0-12 )>54 microg.h/ml, and 3 (15%) showed an AUC(0-12 )<36 microg x h/ml.",Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),[h·μg] / [ml],36,21635,DB00091,Cyclosporine
>/=,12644921,C(max ),A C(max )>/=10 microg/ml was seen in 13 (65%) children.,Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),[μg] / [ml],10,21636,DB00091,Cyclosporine
,19122342,bioavailability,"The bioavailability after intraportal and intraintestinal administration were 48.0% and 21.2%, respectively.",Effect of intestinal and hepatic first-pass extraction on the pharmacokinetics of everolimus in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19122342/),%,48.0,21662,DB00091,Cyclosporine
,19122342,bioavailability,"The bioavailability after intraportal and intraintestinal administration were 48.0% and 21.2%, respectively.",Effect of intestinal and hepatic first-pass extraction on the pharmacokinetics of everolimus in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19122342/),%,21.2,21663,DB00091,Cyclosporine
,2906601,half-life,"The mean half-life of the lambda 1 phase was 0.11 hr, that of the lambda 2 phase was 1.82 hr, and the half-life of the estimated lambda 3 phase was 23.79 hr.","Cyclosporine pharmacokinetics in rats and interspecies comparison in dogs, rabbits, rats, and humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906601/),h,0.11,21923,DB00091,Cyclosporine
,2906601,half-life,"The mean half-life of the lambda 1 phase was 0.11 hr, that of the lambda 2 phase was 1.82 hr, and the half-life of the estimated lambda 3 phase was 23.79 hr.","Cyclosporine pharmacokinetics in rats and interspecies comparison in dogs, rabbits, rats, and humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906601/),h,1.82,21924,DB00091,Cyclosporine
,2906601,half-life,"The mean half-life of the lambda 1 phase was 0.11 hr, that of the lambda 2 phase was 1.82 hr, and the half-life of the estimated lambda 3 phase was 23.79 hr.","Cyclosporine pharmacokinetics in rats and interspecies comparison in dogs, rabbits, rats, and humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906601/),h,23.79,21925,DB00091,Cyclosporine
,2906601,apparent volume of distribution,"The mean apparent volume of distribution and Vss were 5.69 and 4.54 liters/kg, respectively.","Cyclosporine pharmacokinetics in rats and interspecies comparison in dogs, rabbits, rats, and humans. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906601/),[l] / [kg],5.69,21926,DB00091,Cyclosporine
,2906601,Vss,"The mean apparent volume of distribution and Vss were 5.69 and 4.54 liters/kg, respectively.","Cyclosporine pharmacokinetics in rats and interspecies comparison in dogs, rabbits, rats, and humans. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906601/),[l] / [kg],4.54,21927,DB00091,Cyclosporine
,2906601,blood total body clearance,The mean blood total body clearance was 3.38 ml/min/kg.,"Cyclosporine pharmacokinetics in rats and interspecies comparison in dogs, rabbits, rats, and humans. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906601/),[ml] / [kg·min],3.38,21928,DB00091,Cyclosporine
less,6392355,clearance,The mean dialysis clearance was less than 1 ml/min.,The clearance of cyclosporine by hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6392355/),[ml] / [min],1,22421,DB00091,Cyclosporine
,10999729,Cmax,"Mean paclitaxel Cmax values approached plasma concentrations achieved with clinically relevant parenteral dose schedules, averaging 268+/-164 ng/ml.",Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10999729/),[ng] / [ml],268,22526,DB00091,Cyclosporine
,10999729,AUC,"AUC values averaged 3306+/-1977 ng x h/ ml, which was significantly lower than AUC values achieved with clinically relevant i.v. paclitaxel dose schedules.",Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10999729/),[h·ng] / [ml],3306,22527,DB00091,Cyclosporine
at,10999729,steady-state plasma paclitaxel concentrations,"However, computer simulations using pharmacokinetic parameters derived from the present study demonstrated that pharmacodynamically relevant steady-state plasma paclitaxel concentrations of at least 0.06 microM would be achieved after protracted once daily and twice daily dosing with oral paclitaxel and cyclosporin A.",Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10999729/),μ,0.06,22528,DB00091,Cyclosporine
,10999729,AUC ratios,"Paclitaxel metabolites were detectable in three patients, and the 6-alpha-hydroxypaclitaxel: paclitaxel and 3-p-hydroxypaclitaxel:paclitaxel AUC ratios averaged 0.63 and 0.86, respectively; these values were substantially higher than values reported in patients treated with i.v. paclitaxel.",Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10999729/),,0.63,22529,DB00091,Cyclosporine
,10999729,AUC ratios,"Paclitaxel metabolites were detectable in three patients, and the 6-alpha-hydroxypaclitaxel: paclitaxel and 3-p-hydroxypaclitaxel:paclitaxel AUC ratios averaged 0.63 and 0.86, respectively; these values were substantially higher than values reported in patients treated with i.v. paclitaxel.",Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10999729/),,0.86,22530,DB00091,Cyclosporine
,3952805,Bioavailability,"Bioavailability was 20.4% and 27.0% when estimated using HPLC and RIA data, respectively.",Cyclosporine metabolism and pharmacokinetics following intravenous and oral administration in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3952805/),%,20.4,22565,DB00091,Cyclosporine
,3952805,Bioavailability,"Bioavailability was 20.4% and 27.0% when estimated using HPLC and RIA data, respectively.",Cyclosporine metabolism and pharmacokinetics following intravenous and oral administration in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3952805/),%,27.0,22566,DB00091,Cyclosporine
,3952805,hepatic extraction ratio (HER),The mean hepatic extraction ratio (HER) of the parent drug and for CsA metabolites was approximately 23% in i.v. and p.o. studies.,Cyclosporine metabolism and pharmacokinetics following intravenous and oral administration in the dog. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3952805/),%,23,22567,DB00091,Cyclosporine
,25247760,clearance (CL),"The typical values for clearance (CL), volume of distribution (V), and bioavailability were 29.6 L/hr, 605 L, and 0.619, respectively.",Population pharmacokinetics and individualized dosage prediction of cyclosporine in allogeneic hematopoietic stem cell transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25247760/),[l] / [h],29.6,23296,DB00091,Cyclosporine
,25247760,volume of distribution (V),"The typical values for clearance (CL), volume of distribution (V), and bioavailability were 29.6 L/hr, 605 L, and 0.619, respectively.",Population pharmacokinetics and individualized dosage prediction of cyclosporine in allogeneic hematopoietic stem cell transplant patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25247760/),l,605,23297,DB00091,Cyclosporine
,25247760,bioavailability,"The typical values for clearance (CL), volume of distribution (V), and bioavailability were 29.6 L/hr, 605 L, and 0.619, respectively.",Population pharmacokinetics and individualized dosage prediction of cyclosporine in allogeneic hematopoietic stem cell transplant patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25247760/),,0.619,23298,DB00091,Cyclosporine
,10440399,AUC,"A total of 154 adult recipients of a primary or secondary cadaveric kidney graft were randomly allocated, in this double-blind trial, to receive MMF treatment aimed at three predefined target MPA AUC values (16.1, 32.2, and 60.6 microg x hr/ml).","A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440399/),[h·μg] / [ml],16.1,24351,DB00091,Cyclosporine
,10440399,AUC,"A total of 154 adult recipients of a primary or secondary cadaveric kidney graft were randomly allocated, in this double-blind trial, to receive MMF treatment aimed at three predefined target MPA AUC values (16.1, 32.2, and 60.6 microg x hr/ml).","A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440399/),[h·μg] / [ml],32.2,24352,DB00091,Cyclosporine
,10440399,AUC,"A total of 154 adult recipients of a primary or secondary cadaveric kidney graft were randomly allocated, in this double-blind trial, to receive MMF treatment aimed at three predefined target MPA AUC values (16.1, 32.2, and 60.6 microg x hr/ml).","A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440399/),[h·μg] / [ml],60.6,24353,DB00091,Cyclosporine
,7527198,50% inhibitory concentration,"Furthermore, its antiviral activity against laboratory strains and against clinical isolates from geographically distinct regions in primary T4 lymphocytes and in primary monocytes (50% inhibitory concentration = 0.011 to 0.057 micrograms/ml) was demonstrated.","Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7527198/),[μg] / [ml],0.011 to 0.057,24430,DB00091,Cyclosporine
,16563975,C0,This dose yielded median C0 levels of 6.6 ng/ml (10th to 90th percentiles: 2.8 to 11.8 ng/ml).,Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16563975/),[ng] / [ml],6.6,24661,DB00091,Cyclosporine
,9129559,blood/plasma ratio,"Sirolimus distribution between whole blood and plasma was concentration-independent, with a mean blood/plasma ratio (coefficient of variation) of 30.9 (48.5%).",Population pharmacokinetics of sirolimus in kidney transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129559/),,30.9,24920,DB00091,Cyclosporine
,9129559,terminal half-life,"Elimination was not influenced by dose, as shown by estimates of the terminal half-life of 63 hours (27.5%) and apparent oral blood clearance of 8.9 L/hr (38.2%).",Population pharmacokinetics of sirolimus in kidney transplant patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129559/),h,63,24921,DB00091,Cyclosporine
,9129559,apparent oral blood clearance,"Elimination was not influenced by dose, as shown by estimates of the terminal half-life of 63 hours (27.5%) and apparent oral blood clearance of 8.9 L/hr (38.2%).",Population pharmacokinetics of sirolimus in kidney transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129559/),[l] / [h],8.9,24922,DB00091,Cyclosporine
,9129559,absorption lag-time,"Sirolimus was rapidly absorbed, as shown by the absorption lag-time of 0.27 hour (35.1%), and ka of 2.77 hr-1 (48.4%).",Population pharmacokinetics of sirolimus in kidney transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129559/),h,0.27,24923,DB00091,Cyclosporine
,9129559,ka,"Sirolimus was rapidly absorbed, as shown by the absorption lag-time of 0.27 hour (35.1%), and ka of 2.77 hr-1 (48.4%).",Population pharmacokinetics of sirolimus in kidney transplant patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129559/),1/[h],2.77,24924,DB00091,Cyclosporine
,26274696,time of the conversion,Mean time of the conversion was 61 months after transplantation.,Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),month,61,25023,DB00091,Cyclosporine
,26274696,trough blood concentration,"In the first 7 patients, the initial EVR dose of 3 mg BID resulted in mean EVR trough blood concentration of 14.7 ± 3.7 ng/mL at day 7.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[ng] / [ml],14.7,25024,DB00091,Cyclosporine
,26274696,trough blood concentration,"Four weeks after conversion, mean EVR dose was 1.7 ± 0.5 mg BID (7 patients were receiving 1 mg BID and 17 were receiving 2 mg BID) resulting in mean EVR trough blood concentration of 4.0 ± 1.4 ng/mL.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[ng] / [ml],4.0,25025,DB00091,Cyclosporine
,26274696,maximum concentration,"Whereas mean maximum concentration (13.4 ± 2.8 versus 22.9 ± 7.4 ng/mL, P = 0.003) and mean apparent clearance (232 ± 79 versus 366 ± 173 mL/min, P = 0.016) were higher, mean area under the curve (78.2 ± 22.1 versus 102.5 ± 38.5 ng.h/mL, P = 0.067) and mean C0 (3.7 ± 1.3 versus 4.1 ± 1.5 ng/mL, P = 0.852) were no different comparing patients receiving 1 mg and 2 mg EVR BID.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[ng] / [ml],13.4,25026,DB00091,Cyclosporine
,26274696,maximum concentration,"Whereas mean maximum concentration (13.4 ± 2.8 versus 22.9 ± 7.4 ng/mL, P = 0.003) and mean apparent clearance (232 ± 79 versus 366 ± 173 mL/min, P = 0.016) were higher, mean area under the curve (78.2 ± 22.1 versus 102.5 ± 38.5 ng.h/mL, P = 0.067) and mean C0 (3.7 ± 1.3 versus 4.1 ± 1.5 ng/mL, P = 0.852) were no different comparing patients receiving 1 mg and 2 mg EVR BID.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[ng] / [ml],22.9,25027,DB00091,Cyclosporine
,26274696,apparent clearance,"Whereas mean maximum concentration (13.4 ± 2.8 versus 22.9 ± 7.4 ng/mL, P = 0.003) and mean apparent clearance (232 ± 79 versus 366 ± 173 mL/min, P = 0.016) were higher, mean area under the curve (78.2 ± 22.1 versus 102.5 ± 38.5 ng.h/mL, P = 0.067) and mean C0 (3.7 ± 1.3 versus 4.1 ± 1.5 ng/mL, P = 0.852) were no different comparing patients receiving 1 mg and 2 mg EVR BID.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[ml] / [min],232,25028,DB00091,Cyclosporine
,26274696,apparent clearance,"Whereas mean maximum concentration (13.4 ± 2.8 versus 22.9 ± 7.4 ng/mL, P = 0.003) and mean apparent clearance (232 ± 79 versus 366 ± 173 mL/min, P = 0.016) were higher, mean area under the curve (78.2 ± 22.1 versus 102.5 ± 38.5 ng.h/mL, P = 0.067) and mean C0 (3.7 ± 1.3 versus 4.1 ± 1.5 ng/mL, P = 0.852) were no different comparing patients receiving 1 mg and 2 mg EVR BID.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[ml] / [min],366,25029,DB00091,Cyclosporine
,26274696,area under the curve,"Whereas mean maximum concentration (13.4 ± 2.8 versus 22.9 ± 7.4 ng/mL, P = 0.003) and mean apparent clearance (232 ± 79 versus 366 ± 173 mL/min, P = 0.016) were higher, mean area under the curve (78.2 ± 22.1 versus 102.5 ± 38.5 ng.h/mL, P = 0.067) and mean C0 (3.7 ± 1.3 versus 4.1 ± 1.5 ng/mL, P = 0.852) were no different comparing patients receiving 1 mg and 2 mg EVR BID.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[h·ng] / [ml],78.2,25030,DB00091,Cyclosporine
,26274696,area under the curve,"Whereas mean maximum concentration (13.4 ± 2.8 versus 22.9 ± 7.4 ng/mL, P = 0.003) and mean apparent clearance (232 ± 79 versus 366 ± 173 mL/min, P = 0.016) were higher, mean area under the curve (78.2 ± 22.1 versus 102.5 ± 38.5 ng.h/mL, P = 0.067) and mean C0 (3.7 ± 1.3 versus 4.1 ± 1.5 ng/mL, P = 0.852) were no different comparing patients receiving 1 mg and 2 mg EVR BID.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[h·ng] / [ml],102.5,25031,DB00091,Cyclosporine
,26274696,C0,"Whereas mean maximum concentration (13.4 ± 2.8 versus 22.9 ± 7.4 ng/mL, P = 0.003) and mean apparent clearance (232 ± 79 versus 366 ± 173 mL/min, P = 0.016) were higher, mean area under the curve (78.2 ± 22.1 versus 102.5 ± 38.5 ng.h/mL, P = 0.067) and mean C0 (3.7 ± 1.3 versus 4.1 ± 1.5 ng/mL, P = 0.852) were no different comparing patients receiving 1 mg and 2 mg EVR BID.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[ng] / [ml],3.7,25032,DB00091,Cyclosporine
,26274696,C0,"Whereas mean maximum concentration (13.4 ± 2.8 versus 22.9 ± 7.4 ng/mL, P = 0.003) and mean apparent clearance (232 ± 79 versus 366 ± 173 mL/min, P = 0.016) were higher, mean area under the curve (78.2 ± 22.1 versus 102.5 ± 38.5 ng.h/mL, P = 0.067) and mean C0 (3.7 ± 1.3 versus 4.1 ± 1.5 ng/mL, P = 0.852) were no different comparing patients receiving 1 mg and 2 mg EVR BID.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[ng] / [ml],4.1,25033,DB00091,Cyclosporine
,11149104,Tdel in absorption,"The Tdel in absorption varied from 0.3 to 1.6 (mean 0.73) h, resulting in a similarly variable time to Tmax of 1-2.4 h (mean 1.59).",Pharmacokinetics of cyclosporin in children with stable renal transplants. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11149104/),h,0.73,25934,DB00091,Cyclosporine
,11149104,time to Tmax,"The Tdel in absorption varied from 0.3 to 1.6 (mean 0.73) h, resulting in a similarly variable time to Tmax of 1-2.4 h (mean 1.59).",Pharmacokinetics of cyclosporin in children with stable renal transplants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11149104/),h,1.59,25935,DB00091,Cyclosporine
,32482623,half-life,"CPI-d8 has a half-life and bioavailability of 7.6 hours and 3.2%, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),h,7.6,26063,DB00091,Cyclosporine
,32482623,bioavailability,"CPI-d8 has a half-life and bioavailability of 7.6 hours and 3.2%, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),%,3.2,26064,DB00091,Cyclosporine
,32482623,maximum blood concentrations (C max),"Cynomolgus monkeys received oral cyclosporin A (CsA) at 4, 20, and 100 mg/kg which yielded maximum blood concentrations (C max) and area under the plasma concentration-time curve (AUC) values of 0.19, 2.5, and 3.8 µM, and 2.7, 10.5, and 26.6 µM·h, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),μM,0.19,26065,DB00091,Cyclosporine
,32482623,maximum blood concentrations (C max),"Cynomolgus monkeys received oral cyclosporin A (CsA) at 4, 20, and 100 mg/kg which yielded maximum blood concentrations (C max) and area under the plasma concentration-time curve (AUC) values of 0.19, 2.5, and 3.8 µM, and 2.7, 10.5, and 26.6 µM·h, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),μM,2.5,26066,DB00091,Cyclosporine
,32482623,area under the plasma concentration-time curve (AUC),"Cynomolgus monkeys received oral cyclosporin A (CsA) at 4, 20, and 100 mg/kg which yielded maximum blood concentrations (C max) and area under the plasma concentration-time curve (AUC) values of 0.19, 2.5, and 3.8 µM, and 2.7, 10.5, and 26.6 µM·h, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),μM,3.8,26067,DB00091,Cyclosporine
,32482623,area under the plasma concentration-time curve (AUC),"Cynomolgus monkeys received oral cyclosporin A (CsA) at 4, 20, and 100 mg/kg which yielded maximum blood concentrations (C max) and area under the plasma concentration-time curve (AUC) values of 0.19, 2.5, and 3.8 µM, and 2.7, 10.5, and 26.6 µM·h, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),h·μM,2.7,26068,DB00091,Cyclosporine
,32482623,area under the plasma concentration-time curve (AUC),"Cynomolgus monkeys received oral cyclosporin A (CsA) at 4, 20, and 100 mg/kg which yielded maximum blood concentrations (C max) and area under the plasma concentration-time curve (AUC) values of 0.19, 2.5, and 3.8 µM, and 2.7, 10.5, and 26.6 µM·h, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),h·μM,10.5,26069,DB00091,Cyclosporine
,32482623,area under the plasma concentration-time curve (AUC),"Cynomolgus monkeys received oral cyclosporin A (CsA) at 4, 20, and 100 mg/kg which yielded maximum blood concentrations (C max) and area under the plasma concentration-time curve (AUC) values of 0.19, 2.5, and 3.8 µM, and 2.7, 10.5, and 26.6 µM·h, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),h·μM,26.6,26070,DB00091,Cyclosporine
,32482623,AUC ratio,"The apparent CsA-dose dependent increase in the AUC ratio of CPI-d8 (1.8, 6.2, and 10.5), CPI (1.1, 1.4, and 4.4), and CPIII (1.1, 1.8, and 4.6) at 4, 20, and 100 mg, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),,1.8,26071,DB00091,Cyclosporine
,32482623,AUC ratio,"The apparent CsA-dose dependent increase in the AUC ratio of CPI-d8 (1.8, 6.2, and 10.5), CPI (1.1, 1.4, and 4.4), and CPIII (1.1, 1.8, and 4.6) at 4, 20, and 100 mg, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),,6.2,26072,DB00091,Cyclosporine
,32482623,AUC ratio,"The apparent CsA-dose dependent increase in the AUC ratio of CPI-d8 (1.8, 6.2, and 10.5), CPI (1.1, 1.4, and 4.4), and CPIII (1.1, 1.8, and 4.6) at 4, 20, and 100 mg, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),,10.5,26073,DB00091,Cyclosporine
,32482623,AUC ratio,"The apparent CsA-dose dependent increase in the AUC ratio of CPI-d8 (1.8, 6.2, and 10.5), CPI (1.1, 1.4, and 4.4), and CPIII (1.1, 1.8, and 4.6) at 4, 20, and 100 mg, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),,1,26074,DB00091,Cyclosporine
,32482623,AUC ratio,"The apparent CsA-dose dependent increase in the AUC ratio of CPI-d8 (1.8, 6.2, and 10.5), CPI (1.1, 1.4, and 4.4), and CPIII (1.1, 1.8, and 4.6) at 4, 20, and 100 mg, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),,1.4,26075,DB00091,Cyclosporine
,32482623,AUC ratio,"The apparent CsA-dose dependent increase in the AUC ratio of CPI-d8 (1.8, 6.2, and 10.5), CPI (1.1, 1.4, and 4.4), and CPIII (1.1, 1.8, and 4.6) at 4, 20, and 100 mg, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),,4.4,26076,DB00091,Cyclosporine
,32482623,AUC ratio,"The apparent CsA-dose dependent increase in the AUC ratio of CPI-d8 (1.8, 6.2, and 10.5), CPI (1.1, 1.4, and 4.4), and CPIII (1.1, 1.8, and 4.6) at 4, 20, and 100 mg, respectively.",Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32482623/),,4.6,26077,DB00091,Cyclosporine
,8693526,area under the concentration versus time curve,"Grapefruit juice increased the area under the concentration versus time curve (4218+/-1497 ng x hr/ml [grapefruit juice] vs. 3415+/-1288 ng x hr/ml [water], P=0.029) and 12-hr trough (244+/-214 ng x ml [grapefruit juice] vs. 132+/-56 ng x ml [water], P=0.09), but it did not change peak concentration (734+/-290 ng x ml [grapefruit juice] vs. 708+/-305 ng x ml [water], P=0.76).",Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8693526/),[h·ng] / [ml],4218,26105,DB00091,Cyclosporine
,8693526,area under the concentration versus time curve,"Grapefruit juice increased the area under the concentration versus time curve (4218+/-1497 ng x hr/ml [grapefruit juice] vs. 3415+/-1288 ng x hr/ml [water], P=0.029) and 12-hr trough (244+/-214 ng x ml [grapefruit juice] vs. 132+/-56 ng x ml [water], P=0.09), but it did not change peak concentration (734+/-290 ng x ml [grapefruit juice] vs. 708+/-305 ng x ml [water], P=0.76).",Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8693526/),[h·ng] / [ml],3415,26106,DB00091,Cyclosporine
,8693526,trough,"Grapefruit juice increased the area under the concentration versus time curve (4218+/-1497 ng x hr/ml [grapefruit juice] vs. 3415+/-1288 ng x hr/ml [water], P=0.029) and 12-hr trough (244+/-214 ng x ml [grapefruit juice] vs. 132+/-56 ng x ml [water], P=0.09), but it did not change peak concentration (734+/-290 ng x ml [grapefruit juice] vs. 708+/-305 ng x ml [water], P=0.76).",Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8693526/),ml·ng,244,26107,DB00091,Cyclosporine
,8693526,trough,"Grapefruit juice increased the area under the concentration versus time curve (4218+/-1497 ng x hr/ml [grapefruit juice] vs. 3415+/-1288 ng x hr/ml [water], P=0.029) and 12-hr trough (244+/-214 ng x ml [grapefruit juice] vs. 132+/-56 ng x ml [water], P=0.09), but it did not change peak concentration (734+/-290 ng x ml [grapefruit juice] vs. 708+/-305 ng x ml [water], P=0.76).",Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8693526/),ml·ng,132,26108,DB00091,Cyclosporine
,8693526,peak concentration,"Grapefruit juice increased the area under the concentration versus time curve (4218+/-1497 ng x hr/ml [grapefruit juice] vs. 3415+/-1288 ng x hr/ml [water], P=0.029) and 12-hr trough (244+/-214 ng x ml [grapefruit juice] vs. 132+/-56 ng x ml [water], P=0.09), but it did not change peak concentration (734+/-290 ng x ml [grapefruit juice] vs. 708+/-305 ng x ml [water], P=0.76).",Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8693526/),ml·ng,734,26109,DB00091,Cyclosporine
,8693526,peak concentration,"Grapefruit juice increased the area under the concentration versus time curve (4218+/-1497 ng x hr/ml [grapefruit juice] vs. 3415+/-1288 ng x hr/ml [water], P=0.029) and 12-hr trough (244+/-214 ng x ml [grapefruit juice] vs. 132+/-56 ng x ml [water], P=0.09), but it did not change peak concentration (734+/-290 ng x ml [grapefruit juice] vs. 708+/-305 ng x ml [water], P=0.76).",Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8693526/),ml·ng,708,26110,DB00091,Cyclosporine
,8693526,time to peak concentration,"In addition, grapefruit juice delayed the time to peak concentration compared with water (5.4+/-3.0 hr [grapefruit juice] vs. 2.8+/-0.8 hr [water], P=0.025).",Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8693526/),h,5.4,26111,DB00091,Cyclosporine
,8693526,time to peak concentration,"In addition, grapefruit juice delayed the time to peak concentration compared with water (5.4+/-3.0 hr [grapefruit juice] vs. 2.8+/-0.8 hr [water], P=0.025).",Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8693526/),h,2.8,26112,DB00091,Cyclosporine
,21088289,area under the curve,"In renal transplant recipients, MMF therapy is optimal when the area under the curve of MPA is 30 to 60 mg·h/L.",Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088289/),[h·mg] / [l],30 to 60,26320,DB00091,Cyclosporine
,21088289,relative bioavailability,"Compared with an MMF dose of 1000 mg (=100%), relative bioavailability was 123%, 111%, 94%, and 90% in patients receiving MMF doses of 250, 500, 1500, and 2000 mg in combination with cyclosporine (P < 0.001); respective values in tacrolimus-cotreated patients were 176%, 133%, 85%, and 76% (P < 0.001).",Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088289/),%,123,26321,DB00091,Cyclosporine
,21088289,relative bioavailability,"Compared with an MMF dose of 1000 mg (=100%), relative bioavailability was 123%, 111%, 94%, and 90% in patients receiving MMF doses of 250, 500, 1500, and 2000 mg in combination with cyclosporine (P < 0.001); respective values in tacrolimus-cotreated patients were 176%, 133%, 85%, and 76% (P < 0.001).",Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088289/),%,111,26322,DB00091,Cyclosporine
,21088289,relative bioavailability,"Compared with an MMF dose of 1000 mg (=100%), relative bioavailability was 123%, 111%, 94%, and 90% in patients receiving MMF doses of 250, 500, 1500, and 2000 mg in combination with cyclosporine (P < 0.001); respective values in tacrolimus-cotreated patients were 176%, 133%, 85%, and 76% (P < 0.001).",Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088289/),%,94,26323,DB00091,Cyclosporine
,21088289,relative bioavailability,"Compared with an MMF dose of 1000 mg (=100%), relative bioavailability was 123%, 111%, 94%, and 90% in patients receiving MMF doses of 250, 500, 1500, and 2000 mg in combination with cyclosporine (P < 0.001); respective values in tacrolimus-cotreated patients were 176%, 133%, 85%, and 76% (P < 0.001).",Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088289/),%,90,26324,DB00091,Cyclosporine
,21088289,relative bioavailability,"Compared with an MMF dose of 1000 mg (=100%), relative bioavailability was 123%, 111%, 94%, and 90% in patients receiving MMF doses of 250, 500, 1500, and 2000 mg in combination with cyclosporine (P < 0.001); respective values in tacrolimus-cotreated patients were 176%, 133%, 85%, and 76% (P < 0.001).",Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088289/),%,176,26325,DB00091,Cyclosporine
,21088289,relative bioavailability,"Compared with an MMF dose of 1000 mg (=100%), relative bioavailability was 123%, 111%, 94%, and 90% in patients receiving MMF doses of 250, 500, 1500, and 2000 mg in combination with cyclosporine (P < 0.001); respective values in tacrolimus-cotreated patients were 176%, 133%, 85%, and 76% (P < 0.001).",Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088289/),%,133,26326,DB00091,Cyclosporine
,21088289,relative bioavailability,"Compared with an MMF dose of 1000 mg (=100%), relative bioavailability was 123%, 111%, 94%, and 90% in patients receiving MMF doses of 250, 500, 1500, and 2000 mg in combination with cyclosporine (P < 0.001); respective values in tacrolimus-cotreated patients were 176%, 133%, 85%, and 76% (P < 0.001).",Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088289/),%,85,26327,DB00091,Cyclosporine
,21088289,relative bioavailability,"Compared with an MMF dose of 1000 mg (=100%), relative bioavailability was 123%, 111%, 94%, and 90% in patients receiving MMF doses of 250, 500, 1500, and 2000 mg in combination with cyclosporine (P < 0.001); respective values in tacrolimus-cotreated patients were 176%, 133%, 85%, and 76% (P < 0.001).",Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088289/),%,76,26328,DB00091,Cyclosporine
,20811346,C(max),"Marginal increases were observed for CsA C(max) (906 vs. 1,014 ng/ml) and AUC(0-τ) (3.05 vs. 3.37 µg·h/ml) in the presence of ABS.",Potential for pharmacokinetic interactions between ambrisentan and cyclosporine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20811346/),[ng] / [ml],906,26395,DB00091,Cyclosporine
,20811346,C(max),"Marginal increases were observed for CsA C(max) (906 vs. 1,014 ng/ml) and AUC(0-τ) (3.05 vs. 3.37 µg·h/ml) in the presence of ABS.",Potential for pharmacokinetic interactions between ambrisentan and cyclosporine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20811346/),[ng] / [ml],"1,014",26396,DB00091,Cyclosporine
,20811346,AUC(0-τ),"Marginal increases were observed for CsA C(max) (906 vs. 1,014 ng/ml) and AUC(0-τ) (3.05 vs. 3.37 µg·h/ml) in the presence of ABS.",Potential for pharmacokinetic interactions between ambrisentan and cyclosporine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20811346/),[h·μg] / [ml],3.05,26397,DB00091,Cyclosporine
,20811346,AUC(0-τ),"Marginal increases were observed for CsA C(max) (906 vs. 1,014 ng/ml) and AUC(0-τ) (3.05 vs. 3.37 µg·h/ml) in the presence of ABS.",Potential for pharmacokinetic interactions between ambrisentan and cyclosporine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20811346/),[h·μg] / [ml],3.37,26398,DB00091,Cyclosporine
,11720431,C(max),"When formulated in Cremophor EL 15 ml m(-2), paclitaxel C(max) and AUC values were 0.10 +/- 0.06 microM and 1.29 +/- 0.99 microM h(-1), respectively, whereas these values were 0.31 +/- 0.06 microM and 2.61 +/- 1.54 microM h(-1), respectively, when formulated in polysorbate 80.",The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11720431/),μM,0.10,26762,DB00091,Cyclosporine
,11720431,C(max),"When formulated in Cremophor EL 15 ml m(-2), paclitaxel C(max) and AUC values were 0.10 +/- 0.06 microM and 1.29 +/- 0.99 microM h(-1), respectively, whereas these values were 0.31 +/- 0.06 microM and 2.61 +/- 1.54 microM h(-1), respectively, when formulated in polysorbate 80.",The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11720431/),μM,0.31,26763,DB00091,Cyclosporine
,11720431,AUC,"When formulated in Cremophor EL 15 ml m(-2), paclitaxel C(max) and AUC values were 0.10 +/- 0.06 microM and 1.29 +/- 0.99 microM h(-1), respectively, whereas these values were 0.31 +/- 0.06 microM and 2.61 +/- 1.54 microM h(-1), respectively, when formulated in polysorbate 80.",The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11720431/),[μM] / [h],1.29,26764,DB00091,Cyclosporine
,11720431,AUC,"When formulated in Cremophor EL 15 ml m(-2), paclitaxel C(max) and AUC values were 0.10 +/- 0.06 microM and 1.29 +/- 0.99 microM h(-1), respectively, whereas these values were 0.31 +/- 0.06 microM and 2.61 +/- 1.54 microM h(-1), respectively, when formulated in polysorbate 80.",The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11720431/),[μM] / [h],2.61,26765,DB00091,Cyclosporine
,11720431,excretion,"When formulated in Cremophor EL 15 ml m(-2), paclitaxel excretion in faeces was 38.8 +/- 13.0% of the administered dose, whereas this value was 18.3 +/-15.5% for the polysorbate 80 formulation.",The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11720431/),%,38.8,26766,DB00091,Cyclosporine
,11720431,excretion,"When formulated in Cremophor EL 15 ml m(-2), paclitaxel excretion in faeces was 38.8 +/- 13.0% of the administered dose, whereas this value was 18.3 +/-15.5% for the polysorbate 80 formulation.",The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11720431/),%,18.3,26767,DB00091,Cyclosporine
,12698308,C2/dose ratio,"On the contrary, a significant difference ( P<0.05) was found for the C2/dose ratio between W1 and M3 and between W1 and Y1 (mean+/-SD =5.47+/-2.33; 7.78+/-1.05; 6.98+/-2.17 ml(-1 )for W1, M3 and Y1, respectively).",Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC(0-12) monitoring in cardiac transplant recipients over the first year post-transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12698308/),1/[ml],5.47,28005,DB00091,Cyclosporine
,12698308,C2/dose ratio,"On the contrary, a significant difference ( P<0.05) was found for the C2/dose ratio between W1 and M3 and between W1 and Y1 (mean+/-SD =5.47+/-2.33; 7.78+/-1.05; 6.98+/-2.17 ml(-1 )for W1, M3 and Y1, respectively).",Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC(0-12) monitoring in cardiac transplant recipients over the first year post-transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12698308/),1/[ml],7.78,28006,DB00091,Cyclosporine
,12698308,C2/dose ratio,"On the contrary, a significant difference ( P<0.05) was found for the C2/dose ratio between W1 and M3 and between W1 and Y1 (mean+/-SD =5.47+/-2.33; 7.78+/-1.05; 6.98+/-2.17 ml(-1 )for W1, M3 and Y1, respectively).",Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC(0-12) monitoring in cardiac transplant recipients over the first year post-transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12698308/),1/[ml],6.98,28007,DB00091,Cyclosporine
,11223552,IC(50),Ex-vivo bioassay revealed that activity in serum for reversing multidrug resistance was achieved in all patients; IC(50) of P-glycoprotein expressing 8226 / Dox(6) in patients' serum was decreased from 5.9 to 1.3 microg / ml (P < 0.0001) by PSC-833 administration.,Phase I study of intravenous PSC-833 and doxorubicin: reversal of multidrug resistance. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11223552/),[μg] / [ml],5.9,28087,DB00091,Cyclosporine
,11223552,IC(50),Ex-vivo bioassay revealed that activity in serum for reversing multidrug resistance was achieved in all patients; IC(50) of P-glycoprotein expressing 8226 / Dox(6) in patients' serum was decreased from 5.9 to 1.3 microg / ml (P < 0.0001) by PSC-833 administration.,Phase I study of intravenous PSC-833 and doxorubicin: reversal of multidrug resistance. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11223552/),[μg] / [ml],1.3,28088,DB00091,Cyclosporine
,11223552,clearance,"Doxorubicin clearance was 24.3 +/- 13.7 (mean +/- SD) liter / h/m(2), which was lower than the 49.0 +/- 16.9 liter / h/m(2) without PSC-833 (P < 0.0001).",Phase I study of intravenous PSC-833 and doxorubicin: reversal of multidrug resistance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11223552/),[h·l] / [m(2],24.3,28089,DB00091,Cyclosporine
,11223552,clearance,"Doxorubicin clearance was 24.3 +/- 13.7 (mean +/- SD) liter / h/m(2), which was lower than the 49.0 +/- 16.9 liter / h/m(2) without PSC-833 (P < 0.0001).",Phase I study of intravenous PSC-833 and doxorubicin: reversal of multidrug resistance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11223552/),[h·l] / [m(2],49.0,28090,DB00091,Cyclosporine
,14620947,accumulation ratio,The accumulation ratio of cerivastatin (after 3 months/ Day 1) was 1.6.,"Determination of the pharmacokinetics of cerivastatin when administered in combination with sirolimus and cyclosporin A in patients with kidney transplant, and review of the relevant literature. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14620947/),,1.6,28833,DB00091,Cyclosporine
,8591650,bio-availability,This drug's bio-availability averages 25-35% but is highly variable.,"Innovative treatment approaches for rheumatoid arthritis. Cyclosporin, leflunomide and nitrogen mustard. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8591650/),%,25-35,29074,DB00091,Cyclosporine
,8591650,elimination half-life,CSA is metabolized to numerous metabolites by the liver and its elimination half-life is 6-12 hours in the absence of severe liver disease.,"Innovative treatment approaches for rheumatoid arthritis. Cyclosporin, leflunomide and nitrogen mustard. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8591650/),h,6-12,29075,DB00091,Cyclosporine
,8591650,elimination half-life,"Its active metabolite is excreted renally to a large degree, with a prolonged elimination half-life of about 11 days.","Innovative treatment approaches for rheumatoid arthritis. Cyclosporin, leflunomide and nitrogen mustard. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8591650/),d,11,29076,DB00091,Cyclosporine
,10638396,trough levels,"Cyclosporin trough levels (98 ng/ml vs 52 ng/ml), maximum concentrations (532 ng/ml vs 74 ng/ml) and the area under the blood drug concentration-time curve (2832 ng h ml-1 vs 700 ng h ml-1) were greatly reduced with orlistat.",Effect of orlistat on blood cyclosporin concentration in an obese heart transplant patient. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10638396/),[ng] / [ml],98,29386,DB00091,Cyclosporine
,10638396,trough levels,"Cyclosporin trough levels (98 ng/ml vs 52 ng/ml), maximum concentrations (532 ng/ml vs 74 ng/ml) and the area under the blood drug concentration-time curve (2832 ng h ml-1 vs 700 ng h ml-1) were greatly reduced with orlistat.",Effect of orlistat on blood cyclosporin concentration in an obese heart transplant patient. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10638396/),[ng] / [ml],52,29387,DB00091,Cyclosporine
,10638396,maximum concentrations,"Cyclosporin trough levels (98 ng/ml vs 52 ng/ml), maximum concentrations (532 ng/ml vs 74 ng/ml) and the area under the blood drug concentration-time curve (2832 ng h ml-1 vs 700 ng h ml-1) were greatly reduced with orlistat.",Effect of orlistat on blood cyclosporin concentration in an obese heart transplant patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10638396/),[ng] / [ml],532,29388,DB00091,Cyclosporine
,10638396,maximum concentrations,"Cyclosporin trough levels (98 ng/ml vs 52 ng/ml), maximum concentrations (532 ng/ml vs 74 ng/ml) and the area under the blood drug concentration-time curve (2832 ng h ml-1 vs 700 ng h ml-1) were greatly reduced with orlistat.",Effect of orlistat on blood cyclosporin concentration in an obese heart transplant patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10638396/),[ng] / [ml],74,29389,DB00091,Cyclosporine
,10638396,area under the blood drug concentration-time curve,"Cyclosporin trough levels (98 ng/ml vs 52 ng/ml), maximum concentrations (532 ng/ml vs 74 ng/ml) and the area under the blood drug concentration-time curve (2832 ng h ml-1 vs 700 ng h ml-1) were greatly reduced with orlistat.",Effect of orlistat on blood cyclosporin concentration in an obese heart transplant patient. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10638396/),[h·ng] / [ml],2832,29390,DB00091,Cyclosporine
,10638396,area under the blood drug concentration-time curve,"Cyclosporin trough levels (98 ng/ml vs 52 ng/ml), maximum concentrations (532 ng/ml vs 74 ng/ml) and the area under the blood drug concentration-time curve (2832 ng h ml-1 vs 700 ng h ml-1) were greatly reduced with orlistat.",Effect of orlistat on blood cyclosporin concentration in an obese heart transplant patient. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10638396/),[h·ng] / [ml],700,29391,DB00091,Cyclosporine
,15602664,blood concentration,"The mean CsA dose and the mean CsA blood concentration were 4.4 mg/kg per day (range 3.6-5.8) and 276.6 ng/ml (range 162-346), respectively.",Cyclosporine therapy monitored with abbreviated area under curve in nephrotic syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15602664/),[ng] / [ml],276.6,29528,DB00091,Cyclosporine
,17465638,AUC(12),The mean MPA AUC(12) was 52.97 +/- 15.09 mg .,Pharmacokinetics of mycophenolic acid and estimation of exposure using multiple linear regression equations in Chinese renal allograft recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17465638/),mg,52.97,29790,DB00091,Cyclosporine
,11069439,"area under the blood concentration-time curve to 12 h (AUC(0,12 h))","The mean area under the blood concentration-time curve to 12 h (AUC(0,12 h)) was 4244 +/- 1311 microg l-1 h for cyclosporin before SDZ RAD treatment and 4683 +/- 1174 microg l-1 h (P = 0.106) on the day of SDZ RAD treatment (95% CI for difference -126, 1003).",Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069439/),[h·μg] / [l],4244,29800,DB00091,Cyclosporine
,11069439,"area under the blood concentration-time curve to 12 h (AUC(0,12 h))","The mean area under the blood concentration-time curve to 12 h (AUC(0,12 h)) was 4244 +/- 1311 microg l-1 h for cyclosporin before SDZ RAD treatment and 4683 +/- 1174 microg l-1 h (P = 0.106) on the day of SDZ RAD treatment (95% CI for difference -126, 1003).",Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069439/),[h·μg] / [l],4683,29801,DB00091,Cyclosporine
,11069439,"AUC(0,24 h)","The pharmacokinetic data of SDZ RAD dose-normalized to 1 mg SDZ RAD were as follows: AUC(0,24 h): 35.4 +/- 13.1 microg l-1 h, Cmax: 7.9 +/- 2.7 microg l-1 and tmax: 1.5 +/- 0.9 h.",Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069439/),[h·μg] / [l],35.4,29802,DB00091,Cyclosporine
,11069439,Cmax,"The pharmacokinetic data of SDZ RAD dose-normalized to 1 mg SDZ RAD were as follows: AUC(0,24 h): 35.4 +/- 13.1 microg l-1 h, Cmax: 7.9 +/- 2.7 microg l-1 and tmax: 1.5 +/- 0.9 h.",Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069439/),[μg] / [l],7.9,29803,DB00091,Cyclosporine
,11069439,tmax,"The pharmacokinetic data of SDZ RAD dose-normalized to 1 mg SDZ RAD were as follows: AUC(0,24 h): 35.4 +/- 13.1 microg l-1 h, Cmax: 7.9 +/- 2.7 microg l-1 and tmax: 1.5 +/- 0.9 h.",Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11069439/),h,1.5,29804,DB00091,Cyclosporine
,11142688,area under the plasma concentration-time curve,The area under the plasma concentration-time curve of paclitaxel after i.v. administration (175 mg/m2) was 16.2 +/- 1.7 microM x h and after oral administration (300 mg/m2) 3.8 +/- 1.5 microM x h.,Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11142688/),h·μM,16.2,29843,DB00091,Cyclosporine
,11142688,area under the plasma concentration-time curve,The area under the plasma concentration-time curve of paclitaxel after i.v. administration (175 mg/m2) was 16.2 +/- 1.7 microM x h and after oral administration (300 mg/m2) 3.8 +/- 1.5 microM x h.,Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11142688/),h·μM,3.8,29844,DB00091,Cyclosporine
,11142688,total fecal excretion,"Following i.v. infusion of paclitaxel, total fecal excretion was 56 +/- 25%, with the metabolite 6alpha-hydroxypaclitaxel being the main excretory product (37 +/- 18%).",Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11142688/),%,56,29845,DB00091,Cyclosporine
,11142688,total fecal excretion,"Following i.v. infusion of paclitaxel, total fecal excretion was 56 +/- 25%, with the metabolite 6alpha-hydroxypaclitaxel being the main excretory product (37 +/- 18%).",Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11142688/),%,37,29846,DB00091,Cyclosporine
,11142688,total fecal excretion,"After oral administration of paclitaxel, total fecal excretion was 76 +/- 21%, of which paclitaxel accounted for 61 +/- 14%.",Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11142688/),%,76,29847,DB00091,Cyclosporine
,11142688,total fecal excretion,"After oral administration of paclitaxel, total fecal excretion was 76 +/- 21%, of which paclitaxel accounted for 61 +/- 14%.",Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11142688/),%,61,29848,DB00091,Cyclosporine
,12374451,Relapse rates,"Relapse rates were 21% for 34 patients with acute myeloid leukemia (AML) in complete remission or chronic myeloid leukemia in chronic phase (low-risk), 66% for 19 patients with high-risk AML, and 18% for 17 patients with other active malignancy.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,21,30243,DB00091,Cyclosporine
,12374451,Relapse rates,"Relapse rates were 21% for 34 patients with acute myeloid leukemia (AML) in complete remission or chronic myeloid leukemia in chronic phase (low-risk), 66% for 19 patients with high-risk AML, and 18% for 17 patients with other active malignancy.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,66,30244,DB00091,Cyclosporine
,12374451,Relapse rates,"Relapse rates were 21% for 34 patients with acute myeloid leukemia (AML) in complete remission or chronic myeloid leukemia in chronic phase (low-risk), 66% for 19 patients with high-risk AML, and 18% for 17 patients with other active malignancy.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,18,30245,DB00091,Cyclosporine
,12374451,disease-free,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,74,30246,DB00091,Cyclosporine
,12374451,disease-free,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,26,30247,DB00091,Cyclosporine
,12374451,disease-free,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,37,30248,DB00091,Cyclosporine
,12374451,disease-free,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,65,30249,DB00091,Cyclosporine
,12374451,overall survival rates,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,88,30250,DB00091,Cyclosporine
,12374451,overall survival rates,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,26,30251,DB00091,Cyclosporine
,12374451,overall survival rates,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,37,30252,DB00091,Cyclosporine
,12374451,overall survival rates,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,65,30253,DB00091,Cyclosporine
,12374451,overall survival rates,"Projected disease-free and overall survival rates at 2 years were 74% and 88% for low-risk disease, 26% and 37% for advanced AML, and 65% and 71% for other high-risk disease, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),%,71,30254,DB00091,Cyclosporine
,12374451,half-lives,"Kinetics were linear, and for the first and fourth doses, the half-lives were 2.60 +/- 0.44 and 2.57 +/- 0.36 hours, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),h,2.60,30255,DB00091,Cyclosporine
,12374451,half-lives,"Kinetics were linear, and for the first and fourth doses, the half-lives were 2.60 +/- 0.44 and 2.57 +/- 0.36 hours, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),h,2.57,30256,DB00091,Cyclosporine
,12374451,Clearances,"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),[ml] / [m2·min],106.77,30257,DB00091,Cyclosporine
,12374451,Clearances,"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),[ml] / [m2·min],106.86,30258,DB00091,Cyclosporine
,12374451,peak concentrations (Cmax),"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),[mcg] / [ml],3.92,30259,DB00091,Cyclosporine
,12374451,peak concentrations (Cmax),"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),[mcg] / [ml],3.96,30260,DB00091,Cyclosporine
,12374451,areas under the plasma concentration versus time curve (AUC),"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),min·μM,4866.51,30261,DB00091,Cyclosporine
,12374451,areas under the plasma concentration versus time curve (AUC),"Clearances were 106.77 +/- 16.68 and 106.86 +/- 21.57 mL/min per m2, peak concentrations (Cmax) were 3.92 +/- 0.31 and 3.96 +/- 0.28 mcg/mL, and Bu areas under the plasma concentration versus time curve (AUC) were 4866.51 +/- 771.42 and 4980 +/- 882.80 microM x min, respectively.",Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374451/),min·μM,4980,30262,DB00091,Cyclosporine
,32265712,Apparent clearance (CL/F),"Apparent clearance (CL/F) and central volume of distribution (VC/F) of uMPA (CLuMPA/F and VCuMPA/F, respectively) and protein binding rate constant (k B) were estimated to be 851 L/h [relative standard error (RSE), 7.1%], 718 L (18.5%) and 53.4/h (2.3%), respectively.",Effect of Protein Binding on Exposure of Unbound and Total Mycophenolic Acid: A Population Pharmacokinetic Analysis in Chinese Adult Kidney Transplant Recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32265712/),[l] / [h],851,30373,DB00091,Cyclosporine
,32265712,central volume of distribution (VC/F),"Apparent clearance (CL/F) and central volume of distribution (VC/F) of uMPA (CLuMPA/F and VCuMPA/F, respectively) and protein binding rate constant (k B) were estimated to be 851 L/h [relative standard error (RSE), 7.1%], 718 L (18.5%) and 53.4/h (2.3%), respectively.",Effect of Protein Binding on Exposure of Unbound and Total Mycophenolic Acid: A Population Pharmacokinetic Analysis in Chinese Adult Kidney Transplant Recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32265712/),l,718,30374,DB00091,Cyclosporine
,32265712,central volume of distribution (VC/F),"Apparent clearance (CL/F) and central volume of distribution (VC/F) of uMPA (CLuMPA/F and VCuMPA/F, respectively) and protein binding rate constant (k B) were estimated to be 851 L/h [relative standard error (RSE), 7.1%], 718 L (18.5%) and 53.4/h (2.3%), respectively.",Effect of Protein Binding on Exposure of Unbound and Total Mycophenolic Acid: A Population Pharmacokinetic Analysis in Chinese Adult Kidney Transplant Recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32265712/),1/[h],53.4,30375,DB00091,Cyclosporine
,32265712,CL/F,"For uMPAG, the population values (RSE) of CL/F (CLuMPAG) and VC/F (VCuMPAG/F) were 5.71 L/h (4.4%) and 29.9 L (7.7%), respectively.",Effect of Protein Binding on Exposure of Unbound and Total Mycophenolic Acid: A Population Pharmacokinetic Analysis in Chinese Adult Kidney Transplant Recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32265712/),[l] / [h],5.71,30376,DB00091,Cyclosporine
,32265712,VC/F (VCuMPAG/F,"For uMPAG, the population values (RSE) of CL/F (CLuMPAG) and VC/F (VCuMPAG/F) were 5.71 L/h (4.4%) and 29.9 L (7.7%), respectively.",Effect of Protein Binding on Exposure of Unbound and Total Mycophenolic Acid: A Population Pharmacokinetic Analysis in Chinese Adult Kidney Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32265712/),l,29.9,30377,DB00091,Cyclosporine
,10823378,t(max),"Pharmacokinetic studies in adult renal transplant patients have shown that sirolimus may be characterized as a drug with rapid absorption (t(max) = 1 to 2 hours), low systemic availability (F = 14%), linear dose proportionality (2 to 24 mg), extensive partitioning into formed blood elements (B/P = 36), large apparent volume of distribution (1.7 L/kg), prolonged terminal half-life (62 hours), and large intersubject (CV = 52%) and intrasubject (CV = 26%) variability in oral-dose clearance.",Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823378/),h,1 to 2,30721,DB00091,Cyclosporine
,10823378,systemic availability (F,"Pharmacokinetic studies in adult renal transplant patients have shown that sirolimus may be characterized as a drug with rapid absorption (t(max) = 1 to 2 hours), low systemic availability (F = 14%), linear dose proportionality (2 to 24 mg), extensive partitioning into formed blood elements (B/P = 36), large apparent volume of distribution (1.7 L/kg), prolonged terminal half-life (62 hours), and large intersubject (CV = 52%) and intrasubject (CV = 26%) variability in oral-dose clearance.",Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823378/),%,14,30722,DB00091,Cyclosporine
,10823378,partitioning into,"Pharmacokinetic studies in adult renal transplant patients have shown that sirolimus may be characterized as a drug with rapid absorption (t(max) = 1 to 2 hours), low systemic availability (F = 14%), linear dose proportionality (2 to 24 mg), extensive partitioning into formed blood elements (B/P = 36), large apparent volume of distribution (1.7 L/kg), prolonged terminal half-life (62 hours), and large intersubject (CV = 52%) and intrasubject (CV = 26%) variability in oral-dose clearance.",Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823378/),,36,30723,DB00091,Cyclosporine
,10823378,B/P,"Pharmacokinetic studies in adult renal transplant patients have shown that sirolimus may be characterized as a drug with rapid absorption (t(max) = 1 to 2 hours), low systemic availability (F = 14%), linear dose proportionality (2 to 24 mg), extensive partitioning into formed blood elements (B/P = 36), large apparent volume of distribution (1.7 L/kg), prolonged terminal half-life (62 hours), and large intersubject (CV = 52%) and intrasubject (CV = 26%) variability in oral-dose clearance.",Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823378/),,36,30724,DB00091,Cyclosporine
,10823378,apparent volume of distribution,"Pharmacokinetic studies in adult renal transplant patients have shown that sirolimus may be characterized as a drug with rapid absorption (t(max) = 1 to 2 hours), low systemic availability (F = 14%), linear dose proportionality (2 to 24 mg), extensive partitioning into formed blood elements (B/P = 36), large apparent volume of distribution (1.7 L/kg), prolonged terminal half-life (62 hours), and large intersubject (CV = 52%) and intrasubject (CV = 26%) variability in oral-dose clearance.",Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823378/),[l] / [kg],1.7,30725,DB00091,Cyclosporine
,10823378,terminal half-life,"Pharmacokinetic studies in adult renal transplant patients have shown that sirolimus may be characterized as a drug with rapid absorption (t(max) = 1 to 2 hours), low systemic availability (F = 14%), linear dose proportionality (2 to 24 mg), extensive partitioning into formed blood elements (B/P = 36), large apparent volume of distribution (1.7 L/kg), prolonged terminal half-life (62 hours), and large intersubject (CV = 52%) and intrasubject (CV = 26%) variability in oral-dose clearance.",Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823378/),h,62,30726,DB00091,Cyclosporine
,10823378,therapeutic window,A whole-blood sirolimus therapeutic window of 5 to 15 ng/mL (measured by microparticle enzyme immunoassay) is recommended for patients at standard risk of rejection.,Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823378/),,5 to 15,30727,DB00091,Cyclosporine
,17969194,area under the plasma concentration-time curve from 0 to 12 hours [AUC(0-12)],The aim of this study was to assess the pharmacokinetics of MMF in stable pediatric liver transplant patients and estimate the dose of MMF required to provide a mycophenolic acid (MPA) exposure similar to that observed in adult liver transplant recipients receiving the recommended dose of MMF (target area under the plasma concentration-time curve from 0 to 12 hours [AUC(0-12)] for MPA of 29 mug.hour/mL in the immediate posttransplantation period and 58 microg x hour/mL after 6 months).,Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17969194/),[h·μg] / [ml],29,30884,DB00091,Cyclosporine
,17969194,area under the plasma concentration-time curve from 0 to 12 hours [AUC(0-12)],The aim of this study was to assess the pharmacokinetics of MMF in stable pediatric liver transplant patients and estimate the dose of MMF required to provide a mycophenolic acid (MPA) exposure similar to that observed in adult liver transplant recipients receiving the recommended dose of MMF (target area under the plasma concentration-time curve from 0 to 12 hours [AUC(0-12)] for MPA of 29 mug.hour/mL in the immediate posttransplantation period and 58 microg x hour/mL after 6 months).,Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17969194/),[h·μg] / [ml],58,30885,DB00091,Cyclosporine
,17969194,AUC(0-12),"Of 8 patients, 7 had a MPA AUC(0-12) (range, 11.0-37.2 microg x hour/mL) well below the target.",Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17969194/),[h·μg] / [ml],11.0-37.2,30886,DB00091,Cyclosporine
> or =,17969194,AUC(0-12),One patient had an AUC(0-12) > or = 58 microg x hour/mL but was considered an outlier and was excluded from analyses.,Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17969194/),[h·μg] / [ml],58,30887,DB00091,Cyclosporine
,17969194,AUC(0-12),"Mean MPA AUC(0-12) and maximum plasma concentration values were 22.7 +/- 10.5 microg x hour/mL and 7.23 +/- 3.27 microg/mL, respectively; values normalized to 600 mg/m(2) (the approved pediatric dose in renal transplantation) were 47.0 +/- 21.8 microg x hour/mL and 14.5 +/- 4.21 microg/mL.",Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17969194/),[h·μg] / [ml],22.7,30888,DB00091,Cyclosporine
,17969194,AUC(0-12),"Mean MPA AUC(0-12) and maximum plasma concentration values were 22.7 +/- 10.5 microg x hour/mL and 7.23 +/- 3.27 microg/mL, respectively; values normalized to 600 mg/m(2) (the approved pediatric dose in renal transplantation) were 47.0 +/- 21.8 microg x hour/mL and 14.5 +/- 4.21 microg/mL.",Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17969194/),[h·μg] / [ml],47.0,30889,DB00091,Cyclosporine
,17969194,maximum plasma concentration,"Mean MPA AUC(0-12) and maximum plasma concentration values were 22.7 +/- 10.5 microg x hour/mL and 7.23 +/- 3.27 microg/mL, respectively; values normalized to 600 mg/m(2) (the approved pediatric dose in renal transplantation) were 47.0 +/- 21.8 microg x hour/mL and 14.5 +/- 4.21 microg/mL.",Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17969194/),[μg] / [ml],7.23,30890,DB00091,Cyclosporine
,17969194,maximum plasma concentration,"Mean MPA AUC(0-12) and maximum plasma concentration values were 22.7 +/- 10.5 microg x hour/mL and 7.23 +/- 3.27 microg/mL, respectively; values normalized to 600 mg/m(2) (the approved pediatric dose in renal transplantation) were 47.0 +/- 21.8 microg x hour/mL and 14.5 +/- 4.21 microg/mL.",Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17969194/),[h·μg] / [ml],47.0,30891,DB00091,Cyclosporine
,17969194,maximum plasma concentration,"Mean MPA AUC(0-12) and maximum plasma concentration values were 22.7 +/- 10.5 microg x hour/mL and 7.23 +/- 3.27 microg/mL, respectively; values normalized to 600 mg/m(2) (the approved pediatric dose in renal transplantation) were 47.0 +/- 21.8 microg x hour/mL and 14.5 +/- 4.21 microg/mL.",Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17969194/),[μg] / [ml],14.5,30892,DB00091,Cyclosporine
,19307937,area under the concentration-time curves (AUCs),MPA area under the concentration-time curves (AUCs) ranged from 31.8 to 102.1 (median: 52.9) mg.h(-1).,Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19307937/),[mg] / [h],52.9,30923,DB00091,Cyclosporine
,19214147,AUCs-LC-MS/MS,"MPA exposure determined with either method at different time points after transplantation agreed well (eg, 25th/50th/75th percentile of day 10 AUCs-LC-MS/MS: 25.8/33.8/45.2 versus enzymatic assay: 26.2/34.4/45.3 mg.h/L).",Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[h·mg] / [l],25.8,30938,DB00091,Cyclosporine
,19214147,AUCs-LC-MS/MS,"MPA exposure determined with either method at different time points after transplantation agreed well (eg, 25th/50th/75th percentile of day 10 AUCs-LC-MS/MS: 25.8/33.8/45.2 versus enzymatic assay: 26.2/34.4/45.3 mg.h/L).",Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[h·mg] / [l],33.8,30939,DB00091,Cyclosporine
,19214147,AUCs-LC-MS/MS,"MPA exposure determined with either method at different time points after transplantation agreed well (eg, 25th/50th/75th percentile of day 10 AUCs-LC-MS/MS: 25.8/33.8/45.2 versus enzymatic assay: 26.2/34.4/45.3 mg.h/L).",Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[h·mg] / [l],45.2,30940,DB00091,Cyclosporine
,19214147,AUCs-LC-MS/MS,"MPA exposure determined with either method at different time points after transplantation agreed well (eg, 25th/50th/75th percentile of day 10 AUCs-LC-MS/MS: 25.8/33.8/45.2 versus enzymatic assay: 26.2/34.4/45.3 mg.h/L).",Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[h·mg] / [l],26.2,30941,DB00091,Cyclosporine
,19214147,AUCs-LC-MS/MS,"MPA exposure determined with either method at different time points after transplantation agreed well (eg, 25th/50th/75th percentile of day 10 AUCs-LC-MS/MS: 25.8/33.8/45.2 versus enzymatic assay: 26.2/34.4/45.3 mg.h/L).",Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[h·mg] / [l],34.4,30942,DB00091,Cyclosporine
,19214147,AUCs-LC-MS/MS,"MPA exposure determined with either method at different time points after transplantation agreed well (eg, 25th/50th/75th percentile of day 10 AUCs-LC-MS/MS: 25.8/33.8/45.2 versus enzymatic assay: 26.2/34.4/45.3 mg.h/L).",Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[h·mg] / [l],45.3,30943,DB00091,Cyclosporine
,19214147,AUCs,AUCs calculated for both methods were lower at the first 3 time points in patients on cyclosporine compared with tacrolimus (week 4 median cyclosporine/tacrolimus: LC-MS/MS 39.6/56.4 versus enzymatic assay 40.5/56.0 mg.h/L).,Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[h·mg] / [l],39.6,30944,DB00091,Cyclosporine
,19214147,AUCs,AUCs calculated for both methods were lower at the first 3 time points in patients on cyclosporine compared with tacrolimus (week 4 median cyclosporine/tacrolimus: LC-MS/MS 39.6/56.4 versus enzymatic assay 40.5/56.0 mg.h/L).,Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[h·mg] / [l],56.4,30945,DB00091,Cyclosporine
,19214147,AUCs,AUCs calculated for both methods were lower at the first 3 time points in patients on cyclosporine compared with tacrolimus (week 4 median cyclosporine/tacrolimus: LC-MS/MS 39.6/56.4 versus enzymatic assay 40.5/56.0 mg.h/L).,Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[h·mg] / [l],40.5,30946,DB00091,Cyclosporine
,19214147,AUCs,AUCs calculated for both methods were lower at the first 3 time points in patients on cyclosporine compared with tacrolimus (week 4 median cyclosporine/tacrolimus: LC-MS/MS 39.6/56.4 versus enzymatic assay 40.5/56.0 mg.h/L).,Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[h·mg] / [l],56.0,30947,DB00091,Cyclosporine
,19214147,AUCs,Both LC-MS/MS and the enzymatic methods revealed a tendency toward lower AUCs and predose levels in patients with biopsy-proven acute rejection (BPAR) (day 10 median: 0.9 mg/L with BPAR and 1.7 mg/L without BPAR).,Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[mg] / [l],0.9,30948,DB00091,Cyclosporine
,19214147,AUCs,Both LC-MS/MS and the enzymatic methods revealed a tendency toward lower AUCs and predose levels in patients with biopsy-proven acute rejection (BPAR) (day 10 median: 0.9 mg/L with BPAR and 1.7 mg/L without BPAR).,Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[mg] / [l],1.7,30949,DB00091,Cyclosporine
,18089382,C0,"The mean CsA dose and C0, C2, and C0/C2 ratio were 85+/-23 mg/12 hours, 123+/-41 ng/mL, 572+/-274 ng/mL and 4.8+/-2.1, respectively.",Assessment of cyclosporine pharmacokinetic parameters to facilitate conversion from C0 to C2 monitoring in heart transplant recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18089382/),[mg] / [12·h],85,31144,DB00091,Cyclosporine
,18089382,C2,"The mean CsA dose and C0, C2, and C0/C2 ratio were 85+/-23 mg/12 hours, 123+/-41 ng/mL, 572+/-274 ng/mL and 4.8+/-2.1, respectively.",Assessment of cyclosporine pharmacokinetic parameters to facilitate conversion from C0 to C2 monitoring in heart transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18089382/),[ng] / [ml],123,31145,DB00091,Cyclosporine
,18089382,C2,"The mean CsA dose and C0, C2, and C0/C2 ratio were 85+/-23 mg/12 hours, 123+/-41 ng/mL, 572+/-274 ng/mL and 4.8+/-2.1, respectively.",Assessment of cyclosporine pharmacokinetic parameters to facilitate conversion from C0 to C2 monitoring in heart transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18089382/),[ng] / [ml],572,31146,DB00091,Cyclosporine
,18089382,C0/C2 ratio,"The mean CsA dose and C0, C2, and C0/C2 ratio were 85+/-23 mg/12 hours, 123+/-41 ng/mL, 572+/-274 ng/mL and 4.8+/-2.1, respectively.",Assessment of cyclosporine pharmacokinetic parameters to facilitate conversion from C0 to C2 monitoring in heart transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18089382/),,4.8,31147,DB00091,Cyclosporine
,18089382,C0,"Among patients with C0 within our target of 100 to 150 ug/L, six had C2 above 300 to 600 ug/L as suggested by the literature.",Assessment of cyclosporine pharmacokinetic parameters to facilitate conversion from C0 to C2 monitoring in heart transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18089382/),[ug] / [l],100 to 150,31148,DB00091,Cyclosporine
above,18089382,C2,"Among patients with C0 within our target of 100 to 150 ug/L, six had C2 above 300 to 600 ug/L as suggested by the literature.",Assessment of cyclosporine pharmacokinetic parameters to facilitate conversion from C0 to C2 monitoring in heart transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18089382/),[ug] / [l],300 to 600,31149,DB00091,Cyclosporine
<,17322623,AUC(0-12 h),"Two patients (man in his 30 s; woman in her 40 s) had acute rejection with a mycophenolic acid (MPA) AUC(0-12 h) <30 microg x h x ml(-1) and low CsA AUC (AUC(0-4 h); 2,408 ng x h x ml-1, 1,735 ng x h x ml-1).",Relationship between acute rejection and cyclosporine or mycophenolic acid levels in Japanese heart transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17322623/),[h·μg] / [ml],30,31388,DB00091,Cyclosporine
,17322623,AUC (AUC(0-4 h),"Two patients (man in his 30 s; woman in her 40 s) had acute rejection with a mycophenolic acid (MPA) AUC(0-12 h) <30 microg x h x ml(-1) and low CsA AUC (AUC(0-4 h); 2,408 ng x h x ml-1, 1,735 ng x h x ml-1).",Relationship between acute rejection and cyclosporine or mycophenolic acid levels in Japanese heart transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17322623/),[h·ng] / [ml],"2,408",31389,DB00091,Cyclosporine
,17322623,AUC (AUC(0-4 h),"Two patients (man in his 30 s; woman in her 40 s) had acute rejection with a mycophenolic acid (MPA) AUC(0-12 h) <30 microg x h x ml(-1) and low CsA AUC (AUC(0-4 h); 2,408 ng x h x ml-1, 1,735 ng x h x ml-1).",Relationship between acute rejection and cyclosporine or mycophenolic acid levels in Japanese heart transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17322623/),[h·ng] / [ml],"1,735",31390,DB00091,Cyclosporine
,17322623,AUC(0-4 h),"However, 1 patient (man in his 30 s) with a high CsA AUC(0-4 h) (4,019 ng x h x ml-1) did not develop cardiac allograft rejection even if the MMF was temporarily stopped.",Relationship between acute rejection and cyclosporine or mycophenolic acid levels in Japanese heart transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17322623/),[h·ng] / [ml],"4,019",31391,DB00091,Cyclosporine
,9796957,oral bioavailability,"Calculated relative to the area under the plasma concentration-time curve of i.v. administered paclitaxel in mice treated without cyclosporin A, the oral bioavailability of paclitaxel increased from 9.3% up to 67% with coadministration of cyclosporin A.",Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9796957/),%,9.3,31811,DB00091,Cyclosporine
,9796957,oral bioavailability,"Calculated relative to the area under the plasma concentration-time curve of i.v. administered paclitaxel in mice treated without cyclosporin A, the oral bioavailability of paclitaxel increased from 9.3% up to 67% with coadministration of cyclosporin A.",Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9796957/),%,67,31812,DB00091,Cyclosporine
,23813218,trough level,"We conducted a randomized, multicenter, open-label, crossover study comparing the efficacy and safety of a 1-year treatment with mycophenolate mofetil (MMF; target plasma mycophenolic acid trough level of 1.5-2.5 µg/ml) or CsA (target trough level of 80-100 ng/ml) in 60 pediatric patients with FR-SSNS.",Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23813218/),[μg] / [ml],1.5-2.5,31840,DB00091,Cyclosporine
,23813218,trough level,"We conducted a randomized, multicenter, open-label, crossover study comparing the efficacy and safety of a 1-year treatment with mycophenolate mofetil (MMF; target plasma mycophenolic acid trough level of 1.5-2.5 µg/ml) or CsA (target trough level of 80-100 ng/ml) in 60 pediatric patients with FR-SSNS.",Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23813218/),[ng] / [ml],80-100,31841,DB00091,Cyclosporine
<,23813218,AUC,"In post hoc analysis, patients with low mycophenolic acid exposure (AUC <50 µg⋅h/ml) experienced 1.4 relapses per year compared with 0.27 relapses per year in those with high exposure (AUC>50 µg⋅h/ml; P<0.05).",Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23813218/),[h·μg] / [ml],50,31842,DB00091,Cyclosporine
>,23813218,AUC,"In post hoc analysis, patients with low mycophenolic acid exposure (AUC <50 µg⋅h/ml) experienced 1.4 relapses per year compared with 0.27 relapses per year in those with high exposure (AUC>50 µg⋅h/ml; P<0.05).",Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23813218/),[h·μg] / [ml],50,31843,DB00091,Cyclosporine
,7652760,clearance,The 7 patients with a rejection within the first 10 days had a methylprednisolone clearance of 437 ml/min (162-756) that was significantly higher than the 220 ml/min (121-604) in the 22 patients without a rejection episode (P = 0.04).,Pharmacokinetics of methylprednisolone and rejection episodes in kidney transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7652760/),[ml] / [min],437,32175,DB00091,Cyclosporine
,7652760,clearance,The 7 patients with a rejection within the first 10 days had a methylprednisolone clearance of 437 ml/min (162-756) that was significantly higher than the 220 ml/min (121-604) in the 22 patients without a rejection episode (P = 0.04).,Pharmacokinetics of methylprednisolone and rejection episodes in kidney transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7652760/),[ml] / [min],220,32176,DB00091,Cyclosporine
,7652760,elimination half-life,"In the complete group of 18 patients having a transplant rejection episode within 6 months, the methylprednisolone elimination half-life after oral dosage was 2.5 hr (1.6-3.9) and significantly shorter than 2.9 hr (1.7-4.0) in 22 patients without rejections (P = 0.03).",Pharmacokinetics of methylprednisolone and rejection episodes in kidney transplant patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7652760/),h,2.5,32177,DB00091,Cyclosporine
shorter,7652760,elimination half-life,"In the complete group of 18 patients having a transplant rejection episode within 6 months, the methylprednisolone elimination half-life after oral dosage was 2.5 hr (1.6-3.9) and significantly shorter than 2.9 hr (1.7-4.0) in 22 patients without rejections (P = 0.03).",Pharmacokinetics of methylprednisolone and rejection episodes in kidney transplant patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7652760/),h,2.9,32178,DB00091,Cyclosporine
,11897977,free fraction,"The average MPA free fraction in healthy adult individuals, stable renal transplant recipients, and heart transplant recipients is approximately 2 to 3%.",Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11897977/),%,2 to 3,32179,DB00091,Cyclosporine
,11897977,AUC,"Mean (+/- SD) AUC was 45.78 +/- 18.35 microg.h/mL (range, 16.56-74.22 microg.h/mL), Cmax was 17.37 +/- 7.69 microg/mL (range, 4.92-26.63 microg/mL), Tmax was 1.2 +/- 0.4 hours (range, 1.0-2.0 h), Cmin was 3.12 +/- 1.41 microg/mL (range, 1.47-4.82 microg/mL), f was 2.90 +/- 0.56% (range, 2.00-3.40%), and free MPA AUC was 1.29 +/- 0.50 microg.h/mL (range, 0.54-1.88 microg.h/mL).",Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11897977/),[h·μg] / [ml],45.78,32180,DB00091,Cyclosporine
,11897977,Cmax,"Mean (+/- SD) AUC was 45.78 +/- 18.35 microg.h/mL (range, 16.56-74.22 microg.h/mL), Cmax was 17.37 +/- 7.69 microg/mL (range, 4.92-26.63 microg/mL), Tmax was 1.2 +/- 0.4 hours (range, 1.0-2.0 h), Cmin was 3.12 +/- 1.41 microg/mL (range, 1.47-4.82 microg/mL), f was 2.90 +/- 0.56% (range, 2.00-3.40%), and free MPA AUC was 1.29 +/- 0.50 microg.h/mL (range, 0.54-1.88 microg.h/mL).",Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11897977/),[μg] / [ml],17.37,32181,DB00091,Cyclosporine
,11897977,Tmax,"Mean (+/- SD) AUC was 45.78 +/- 18.35 microg.h/mL (range, 16.56-74.22 microg.h/mL), Cmax was 17.37 +/- 7.69 microg/mL (range, 4.92-26.63 microg/mL), Tmax was 1.2 +/- 0.4 hours (range, 1.0-2.0 h), Cmin was 3.12 +/- 1.41 microg/mL (range, 1.47-4.82 microg/mL), f was 2.90 +/- 0.56% (range, 2.00-3.40%), and free MPA AUC was 1.29 +/- 0.50 microg.h/mL (range, 0.54-1.88 microg.h/mL).",Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11897977/),h,1.2,32182,DB00091,Cyclosporine
,11897977,Cmin,"Mean (+/- SD) AUC was 45.78 +/- 18.35 microg.h/mL (range, 16.56-74.22 microg.h/mL), Cmax was 17.37 +/- 7.69 microg/mL (range, 4.92-26.63 microg/mL), Tmax was 1.2 +/- 0.4 hours (range, 1.0-2.0 h), Cmin was 3.12 +/- 1.41 microg/mL (range, 1.47-4.82 microg/mL), f was 2.90 +/- 0.56% (range, 2.00-3.40%), and free MPA AUC was 1.29 +/- 0.50 microg.h/mL (range, 0.54-1.88 microg.h/mL).",Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11897977/),[μg] / [ml],3.12,32183,DB00091,Cyclosporine
,11897977,f,"Mean (+/- SD) AUC was 45.78 +/- 18.35 microg.h/mL (range, 16.56-74.22 microg.h/mL), Cmax was 17.37 +/- 7.69 microg/mL (range, 4.92-26.63 microg/mL), Tmax was 1.2 +/- 0.4 hours (range, 1.0-2.0 h), Cmin was 3.12 +/- 1.41 microg/mL (range, 1.47-4.82 microg/mL), f was 2.90 +/- 0.56% (range, 2.00-3.40%), and free MPA AUC was 1.29 +/- 0.50 microg.h/mL (range, 0.54-1.88 microg.h/mL).",Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11897977/),%,2.90,32184,DB00091,Cyclosporine
,11897977,AUC,"Mean (+/- SD) AUC was 45.78 +/- 18.35 microg.h/mL (range, 16.56-74.22 microg.h/mL), Cmax was 17.37 +/- 7.69 microg/mL (range, 4.92-26.63 microg/mL), Tmax was 1.2 +/- 0.4 hours (range, 1.0-2.0 h), Cmin was 3.12 +/- 1.41 microg/mL (range, 1.47-4.82 microg/mL), f was 2.90 +/- 0.56% (range, 2.00-3.40%), and free MPA AUC was 1.29 +/- 0.50 microg.h/mL (range, 0.54-1.88 microg.h/mL).",Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11897977/),[h·μg] / [ml],1.29,32185,DB00091,Cyclosporine
,24623479,CLuptake,"Estimated repaglinide CLuptake corresponded to 217 and 113 μL/min/10(6) cells for SLCO1B1 c.521TT/TC and CC, respectively.",Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24623479/),[min·μl] / [10(6)·cells],217,32378,DB00091,Cyclosporine
,24623479,CLuptake,"Estimated repaglinide CLuptake corresponded to 217 and 113 μL/min/10(6) cells for SLCO1B1 c.521TT/TC and CC, respectively.",Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24623479/),[min·μl] / [10(6)·cells],113,32379,DB00091,Cyclosporine
,16787721,relative bioavailability,The relative bioavailability of S-CyA-S100 NP initial compared with Neoral was 162.8%.,Long-term studies on the stability and oral bioavailability of cyclosporine A nanoparticle colloid. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16787721/),%,162.8,32434,DB00091,Cyclosporine
,1627753,trough CsA,The baseline trough CsA levels of the patients were 208 +/- 92 ng/mL.,A pilot study to assess the ability of an orally available selective thromboxane synthase inhibitor to improve renal function in cyclosporine-treated renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1627753/),[ng] / [ml],208,32679,DB00091,Cyclosporine
,16419071,progression-free survival,Median progression-free survival was 7 months with VAD alone and 4.9 months with valspodar (P = 0.50).,"Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16419071/),month,7,32967,DB00091,Cyclosporine
,16419071,progression-free survival,Median progression-free survival was 7 months with VAD alone and 4.9 months with valspodar (P = 0.50).,"Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16419071/),month,4.9,32968,DB00091,Cyclosporine
,16419071,Subjective response,Subjective response was 19% with VAD alone and 17% with valspodar (P = 1.0).,"Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16419071/),,19,32969,DB00091,Cyclosporine
,16419071,survival,Median survival with VAD alone was 18.5 months and 15.3 with the addition of valspodar (P = 0.055).,"Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16419071/),month,18.,32970,DB00091,Cyclosporine
,16419071,Toxicity,Toxicity of Grade 3 or greater was higher (P < 0.0001) in the valspodar arm (89%) compared with the VAD-alone arm (58%).,"Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16419071/),%,89,32971,DB00091,Cyclosporine
,16419071,Toxicity,Toxicity of Grade 3 or greater was higher (P < 0.0001) in the valspodar arm (89%) compared with the VAD-alone arm (58%).,"Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16419071/),%,58,32972,DB00091,Cyclosporine
,30335192,Cmax ratios,The effect of GDC-0810 on pravastatin PK was predicted to be low to moderate (pravastatin Cmax ratios 1.01-2.05 and AUC ratio 1.04-2.23).,Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30335192/),,1.01-2.05,33112,DB00091,Cyclosporine
,30335192,AUC ratio,The effect of GDC-0810 on pravastatin PK was predicted to be low to moderate (pravastatin Cmax ratios 1.01-2.05 and AUC ratio 1.04-2.23).,Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30335192/),,1.04-2.23,33113,DB00091,Cyclosporine
,30335192,Cmax ratio,The observed tDDI (Cmax ratio 1.20 and AUC ratio 1.41) was within the range of the predicted values.,Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30335192/),,1.20,33114,DB00091,Cyclosporine
,30335192,AUC ratio,The observed tDDI (Cmax ratio 1.20 and AUC ratio 1.41) was within the range of the predicted values.,Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30335192/),,1.20,33115,DB00091,Cyclosporine
,30335192,AUC ratio,The observed tDDI (Cmax ratio 1.20 and AUC ratio 1.41) was within the range of the predicted values.,Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30335192/),,1.41,33116,DB00091,Cyclosporine
,15138297,maximum concentration (C(max)),"Cyclosporine coadministration compared with FTY720 given alone did not significantly alter FTY720 maximum concentration (C(max)) (0.57 +/- 0.17 vs 0.58 +/- 0.19. ng/mL, respectively) or AUC(0-t) (41 +/- 13 vs 41 +/- 13 ng. h/mL, respectively).",FTY720 and cyclosporine: evaluation for a pharmacokinetic interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15138297/),[ng] / [ml],0.57,33214,DB00091,Cyclosporine
,15138297,maximum concentration (C(max)),"Cyclosporine coadministration compared with FTY720 given alone did not significantly alter FTY720 maximum concentration (C(max)) (0.57 +/- 0.17 vs 0.58 +/- 0.19. ng/mL, respectively) or AUC(0-t) (41 +/- 13 vs 41 +/- 13 ng. h/mL, respectively).",FTY720 and cyclosporine: evaluation for a pharmacokinetic interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15138297/),[ng] / [ml],0.58,33215,DB00091,Cyclosporine
,15138297,AUC(0-t),"Cyclosporine coadministration compared with FTY720 given alone did not significantly alter FTY720 maximum concentration (C(max)) (0.57 +/- 0.17 vs 0.58 +/- 0.19. ng/mL, respectively) or AUC(0-t) (41 +/- 13 vs 41 +/- 13 ng. h/mL, respectively).",FTY720 and cyclosporine: evaluation for a pharmacokinetic interaction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15138297/),[h·ng] / [ml],41,33216,DB00091,Cyclosporine
,15138297,steady-state Cmax,"Likewise for cyclosporine, FTY720 coadministration did not alter the steady-state Cmax compared with cyclosporine given alone (1452 +/- 308 vs 1376 +/- 149 ng/mL, respectively) or AUC(tau) (6385 +/- 1578 vs 6031 +/- 1051 ng. h/mL, respectively).",FTY720 and cyclosporine: evaluation for a pharmacokinetic interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15138297/),[ng] / [ml],1452,33217,DB00091,Cyclosporine
,15138297,steady-state Cmax,"Likewise for cyclosporine, FTY720 coadministration did not alter the steady-state Cmax compared with cyclosporine given alone (1452 +/- 308 vs 1376 +/- 149 ng/mL, respectively) or AUC(tau) (6385 +/- 1578 vs 6031 +/- 1051 ng. h/mL, respectively).",FTY720 and cyclosporine: evaluation for a pharmacokinetic interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15138297/),[ng] / [ml],1376,33218,DB00091,Cyclosporine
,15138297,AUC(tau),"Likewise for cyclosporine, FTY720 coadministration did not alter the steady-state Cmax compared with cyclosporine given alone (1452 +/- 308 vs 1376 +/- 149 ng/mL, respectively) or AUC(tau) (6385 +/- 1578 vs 6031 +/- 1051 ng. h/mL, respectively).",FTY720 and cyclosporine: evaluation for a pharmacokinetic interaction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15138297/),[h·ng] / [ml],6385,33219,DB00091,Cyclosporine
,15138297,AUC(tau),"Likewise for cyclosporine, FTY720 coadministration did not alter the steady-state Cmax compared with cyclosporine given alone (1452 +/- 308 vs 1376 +/- 149 ng/mL, respectively) or AUC(tau) (6385 +/- 1578 vs 6031 +/- 1051 ng. h/mL, respectively).",FTY720 and cyclosporine: evaluation for a pharmacokinetic interaction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15138297/),[h·ng] / [ml],6031,33220,DB00091,Cyclosporine
,9631925,T1/2,"For the entire population (n = 69 patients), the average CsA CL and terminal half-life (T1/2) were, respectively: CL (l/h) = 0.256 x weight (kg); T1/2 = 11.0 hours, or CL (l/h) = 0.184 x weight (kg); T1/2 = 14.7 hours, if there was concomitant diltiazem administration.",NONMEM population pharmacokinetic modeling of orally administered cyclosporine from routine drug monitoring data after heart transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9631925/),h,11.0,33476,DB00091,Cyclosporine
,9631925,CL,"For the entire population (n = 69 patients), the average CsA CL and terminal half-life (T1/2) were, respectively: CL (l/h) = 0.256 x weight (kg); T1/2 = 11.0 hours, or CL (l/h) = 0.184 x weight (kg); T1/2 = 14.7 hours, if there was concomitant diltiazem administration.",NONMEM population pharmacokinetic modeling of orally administered cyclosporine from routine drug monitoring data after heart transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9631925/),[l] / [h],0,33477,DB00091,Cyclosporine
,9631925,T1/2,"For the entire population (n = 69 patients), the average CsA CL and terminal half-life (T1/2) were, respectively: CL (l/h) = 0.256 x weight (kg); T1/2 = 11.0 hours, or CL (l/h) = 0.184 x weight (kg); T1/2 = 14.7 hours, if there was concomitant diltiazem administration.",NONMEM population pharmacokinetic modeling of orally administered cyclosporine from routine drug monitoring data after heart transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9631925/),h,14.7,33478,DB00091,Cyclosporine
,12404880,radioactivity concentration,"After i.v. administration of 14C-labeled TAK-044 ([14C]TAK-044 alone at a dose of 3 mg/kg, the radioactivity concentration in the plasma was 1.65 micrograms/ml at 5 min and decreased biphasically with half-lives of 0.09 h and 0.39 h.","Pharmacokinetic interaction between TAK-044, a new endothelin antagonist, and ciclosporin in rats. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404880/),,1.,34172,DB00091,Cyclosporine
,12404880,half-lives,"After i.v. administration of 14C-labeled TAK-044 ([14C]TAK-044 alone at a dose of 3 mg/kg, the radioactivity concentration in the plasma was 1.65 micrograms/ml at 5 min and decreased biphasically with half-lives of 0.09 h and 0.39 h.","Pharmacokinetic interaction between TAK-044, a new endothelin antagonist, and ciclosporin in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404880/),h,0.09,34173,DB00091,Cyclosporine
,12404880,half-lives,"After i.v. administration of 14C-labeled TAK-044 ([14C]TAK-044 alone at a dose of 3 mg/kg, the radioactivity concentration in the plasma was 1.65 micrograms/ml at 5 min and decreased biphasically with half-lives of 0.09 h and 0.39 h.","Pharmacokinetic interaction between TAK-044, a new endothelin antagonist, and ciclosporin in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404880/),h,0.39,34174,DB00091,Cyclosporine
,12404880,AUC0-1 h,AUC0-1 h was 0.38 microgram.h/ml.,"Pharmacokinetic interaction between TAK-044, a new endothelin antagonist, and ciclosporin in rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404880/),[h·μg] / [ml],0.38,34175,DB00091,Cyclosporine
,11605779,g,"Eight children were studied with a median age of 10.6 years, a mean glomerular filtration rate (inulin clearance) of 55 ml/min per 1.73 m2 (range 29-95), and a mean follow-up after transplantation of 5.6 months.",Renal hemodynamic effect of tacrolimus in renal transplanted children. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11605779/),[ml] / [1.73·m2·min],55,34514,DB00091,Cyclosporine
,11605779,ERPF,"Average ERPF at the start of the test was 289 ml/min per 1.73 m2 (range 177-404, SD +/- 106).",Renal hemodynamic effect of tacrolimus in renal transplanted children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11605779/),[ml] / [1.73·m2·min],289,34515,DB00091,Cyclosporine
,10952769,Ki,"When triazolam is the P450 3A4 substrate and ketoconazole the competitive inhibitor, Ki approximately 1.2 microg/mL in humans.",Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10952769/),[μg] / [ml],1.2,34568,DB00091,Cyclosporine
,10952769,hepatic extraction,"For example, human terfenadine hepatic extraction goes from 95% in the absence of a competitive inhibitor to 35% in the presence of one (ketoconazole, 200 mg po Q 12 h dosed to steady-state).",Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10952769/),%,95,34569,DB00091,Cyclosporine
,10952769,hepatic extraction,"For example, human terfenadine hepatic extraction goes from 95% in the absence of a competitive inhibitor to 35% in the presence of one (ketoconazole, 200 mg po Q 12 h dosed to steady-state).",Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10952769/),%,35,34570,DB00091,Cyclosporine
,14749551,area under the curve (AUC),"Mean +/- SD of area under the curve (AUC), maximum concentration (C(max)), and concentration at the second hour (C2) of Zinograf were not statistically different from those with Neoral (4019 +/- 1466 vs 3971 +/- 1325 ng x h/mL, 998 +/- 376 vs 1021 +/- 356 ng/mL, and 707 +/- 254 vs 734 +/- 229 ng/mL, respectively).",Bioequivalence of a new cyclosporine a formulation to Neoral. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749551/),[h·ng] / [ml],4019,34870,DB00091,Cyclosporine
,14749551,maximum concentration (C(max)),"Mean +/- SD of area under the curve (AUC), maximum concentration (C(max)), and concentration at the second hour (C2) of Zinograf were not statistically different from those with Neoral (4019 +/- 1466 vs 3971 +/- 1325 ng x h/mL, 998 +/- 376 vs 1021 +/- 356 ng/mL, and 707 +/- 254 vs 734 +/- 229 ng/mL, respectively).",Bioequivalence of a new cyclosporine a formulation to Neoral. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749551/),[h·ng] / [ml],3971,34871,DB00091,Cyclosporine
,14749551,maximum concentration (C(max)),"Mean +/- SD of area under the curve (AUC), maximum concentration (C(max)), and concentration at the second hour (C2) of Zinograf were not statistically different from those with Neoral (4019 +/- 1466 vs 3971 +/- 1325 ng x h/mL, 998 +/- 376 vs 1021 +/- 356 ng/mL, and 707 +/- 254 vs 734 +/- 229 ng/mL, respectively).",Bioequivalence of a new cyclosporine a formulation to Neoral. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749551/),[ng] / [ml],998,34872,DB00091,Cyclosporine
,14749551,maximum concentration (C(max)),"Mean +/- SD of area under the curve (AUC), maximum concentration (C(max)), and concentration at the second hour (C2) of Zinograf were not statistically different from those with Neoral (4019 +/- 1466 vs 3971 +/- 1325 ng x h/mL, 998 +/- 376 vs 1021 +/- 356 ng/mL, and 707 +/- 254 vs 734 +/- 229 ng/mL, respectively).",Bioequivalence of a new cyclosporine a formulation to Neoral. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749551/),[ng] / [ml],1021,34873,DB00091,Cyclosporine
,14749551,concentration at the second hour (C2),"Mean +/- SD of area under the curve (AUC), maximum concentration (C(max)), and concentration at the second hour (C2) of Zinograf were not statistically different from those with Neoral (4019 +/- 1466 vs 3971 +/- 1325 ng x h/mL, 998 +/- 376 vs 1021 +/- 356 ng/mL, and 707 +/- 254 vs 734 +/- 229 ng/mL, respectively).",Bioequivalence of a new cyclosporine a formulation to Neoral. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749551/),[ng] / [ml],1021,34874,DB00091,Cyclosporine
,14749551,concentration at the second hour (C2),"Mean +/- SD of area under the curve (AUC), maximum concentration (C(max)), and concentration at the second hour (C2) of Zinograf were not statistically different from those with Neoral (4019 +/- 1466 vs 3971 +/- 1325 ng x h/mL, 998 +/- 376 vs 1021 +/- 356 ng/mL, and 707 +/- 254 vs 734 +/- 229 ng/mL, respectively).",Bioequivalence of a new cyclosporine a formulation to Neoral. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749551/),[ng] / [ml],707,34875,DB00091,Cyclosporine
,14749551,concentration at the second hour (C2),"Mean +/- SD of area under the curve (AUC), maximum concentration (C(max)), and concentration at the second hour (C2) of Zinograf were not statistically different from those with Neoral (4019 +/- 1466 vs 3971 +/- 1325 ng x h/mL, 998 +/- 376 vs 1021 +/- 356 ng/mL, and 707 +/- 254 vs 734 +/- 229 ng/mL, respectively).",Bioequivalence of a new cyclosporine a formulation to Neoral. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749551/),[ng] / [ml],734,34876,DB00091,Cyclosporine
,8881903,PASI,In Group B mean PASI decreased from 20.3 to 3.7 (P < 0.05) at a dose of 3.1 mg/kg per day.,"Increased bioavailability and improved efficacy, in severe psoriasis, of a new microemulsion formulation of cyclosporin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8881903/),,20.3,34907,DB00091,Cyclosporine
,8881903,tmax,Pharmacokinetic data demonstrated significant decrease in tmax from 2.3 to 1.4 hours.,"Increased bioavailability and improved efficacy, in severe psoriasis, of a new microemulsion formulation of cyclosporin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8881903/),h,2.3,34908,DB00091,Cyclosporine
,8881903,tmax,Pharmacokinetic data demonstrated significant decrease in tmax from 2.3 to 1.4 hours.,"Increased bioavailability and improved efficacy, in severe psoriasis, of a new microemulsion formulation of cyclosporin. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8881903/),h,1.4,34909,DB00091,Cyclosporine
,21546866,Acute cellular rejection rate,"Acute cellular rejection rate was lower in the 4-hr CYA-IV group (0%) compared with the CYA-ME group (17%, P=0.038).",Cyclosporine A-based immunotherapy in adult living donor liver transplantation: accurate and improved therapeutic drug monitoring by 4-hr intravenous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21546866/),%,0,34931,DB00091,Cyclosporine
,21546866,Acute cellular rejection rate,"Acute cellular rejection rate was lower in the 4-hr CYA-IV group (0%) compared with the CYA-ME group (17%, P=0.038).",Cyclosporine A-based immunotherapy in adult living donor liver transplantation: accurate and improved therapeutic drug monitoring by 4-hr intravenous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21546866/),,17,34932,DB00091,Cyclosporine
<,7932103,Tmax,"The patients were divided into three absorption phase groups with the Tmax times as follows, group A (n = 26); OH < or = Tmax < 3 h, group B (n = 6); 3 h < or = Tmax < 6 h and group C (n = 11); 6 h < or = Tmax < or = 12 h.",[Cyclosporine level in blood as monitored by area-under-the-curve (AUC). The influence of absorption phase after orally dosing]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7932103/),h,3,35034,DB00091,Cyclosporine
,7932103,Tmax,"The patients were divided into three absorption phase groups with the Tmax times as follows, group A (n = 26); OH < or = Tmax < 3 h, group B (n = 6); 3 h < or = Tmax < 6 h and group C (n = 11); 6 h < or = Tmax < or = 12 h.",[Cyclosporine level in blood as monitored by area-under-the-curve (AUC). The influence of absorption phase after orally dosing]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7932103/),h,3,35035,DB00091,Cyclosporine
<,7932103,Tmax,"The patients were divided into three absorption phase groups with the Tmax times as follows, group A (n = 26); OH < or = Tmax < 3 h, group B (n = 6); 3 h < or = Tmax < 6 h and group C (n = 11); 6 h < or = Tmax < or = 12 h.",[Cyclosporine level in blood as monitored by area-under-the-curve (AUC). The influence of absorption phase after orally dosing]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7932103/),h,6,35036,DB00091,Cyclosporine
,7932103,Tmax,"The patients were divided into three absorption phase groups with the Tmax times as follows, group A (n = 26); OH < or = Tmax < 3 h, group B (n = 6); 3 h < or = Tmax < 6 h and group C (n = 11); 6 h < or = Tmax < or = 12 h.",[Cyclosporine level in blood as monitored by area-under-the-curve (AUC). The influence of absorption phase after orally dosing]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7932103/),h,6,35037,DB00091,Cyclosporine
<,7932103,Tmax,"The patients were divided into three absorption phase groups with the Tmax times as follows, group A (n = 26); OH < or = Tmax < 3 h, group B (n = 6); 3 h < or = Tmax < 6 h and group C (n = 11); 6 h < or = Tmax < or = 12 h.",[Cyclosporine level in blood as monitored by area-under-the-curve (AUC). The influence of absorption phase after orally dosing]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7932103/),h,12,35038,DB00091,Cyclosporine
>,12890006,C2,"Patients achieving C2 > 1.5 microg/mL by the fifth postoperative day experienced no acute rejection in the first 6 months, compared with a 50% rejection rate among patients with C2 < 1.5 microg/mL (P < 0.05).",Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12890006/),[μg] / [ml],1.5,35283,DB00091,Cyclosporine
<,12890006,C2,"Patients achieving C2 > 1.5 microg/mL by the fifth postoperative day experienced no acute rejection in the first 6 months, compared with a 50% rejection rate among patients with C2 < 1.5 microg/mL (P < 0.05).",Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12890006/),[μg] / [ml],1.5,35284,DB00091,Cyclosporine
>,12890006,C2 level,Binary logistic regression analysis showed that C2 level >1.7 microg/mL was associated with approximately 90% probability of freedom from acute rejection.,Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12890006/),[μg] / [ml],1.7,35285,DB00091,Cyclosporine
,12890006,C2 target,A C2 target of 1.7 microg/mL appears appropriate in this population during the immediate post-transplant period in order to maximize clinical benefit.,Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12890006/),[μg] / [ml],1.7,35286,DB00091,Cyclosporine
,2595785,total clearance,The mean total clearance of methylprednisolone was 379 ml/hr/kg (range 105-672) and the volume of distribution was 1.4 +/- 0.5 L/kg.,Methylprednisolone disposition in renal transplant recipients receiving triple-drug immunosuppression. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595785/),[ml] / [h·kg],379,35683,DB00091,Cyclosporine
,2595785,volume of distribution,The mean total clearance of methylprednisolone was 379 ml/hr/kg (range 105-672) and the volume of distribution was 1.4 +/- 0.5 L/kg.,Methylprednisolone disposition in renal transplant recipients receiving triple-drug immunosuppression. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595785/),[l] / [kg],1.4,35684,DB00091,Cyclosporine
,2595785,plasma half-life,The mean plasma half-life was 2.7 +/- 1.1 hr.,Methylprednisolone disposition in renal transplant recipients receiving triple-drug immunosuppression. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595785/),h,2.7,35685,DB00091,Cyclosporine
,2595785,peak concentration,"When normalized to a 1 mg dose of methylprednisolone, the mean peak concentration at 1 hr was 10.0 +/- 3.5 ng/ml with an 8 hr concentration ranging from 0.3 to 5.5 ng/ml.",Methylprednisolone disposition in renal transplant recipients receiving triple-drug immunosuppression. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2595785/),[ng] / [ml],10.0,35686,DB00091,Cyclosporine
,30567289,Tmax,"Importantly, the pharmacokinetic parameters were improved by extending Tmax from 2 to 3 h after the oral administration in rats, and eventually preventing the enterohepatic circulation.",Enhanced Dissolution and Oral Bioavailability of Cyclosporine A: Microspheres Based on αβ-Cyclodextrins Polymers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30567289/),h,2,36264,DB00091,Cyclosporine
,30567289,Tmax,"Importantly, the pharmacokinetic parameters were improved by extending Tmax from 2 to 3 h after the oral administration in rats, and eventually preventing the enterohepatic circulation.",Enhanced Dissolution and Oral Bioavailability of Cyclosporine A: Microspheres Based on αβ-Cyclodextrins Polymers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30567289/),h,3,36265,DB00091,Cyclosporine
,8302687,maximum blood concentration (Cmax),"For all three treatments, the mean maximum blood concentration (Cmax) of approximately 1100 ng/ml was reached at about 1.3 hours (tmax) after administration; the area under the blood concentration-time curve (AUC) was, on average, 4700 ng.hr/ml.",Bioequivalence of soft gelatin capsules and oral solution of a new cyclosporine formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8302687/),[ng] / [ml],1100,37720,DB00091,Cyclosporine
,8302687,tmax,"For all three treatments, the mean maximum blood concentration (Cmax) of approximately 1100 ng/ml was reached at about 1.3 hours (tmax) after administration; the area under the blood concentration-time curve (AUC) was, on average, 4700 ng.hr/ml.",Bioequivalence of soft gelatin capsules and oral solution of a new cyclosporine formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8302687/),h,1.3,37721,DB00091,Cyclosporine
,8302687,area under the blood concentration-time curve (AUC),"For all three treatments, the mean maximum blood concentration (Cmax) of approximately 1100 ng/ml was reached at about 1.3 hours (tmax) after administration; the area under the blood concentration-time curve (AUC) was, on average, 4700 ng.hr/ml.",Bioequivalence of soft gelatin capsules and oral solution of a new cyclosporine formulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8302687/),[h·ng] / [ml],4700,37722,DB00091,Cyclosporine
,16722827,elimination rate constant of,The model analysis revealed that the induction of the detoxicating proteins by SJW was saturable with an elimination rate constant of the detoxicating proteins (ke) of 4.72 month(-1).,Pharmacokinetic modelling of the interaction between St John's wort and ciclosporin A. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16722827/),1/[month],4.72,38155,DB00091,Cyclosporine
,16722827,Elimination half-life,"Elimination half-life of the detoxicating proteins calculated from the ke value was 4.4 days, suggesting that the dose of CsA should be carefully monitored for up to 2 weeks after the cessation of SJW intake.",Pharmacokinetic modelling of the interaction between St John's wort and ciclosporin A. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16722827/),d,4.4,38156,DB00091,Cyclosporine
,14633187,AUC,"Mean values for the i.v. data included AUC (7413 ng/mL.h), t1/2 distribution and elimination (0.705 and 9.7 h, respectively), Cmax (1513 ng/mL), and Vd(ss) (1.71 L/kg).",Disposition of cyclosporine after intravenous and multi-dose oral administration in cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633187/),[ng] / [h·ml],7413,38388,DB00091,Cyclosporine
,14633187,t1/2 distribution,"Mean values for the i.v. data included AUC (7413 ng/mL.h), t1/2 distribution and elimination (0.705 and 9.7 h, respectively), Cmax (1513 ng/mL), and Vd(ss) (1.71 L/kg).",Disposition of cyclosporine after intravenous and multi-dose oral administration in cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633187/),h,0.705,38389,DB00091,Cyclosporine
,14633187,elimination,"Mean values for the i.v. data included AUC (7413 ng/mL.h), t1/2 distribution and elimination (0.705 and 9.7 h, respectively), Cmax (1513 ng/mL), and Vd(ss) (1.71 L/kg).",Disposition of cyclosporine after intravenous and multi-dose oral administration in cats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633187/),h,0.705,38390,DB00091,Cyclosporine
,14633187,elimination,"Mean values for the i.v. data included AUC (7413 ng/mL.h), t1/2 distribution and elimination (0.705 and 9.7 h, respectively), Cmax (1513 ng/mL), and Vd(ss) (1.71 L/kg).",Disposition of cyclosporine after intravenous and multi-dose oral administration in cats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633187/),h,9.7,38391,DB00091,Cyclosporine
,14633187,Cmax,"Mean values for the i.v. data included AUC (7413 ng/mL.h), t1/2 distribution and elimination (0.705 and 9.7 h, respectively), Cmax (1513 ng/mL), and Vd(ss) (1.71 L/kg).",Disposition of cyclosporine after intravenous and multi-dose oral administration in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633187/),[ng] / [ml],1513,38392,DB00091,Cyclosporine
,14633187,Vd(ss),"Mean values for the i.v. data included AUC (7413 ng/mL.h), t1/2 distribution and elimination (0.705 and 9.7 h, respectively), Cmax (1513 ng/mL), and Vd(ss) (1.71 L/kg).",Disposition of cyclosporine after intravenous and multi-dose oral administration in cats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633187/),[l] / [kg],1.71,38393,DB00091,Cyclosporine
,14633187,AUC,"Mean values for the oral data included AUC (6243 ng/mL.h), t1/2 of absorption and elimination (0.227 and 8.19 h, respectively), and Cmax (480.0 ng/mL).",Disposition of cyclosporine after intravenous and multi-dose oral administration in cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633187/),[ng] / [h·ml],6243,38394,DB00091,Cyclosporine
,14633187,t1/2 of absorption,"Mean values for the oral data included AUC (6243 ng/mL.h), t1/2 of absorption and elimination (0.227 and 8.19 h, respectively), and Cmax (480.0 ng/mL).",Disposition of cyclosporine after intravenous and multi-dose oral administration in cats. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633187/),h,0.227,38395,DB00091,Cyclosporine
,14633187,t1/2 of absorption,"Mean values for the oral data included AUC (6243 ng/mL.h), t1/2 of absorption and elimination (0.227 and 8.19 h, respectively), and Cmax (480.0 ng/mL).",Disposition of cyclosporine after intravenous and multi-dose oral administration in cats. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633187/),h,8.19,38396,DB00091,Cyclosporine
,14633187,elimination,"Mean values for the oral data included AUC (6243 ng/mL.h), t1/2 of absorption and elimination (0.227 and 8.19 h, respectively), and Cmax (480.0 ng/mL).",Disposition of cyclosporine after intravenous and multi-dose oral administration in cats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633187/),h,0.227,38397,DB00091,Cyclosporine
,14633187,elimination,"Mean values for the oral data included AUC (6243 ng/mL.h), t1/2 of absorption and elimination (0.227 and 8.19 h, respectively), and Cmax (480.0 ng/mL).",Disposition of cyclosporine after intravenous and multi-dose oral administration in cats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633187/),h,8.19,38398,DB00091,Cyclosporine
,14633187,Cmax,"Mean values for the oral data included AUC (6243 ng/mL.h), t1/2 of absorption and elimination (0.227 and 8.19 h, respectively), and Cmax (480.0 ng/mL).",Disposition of cyclosporine after intravenous and multi-dose oral administration in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633187/),[ng] / [ml],480.0,38399,DB00091,Cyclosporine
,14633187,Bioavailability,Bioavailability of orally administered cyclosporine was 29 and 25% on days 7 and 14 respectively.,Disposition of cyclosporine after intravenous and multi-dose oral administration in cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633187/),%,29,38400,DB00091,Cyclosporine
,14633187,Bioavailability,Bioavailability of orally administered cyclosporine was 29 and 25% on days 7 and 14 respectively.,Disposition of cyclosporine after intravenous and multi-dose oral administration in cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633187/),%,25,38401,DB00091,Cyclosporine
,32803290,AUC0-12h/D,"From 146 SNPs within 39 genes screened, AUC0-12h/D was found higher in recipients with CREB1 rs11904814 TT than with G allele carriers (3.135 ± 0.928 versus 2.084 ± 0.379 μg h ml-1 mg-1, p = 0.007).",Genetic and clinical determinants of mizoribine pharmacokinetics in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32803290/),[h·μg] / [mg·ml],3.135,38847,DB00091,Cyclosporine
,32803290,AUC0-12h/D,"From 146 SNPs within 39 genes screened, AUC0-12h/D was found higher in recipients with CREB1 rs11904814 TT than with G allele carriers (3.135 ± 0.928 versus 2.084 ± 0.379 μg h ml-1 mg-1, p = 0.007).",Genetic and clinical determinants of mizoribine pharmacokinetics in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32803290/),[h·μg] / [mg·ml],2.084,38848,DB00091,Cyclosporine
,32803290,t1/2,"Recipients with SLC28A3 rs10868138 TT had lower t1/2 as compared to C allele carriers (0.728 ± 0.189 versus 0.951 ± 0.196 h, p = 0.001).",Genetic and clinical determinants of mizoribine pharmacokinetics in renal transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32803290/),h,0.728,38849,DB00091,Cyclosporine
,32803290,t1/2,"Recipients with SLC28A3 rs10868138 TT had lower t1/2 as compared to C allele carriers (0.728 ± 0.189 versus 0.951 ± 0.196 h, p = 0.001).",Genetic and clinical determinants of mizoribine pharmacokinetics in renal transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32803290/),h,0.951,38850,DB00091,Cyclosporine
,8832486,apparent cyclosporin binding affinity (Kd),"The apparent cyclosporin binding affinity (Kd) to erythrocytes under in-vivo conditions averaged 452.2 +/- 47.6 nM (543.5 +/- 57.2 ng mL-1) for group A and 419.4 +/- 41.2 nM (504.1 +/- 49.5 ng mL-1) for group B, whereas apparent cyclosporin binding capacity (Bmax) of the blood cell averaged 0.83 +/- 0.07 nmol mL-1 for group A and 0.78 +/- 0.07 nmol mL-1 for group B.",In-vivo distribution and erythrocyte binding characteristics of cyclosporin in renal transplant patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8832486/),nM,452.2,39003,DB00091,Cyclosporine
,8832486,apparent cyclosporin binding affinity (Kd),"The apparent cyclosporin binding affinity (Kd) to erythrocytes under in-vivo conditions averaged 452.2 +/- 47.6 nM (543.5 +/- 57.2 ng mL-1) for group A and 419.4 +/- 41.2 nM (504.1 +/- 49.5 ng mL-1) for group B, whereas apparent cyclosporin binding capacity (Bmax) of the blood cell averaged 0.83 +/- 0.07 nmol mL-1 for group A and 0.78 +/- 0.07 nmol mL-1 for group B.",In-vivo distribution and erythrocyte binding characteristics of cyclosporin in renal transplant patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8832486/),[ng] / [ml],543.5,39004,DB00091,Cyclosporine
,8832486,apparent cyclosporin binding affinity (Kd),"The apparent cyclosporin binding affinity (Kd) to erythrocytes under in-vivo conditions averaged 452.2 +/- 47.6 nM (543.5 +/- 57.2 ng mL-1) for group A and 419.4 +/- 41.2 nM (504.1 +/- 49.5 ng mL-1) for group B, whereas apparent cyclosporin binding capacity (Bmax) of the blood cell averaged 0.83 +/- 0.07 nmol mL-1 for group A and 0.78 +/- 0.07 nmol mL-1 for group B.",In-vivo distribution and erythrocyte binding characteristics of cyclosporin in renal transplant patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8832486/),nM,419.4,39005,DB00091,Cyclosporine
,8832486,apparent cyclosporin binding affinity (Kd),"The apparent cyclosporin binding affinity (Kd) to erythrocytes under in-vivo conditions averaged 452.2 +/- 47.6 nM (543.5 +/- 57.2 ng mL-1) for group A and 419.4 +/- 41.2 nM (504.1 +/- 49.5 ng mL-1) for group B, whereas apparent cyclosporin binding capacity (Bmax) of the blood cell averaged 0.83 +/- 0.07 nmol mL-1 for group A and 0.78 +/- 0.07 nmol mL-1 for group B.",In-vivo distribution and erythrocyte binding characteristics of cyclosporin in renal transplant patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8832486/),[ng] / [ml],504.1,39006,DB00091,Cyclosporine
,8832486,apparent cyclosporin binding capacity (Bmax),"The apparent cyclosporin binding affinity (Kd) to erythrocytes under in-vivo conditions averaged 452.2 +/- 47.6 nM (543.5 +/- 57.2 ng mL-1) for group A and 419.4 +/- 41.2 nM (504.1 +/- 49.5 ng mL-1) for group B, whereas apparent cyclosporin binding capacity (Bmax) of the blood cell averaged 0.83 +/- 0.07 nmol mL-1 for group A and 0.78 +/- 0.07 nmol mL-1 for group B.",In-vivo distribution and erythrocyte binding characteristics of cyclosporin in renal transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8832486/),[nM] / [ml],0.83,39007,DB00091,Cyclosporine
,8832486,apparent cyclosporin binding capacity (Bmax),"The apparent cyclosporin binding affinity (Kd) to erythrocytes under in-vivo conditions averaged 452.2 +/- 47.6 nM (543.5 +/- 57.2 ng mL-1) for group A and 419.4 +/- 41.2 nM (504.1 +/- 49.5 ng mL-1) for group B, whereas apparent cyclosporin binding capacity (Bmax) of the blood cell averaged 0.83 +/- 0.07 nmol mL-1 for group A and 0.78 +/- 0.07 nmol mL-1 for group B.",In-vivo distribution and erythrocyte binding characteristics of cyclosporin in renal transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8832486/),[nM] / [ml],0.78,39008,DB00091,Cyclosporine
,8832486,Kd,"Significantly reduced average Kd (262.7 +/- 40.2 nM or 315.8 +/- 48.9 ng mL-1, P < 0.01) and Bmax (0.56 +/- 0.08 nmol mL-1, P < 0.05) values were observed during the period after Tmax (4-12 h after the drug ingestion) in group A patients.",In-vivo distribution and erythrocyte binding characteristics of cyclosporin in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8832486/),nM,262.7,39009,DB00091,Cyclosporine
,8832486,Kd,"Significantly reduced average Kd (262.7 +/- 40.2 nM or 315.8 +/- 48.9 ng mL-1, P < 0.01) and Bmax (0.56 +/- 0.08 nmol mL-1, P < 0.05) values were observed during the period after Tmax (4-12 h after the drug ingestion) in group A patients.",In-vivo distribution and erythrocyte binding characteristics of cyclosporin in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8832486/),[ng] / [ml],315.8,39010,DB00091,Cyclosporine
,8832486,Bmax,"Significantly reduced average Kd (262.7 +/- 40.2 nM or 315.8 +/- 48.9 ng mL-1, P < 0.01) and Bmax (0.56 +/- 0.08 nmol mL-1, P < 0.05) values were observed during the period after Tmax (4-12 h after the drug ingestion) in group A patients.",In-vivo distribution and erythrocyte binding characteristics of cyclosporin in renal transplant patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8832486/),[nM] / [ml],0.56,39011,DB00091,Cyclosporine
,8832486,Apparent Kd,"Apparent Kd and Bmax, determined by a nonlinear regression technique, were 131.6 +/- 29.4 and 1088.0 +/- 114.7 nM (158.2 +/- 35.4 and 1307.8 +/- 137.9 ng mL-1) and 0.178 +/- 0.024 and 0.814 +/- 0.078 nmol mL-1, respectively, during the 4-12 h period in group A patients.",In-vivo distribution and erythrocyte binding characteristics of cyclosporin in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8832486/),nM,131.6,39012,DB00091,Cyclosporine
,8832486,Apparent Kd,"Apparent Kd and Bmax, determined by a nonlinear regression technique, were 131.6 +/- 29.4 and 1088.0 +/- 114.7 nM (158.2 +/- 35.4 and 1307.8 +/- 137.9 ng mL-1) and 0.178 +/- 0.024 and 0.814 +/- 0.078 nmol mL-1, respectively, during the 4-12 h period in group A patients.",In-vivo distribution and erythrocyte binding characteristics of cyclosporin in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8832486/),nM,1088.0,39013,DB00091,Cyclosporine
,8832486,Apparent Kd,"Apparent Kd and Bmax, determined by a nonlinear regression technique, were 131.6 +/- 29.4 and 1088.0 +/- 114.7 nM (158.2 +/- 35.4 and 1307.8 +/- 137.9 ng mL-1) and 0.178 +/- 0.024 and 0.814 +/- 0.078 nmol mL-1, respectively, during the 4-12 h period in group A patients.",In-vivo distribution and erythrocyte binding characteristics of cyclosporin in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8832486/),[ng] / [ml],158.2,39014,DB00091,Cyclosporine
,8832486,Bmax,"Apparent Kd and Bmax, determined by a nonlinear regression technique, were 131.6 +/- 29.4 and 1088.0 +/- 114.7 nM (158.2 +/- 35.4 and 1307.8 +/- 137.9 ng mL-1) and 0.178 +/- 0.024 and 0.814 +/- 0.078 nmol mL-1, respectively, during the 4-12 h period in group A patients.",In-vivo distribution and erythrocyte binding characteristics of cyclosporin in renal transplant patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8832486/),nM,1088.0,39015,DB00091,Cyclosporine
,8832486,Bmax,"Apparent Kd and Bmax, determined by a nonlinear regression technique, were 131.6 +/- 29.4 and 1088.0 +/- 114.7 nM (158.2 +/- 35.4 and 1307.8 +/- 137.9 ng mL-1) and 0.178 +/- 0.024 and 0.814 +/- 0.078 nmol mL-1, respectively, during the 4-12 h period in group A patients.",In-vivo distribution and erythrocyte binding characteristics of cyclosporin in renal transplant patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8832486/),[ng] / [ml],1307.8,39016,DB00091,Cyclosporine
,8832486,Bmax,"Apparent Kd and Bmax, determined by a nonlinear regression technique, were 131.6 +/- 29.4 and 1088.0 +/- 114.7 nM (158.2 +/- 35.4 and 1307.8 +/- 137.9 ng mL-1) and 0.178 +/- 0.024 and 0.814 +/- 0.078 nmol mL-1, respectively, during the 4-12 h period in group A patients.",In-vivo distribution and erythrocyte binding characteristics of cyclosporin in renal transplant patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8832486/),[nM] / [ml],0.178,39017,DB00091,Cyclosporine
,8832486,Bmax,"Apparent Kd and Bmax, determined by a nonlinear regression technique, were 131.6 +/- 29.4 and 1088.0 +/- 114.7 nM (158.2 +/- 35.4 and 1307.8 +/- 137.9 ng mL-1) and 0.178 +/- 0.024 and 0.814 +/- 0.078 nmol mL-1, respectively, during the 4-12 h period in group A patients.",In-vivo distribution and erythrocyte binding characteristics of cyclosporin in renal transplant patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8832486/),[nM] / [ml],0.814,39018,DB00091,Cyclosporine
,15067702,C(max),"A C(max) of approximately 1300 ng/mL was found after 2 h of oral intake of four capsules, each loaded with 50 mg cyclosporin.",Cyclosporin nanoparticulate lipospheres for oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15067702/),[ng] / [ml],1300,39043,DB00091,Cyclosporine
,2316917,half life of distribution,"Resulting mean (+/- SD) pharmacokinetic variables were as follows: half life of distribution, 0.96 (+/- 0.7) hours; half life of elimination, 7.71 (+/- 2.6) hours; volume of distribution at steady state, 4.47 (+/- 2.22) L/kg; volume of the central compartment, 1.71 (+/- 0.78) L/kg; and systemic clearance, 8.95 (+/- 2.7) ml/kg/min.","Pharmacokinetics, inhibition of lymphoblast transformation, and toxicity of cyclosporine in clinically normal pigs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316917/),h,0.96,39327,DB00091,Cyclosporine
,2316917,half life of elimination,"Resulting mean (+/- SD) pharmacokinetic variables were as follows: half life of distribution, 0.96 (+/- 0.7) hours; half life of elimination, 7.71 (+/- 2.6) hours; volume of distribution at steady state, 4.47 (+/- 2.22) L/kg; volume of the central compartment, 1.71 (+/- 0.78) L/kg; and systemic clearance, 8.95 (+/- 2.7) ml/kg/min.","Pharmacokinetics, inhibition of lymphoblast transformation, and toxicity of cyclosporine in clinically normal pigs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316917/),h,7.71,39328,DB00091,Cyclosporine
,2316917,volume of distribution at steady state,"Resulting mean (+/- SD) pharmacokinetic variables were as follows: half life of distribution, 0.96 (+/- 0.7) hours; half life of elimination, 7.71 (+/- 2.6) hours; volume of distribution at steady state, 4.47 (+/- 2.22) L/kg; volume of the central compartment, 1.71 (+/- 0.78) L/kg; and systemic clearance, 8.95 (+/- 2.7) ml/kg/min.","Pharmacokinetics, inhibition of lymphoblast transformation, and toxicity of cyclosporine in clinically normal pigs. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316917/),[l] / [kg],4.47,39329,DB00091,Cyclosporine
,2316917,volume of the central compartment,"Resulting mean (+/- SD) pharmacokinetic variables were as follows: half life of distribution, 0.96 (+/- 0.7) hours; half life of elimination, 7.71 (+/- 2.6) hours; volume of distribution at steady state, 4.47 (+/- 2.22) L/kg; volume of the central compartment, 1.71 (+/- 0.78) L/kg; and systemic clearance, 8.95 (+/- 2.7) ml/kg/min.","Pharmacokinetics, inhibition of lymphoblast transformation, and toxicity of cyclosporine in clinically normal pigs. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316917/),[l] / [kg],1.71,39330,DB00091,Cyclosporine
,2316917,systemic clearance,"Resulting mean (+/- SD) pharmacokinetic variables were as follows: half life of distribution, 0.96 (+/- 0.7) hours; half life of elimination, 7.71 (+/- 2.6) hours; volume of distribution at steady state, 4.47 (+/- 2.22) L/kg; volume of the central compartment, 1.71 (+/- 0.78) L/kg; and systemic clearance, 8.95 (+/- 2.7) ml/kg/min.","Pharmacokinetics, inhibition of lymphoblast transformation, and toxicity of cyclosporine in clinically normal pigs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316917/),[ml] / [kg·min],8.95,39331,DB00091,Cyclosporine
,2316917,Oral bioavailability,"Oral bioavailability was: overall 57 (+/- 19) %; group A, 44 (+/- 11) %; group B, 78 (+/- 15) %; group C, 48 (+/- 6) %.","Pharmacokinetics, inhibition of lymphoblast transformation, and toxicity of cyclosporine in clinically normal pigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316917/),%,57,39332,DB00091,Cyclosporine
,2316917,Oral bioavailability,"Oral bioavailability was: overall 57 (+/- 19) %; group A, 44 (+/- 11) %; group B, 78 (+/- 15) %; group C, 48 (+/- 6) %.","Pharmacokinetics, inhibition of lymphoblast transformation, and toxicity of cyclosporine in clinically normal pigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316917/),%,44,39333,DB00091,Cyclosporine
,2316917,Oral bioavailability,"Oral bioavailability was: overall 57 (+/- 19) %; group A, 44 (+/- 11) %; group B, 78 (+/- 15) %; group C, 48 (+/- 6) %.","Pharmacokinetics, inhibition of lymphoblast transformation, and toxicity of cyclosporine in clinically normal pigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316917/),%,78,39334,DB00091,Cyclosporine
,2316917,Oral bioavailability,"Oral bioavailability was: overall 57 (+/- 19) %; group A, 44 (+/- 11) %; group B, 78 (+/- 15) %; group C, 48 (+/- 6) %.","Pharmacokinetics, inhibition of lymphoblast transformation, and toxicity of cyclosporine in clinically normal pigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316917/),%,48,39335,DB00091,Cyclosporine
,2316917,Time to peak concentration,Time to peak concentration was 3.55 (+/- 0.88) hours.,"Pharmacokinetics, inhibition of lymphoblast transformation, and toxicity of cyclosporine in clinically normal pigs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316917/),h,3.55,39336,DB00091,Cyclosporine
,2316917,blood 24-hour trough concentrations,"During the 22 days of daily oral cyclosporine administration, blood 24-hour trough concentrations were: group A, 224.3 (+/- 78.4) ng/ml; group B, 640.7 (+/- 174.6) ng/ml; and group C, 2,344 (+/- 1,095) ng/ml.","Pharmacokinetics, inhibition of lymphoblast transformation, and toxicity of cyclosporine in clinically normal pigs. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316917/),[ng] / [ml],224.3,39337,DB00091,Cyclosporine
,2316917,blood 24-hour trough concentrations,"During the 22 days of daily oral cyclosporine administration, blood 24-hour trough concentrations were: group A, 224.3 (+/- 78.4) ng/ml; group B, 640.7 (+/- 174.6) ng/ml; and group C, 2,344 (+/- 1,095) ng/ml.","Pharmacokinetics, inhibition of lymphoblast transformation, and toxicity of cyclosporine in clinically normal pigs. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316917/),[ng] / [ml],640.7,39338,DB00091,Cyclosporine
,2316917,blood 24-hour trough concentrations,"During the 22 days of daily oral cyclosporine administration, blood 24-hour trough concentrations were: group A, 224.3 (+/- 78.4) ng/ml; group B, 640.7 (+/- 174.6) ng/ml; and group C, 2,344 (+/- 1,095) ng/ml.","Pharmacokinetics, inhibition of lymphoblast transformation, and toxicity of cyclosporine in clinically normal pigs. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316917/),[ng] / [ml],"2,344",39339,DB00091,Cyclosporine
,17365275,apparent elimination half-life,[3H]BNP was eliminated with an apparent elimination half-life of 27.5 min after microinjection into the parietal cortex area 2 regions of the rat brain.,P-glycoprotein mediates brain-to-blood efflux transport of buprenorphine across the blood-brain barrier. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17365275/),min,27.5,39422,DB00091,Cyclosporine
,17365275,apparent efflux clearance,"The apparent efflux clearance of [3H]BNP across the BBB was 0.154 ml/min/g brain, which was calculated from the elimination rate constant (2.52 x 10- 2 min- 1) and the distribution volume in the brain (6.11 ml/g brain).",P-glycoprotein mediates brain-to-blood efflux transport of buprenorphine across the blood-brain barrier. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17365275/),[ml] / [brain·g·min],0.154,39423,DB00091,Cyclosporine
,17365275,elimination rate constant,"The apparent efflux clearance of [3H]BNP across the BBB was 0.154 ml/min/g brain, which was calculated from the elimination rate constant (2.52 x 10- 2 min- 1) and the distribution volume in the brain (6.11 ml/g brain).",P-glycoprotein mediates brain-to-blood efflux transport of buprenorphine across the blood-brain barrier. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17365275/),1·min-,2.52 x 10- 2,39424,DB00091,Cyclosporine
,17365275,distribution volume,"The apparent efflux clearance of [3H]BNP across the BBB was 0.154 ml/min/g brain, which was calculated from the elimination rate constant (2.52 x 10- 2 min- 1) and the distribution volume in the brain (6.11 ml/g brain).",P-glycoprotein mediates brain-to-blood efflux transport of buprenorphine across the blood-brain barrier. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17365275/),[ml] / [g],6.11,39425,DB00091,Cyclosporine
,16336287,Cl/F(f),"The population PK-f parameters were, for apparent clearance [mean, 95% confidence interval (interindividual CV%)] Cl/F(f) = 17.0 (13.8-20.2) L/h (27%), apparent central compartment volume of distribution, V/F(f) = 134 L (108-160) (28%), and lambda = 0.037/day (0.005-0.069) (120%).",Time-dependent pharmacokinetics of cyclosporine (Neoral) in de novo renal transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16336287/),[l] / [h],17.0,40026,DB00091,Cyclosporine
,16336287,"apparent central compartment volume of distribution, V/F(f)","The population PK-f parameters were, for apparent clearance [mean, 95% confidence interval (interindividual CV%)] Cl/F(f) = 17.0 (13.8-20.2) L/h (27%), apparent central compartment volume of distribution, V/F(f) = 134 L (108-160) (28%), and lambda = 0.037/day (0.005-0.069) (120%).",Time-dependent pharmacokinetics of cyclosporine (Neoral) in de novo renal transplant patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16336287/),l,134,40027,DB00091,Cyclosporine
,16336287,lambda,"The population PK-f parameters were, for apparent clearance [mean, 95% confidence interval (interindividual CV%)] Cl/F(f) = 17.0 (13.8-20.2) L/h (27%), apparent central compartment volume of distribution, V/F(f) = 134 L (108-160) (28%), and lambda = 0.037/day (0.005-0.069) (120%).",Time-dependent pharmacokinetics of cyclosporine (Neoral) in de novo renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16336287/),1/[d],0.037,40028,DB00091,Cyclosporine
,16336287,absorption rate k(a),The absorption rate k(a) and the parameter alpha were approximated iteratively as 4/h and 0.62 respectively.,Time-dependent pharmacokinetics of cyclosporine (Neoral) in de novo renal transplant patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16336287/),1/[h],4,40029,DB00091,Cyclosporine
,16336287,absorption rate k(a),The absorption rate k(a) and the parameter alpha were approximated iteratively as 4/h and 0.62 respectively.,Time-dependent pharmacokinetics of cyclosporine (Neoral) in de novo renal transplant patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16336287/),,0,40030,DB00091,Cyclosporine
,8009562,Cav,Correlation between predicted and actual Cav at 1 month posttransplant was poor (mean actual Cav = 365 ng/ml versus mean predicted Cav = 238 ng/ml; r2 = 0.361).,Utility of pretransplantation cyclosporine pharmacokinetic studies. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8009562/),[ng] / [ml],365,40124,DB00091,Cyclosporine
,8009562,Cav,Correlation between predicted and actual Cav at 1 month posttransplant was poor (mean actual Cav = 365 ng/ml versus mean predicted Cav = 238 ng/ml; r2 = 0.361).,Utility of pretransplantation cyclosporine pharmacokinetic studies. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8009562/),[ng] / [ml],238,40125,DB00091,Cyclosporine
,15942626,total doxorubicin clearance,The mean (range) total doxorubicin clearance decreased from 27 (10-73) ml h(-1) m(-2) in cycle 1 to 18 (3-37) ml h(-1) m(-2) with the addition of valspodar in cycle 2 (P=0.009).,"Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15942626/),[ml] / [(m)^2·h],27,40557,DB00091,Cyclosporine
,15942626,total doxorubicin clearance,The mean (range) total doxorubicin clearance decreased from 27 (10-73) ml h(-1) m(-2) in cycle 1 to 18 (3-37) ml h(-1) m(-2) with the addition of valspodar in cycle 2 (P=0.009).,"Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15942626/),[ml] / [(m)^2·h],18,40558,DB00091,Cyclosporine
,8491242,trough level,The evening trough level was significantly lower than the morning trough level; 185 ng.,On the intraindividual variability and chronobiology of cyclosporine pharmacokinetics in renal transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491242/),ng,185,40818,DB00091,Cyclosporine
,12752317,Cmins,"Cmins averaged 4.3 +/- 2.4 and 7.2 +/- 4.2 ng/mL at 0.75 and 1.5 mg bid, indicating a 20% under-proportionality at the upper dose level.",Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12752317/),[ng] / [ml],4.3,40943,DB00091,Cyclosporine
,12752317,Cmins,"Cmins averaged 4.3 +/- 2.4 and 7.2 +/- 4.2 ng/mL at 0.75 and 1.5 mg bid, indicating a 20% under-proportionality at the upper dose level.",Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12752317/),[ng] / [ml],7.2,40944,DB00091,Cyclosporine
,12752317,AUC,"AUC was dose-proportional and stable over time, averaging 77 +/- 32 and 136 +/- 57 ng.h.mL-1 at the two dose levels.",Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12752317/),[h·ng] / [ml],77,40945,DB00091,Cyclosporine
,12752317,AUC,"AUC was dose-proportional and stable over time, averaging 77 +/- 32 and 136 +/- 57 ng.h.mL-1 at the two dose levels.",Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12752317/),[h·ng] / [ml],136,40946,DB00091,Cyclosporine
,29433307,Michaelis-Menten constant ( Km),"Using stably transfected HEK293 cells, both enantiomers were found to be substrates of organic anion transporter (OAT)2 with a Michaelis-Menten constant ( Km) of ∼7-12 μM but did not show substrate affinity for other major hepatic uptake transporters.",Role of Hepatic Organic Anion Transporter 2 in the Pharmacokinetics of R- and S-Warfarin: In Vitro Studies and Mechanistic Evaluation. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29433307/),μM,∼7-12,41110,DB00091,Cyclosporine
,29433307,Km,"Uptake of both enantiomers by primary human hepatocytes was saturable ( Km ≈ 7-10 μM) and inhibitable by OAT2 inhibitors (e.g., ketoprofen) but not by OATP1B1/1B3 inhibitors (e.g., cyclosporine).",Role of Hepatic Organic Anion Transporter 2 in the Pharmacokinetics of R- and S-Warfarin: In Vitro Studies and Mechanistic Evaluation. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29433307/),μM,7-10,41111,DB00091,Cyclosporine
,1455195,bioavailability (f),"The median bioavailability (f) was 23.7% (range, 0-49.1%); the distribution volume at steady state, 2.3 l/kg (range, 1.0-3.5 l/kg); clearance (CL), 7.6 ml/min/kg (range, 4.8-10.8 ml/min/kg); and t1/2(z) 7.9 h (range, 3.2-13.9 h).",Cyclosporin pharmacokinetics after intravenous and oral administration in patients with Crohn's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1455195/),%,23.7,41297,DB00091,Cyclosporine
,1455195,distribution volume at steady state,"The median bioavailability (f) was 23.7% (range, 0-49.1%); the distribution volume at steady state, 2.3 l/kg (range, 1.0-3.5 l/kg); clearance (CL), 7.6 ml/min/kg (range, 4.8-10.8 ml/min/kg); and t1/2(z) 7.9 h (range, 3.2-13.9 h).",Cyclosporin pharmacokinetics after intravenous and oral administration in patients with Crohn's disease. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1455195/),[l] / [kg],2.3,41298,DB00091,Cyclosporine
,1455195,clearance (CL),"The median bioavailability (f) was 23.7% (range, 0-49.1%); the distribution volume at steady state, 2.3 l/kg (range, 1.0-3.5 l/kg); clearance (CL), 7.6 ml/min/kg (range, 4.8-10.8 ml/min/kg); and t1/2(z) 7.9 h (range, 3.2-13.9 h).",Cyclosporin pharmacokinetics after intravenous and oral administration in patients with Crohn's disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1455195/),[ml] / [kg·min],7.6,41299,DB00091,Cyclosporine
,1455195,t1/2(z),"The median bioavailability (f) was 23.7% (range, 0-49.1%); the distribution volume at steady state, 2.3 l/kg (range, 1.0-3.5 l/kg); clearance (CL), 7.6 ml/min/kg (range, 4.8-10.8 ml/min/kg); and t1/2(z) 7.9 h (range, 3.2-13.9 h).",Cyclosporin pharmacokinetics after intravenous and oral administration in patients with Crohn's disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1455195/),h,7.9,41300,DB00091,Cyclosporine
,12372043,AUC0-12,"Morning and evening doses were independently adjusted to reach an AUC0-12 of 6600-7200 ng h/mL and a C0 of 250-325 ng/mL, respectively.",Can a pharmacokinetic approach to immunosuppression eliminate ethnic disparities in renal allograft outcome? ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12372043/),[h·ng] / [ml],6600-7200,41559,DB00091,Cyclosporine
,12372043,C0,"Morning and evening doses were independently adjusted to reach an AUC0-12 of 6600-7200 ng h/mL and a C0 of 250-325 ng/mL, respectively.",Can a pharmacokinetic approach to immunosuppression eliminate ethnic disparities in renal allograft outcome? ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12372043/),[ng] / [ml],250-325,41560,DB00091,Cyclosporine
,12372043,AUCs,An average of 8 AUCs (range 5-13) were measured in the first 3 months.,Can a pharmacokinetic approach to immunosuppression eliminate ethnic disparities in renal allograft outcome? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12372043/),,8,41561,DB00091,Cyclosporine
,15813023,relative bioavailability,The relative bioavailability of CsA was 40% higher in subjects who carried at least one 3435C allele compared to that of TT type individuals in the study population.,[Effect of MDR1 polymorphic expression on oral disposition of cyclosporine A]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15813023/),%,40,42280,DB00091,Cyclosporine
>,26429767,specific activity,"(R)- and (S)-[(11)C]EMP yields were ~30%, with specific activity>74 GBq/μmol and radiochemical purity>99%.",(R)-[¹¹C]Emopamil as a novel tracer for imaging enhanced P-glycoprotein function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26429767/),[gbq] / [μM],74,42704,DB00091,Cyclosporine
,8719464,aerodynamic diameter,"With a jet nebulizer, the mass median aerodynamic diameter was 2.5 microns, with a standard geometric deviation of 2.3.",Nebulized cyclosporine for prevention of acute pulmonary allograft rejection in the rat: pharmacokinetic and histologic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8719464/),μns,2.5,42717,DB00091,Cyclosporine
,8719464,area under the concentration curve,"In blood, the area under the concentration curve was greater for intramuscular (80.6 ng.hr/ml) than for aerosol administrations at 10 (15.1 ng.hr/ml) and 25 mg/kg (41.0 ng.hr/ml) doses.",Nebulized cyclosporine for prevention of acute pulmonary allograft rejection in the rat: pharmacokinetic and histologic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8719464/),[h·ng] / [ml],80.6,42718,DB00091,Cyclosporine
,8719464,area under the concentration curve,"In blood, the area under the concentration curve was greater for intramuscular (80.6 ng.hr/ml) than for aerosol administrations at 10 (15.1 ng.hr/ml) and 25 mg/kg (41.0 ng.hr/ml) doses.",Nebulized cyclosporine for prevention of acute pulmonary allograft rejection in the rat: pharmacokinetic and histologic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8719464/),[h·ng] / [ml],15.1,42719,DB00091,Cyclosporine
,8719464,area under the concentration curve,"In blood, the area under the concentration curve was greater for intramuscular (80.6 ng.hr/ml) than for aerosol administrations at 10 (15.1 ng.hr/ml) and 25 mg/kg (41.0 ng.hr/ml) doses.",Nebulized cyclosporine for prevention of acute pulmonary allograft rejection in the rat: pharmacokinetic and histologic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8719464/),[h·ng] / [ml],41.0,42720,DB00091,Cyclosporine
,8719464,area under the concentration curve,"In the lungs, the area under the concentration curve was greater for the aerosol route at 25 mg/kg doses (588 ng.hr/mg) than for the low-dose (200 ng.hr/mg) or intramuscular administration (200 ng.hr/mg).",Nebulized cyclosporine for prevention of acute pulmonary allograft rejection in the rat: pharmacokinetic and histologic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8719464/),[h·ng] / [mg],588,42721,DB00091,Cyclosporine
,3957569,maximal concentration,When a single drop of 10 microliters was given CS-A reached a maximal concentration of 900-1400 ng/ml in the cornea 6 hr after application and then slowly decreased.,Pharmacokinetic of topical cyclosporin A in the rabbit eye. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957569/),[ng] / [ml],900-1400,42813,DB00091,Cyclosporine
,19584690,trough level,"In a 12-month multicenter open-label study, cardiac transplant patients received everolimus (trough level 3-8 ng/mL) with reduced cyclosporine A (CsA) or MMF (3 g/day) with standard CsA, both with corticosteroids+/-induction therapy.",Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19584690/),[ng] / [ml],3-8,42949,DB00091,Cyclosporine
,16049701,apparent clearance (CL/F),The best base model had bi-exponential elimination with a typical population (SE%) apparent clearance (CL/F) of 29 l/h (5%) and apparent volume of the central compartment of 65 l (7%).,Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16049701/),[l] / [h],29,43642,DB00091,Cyclosporine
,16049701,apparent volume of the central compartment,The best base model had bi-exponential elimination with a typical population (SE%) apparent clearance (CL/F) of 29 l/h (5%) and apparent volume of the central compartment of 65 l (7%).,Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16049701/),l,65,43643,DB00091,Cyclosporine
,7624927,oral F,"Values of the calculated kinetic parameters were oral F = 22-63%; half-life, t1/2 beta, = 11.05-13.70 h; volume of distribution, Vd, = 4.00-5.02/L/kg; total body clearance, Cl, = 4.25-4.14 ml/min/kg.",Oral and intravenous disposition of cyclosporine in psoriatic patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7624927/),%,22-63,44496,DB00091,Cyclosporine
,7624927,"half-life, t1/2 beta","Values of the calculated kinetic parameters were oral F = 22-63%; half-life, t1/2 beta, = 11.05-13.70 h; volume of distribution, Vd, = 4.00-5.02/L/kg; total body clearance, Cl, = 4.25-4.14 ml/min/kg.",Oral and intravenous disposition of cyclosporine in psoriatic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7624927/),h,11.05-13.70,44497,DB00091,Cyclosporine
,7624927,"volume of distribution, Vd","Values of the calculated kinetic parameters were oral F = 22-63%; half-life, t1/2 beta, = 11.05-13.70 h; volume of distribution, Vd, = 4.00-5.02/L/kg; total body clearance, Cl, = 4.25-4.14 ml/min/kg.",Oral and intravenous disposition of cyclosporine in psoriatic patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7624927/),1/[kg·l],4.00-5.02,44498,DB00091,Cyclosporine
,7624927,"total body clearance, Cl","Values of the calculated kinetic parameters were oral F = 22-63%; half-life, t1/2 beta, = 11.05-13.70 h; volume of distribution, Vd, = 4.00-5.02/L/kg; total body clearance, Cl, = 4.25-4.14 ml/min/kg.",Oral and intravenous disposition of cyclosporine in psoriatic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7624927/),[ml] / [kg·min],4.25-4.14,44499,DB00091,Cyclosporine
,2350530,area under the blood concentration vs time curve (AUC),"2. There was a significant increase in the area under the blood concentration vs time curve (AUC) of cyclosporin when the drug was taken together with breakfast and bile acid tablets (9078 ng ml-1 h) as compared with breakfast alone (7453 ng ml-1 h, P less than 0.05) or fasting conditions (7283 ng ml-1 h, P less than 0.01).",The effect of food and bile acid administration on the relative bioavailability of cyclosporin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350530/),[h·ng] / [ml],9078,44597,DB00091,Cyclosporine
,2350530,area under the blood concentration vs time curve (AUC),"2. There was a significant increase in the area under the blood concentration vs time curve (AUC) of cyclosporin when the drug was taken together with breakfast and bile acid tablets (9078 ng ml-1 h) as compared with breakfast alone (7453 ng ml-1 h, P less than 0.05) or fasting conditions (7283 ng ml-1 h, P less than 0.01).",The effect of food and bile acid administration on the relative bioavailability of cyclosporin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350530/),[h·ng] / [ml],7453,44598,DB00091,Cyclosporine
,2350530,area under the blood concentration vs time curve (AUC),"2. There was a significant increase in the area under the blood concentration vs time curve (AUC) of cyclosporin when the drug was taken together with breakfast and bile acid tablets (9078 ng ml-1 h) as compared with breakfast alone (7453 ng ml-1 h, P less than 0.05) or fasting conditions (7283 ng ml-1 h, P less than 0.01).",The effect of food and bile acid administration on the relative bioavailability of cyclosporin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350530/),[h·ng] / [ml],7283,44599,DB00091,Cyclosporine
,2350530,blood concentrations,There was no significant difference in the blood concentrations of cyclosporin before and after bile acid treatment (114 +/- 38 ng ml-1 vs 121 +/- 38 ng ml-1).,The effect of food and bile acid administration on the relative bioavailability of cyclosporin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2350530/),[ng] / [ml],121,44600,DB00091,Cyclosporine
,10348798,biliary excretion clearance,"One-tenth milligram per kilogram PSC 833 was sufficient to significantly reduce the biliary excretion clearance of DGX from 3.0 ml/min/kg to 0.5 ml/min/kg, whereas 3 mg/kg PSC 833 was needed to significantly reduce the biliary excretion clearance of VCR from 36 ml/min/kg to 9 ml/min/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),[ml] / [kg·min],3.0,44601,DB00091,Cyclosporine
,10348798,biliary excretion clearance,"One-tenth milligram per kilogram PSC 833 was sufficient to significantly reduce the biliary excretion clearance of DGX from 3.0 ml/min/kg to 0.5 ml/min/kg, whereas 3 mg/kg PSC 833 was needed to significantly reduce the biliary excretion clearance of VCR from 36 ml/min/kg to 9 ml/min/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),[ml] / [kg·min],0.5,44602,DB00091,Cyclosporine
,10348798,biliary excretion clearance,"One-tenth milligram per kilogram PSC 833 was sufficient to significantly reduce the biliary excretion clearance of DGX from 3.0 ml/min/kg to 0.5 ml/min/kg, whereas 3 mg/kg PSC 833 was needed to significantly reduce the biliary excretion clearance of VCR from 36 ml/min/kg to 9 ml/min/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),[ml] / [kg·min],36,44603,DB00091,Cyclosporine
,10348798,biliary excretion clearance,"One-tenth milligram per kilogram PSC 833 was sufficient to significantly reduce the biliary excretion clearance of DGX from 3.0 ml/min/kg to 0.5 ml/min/kg, whereas 3 mg/kg PSC 833 was needed to significantly reduce the biliary excretion clearance of VCR from 36 ml/min/kg to 9 ml/min/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),[ml] / [kg·min],9,44604,DB00091,Cyclosporine
,10348798,tissue-to-plasma,"The tissue-to-plasma DGX concentration ratio in the brain at 6 h after administration (0.34 versus 1.64), but not that of VCR at 2 h (1.07 versus 1.37), was significantly increased by PSC 833, 3 mg/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),,0.34,44605,DB00091,Cyclosporine
,10348798,tissue-to-plasma,"The tissue-to-plasma DGX concentration ratio in the brain at 6 h after administration (0.34 versus 1.64), but not that of VCR at 2 h (1.07 versus 1.37), was significantly increased by PSC 833, 3 mg/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),,1.64,44606,DB00091,Cyclosporine
,10348798,tissue-to-plasma,"The tissue-to-plasma DGX concentration ratio in the brain at 6 h after administration (0.34 versus 1.64), but not that of VCR at 2 h (1.07 versus 1.37), was significantly increased by PSC 833, 3 mg/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),,1.07,44607,DB00091,Cyclosporine
,10348798,tissue-to-plasma,"The tissue-to-plasma DGX concentration ratio in the brain at 6 h after administration (0.34 versus 1.64), but not that of VCR at 2 h (1.07 versus 1.37), was significantly increased by PSC 833, 3 mg/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),,1.37,44608,DB00091,Cyclosporine
,10348798,concentration ratio,"The tissue-to-plasma DGX concentration ratio in the brain at 6 h after administration (0.34 versus 1.64), but not that of VCR at 2 h (1.07 versus 1.37), was significantly increased by PSC 833, 3 mg/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),,0.34,44609,DB00091,Cyclosporine
,10348798,concentration ratio,"The tissue-to-plasma DGX concentration ratio in the brain at 6 h after administration (0.34 versus 1.64), but not that of VCR at 2 h (1.07 versus 1.37), was significantly increased by PSC 833, 3 mg/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),,1.64,44610,DB00091,Cyclosporine
,10348798,concentration ratio,"The tissue-to-plasma DGX concentration ratio in the brain at 6 h after administration (0.34 versus 1.64), but not that of VCR at 2 h (1.07 versus 1.37), was significantly increased by PSC 833, 3 mg/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),,1.07,44611,DB00091,Cyclosporine
,10348798,concentration ratio,"The tissue-to-plasma DGX concentration ratio in the brain at 6 h after administration (0.34 versus 1.64), but not that of VCR at 2 h (1.07 versus 1.37), was significantly increased by PSC 833, 3 mg/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),,1.37,44612,DB00091,Cyclosporine
,1824006,T1/2 beta,"Pharmacokinetic parameters were calculated from micro-computer pharmacokinetic programme T1/2 beta = 8.6 +/- 3.4 h, Vd = 3.2 +/- 1.3 L.kg-1.",[Pharmacokinetics of cyclosporin A in renal transplant patients after infusion]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1824006/),h,8.6,45312,DB00091,Cyclosporine
,1824006,Vd,"Pharmacokinetic parameters were calculated from micro-computer pharmacokinetic programme T1/2 beta = 8.6 +/- 3.4 h, Vd = 3.2 +/- 1.3 L.kg-1.",[Pharmacokinetics of cyclosporin A in renal transplant patients after infusion]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1824006/),[l] / [kg],3.2,45313,DB00091,Cyclosporine
,25975616,trough blood concentrations (TBC),Current recommendations state that CsA trough blood concentrations (TBC) should be maintained between 200 and 400 ng/mL despite the lack of supporting data.,Model-Based Determination of Effective Blood Concentrations of Cyclosporine for Neutrophil Response in the Treatment of Severe Aplastic Anemia in Children. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25975616/),[ng] / [ml],200 and 400,45478,DB00091,Cyclosporine
,25975616,TBC,The efficient range of CsA TBC was estimated between 87 and 120 ng/mL.,Model-Based Determination of Effective Blood Concentrations of Cyclosporine for Neutrophil Response in the Treatment of Severe Aplastic Anemia in Children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25975616/),[ng] / [ml],87 and 120,45479,DB00091,Cyclosporine
,12677364,steady-state,"Mean steady-state, dose-adjusted trough cyclosporine blood concentrations increased from 1.1+/-0.60 (day 7) to 2.0+/-1.20 ng/ml per mg (day 30, P<0.01).",Time-dependent changes in cyclosporine exposure: implications for achieving target concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12677364/),[ng] / [mg·ml],1.1,46193,DB00091,Cyclosporine
,12677364,steady-state,"Mean steady-state, dose-adjusted trough cyclosporine blood concentrations increased from 1.1+/-0.60 (day 7) to 2.0+/-1.20 ng/ml per mg (day 30, P<0.01).",Time-dependent changes in cyclosporine exposure: implications for achieving target concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12677364/),[ng] / [mg·ml],2.0,46194,DB00091,Cyclosporine
,12677364,dose-adjusted trough cyclosporine blood concentrations,"Mean steady-state, dose-adjusted trough cyclosporine blood concentrations increased from 1.1+/-0.60 (day 7) to 2.0+/-1.20 ng/ml per mg (day 30, P<0.01).",Time-dependent changes in cyclosporine exposure: implications for achieving target concentrations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12677364/),[ng] / [mg·ml],1.1,46195,DB00091,Cyclosporine
,12677364,dose-adjusted trough cyclosporine blood concentrations,"Mean steady-state, dose-adjusted trough cyclosporine blood concentrations increased from 1.1+/-0.60 (day 7) to 2.0+/-1.20 ng/ml per mg (day 30, P<0.01).",Time-dependent changes in cyclosporine exposure: implications for achieving target concentrations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12677364/),[ng] / [mg·ml],2.0,46196,DB00091,Cyclosporine
below,12677364,blood trough c,"The incidence of biopsy-proven acute rejection was 20.5% and was not associated with ethnicity, HLA mismatch, adjunctive therapy, or blood trough cyclosporine concentrations below 200 ng/ml at day 3.",Time-dependent changes in cyclosporine exposure: implications for achieving target concentrations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12677364/),[ng] / [ml],200,46197,DB00091,Cyclosporine
,18641547,AUC-12,The mean AUC-12 calculated using all eight concentration versus time points was 2793 +/- 1165.6 microg/L.hr.,Determination of area under the whole blood concentration versus time curve after first intravenous cyclosporine dose in children undergoing hematopoietic stem cell transplant: limited sampling strategies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641547/),[μg] / [h·l],2793,46262,DB00091,Cyclosporine
,12962870,trough levels (C0),The CyA dosage had been adjusted to maintain trough levels (C0) in the putative target ranges of 200 to 400 ng/mL in group I and between 100 to 300 ng/mL in group II.,New strategies of cyclosporine monitoring in heart transplantation: initial results. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12962870/),[ng] / [ml],200 to 400,46302,DB00091,Cyclosporine
,12962870,trough levels (C0),The CyA dosage had been adjusted to maintain trough levels (C0) in the putative target ranges of 200 to 400 ng/mL in group I and between 100 to 300 ng/mL in group II.,New strategies of cyclosporine monitoring in heart transplantation: initial results. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12962870/),[ng] / [ml],100 to 300,46303,DB00091,Cyclosporine
,28093327,span factor,"The ASD/CsA was obtained in the form of uniform spherical particles, and the span factor was calculated to be ca. 0.4.",Amorphous solid dispersion of cyclosporine A prepared with fine droplet drying process: Physicochemical and pharmacokinetic characterization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28093327/),,0.4,46395,DB00091,Cyclosporine
,9039300,bioavailability,"The bioavailability of the oral CyA formulation (Sandimmun) is approximately 30%, showing high interpatient and intrapatient variability.",Comparison of cyclosporin A pharmacokinetics of a new microemulsion formulation and standard oral preparation in patients with psoriasis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9039300/),%,30,46978,DB00091,Cyclosporine
,24555822,EC50 (the half-maximal effective concentration),2. We found that SNX-2112 significantly stimulated P-gp ATPase activity in in vitro ATPase assay with a small EC50 (the half-maximal effective concentration) value of 0.32 µM.,P-glycoprotein (P-gp)-mediated efflux limits intestinal absorption of the Hsp90 inhibitor SNX-2112 in rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24555822/),μM,0.32,47034,DB00091,Cyclosporine
,24555822,wall permeability,"3. In the single-pass perfused rat intestine model, absorption of SNX-2112 was not favored in the small intestine with a [Formula: see text] (the wall permeability) value of 0.38-0.64.",P-glycoprotein (P-gp)-mediated efflux limits intestinal absorption of the Hsp90 inhibitor SNX-2112 in rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24555822/),,0.38-0.64,47035,DB00091,Cyclosporine
,24555822,[Formula,"By contrast, the compound was well absorbed in the colon with a [Formula: see text] value of 1.19.",P-glycoprotein (P-gp)-mediated efflux limits intestinal absorption of the Hsp90 inhibitor SNX-2112 in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24555822/),,1.19,47036,DB00091,Cyclosporine
,11044692,AUC,"At an equivalent 5 mg/kg dose, the cyclosporine AUC was 3 times higher with aerosol delivery than with intramuscular delivery in lung tissue (477,965 vs 157,706 ng x hour/g, respectively).",In the lung aerosol cyclosporine provides a regional concentration advantage over intramuscular cyclosporine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11044692/),[h·ng] / [g],"477,965",47163,DB00091,Cyclosporine
,11044692,AUC,"At an equivalent 5 mg/kg dose, the cyclosporine AUC was 3 times higher with aerosol delivery than with intramuscular delivery in lung tissue (477,965 vs 157,706 ng x hour/g, respectively).",In the lung aerosol cyclosporine provides a regional concentration advantage over intramuscular cyclosporine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11044692/),[h·ng] / [g],"157,706",47164,DB00091,Cyclosporine
,11044692,lung tissue: blood AUC ratio,The lung tissue: blood AUC ratio was highest in the aerosol groups (27.3:1 and 17.4:1) compared with the intramuscular groups (8.1:1 and 9.4:1).,In the lung aerosol cyclosporine provides a regional concentration advantage over intramuscular cyclosporine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11044692/),:1,27.3,47165,DB00091,Cyclosporine
,11044692,lung tissue: blood AUC ratio,The lung tissue: blood AUC ratio was highest in the aerosol groups (27.3:1 and 17.4:1) compared with the intramuscular groups (8.1:1 and 9.4:1).,In the lung aerosol cyclosporine provides a regional concentration advantage over intramuscular cyclosporine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11044692/),:1,17.4,47166,DB00091,Cyclosporine
,11044692,lung tissue: blood AUC ratio,The lung tissue: blood AUC ratio was highest in the aerosol groups (27.3:1 and 17.4:1) compared with the intramuscular groups (8.1:1 and 9.4:1).,In the lung aerosol cyclosporine provides a regional concentration advantage over intramuscular cyclosporine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11044692/),:1,8.1,47167,DB00091,Cyclosporine
,11044692,lung tissue: blood AUC ratio,The lung tissue: blood AUC ratio was highest in the aerosol groups (27.3:1 and 17.4:1) compared with the intramuscular groups (8.1:1 and 9.4:1).,In the lung aerosol cyclosporine provides a regional concentration advantage over intramuscular cyclosporine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11044692/),:1,9.4,47168,DB00091,Cyclosporine
,17924828,AUC(0-12),"Differences in the MPA pharmacokinetic profiles confirmed large interpatient variability of MPA exposure, with AUC(0-12) values ranging from 7.9 to 50.1 mg*h/ml.",C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17924828/),[h·mg] / [ml],7.9 to 50.1,47677,DB00091,Cyclosporine
,17924828,AUC(0-12),"MPA AUC(0-12) was significantly associated with the presence of UGT1A9 -440/-331 genotypes (TT/CC: 61.5 +/- 2.7 mg*h/ml/g MMF; TC/CT: 45.4 +/- 14.0 mg*h/ml/g MMF; CC/TT: 40.8 +/- 10.8 mg*h/ml/g MMF; p = 0.005), whereas MPAG exposure was mainly influenced by renal function.",C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17924828/),[h·mg] / [g·ml],61.5,47678,DB00091,Cyclosporine
,17924828,AUC(0-12),"MPA AUC(0-12) was significantly associated with the presence of UGT1A9 -440/-331 genotypes (TT/CC: 61.5 +/- 2.7 mg*h/ml/g MMF; TC/CT: 45.4 +/- 14.0 mg*h/ml/g MMF; CC/TT: 40.8 +/- 10.8 mg*h/ml/g MMF; p = 0.005), whereas MPAG exposure was mainly influenced by renal function.",C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17924828/),[h·mg] / [g·ml],45.4,47679,DB00091,Cyclosporine
,17924828,AUC(0-12),"MPA AUC(0-12) was significantly associated with the presence of UGT1A9 -440/-331 genotypes (TT/CC: 61.5 +/- 2.7 mg*h/ml/g MMF; TC/CT: 45.4 +/- 14.0 mg*h/ml/g MMF; CC/TT: 40.8 +/- 10.8 mg*h/ml/g MMF; p = 0.005), whereas MPAG exposure was mainly influenced by renal function.",C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17924828/),[h·mg] / [g·ml],40.8,47680,DB00091,Cyclosporine
,11825097,AUC to 24 hours,Mean [+/- SD; coefficient of variation (%CV)] CsA-S doses of 245mg (+/- 92) resulted in cyclosporin blood concentrations of 214 microg/L (+/- 70) after 12 hours and 108 microg/L (+/- 23) after 24 hours; the mean estimated AUC to 24 hours was 7658 microg x h/L (30%).,Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11825097/),[h·μg] / [l],7658,47906,DB00091,Cyclosporine
,11825097,AUC(24),"With mean CsA-ME doses of 206mg (+/- 59), cyclosporin blood concentrations were 212 microg/L (+/- 33) and 132 microg/L (25%) after 12 and 24 hours, respectively, and the mean estimated AUC(24) was 9357 microg x h/L (23%).",Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11825097/),[h·μg] / [l],9357,47907,DB00091,Cyclosporine
,16130190,C(max),"The mean C(max), t(max), and AUC((0-12))were (21.88+/-10.52) microg/ml, (1.20+/-0.95) h, and (52.546+/-13.215) microg.h/ml, respectively.",Pharmacokinetics of mycophenolic acid in Chinese kidney transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16130190/),[μg] / [ml],21.88,48538,DB00091,Cyclosporine
,16130190,t(max),"The mean C(max), t(max), and AUC((0-12))were (21.88+/-10.52) microg/ml, (1.20+/-0.95) h, and (52.546+/-13.215) microg.h/ml, respectively.",Pharmacokinetics of mycophenolic acid in Chinese kidney transplant patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16130190/),h,1.20,48539,DB00091,Cyclosporine
,16130190,AUC((0-12)),"The mean C(max), t(max), and AUC((0-12))were (21.88+/-10.52) microg/ml, (1.20+/-0.95) h, and (52.546+/-13.215) microg.h/ml, respectively.",Pharmacokinetics of mycophenolic acid in Chinese kidney transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16130190/),[h·μg] / [ml],52.546,48540,DB00091,Cyclosporine
,8651950,corrected brain-blood ratio (BBR (corr)),"The corrected brain-blood ratio (BBR (corr)) was 0.36 +/- 0.18 prior to CSA treatment, and although CNS concentrations increased upon the addition of CSA, there was no increase in the BBR(corr) (0.24 +/- 0.10).",Modulation effects of cyclosporine on etoposide pharmacokinetics and CNS distribution in the rat utilizing microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8651950/),,0.36,48665,DB00091,Cyclosporine
,8651950,BBR(corr),"The corrected brain-blood ratio (BBR (corr)) was 0.36 +/- 0.18 prior to CSA treatment, and although CNS concentrations increased upon the addition of CSA, there was no increase in the BBR(corr) (0.24 +/- 0.10).",Modulation effects of cyclosporine on etoposide pharmacokinetics and CNS distribution in the rat utilizing microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8651950/),,0.24,48666,DB00091,Cyclosporine
,2257862,time,"Withdrawal of prednisolone produced no significant change in the mean time and concentration of maximum blood cyclosporine (3.3 h and 1160 micrograms/l, respectively), the initial and terminal elimination half-life (3.5 h and 18.4 h, respectively) and the area under the blood concentration versus time curve (AUC) measured with either the specific or non-specific monoclonal antibody.",Effects of low-dose prednisolone on cyclosporine pharmacokinetics in liver transplant recipients: radioimmunoassay with specific and non-specific monoclonal antibodies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2257862/),h,3.3,49090,DB00091,Cyclosporine
,2257862,time,"Withdrawal of prednisolone produced no significant change in the mean time and concentration of maximum blood cyclosporine (3.3 h and 1160 micrograms/l, respectively), the initial and terminal elimination half-life (3.5 h and 18.4 h, respectively) and the area under the blood concentration versus time curve (AUC) measured with either the specific or non-specific monoclonal antibody.",Effects of low-dose prednisolone on cyclosporine pharmacokinetics in liver transplant recipients: radioimmunoassay with specific and non-specific monoclonal antibodies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2257862/),[μg] / [l],116,49091,DB00091,Cyclosporine
,2257862,initial,"Withdrawal of prednisolone produced no significant change in the mean time and concentration of maximum blood cyclosporine (3.3 h and 1160 micrograms/l, respectively), the initial and terminal elimination half-life (3.5 h and 18.4 h, respectively) and the area under the blood concentration versus time curve (AUC) measured with either the specific or non-specific monoclonal antibody.",Effects of low-dose prednisolone on cyclosporine pharmacokinetics in liver transplant recipients: radioimmunoassay with specific and non-specific monoclonal antibodies. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2257862/),h,3.5,49092,DB00091,Cyclosporine
,2257862,terminal elimination half-life,"Withdrawal of prednisolone produced no significant change in the mean time and concentration of maximum blood cyclosporine (3.3 h and 1160 micrograms/l, respectively), the initial and terminal elimination half-life (3.5 h and 18.4 h, respectively) and the area under the blood concentration versus time curve (AUC) measured with either the specific or non-specific monoclonal antibody.",Effects of low-dose prednisolone on cyclosporine pharmacokinetics in liver transplant recipients: radioimmunoassay with specific and non-specific monoclonal antibodies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2257862/),h,18.4,49093,DB00091,Cyclosporine
,2257862,half-life,"Measurements with these two antibodies indicated that the terminal elimination of cyclosporine metabolites was more rapid than for the parent drug (half-life: 14.5 vs 18.4, respectively).",Effects of low-dose prednisolone on cyclosporine pharmacokinetics in liver transplant recipients: radioimmunoassay with specific and non-specific monoclonal antibodies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2257862/),,14.5,49094,DB00091,Cyclosporine
,2257862,half-life,"Measurements with these two antibodies indicated that the terminal elimination of cyclosporine metabolites was more rapid than for the parent drug (half-life: 14.5 vs 18.4, respectively).",Effects of low-dose prednisolone on cyclosporine pharmacokinetics in liver transplant recipients: radioimmunoassay with specific and non-specific monoclonal antibodies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2257862/),,18.4,49095,DB00091,Cyclosporine
,21254847,trough levels,"The trough levels of ciclosporin with 200 mg/day, 150 mg/day, and 100 mg/day administration were 96.5 ng/ml, 66.4 ng/ml, and 75.3 ng/ml, respectively.",Favorable clinical response by pre-prandial administration of low-dose ciclosporin to severe adult atopic dermatitis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21254847/),[ng] / [ml],96.5,49484,DB00091,Cyclosporine
,21254847,trough levels,"The trough levels of ciclosporin with 200 mg/day, 150 mg/day, and 100 mg/day administration were 96.5 ng/ml, 66.4 ng/ml, and 75.3 ng/ml, respectively.",Favorable clinical response by pre-prandial administration of low-dose ciclosporin to severe adult atopic dermatitis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21254847/),[ng] / [ml],66.4,49485,DB00091,Cyclosporine
,21254847,trough levels,"The trough levels of ciclosporin with 200 mg/day, 150 mg/day, and 100 mg/day administration were 96.5 ng/ml, 66.4 ng/ml, and 75.3 ng/ml, respectively.",Favorable clinical response by pre-prandial administration of low-dose ciclosporin to severe adult atopic dermatitis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21254847/),[ng] / [ml],75.3,49486,DB00091,Cyclosporine
,21254847,AUC of 0-4 hours (AUC 0-4),"The AUC of 0-4 hours (AUC 0-4) were 2099.5 ng · h/ml (200 mg/day), 1782.6 ng · h/ml (150 mg/day) and 1696.2 ng · h/ml (100 mg/day).",Favorable clinical response by pre-prandial administration of low-dose ciclosporin to severe adult atopic dermatitis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21254847/),[h·ng] / [ml],2099.5,49487,DB00091,Cyclosporine
,21254847,AUC of 0-4 hours (AUC 0-4),"The AUC of 0-4 hours (AUC 0-4) were 2099.5 ng · h/ml (200 mg/day), 1782.6 ng · h/ml (150 mg/day) and 1696.2 ng · h/ml (100 mg/day).",Favorable clinical response by pre-prandial administration of low-dose ciclosporin to severe adult atopic dermatitis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21254847/),[h·ng] / [ml],1782.6,49488,DB00091,Cyclosporine
,21254847,AUC of 0-4 hours (AUC 0-4),"The AUC of 0-4 hours (AUC 0-4) were 2099.5 ng · h/ml (200 mg/day), 1782.6 ng · h/ml (150 mg/day) and 1696.2 ng · h/ml (100 mg/day).",Favorable clinical response by pre-prandial administration of low-dose ciclosporin to severe adult atopic dermatitis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21254847/),[h·ng] / [ml],1696.2,49489,DB00091,Cyclosporine
,15909536,flow rate,The flow rate was 1.0 m/min.,"Concurrent measurement of unbound genistein in the blood, brain and bile of anesthetized rats using microdialysis and its pharmacokinetic application. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15909536/),[m] / [min],1.0,50004,DB00091,Cyclosporine
,15909536,recoveries,"The in vitro recoveries of genistein were 31 +/- 1, 13 +/- 1 and 59 +/- 4% in microdialysis probes of blood, brain and bile, respectively (n = 4).","Concurrent measurement of unbound genistein in the blood, brain and bile of anesthetized rats using microdialysis and its pharmacokinetic application. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15909536/),%,31,50005,DB00091,Cyclosporine
,15909536,recoveries,"The in vitro recoveries of genistein were 31 +/- 1, 13 +/- 1 and 59 +/- 4% in microdialysis probes of blood, brain and bile, respectively (n = 4).","Concurrent measurement of unbound genistein in the blood, brain and bile of anesthetized rats using microdialysis and its pharmacokinetic application. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15909536/),%,13,50006,DB00091,Cyclosporine
,15909536,recoveries,"The in vitro recoveries of genistein were 31 +/- 1, 13 +/- 1 and 59 +/- 4% in microdialysis probes of blood, brain and bile, respectively (n = 4).","Concurrent measurement of unbound genistein in the blood, brain and bile of anesthetized rats using microdialysis and its pharmacokinetic application. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15909536/),%,59,50007,DB00091,Cyclosporine
,15909536,AUC(brain)/AUC(blood),"The brain-to-blood (AUC(brain)/AUC(blood)) and bile-to-blood (AUC(bile)/AUC(blood)) distribution ratios were 0.04 +/- 0.01 and 1.85 +/- 0.42, respectively for the dosage of genistein 30 mg/kg.","Concurrent measurement of unbound genistein in the blood, brain and bile of anesthetized rats using microdialysis and its pharmacokinetic application. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15909536/),,0.04,50008,DB00091,Cyclosporine
,15909536,distribution ratios,"The brain-to-blood (AUC(brain)/AUC(blood)) and bile-to-blood (AUC(bile)/AUC(blood)) distribution ratios were 0.04 +/- 0.01 and 1.85 +/- 0.42, respectively for the dosage of genistein 30 mg/kg.","Concurrent measurement of unbound genistein in the blood, brain and bile of anesthetized rats using microdialysis and its pharmacokinetic application. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15909536/),,1.85,50009,DB00091,Cyclosporine
,15251324,AUC,We used first-order PK modeling to calculate the doses for a mycophenolic acid (MPA) AUC of 60 ug*h/mL and a Tac AUC of 150 ng*h/mL.,Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15251324/),[h·ug] / [ml],60,50026,DB00091,Cyclosporine
,15251324,AUC,We used first-order PK modeling to calculate the doses for a mycophenolic acid (MPA) AUC of 60 ug*h/mL and a Tac AUC of 150 ng*h/mL.,Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15251324/),[h·ng] / [ml],150,50027,DB00091,Cyclosporine
,15251324,AUC,"The mean Tac dose was 2.6 +/- 1.2 mg/m2/d or 0.086 +/- 0.038 mg/kg/d, resulting in an average AUC of 120.6 +/- 30.4 ng*h/mL.",Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15251324/),[h·ng] / [ml],120.6,50028,DB00091,Cyclosporine
,15251324,AUC,"The MMF dose was not normally distributed; the median dose was 549 mg/m2/d (range, 146-1413) and the median MPA AUC was 49.8 ug*h/mL (range, 26.7-156.0).",Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15251324/),[h·ug] / [ml],49.8,50029,DB00091,Cyclosporine
,15251324,AUC,The mean dose for a Tac AUC of 150 ng*h/mL was 3.50 +/- 1.77 mg/m2/d (0.117 +/- 0.058 mg/kg) and was independent of age or time after transplantation.,Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15251324/),[mg] / [d·m2],150,50030,DB00091,Cyclosporine
,15251324,AUC,The mean dose for a Tac AUC of 150 ng*h/mL was 3.50 +/- 1.77 mg/m2/d (0.117 +/- 0.058 mg/kg) and was independent of age or time after transplantation.,Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15251324/),[mg] / [d·m2],3.50,50031,DB00091,Cyclosporine
,15251324,AUC,"By contrast, we found a negative relationship between the dose per m2 (r2 = 0.29; P = 0.0038) or per kg (r2 = 0.58; P < .0001) required for an MPA AUC of 60 ug*h/mL and patient age.",Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15251324/),[h·ug] / [ml],60,50032,DB00091,Cyclosporine
,16080714,maximum whole blood concentration (C(max)),"Among these tests, CsA-loaded AOBs stabilized by the recombinant caleosin exhibited better bioavailability than the commercial formulation and possessed the highest maximum whole blood concentration (C(max)), 1247.4 +/- 106.8 ng/mL, in the experimental animals 4.3 +/- 0.7 h (t(max)) after oral administration.",Elevating bioavailability of cyclosporine a via encapsulation in artificial oil bodies stabilized by caleosin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16080714/),[ng] / [ml],1247.4,50489,DB00091,Cyclosporine
,16080714,t(max),"Among these tests, CsA-loaded AOBs stabilized by the recombinant caleosin exhibited better bioavailability than the commercial formulation and possessed the highest maximum whole blood concentration (C(max)), 1247.4 +/- 106.8 ng/mL, in the experimental animals 4.3 +/- 0.7 h (t(max)) after oral administration.",Elevating bioavailability of cyclosporine a via encapsulation in artificial oil bodies stabilized by caleosin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16080714/),h,4.3,50490,DB00091,Cyclosporine
,1837629,trough specific level,"The mean trough specific level was 121 +/- 14 micrograms/L following placebo, compared to 120 +/- 14 micrograms/L during isradipine.",Lack of effect of the calcium antagonist isradipine on cyclosporine pharmacokinetics in renal transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1837629/),[μg] / [l],121,50560,DB00091,Cyclosporine
,1837629,trough specific level,"The mean trough specific level was 121 +/- 14 micrograms/L following placebo, compared to 120 +/- 14 micrograms/L during isradipine.",Lack of effect of the calcium antagonist isradipine on cyclosporine pharmacokinetics in renal transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1837629/),[μg] / [l],120,50561,DB00091,Cyclosporine
,17910813,bioavailability,Co-administration with carvedilol increased ciclosporin bioavailability from 33% to 70%.,Carvedilol increases ciclosporin bioavailability by inhibiting P-glycoprotein-mediated transport. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17910813/),%,33,50838,DB00091,Cyclosporine
,17910813,bioavailability,Co-administration with carvedilol increased ciclosporin bioavailability from 33% to 70%.,Carvedilol increases ciclosporin bioavailability by inhibiting P-glycoprotein-mediated transport. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17910813/),%,70,50839,DB00091,Cyclosporine
,8176256,peak blood concentration,"The mean peak blood concentration of cyclosporin when taken alone was 958 micrograms/l, and 822 when taken with terbinafine.",Effect of terbinafine on the pharmacokinetics of cyclosporin in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8176256/),[μg] / [l],958,51989,DB00091,Cyclosporine
,8176256,peak blood concentration,"The mean peak blood concentration of cyclosporin when taken alone was 958 micrograms/l, and 822 when taken with terbinafine.",Effect of terbinafine on the pharmacokinetics of cyclosporin in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8176256/),,822,51990,DB00091,Cyclosporine
,8176256,area under the curve,The mean area under the curve for cyclosporin was 4207 micrograms/l/h when taken alone and 3665 when taken with terbinafine.,Effect of terbinafine on the pharmacokinetics of cyclosporin in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8176256/),[μg] / [h·l],4207,51991,DB00091,Cyclosporine
,8176256,area under the curve,The mean area under the curve for cyclosporin was 4207 micrograms/l/h when taken alone and 3665 when taken with terbinafine.,Effect of terbinafine on the pharmacokinetics of cyclosporin in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8176256/),,3665,51992,DB00091,Cyclosporine
,8176256,absorption half-life,"The mean absorption half-life for cyclosporin when taken alone was 0.29 h, and 0.33 when taken with terbinafine.",Effect of terbinafine on the pharmacokinetics of cyclosporin in humans. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8176256/),h,0.29,51993,DB00091,Cyclosporine
,8176256,absorption half-life,"The mean absorption half-life for cyclosporin when taken alone was 0.29 h, and 0.33 when taken with terbinafine.",Effect of terbinafine on the pharmacokinetics of cyclosporin in humans. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8176256/),,0.33,51994,DB00091,Cyclosporine
,11371999,area under the cyclosporine concentration-time curve,"The microemulsion cyclosporine formulation (area under the cyclosporine concentration-time curve, 7432 +/- 560 ng.",Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11371999/),ng,7432,52117,DB00091,Cyclosporine
,11371999,area under the cyclosporine concentration-time curve,"h/mL in white subjects) was more bioavailable than the standard formulation (area under the cyclosporine concentration-time curve, 4828 +/- 319 ng.",Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11371999/),ng,4828,52118,DB00091,Cyclosporine
,10092957,alpha,"A 1-hour infusion every 3 weeks has been favoured in phase II and III studies, and the disposition of docetaxel after such treatment is best described by a 3 compartment model with alpha, beta and gamma half-lives of 4.5 minutes, 38.3 minutes and 12.2 hours, respectively.",Clinical pharmacokinetics of docetaxel. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10092957/),min,4.5,52392,DB00091,Cyclosporine
,10092957,beta,"A 1-hour infusion every 3 weeks has been favoured in phase II and III studies, and the disposition of docetaxel after such treatment is best described by a 3 compartment model with alpha, beta and gamma half-lives of 4.5 minutes, 38.3 minutes and 12.2 hours, respectively.",Clinical pharmacokinetics of docetaxel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10092957/),min,38.3,52393,DB00091,Cyclosporine
,10092957,gamma half-lives,"A 1-hour infusion every 3 weeks has been favoured in phase II and III studies, and the disposition of docetaxel after such treatment is best described by a 3 compartment model with alpha, beta and gamma half-lives of 4.5 minutes, 38.3 minutes and 12.2 hours, respectively.",Clinical pharmacokinetics of docetaxel. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10092957/),h,12.2,52394,DB00091,Cyclosporine
,10092957,volume of distribution,"Docetaxel is widely distributed in tissues with a mean volume of distribution of 74 L/m2 after 100 mg/m2, every 3 weeks.",Clinical pharmacokinetics of docetaxel. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10092957/),[l] / [m2],74,52395,DB00091,Cyclosporine
,10092957,total body clearance,"The mean total body clearance after this schedule is approximately 22 L/h/m2, principally because of hepatic metabolism by the cytochrome P450 (CYP)3A4 system and biliary excretion into the faeces.",Clinical pharmacokinetics of docetaxel. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10092957/),[l] / [h·m2],22,52396,DB00091,Cyclosporine
<,10092957,Renal excretion,Renal excretion is minimal (< 5%).,Clinical pharmacokinetics of docetaxel. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10092957/),%,5,52397,DB00091,Cyclosporine
,1994529,trough whole-blood,"The mean trough whole-blood cyclosporine concentrations measured by HPLC, were 130 ng/mL preketoconazole and 149 ng/mL after 1 year of combination therapy.",Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1994529/),[ng] / [ml],130,52439,DB00091,Cyclosporine
,1994529,trough whole-blood,"The mean trough whole-blood cyclosporine concentrations measured by HPLC, were 130 ng/mL preketoconazole and 149 ng/mL after 1 year of combination therapy.",Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1994529/),[ng] / [ml],149,52440,DB00091,Cyclosporine
,11557912,absorption rate constant,"For a reference 44-year-old, 71-kg Caucasian kidney allograft recipient receiving everolimus as part of a cyclosporine (INN, ciclosporin)-prednisone immunosuppressive regimen, the absorption rate constant was 6.07 h(-1) (standard error [SE], 0.70 h(-1)), the apparent clearance was 8.8 L/h (SE, 0.2 L/h), and the apparent central distribution volume was 110 L (SE, 5 L).",Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11557912/),1/[h],6.07,52477,DB00091,Cyclosporine
,11557912,apparent clearance,"For a reference 44-year-old, 71-kg Caucasian kidney allograft recipient receiving everolimus as part of a cyclosporine (INN, ciclosporin)-prednisone immunosuppressive regimen, the absorption rate constant was 6.07 h(-1) (standard error [SE], 0.70 h(-1)), the apparent clearance was 8.8 L/h (SE, 0.2 L/h), and the apparent central distribution volume was 110 L (SE, 5 L).",Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11557912/),[l] / [h],8.8,52478,DB00091,Cyclosporine
,11557912,apparent central distribution volume,"For a reference 44-year-old, 71-kg Caucasian kidney allograft recipient receiving everolimus as part of a cyclosporine (INN, ciclosporin)-prednisone immunosuppressive regimen, the absorption rate constant was 6.07 h(-1) (standard error [SE], 0.70 h(-1)), the apparent clearance was 8.8 L/h (SE, 0.2 L/h), and the apparent central distribution volume was 110 L (SE, 5 L).",Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11557912/),l,110,52479,DB00091,Cyclosporine
>,21976740,trough concentrations,"In 18 patients, mycophenolate mofetil (MMF) (adjusted to achieve blood mycophenolic acid trough concentrations > 2 μg/mL) was sequentially added, and 16 patients were converted to MMF monotherapy.",Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21976740/),[μg] / [ml],2,52509,DB00091,Cyclosporine
,12019192,bioavailability,"The bioavailability of EON was 15% lower [area under the curve (AUC)(SS blood CsA), 27.9 +/- 3.69 mg.",Comparison of bioavailability and metabolism with two commercial formulations of cyclosporine a in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019192/),%,15,52521,DB00091,Cyclosporine
,12019192,area under the curve (AUC),"The bioavailability of EON was 15% lower [area under the curve (AUC)(SS blood CsA), 27.9 +/- 3.69 mg.",Comparison of bioavailability and metabolism with two commercial formulations of cyclosporine a in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019192/),mg,27.9,52522,DB00091,Cyclosporine
,12019192,AUC,"h/l] in the blood and was 40% lower (AUC(SS kidney CsA), 136.2 +/- 21.2 mg.",Comparison of bioavailability and metabolism with two commercial formulations of cyclosporine a in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019192/),mg,136.2,52523,DB00091,Cyclosporine
,12019192,AUC,"h/l) in the kidney in contrast to NEO (AUC(SS blood CsA), 32.1 +/- 4.32 mg.",Comparison of bioavailability and metabolism with two commercial formulations of cyclosporine a in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019192/),mg,32.1,52524,DB00091,Cyclosporine
,12019192,AUC,"h/l and AUC(SS kidney CsA), 220.8 +/- 29.5 mg.",Comparison of bioavailability and metabolism with two commercial formulations of cyclosporine a in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019192/),mg,220.8,52525,DB00091,Cyclosporine
,12019192,AUC(SS blood,"In contrast, the plasma AM4N level was significantly elevated in group receiving EON (AUC(SS blood AM4N), 4.1 +/- 0.42 mg.",Comparison of bioavailability and metabolism with two commercial formulations of cyclosporine a in rats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019192/),mg,4.1,52526,DB00091,Cyclosporine
,12019192,AUC,"h/l) compared with the other group treated with NEO (AUC(SS blood AM4N), 2.9 +/- 0.39 mg.",Comparison of bioavailability and metabolism with two commercial formulations of cyclosporine a in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019192/),mg,2.9,52527,DB00091,Cyclosporine
,12019192,AUC,"In the kidneys, no significant differences were observed concerning the AM4N concentrations of NEO (AUC(SS kidney AM4N), 11.8 +/- 1.87 mg.",Comparison of bioavailability and metabolism with two commercial formulations of cyclosporine a in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019192/),mg,11.8,52528,DB00091,Cyclosporine
,12019192,AUC,"h/l) versus EON (AUC(SS kidney AM4N), 12.1 +/- 2.14 mg.",Comparison of bioavailability and metabolism with two commercial formulations of cyclosporine a in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019192/),mg,12.1,52529,DB00091,Cyclosporine
,12019192,AUC,"h/l), but AM1 was increased (AUC(SS kidney AM1), 54.3 +/- 11.2 mg.",Comparison of bioavailability and metabolism with two commercial formulations of cyclosporine a in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019192/),mg,54.3,52530,DB00091,Cyclosporine
,12019192,AUC,"h/l) in comparison to NEO (AUC(SS kidney AM1), 20.5 +/- 3.56 mg.",Comparison of bioavailability and metabolism with two commercial formulations of cyclosporine a in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12019192/),mg,20.5,52531,DB00091,Cyclosporine
,17323793,maximum blood concentration (Cmax),"For both treatments, a mean maximum blood concentration (Cmax) of approximately 1,200 ng/ml was obtained at about 1.6 hours (tmax) after administration and the geometric mean of the area under the blood concentration-time curve (AUC) both for test and reference was approximately 4,900 ng x h/ml.",Comparative in vivo bioequivalence and in vitro dissolution of two cyclosporin A soft gelatin capsule formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17323793/),[ng] / [ml],"1,200",53784,DB00091,Cyclosporine
,17323793,tmax,"For both treatments, a mean maximum blood concentration (Cmax) of approximately 1,200 ng/ml was obtained at about 1.6 hours (tmax) after administration and the geometric mean of the area under the blood concentration-time curve (AUC) both for test and reference was approximately 4,900 ng x h/ml.",Comparative in vivo bioequivalence and in vitro dissolution of two cyclosporin A soft gelatin capsule formulations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17323793/),h,1.6,53785,DB00091,Cyclosporine
,17323793,area under the blood concentration-time curve (AUC),"For both treatments, a mean maximum blood concentration (Cmax) of approximately 1,200 ng/ml was obtained at about 1.6 hours (tmax) after administration and the geometric mean of the area under the blood concentration-time curve (AUC) both for test and reference was approximately 4,900 ng x h/ml.",Comparative in vivo bioequivalence and in vitro dissolution of two cyclosporin A soft gelatin capsule formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17323793/),[h·ng] / [ml],"4,900",53786,DB00091,Cyclosporine
,17870611,total clearance,"Compared to renal transplant patients, pigs had approximately the same total clearance of CsA (mean 0.31-0.34lh(-1)kg(-1)), which yields comparable AUC after equivalent dosage in both species.",Pharmacokinetic characterization of a pig model of ciclosporin A nephrotoxicity following intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17870611/),1/[lh],0.31-0.34,55521,DB00091,Cyclosporine
,17870611,volume of distribution at steady state,"However, the volume of distribution at steady state (mean 1.9-3.0lkg(-1)) was lower in pigs.",Pharmacokinetic characterization of a pig model of ciclosporin A nephrotoxicity following intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17870611/),1/[lkg],1.9-3.0,55522,DB00091,Cyclosporine
,1777368,clearance,3. Cyclosporine clearance after i.v. administration decreased from 3.9 +/- 1.7 ml min-1 kg-1 to 2.0 +/- 0.6 ml min-1 kg-1 after 14 days of treatment.,The kinetics of cyclosporine and its metabolites in bone marrow transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1777368/),[ml] / [kg·min],3.9,55859,DB00091,Cyclosporine
,1777368,clearance,3. Cyclosporine clearance after i.v. administration decreased from 3.9 +/- 1.7 ml min-1 kg-1 to 2.0 +/- 0.6 ml min-1 kg-1 after 14 days of treatment.,The kinetics of cyclosporine and its metabolites in bone marrow transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1777368/),[ml] / [kg·min],2.0,55860,DB00091,Cyclosporine
,1777368,absolute oral bioavailability,The mean +/- s.d. absolute oral bioavailability of cyclosporine was 17 +/- 11%.,The kinetics of cyclosporine and its metabolites in bone marrow transplant patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1777368/),%,17,55861,DB00091,Cyclosporine
,19216227,relative bioavailabilities,The relative bioavailabilities of CyA-NP and Lac-CyA-NP were 162.1% and 130.1% compared with Neoral after oral administration at the same dosage.,Preparation of an alternative freeze-dried pH-sensitive cyclosporine A loaded nanoparticles formulation and its pharmacokinetic profile in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19216227/),%,162.1,56431,DB00091,Cyclosporine
,19216227,relative bioavailabilities,The relative bioavailabilities of CyA-NP and Lac-CyA-NP were 162.1% and 130.1% compared with Neoral after oral administration at the same dosage.,Preparation of an alternative freeze-dried pH-sensitive cyclosporine A loaded nanoparticles formulation and its pharmacokinetic profile in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19216227/),%,130.1,56432,DB00091,Cyclosporine
,12637480,clearance,"Pharmacokinetic studies demonstrated that irinotecan clearance was reduced from 13.4 to 5.8 L/h/m(2) and area under the curve (AUC)(0-tn) was increased 2.2-fold by the coadministration of Cs. Similar significant increases in AUC(0-24h) were seen for both SN38 and SN38G (2.2-fold and 2.3-fold, respectively) in the presence of Cs.",Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12637480/),[h·l] / [m(2],13.4 to 5.8,56588,DB00091,Cyclosporine
,9542781,"AUC tau, bss","The results showed that the bioavailability of CyA-NF was greater than that of CyA-ST (AUC tau, bss: 3335 +/- 1300 vs 2667 +/- 1155 ng.h/ml, P = 0.0073; AUC tau, bss ratio 1.26 +/- 0.40 vs 1.0 as reference, P < 0.05), with higher and earlier peak blood concentrations (Cmax: 677 +/- 256 vs 475 +/- 213 ng/ml, P = 0.0329; tmax: 1.5 +/- 0.7 vs 2.6 +/- 1.6 h, P = 0.0720).",Pharmacokinetic effects of conversion to a new formulation of cyclosporin A in rheumatoid arthritis patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542781/),[h·ng] / [ml],3335,56855,DB00091,Cyclosporine
,9542781,"AUC tau, bss","The results showed that the bioavailability of CyA-NF was greater than that of CyA-ST (AUC tau, bss: 3335 +/- 1300 vs 2667 +/- 1155 ng.h/ml, P = 0.0073; AUC tau, bss ratio 1.26 +/- 0.40 vs 1.0 as reference, P < 0.05), with higher and earlier peak blood concentrations (Cmax: 677 +/- 256 vs 475 +/- 213 ng/ml, P = 0.0329; tmax: 1.5 +/- 0.7 vs 2.6 +/- 1.6 h, P = 0.0720).",Pharmacokinetic effects of conversion to a new formulation of cyclosporin A in rheumatoid arthritis patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542781/),[h·ng] / [ml],2667,56856,DB00091,Cyclosporine
,9542781,"AUC tau, bss ratio","The results showed that the bioavailability of CyA-NF was greater than that of CyA-ST (AUC tau, bss: 3335 +/- 1300 vs 2667 +/- 1155 ng.h/ml, P = 0.0073; AUC tau, bss ratio 1.26 +/- 0.40 vs 1.0 as reference, P < 0.05), with higher and earlier peak blood concentrations (Cmax: 677 +/- 256 vs 475 +/- 213 ng/ml, P = 0.0329; tmax: 1.5 +/- 0.7 vs 2.6 +/- 1.6 h, P = 0.0720).",Pharmacokinetic effects of conversion to a new formulation of cyclosporin A in rheumatoid arthritis patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542781/),,1.26,56857,DB00091,Cyclosporine
,9542781,"AUC tau, bss ratio","The results showed that the bioavailability of CyA-NF was greater than that of CyA-ST (AUC tau, bss: 3335 +/- 1300 vs 2667 +/- 1155 ng.h/ml, P = 0.0073; AUC tau, bss ratio 1.26 +/- 0.40 vs 1.0 as reference, P < 0.05), with higher and earlier peak blood concentrations (Cmax: 677 +/- 256 vs 475 +/- 213 ng/ml, P = 0.0329; tmax: 1.5 +/- 0.7 vs 2.6 +/- 1.6 h, P = 0.0720).",Pharmacokinetic effects of conversion to a new formulation of cyclosporin A in rheumatoid arthritis patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542781/),[ng] / [ml],1.0,56858,DB00091,Cyclosporine
,9542781,Cmax,"The results showed that the bioavailability of CyA-NF was greater than that of CyA-ST (AUC tau, bss: 3335 +/- 1300 vs 2667 +/- 1155 ng.h/ml, P = 0.0073; AUC tau, bss ratio 1.26 +/- 0.40 vs 1.0 as reference, P < 0.05), with higher and earlier peak blood concentrations (Cmax: 677 +/- 256 vs 475 +/- 213 ng/ml, P = 0.0329; tmax: 1.5 +/- 0.7 vs 2.6 +/- 1.6 h, P = 0.0720).",Pharmacokinetic effects of conversion to a new formulation of cyclosporin A in rheumatoid arthritis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542781/),[ng] / [ml],677,56859,DB00091,Cyclosporine
,9542781,Cmax,"The results showed that the bioavailability of CyA-NF was greater than that of CyA-ST (AUC tau, bss: 3335 +/- 1300 vs 2667 +/- 1155 ng.h/ml, P = 0.0073; AUC tau, bss ratio 1.26 +/- 0.40 vs 1.0 as reference, P < 0.05), with higher and earlier peak blood concentrations (Cmax: 677 +/- 256 vs 475 +/- 213 ng/ml, P = 0.0329; tmax: 1.5 +/- 0.7 vs 2.6 +/- 1.6 h, P = 0.0720).",Pharmacokinetic effects of conversion to a new formulation of cyclosporin A in rheumatoid arthritis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542781/),[ng] / [ml],475,56860,DB00091,Cyclosporine
,9542781,tmax,"The results showed that the bioavailability of CyA-NF was greater than that of CyA-ST (AUC tau, bss: 3335 +/- 1300 vs 2667 +/- 1155 ng.h/ml, P = 0.0073; AUC tau, bss ratio 1.26 +/- 0.40 vs 1.0 as reference, P < 0.05), with higher and earlier peak blood concentrations (Cmax: 677 +/- 256 vs 475 +/- 213 ng/ml, P = 0.0329; tmax: 1.5 +/- 0.7 vs 2.6 +/- 1.6 h, P = 0.0720).",Pharmacokinetic effects of conversion to a new formulation of cyclosporin A in rheumatoid arthritis patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542781/),h,1.5,56861,DB00091,Cyclosporine
,9542781,tmax,"The results showed that the bioavailability of CyA-NF was greater than that of CyA-ST (AUC tau, bss: 3335 +/- 1300 vs 2667 +/- 1155 ng.h/ml, P = 0.0073; AUC tau, bss ratio 1.26 +/- 0.40 vs 1.0 as reference, P < 0.05), with higher and earlier peak blood concentrations (Cmax: 677 +/- 256 vs 475 +/- 213 ng/ml, P = 0.0329; tmax: 1.5 +/- 0.7 vs 2.6 +/- 1.6 h, P = 0.0720).",Pharmacokinetic effects of conversion to a new formulation of cyclosporin A in rheumatoid arthritis patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542781/),h,2.6,56862,DB00091,Cyclosporine
above,21105879,peak level,"To estimate the safety and efficacy of a new strategy, we investigated the pharmacokinetics of cyclosporine A (CyA) delivered by twice-daily infusion and oral administration maintained with a peak level above 1000 ng/mL to keep 24 h area under the concentration-time curve (AUC0-24) higher than 10 000 ng·h/mL in 12 patients.",Pharmacokinetics of cyclosporine A at a high-peak concentration of twice-daily infusion and oral administration in allogeneic haematopoietic stem cell transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21105879/),[ng] / [ml],1000,56977,DB00091,Cyclosporine
higher,21105879,area under the concentration-time curve (AUC0-24),"To estimate the safety and efficacy of a new strategy, we investigated the pharmacokinetics of cyclosporine A (CyA) delivered by twice-daily infusion and oral administration maintained with a peak level above 1000 ng/mL to keep 24 h area under the concentration-time curve (AUC0-24) higher than 10 000 ng·h/mL in 12 patients.",Pharmacokinetics of cyclosporine A at a high-peak concentration of twice-daily infusion and oral administration in allogeneic haematopoietic stem cell transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21105879/),[h·ng] / [ml],10 000,56978,DB00091,Cyclosporine
,21105879,trough blood concentration,"Cyclosporine A was started as a twice-daily infusion at 1·5 mg/kg and then orally administered at twice the infusion dose to maintain the trough blood concentration between 200 and 500 ng/mL, and with a peak level above 1000 ng/mL.",Pharmacokinetics of cyclosporine A at a high-peak concentration of twice-daily infusion and oral administration in allogeneic haematopoietic stem cell transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21105879/),[ng] / [ml],200 and 500,56979,DB00091,Cyclosporine
above,21105879,peak level,"Cyclosporine A was started as a twice-daily infusion at 1·5 mg/kg and then orally administered at twice the infusion dose to maintain the trough blood concentration between 200 and 500 ng/mL, and with a peak level above 1000 ng/mL.",Pharmacokinetics of cyclosporine A at a high-peak concentration of twice-daily infusion and oral administration in allogeneic haematopoietic stem cell transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21105879/),[ng] / [ml],1000,56980,DB00091,Cyclosporine
higher,21105879,AUC0-24,"In all patients, the AUC0-24 for both twice-daily infusion and oral administration was higher than 10 000 ng·h/mL.",Pharmacokinetics of cyclosporine A at a high-peak concentration of twice-daily infusion and oral administration in allogeneic haematopoietic stem cell transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21105879/),[h·ng] / [ml],10 000,56981,DB00091,Cyclosporine
,20332028,solubility,High loading level was achieved for valspodar in PEO-b-PCL leading to an aqueous solubility of 2.8 mg/mL.,Development of a polymeric micellar formulation for valspodar and assessment of its pharmacokinetics in rat. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20332028/),[mg] / [ml],2.8,57356,DB00091,Cyclosporine
,20332028,plasma unbound fraction,The plasma unbound fraction of valspodar in the polymeric micellar formulation was significantly lower than control (8.27% versus 14.85%).,Development of a polymeric micellar formulation for valspodar and assessment of its pharmacokinetics in rat. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20332028/),%,8.27,57357,DB00091,Cyclosporine
,20332028,plasma unbound fraction,The plasma unbound fraction of valspodar in the polymeric micellar formulation was significantly lower than control (8.27% versus 14.85%).,Development of a polymeric micellar formulation for valspodar and assessment of its pharmacokinetics in rat. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20332028/),%,14.85,57358,DB00091,Cyclosporine
,16680462,AUC,"The AUC (mean +/- standard deviation) values of paclitaxel after oral administration without CsA and with CsA were 476 +/- 254 and 967 +/- 779 ng/ml h, respectively.",A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16680462/),[ng] / [h·ml],476,57895,DB00091,Cyclosporine
,16680462,AUC,"The AUC (mean +/- standard deviation) values of paclitaxel after oral administration without CsA and with CsA were 476 +/- 254 and 967 +/- 779 ng/ml h, respectively.",A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16680462/),[ng] / [h·ml],967,57896,DB00091,Cyclosporine
,16680462,T (max),"T (max) was 4.0 +/- 0.9 h after oral paclitaxel without CsA, and 6.0 +/- 3.1 h after oral paclitaxel with CsA.",A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16680462/),h,4.0,57897,DB00091,Cyclosporine
,16680462,T (max),"T (max) was 4.0 +/- 0.9 h after oral paclitaxel without CsA, and 6.0 +/- 3.1 h after oral paclitaxel with CsA.",A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16680462/),h,6.0,57898,DB00091,Cyclosporine
,10051050,linear rejection rate,"The linear rejection rate in the Sandimmune group was 1.87 episodes per patient year, which was similar to the rejection rate of 1.97 episodes per patient year in the Neoral group.","Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051050/),[episodes] / [patient·year],1.87,58231,DB00091,Cyclosporine
,10051050,rejection rate,"The linear rejection rate in the Sandimmune group was 1.87 episodes per patient year, which was similar to the rejection rate of 1.97 episodes per patient year in the Neoral group.","Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051050/),[episodes] / [patient·year],1.97,58232,DB00091,Cyclosporine
,16926835,area under the plasma concentration-time curve,"The median (range) area under the plasma concentration-time curve of paclitaxel was 2.06 (1.15-3.47) microg h ml(-1) and 1.97 (0.58-3.22) microg h ml(-1) after oral administration of SMEOF#3 and Taxol, respectively, and 4.69 (3.90-6.09) microg h ml(-1) after intravenous Taxol.",A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16926835/),[h·μg] / [ml],2.06,58417,DB00091,Cyclosporine
,16926835,area under the plasma concentration-time curve,"The median (range) area under the plasma concentration-time curve of paclitaxel was 2.06 (1.15-3.47) microg h ml(-1) and 1.97 (0.58-3.22) microg h ml(-1) after oral administration of SMEOF#3 and Taxol, respectively, and 4.69 (3.90-6.09) microg h ml(-1) after intravenous Taxol.",A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16926835/),[h·μg] / [ml],1.97,58418,DB00091,Cyclosporine
,16926835,area under the plasma concentration-time curve,"The median (range) area under the plasma concentration-time curve of paclitaxel was 2.06 (1.15-3.47) microg h ml(-1) and 1.97 (0.58-3.22) microg h ml(-1) after oral administration of SMEOF#3 and Taxol, respectively, and 4.69 (3.90-6.09) microg h ml(-1) after intravenous Taxol.",A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16926835/),[h·μg] / [ml],4.69,58419,DB00091,Cyclosporine
,16926835,T(max),"Oral SMEOF#3 resulted in a lower median T(max) of 2.0 (0.5-2.0) h than orally applied Taxol (T(max)=4.0 (0.8-6.1) h, P=0.02).",A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16926835/),h,2.0,58420,DB00091,Cyclosporine
,16926835,T(max),"Oral SMEOF#3 resulted in a lower median T(max) of 2.0 (0.5-2.0) h than orally applied Taxol (T(max)=4.0 (0.8-6.1) h, P=0.02).",A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16926835/),h,4.0,58421,DB00091,Cyclosporine
,16926835,apparent bioavailability,"The median apparent bioavailability of paclitaxel was 40 (19-83)% and 55 (9-70)% for the oral SMEOF#3 and oral Taxol formulation, respectively.",A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16926835/),%,40,58422,DB00091,Cyclosporine
,16926835,apparent bioavailability,"The median apparent bioavailability of paclitaxel was 40 (19-83)% and 55 (9-70)% for the oral SMEOF#3 and oral Taxol formulation, respectively.",A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16926835/),%,55,58423,DB00091,Cyclosporine
,24011632,RE,"The result showed that RE of gefitinib at the concentrations of 1 μM and 10 μM was 4.12 and 4.05, respectively, but significantly decreased to 1 and 1.35 after adding a P-glycoprotein (P-gp) inhibitor, cyclosporine A.",Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24011632/),,4.12,58993,DB00091,Cyclosporine
,24011632,RE,"The result showed that RE of gefitinib at the concentrations of 1 μM and 10 μM was 4.12 and 4.05, respectively, but significantly decreased to 1 and 1.35 after adding a P-glycoprotein (P-gp) inhibitor, cyclosporine A.",Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24011632/),,4.05,58994,DB00091,Cyclosporine
,24011632,RE,"The result showed that RE of gefitinib at the concentrations of 1 μM and 10 μM was 4.12 and 4.05, respectively, but significantly decreased to 1 and 1.35 after adding a P-glycoprotein (P-gp) inhibitor, cyclosporine A.",Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24011632/),,1,58995,DB00091,Cyclosporine
,24011632,RE,"The result showed that RE of gefitinib at the concentrations of 1 μM and 10 μM was 4.12 and 4.05, respectively, but significantly decreased to 1 and 1.35 after adding a P-glycoprotein (P-gp) inhibitor, cyclosporine A.",Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24011632/),,1.35,58996,DB00091,Cyclosporine
,24011632,AUC(,"In BM model, AUC(totalbrain)/AUC(totalblood) in 50 mg/kg and 200 mg/kg groups were 0.4 and 0.7, respectively, while AUC(CSF)/AUC(freeblood) were 0.21 and 0.18, respectively.",Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24011632/),,0.4,58997,DB00091,Cyclosporine
,24011632,AUC(,"In BM model, AUC(totalbrain)/AUC(totalblood) in 50 mg/kg and 200 mg/kg groups were 0.4 and 0.7, respectively, while AUC(CSF)/AUC(freeblood) were 0.21 and 0.18, respectively.",Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24011632/),,0.7,58998,DB00091,Cyclosporine
,24011632,AUC(CSF)/AUC,"In BM model, AUC(totalbrain)/AUC(totalblood) in 50 mg/kg and 200 mg/kg groups were 0.4 and 0.7, respectively, while AUC(CSF)/AUC(freeblood) were 0.21 and 0.18, respectively.",Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24011632/),,0.21,58999,DB00091,Cyclosporine
,24011632,AUC(CSF)/AUC,"In BM model, AUC(totalbrain)/AUC(totalblood) in 50 mg/kg and 200 mg/kg groups were 0.4 and 0.7, respectively, while AUC(CSF)/AUC(freeblood) were 0.21 and 0.18, respectively.",Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24011632/),,0.18,59000,DB00091,Cyclosporine
,33430689,Volume of distribution (Vd),"A significant difference was observed between population Volume of distribution (Vd) and individualized Vd (mean 57.33 L vs 162.86 L, p value 0.019) and trough and peak levels (p values 0.0001 and 0.001; for mean trough and peak levels respectively).",Vancomycin pharmacokinetic parameters in patients undergoing hematopoietic stem cell transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33430689/),l,57.33,59120,DB00091,Cyclosporine
,33430689,Vd,"A significant difference was observed between population Volume of distribution (Vd) and individualized Vd (mean 57.33 L vs 162.86 L, p value 0.019) and trough and peak levels (p values 0.0001 and 0.001; for mean trough and peak levels respectively).",Vancomycin pharmacokinetic parameters in patients undergoing hematopoietic stem cell transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33430689/),l,162.86,59121,DB00091,Cyclosporine
,8132853,blood clearance,"Mean (+/- standard deviation) CSA blood clearance was .47 +/- .15 L/hour/kg, steady-state volume of distribution (Vss) was 1.9 +/- .5 L/kg, and mean residence time (MRT) was 4.4 +/- 1.8 hours after intravenous dosing.",Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8132853/),[l] / [h·kg],.47,60331,DB00091,Cyclosporine
,8132853,steady-state volume of distribution (Vss),"Mean (+/- standard deviation) CSA blood clearance was .47 +/- .15 L/hour/kg, steady-state volume of distribution (Vss) was 1.9 +/- .5 L/kg, and mean residence time (MRT) was 4.4 +/- 1.8 hours after intravenous dosing.",Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8132853/),[l] / [kg],1.9,60332,DB00091,Cyclosporine
,8132853,mean residence time (MRT),"Mean (+/- standard deviation) CSA blood clearance was .47 +/- .15 L/hour/kg, steady-state volume of distribution (Vss) was 1.9 +/- .5 L/kg, and mean residence time (MRT) was 4.4 +/- 1.8 hours after intravenous dosing.",Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8132853/),h,4.4,60333,DB00091,Cyclosporine
,8132853,clearance,"With plasma, mean clearance was .70 +/- .31 L/hour/kg, Vss was 2.4 +/- 1.2 L/kg, and MRT was 3.7 +/- 2.2 hours.",Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8132853/),[l] / [h·kg],.70,60334,DB00091,Cyclosporine
,8132853,Vss,"With plasma, mean clearance was .70 +/- .31 L/hour/kg, Vss was 2.4 +/- 1.2 L/kg, and MRT was 3.7 +/- 2.2 hours.",Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8132853/),[l] / [kg],2.4,60335,DB00091,Cyclosporine
,8132853,MRT,"With plasma, mean clearance was .70 +/- .31 L/hour/kg, Vss was 2.4 +/- 1.2 L/kg, and MRT was 3.7 +/- 2.2 hours.",Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8132853/),h,3.7,60336,DB00091,Cyclosporine
,8132853,bioavailability (F),"Cyclosporine bioavailability (F) averaged 24 +/- 11 and 24 +/- 15%, using blood and plasma, respectively.",Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8132853/),%,24,60337,DB00091,Cyclosporine
,8132853,bioavailability (F),"Cyclosporine bioavailability (F) averaged 24 +/- 11 and 24 +/- 15%, using blood and plasma, respectively.",Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8132853/),%,24,60338,DB00091,Cyclosporine
,29988733,Papp[BL-AP],"Compared to raw BBR and physical mixture, BBR-BS20-NCs facilitated the dissolution rate and extent of release of BBR in aqueous solution, and further increased the absorption of BBR in MDCK-MDR1 monolayer by overcoming the Pgp-mediated secretory transport (Papp[BL-AP] values of 2.85 ± 0.04 × 10-6 cm/s, 2.21 ± 0.14 × 10-6 cm/s, and 2.00 ± 0.07 × 10-6 cm/s for pure BBR, physical mixture, and BBR-BS20-NCs, respectively).",Dual-functional Brij-S20-modified nanocrystal formulation enhances the intestinal transport and oral bioavailability of berberine. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29988733/),[cm] / [s],2.85,60490,DB00091,Cyclosporine
,29988733,Papp[BL-AP],"Compared to raw BBR and physical mixture, BBR-BS20-NCs facilitated the dissolution rate and extent of release of BBR in aqueous solution, and further increased the absorption of BBR in MDCK-MDR1 monolayer by overcoming the Pgp-mediated secretory transport (Papp[BL-AP] values of 2.85 ± 0.04 × 10-6 cm/s, 2.21 ± 0.14 × 10-6 cm/s, and 2.00 ± 0.07 × 10-6 cm/s for pure BBR, physical mixture, and BBR-BS20-NCs, respectively).",Dual-functional Brij-S20-modified nanocrystal formulation enhances the intestinal transport and oral bioavailability of berberine. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29988733/),[cm] / [s],2.21,60491,DB00091,Cyclosporine
,29988733,Papp[BL-AP],"Compared to raw BBR and physical mixture, BBR-BS20-NCs facilitated the dissolution rate and extent of release of BBR in aqueous solution, and further increased the absorption of BBR in MDCK-MDR1 monolayer by overcoming the Pgp-mediated secretory transport (Papp[BL-AP] values of 2.85 ± 0.04 × 10-6 cm/s, 2.21 ± 0.14 × 10-6 cm/s, and 2.00 ± 0.07 × 10-6 cm/s for pure BBR, physical mixture, and BBR-BS20-NCs, respectively).",Dual-functional Brij-S20-modified nanocrystal formulation enhances the intestinal transport and oral bioavailability of berberine. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29988733/),[cm] / [s],2.00,60492,DB00091,Cyclosporine
,29988733,relative bioavailability,"Significant improvements in the maximum concentration observed (Cmax) and area under drug concentration-time curve (AUC0-t) of BBR-BS20-NCs were obtained in pharmacokinetic studies compared to pure BBR, and the relative bioavailability of BBR-BS20-NCs to pure BBR was 404.1%.",Dual-functional Brij-S20-modified nanocrystal formulation enhances the intestinal transport and oral bioavailability of berberine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29988733/),%,404.1,60493,DB00091,Cyclosporine
excess of,9133469,peak CD4 saturations,Ninety-three percent of patients treated at 0.5 mg/kg OKT4A and all patients at higher doses had mean peak CD4 saturations in excess of 90%.,Murine OKT4A immunosuppression in cadaver donor renal allograft recipients: a Cooperative Clinical Trials in Transplantation pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9133469/),%,90,60628,DB00091,Cyclosporine
,23851346,area under the plasma morphine concentration versus time curve,"Cyclosporine minimally altered morphine disposition, increasing the area under the plasma morphine concentration versus time curve to 100 ± 21 versus 85 ± 24 ng/ml·h (P < 0.05) without changing maximum plasma concentration.",Cyclosporine-inhibitable blood-brain barrier drug transport influences clinical morphine pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23851346/),[ng] / [h·ml],100,60952,DB00091,Cyclosporine
,23851346,area under the plasma morphine concentration versus time curve,"Cyclosporine minimally altered morphine disposition, increasing the area under the plasma morphine concentration versus time curve to 100 ± 21 versus 85 ± 24 ng/ml·h (P < 0.05) without changing maximum plasma concentration.",Cyclosporine-inhibitable blood-brain barrier drug transport influences clinical morphine pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23851346/),[ng] / [h·ml],85,60953,DB00091,Cyclosporine
,23851346,area under the miosis-time curve,"Cyclosporine enhanced (3.2 ± 0.9 vs. 2.5 ± 1.0 mm peak) and prolonged miosis, and increased the area under the miosis-time curve (18 ± 9 vs. 11 ± 5 mm·h), plasma effect-site transfer rate constant (k(e0), median 0.27 vs. 0.17 h(-1)), and maximum calculated effect-site morphine concentration (11.5 ± 3.7 vs. 7.6 ± 2.9 ng/ml; all P < 0.05).",Cyclosporine-inhibitable blood-brain barrier drug transport influences clinical morphine pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23851346/),h·mm,18,60954,DB00091,Cyclosporine
,23851346,area under the miosis-time curve,"Cyclosporine enhanced (3.2 ± 0.9 vs. 2.5 ± 1.0 mm peak) and prolonged miosis, and increased the area under the miosis-time curve (18 ± 9 vs. 11 ± 5 mm·h), plasma effect-site transfer rate constant (k(e0), median 0.27 vs. 0.17 h(-1)), and maximum calculated effect-site morphine concentration (11.5 ± 3.7 vs. 7.6 ± 2.9 ng/ml; all P < 0.05).",Cyclosporine-inhibitable blood-brain barrier drug transport influences clinical morphine pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23851346/),h·mm,11,60955,DB00091,Cyclosporine
,23851346,plasma effect-site transfer rate constant (k(e0),"Cyclosporine enhanced (3.2 ± 0.9 vs. 2.5 ± 1.0 mm peak) and prolonged miosis, and increased the area under the miosis-time curve (18 ± 9 vs. 11 ± 5 mm·h), plasma effect-site transfer rate constant (k(e0), median 0.27 vs. 0.17 h(-1)), and maximum calculated effect-site morphine concentration (11.5 ± 3.7 vs. 7.6 ± 2.9 ng/ml; all P < 0.05).",Cyclosporine-inhibitable blood-brain barrier drug transport influences clinical morphine pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23851346/),1/[h],0.27,60956,DB00091,Cyclosporine
,23851346,plasma effect-site transfer rate constant (k(e0),"Cyclosporine enhanced (3.2 ± 0.9 vs. 2.5 ± 1.0 mm peak) and prolonged miosis, and increased the area under the miosis-time curve (18 ± 9 vs. 11 ± 5 mm·h), plasma effect-site transfer rate constant (k(e0), median 0.27 vs. 0.17 h(-1)), and maximum calculated effect-site morphine concentration (11.5 ± 3.7 vs. 7.6 ± 2.9 ng/ml; all P < 0.05).",Cyclosporine-inhibitable blood-brain barrier drug transport influences clinical morphine pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23851346/),1/[h],0.17,60957,DB00091,Cyclosporine
,23851346,maximum calculated effect-site morphine concentration,"Cyclosporine enhanced (3.2 ± 0.9 vs. 2.5 ± 1.0 mm peak) and prolonged miosis, and increased the area under the miosis-time curve (18 ± 9 vs. 11 ± 5 mm·h), plasma effect-site transfer rate constant (k(e0), median 0.27 vs. 0.17 h(-1)), and maximum calculated effect-site morphine concentration (11.5 ± 3.7 vs. 7.6 ± 2.9 ng/ml; all P < 0.05).",Cyclosporine-inhibitable blood-brain barrier drug transport influences clinical morphine pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23851346/),[ng] / [ml],11.5,60958,DB00091,Cyclosporine
,23851346,maximum calculated effect-site morphine concentration,"Cyclosporine enhanced (3.2 ± 0.9 vs. 2.5 ± 1.0 mm peak) and prolonged miosis, and increased the area under the miosis-time curve (18 ± 9 vs. 11 ± 5 mm·h), plasma effect-site transfer rate constant (k(e0), median 0.27 vs. 0.17 h(-1)), and maximum calculated effect-site morphine concentration (11.5 ± 3.7 vs. 7.6 ± 2.9 ng/ml; all P < 0.05).",Cyclosporine-inhibitable blood-brain barrier drug transport influences clinical morphine pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23851346/),[ng] / [ml],7.6,60959,DB00091,Cyclosporine
,23131698,apparent clearance,Estimation of EVE apparent clearance (3.33 ± 0.20 L/h) and apparent volume of distribution (146 ± 33 L) were in accordance with previously published data.,"Population pharmacokinetics of everolimus in cardiac recipients: comedications, ABCB1, and CYP3A5 polymorphisms. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23131698/),[l] / [h],3.33,60994,DB00091,Cyclosporine
,23131698,apparent volume of distribution,Estimation of EVE apparent clearance (3.33 ± 0.20 L/h) and apparent volume of distribution (146 ± 33 L) were in accordance with previously published data.,"Population pharmacokinetics of everolimus in cardiac recipients: comedications, ABCB1, and CYP3A5 polymorphisms. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23131698/),l,146,60995,DB00091,Cyclosporine
,33560100,C0,"Linear regression analysis showed a strong negative correlation between urine output and the serum trough concentration (C0) of CSA, pharmacokinetic analysis showed the main PK parameters of CSA as follows: C0, 50.2 mcg/L; peak concentration (Cmax), 723.4 mcg/L; area under the curve0-24, 7478.2 mcg·h/L; clearance, 0.77 L/h/kg, elimination half-life, 5.3 hours, and volume of distribution, 6.0 L/kg.",Therapeutic Drug Monitoring and Pharmacokinetic Analysis of Cyclosporine in a Pediatric Patient with Hemophagocytic Lymphohistiocytosis Complicated by Diabetes Insipidus: A Grand Round. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33560100/),[mcg] / [l],50.2,61166,DB00091,Cyclosporine
,33560100,peak concentration (Cmax),"Linear regression analysis showed a strong negative correlation between urine output and the serum trough concentration (C0) of CSA, pharmacokinetic analysis showed the main PK parameters of CSA as follows: C0, 50.2 mcg/L; peak concentration (Cmax), 723.4 mcg/L; area under the curve0-24, 7478.2 mcg·h/L; clearance, 0.77 L/h/kg, elimination half-life, 5.3 hours, and volume of distribution, 6.0 L/kg.",Therapeutic Drug Monitoring and Pharmacokinetic Analysis of Cyclosporine in a Pediatric Patient with Hemophagocytic Lymphohistiocytosis Complicated by Diabetes Insipidus: A Grand Round. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33560100/),[mcg] / [l],723.4,61167,DB00091,Cyclosporine
,33560100,area under the curve0-24,"Linear regression analysis showed a strong negative correlation between urine output and the serum trough concentration (C0) of CSA, pharmacokinetic analysis showed the main PK parameters of CSA as follows: C0, 50.2 mcg/L; peak concentration (Cmax), 723.4 mcg/L; area under the curve0-24, 7478.2 mcg·h/L; clearance, 0.77 L/h/kg, elimination half-life, 5.3 hours, and volume of distribution, 6.0 L/kg.",Therapeutic Drug Monitoring and Pharmacokinetic Analysis of Cyclosporine in a Pediatric Patient with Hemophagocytic Lymphohistiocytosis Complicated by Diabetes Insipidus: A Grand Round. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33560100/),[h·mcg] / [l],7478.2,61168,DB00091,Cyclosporine
,33560100,clearance,"Linear regression analysis showed a strong negative correlation between urine output and the serum trough concentration (C0) of CSA, pharmacokinetic analysis showed the main PK parameters of CSA as follows: C0, 50.2 mcg/L; peak concentration (Cmax), 723.4 mcg/L; area under the curve0-24, 7478.2 mcg·h/L; clearance, 0.77 L/h/kg, elimination half-life, 5.3 hours, and volume of distribution, 6.0 L/kg.",Therapeutic Drug Monitoring and Pharmacokinetic Analysis of Cyclosporine in a Pediatric Patient with Hemophagocytic Lymphohistiocytosis Complicated by Diabetes Insipidus: A Grand Round. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33560100/),[l] / [h·kg],0.77,61169,DB00091,Cyclosporine
,33560100,elimination half-life,"Linear regression analysis showed a strong negative correlation between urine output and the serum trough concentration (C0) of CSA, pharmacokinetic analysis showed the main PK parameters of CSA as follows: C0, 50.2 mcg/L; peak concentration (Cmax), 723.4 mcg/L; area under the curve0-24, 7478.2 mcg·h/L; clearance, 0.77 L/h/kg, elimination half-life, 5.3 hours, and volume of distribution, 6.0 L/kg.",Therapeutic Drug Monitoring and Pharmacokinetic Analysis of Cyclosporine in a Pediatric Patient with Hemophagocytic Lymphohistiocytosis Complicated by Diabetes Insipidus: A Grand Round. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33560100/),h,5.3,61170,DB00091,Cyclosporine
,33560100,volume of distribution,"Linear regression analysis showed a strong negative correlation between urine output and the serum trough concentration (C0) of CSA, pharmacokinetic analysis showed the main PK parameters of CSA as follows: C0, 50.2 mcg/L; peak concentration (Cmax), 723.4 mcg/L; area under the curve0-24, 7478.2 mcg·h/L; clearance, 0.77 L/h/kg, elimination half-life, 5.3 hours, and volume of distribution, 6.0 L/kg.",Therapeutic Drug Monitoring and Pharmacokinetic Analysis of Cyclosporine in a Pediatric Patient with Hemophagocytic Lymphohistiocytosis Complicated by Diabetes Insipidus: A Grand Round. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33560100/),[l] / [kg],6.0,61171,DB00091,Cyclosporine
,11106262,areas under the concentration-time curve,GF120918 increased the plasma values for areas under the concentration-time curve of oral paclitaxel in wild-type mice by 6.6-fold from 408 to 2701 ng x ml(-1) h.,Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11106262/),[h·ng] / [ml],408,61727,DB00091,Cyclosporine
,11106262,areas under the concentration-time curve,GF120918 increased the plasma values for areas under the concentration-time curve of oral paclitaxel in wild-type mice by 6.6-fold from 408 to 2701 ng x ml(-1) h.,Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11106262/),[h·ng] / [ml],2701,61728,DB00091,Cyclosporine
,11106262,oral bioavailability,"Calculated relative to their respective values for area under the concentration-time curve after i.v. administration, GF120918 increased the oral bioavailability of paclitaxel in wild-type mice from 8.5 to 40.2%.",Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11106262/),%,8.5,61729,DB00091,Cyclosporine
,11106262,oral bioavailability,"Calculated relative to their respective values for area under the concentration-time curve after i.v. administration, GF120918 increased the oral bioavailability of paclitaxel in wild-type mice from 8.5 to 40.2%.",Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11106262/),%,40.2,61730,DB00091,Cyclosporine
,1971566,AUC,"CSA delivered via the jugular vein resulted in a significantly greater AUC (22,253 +/- 8,087 ng-hr/ml), compared to the AUC estimated after femoral, penile, or ip routes (11,919 +/- 1,760, 9,718 +/- 1,113, and 4,233 +/- 1,741 ng-hr/ml, respectively; p less than 0.05).",Bioavailability assessment of cyclosporine in the rat. Influence of route of administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971566/),[ng-hr] / [ml],"22,253",61753,DB00091,Cyclosporine
,1971566,AUC,"CSA delivered via the jugular vein resulted in a significantly greater AUC (22,253 +/- 8,087 ng-hr/ml), compared to the AUC estimated after femoral, penile, or ip routes (11,919 +/- 1,760, 9,718 +/- 1,113, and 4,233 +/- 1,741 ng-hr/ml, respectively; p less than 0.05).",Bioavailability assessment of cyclosporine in the rat. Influence of route of administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971566/),[ng-hr] / [ml],"11,919",61754,DB00091,Cyclosporine
,1971566,AUC,"CSA delivered via the jugular vein resulted in a significantly greater AUC (22,253 +/- 8,087 ng-hr/ml), compared to the AUC estimated after femoral, penile, or ip routes (11,919 +/- 1,760, 9,718 +/- 1,113, and 4,233 +/- 1,741 ng-hr/ml, respectively; p less than 0.05).",Bioavailability assessment of cyclosporine in the rat. Influence of route of administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971566/),[ng-hr] / [ml],"9,718",61755,DB00091,Cyclosporine
,1971566,AUC,"CSA delivered via the jugular vein resulted in a significantly greater AUC (22,253 +/- 8,087 ng-hr/ml), compared to the AUC estimated after femoral, penile, or ip routes (11,919 +/- 1,760, 9,718 +/- 1,113, and 4,233 +/- 1,741 ng-hr/ml, respectively; p less than 0.05).",Bioavailability assessment of cyclosporine in the rat. Influence of route of administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971566/),[ng-hr] / [ml],"4,233",61756,DB00091,Cyclosporine
,10391422,metabolic ratios,All subjects were extensive metabolizers of CYP2D6 as determined by metabolic ratios of DM:DT (mean+/-SD 0.0255+/-0.048).,A urine metabolic ratio of dextromethorphan and 3-methoxymorphinan as a probe for CYP3A activity and prediction of cyclosporine clearance in healthy volunteers. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391422/),,0,62218,DB00091,Cyclosporine
,34334682,AUC achieving 50% of the maximum effect (EAUC50),"The baseline renal graft level (E0), maximum effect (Emax), AUC achieving 50% of the maximum effect (EAUC50), and nephrotoxicity slope were estimated as 12.9 mL/min/1.73 m2, 50.7 mL/min/1.73 m2, 1740 ng.h/mL, and 0.00033, respectively.",Time-dissociated Pharmacokinetic Pharmacodynamic Model of Cyclosporine among Malaysian Renal Transplant Recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34334682/),[h·ng] / [ml],1740,62583,DB00091,Cyclosporine
,34334682,slope,"The baseline renal graft level (E0), maximum effect (Emax), AUC achieving 50% of the maximum effect (EAUC50), and nephrotoxicity slope were estimated as 12.9 mL/min/1.73 m2, 50.7 mL/min/1.73 m2, 1740 ng.h/mL, and 0.00033, respectively.",Time-dissociated Pharmacokinetic Pharmacodynamic Model of Cyclosporine among Malaysian Renal Transplant Recipients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34334682/),,0.,62584,DB00091,Cyclosporine
,8402670,MTD,"The MTD of CsA was 6 micrograms/kg/min, and for dox it was 45 mg/m2.",Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8402670/),[μg] / [kg·min],6,62794,DB00091,Cyclosporine
,8402670,MTD,"The MTD of CsA was 6 micrograms/kg/min, and for dox it was 45 mg/m2.",Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8402670/),[mg] / [m],45,62795,DB00091,Cyclosporine
,8402670,whole blood steady state concentrations,Mean whole blood steady state concentrations of CsA were 2210 ng/ml during the infusion with total body clearance of 0.177 liter/h/kg.,Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8402670/),[ng] / [ml],2210,62796,DB00091,Cyclosporine
,8402670,total body clearance,Mean whole blood steady state concentrations of CsA were 2210 ng/ml during the infusion with total body clearance of 0.177 liter/h/kg.,Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8402670/),[l] / [h·kg],0.177,62797,DB00091,Cyclosporine
,8402670,total body clearance,"The mean total body clearance was 2.46 liters/h/m2, and terminal half-life was 49.6 h.",Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8402670/),[l] / [h·m2],2.46,62798,DB00091,Cyclosporine
,8402670,terminal half-life,"The mean total body clearance was 2.46 liters/h/m2, and terminal half-life was 49.6 h.",Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8402670/),h,49.6,62799,DB00091,Cyclosporine
,17042920,C(0),"The median cyclosporine dose-adjusted C(0) in CYP3A5*1/*1 genotype subjects (n = 6) was 14.8 ng/mL per mg per kg (range 11.1-26.8 ng/mL per mg per kg), in CYP3A5*1/*3 patients (n = 34) it was 23.7 ng/mL per mg per kg (range 9.0-61.0 ng/mL per mg per kg) and for CYP3A5*3/*3 patients (n = 66) it was 26.4 ng/mL per mg per kg (range 9.8-85.8 ng/mL per mg per kg; P = 0.012, Kruskal-Wallis test).","Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17042920/),[ng] / [kg·mg·ml],14.8,62945,DB00091,Cyclosporine
,17042920,C(0),"The median cyclosporine dose-adjusted C(0) in CYP3A5*1/*1 genotype subjects (n = 6) was 14.8 ng/mL per mg per kg (range 11.1-26.8 ng/mL per mg per kg), in CYP3A5*1/*3 patients (n = 34) it was 23.7 ng/mL per mg per kg (range 9.0-61.0 ng/mL per mg per kg) and for CYP3A5*3/*3 patients (n = 66) it was 26.4 ng/mL per mg per kg (range 9.8-85.8 ng/mL per mg per kg; P = 0.012, Kruskal-Wallis test).","Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17042920/),[ng] / [kg·mg·ml],23.7,62946,DB00091,Cyclosporine
,17042920,C(0),"The median cyclosporine dose-adjusted C(0) in CYP3A5*1/*1 genotype subjects (n = 6) was 14.8 ng/mL per mg per kg (range 11.1-26.8 ng/mL per mg per kg), in CYP3A5*1/*3 patients (n = 34) it was 23.7 ng/mL per mg per kg (range 9.0-61.0 ng/mL per mg per kg) and for CYP3A5*3/*3 patients (n = 66) it was 26.4 ng/mL per mg per kg (range 9.8-85.8 ng/mL per mg per kg; P = 0.012, Kruskal-Wallis test).","Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17042920/),[ng] / [kg·mg·ml],26.4,62947,DB00091,Cyclosporine
,17042920,C0,"In addition, wild-type homozygotes (n = 21) for MDR1 C3435T had a slight but significantly lower dose-adjusted C0 compared with heterozygotes (n = 58): 17.7 (10.3-60.8) versus 26.4 (9.0-67.3) ng/mL per mg per kg, respectively (P = 0.014, Mann-Whitney U-test).","Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17042920/),[ng] / [kg·mg·ml],17.7,62948,DB00091,Cyclosporine
,17042920,C0,"In addition, wild-type homozygotes (n = 21) for MDR1 C3435T had a slight but significantly lower dose-adjusted C0 compared with heterozygotes (n = 58): 17.7 (10.3-60.8) versus 26.4 (9.0-67.3) ng/mL per mg per kg, respectively (P = 0.014, Mann-Whitney U-test).","Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17042920/),[ng] / [kg·mg·ml],26.4,62949,DB00091,Cyclosporine
,11210676,blood levels,"On the other hand, CyA blood levels (90.66 +/- 22.25 ng/ml) decreased after ovariectomy, even more in the case of gonadectomized female rats receiving estradiol replacement (67.83 +/- 24.15 ng/ml).",Effect of gonadectomy on cyclosporine pharmacokinetics in male and female rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210676/),[ng] / [ml],90,63012,DB00091,Cyclosporine
,9255708,total plasma clearance,"Among the modified liposomes, those modified with carbopol 941 showed the most remarkable enhancing effect on the delivery of sudan black to these organs and total plasma clearance of sudan black decreased to 38.6 +/- 7.8 mL h-1 kg-1 (standard liposomes, 58.9 +/- 6.4 mL h-1 kg-1).",Biodistribution of cyclosporin encapsulated in liposomes modified with bioadhesive polymer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9255708/),[ml] / [h·kg],38.6,63485,DB00091,Cyclosporine
,9255708,total plasma clearance,"Among the modified liposomes, those modified with carbopol 941 showed the most remarkable enhancing effect on the delivery of sudan black to these organs and total plasma clearance of sudan black decreased to 38.6 +/- 7.8 mL h-1 kg-1 (standard liposomes, 58.9 +/- 6.4 mL h-1 kg-1).",Biodistribution of cyclosporin encapsulated in liposomes modified with bioadhesive polymer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9255708/),[ml] / [h·kg],58.9,63486,DB00091,Cyclosporine
,9255708,survival days,"In the preliminary study on the allogenic rat-heart-transplantation model, the mean survival days of the graft were 18.8 +/- 2.9 days for the group receiving cyclosporin liposomes modified with carbopol 941, 14.2 +/- 4.4 days for the group receiving standard cyclosporin liposomes and 7.6 +/- 0.5 days for the group receiving cyclosporin solution.",Biodistribution of cyclosporin encapsulated in liposomes modified with bioadhesive polymer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9255708/),d,18.8,63487,DB00091,Cyclosporine
,9255708,survival days,"In the preliminary study on the allogenic rat-heart-transplantation model, the mean survival days of the graft were 18.8 +/- 2.9 days for the group receiving cyclosporin liposomes modified with carbopol 941, 14.2 +/- 4.4 days for the group receiving standard cyclosporin liposomes and 7.6 +/- 0.5 days for the group receiving cyclosporin solution.",Biodistribution of cyclosporin encapsulated in liposomes modified with bioadhesive polymer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9255708/),d,14.2,63488,DB00091,Cyclosporine
,9255708,survival days,"In the preliminary study on the allogenic rat-heart-transplantation model, the mean survival days of the graft were 18.8 +/- 2.9 days for the group receiving cyclosporin liposomes modified with carbopol 941, 14.2 +/- 4.4 days for the group receiving standard cyclosporin liposomes and 7.6 +/- 0.5 days for the group receiving cyclosporin solution.",Biodistribution of cyclosporin encapsulated in liposomes modified with bioadhesive polymer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9255708/),d,7.6,63489,DB00091,Cyclosporine
,12766555,elimination rate constant,"On the day of angioplasty, the calculated elimination rate constant of cyclosporin was 0.036 hr(-1), while its apparent basal value was 0.078 hr(-1).",Hepatic venous stenosis-related reduction of cyclosporin clearance in a pediatric patient after liver transplantation. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12766555/),1/[hr],0.036,63799,DB00091,Cyclosporine
,12766555,apparent basal value,"On the day of angioplasty, the calculated elimination rate constant of cyclosporin was 0.036 hr(-1), while its apparent basal value was 0.078 hr(-1).",Hepatic venous stenosis-related reduction of cyclosporin clearance in a pediatric patient after liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12766555/),1/[hr],0.078,63800,DB00091,Cyclosporine
,9333107,area under the curve [AUC(0-24)],"The median area under the curve [AUC(0-24)] of pravastatin was 249 microg x hr/L (range, 104 to 1026 microg x hr/L) after a single dose (day 1) and 241 microg x hr/L (114 to 969 microg x hr/L) after multiple doses (day 28) and was fivefold higher than values reported in the absence of cyclosporine.","Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333107/),[h·μg] / [l],249,63881,DB00091,Cyclosporine
,9333107,area under the curve [AUC(0-24)],"The median area under the curve [AUC(0-24)] of pravastatin was 249 microg x hr/L (range, 104 to 1026 microg x hr/L) after a single dose (day 1) and 241 microg x hr/L (114 to 969 microg x hr/L) after multiple doses (day 28) and was fivefold higher than values reported in the absence of cyclosporine.","Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333107/),[h·μg] / [l],241,63882,DB00091,Cyclosporine
,9333107,AUC(0-24),The median AUC(0-24) of lovastatin was 243 microg x hr/L (105 to 858 microg x hr/L) on day 1 and 459 microg x hr/L (140 to 1508 microg x hr/L) on day 28.,"Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333107/),[h·μg] / [l],243,63883,DB00091,Cyclosporine
,9333107,AUC(0-24),The median AUC(0-24) of lovastatin was 243 microg x hr/L (105 to 858 microg x hr/L) on day 1 and 459 microg x hr/L (140 to 1508 microg x hr/L) on day 28.,"Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9333107/),[h·μg] / [l],459,63884,DB00091,Cyclosporine
,15205706,relative bioavailability,"Compared with the reference Neoral microemulsion, the relative bioavailability of 2 g/L Carbopol, 5 g/L Vanzan, 8, 5, 3 g/L HPMC suspended nanoparticles were 70.2%, 84.3%, 90.0%, 94.5% and 97.7%, respectively.",[Influence of suspending agents on relative bioavailability of cyclosporine A-loaded HPMCP nanoparticles for oral administration to rats]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15205706/),%,70.2,64124,DB00091,Cyclosporine
,15205706,relative bioavailability,"Compared with the reference Neoral microemulsion, the relative bioavailability of 2 g/L Carbopol, 5 g/L Vanzan, 8, 5, 3 g/L HPMC suspended nanoparticles were 70.2%, 84.3%, 90.0%, 94.5% and 97.7%, respectively.",[Influence of suspending agents on relative bioavailability of cyclosporine A-loaded HPMCP nanoparticles for oral administration to rats]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15205706/),%,84.3,64125,DB00091,Cyclosporine
,15205706,relative bioavailability,"Compared with the reference Neoral microemulsion, the relative bioavailability of 2 g/L Carbopol, 5 g/L Vanzan, 8, 5, 3 g/L HPMC suspended nanoparticles were 70.2%, 84.3%, 90.0%, 94.5% and 97.7%, respectively.",[Influence of suspending agents on relative bioavailability of cyclosporine A-loaded HPMCP nanoparticles for oral administration to rats]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15205706/),%,90.0,64126,DB00091,Cyclosporine
,15205706,relative bioavailability,"Compared with the reference Neoral microemulsion, the relative bioavailability of 2 g/L Carbopol, 5 g/L Vanzan, 8, 5, 3 g/L HPMC suspended nanoparticles were 70.2%, 84.3%, 90.0%, 94.5% and 97.7%, respectively.",[Influence of suspending agents on relative bioavailability of cyclosporine A-loaded HPMCP nanoparticles for oral administration to rats]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15205706/),%,94.5,64127,DB00091,Cyclosporine
,15205706,relative bioavailability,"Compared with the reference Neoral microemulsion, the relative bioavailability of 2 g/L Carbopol, 5 g/L Vanzan, 8, 5, 3 g/L HPMC suspended nanoparticles were 70.2%, 84.3%, 90.0%, 94.5% and 97.7%, respectively.",[Influence of suspending agents on relative bioavailability of cyclosporine A-loaded HPMCP nanoparticles for oral administration to rats]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15205706/),%,97.7,64128,DB00091,Cyclosporine
,15205706,viscosity,"Their viscosity values were 550, 362, 105, 30 and 15 mPaxs, respectively.",[Influence of suspending agents on relative bioavailability of cyclosporine A-loaded HPMCP nanoparticles for oral administration to rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15205706/),mpa·s,550,64129,DB00091,Cyclosporine
,15205706,viscosity,"Their viscosity values were 550, 362, 105, 30 and 15 mPaxs, respectively.",[Influence of suspending agents on relative bioavailability of cyclosporine A-loaded HPMCP nanoparticles for oral administration to rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15205706/),mpa·s,362,64130,DB00091,Cyclosporine
,15205706,viscosity,"Their viscosity values were 550, 362, 105, 30 and 15 mPaxs, respectively.",[Influence of suspending agents on relative bioavailability of cyclosporine A-loaded HPMCP nanoparticles for oral administration to rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15205706/),mpa·s,105,64131,DB00091,Cyclosporine
,15205706,viscosity,"Their viscosity values were 550, 362, 105, 30 and 15 mPaxs, respectively.",[Influence of suspending agents on relative bioavailability of cyclosporine A-loaded HPMCP nanoparticles for oral administration to rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15205706/),mpa·s,30,64132,DB00091,Cyclosporine
,15205706,viscosity,"Their viscosity values were 550, 362, 105, 30 and 15 mPaxs, respectively.",[Influence of suspending agents on relative bioavailability of cyclosporine A-loaded HPMCP nanoparticles for oral administration to rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15205706/),mpa·s,15,64133,DB00091,Cyclosporine
,20538723,bioavailability (F),The bioavailability (F) of talinolol after high-dose administration to the stomach was significantly greater than that achieved by the low dose (approximately 18 versus 2%).,Role of p-glycoprotein in region-specific gastrointestinal absorption of talinolol in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20538723/),%,18,64134,DB00091,Cyclosporine
,20538723,bioavailability (F),The bioavailability (F) of talinolol after high-dose administration to the stomach was significantly greater than that achieved by the low dose (approximately 18 versus 2%).,Role of p-glycoprotein in region-specific gastrointestinal absorption of talinolol in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20538723/),%,2,64135,DB00091,Cyclosporine
,9013365,peak plasma concentration (Cmax),Mean pharmacokinetic values of prednisolone found before sirolimus administration were as follows: peak plasma concentration (Cmax) was 187 ng/mL; time to peak plasma concentration (tmax) was 2.03 hours; rate of reaching peak plasma concentration (Cmax divided by the area under the concentration-time curve [AUC]) was 0.149 hour-1; terminal half-life (t1/2) was 3.60 hours; AUC was 1206 ng.hour/mL; and apparent clearance (Cl/F) was 0.094 L/hour/kg.,Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013365/),[ng] / [ml],187,64277,DB00091,Cyclosporine
,9013365,time to peak plasma concentration (tmax),Mean pharmacokinetic values of prednisolone found before sirolimus administration were as follows: peak plasma concentration (Cmax) was 187 ng/mL; time to peak plasma concentration (tmax) was 2.03 hours; rate of reaching peak plasma concentration (Cmax divided by the area under the concentration-time curve [AUC]) was 0.149 hour-1; terminal half-life (t1/2) was 3.60 hours; AUC was 1206 ng.hour/mL; and apparent clearance (Cl/F) was 0.094 L/hour/kg.,Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013365/),h,2.03,64278,DB00091,Cyclosporine
,9013365,rate of reaching peak plasma concentration (Cmax divided by the area under the concentration-time curve [AUC]),Mean pharmacokinetic values of prednisolone found before sirolimus administration were as follows: peak plasma concentration (Cmax) was 187 ng/mL; time to peak plasma concentration (tmax) was 2.03 hours; rate of reaching peak plasma concentration (Cmax divided by the area under the concentration-time curve [AUC]) was 0.149 hour-1; terminal half-life (t1/2) was 3.60 hours; AUC was 1206 ng.hour/mL; and apparent clearance (Cl/F) was 0.094 L/hour/kg.,Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013365/),1/[h],0.149,64279,DB00091,Cyclosporine
,9013365,terminal half-life (t1/2),Mean pharmacokinetic values of prednisolone found before sirolimus administration were as follows: peak plasma concentration (Cmax) was 187 ng/mL; time to peak plasma concentration (tmax) was 2.03 hours; rate of reaching peak plasma concentration (Cmax divided by the area under the concentration-time curve [AUC]) was 0.149 hour-1; terminal half-life (t1/2) was 3.60 hours; AUC was 1206 ng.hour/mL; and apparent clearance (Cl/F) was 0.094 L/hour/kg.,Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013365/),h,3.60,64280,DB00091,Cyclosporine
,9013365,AUC,Mean pharmacokinetic values of prednisolone found before sirolimus administration were as follows: peak plasma concentration (Cmax) was 187 ng/mL; time to peak plasma concentration (tmax) was 2.03 hours; rate of reaching peak plasma concentration (Cmax divided by the area under the concentration-time curve [AUC]) was 0.149 hour-1; terminal half-life (t1/2) was 3.60 hours; AUC was 1206 ng.hour/mL; and apparent clearance (Cl/F) was 0.094 L/hour/kg.,Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013365/),[h·ng] / [ml],1206,64281,DB00091,Cyclosporine
,9013365,apparent clearance (Cl/F),Mean pharmacokinetic values of prednisolone found before sirolimus administration were as follows: peak plasma concentration (Cmax) was 187 ng/mL; time to peak plasma concentration (tmax) was 2.03 hours; rate of reaching peak plasma concentration (Cmax divided by the area under the concentration-time curve [AUC]) was 0.149 hour-1; terminal half-life (t1/2) was 3.60 hours; AUC was 1206 ng.hour/mL; and apparent clearance (Cl/F) was 0.094 L/hour/kg.,Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9013365/),[l] / [h·kg],0.094,64282,DB00091,Cyclosporine
,23720091,trough levels,"G1199A variant showed higher CsA blood concentrations in stable patients, that was significant for trough levels (198 vs. 136 ng/mL on Day 7, P = .004, 196 vs. 125 ng/mL on Day 30, P = .007, 194 vs. 121 ng/mL on Day 90, P = .005 for stable vs. unstable groups).",Functional G1199A ABCB1 polymorphism may have an effect on cyclosporine blood concentration in renal transplanted patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23720091/),[ng] / [ml],198,64286,DB00091,Cyclosporine
,23720091,trough levels,"G1199A variant showed higher CsA blood concentrations in stable patients, that was significant for trough levels (198 vs. 136 ng/mL on Day 7, P = .004, 196 vs. 125 ng/mL on Day 30, P = .007, 194 vs. 121 ng/mL on Day 90, P = .005 for stable vs. unstable groups).",Functional G1199A ABCB1 polymorphism may have an effect on cyclosporine blood concentration in renal transplanted patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23720091/),[ng] / [ml],136,64287,DB00091,Cyclosporine
,23720091,trough levels,"G1199A variant showed higher CsA blood concentrations in stable patients, that was significant for trough levels (198 vs. 136 ng/mL on Day 7, P = .004, 196 vs. 125 ng/mL on Day 30, P = .007, 194 vs. 121 ng/mL on Day 90, P = .005 for stable vs. unstable groups).",Functional G1199A ABCB1 polymorphism may have an effect on cyclosporine blood concentration in renal transplanted patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23720091/),[ng] / [ml],196,64288,DB00091,Cyclosporine
,23720091,trough levels,"G1199A variant showed higher CsA blood concentrations in stable patients, that was significant for trough levels (198 vs. 136 ng/mL on Day 7, P = .004, 196 vs. 125 ng/mL on Day 30, P = .007, 194 vs. 121 ng/mL on Day 90, P = .005 for stable vs. unstable groups).",Functional G1199A ABCB1 polymorphism may have an effect on cyclosporine blood concentration in renal transplanted patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23720091/),[ng] / [ml],125,64289,DB00091,Cyclosporine
,23720091,trough levels,"G1199A variant showed higher CsA blood concentrations in stable patients, that was significant for trough levels (198 vs. 136 ng/mL on Day 7, P = .004, 196 vs. 125 ng/mL on Day 30, P = .007, 194 vs. 121 ng/mL on Day 90, P = .005 for stable vs. unstable groups).",Functional G1199A ABCB1 polymorphism may have an effect on cyclosporine blood concentration in renal transplanted patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23720091/),[ng] / [ml],194,64290,DB00091,Cyclosporine
,23720091,trough levels,"G1199A variant showed higher CsA blood concentrations in stable patients, that was significant for trough levels (198 vs. 136 ng/mL on Day 7, P = .004, 196 vs. 125 ng/mL on Day 30, P = .007, 194 vs. 121 ng/mL on Day 90, P = .005 for stable vs. unstable groups).",Functional G1199A ABCB1 polymorphism may have an effect on cyclosporine blood concentration in renal transplanted patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23720091/),[ng] / [ml],121,64291,DB00091,Cyclosporine
,11549208,area under the blood concentration-time curve (AUC),The area under the blood concentration-time curve (AUC) of CsA when combined with docetaxel 75 mg/m2 was 31.0+/-9.3 mg/l h (mean +/- SD).,Pharmacokinetics of oral cyclosporin A when co-administered to enhance the absorption of orally administered docetaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11549208/),[mg] / [h·l],31.0,64700,DB00091,Cyclosporine
,2390433,Ks-,2. In vitro evaluation of the binding of cyclosporin A to rat microsomal cytochrome P-450 indicated a Ks-value of 0.4 microM.,Is cyclosporin A an inhibitor of drug metabolism? ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390433/),μM,0.4,64894,DB00091,Cyclosporine
,2390433,IC50,"In further studies with rat liver microsomes IC50-values of 6, 8 and 70 microM cyclosporin A were determined for the inhibition of the metabolism of midazolam to its alpha-OH-,4-OH- and di-OH-metabolites, respectively.",Is cyclosporin A an inhibitor of drug metabolism? ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390433/),μM,6,64895,DB00091,Cyclosporine
,2390433,IC50,"In further studies with rat liver microsomes IC50-values of 6, 8 and 70 microM cyclosporin A were determined for the inhibition of the metabolism of midazolam to its alpha-OH-,4-OH- and di-OH-metabolites, respectively.",Is cyclosporin A an inhibitor of drug metabolism? ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390433/),μM,8,64896,DB00091,Cyclosporine
,2390433,IC50,"In further studies with rat liver microsomes IC50-values of 6, 8 and 70 microM cyclosporin A were determined for the inhibition of the metabolism of midazolam to its alpha-OH-,4-OH- and di-OH-metabolites, respectively.",Is cyclosporin A an inhibitor of drug metabolism? ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390433/),μM,70,64897,DB00091,Cyclosporine
,2390433,IC50-,3. Comparative studies with human liver microsomes indicated IC50-values of approximately 300 microM for the formation of alpha-OH-midazolam and of 65 microM for the formation of 4-OH-midazolam.,Is cyclosporin A an inhibitor of drug metabolism? ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390433/),μM,300,64898,DB00091,Cyclosporine
,2390433,IC50-,3. Comparative studies with human liver microsomes indicated IC50-values of approximately 300 microM for the formation of alpha-OH-midazolam and of 65 microM for the formation of 4-OH-midazolam.,Is cyclosporin A an inhibitor of drug metabolism? ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390433/),μM,65,64899,DB00091,Cyclosporine
,2390433,t1/2,5. In these patients the hepatic elimination of midazolam was characterized by a mean t1/2 (+/- s.d.) of 2.3 +/- 1.2 h and a plasma clearance (CL) of 414 +/- 95 ml min-1.,Is cyclosporin A an inhibitor of drug metabolism? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390433/),h,2.3,64900,DB00091,Cyclosporine
,2390433,plasma clearance (CL),5. In these patients the hepatic elimination of midazolam was characterized by a mean t1/2 (+/- s.d.) of 2.3 +/- 1.2 h and a plasma clearance (CL) of 414 +/- 95 ml min-1.,Is cyclosporin A an inhibitor of drug metabolism? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390433/),[ml] / [min],414,64901,DB00091,Cyclosporine
,2390433,t1/2,"These values were not different from those of normal human subjects (t1/2 = 1.5 to 4 h, CL = 350 to 700 ml min-1).",Is cyclosporin A an inhibitor of drug metabolism? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390433/),h,1.5 to 4,64902,DB00091,Cyclosporine
,2390433,CL,"These values were not different from those of normal human subjects (t1/2 = 1.5 to 4 h, CL = 350 to 700 ml min-1).",Is cyclosporin A an inhibitor of drug metabolism? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390433/),[ml] / [min],350 to 700,64903,DB00091,Cyclosporine
,17524936,Relative bioavailability,Relative bioavailability of Iminoral in healthy subjects was 99.0%.,"Pharmacokinetics, efficacy, and safety of Iminoral compared with Neoral in healthy volunteers and renal transplant recipients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17524936/),%,99.0,65627,DB00091,Cyclosporine
,9730427,first-dose time at which maximal concentration is reached (t(max)),"The interpatient variance in pharmacokinetic parameters in a subset of 10 patients was much higher after the first oral dose of tacrolimus than at steady-state (eg, first-dose time at which maximal concentration is reached (t(max)): 3.5+/-2.5h, steady-state t(max): 2.0+/-0.7h), and patients treated with intravenous tacrolimus (n=13) rather than oral tacrolimus (n=30) reached target concentrations faster and with less interpatient variability (eg, at day 0: 9.72+/-10.9 ng/mL intravenously vs 3.31+/-8.1 orally).",Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9730427/),h,3.5,65957,DB00091,Cyclosporine
,9730427,steady-state t(max),"The interpatient variance in pharmacokinetic parameters in a subset of 10 patients was much higher after the first oral dose of tacrolimus than at steady-state (eg, first-dose time at which maximal concentration is reached (t(max)): 3.5+/-2.5h, steady-state t(max): 2.0+/-0.7h), and patients treated with intravenous tacrolimus (n=13) rather than oral tacrolimus (n=30) reached target concentrations faster and with less interpatient variability (eg, at day 0: 9.72+/-10.9 ng/mL intravenously vs 3.31+/-8.1 orally).",Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9730427/),h,2.0,65958,DB00091,Cyclosporine
,9730427,steady-state t(max),"The interpatient variance in pharmacokinetic parameters in a subset of 10 patients was much higher after the first oral dose of tacrolimus than at steady-state (eg, first-dose time at which maximal concentration is reached (t(max)): 3.5+/-2.5h, steady-state t(max): 2.0+/-0.7h), and patients treated with intravenous tacrolimus (n=13) rather than oral tacrolimus (n=30) reached target concentrations faster and with less interpatient variability (eg, at day 0: 9.72+/-10.9 ng/mL intravenously vs 3.31+/-8.1 orally).",Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9730427/),,3.31,65959,DB00091,Cyclosporine
,21923441,absorption rate constant,"The absorption rate constant was fixed at 1.28 hour(-1), and the following population pharmacokinetic estimates were calculated: cyclosporine clearance 43.6 L/hour, apparent volume of distribution 1990 L, and interpatient variability for clearance (coefficient of variation) 17.69%.",Population pharmacokinetics of cyclosporine in Korean adults undergoing living-donor kidney transplantation. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21923441/),1/[hour],1.28,66359,DB00091,Cyclosporine
,21923441,clearance,"The absorption rate constant was fixed at 1.28 hour(-1), and the following population pharmacokinetic estimates were calculated: cyclosporine clearance 43.6 L/hour, apparent volume of distribution 1990 L, and interpatient variability for clearance (coefficient of variation) 17.69%.",Population pharmacokinetics of cyclosporine in Korean adults undergoing living-donor kidney transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21923441/),[l] / [h],43.6,66360,DB00091,Cyclosporine
,21923441,apparent volume of distribution,"The absorption rate constant was fixed at 1.28 hour(-1), and the following population pharmacokinetic estimates were calculated: cyclosporine clearance 43.6 L/hour, apparent volume of distribution 1990 L, and interpatient variability for clearance (coefficient of variation) 17.69%.",Population pharmacokinetics of cyclosporine in Korean adults undergoing living-donor kidney transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21923441/),l,1990,66361,DB00091,Cyclosporine
,2723114,Bioavailability (F),Bioavailability (F) and CL were calculated by noncompartmental models and were significantly different depending upon the assay method except for FSR = FWR: FSR = 43.2 +/- 21.7%; FWR = 43.5 +/- 18.5%; FWH = 36.4 +/- 17.3%; CLSR = 849 +/- 363 ml/min; CLWR = 380 +/- 156 ml/min; CLWH = 559 +/- 174 ml/min.,Influence of demographic factors on cyclosporine pharmacokinetics in adult uremic patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723114/),%,43.2,66668,DB00091,Cyclosporine
,2723114,FWR,Bioavailability (F) and CL were calculated by noncompartmental models and were significantly different depending upon the assay method except for FSR = FWR: FSR = 43.2 +/- 21.7%; FWR = 43.5 +/- 18.5%; FWH = 36.4 +/- 17.3%; CLSR = 849 +/- 363 ml/min; CLWR = 380 +/- 156 ml/min; CLWH = 559 +/- 174 ml/min.,Influence of demographic factors on cyclosporine pharmacokinetics in adult uremic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723114/),%,43.5,66669,DB00091,Cyclosporine
,2723114,FWH,Bioavailability (F) and CL were calculated by noncompartmental models and were significantly different depending upon the assay method except for FSR = FWR: FSR = 43.2 +/- 21.7%; FWR = 43.5 +/- 18.5%; FWH = 36.4 +/- 17.3%; CLSR = 849 +/- 363 ml/min; CLWR = 380 +/- 156 ml/min; CLWH = 559 +/- 174 ml/min.,Influence of demographic factors on cyclosporine pharmacokinetics in adult uremic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723114/),%,36.4,66670,DB00091,Cyclosporine
,2723114,CLSR,Bioavailability (F) and CL were calculated by noncompartmental models and were significantly different depending upon the assay method except for FSR = FWR: FSR = 43.2 +/- 21.7%; FWR = 43.5 +/- 18.5%; FWH = 36.4 +/- 17.3%; CLSR = 849 +/- 363 ml/min; CLWR = 380 +/- 156 ml/min; CLWH = 559 +/- 174 ml/min.,Influence of demographic factors on cyclosporine pharmacokinetics in adult uremic patients. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723114/),[ml] / [min],849,66671,DB00091,Cyclosporine
,2723114,CLWR,Bioavailability (F) and CL were calculated by noncompartmental models and were significantly different depending upon the assay method except for FSR = FWR: FSR = 43.2 +/- 21.7%; FWR = 43.5 +/- 18.5%; FWH = 36.4 +/- 17.3%; CLSR = 849 +/- 363 ml/min; CLWR = 380 +/- 156 ml/min; CLWH = 559 +/- 174 ml/min.,Influence of demographic factors on cyclosporine pharmacokinetics in adult uremic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723114/),[ml] / [min],380,66672,DB00091,Cyclosporine
,2723114,CLWH,Bioavailability (F) and CL were calculated by noncompartmental models and were significantly different depending upon the assay method except for FSR = FWR: FSR = 43.2 +/- 21.7%; FWR = 43.5 +/- 18.5%; FWH = 36.4 +/- 17.3%; CLSR = 849 +/- 363 ml/min; CLWR = 380 +/- 156 ml/min; CLWH = 559 +/- 174 ml/min.,Influence of demographic factors on cyclosporine pharmacokinetics in adult uremic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723114/),[ml] / [min],559,66673,DB00091,Cyclosporine
,10692646,volume of distribution at steady state,"After intravenous administration to rats with U-ARF, the volume of distribution at steady state (1.97 vs. 2.56 l/kg) was significantly smaller, and the area under the blood concentration-time curve (348 vs. 296 microg h/ml) tended to be greater and total body clearance (0.0851 vs. 0. 102 l/h per kg) tended to be slower than those in control rats.",Pharmacokinetic changes of cyclosporine after intravenous and oral administration to rats with uranyl nitrate-induced acute renal failure. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10692646/),[l] / [kg],1.97,67165,DB00091,Cyclosporine
,10692646,volume of distribution at steady state,"After intravenous administration to rats with U-ARF, the volume of distribution at steady state (1.97 vs. 2.56 l/kg) was significantly smaller, and the area under the blood concentration-time curve (348 vs. 296 microg h/ml) tended to be greater and total body clearance (0.0851 vs. 0. 102 l/h per kg) tended to be slower than those in control rats.",Pharmacokinetic changes of cyclosporine after intravenous and oral administration to rats with uranyl nitrate-induced acute renal failure. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10692646/),[l] / [kg],2.56,67166,DB00091,Cyclosporine
,10692646,area under the blood concentration-time curve,"After intravenous administration to rats with U-ARF, the volume of distribution at steady state (1.97 vs. 2.56 l/kg) was significantly smaller, and the area under the blood concentration-time curve (348 vs. 296 microg h/ml) tended to be greater and total body clearance (0.0851 vs. 0. 102 l/h per kg) tended to be slower than those in control rats.",Pharmacokinetic changes of cyclosporine after intravenous and oral administration to rats with uranyl nitrate-induced acute renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10692646/),[h·μg] / [ml],348,67167,DB00091,Cyclosporine
,10692646,area under the blood concentration-time curve,"After intravenous administration to rats with U-ARF, the volume of distribution at steady state (1.97 vs. 2.56 l/kg) was significantly smaller, and the area under the blood concentration-time curve (348 vs. 296 microg h/ml) tended to be greater and total body clearance (0.0851 vs. 0. 102 l/h per kg) tended to be slower than those in control rats.",Pharmacokinetic changes of cyclosporine after intravenous and oral administration to rats with uranyl nitrate-induced acute renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10692646/),[h·μg] / [ml],296,67168,DB00091,Cyclosporine
,10692646,total body clearance,"After intravenous administration to rats with U-ARF, the volume of distribution at steady state (1.97 vs. 2.56 l/kg) was significantly smaller, and the area under the blood concentration-time curve (348 vs. 296 microg h/ml) tended to be greater and total body clearance (0.0851 vs. 0. 102 l/h per kg) tended to be slower than those in control rats.",Pharmacokinetic changes of cyclosporine after intravenous and oral administration to rats with uranyl nitrate-induced acute renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10692646/),[l] / [h·kg],0.0851,67169,DB00091,Cyclosporine
,10692646,total body clearance,"After intravenous administration to rats with U-ARF, the volume of distribution at steady state (1.97 vs. 2.56 l/kg) was significantly smaller, and the area under the blood concentration-time curve (348 vs. 296 microg h/ml) tended to be greater and total body clearance (0.0851 vs. 0. 102 l/h per kg) tended to be slower than those in control rats.",Pharmacokinetic changes of cyclosporine after intravenous and oral administration to rats with uranyl nitrate-induced acute renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10692646/),[l] / [h·kg],0. 102,67170,DB00091,Cyclosporine
longer,17275485,AUC(0-8h),Exposure phase (85% of AUC(0-8h)) was longer than 4 hours in all completed (48/54; 89%) profiles; it was longer than 6 hours in 20 profiles.,Pharmacokinetics of neoral in stable renal transplant recipients with long-term diabetes mellitus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17275485/),h,4,67190,DB00091,Cyclosporine
longer,17275485,AUC(0-8h),Exposure phase (85% of AUC(0-8h)) was longer than 4 hours in all completed (48/54; 89%) profiles; it was longer than 6 hours in 20 profiles.,Pharmacokinetics of neoral in stable renal transplant recipients with long-term diabetes mellitus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17275485/),h,6,67191,DB00091,Cyclosporine
,17429314,Km,"Km values were 0.20, 0.25 and 0.44 mmol/l for the GG-842, G-842A and -842AA genotypes, respectively.",Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429314/),[mM] / [l],0.20,67246,DB00091,Cyclosporine
,17429314,Km,"Km values were 0.20, 0.25 and 0.44 mmol/l for the GG-842, G-842A and -842AA genotypes, respectively.",Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429314/),[mM] / [l],0.25,67247,DB00091,Cyclosporine
,17429314,Km,"Km values were 0.20, 0.25 and 0.44 mmol/l for the GG-842, G-842A and -842AA genotypes, respectively.",Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429314/),[mM] / [l],0.44,67248,DB00091,Cyclosporine
,31678424,Km,"Seletalisib was found to be actively transported by rodent and human P-gp in vitro (transfected LLC-PK1 cells; Km of ca. 20 µM), with minimal or no affinity for the other tested transporters.",Role of P-glycoprotein in the brain disposition of seletalisib: Evaluation of the potential for drug-drug interactions. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31678424/),μM,20,67423,DB00091,Cyclosporine
,31678424,"Kp,uu","Restricted brain penetration was also observed in cynomolgus monkeys (single oral dosing at 30 mg kg-1) using brain microdialysis and cerebrospinal fluid sampling (Kp,uu of 0.09 and 0.24, respectively).",Role of P-glycoprotein in the brain disposition of seletalisib: Evaluation of the potential for drug-drug interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31678424/),,0.09,67424,DB00091,Cyclosporine
,31678424,"Kp,uu","Restricted brain penetration was also observed in cynomolgus monkeys (single oral dosing at 30 mg kg-1) using brain microdialysis and cerebrospinal fluid sampling (Kp,uu of 0.09 and 0.24, respectively).",Role of P-glycoprotein in the brain disposition of seletalisib: Evaluation of the potential for drug-drug interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31678424/),,0.24,67425,DB00091,Cyclosporine
,31678424,IC50,"In vitro, CsA inhibited the active transport of seletalisib with an IC50 of 0.13 µM.",Role of P-glycoprotein in the brain disposition of seletalisib: Evaluation of the potential for drug-drug interactions. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31678424/),μM,0.13,67426,DB00091,Cyclosporine
,9862055,alpha half life,"Pharmacokinetics were similar with both infusion schedules with a mean alpha half life of 11.3 and 13.2 minutes, for the 30-minute and 150-minute infusion, and a terminal half life of 13.5 and 15 hours, respectively.",Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862055/),min,11.3,67530,DB00091,Cyclosporine
,9862055,alpha half life,"Pharmacokinetics were similar with both infusion schedules with a mean alpha half life of 11.3 and 13.2 minutes, for the 30-minute and 150-minute infusion, and a terminal half life of 13.5 and 15 hours, respectively.",Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862055/),min,13.2,67531,DB00091,Cyclosporine
,9862055,terminal half life,"Pharmacokinetics were similar with both infusion schedules with a mean alpha half life of 11.3 and 13.2 minutes, for the 30-minute and 150-minute infusion, and a terminal half life of 13.5 and 15 hours, respectively.",Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862055/),h,13.5,67532,DB00091,Cyclosporine
,9862055,terminal half life,"Pharmacokinetics were similar with both infusion schedules with a mean alpha half life of 11.3 and 13.2 minutes, for the 30-minute and 150-minute infusion, and a terminal half life of 13.5 and 15 hours, respectively.",Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862055/),h,15,67533,DB00091,Cyclosporine
,29159710,K B,"The protein-binding rate constant (KB [relative standard error, RSE%]) increased nonlinearly with renal function according to K B = 43.1 (3.13)·(CLCR/59.51)0.394(10.66) h-1.",Prediction of Free from Total Mycophenolic Acid Concentrations in Stable Renal Transplant Patients: A Population-Based Approach. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29159710/),1/[h],43.1,67746,DB00091,Cyclosporine
,29159710,K B,"The protein-binding rate constant (KB [relative standard error, RSE%]) increased nonlinearly with renal function according to K B = 43.1 (3.13)·(CLCR/59.51)0.394(10.66) h-1.",Prediction of Free from Total Mycophenolic Acid Concentrations in Stable Renal Transplant Patients: A Population-Based Approach. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29159710/),1/[h],0.394,67747,DB00091,Cyclosporine
<,8354028,F,"The following posttransplant pharmacokinetic risk factors were associated with a poorer graft survival and a higher incidence of acute rejection: F, < 25%; clearance, > 325 ml/min; steady-state cyclosporine concentrations, < 350 ng/ml during intravenous infusion; or average cyclosporine concentrations, < 400 ng/ml during the first oral study.","Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8354028/),,25,68110,DB00091,Cyclosporine
>,8354028,clearance,"The following posttransplant pharmacokinetic risk factors were associated with a poorer graft survival and a higher incidence of acute rejection: F, < 25%; clearance, > 325 ml/min; steady-state cyclosporine concentrations, < 350 ng/ml during intravenous infusion; or average cyclosporine concentrations, < 400 ng/ml during the first oral study.","Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8354028/),[ml] / [min],325,68111,DB00091,Cyclosporine
<,8354028,steady-state cy,"The following posttransplant pharmacokinetic risk factors were associated with a poorer graft survival and a higher incidence of acute rejection: F, < 25%; clearance, > 325 ml/min; steady-state cyclosporine concentrations, < 350 ng/ml during intravenous infusion; or average cyclosporine concentrations, < 400 ng/ml during the first oral study.","Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8354028/),[ng] / [ml],350,68112,DB00091,Cyclosporine
,11103750,clearance,"The clearance of intravenous and oral cyclosporine was 4.3 +/- 0.9 mL/min/kg and 13.5 +/- 4.5 mL/min/kg, respectively, in African Americans and 3.7 +/- 0.5 mL/min/kg and 9.6 mL/min/kg, respectively, in the white volunteers (P = .0001).",Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103750/),[ml] / [kg·min],4.3,68999,DB00091,Cyclosporine
,11103750,clearance,"The clearance of intravenous and oral cyclosporine was 4.3 +/- 0.9 mL/min/kg and 13.5 +/- 4.5 mL/min/kg, respectively, in African Americans and 3.7 +/- 0.5 mL/min/kg and 9.6 mL/min/kg, respectively, in the white volunteers (P = .0001).",Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103750/),[ml] / [kg·min],13.5,69000,DB00091,Cyclosporine
,11103750,clearance,"The clearance of intravenous and oral cyclosporine was 4.3 +/- 0.9 mL/min/kg and 13.5 +/- 4.5 mL/min/kg, respectively, in African Americans and 3.7 +/- 0.5 mL/min/kg and 9.6 mL/min/kg, respectively, in the white volunteers (P = .0001).",Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103750/),[ml] / [kg·min],3.7,69001,DB00091,Cyclosporine
,11103750,clearance,"The clearance of intravenous and oral cyclosporine was 4.3 +/- 0.9 mL/min/kg and 13.5 +/- 4.5 mL/min/kg, respectively, in African Americans and 3.7 +/- 0.5 mL/min/kg and 9.6 mL/min/kg, respectively, in the white volunteers (P = .0001).",Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103750/),[ml] / [kg·min],9.6,69002,DB00091,Cyclosporine
,11103750,Bioavailability,"Bioavailability was lower in African Americans (32.8 +/- 6.6%) compared with white volunteers (39.3 +/- 7.1%; P = .049), with a significant race and gender interaction (P = .048).",Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103750/),%,32.8,69003,DB00091,Cyclosporine
,11103750,Bioavailability,"Bioavailability was lower in African Americans (32.8 +/- 6.6%) compared with white volunteers (39.3 +/- 7.1%; P = .049), with a significant race and gender interaction (P = .048).",Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103750/),%,39.3,69004,DB00091,Cyclosporine
,11103750,area under the curve (AUC),"The dose-adjusted area under the curve (AUC) of intravenous and oral cyclosporine was 54.3 +/- 10.6 ng x hr/mL per milligram and 18.1 +/- 4.1 ng x hr/mL per milligram, respectively, in African Americans and 61.9 +/- 6.8 ng x hr/mL per milligram and 24.2 +/- 4.6 ng x hr/mL per milligram, respectively, in white volunteers (P = .023).",Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103750/),[h·ng] / [milligram·ml],54.3,69005,DB00091,Cyclosporine
,11103750,area under the curve (AUC),"The dose-adjusted area under the curve (AUC) of intravenous and oral cyclosporine was 54.3 +/- 10.6 ng x hr/mL per milligram and 18.1 +/- 4.1 ng x hr/mL per milligram, respectively, in African Americans and 61.9 +/- 6.8 ng x hr/mL per milligram and 24.2 +/- 4.6 ng x hr/mL per milligram, respectively, in white volunteers (P = .023).",Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103750/),[h·ng] / [milligram·ml],18.1,69006,DB00091,Cyclosporine
,11103750,area under the curve (AUC),"The dose-adjusted area under the curve (AUC) of intravenous and oral cyclosporine was 54.3 +/- 10.6 ng x hr/mL per milligram and 18.1 +/- 4.1 ng x hr/mL per milligram, respectively, in African Americans and 61.9 +/- 6.8 ng x hr/mL per milligram and 24.2 +/- 4.6 ng x hr/mL per milligram, respectively, in white volunteers (P = .023).",Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103750/),[h·ng] / [milligram·ml],61.9,69007,DB00091,Cyclosporine
,11103750,area under the curve (AUC),"The dose-adjusted area under the curve (AUC) of intravenous and oral cyclosporine was 54.3 +/- 10.6 ng x hr/mL per milligram and 18.1 +/- 4.1 ng x hr/mL per milligram, respectively, in African Americans and 61.9 +/- 6.8 ng x hr/mL per milligram and 24.2 +/- 4.6 ng x hr/mL per milligram, respectively, in white volunteers (P = .023).",Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103750/),[h·ng] / [milligram·ml],24.2,69008,DB00091,Cyclosporine
,12966368,trough levels,"Tacrolimus dose-adjusted trough levels were higher in CYP3A5*3/*3 patients (n = 45) than in *1/*3 plus *1/*1 patients (n = 17), as follows: median and range, 94 (34-398) ng/mL per mg/kg versus 61 (37-163) ng/mL per mg/kg (P <.0001, Mann-Whitney test).","Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12966368/),[ng] / [kg·mg·ml],94,69586,DB00091,Cyclosporine
,12966368,trough levels,"Tacrolimus dose-adjusted trough levels were higher in CYP3A5*3/*3 patients (n = 45) than in *1/*3 plus *1/*1 patients (n = 17), as follows: median and range, 94 (34-398) ng/mL per mg/kg versus 61 (37-163) ng/mL per mg/kg (P <.0001, Mann-Whitney test).","Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12966368/),[ng] / [kg·mg·ml],61,69587,DB00091,Cyclosporine
,12966368,trough levels,"CYP3A4*1B allele carriers (n = 10) had lower tacrolimus dose-adjusted trough levels compared with those in patients with the wild-type (*1/*1) genotype (n = 54): median and range, 57 (40-163) ng/mL per mg/kg versus 89 (34-398) ng/mL per mg/kg) (P =.003, Mann-Whitney test).","Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12966368/),[ng] / [kg·mg·ml],57,69588,DB00091,Cyclosporine
,12966368,trough levels,"CYP3A4*1B allele carriers (n = 10) had lower tacrolimus dose-adjusted trough levels compared with those in patients with the wild-type (*1/*1) genotype (n = 54): median and range, 57 (40-163) ng/mL per mg/kg versus 89 (34-398) ng/mL per mg/kg) (P =.003, Mann-Whitney test).","Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12966368/),[ng] / [kg·mg·ml],89,69589,DB00091,Cyclosporine
,9280398,bioavailability,"After intratracheal (i.t.) instillation of saline suspended CyA to adult rats, the CyA plasma levels peaked at 30 min with a bioavailability of 78.1 +/- 6.9%.",Pulmonary delivery of intratracheally instilled and aerosolized cyclosporine A to young and adult rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280398/),%,78.1,70417,DB00091,Cyclosporine
,9280398,bioavailability,"After the i.t. instillation of CyA with micelles forming surfactant, Cremophor EL, in adult and young rats, the plasma levels peaked at 5 min with a bioavailability of 77.5 +/- 7.2% and 66.3 +/- 4.5%, respectively.",Pulmonary delivery of intratracheally instilled and aerosolized cyclosporine A to young and adult rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280398/),%,77.5,70418,DB00091,Cyclosporine
,9280398,bioavailability,"After the i.t. instillation of CyA with micelles forming surfactant, Cremophor EL, in adult and young rats, the plasma levels peaked at 5 min with a bioavailability of 77.5 +/- 7.2% and 66.3 +/- 4.5%, respectively.",Pulmonary delivery of intratracheally instilled and aerosolized cyclosporine A to young and adult rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280398/),%,66.3,70419,DB00091,Cyclosporine
,9280398,bioavailability,The bioavailability of aerosolized CyA was 80.1 +/- 4.1% in adults.,Pulmonary delivery of intratracheally instilled and aerosolized cyclosporine A to young and adult rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9280398/),%,80.1,70420,DB00091,Cyclosporine
,18489992,Relapse rate,Relapse rate was 25% at 2 years.,Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18489992/),%,25,71153,DB00091,Cyclosporine
,11737117,area under the curve (AUC) from 0 to 12 h,"Despite a comparable MMF dose, a large interindividual variability in both MPA area under the curve (AUC) from 0 to 12 h (range 10.1-99.8 microg/mL. h) and in trough levels (range 0.24-7.04 microg/mL) was found.",Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11737117/),[μg] / [h·ml],10.1-99.8,71215,DB00091,Cyclosporine
,11737117,trough levels,"Despite a comparable MMF dose, a large interindividual variability in both MPA area under the curve (AUC) from 0 to 12 h (range 10.1-99.8 microg/mL. h) and in trough levels (range 0.24-7.04 microg/mL) was found.",Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11737117/),[μg] / [ml],0.24-7.04,71216,DB00091,Cyclosporine
>,11737117,AUC,"Patients with AUC >40 microg/mL. h showed a better (p<0.05) renal function than patients with lower AUC (creatinine clearance 85.7+/-23.2 versus 64.5+/-17.5 mL/min), despite no difference in CsA dose, CsA AUC and blood CsA trough level.",Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11737117/),[μg] / [h·ml],40,71217,DB00091,Cyclosporine
,11737117,AUC,"Patients with AUC >40 microg/mL. h showed a better (p<0.05) renal function than patients with lower AUC (creatinine clearance 85.7+/-23.2 versus 64.5+/-17.5 mL/min), despite no difference in CsA dose, CsA AUC and blood CsA trough level.",Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11737117/),[ml] / [min],85.7,71218,DB00091,Cyclosporine
,11737117,AUC,"Patients with AUC >40 microg/mL. h showed a better (p<0.05) renal function than patients with lower AUC (creatinine clearance 85.7+/-23.2 versus 64.5+/-17.5 mL/min), despite no difference in CsA dose, CsA AUC and blood CsA trough level.",Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11737117/),[ml] / [min],64.5,71219,DB00091,Cyclosporine
,8102639,overall response rate,"Twenty-six (62%) patients achieved a complete remission (CR) or restored chronic phase and three patients achieved a partial remission (PR) for an overall response rate of 69% (95% confidence interval, 54% to 84%).",Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8102639/),%,69,71305,DB00091,Cyclosporine
,12099517,Area under the time-concentration curve (AUC) over the first 4 h of the 12-h dosage interval (AUC[0-4]),"Area under the time-concentration curve (AUC) over the first 4 h of the 12-h dosage interval (AUC[0-4]) and AUC over the entire 12-h dosage interval (AUC[0-12]) reached 3803 +/- 1033 and 7462 +/- 2120 microg.h/L respectively, by day 3, remained stable throughout the first 2 weeks, and declined to 2310 +/- 698 and 4062 +/- 1158 microg.h/L by day 84 (p < 0.001).",Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12099517/),[h·μg] / [l],3803,71554,DB00091,Cyclosporine
,12099517,AUC over the entire 12-h dosage interval (AUC[0-12]),"Area under the time-concentration curve (AUC) over the first 4 h of the 12-h dosage interval (AUC[0-4]) and AUC over the entire 12-h dosage interval (AUC[0-12]) reached 3803 +/- 1033 and 7462 +/- 2120 microg.h/L respectively, by day 3, remained stable throughout the first 2 weeks, and declined to 2310 +/- 698 and 4062 +/- 1158 microg.h/L by day 84 (p < 0.001).",Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12099517/),[h·μg] / [l],7462,71555,DB00091,Cyclosporine
,12099517,AUC over the entire 12-h dosage interval (AUC[0-12]),"Area under the time-concentration curve (AUC) over the first 4 h of the 12-h dosage interval (AUC[0-4]) and AUC over the entire 12-h dosage interval (AUC[0-12]) reached 3803 +/- 1033 and 7462 +/- 2120 microg.h/L respectively, by day 3, remained stable throughout the first 2 weeks, and declined to 2310 +/- 698 and 4062 +/- 1158 microg.h/L by day 84 (p < 0.001).",Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12099517/),[h·μg] / [l],2310,71556,DB00091,Cyclosporine
,12099517,AUC over the entire 12-h dosage interval (AUC[0-12]),"Area under the time-concentration curve (AUC) over the first 4 h of the 12-h dosage interval (AUC[0-4]) and AUC over the entire 12-h dosage interval (AUC[0-12]) reached 3803 +/- 1033 and 7462 +/- 2120 microg.h/L respectively, by day 3, remained stable throughout the first 2 weeks, and declined to 2310 +/- 698 and 4062 +/- 1158 microg.h/L by day 84 (p < 0.001).",Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12099517/),[h·μg] / [l],4062,71557,DB00091,Cyclosporine
,12099517,dose,"The dose- and weight-corrected AUC[0-4h] (DWC.AUC[0-4]) rose by over 100% (p < 0.001) from 753 +/- 202 at day 3 to 905 +/- 232 at day 7, 1080 +/- 330 at day 14 and 1521 +/- 316 by day 84, while the dose-and weight-corrected AUC[0-12h] (DWC.AUC[0-12]) rose by over 80% (p < 0.001) from 1477 +/- 390 microg.h/L/ mg/kg on day 3, to 1721 +/- 426 on day 7, 2086 +/- 478 on day 14 and 2690 +/- 602 on day 84 (p < 0.001).",Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12099517/),,753,71558,DB00091,Cyclosporine
,12099517,dose,"The dose- and weight-corrected AUC[0-4h] (DWC.AUC[0-4]) rose by over 100% (p < 0.001) from 753 +/- 202 at day 3 to 905 +/- 232 at day 7, 1080 +/- 330 at day 14 and 1521 +/- 316 by day 84, while the dose-and weight-corrected AUC[0-12h] (DWC.AUC[0-12]) rose by over 80% (p < 0.001) from 1477 +/- 390 microg.h/L/ mg/kg on day 3, to 1721 +/- 426 on day 7, 2086 +/- 478 on day 14 and 2690 +/- 602 on day 84 (p < 0.001).",Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12099517/),,905,71559,DB00091,Cyclosporine
,12099517,dose,"The dose- and weight-corrected AUC[0-4h] (DWC.AUC[0-4]) rose by over 100% (p < 0.001) from 753 +/- 202 at day 3 to 905 +/- 232 at day 7, 1080 +/- 330 at day 14 and 1521 +/- 316 by day 84, while the dose-and weight-corrected AUC[0-12h] (DWC.AUC[0-12]) rose by over 80% (p < 0.001) from 1477 +/- 390 microg.h/L/ mg/kg on day 3, to 1721 +/- 426 on day 7, 2086 +/- 478 on day 14 and 2690 +/- 602 on day 84 (p < 0.001).",Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12099517/),,1080,71560,DB00091,Cyclosporine
,12099517,dose,"The dose- and weight-corrected AUC[0-4h] (DWC.AUC[0-4]) rose by over 100% (p < 0.001) from 753 +/- 202 at day 3 to 905 +/- 232 at day 7, 1080 +/- 330 at day 14 and 1521 +/- 316 by day 84, while the dose-and weight-corrected AUC[0-12h] (DWC.AUC[0-12]) rose by over 80% (p < 0.001) from 1477 +/- 390 microg.h/L/ mg/kg on day 3, to 1721 +/- 426 on day 7, 2086 +/- 478 on day 14 and 2690 +/- 602 on day 84 (p < 0.001).",Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12099517/),,1521,71561,DB00091,Cyclosporine
,12099517,AUC[0-4h],"The dose- and weight-corrected AUC[0-4h] (DWC.AUC[0-4]) rose by over 100% (p < 0.001) from 753 +/- 202 at day 3 to 905 +/- 232 at day 7, 1080 +/- 330 at day 14 and 1521 +/- 316 by day 84, while the dose-and weight-corrected AUC[0-12h] (DWC.AUC[0-12]) rose by over 80% (p < 0.001) from 1477 +/- 390 microg.h/L/ mg/kg on day 3, to 1721 +/- 426 on day 7, 2086 +/- 478 on day 14 and 2690 +/- 602 on day 84 (p < 0.001).",Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12099517/),,753,71562,DB00091,Cyclosporine
,12099517,AUC[0-4h],"The dose- and weight-corrected AUC[0-4h] (DWC.AUC[0-4]) rose by over 100% (p < 0.001) from 753 +/- 202 at day 3 to 905 +/- 232 at day 7, 1080 +/- 330 at day 14 and 1521 +/- 316 by day 84, while the dose-and weight-corrected AUC[0-12h] (DWC.AUC[0-12]) rose by over 80% (p < 0.001) from 1477 +/- 390 microg.h/L/ mg/kg on day 3, to 1721 +/- 426 on day 7, 2086 +/- 478 on day 14 and 2690 +/- 602 on day 84 (p < 0.001).",Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12099517/),,905,71563,DB00091,Cyclosporine
,12099517,AUC[0-4h],"The dose- and weight-corrected AUC[0-4h] (DWC.AUC[0-4]) rose by over 100% (p < 0.001) from 753 +/- 202 at day 3 to 905 +/- 232 at day 7, 1080 +/- 330 at day 14 and 1521 +/- 316 by day 84, while the dose-and weight-corrected AUC[0-12h] (DWC.AUC[0-12]) rose by over 80% (p < 0.001) from 1477 +/- 390 microg.h/L/ mg/kg on day 3, to 1721 +/- 426 on day 7, 2086 +/- 478 on day 14 and 2690 +/- 602 on day 84 (p < 0.001).",Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12099517/),,1080,71564,DB00091,Cyclosporine
,12099517,AUC[0-4h],"The dose- and weight-corrected AUC[0-4h] (DWC.AUC[0-4]) rose by over 100% (p < 0.001) from 753 +/- 202 at day 3 to 905 +/- 232 at day 7, 1080 +/- 330 at day 14 and 1521 +/- 316 by day 84, while the dose-and weight-corrected AUC[0-12h] (DWC.AUC[0-12]) rose by over 80% (p < 0.001) from 1477 +/- 390 microg.h/L/ mg/kg on day 3, to 1721 +/- 426 on day 7, 2086 +/- 478 on day 14 and 2690 +/- 602 on day 84 (p < 0.001).",Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12099517/),,1521,71565,DB00091,Cyclosporine
,12099517,dose,"The dose- and weight-corrected AUC[0-4h] (DWC.AUC[0-4]) rose by over 100% (p < 0.001) from 753 +/- 202 at day 3 to 905 +/- 232 at day 7, 1080 +/- 330 at day 14 and 1521 +/- 316 by day 84, while the dose-and weight-corrected AUC[0-12h] (DWC.AUC[0-12]) rose by over 80% (p < 0.001) from 1477 +/- 390 microg.h/L/ mg/kg on day 3, to 1721 +/- 426 on day 7, 2086 +/- 478 on day 14 and 2690 +/- 602 on day 84 (p < 0.001).",Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12099517/),[h·μg] / [·kg·l·mg],1477,71566,DB00091,Cyclosporine
,12099517,weight-corrected,"The dose- and weight-corrected AUC[0-4h] (DWC.AUC[0-4]) rose by over 100% (p < 0.001) from 753 +/- 202 at day 3 to 905 +/- 232 at day 7, 1080 +/- 330 at day 14 and 1521 +/- 316 by day 84, while the dose-and weight-corrected AUC[0-12h] (DWC.AUC[0-12]) rose by over 80% (p < 0.001) from 1477 +/- 390 microg.h/L/ mg/kg on day 3, to 1721 +/- 426 on day 7, 2086 +/- 478 on day 14 and 2690 +/- 602 on day 84 (p < 0.001).",Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12099517/),[h·μg] / [·kg·l·mg],1477,71567,DB00091,Cyclosporine
,12099517,AUC[0-12h],"The dose- and weight-corrected AUC[0-4h] (DWC.AUC[0-4]) rose by over 100% (p < 0.001) from 753 +/- 202 at day 3 to 905 +/- 232 at day 7, 1080 +/- 330 at day 14 and 1521 +/- 316 by day 84, while the dose-and weight-corrected AUC[0-12h] (DWC.AUC[0-12]) rose by over 80% (p < 0.001) from 1477 +/- 390 microg.h/L/ mg/kg on day 3, to 1721 +/- 426 on day 7, 2086 +/- 478 on day 14 and 2690 +/- 602 on day 84 (p < 0.001).",Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12099517/),[h·μg] / [·kg·l·mg],1477,71568,DB00091,Cyclosporine
,12099517,AUC[0-12h],"The dose- and weight-corrected AUC[0-4h] (DWC.AUC[0-4]) rose by over 100% (p < 0.001) from 753 +/- 202 at day 3 to 905 +/- 232 at day 7, 1080 +/- 330 at day 14 and 1521 +/- 316 by day 84, while the dose-and weight-corrected AUC[0-12h] (DWC.AUC[0-12]) rose by over 80% (p < 0.001) from 1477 +/- 390 microg.h/L/ mg/kg on day 3, to 1721 +/- 426 on day 7, 2086 +/- 478 on day 14 and 2690 +/- 602 on day 84 (p < 0.001).",Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12099517/),[h·μg] / [·kg·l·mg],1721,71569,DB00091,Cyclosporine
,12099517,AUC[0-12h],"The dose- and weight-corrected AUC[0-4h] (DWC.AUC[0-4]) rose by over 100% (p < 0.001) from 753 +/- 202 at day 3 to 905 +/- 232 at day 7, 1080 +/- 330 at day 14 and 1521 +/- 316 by day 84, while the dose-and weight-corrected AUC[0-12h] (DWC.AUC[0-12]) rose by over 80% (p < 0.001) from 1477 +/- 390 microg.h/L/ mg/kg on day 3, to 1721 +/- 426 on day 7, 2086 +/- 478 on day 14 and 2690 +/- 602 on day 84 (p < 0.001).",Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12099517/),[h·μg] / [·kg·l·mg],2086,71570,DB00091,Cyclosporine
,12099517,AUC[0-12h],"The dose- and weight-corrected AUC[0-4h] (DWC.AUC[0-4]) rose by over 100% (p < 0.001) from 753 +/- 202 at day 3 to 905 +/- 232 at day 7, 1080 +/- 330 at day 14 and 1521 +/- 316 by day 84, while the dose-and weight-corrected AUC[0-12h] (DWC.AUC[0-12]) rose by over 80% (p < 0.001) from 1477 +/- 390 microg.h/L/ mg/kg on day 3, to 1721 +/- 426 on day 7, 2086 +/- 478 on day 14 and 2690 +/- 602 on day 84 (p < 0.001).",Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12099517/),[h·μg] / [·kg·l·mg],2690,71571,DB00091,Cyclosporine
,3967349,Analytical recovery,Analytical recovery for this step averages 90% with whole blood and 98% with serum and plasma.,"Improved liquid-chromatographic determination of cyclosporine, with concomitant detection of a cell-bound metabolite. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3967349/),%,90,71953,DB00091,Cyclosporine
,3967349,Analytical recovery,Analytical recovery for this step averages 90% with whole blood and 98% with serum and plasma.,"Improved liquid-chromatographic determination of cyclosporine, with concomitant detection of a cell-bound metabolite. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3967349/),%,98,71954,DB00091,Cyclosporine
,3967349,minimum detection limit,The minimum detection limit is 10 to 15 micrograms/L.,"Improved liquid-chromatographic determination of cyclosporine, with concomitant detection of a cell-bound metabolite. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3967349/),[μg] / [l],10 to 15,71955,DB00091,Cyclosporine
,21293979,C0,"C2 was associated with lower daily CsA doses (C0 208.7 mg/d vs. C2 182.3 mg/d, p <0.0001) while dose reduction over time was not different during both periods (C0 -13.3 mg/d vs. C2 -22.5 mg/d, p = 0.259).",Cyclosporine C0- versus C2-monitoring over three years in maintenance heart transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21293979/),[mg] / [d],208.7,72203,DB00091,Cyclosporine
,3347936,terminal elimination half-life,"Based on HPLC determinations, a mean terminal elimination half-life of 18.9 hr was calculated.",Pharmacokinetics of cyclosporine G in patients with renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3347936/),h,18.9,72226,DB00091,Cyclosporine
,3347936,total body clearance,"The total body clearance was 0.55 L/hr/kg, the volume of the central compartment was 0.32 L/kg, and the steady-state volume of distribution was 5.97 L/kg.",Pharmacokinetics of cyclosporine G in patients with renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3347936/),[l] / [h·kg],0.55,72227,DB00091,Cyclosporine
,3347936,volume of the central compartment,"The total body clearance was 0.55 L/hr/kg, the volume of the central compartment was 0.32 L/kg, and the steady-state volume of distribution was 5.97 L/kg.",Pharmacokinetics of cyclosporine G in patients with renal failure. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3347936/),[l] / [kg],0.32,72228,DB00091,Cyclosporine
,3347936,steady-state volume of distribution,"The total body clearance was 0.55 L/hr/kg, the volume of the central compartment was 0.32 L/kg, and the steady-state volume of distribution was 5.97 L/kg.",Pharmacokinetics of cyclosporine G in patients with renal failure. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3347936/),[l] / [kg],5.97,72229,DB00091,Cyclosporine
,3347936,bioavailability,"After oral administration maximum CsG concentrations in blood were reached between 2.5 and 3 hr, and the bioavailability was in the range of 24-55% (mean 36%).",Pharmacokinetics of cyclosporine G in patients with renal failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3347936/),%,24-55,72230,DB00091,Cyclosporine
,3347936,bioavailability,"After oral administration maximum CsG concentrations in blood were reached between 2.5 and 3 hr, and the bioavailability was in the range of 24-55% (mean 36%).",Pharmacokinetics of cyclosporine G in patients with renal failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3347936/),%,36,72231,DB00091,Cyclosporine
,3347936,blood-to-plasma ratio,"The blood-to-plasma ratio was 1.23, which is smaller than that observed for CsA.",Pharmacokinetics of cyclosporine G in patients with renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3347936/),,1.23,72232,DB00091,Cyclosporine
,19038099,AUC,"Regarding mycophenolate mofetil, the targeted AUC has been defined between 30 and 60 mg/h/l.",[Recents advances in the pharmacology of immunosuppressive drugs used in organ transplantation]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19038099/),[mg] / [h·l],30 and 60,72503,DB00091,Cyclosporine
,26554649,Maximum tolerated dose,"Maximum tolerated dose was 8 μg kg(-1) for MOC31PE alone, and 6.5 μg kg(-1) when combined with CsA.","Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26554649/),[μg] / [kg],8,72552,DB00091,Cyclosporine
,26554649,Maximum tolerated dose,"Maximum tolerated dose was 8 μg kg(-1) for MOC31PE alone, and 6.5 μg kg(-1) when combined with CsA.","Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26554649/),[μg] / [kg],6.5,72553,DB00091,Cyclosporine
,26554649,half-life,The pharmacokinetic profile of MOC31PE was characterised by linear kinetics and with a half-life of ∼3 h.,"Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26554649/),h,∼3,72554,DB00091,Cyclosporine
,8803529,AUC,"There was no significant effect of ursodiol on CsA absorption: AUC was 5011 vs 5486 ng.h.ml-1, Cmax was 832 vs 871 ng.",A single dose of ursodiol does not affect cyclosporine absorption in liver transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803529/),[h·ng] / [ml],5011,72733,DB00091,Cyclosporine
,8803529,AUC,"There was no significant effect of ursodiol on CsA absorption: AUC was 5011 vs 5486 ng.h.ml-1, Cmax was 832 vs 871 ng.",A single dose of ursodiol does not affect cyclosporine absorption in liver transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803529/),[h·ng] / [ml],5486,72734,DB00091,Cyclosporine
,8803529,Cmax,"There was no significant effect of ursodiol on CsA absorption: AUC was 5011 vs 5486 ng.h.ml-1, Cmax was 832 vs 871 ng.",A single dose of ursodiol does not affect cyclosporine absorption in liver transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803529/),ng,832,72735,DB00091,Cyclosporine
,8803529,Cmax,"There was no significant effect of ursodiol on CsA absorption: AUC was 5011 vs 5486 ng.h.ml-1, Cmax was 832 vs 871 ng.",A single dose of ursodiol does not affect cyclosporine absorption in liver transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803529/),ng,871,72736,DB00091,Cyclosporine
,8803529,tmax,"ml-1 and tmax was 2 vs 2 h, after ursodiol and placebo, respectively.",A single dose of ursodiol does not affect cyclosporine absorption in liver transplant patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803529/),h,2,72737,DB00091,Cyclosporine
,15568889,absolute bioavailability,The absolute bioavailability is about 50%.,"Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568889/),%,50,73755,DB00091,Cyclosporine
,15568889,volume of distribution,"Bosentan is approximately 98% bound to albumin and, during multiple-dose administration, has a volume of distribution of 30 L and a clearance of 17 L/h.","Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568889/),l,30,73756,DB00091,Cyclosporine
,15568889,clearance,"Bosentan is approximately 98% bound to albumin and, during multiple-dose administration, has a volume of distribution of 30 L and a clearance of 17 L/h.","Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568889/),[l] / [h],17,73757,DB00091,Cyclosporine
,15568889,terminal half-life,The terminal half-life after oral administration is 5.4 hours and is unchanged at steady state.,"Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15568889/),h,5.4,73758,DB00091,Cyclosporine
,10071016,trough blood level,"The mean trough blood level of MPA in 10 patients was 0.28 microg/ml, and 5.7 microg/ml for MPA glucoronide.",Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071016/),[μg] / [ml],0.28,74256,DB00091,Cyclosporine
,10071016,trough blood level,"The mean trough blood level of MPA in 10 patients was 0.28 microg/ml, and 5.7 microg/ml for MPA glucoronide.",Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071016/),[μg] / [ml],5.7,74257,DB00091,Cyclosporine
,1928382,clearance ratio,"Judged by a 131I-hippuran-to-PAH clearance ratio of 0.75 +/- 0.05, extraction ratio of hippuran was less efficient than EPAH in three glomerulopathic patients.",PAH extraction and estimation of plasma flow in diseased human kidneys. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1928382/),,0.75,74525,DB00091,Cyclosporine
,29432892,Tmax,"Under the same conditions with 10% CyA MN administered to rats, CyA MN showed Tmax of 8 h, Cmax of 15.9 ng/ml, and area under curve (AUC) of 686, compared to Tmax of 2 h, Cmax of 18.205 ng/ml, and AUC of 254 for oral administration of solubilized CyA.","Local dermal delivery of cyclosporin A, a hydrophobic and high molecular weight drug, using dissolving microneedles. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29432892/),h,8,76330,DB00091,Cyclosporine
,29432892,Cmax,"Under the same conditions with 10% CyA MN administered to rats, CyA MN showed Tmax of 8 h, Cmax of 15.9 ng/ml, and area under curve (AUC) of 686, compared to Tmax of 2 h, Cmax of 18.205 ng/ml, and AUC of 254 for oral administration of solubilized CyA.","Local dermal delivery of cyclosporin A, a hydrophobic and high molecular weight drug, using dissolving microneedles. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29432892/),[ng] / [ml],15.9,76331,DB00091,Cyclosporine
,29432892,area under curve (AUC),"Under the same conditions with 10% CyA MN administered to rats, CyA MN showed Tmax of 8 h, Cmax of 15.9 ng/ml, and area under curve (AUC) of 686, compared to Tmax of 2 h, Cmax of 18.205 ng/ml, and AUC of 254 for oral administration of solubilized CyA.","Local dermal delivery of cyclosporin A, a hydrophobic and high molecular weight drug, using dissolving microneedles. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29432892/),,686,76332,DB00091,Cyclosporine
,29432892,Tmax,"Under the same conditions with 10% CyA MN administered to rats, CyA MN showed Tmax of 8 h, Cmax of 15.9 ng/ml, and area under curve (AUC) of 686, compared to Tmax of 2 h, Cmax of 18.205 ng/ml, and AUC of 254 for oral administration of solubilized CyA.","Local dermal delivery of cyclosporin A, a hydrophobic and high molecular weight drug, using dissolving microneedles. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29432892/),h,2,76333,DB00091,Cyclosporine
,29432892,Cmax,"Under the same conditions with 10% CyA MN administered to rats, CyA MN showed Tmax of 8 h, Cmax of 15.9 ng/ml, and area under curve (AUC) of 686, compared to Tmax of 2 h, Cmax of 18.205 ng/ml, and AUC of 254 for oral administration of solubilized CyA.","Local dermal delivery of cyclosporin A, a hydrophobic and high molecular weight drug, using dissolving microneedles. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29432892/),[ng] / [ml],18.205,76334,DB00091,Cyclosporine
,29432892,AUC,"Under the same conditions with 10% CyA MN administered to rats, CyA MN showed Tmax of 8 h, Cmax of 15.9 ng/ml, and area under curve (AUC) of 686, compared to Tmax of 2 h, Cmax of 18.205 ng/ml, and AUC of 254 for oral administration of solubilized CyA.","Local dermal delivery of cyclosporin A, a hydrophobic and high molecular weight drug, using dissolving microneedles. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29432892/),,254,76335,DB00091,Cyclosporine
,16625985,AUC0-12,"Treatment with fluvastatin XL, 80 mg for 7 days, had no significant effect on either the AUC0-12 (3,644 ng x h/ml in the absence of fluvastatin vs. 3,534 ng x h/ml in the presence of fluvastatin) or the Cmax of cyclosporine (983 ng/ml in the absence of fluvastatin vs. 945 ng/ml in the presence of fluvastatin).",Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16625985/),[h·ng] / [ml],"3,644",76871,DB00091,Cyclosporine
,16625985,AUC0-12,"Treatment with fluvastatin XL, 80 mg for 7 days, had no significant effect on either the AUC0-12 (3,644 ng x h/ml in the absence of fluvastatin vs. 3,534 ng x h/ml in the presence of fluvastatin) or the Cmax of cyclosporine (983 ng/ml in the absence of fluvastatin vs. 945 ng/ml in the presence of fluvastatin).",Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16625985/),[h·ng] / [ml],"3,534",76872,DB00091,Cyclosporine
,16625985,Cmax,"Treatment with fluvastatin XL, 80 mg for 7 days, had no significant effect on either the AUC0-12 (3,644 ng x h/ml in the absence of fluvastatin vs. 3,534 ng x h/ml in the presence of fluvastatin) or the Cmax of cyclosporine (983 ng/ml in the absence of fluvastatin vs. 945 ng/ml in the presence of fluvastatin).",Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16625985/),[ng] / [ml],983,76873,DB00091,Cyclosporine
,16625985,Cmax,"Treatment with fluvastatin XL, 80 mg for 7 days, had no significant effect on either the AUC0-12 (3,644 ng x h/ml in the absence of fluvastatin vs. 3,534 ng x h/ml in the presence of fluvastatin) or the Cmax of cyclosporine (983 ng/ml in the absence of fluvastatin vs. 945 ng/ml in the presence of fluvastatin).",Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16625985/),[ng] / [ml],945,76874,DB00091,Cyclosporine
,16625985,AUC0-24,"The AUC and Cmax for fluvastatin XL in the presence of cyclosporine (AUC0-24 1,192 ng.",Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16625985/),ng,"1,192",76875,DB00091,Cyclosporine
,16625985,Cmax,"x h/ml, Cmax 271 ng/ml) were approximately 2-fold higher compared with historical data for fluvastatin XL alone in healthy volunteers (AUC0-24 630 ng x h/ml, Cmax 102 ng/ml) but lower than the historical data for fluvastatin IR, 40 mg b.i.d. alone in healthy volunteers (AUC0-24 1,340 ng x h/ml, Cmax 443 ng/ml).",Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16625985/),[ng] / [ml],271,76876,DB00091,Cyclosporine
,16625985,AUC0-24,"x h/ml, Cmax 271 ng/ml) were approximately 2-fold higher compared with historical data for fluvastatin XL alone in healthy volunteers (AUC0-24 630 ng x h/ml, Cmax 102 ng/ml) but lower than the historical data for fluvastatin IR, 40 mg b.i.d. alone in healthy volunteers (AUC0-24 1,340 ng x h/ml, Cmax 443 ng/ml).",Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16625985/),[h·ng] / [ml],630,76877,DB00091,Cyclosporine
,16625985,Cmax,"x h/ml, Cmax 271 ng/ml) were approximately 2-fold higher compared with historical data for fluvastatin XL alone in healthy volunteers (AUC0-24 630 ng x h/ml, Cmax 102 ng/ml) but lower than the historical data for fluvastatin IR, 40 mg b.i.d. alone in healthy volunteers (AUC0-24 1,340 ng x h/ml, Cmax 443 ng/ml).",Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16625985/),[ng] / [ml],102,76878,DB00091,Cyclosporine
,16625985,AUC0-24,"x h/ml, Cmax 271 ng/ml) were approximately 2-fold higher compared with historical data for fluvastatin XL alone in healthy volunteers (AUC0-24 630 ng x h/ml, Cmax 102 ng/ml) but lower than the historical data for fluvastatin IR, 40 mg b.i.d. alone in healthy volunteers (AUC0-24 1,340 ng x h/ml, Cmax 443 ng/ml).",Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16625985/),[h·ng] / [ml],"1,340",76879,DB00091,Cyclosporine
,16625985,Cmax,"x h/ml, Cmax 271 ng/ml) were approximately 2-fold higher compared with historical data for fluvastatin XL alone in healthy volunteers (AUC0-24 630 ng x h/ml, Cmax 102 ng/ml) but lower than the historical data for fluvastatin IR, 40 mg b.i.d. alone in healthy volunteers (AUC0-24 1,340 ng x h/ml, Cmax 443 ng/ml).",Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16625985/),[ng] / [ml],443,76880,DB00091,Cyclosporine
,18240156,oral bioavailability,"The oral bioavailability of CyA after 1.5 or 3.0 mg/kg AMB treatment was decreased to 67% or 46%, respectively, of that of the control group.",Mechanism of decrease of oral bioavailability of cyclosporin A during immunotherapy upon coadministration of amphotericin B. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18240156/),%,67,77048,DB00091,Cyclosporine
,18240156,oral bioavailability,"The oral bioavailability of CyA after 1.5 or 3.0 mg/kg AMB treatment was decreased to 67% or 46%, respectively, of that of the control group.",Mechanism of decrease of oral bioavailability of cyclosporin A during immunotherapy upon coadministration of amphotericin B. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18240156/),%,46,77049,DB00091,Cyclosporine
,14570757,AUC,"For the dual CYP3A and P-gp substrate, tacrolimus, AUC +/- S.D. was decreased from control (2,260 +/- 430 ng. min/ml) by GG918 (1,730 +/- 270 ng. min/ml, P < 0.05) and was increased by troleandomycin (5,200 +/- 2,470 ng. min/ml, P < 0.05) and cyclosporine (4,390 +/- 2,080 ng. min/ml, P < 0.05).","Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570757/),[min·ng] / [ml],"2,260",77923,DB00091,Cyclosporine
,14570757,AUC,"For the dual CYP3A and P-gp substrate, tacrolimus, AUC +/- S.D. was decreased from control (2,260 +/- 430 ng. min/ml) by GG918 (1,730 +/- 270 ng. min/ml, P < 0.05) and was increased by troleandomycin (5,200 +/- 2,470 ng. min/ml, P < 0.05) and cyclosporine (4,390 +/- 2,080 ng. min/ml, P < 0.05).","Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570757/),[min·ng] / [ml],"1,730",77924,DB00091,Cyclosporine
,14570757,AUC,"For the dual CYP3A and P-gp substrate, tacrolimus, AUC +/- S.D. was decreased from control (2,260 +/- 430 ng. min/ml) by GG918 (1,730 +/- 270 ng. min/ml, P < 0.05) and was increased by troleandomycin (5,200 +/- 2,470 ng. min/ml, P < 0.05) and cyclosporine (4,390 +/- 2,080 ng. min/ml, P < 0.05).","Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570757/),[min·ng] / [ml],"5,200",77925,DB00091,Cyclosporine
,14570757,AUC,"For the dual CYP3A and P-gp substrate, tacrolimus, AUC +/- S.D. was decreased from control (2,260 +/- 430 ng. min/ml) by GG918 (1,730 +/- 270 ng. min/ml, P < 0.05) and was increased by troleandomycin (5,200 +/- 2,470 ng. min/ml, P < 0.05) and cyclosporine (4,390 +/- 2,080 ng. min/ml, P < 0.05).","Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570757/),[min·ng] / [ml],"4,390",77926,DB00091,Cyclosporine
,31376625,trough EVR level,The trough EVR level in both groups was maintained within 3-8 ng/mL during the perioperative period.,Optimal dose of everolimus administered with tacrolimus in living donor kidney transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31376625/),[ng] / [ml],3-8,78330,DB00091,Cyclosporine
,21168674,time after transplantation,"Mean patient age was 58.2 ± 8.8 years, and mean time after transplantation was 2.3 ± 4.0 years (range, 0.2-13.0 years).",Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168674/),years,2.3,78356,DB00091,Cyclosporine
,21168674,serum concentrations,Mean predose (C0) MPA serum concentrations were insignificantly lower with PPI comedication (2.5 ± 2.2 mg/L vs 2.8 ± 1.7 mg/L; P = .15).,Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168674/),[mg] / [l],2.5,78357,DB00091,Cyclosporine
,21168674,serum concentrations,Mean predose (C0) MPA serum concentrations were insignificantly lower with PPI comedication (2.5 ± 2.2 mg/L vs 2.8 ± 1.7 mg/L; P = .15).,Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168674/),[mg] / [l],2.8,78358,DB00091,Cyclosporine
,21168674,AUCs,Dose-adjusted abbreviated MPA AUCs (adjusted to morning dose) were significantly lower during PPI therapy (45.2 ± 20.3 vs 65.2 ± 38.8 mg·h/L·g [MMF]; P = .02).,Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168674/),[h·mg] / [g·l],45.2,78359,DB00091,Cyclosporine
,21168674,AUCs,Dose-adjusted abbreviated MPA AUCs (adjusted to morning dose) were significantly lower during PPI therapy (45.2 ± 20.3 vs 65.2 ± 38.8 mg·h/L·g [MMF]; P = .02).,Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168674/),[h·mg] / [g·l],65.2,78360,DB00091,Cyclosporine
,11054441,area under the plasma concentration versus time curve (AUC),Fifty-eight patients were treated with escalating doses of paclitaxel ranging from 54 to 94.5 mg/m(2) and carboplatin area under the plasma concentration versus time curve (AUC) ranging from 6 to 9 mg.,Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11054441/),mg,6 to 9,78361,DB00091,Cyclosporine
,11054441,AUC,"The MTD was determined for the following two groups: (1) previously treated patients, where paclitaxel and carboplatin doses were escalated; and (2) chemotherapy-naïve patients, where paclitaxel dose was escalated and carboplatin AUC was fixed at 6 mg.",Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11054441/),mg,6,78362,DB00091,Cyclosporine
,11054441,AUC,"In previously treated patients, no DLTs occurred at the first dose level (paclitaxel 54 mg/m(2) and carboplatin AUC 6 mg.min/mL).",Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11054441/),[mg·min] / [ml],6,78363,DB00091,Cyclosporine
,11054441,AUC,"However, one of 12, two of six, two of four, four of 11, and two of five patients experienced DLTs at doses of paclitaxel (mg/m(2))/carboplatin AUC (mg.min/mL) of 67.5/6, 81/6, 94.5/6, 67.",Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11054441/),[mg·min] / [ml],67.5,78364,DB00091,Cyclosporine
,11054441,AUC,"However, one of 12, two of six, two of four, four of 11, and two of five patients experienced DLTs at doses of paclitaxel (mg/m(2))/carboplatin AUC (mg.min/mL) of 67.5/6, 81/6, 94.5/6, 67.",Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11054441/),[mg·min] / [ml],81,78365,DB00091,Cyclosporine
,11054441,AUC,"However, one of 12, two of six, two of four, four of 11, and two of five patients experienced DLTs at doses of paclitaxel (mg/m(2))/carboplatin AUC (mg.min/mL) of 67.5/6, 81/6, 94.5/6, 67.",Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11054441/),[mg·min] / [ml],94.5,78366,DB00091,Cyclosporine
,11054441,AUC,"In chemotherapy-naïve patients, one of 17 developed DLT at paclitaxel 81 mg/m(2) and carboplatin AUC 6 mg/mL.min.",Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11054441/),[mg] / [min·ml],6,78367,DB00091,Cyclosporine
,11054441,time that,"There was prolongation of the terminal phase of paclitaxel elimination as evidenced by an increased time that plasma paclitaxel concentration was >/= 0.05 micromol/L, ranging from 16.6 +/- 6.7 hours to 41.5 +/- 9.8 hours for paclitaxel doses of 54.5 mg/m(2) to 94.5 mg/m(2), respectively.",Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11054441/),h,16.6,78368,DB00091,Cyclosporine
,11054441,time that,"There was prolongation of the terminal phase of paclitaxel elimination as evidenced by an increased time that plasma paclitaxel concentration was >/= 0.05 micromol/L, ranging from 16.6 +/- 6.7 hours to 41.5 +/- 9.8 hours for paclitaxel doses of 54.5 mg/m(2) to 94.5 mg/m(2), respectively.",Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11054441/),h,41.5,78369,DB00091,Cyclosporine
,11054441,AUC,"In previously treated patients, the recommended phase II dose is paclitaxel 67.5 mg/m(2), carboplatin AUC 6 mg.",Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11054441/),,6,78370,DB00091,Cyclosporine
,22105586,Cl,"Of 19 volunteers, 12 were men, with age (mean ± SD) 46 ± 11 years, weight 83 ± 19 kg, and calculated Cl(creatinine) 64 ± 27 mL/min.","Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22105586/),,64,79249,DB00091,Cyclosporine
,3898491,clearance,"In the course of CsA treatment, prolongation of half-life was found in most cases, with a significant decrease in clearance (46 +/- 17 L/hr on day 3 versus 28 +/- 10 L/hr on day 15).",Pharmacokinetics and nephrotoxicity of cyclosporine in renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3898491/),[l] / [h],46,79353,DB00091,Cyclosporine
,3898491,clearance,"In the course of CsA treatment, prolongation of half-life was found in most cases, with a significant decrease in clearance (46 +/- 17 L/hr on day 3 versus 28 +/- 10 L/hr on day 15).",Pharmacokinetics and nephrotoxicity of cyclosporine in renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3898491/),[l] / [h],28,79354,DB00091,Cyclosporine
,3898491,terminal half-life,The terminal half-life varied considerably among the patients (24-93 hr) and did not correlate with other pharmacokinetic parameters.,Pharmacokinetics and nephrotoxicity of cyclosporine in renal transplant recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3898491/),h,24-93,79355,DB00091,Cyclosporine
,26483433,concentrations,The mean posaconazole concentrations in patients with regular nutrition was 1123 ± 811 ng/ml and with higher-fat nutrition was 1191 ± 673 ng/ml.,Posaconazole plasma concentration in pediatric patients receiving antifungal prophylaxis after allogeneic hematopoietic stem cell transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26483433/),[ng] / [ml],1123,79565,DB00091,Cyclosporine
,26483433,concentrations,The mean posaconazole concentrations in patients with regular nutrition was 1123 ± 811 ng/ml and with higher-fat nutrition was 1191 ± 673 ng/ml.,Posaconazole plasma concentration in pediatric patients receiving antifungal prophylaxis after allogeneic hematopoietic stem cell transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26483433/),[ng] / [ml],1191,79566,DB00091,Cyclosporine
,13680852,detection limit,The detection limit was of 5.0 microg/L cyclosporin A.,Improvement of cyclosporin A determination in whole blood by reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13680852/),[μg] / [l],5.0,80321,DB00091,Cyclosporine
,31156436,clearance/F,"In the popPK analysis, a two-compartment model (clearance/F 62.8 L/h, central and peripheral volume of distribution/F 254 L and 388 L) with transit compartments for absorption appropriately described CsA concentrations.",A Single Dose of Baicalin Has No Clinically Significant Effect on the Pharmacokinetics of Cyclosporine A in Healthy Chinese Volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31156436/),[l] / [h],62.8,80407,DB00091,Cyclosporine
,31156436,central,"In the popPK analysis, a two-compartment model (clearance/F 62.8 L/h, central and peripheral volume of distribution/F 254 L and 388 L) with transit compartments for absorption appropriately described CsA concentrations.",A Single Dose of Baicalin Has No Clinically Significant Effect on the Pharmacokinetics of Cyclosporine A in Healthy Chinese Volunteers. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31156436/),l,254,80408,DB00091,Cyclosporine
,31156436,peripheral volume of distribution/F,"In the popPK analysis, a two-compartment model (clearance/F 62.8 L/h, central and peripheral volume of distribution/F 254 L and 388 L) with transit compartments for absorption appropriately described CsA concentrations.",A Single Dose of Baicalin Has No Clinically Significant Effect on the Pharmacokinetics of Cyclosporine A in Healthy Chinese Volunteers. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31156436/),l,254,80409,DB00091,Cyclosporine
,31156436,peripheral volume of distribution/F,"In the popPK analysis, a two-compartment model (clearance/F 62.8 L/h, central and peripheral volume of distribution/F 254 L and 388 L) with transit compartments for absorption appropriately described CsA concentrations.",A Single Dose of Baicalin Has No Clinically Significant Effect on the Pharmacokinetics of Cyclosporine A in Healthy Chinese Volunteers. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31156436/),l,388,80410,DB00091,Cyclosporine
,12189539,plasma half-life,Pharmacokinetic parameters of melphalan were not significantly altered with its plasma half-life 1.5 h.,Successful allogeneic blood stem cell transplantation for aplastic anemia in a patient with renal insufficiency requiring dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12189539/),h,1.5,80474,DB00091,Cyclosporine
,25818517,CL,The final typical estimate of CL was 21.2 L/h; volume of distribution was 430 L; logit-transformed bioavailability was 1.49 (bioavailability: 81%); and transit compartment rate was 2.87/h.,Population pharmacokinetics of cyclosporine in hematopoietic stem cell transplant patients: consideration of genetic polymorphisms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25818517/),[l] / [h],21.2,81057,DB00091,Cyclosporine
,25818517,volume of distribution,The final typical estimate of CL was 21.2 L/h; volume of distribution was 430 L; logit-transformed bioavailability was 1.49 (bioavailability: 81%); and transit compartment rate was 2.87/h.,Population pharmacokinetics of cyclosporine in hematopoietic stem cell transplant patients: consideration of genetic polymorphisms. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25818517/),l,430,81058,DB00091,Cyclosporine
,25818517,bioavailability,The final typical estimate of CL was 21.2 L/h; volume of distribution was 430 L; logit-transformed bioavailability was 1.49 (bioavailability: 81%); and transit compartment rate was 2.87/h.,Population pharmacokinetics of cyclosporine in hematopoietic stem cell transplant patients: consideration of genetic polymorphisms. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25818517/),,1.49,81059,DB00091,Cyclosporine
,25818517,bioavailability,The final typical estimate of CL was 21.2 L/h; volume of distribution was 430 L; logit-transformed bioavailability was 1.49 (bioavailability: 81%); and transit compartment rate was 2.87/h.,Population pharmacokinetics of cyclosporine in hematopoietic stem cell transplant patients: consideration of genetic polymorphisms. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25818517/),%,81,81060,DB00091,Cyclosporine
,25818517,transit compartment rate,The final typical estimate of CL was 21.2 L/h; volume of distribution was 430 L; logit-transformed bioavailability was 1.49 (bioavailability: 81%); and transit compartment rate was 2.87/h.,Population pharmacokinetics of cyclosporine in hematopoietic stem cell transplant patients: consideration of genetic polymorphisms. ,"λ1, λ2-Q67",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25818517/),1/[h],2.87,81061,DB00091,Cyclosporine
<,15257072,AUC(0-4),"Patients with an AUC(0-4) < 4400 microg x h/L at both PK sampling periods in the first 3 weeks posttransplant had an adjusted relative risk of 48.4% to suffer an acute rejection episode (ARE), whereas in patients with at least 1 AUC0-4 above this threshold, the adjusted relative risk for an ARE was only 13.1% (P < 0.02).",Cyclosporin A absorption profiles in pediatric renal transplant recipients predict the risk of acute rejection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15257072/),[h·μg] / [l],4400,81067,DB00091,Cyclosporine
,7660791,Vd(L),"Population mean values of CL(L.h-1), Vd(L), and Ka(h-1) were 59.8, 227, and 1.28 respectively.",[Evaluation of population pharmacokinetics of cyclosporin A in renal transplantation patients with NONMEM]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7660791/),,227,81148,DB00091,Cyclosporine
,7660791,Ka(h-1),"Population mean values of CL(L.h-1), Vd(L), and Ka(h-1) were 59.8, 227, and 1.28 respectively.",[Evaluation of population pharmacokinetics of cyclosporin A in renal transplantation patients with NONMEM]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7660791/),,1.28,81149,DB00091,Cyclosporine
,8489193,recommend through concentrations,The recommend through concentrations are 150-200 ng/ml during the first three months.,[Pharmacokinetics and therapeutic monitoring of cyclosporine in liver transplant patients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489193/),[ng] / [ml],150-200,81158,DB00091,Cyclosporine
,23400901,apparent oral clearance,"The final population model included sex as a covariate: ciclosporin apparent oral clearance was on average 37 % faster in male than in female patients (34.8 vs. 25.4 L/h, p < 0.001).",Ciclosporin population pharmacokinetics and Bayesian estimation in thoracic transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23400901/),[l] / [h],34.8,81278,DB00091,Cyclosporine
,23400901,apparent oral clearance,"The final population model included sex as a covariate: ciclosporin apparent oral clearance was on average 37 % faster in male than in female patients (34.8 vs. 25.4 L/h, p < 0.001).",Ciclosporin population pharmacokinetics and Bayesian estimation in thoracic transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23400901/),[l] / [h],25.4,81279,DB00091,Cyclosporine
,17096757,trough levels,SRL was dosed to achieve target trough levels between 10 and 20 ng/mL.,Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17096757/),[ng] / [ml],10 and 20,81471,DB00091,Cyclosporine
excess of,9158016,peak CD4 saturations,Ninety-three percent of patients treated at 0.5 mg/kg OKT4A and all patients at higher doses had mean peak CD4 saturations in excess of 90%.,Murine OKT4A immunosuppression in cadaver donor renal allograft recipients: a cooperative clinical trials in transplantation pilot study. Cooperative Clinical Trials in Transplantation Research Group. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9158016/),%,90,82201,DB00091,Cyclosporine
,16027407,apparent oral cyclosporine clearances,"Mean apparent oral cyclosporine clearances were estimated to be 645+/-236 mL/h/kg, 546+/-101 mL/h/kg (P = .01), and 540+/-104 mL/h/kg (P = .02) for days 1, 9, and 15, respectively.",Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16027407/),[ml] / [h·kg],645,82286,DB00091,Cyclosporine
,16027407,apparent oral cyclosporine clearances,"Mean apparent oral cyclosporine clearances were estimated to be 645+/-236 mL/h/kg, 546+/-101 mL/h/kg (P = .01), and 540+/-104 mL/h/kg (P = .02) for days 1, 9, and 15, respectively.",Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16027407/),[ml] / [h·kg],546,82287,DB00091,Cyclosporine
,16027407,apparent oral cyclosporine clearances,"Mean apparent oral cyclosporine clearances were estimated to be 645+/-236 mL/h/kg, 546+/-101 mL/h/kg (P = .01), and 540+/-104 mL/h/kg (P = .02) for days 1, 9, and 15, respectively.",Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16027407/),[ml] / [h·kg],540,82288,DB00091,Cyclosporine
,1871050,Absolute bioavailability,"Absolute bioavailability (mean +/- SD) was 46.0 +/- 11.1 and 45.4 +/- 9.9% for the capsules and tablets, respectively.",The preparation and evaluation of a tablet dosage form of cyclosporine in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1871050/),%,46.0,82340,DB00091,Cyclosporine
,1871050,Absolute bioavailability,"Absolute bioavailability (mean +/- SD) was 46.0 +/- 11.1 and 45.4 +/- 9.9% for the capsules and tablets, respectively.",The preparation and evaluation of a tablet dosage form of cyclosporine in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1871050/),%,45.4,82341,DB00091,Cyclosporine
,12099989,Cmax,"With water vs. apple juice, cyclosporine Cmax was 1263 +/- 203 vs.",Administration diluents differentiate Neoral from a generic cyclosporine oral solution. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12099989/),,1263,82475,DB00091,Cyclosporine
,12099989,AUC,"1191 +/- 225 ng/mL and AUC was 4714 +/- 1117 vs. 4788 +/- 1320 ng h/mL, respectively.",Administration diluents differentiate Neoral from a generic cyclosporine oral solution. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12099989/),[h·ng] / [ml],4714,82476,DB00091,Cyclosporine
,12099989,AUC,"1191 +/- 225 ng/mL and AUC was 4714 +/- 1117 vs. 4788 +/- 1320 ng h/mL, respectively.",Administration diluents differentiate Neoral from a generic cyclosporine oral solution. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12099989/),[h·ng] / [ml],4788,82477,DB00091,Cyclosporine
,2260347,peak serum concentrations,Mean peak serum concentrations achieved in human volunteers after 50 and 100 mg (oral) are 3.1 and 7.0 mumols/L respectively.,Fluconazole: a new triazole antifungal agent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260347/),[mumols] / [l],3.1,82553,DB00091,Cyclosporine
,2260347,peak serum concentrations,Mean peak serum concentrations achieved in human volunteers after 50 and 100 mg (oral) are 3.1 and 7.0 mumols/L respectively.,Fluconazole: a new triazole antifungal agent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260347/),[mumols] / [l],7.0,82554,DB00091,Cyclosporine
,2260347,Protein binding,Protein binding is low (11 percent) and cerebrospinal fluid to serum ratio is 0.58 to 0.89.,Fluconazole: a new triazole antifungal agent. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260347/),%,11,82555,DB00091,Cyclosporine
,2260347,cerebrospinal fluid to serum ratio,Protein binding is low (11 percent) and cerebrospinal fluid to serum ratio is 0.58 to 0.89.,Fluconazole: a new triazole antifungal agent. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260347/),,0.58 to 0.89,82556,DB00091,Cyclosporine
,2260347,Serum half-life,Serum half-life is long (22-32 hours) and elimination is via renal clearance of unchanged drug.,Fluconazole: a new triazole antifungal agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2260347/),h,22-32,82557,DB00091,Cyclosporine
,19448042,CL/F,"The mean+/-SD of CL/F and V/F of the 106 patients were 23.5+/-7.2 L/h and 232.3+/-71.5 L, respectively.",Population pharmacokinetic study of cyclosporine in patients with nephrotic syndrome. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19448042/),[l] / [h],23.5,82610,DB00091,Cyclosporine
,19448042,V/F,"The mean+/-SD of CL/F and V/F of the 106 patients were 23.5+/-7.2 L/h and 232.3+/-71.5 L, respectively.",Population pharmacokinetic study of cyclosporine in patients with nephrotic syndrome. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19448042/),l,232.3,82611,DB00091,Cyclosporine
,16740102,maximum tolerated dose,The maximum tolerated dose of docetaxel was 1.625 mg/kg.,Phase I and pharmacokinetic evaluation of the combination of orally administered docetaxel and cyclosporin A in tumor-bearing dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740102/),mg,1.,83115,DB00091,Cyclosporine
,17931809,liver-to-blood distribution ratios (AUC(liver)/AUC(blood)),"The liver-to-blood distribution ratios (AUC(liver)/AUC(blood)) were 1.8+/-0.6, 1.0+/-0.2 and 0.8+/-0.1, and the bile-to-blood distribution ratios (AUC(bile)/AUC(blood)) were 121.6+/-24.7, 102.2+/-13.4 and 116.5+/-18.4 at dosages of 1, 3 and 10mg/kg, respectively.",Hepatobiliary excretion and enterohepatic circulation of colchicine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17931809/),,1.8,83368,DB00091,Cyclosporine
,17931809,liver-to-blood distribution ratios (AUC(liver)/AUC(blood)),"The liver-to-blood distribution ratios (AUC(liver)/AUC(blood)) were 1.8+/-0.6, 1.0+/-0.2 and 0.8+/-0.1, and the bile-to-blood distribution ratios (AUC(bile)/AUC(blood)) were 121.6+/-24.7, 102.2+/-13.4 and 116.5+/-18.4 at dosages of 1, 3 and 10mg/kg, respectively.",Hepatobiliary excretion and enterohepatic circulation of colchicine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17931809/),,1.0,83369,DB00091,Cyclosporine
,17931809,liver-to-blood distribution ratios (AUC(liver)/AUC(blood)),"The liver-to-blood distribution ratios (AUC(liver)/AUC(blood)) were 1.8+/-0.6, 1.0+/-0.2 and 0.8+/-0.1, and the bile-to-blood distribution ratios (AUC(bile)/AUC(blood)) were 121.6+/-24.7, 102.2+/-13.4 and 116.5+/-18.4 at dosages of 1, 3 and 10mg/kg, respectively.",Hepatobiliary excretion and enterohepatic circulation of colchicine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17931809/),,0.8,83370,DB00091,Cyclosporine
,17931809,bile-to-blood distribution ratios (AUC(bile)/AUC(blood)),"The liver-to-blood distribution ratios (AUC(liver)/AUC(blood)) were 1.8+/-0.6, 1.0+/-0.2 and 0.8+/-0.1, and the bile-to-blood distribution ratios (AUC(bile)/AUC(blood)) were 121.6+/-24.7, 102.2+/-13.4 and 116.5+/-18.4 at dosages of 1, 3 and 10mg/kg, respectively.",Hepatobiliary excretion and enterohepatic circulation of colchicine in rats. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17931809/),,121.6,83371,DB00091,Cyclosporine
,17931809,bile-to-blood distribution ratios (AUC(bile)/AUC(blood)),"The liver-to-blood distribution ratios (AUC(liver)/AUC(blood)) were 1.8+/-0.6, 1.0+/-0.2 and 0.8+/-0.1, and the bile-to-blood distribution ratios (AUC(bile)/AUC(blood)) were 121.6+/-24.7, 102.2+/-13.4 and 116.5+/-18.4 at dosages of 1, 3 and 10mg/kg, respectively.",Hepatobiliary excretion and enterohepatic circulation of colchicine in rats. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17931809/),,102.2,83372,DB00091,Cyclosporine
,17931809,bile-to-blood distribution ratios (AUC(bile)/AUC(blood)),"The liver-to-blood distribution ratios (AUC(liver)/AUC(blood)) were 1.8+/-0.6, 1.0+/-0.2 and 0.8+/-0.1, and the bile-to-blood distribution ratios (AUC(bile)/AUC(blood)) were 121.6+/-24.7, 102.2+/-13.4 and 116.5+/-18.4 at dosages of 1, 3 and 10mg/kg, respectively.",Hepatobiliary excretion and enterohepatic circulation of colchicine in rats. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17931809/),,116.5,83373,DB00091,Cyclosporine
,20357699,area under the curve,Pharmacokinetic parameters for MPA were area under the curve 42.9 +/- 21.6 microg h/mL; dose-normalized AUC 52.9 +/- 25.4 microg h/mL/g; maximal concentration (Cmax) 13.0 +/- 6.2 microg/mL; time to Cmax (tmax) 1.2 +/- 0.4 hours; minimum concentration (Cmin) 1.4 +/- 1.0 microg/mL; and MPA-free fraction 1.2% +/- 1.0%.,Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable islet transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357699/),[h·μg] / [ml],42.9,83387,DB00091,Cyclosporine
,20357699,dose-normalized AUC,Pharmacokinetic parameters for MPA were area under the curve 42.9 +/- 21.6 microg h/mL; dose-normalized AUC 52.9 +/- 25.4 microg h/mL/g; maximal concentration (Cmax) 13.0 +/- 6.2 microg/mL; time to Cmax (tmax) 1.2 +/- 0.4 hours; minimum concentration (Cmin) 1.4 +/- 1.0 microg/mL; and MPA-free fraction 1.2% +/- 1.0%.,Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable islet transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357699/),[h·μg] / [g·ml],52.9,83388,DB00091,Cyclosporine
,20357699,maximal concentration (Cmax),Pharmacokinetic parameters for MPA were area under the curve 42.9 +/- 21.6 microg h/mL; dose-normalized AUC 52.9 +/- 25.4 microg h/mL/g; maximal concentration (Cmax) 13.0 +/- 6.2 microg/mL; time to Cmax (tmax) 1.2 +/- 0.4 hours; minimum concentration (Cmin) 1.4 +/- 1.0 microg/mL; and MPA-free fraction 1.2% +/- 1.0%.,Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable islet transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357699/),[μg] / [ml],13.0,83389,DB00091,Cyclosporine
,20357699,time to Cmax (tmax),Pharmacokinetic parameters for MPA were area under the curve 42.9 +/- 21.6 microg h/mL; dose-normalized AUC 52.9 +/- 25.4 microg h/mL/g; maximal concentration (Cmax) 13.0 +/- 6.2 microg/mL; time to Cmax (tmax) 1.2 +/- 0.4 hours; minimum concentration (Cmin) 1.4 +/- 1.0 microg/mL; and MPA-free fraction 1.2% +/- 1.0%.,Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable islet transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357699/),h,1.2,83390,DB00091,Cyclosporine
,20357699,minimum concentration (Cmin),Pharmacokinetic parameters for MPA were area under the curve 42.9 +/- 21.6 microg h/mL; dose-normalized AUC 52.9 +/- 25.4 microg h/mL/g; maximal concentration (Cmax) 13.0 +/- 6.2 microg/mL; time to Cmax (tmax) 1.2 +/- 0.4 hours; minimum concentration (Cmin) 1.4 +/- 1.0 microg/mL; and MPA-free fraction 1.2% +/- 1.0%.,Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable islet transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357699/),[μg] / [ml],1.4,83391,DB00091,Cyclosporine
,20357699,Area under the curve ratios,"Area under the curve ratios of MPAG/MPA and AcMPAG/MPA were 17.8 +/- 12.4 and 0.1 +/- 0.1, respectively.",Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable islet transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357699/),,17.8,83392,DB00091,Cyclosporine
,20357699,Area under the curve ratios,"Area under the curve ratios of MPAG/MPA and AcMPAG/MPA were 17.8 +/- 12.4 and 0.1 +/- 0.1, respectively.",Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable islet transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357699/),,0.1,83393,DB00091,Cyclosporine
,17889124,C2,"At day 7, CsA C2 and AUC median values were 138 ng/mL and 6377 ng x h/mL, while C0 MPA was 1.0 microg/mL and AUC = 23.9 microg x h/mL.",Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17889124/),[ng] / [ml],138,83527,DB00091,Cyclosporine
,17889124,AUC,"At day 7, CsA C2 and AUC median values were 138 ng/mL and 6377 ng x h/mL, while C0 MPA was 1.0 microg/mL and AUC = 23.9 microg x h/mL.",Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17889124/),[h·ng] / [ml],6377,83528,DB00091,Cyclosporine
,17889124,C0 MPA,"At day 7, CsA C2 and AUC median values were 138 ng/mL and 6377 ng x h/mL, while C0 MPA was 1.0 microg/mL and AUC = 23.9 microg x h/mL.",Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17889124/),[μg] / [ml],1.0,83529,DB00091,Cyclosporine
,17889124,AUC,"At day 7, CsA C2 and AUC median values were 138 ng/mL and 6377 ng x h/mL, while C0 MPA was 1.0 microg/mL and AUC = 23.9 microg x h/mL.",Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17889124/),[h·μg] / [ml],23.9,83530,DB00091,Cyclosporine
,17889124,C2,CsA C2 medians at 3 and 6 months were 1468 and 1720 ng/mL.,Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17889124/),[ng] / [ml],1468,83531,DB00091,Cyclosporine
,17889124,C2,CsA C2 medians at 3 and 6 months were 1468 and 1720 ng/mL.,Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17889124/),[ng] / [ml],1720,83532,DB00091,Cyclosporine
,17889124,AUC,MPA-AUC reached therapeutic targets at 3 months (32.3 microg x h/mL) and was 48.3 microg x h/mL at 6 months.,Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17889124/),[h·μg] / [ml],32.3,83533,DB00091,Cyclosporine
,17889124,AUC,MPA-AUC reached therapeutic targets at 3 months (32.3 microg x h/mL) and was 48.3 microg x h/mL at 6 months.,Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17889124/),[h·μg] / [ml],48.3,83534,DB00091,Cyclosporine
,15787787,trough level,Mean trough level was 11.9 +/- 5.0 ng/mL.,"Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15787787/),[ng] / [ml],11.9,83635,DB00091,Cyclosporine
,15787787,area under the curve (AUC),Mean area under the curve (AUC) was 192 +/- 84 with a range of 78-360 h x (ng/mL).,"Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15787787/),[h·ng] / [ml],192,83636,DB00091,Cyclosporine
,14748618,trough concentration,The target trough concentration of everolimus should range between 3 and 15 microg/L in combination therapy with ciclosporin (trough concentration 100-300 microg/L) and prednisone.,Clinical pharmacokinetics of everolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748618/),[μg] / [l],3 and 15,83849,DB00091,Cyclosporine
,14748618,trough concentration,The target trough concentration of everolimus should range between 3 and 15 microg/L in combination therapy with ciclosporin (trough concentration 100-300 microg/L) and prednisone.,Clinical pharmacokinetics of everolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748618/),[μg] / [l],100-300,83850,DB00091,Cyclosporine
,8497912,F,"Black recipients had significantly lower bioavailability (F) pre- as well as posttransplantation than white recipients, the posttransplant mean F values being 25.8 +/- 9.0% and 38.1 +/- 16.7%, respectively (P < 0.002).",The adverse impact of high cyclosporine. Clearance rates on the incidences of acute rejection and graft loss. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8497912/),%,25.8,84059,DB00091,Cyclosporine
,8497912,F,"Black recipients had significantly lower bioavailability (F) pre- as well as posttransplantation than white recipients, the posttransplant mean F values being 25.8 +/- 9.0% and 38.1 +/- 16.7%, respectively (P < 0.002).",The adverse impact of high cyclosporine. Clearance rates on the incidences of acute rejection and graft loss. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8497912/),%,38.1,84060,DB00091,Cyclosporine
,8497912,CL,"The posttransplant CsA clearance rate (CL) and oral clearance (clearance/bioavailability; CLoral) were significantly higher in patients who had acute rejection than in those who did not, with CL mean values of 425 +/- 141 ml/min and 359 +/- 131 ml/min, respectively (P < 0.02).",The adverse impact of high cyclosporine. Clearance rates on the incidences of acute rejection and graft loss. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8497912/),[ml] / [min],425,84061,DB00091,Cyclosporine
,8497912,CL,"The posttransplant CsA clearance rate (CL) and oral clearance (clearance/bioavailability; CLoral) were significantly higher in patients who had acute rejection than in those who did not, with CL mean values of 425 +/- 141 ml/min and 359 +/- 131 ml/min, respectively (P < 0.02).",The adverse impact of high cyclosporine. Clearance rates on the incidences of acute rejection and graft loss. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8497912/),[ml] / [min],359,84062,DB00091,Cyclosporine
,8497912,F,"The initial posttransplant F was significantly lower, and the CLoral higher in patients who eventually lost their grafts than in those who did not, the mean F values being 26.5 +/- 12.8% and 38.7 +/- 17.5%, respectively (P < 0.002).",The adverse impact of high cyclosporine. Clearance rates on the incidences of acute rejection and graft loss. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8497912/),%,26.5,84063,DB00091,Cyclosporine
,8497912,F,"The initial posttransplant F was significantly lower, and the CLoral higher in patients who eventually lost their grafts than in those who did not, the mean F values being 26.5 +/- 12.8% and 38.7 +/- 17.5%, respectively (P < 0.002).",The adverse impact of high cyclosporine. Clearance rates on the incidences of acute rejection and graft loss. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8497912/),%,38.7,84064,DB00091,Cyclosporine
,19819100,T(max),"However the decrease in NFP efflux did not show any significant changes in NFP PK parameters (T(max); 2.0 vs. 2.5 min, C(max); 0.084 vs. 0.076 microg/ml, T(1/2); 84.0 vs. 91.4 min, AUC(0-t); 4.183 vs. 3.467 microg h/ml, AUC(infinity); 5.915 vs.",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),min,2.0,84534,DB00091,Cyclosporine
,19819100,T(max),"However the decrease in NFP efflux did not show any significant changes in NFP PK parameters (T(max); 2.0 vs. 2.5 min, C(max); 0.084 vs. 0.076 microg/ml, T(1/2); 84.0 vs. 91.4 min, AUC(0-t); 4.183 vs. 3.467 microg h/ml, AUC(infinity); 5.915 vs.",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),min,2.5,84535,DB00091,Cyclosporine
,19819100,C(max),"However the decrease in NFP efflux did not show any significant changes in NFP PK parameters (T(max); 2.0 vs. 2.5 min, C(max); 0.084 vs. 0.076 microg/ml, T(1/2); 84.0 vs. 91.4 min, AUC(0-t); 4.183 vs. 3.467 microg h/ml, AUC(infinity); 5.915 vs.",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[μg] / [ml],0.084,84536,DB00091,Cyclosporine
,19819100,C(max),"However the decrease in NFP efflux did not show any significant changes in NFP PK parameters (T(max); 2.0 vs. 2.5 min, C(max); 0.084 vs. 0.076 microg/ml, T(1/2); 84.0 vs. 91.4 min, AUC(0-t); 4.183 vs. 3.467 microg h/ml, AUC(infinity); 5.915 vs.",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[μg] / [ml],0.076,84537,DB00091,Cyclosporine
,19819100,T(1/2),"However the decrease in NFP efflux did not show any significant changes in NFP PK parameters (T(max); 2.0 vs. 2.5 min, C(max); 0.084 vs. 0.076 microg/ml, T(1/2); 84.0 vs. 91.4 min, AUC(0-t); 4.183 vs. 3.467 microg h/ml, AUC(infinity); 5.915 vs.",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),min,84.0,84538,DB00091,Cyclosporine
,19819100,T(1/2),"However the decrease in NFP efflux did not show any significant changes in NFP PK parameters (T(max); 2.0 vs. 2.5 min, C(max); 0.084 vs. 0.076 microg/ml, T(1/2); 84.0 vs. 91.4 min, AUC(0-t); 4.183 vs. 3.467 microg h/ml, AUC(infinity); 5.915 vs.",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),min,91.4,84539,DB00091,Cyclosporine
,19819100,AUC(0-t),"However the decrease in NFP efflux did not show any significant changes in NFP PK parameters (T(max); 2.0 vs. 2.5 min, C(max); 0.084 vs. 0.076 microg/ml, T(1/2); 84.0 vs. 91.4 min, AUC(0-t); 4.183 vs. 3.467 microg h/ml, AUC(infinity); 5.915 vs.",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[h·μg] / [ml],4.183,84540,DB00091,Cyclosporine
,19819100,AUC(0-t),"However the decrease in NFP efflux did not show any significant changes in NFP PK parameters (T(max); 2.0 vs. 2.5 min, C(max); 0.084 vs. 0.076 microg/ml, T(1/2); 84.0 vs. 91.4 min, AUC(0-t); 4.183 vs. 3.467 microg h/ml, AUC(infinity); 5.915 vs.",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[h·μg] / [ml],3.467,84541,DB00091,Cyclosporine
,19819100,AUC(infinity),"However the decrease in NFP efflux did not show any significant changes in NFP PK parameters (T(max); 2.0 vs. 2.5 min, C(max); 0.084 vs. 0.076 microg/ml, T(1/2); 84.0 vs. 91.4 min, AUC(0-t); 4.183 vs. 3.467 microg h/ml, AUC(infinity); 5.915 vs.",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),,5.915,84542,DB00091,Cyclosporine
,19819100,AUMC(0-t),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[h·μg] / [ml],224.073,84543,DB00091,Cyclosporine
,19819100,AUMC(0-t),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[h·μg] / [ml],173.063,84544,DB00091,Cyclosporine
,19819100,AUMC(infinity),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[h·μg] / [ml],776.871,84545,DB00091,Cyclosporine
,19819100,AUMC(infinity),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[h·μg] / [ml],575.038,84546,DB00091,Cyclosporine
,19819100,MRT(0-t),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[h·μg] / [ml],53.608,84547,DB00091,Cyclosporine
,19819100,MRT(0-t),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[h·μg] / [ml],49.538,84548,DB00091,Cyclosporine
,19819100,MRT(infinity),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[h·μg] / [ml],118.194,84549,DB00091,Cyclosporine
,19819100,MRT(infinity),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[h·μg] / [ml],115.246,84550,DB00091,Cyclosporine
,19819100,CL(tot),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[l] / [h],0.0375,84551,DB00091,Cyclosporine
,19819100,CL(tot),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),[l] / [h],0.0433,84552,DB00091,Cyclosporine
,19819100,Vd(ss),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),l,3.999,84553,DB00091,Cyclosporine
,19819100,Vd(ss),"4.769 microg h/ml, AUMC(0-t); 224.073 vs. 173.063 microg h/ml, AUMC(infinity); 776.871 vs. 575.038 microg h/ml, MRT(0-t); 53.608 vs. 49.538 microg h/ml, MRT(infinity); 118.194 vs. 115.246 microg h/ml, CL(tot); 0.0375 vs. 0.0433 l/h, Vd(ss); 3.999 vs. 4.641 l in NFP alone vs. CSP+NFP groups respectively).",Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19819100/),l,4.641,84554,DB00091,Cyclosporine
,19552842,C(0),No side effect or acute rejection episode occurred with the median MPA-C(0) value of 0.74 mg/L.,[Correlation of mycophenolic acid pharmacokinetic parameters with clinical events in kidney transplant patients treated with mycophenolate mofetil]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19552842/),[mg] / [l],0.74,84570,DB00091,Cyclosporine
,19552842,C(0),Side effects occurred with the median MPA-C(0) value of 1.32 mg/L.,[Correlation of mycophenolic acid pharmacokinetic parameters with clinical events in kidney transplant patients treated with mycophenolate mofetil]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19552842/),[mg] / [l],1.32,84571,DB00091,Cyclosporine
,19552842,C(0),Sixteen case-times demonstrated acute rejection episode with the median MPA-C(0) value of 0.39 mg/L.,[Correlation of mycophenolic acid pharmacokinetic parameters with clinical events in kidney transplant patients treated with mycophenolate mofetil]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19552842/),[mg] / [l],0.39,84572,DB00091,Cyclosporine
,16144801,concentration steady state (Css),"Comparing the twice-daily and 3-times-daily MMF groups, the mean total MPA concentration steady state (Css) was 1.9 and 3.1 microg/mL; the unbound Css was 18 and 36 ng/mL, respectively (P < .001).",Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144801/),[μg] / [ml],1.9,84891,DB00091,Cyclosporine
,16144801,concentration steady state (Css),"Comparing the twice-daily and 3-times-daily MMF groups, the mean total MPA concentration steady state (Css) was 1.9 and 3.1 microg/mL; the unbound Css was 18 and 36 ng/mL, respectively (P < .001).",Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144801/),[μg] / [ml],3.1,84892,DB00091,Cyclosporine
,16144801,unbound Css,"Comparing the twice-daily and 3-times-daily MMF groups, the mean total MPA concentration steady state (Css) was 1.9 and 3.1 microg/mL; the unbound Css was 18 and 36 ng/mL, respectively (P < .001).",Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144801/),[ng] / [ml],18,84893,DB00091,Cyclosporine
,16144801,unbound Css,"Comparing the twice-daily and 3-times-daily MMF groups, the mean total MPA concentration steady state (Css) was 1.9 and 3.1 microg/mL; the unbound Css was 18 and 36 ng/mL, respectively (P < .001).",Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144801/),[ng] / [ml],36,84894,DB00091,Cyclosporine
less,16144801,Css,"Sixteen patients with a total MPA Css less than 3 microg/mL had low (< 50%) donor T-cell chimerism (P = .03), and 6 patients with MPA Css less than 2.5 microg/mL had graft rejection.",Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144801/),[μg] / [ml],3,84895,DB00091,Cyclosporine
less,16144801,Css,"Sixteen patients with a total MPA Css less than 3 microg/mL had low (< 50%) donor T-cell chimerism (P = .03), and 6 patients with MPA Css less than 2.5 microg/mL had graft rejection.",Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144801/),[μg] / [ml],2.5,84896,DB00091,Cyclosporine
greater,16144801,Css's,We conclude that increased MPA Css's predicted higher degrees of donor T-cell chimerism after unrelated donor nonmyeloablative HCT and suggest that targeting MPA Css's greater than 2.5 microg/mL could prevent graft rejection.,Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144801/),[μg] / [ml],2.5,84897,DB00091,Cyclosporine
,10784624,concentrations,The mean dnr concentrations in leukemic cells 24 hours after the start of infusion (before valspodar) were 18.8 micromol/L in Pgp-negative samples and 13.5 micromol/L in Pgp-positive samples.,P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10784624/),[μM] / [l],18.8,85228,DB00091,Cyclosporine
,10784624,concentrations,The mean dnr concentrations in leukemic cells 24 hours after the start of infusion (before valspodar) were 18.8 micromol/L in Pgp-negative samples and 13.5 micromol/L in Pgp-positive samples.,P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10784624/),[μM] / [l],13.5,85229,DB00091,Cyclosporine
,11579295,area under the time-concentration curve over the entire 12-hr dosage interval (AUC[0-12]),"Mean area under the time-concentration curve over the entire 12-hr dosage interval (AUC[0-12]) was 9249+/-3236 microg.hr/L by day 3 and did not change significantly throughout the study, although dose-corrected AUC[0-12] rose by 20% from 1924+/-671 microg.hr/L on day 3 to 2316+/-697 microg.hr/L on day 14 (P=0.067).",Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11579295/),[h·μg] / [l],9249,85369,DB00091,Cyclosporine
,11579295,dose-corrected AUC[0-12],"Mean area under the time-concentration curve over the entire 12-hr dosage interval (AUC[0-12]) was 9249+/-3236 microg.hr/L by day 3 and did not change significantly throughout the study, although dose-corrected AUC[0-12] rose by 20% from 1924+/-671 microg.hr/L on day 3 to 2316+/-697 microg.hr/L on day 14 (P=0.067).",Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11579295/),[h·μg] / [l],1924,85370,DB00091,Cyclosporine
,11579295,dose-corrected AUC[0-12],"Mean area under the time-concentration curve over the entire 12-hr dosage interval (AUC[0-12]) was 9249+/-3236 microg.hr/L by day 3 and did not change significantly throughout the study, although dose-corrected AUC[0-12] rose by 20% from 1924+/-671 microg.hr/L on day 3 to 2316+/-697 microg.hr/L on day 14 (P=0.067).",Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11579295/),[h·μg] / [l],2316,85371,DB00091,Cyclosporine
,11579295,AUC[0-4],"Mean AUC[0-4] was 4566+/-1463 microg.hr/L by day 3 and also did not change significantly, although the dose-adjusted AUC[0-4] rose by 31% from 952+/-317 microg.hr/L on day 3 to 1250+/-697 microg.hr/L on day 14 (P=0.009).",Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11579295/),[h·μg] / [l],4566,85372,DB00091,Cyclosporine
,11579295,AUC[0-4],"Mean AUC[0-4] was 4566+/-1463 microg.hr/L by day 3 and also did not change significantly, although the dose-adjusted AUC[0-4] rose by 31% from 952+/-317 microg.hr/L on day 3 to 1250+/-697 microg.hr/L on day 14 (P=0.009).",Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11579295/),[h·μg] / [l],952,85373,DB00091,Cyclosporine
,11579295,AUC[0-4],"Mean AUC[0-4] was 4566+/-1463 microg.hr/L by day 3 and also did not change significantly, although the dose-adjusted AUC[0-4] rose by 31% from 952+/-317 microg.hr/L on day 3 to 1250+/-697 microg.hr/L on day 14 (P=0.009).",Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11579295/),[h·μg] / [l],1250,85374,DB00091,Cyclosporine
,11579295,Tmax,"Cyclosporine (CsA) concentration profiles became more uniform throughout the first 14 days posttransplant, with a reduction in Tmax from 2.45 to 1.48 hr (P<0.005) and a significant decrease in coefficient of variation for AUC[0-12] (35% vs. 21%, P<0.005) and for Tmax (47.4% vs. 33.1%, P<0.005).",Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11579295/),h,2.45,85375,DB00091,Cyclosporine
,11579295,Tmax,"Cyclosporine (CsA) concentration profiles became more uniform throughout the first 14 days posttransplant, with a reduction in Tmax from 2.45 to 1.48 hr (P<0.005) and a significant decrease in coefficient of variation for AUC[0-12] (35% vs. 21%, P<0.005) and for Tmax (47.4% vs. 33.1%, P<0.005).",Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11579295/),h,1.48,85376,DB00091,Cyclosporine
,11579295,AUC[0-12],"CsA exposure on day 7 (n=29) was significantly lower in patients who experienced acute rejection in the second week than in those who were rejection free whether measured by AUC[0-12] (7976+/-1476 vs. 10,239+/-2759 microg.hr/L; P=0.048), AUC[0-4] (4027+/-412 vs. 5623+/-1389 microg.hr/L; P<0.0001), C2 (1116+/-183 vs. 1852+/-522 microg/L; P<0.0001), or Cmax (1415+/-323 vs. 2084+/-450 microg/L; P=0.005), and rejection was significantly less common in patients with an AUC[0-4]> 4,500 microg.hr/L (7% vs. 40%; P=0.041) or a C2 level>1500 microg/L (0% vs. 58%; P<0.001) on day 7 (sensitivity, 100%; specificity, 75%; positive predictive value, 58%; negative predictive value, 100%).",Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11579295/),[h·μg] / [l],7976,85377,DB00091,Cyclosporine
,11579295,AUC[0-12],"CsA exposure on day 7 (n=29) was significantly lower in patients who experienced acute rejection in the second week than in those who were rejection free whether measured by AUC[0-12] (7976+/-1476 vs. 10,239+/-2759 microg.hr/L; P=0.048), AUC[0-4] (4027+/-412 vs. 5623+/-1389 microg.hr/L; P<0.0001), C2 (1116+/-183 vs. 1852+/-522 microg/L; P<0.0001), or Cmax (1415+/-323 vs. 2084+/-450 microg/L; P=0.005), and rejection was significantly less common in patients with an AUC[0-4]> 4,500 microg.hr/L (7% vs. 40%; P=0.041) or a C2 level>1500 microg/L (0% vs. 58%; P<0.001) on day 7 (sensitivity, 100%; specificity, 75%; positive predictive value, 58%; negative predictive value, 100%).",Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11579295/),[h·μg] / [l],"10,239",85378,DB00091,Cyclosporine
,11579295,AUC[0-4],"CsA exposure on day 7 (n=29) was significantly lower in patients who experienced acute rejection in the second week than in those who were rejection free whether measured by AUC[0-12] (7976+/-1476 vs. 10,239+/-2759 microg.hr/L; P=0.048), AUC[0-4] (4027+/-412 vs. 5623+/-1389 microg.hr/L; P<0.0001), C2 (1116+/-183 vs. 1852+/-522 microg/L; P<0.0001), or Cmax (1415+/-323 vs. 2084+/-450 microg/L; P=0.005), and rejection was significantly less common in patients with an AUC[0-4]> 4,500 microg.hr/L (7% vs. 40%; P=0.041) or a C2 level>1500 microg/L (0% vs. 58%; P<0.001) on day 7 (sensitivity, 100%; specificity, 75%; positive predictive value, 58%; negative predictive value, 100%).",Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11579295/),[h·μg] / [l],4027,85379,DB00091,Cyclosporine
,11579295,AUC[0-4],"CsA exposure on day 7 (n=29) was significantly lower in patients who experienced acute rejection in the second week than in those who were rejection free whether measured by AUC[0-12] (7976+/-1476 vs. 10,239+/-2759 microg.hr/L; P=0.048), AUC[0-4] (4027+/-412 vs. 5623+/-1389 microg.hr/L; P<0.0001), C2 (1116+/-183 vs. 1852+/-522 microg/L; P<0.0001), or Cmax (1415+/-323 vs. 2084+/-450 microg/L; P=0.005), and rejection was significantly less common in patients with an AUC[0-4]> 4,500 microg.hr/L (7% vs. 40%; P=0.041) or a C2 level>1500 microg/L (0% vs. 58%; P<0.001) on day 7 (sensitivity, 100%; specificity, 75%; positive predictive value, 58%; negative predictive value, 100%).",Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11579295/),[h·μg] / [l],5623,85380,DB00091,Cyclosporine
,11579295,C2,"CsA exposure on day 7 (n=29) was significantly lower in patients who experienced acute rejection in the second week than in those who were rejection free whether measured by AUC[0-12] (7976+/-1476 vs. 10,239+/-2759 microg.hr/L; P=0.048), AUC[0-4] (4027+/-412 vs. 5623+/-1389 microg.hr/L; P<0.0001), C2 (1116+/-183 vs. 1852+/-522 microg/L; P<0.0001), or Cmax (1415+/-323 vs. 2084+/-450 microg/L; P=0.005), and rejection was significantly less common in patients with an AUC[0-4]> 4,500 microg.hr/L (7% vs. 40%; P=0.041) or a C2 level>1500 microg/L (0% vs. 58%; P<0.001) on day 7 (sensitivity, 100%; specificity, 75%; positive predictive value, 58%; negative predictive value, 100%).",Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11579295/),[μg] / [l],1116,85381,DB00091,Cyclosporine
,11579295,C2,"CsA exposure on day 7 (n=29) was significantly lower in patients who experienced acute rejection in the second week than in those who were rejection free whether measured by AUC[0-12] (7976+/-1476 vs. 10,239+/-2759 microg.hr/L; P=0.048), AUC[0-4] (4027+/-412 vs. 5623+/-1389 microg.hr/L; P<0.0001), C2 (1116+/-183 vs. 1852+/-522 microg/L; P<0.0001), or Cmax (1415+/-323 vs. 2084+/-450 microg/L; P=0.005), and rejection was significantly less common in patients with an AUC[0-4]> 4,500 microg.hr/L (7% vs. 40%; P=0.041) or a C2 level>1500 microg/L (0% vs. 58%; P<0.001) on day 7 (sensitivity, 100%; specificity, 75%; positive predictive value, 58%; negative predictive value, 100%).",Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11579295/),[μg] / [l],1852,85382,DB00091,Cyclosporine
,11579295,Cmax,"CsA exposure on day 7 (n=29) was significantly lower in patients who experienced acute rejection in the second week than in those who were rejection free whether measured by AUC[0-12] (7976+/-1476 vs. 10,239+/-2759 microg.hr/L; P=0.048), AUC[0-4] (4027+/-412 vs. 5623+/-1389 microg.hr/L; P<0.0001), C2 (1116+/-183 vs. 1852+/-522 microg/L; P<0.0001), or Cmax (1415+/-323 vs. 2084+/-450 microg/L; P=0.005), and rejection was significantly less common in patients with an AUC[0-4]> 4,500 microg.hr/L (7% vs. 40%; P=0.041) or a C2 level>1500 microg/L (0% vs. 58%; P<0.001) on day 7 (sensitivity, 100%; specificity, 75%; positive predictive value, 58%; negative predictive value, 100%).",Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11579295/),[μg] / [l],1415,85383,DB00091,Cyclosporine
,11579295,Cmax,"CsA exposure on day 7 (n=29) was significantly lower in patients who experienced acute rejection in the second week than in those who were rejection free whether measured by AUC[0-12] (7976+/-1476 vs. 10,239+/-2759 microg.hr/L; P=0.048), AUC[0-4] (4027+/-412 vs. 5623+/-1389 microg.hr/L; P<0.0001), C2 (1116+/-183 vs. 1852+/-522 microg/L; P<0.0001), or Cmax (1415+/-323 vs. 2084+/-450 microg/L; P=0.005), and rejection was significantly less common in patients with an AUC[0-4]> 4,500 microg.hr/L (7% vs. 40%; P=0.041) or a C2 level>1500 microg/L (0% vs. 58%; P<0.001) on day 7 (sensitivity, 100%; specificity, 75%; positive predictive value, 58%; negative predictive value, 100%).",Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11579295/),[μg] / [l],2084,85384,DB00091,Cyclosporine
>,11579295,AUC[0-4],"CsA exposure on day 7 (n=29) was significantly lower in patients who experienced acute rejection in the second week than in those who were rejection free whether measured by AUC[0-12] (7976+/-1476 vs. 10,239+/-2759 microg.hr/L; P=0.048), AUC[0-4] (4027+/-412 vs. 5623+/-1389 microg.hr/L; P<0.0001), C2 (1116+/-183 vs. 1852+/-522 microg/L; P<0.0001), or Cmax (1415+/-323 vs. 2084+/-450 microg/L; P=0.005), and rejection was significantly less common in patients with an AUC[0-4]> 4,500 microg.hr/L (7% vs. 40%; P=0.041) or a C2 level>1500 microg/L (0% vs. 58%; P<0.001) on day 7 (sensitivity, 100%; specificity, 75%; positive predictive value, 58%; negative predictive value, 100%).",Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11579295/),[h·μg] / [l],"4,500",85385,DB00091,Cyclosporine
>,11579295,C2,"CsA exposure on day 7 (n=29) was significantly lower in patients who experienced acute rejection in the second week than in those who were rejection free whether measured by AUC[0-12] (7976+/-1476 vs. 10,239+/-2759 microg.hr/L; P=0.048), AUC[0-4] (4027+/-412 vs. 5623+/-1389 microg.hr/L; P<0.0001), C2 (1116+/-183 vs. 1852+/-522 microg/L; P<0.0001), or Cmax (1415+/-323 vs. 2084+/-450 microg/L; P=0.005), and rejection was significantly less common in patients with an AUC[0-4]> 4,500 microg.hr/L (7% vs. 40%; P=0.041) or a C2 level>1500 microg/L (0% vs. 58%; P<0.001) on day 7 (sensitivity, 100%; specificity, 75%; positive predictive value, 58%; negative predictive value, 100%).",Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11579295/),,1500,85386,DB00091,Cyclosporine
,11579295,AUC[0-4],"Acute rejection is significantly more common with low CsA exposure during the first week posttransplant, and levels above the threshold of approximately AUC[0-4] 4500 microg.hr/L or C2 1500 microg/L are desirable to minimize the risk of rejection.",Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11579295/),[h·μg] / [l],4500,85387,DB00091,Cyclosporine
,11579295,C2,"Acute rejection is significantly more common with low CsA exposure during the first week posttransplant, and levels above the threshold of approximately AUC[0-4] 4500 microg.hr/L or C2 1500 microg/L are desirable to minimize the risk of rejection.",Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11579295/),[μg] / [l],1500,85388,DB00091,Cyclosporine
,10456485,area under the concentration time-curve (AUC),"CyA markedly increased the area under the concentration time-curve (AUC) of both IDA [558.26 (197.25) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); P < 0.01] and IDAOL [2896.60 (736.38) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.001] when coadministered as a single modulator, due to a lower total body clearance (CL) [83.51 (52.44) l x h(-1) x m(-2) vs 139.65 (69.45) l x h(-1) x m(-2); NS].",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],558.26,85527,DB00091,Cyclosporine
,10456485,area under the concentration time-curve (AUC),"CyA markedly increased the area under the concentration time-curve (AUC) of both IDA [558.26 (197.25) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); P < 0.01] and IDAOL [2896.60 (736.38) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.001] when coadministered as a single modulator, due to a lower total body clearance (CL) [83.51 (52.44) l x h(-1) x m(-2) vs 139.65 (69.45) l x h(-1) x m(-2); NS].",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],315.44,85528,DB00091,Cyclosporine
,10456485,area under the concentration time-curve (AUC),"CyA markedly increased the area under the concentration time-curve (AUC) of both IDA [558.26 (197.25) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); P < 0.01] and IDAOL [2896.60 (736.38) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.001] when coadministered as a single modulator, due to a lower total body clearance (CL) [83.51 (52.44) l x h(-1) x m(-2) vs 139.65 (69.45) l x h(-1) x m(-2); NS].",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],2896.60,85529,DB00091,Cyclosporine
,10456485,area under the concentration time-curve (AUC),"CyA markedly increased the area under the concentration time-curve (AUC) of both IDA [558.26 (197.25) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); P < 0.01] and IDAOL [2896.60 (736.38) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.001] when coadministered as a single modulator, due to a lower total body clearance (CL) [83.51 (52.44) l x h(-1) x m(-2) vs 139.65 (69.45) l x h(-1) x m(-2); NS].",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],1028.49,85530,DB00091,Cyclosporine
,10456485,total body clearance (CL),"CyA markedly increased the area under the concentration time-curve (AUC) of both IDA [558.26 (197.25) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); P < 0.01] and IDAOL [2896.60 (736.38) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.001] when coadministered as a single modulator, due to a lower total body clearance (CL) [83.51 (52.44) l x h(-1) x m(-2) vs 139.65 (69.45) l x h(-1) x m(-2); NS].",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[l] / [(m)^2·h],83.51,85531,DB00091,Cyclosporine
,10456485,total body clearance (CL),"CyA markedly increased the area under the concentration time-curve (AUC) of both IDA [558.26 (197.25) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); P < 0.01] and IDAOL [2896.60 (736.38) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.001] when coadministered as a single modulator, due to a lower total body clearance (CL) [83.51 (52.44) l x h(-1) x m(-2) vs 139.65 (69.45) l x h(-1) x m(-2); NS].",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[l] / [(m)^2·h],139.65,85532,DB00091,Cyclosporine
,10456485,exposure,"When patients received two MDR modulators simultaneously (D-Ver plus CyA), IDA exposure was essentially the same as in those of the no inhibitor group [331.29 (95.49) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); NS], whereas the IDAOL total body exposure was greater than in the no inhibitor group [2030.32 (401.11) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.01], even if less than in patients receiving CyA as a single MDR modulator (IDA + CyA group) [AUC 2030.32 (401.11) microg x h x l(-1) vs 2896.60 (736.38) microg x h x l(-1); P < 0.05], suggesting an antagonistic effect against those of CyA on IDA and IDAOL elimination and/or an unpredictable redistribution.",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],331.29,85533,DB00091,Cyclosporine
,10456485,exposure,"When patients received two MDR modulators simultaneously (D-Ver plus CyA), IDA exposure was essentially the same as in those of the no inhibitor group [331.29 (95.49) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); NS], whereas the IDAOL total body exposure was greater than in the no inhibitor group [2030.32 (401.11) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.01], even if less than in patients receiving CyA as a single MDR modulator (IDA + CyA group) [AUC 2030.32 (401.11) microg x h x l(-1) vs 2896.60 (736.38) microg x h x l(-1); P < 0.05], suggesting an antagonistic effect against those of CyA on IDA and IDAOL elimination and/or an unpredictable redistribution.",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],315.44,85534,DB00091,Cyclosporine
,10456485,total body exposure,"When patients received two MDR modulators simultaneously (D-Ver plus CyA), IDA exposure was essentially the same as in those of the no inhibitor group [331.29 (95.49) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); NS], whereas the IDAOL total body exposure was greater than in the no inhibitor group [2030.32 (401.11) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.01], even if less than in patients receiving CyA as a single MDR modulator (IDA + CyA group) [AUC 2030.32 (401.11) microg x h x l(-1) vs 2896.60 (736.38) microg x h x l(-1); P < 0.05], suggesting an antagonistic effect against those of CyA on IDA and IDAOL elimination and/or an unpredictable redistribution.",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],2030.32,85535,DB00091,Cyclosporine
,10456485,total body exposure,"When patients received two MDR modulators simultaneously (D-Ver plus CyA), IDA exposure was essentially the same as in those of the no inhibitor group [331.29 (95.49) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); NS], whereas the IDAOL total body exposure was greater than in the no inhibitor group [2030.32 (401.11) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.01], even if less than in patients receiving CyA as a single MDR modulator (IDA + CyA group) [AUC 2030.32 (401.11) microg x h x l(-1) vs 2896.60 (736.38) microg x h x l(-1); P < 0.05], suggesting an antagonistic effect against those of CyA on IDA and IDAOL elimination and/or an unpredictable redistribution.",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],1028.49,85536,DB00091,Cyclosporine
,10456485,AUC,"When patients received two MDR modulators simultaneously (D-Ver plus CyA), IDA exposure was essentially the same as in those of the no inhibitor group [331.29 (95.49) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); NS], whereas the IDAOL total body exposure was greater than in the no inhibitor group [2030.32 (401.11) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.01], even if less than in patients receiving CyA as a single MDR modulator (IDA + CyA group) [AUC 2030.32 (401.11) microg x h x l(-1) vs 2896.60 (736.38) microg x h x l(-1); P < 0.05], suggesting an antagonistic effect against those of CyA on IDA and IDAOL elimination and/or an unpredictable redistribution.",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],2030.32,85537,DB00091,Cyclosporine
,10456485,AUC,"When patients received two MDR modulators simultaneously (D-Ver plus CyA), IDA exposure was essentially the same as in those of the no inhibitor group [331.29 (95.49) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); NS], whereas the IDAOL total body exposure was greater than in the no inhibitor group [2030.32 (401.11) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.01], even if less than in patients receiving CyA as a single MDR modulator (IDA + CyA group) [AUC 2030.32 (401.11) microg x h x l(-1) vs 2896.60 (736.38) microg x h x l(-1); P < 0.05], suggesting an antagonistic effect against those of CyA on IDA and IDAOL elimination and/or an unpredictable redistribution.",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],2896.60,85538,DB00091,Cyclosporine
,22996305,AUC0-36 h,"Interestingly, after a single oral co-administration of WZ and low dose of CsA (1.89 mg/kg), the AUC0-36 h and Cmax of CsA were dramatically increased by 293.1% (from 1103.2 ± 293.0 to 4336.5 ± 1728.3 ng.h/mL; p < 0.05) and 84.1% (from 208.5 ± 67.9 to 383.1 ± 92.5 ng/mL; p < 0.05), respectively.",Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of cyclosporin A in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22996305/),[h·ng] / [ml],1103.2,85610,DB00091,Cyclosporine
,22996305,AUC0-36 h,"Interestingly, after a single oral co-administration of WZ and low dose of CsA (1.89 mg/kg), the AUC0-36 h and Cmax of CsA were dramatically increased by 293.1% (from 1103.2 ± 293.0 to 4336.5 ± 1728.3 ng.h/mL; p < 0.05) and 84.1% (from 208.5 ± 67.9 to 383.1 ± 92.5 ng/mL; p < 0.05), respectively.",Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of cyclosporin A in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22996305/),[h·ng] / [ml],4336.5,85611,DB00091,Cyclosporine
,22996305,Cmax,"Interestingly, after a single oral co-administration of WZ and low dose of CsA (1.89 mg/kg), the AUC0-36 h and Cmax of CsA were dramatically increased by 293.1% (from 1103.2 ± 293.0 to 4336.5 ± 1728.3 ng.h/mL; p < 0.05) and 84.1% (from 208.5 ± 67.9 to 383.1 ± 92.5 ng/mL; p < 0.05), respectively.",Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of cyclosporin A in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22996305/),[h·ng] / [ml],4336.5,85612,DB00091,Cyclosporine
,22996305,Cmax,"Interestingly, after a single oral co-administration of WZ and low dose of CsA (1.89 mg/kg), the AUC0-36 h and Cmax of CsA were dramatically increased by 293.1% (from 1103.2 ± 293.0 to 4336.5 ± 1728.3 ng.h/mL; p < 0.05) and 84.1% (from 208.5 ± 67.9 to 383.1 ± 92.5 ng/mL; p < 0.05), respectively.",Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of cyclosporin A in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22996305/),[ng] / [ml],208.5,85613,DB00091,Cyclosporine
,22996305,Cmax,"Interestingly, after a single oral co-administration of WZ and low dose of CsA (1.89 mg/kg), the AUC0-36 h and Cmax of CsA were dramatically increased by 293.1% (from 1103.2 ± 293.0 to 4336.5 ± 1728.3 ng.h/mL; p < 0.05) and 84.1% (from 208.5 ± 67.9 to 383.1 ± 92.5 ng/mL; p < 0.05), respectively.",Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of cyclosporin A in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22996305/),[ng] / [ml],383.1,85614,DB00091,Cyclosporine
,22996305,CL/F,The CL/F was decreased from 1.7 L/h/kg to 0.5 L/h/kg.,Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of cyclosporin A in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22996305/),[l] / [h·kg],1.7,85615,DB00091,Cyclosporine
,22996305,CL/F,The CL/F was decreased from 1.7 L/h/kg to 0.5 L/h/kg.,Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of cyclosporin A in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22996305/),[l] / [h·kg],0.5,85616,DB00091,Cyclosporine
,15063039,flow rate,The mobile phase was acetonitrile-water (70:30% v/v) and flow rate was set at 1.5 ml min(-1).,Preparation of biodegradable cyclosporine nanoparticles by high-pressure emulsification-solvent evaporation process. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15063039/),[ml] / [min],1.5,85838,DB00091,Cyclosporine
<,15063039,polydispersity index (PI),The photon correlation spectroscopy showed that the particles size were <250 nm and polydispersity index (PI) <0.14.,Preparation of biodegradable cyclosporine nanoparticles by high-pressure emulsification-solvent evaporation process. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15063039/),,0.14,85839,DB00091,Cyclosporine
,15063039,drug loading,The drug loading was between 82% and 92%.,Preparation of biodegradable cyclosporine nanoparticles by high-pressure emulsification-solvent evaporation process. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15063039/),%,82,85840,DB00091,Cyclosporine
,15063039,drug loading,The drug loading was between 82% and 92%.,Preparation of biodegradable cyclosporine nanoparticles by high-pressure emulsification-solvent evaporation process. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15063039/),%,92,85841,DB00091,Cyclosporine
,15063039,cumulative percent release,In-vitro release in intestinal fluid pH 6.8 (USP XXIV) showed a cumulative percent release of 30-45% CsA in 8 h.,Preparation of biodegradable cyclosporine nanoparticles by high-pressure emulsification-solvent evaporation process. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15063039/),%,30-45,85842,DB00091,Cyclosporine
,10492062,Peak CSA concentration,"Peak CSA concentration was not altered by dipyrone, but the time required to reach maximal concentration was longer with dipyrone treatment than with the placebo (3.8 +/- 2.6 h vs 2.1 +/- 0.6 h, P < 0.05).",The effect of short-term dipyrone administration on cyclosporin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492062/),h,3.8,86114,DB00091,Cyclosporine
,10492062,time required to reach maximal concentration,"Peak CSA concentration was not altered by dipyrone, but the time required to reach maximal concentration was longer with dipyrone treatment than with the placebo (3.8 +/- 2.6 h vs 2.1 +/- 0.6 h, P < 0.05).",The effect of short-term dipyrone administration on cyclosporin pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492062/),h,3.8,86115,DB00091,Cyclosporine
,10492062,time required to reach maximal concentration,"Peak CSA concentration was not altered by dipyrone, but the time required to reach maximal concentration was longer with dipyrone treatment than with the placebo (3.8 +/- 2.6 h vs 2.1 +/- 0.6 h, P < 0.05).",The effect of short-term dipyrone administration on cyclosporin pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492062/),h,2.1,86116,DB00091,Cyclosporine
,12270251,oral bioavailability,"It was found that the oral bioavailability of CyA in the Solutol HS 15-based formulation was twofold higher as compared to the microsuspension (69.9+/-2.8 vs. 35.7+/-3.3%, P=0.001).",Improved oral bioavailability of cyclosporin A in male Wistar rats. Comparison of a Solutol HS 15 containing self-dispersing formulation and a microsuspension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12270251/),%,69.9,87217,DB00091,Cyclosporine
,12270251,oral bioavailability,"It was found that the oral bioavailability of CyA in the Solutol HS 15-based formulation was twofold higher as compared to the microsuspension (69.9+/-2.8 vs. 35.7+/-3.3%, P=0.001).",Improved oral bioavailability of cyclosporin A in male Wistar rats. Comparison of a Solutol HS 15 containing self-dispersing formulation and a microsuspension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12270251/),%,35.7,87218,DB00091,Cyclosporine
,12270251,t(max),"By contrast, the time to reach maximum plasma concentration (t(max)) and the terminal half-life (t(1/2)) did not differ significantly with the different formulations (t(max): 7.0+/-1.0 vs. 6.3+/-1.7 h; t(1/2): 20.5+/-2.9 vs. 16.7+/-4.7 h).",Improved oral bioavailability of cyclosporin A in male Wistar rats. Comparison of a Solutol HS 15 containing self-dispersing formulation and a microsuspension. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12270251/),h,7.0,87219,DB00091,Cyclosporine
,12270251,t(max),"By contrast, the time to reach maximum plasma concentration (t(max)) and the terminal half-life (t(1/2)) did not differ significantly with the different formulations (t(max): 7.0+/-1.0 vs. 6.3+/-1.7 h; t(1/2): 20.5+/-2.9 vs. 16.7+/-4.7 h).",Improved oral bioavailability of cyclosporin A in male Wistar rats. Comparison of a Solutol HS 15 containing self-dispersing formulation and a microsuspension. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12270251/),h,6.3,87220,DB00091,Cyclosporine
,12270251,t(1/2),"By contrast, the time to reach maximum plasma concentration (t(max)) and the terminal half-life (t(1/2)) did not differ significantly with the different formulations (t(max): 7.0+/-1.0 vs. 6.3+/-1.7 h; t(1/2): 20.5+/-2.9 vs. 16.7+/-4.7 h).",Improved oral bioavailability of cyclosporin A in male Wistar rats. Comparison of a Solutol HS 15 containing self-dispersing formulation and a microsuspension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12270251/),h,20.5,87221,DB00091,Cyclosporine
,12270251,t(1/2),"By contrast, the time to reach maximum plasma concentration (t(max)) and the terminal half-life (t(1/2)) did not differ significantly with the different formulations (t(max): 7.0+/-1.0 vs. 6.3+/-1.7 h; t(1/2): 20.5+/-2.9 vs. 16.7+/-4.7 h).",Improved oral bioavailability of cyclosporin A in male Wistar rats. Comparison of a Solutol HS 15 containing self-dispersing formulation and a microsuspension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12270251/),h,16.7,87222,DB00091,Cyclosporine
,12270251,solubility,In vitro solubility experiments demonstrated a marked increase in the aqueous solubility of CyA in the presence of the self-dispersing formulation as compared to the micronized powder alone (solubility after 120 min at 37 degrees C: 136 vs. 23.2 microg/ml in human gastric juice; 133 vs. 10.8 microg/ml in simulated intestinal juice).,Improved oral bioavailability of cyclosporin A in male Wistar rats. Comparison of a Solutol HS 15 containing self-dispersing formulation and a microsuspension. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12270251/),[μg] / [ml],136,87223,DB00091,Cyclosporine
,12270251,solubility,In vitro solubility experiments demonstrated a marked increase in the aqueous solubility of CyA in the presence of the self-dispersing formulation as compared to the micronized powder alone (solubility after 120 min at 37 degrees C: 136 vs. 23.2 microg/ml in human gastric juice; 133 vs. 10.8 microg/ml in simulated intestinal juice).,Improved oral bioavailability of cyclosporin A in male Wistar rats. Comparison of a Solutol HS 15 containing self-dispersing formulation and a microsuspension. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12270251/),[μg] / [ml],23.2,87224,DB00091,Cyclosporine
,12270251,solubility,In vitro solubility experiments demonstrated a marked increase in the aqueous solubility of CyA in the presence of the self-dispersing formulation as compared to the micronized powder alone (solubility after 120 min at 37 degrees C: 136 vs. 23.2 microg/ml in human gastric juice; 133 vs. 10.8 microg/ml in simulated intestinal juice).,Improved oral bioavailability of cyclosporin A in male Wistar rats. Comparison of a Solutol HS 15 containing self-dispersing formulation and a microsuspension. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12270251/),[μg] / [ml],133,87225,DB00091,Cyclosporine
,12270251,solubility,In vitro solubility experiments demonstrated a marked increase in the aqueous solubility of CyA in the presence of the self-dispersing formulation as compared to the micronized powder alone (solubility after 120 min at 37 degrees C: 136 vs. 23.2 microg/ml in human gastric juice; 133 vs. 10.8 microg/ml in simulated intestinal juice).,Improved oral bioavailability of cyclosporin A in male Wistar rats. Comparison of a Solutol HS 15 containing self-dispersing formulation and a microsuspension. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12270251/),[μg] / [ml],10.8,87226,DB00091,Cyclosporine
,21988410,Clearance (CL),Clearance (CL) was 21.9 l h(-1) (relative standard deviation [RSD]± 5.2%) with an inter-individual variability of 21%.,Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21988410/),[l] / [h],21.9,87578,DB00091,Cyclosporine
,21988410,central volume of distribution (V(c) ),The central volume of distribution (V(c) ) was 18.3 l (RSD ± 8.7%) with an inter-individual variability of 29%.,Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21988410/),l,18.3,87579,DB00091,Cyclosporine
,21988410,Bioavailability (F),Bioavailability (F) was 0.71 (RSD ± 9.9%) with and inter-individual variability of 25% and lag time (t(lag) ) was 0.44 h (RSD 5.5%).,Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21988410/),,0.71,87580,DB00091,Cyclosporine
,21988410,lag time (t(lag) ),Bioavailability (F) was 0.71 (RSD ± 9.9%) with and inter-individual variability of 25% and lag time (t(lag) ) was 0.44 h (RSD 5.5%).,Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21988410/),h,0.44,87581,DB00091,Cyclosporine
,3896612,terminal disposition rate constant,The mean (+/- SD) terminal disposition rate constant was 0.065 +/- 0.036 hours-1 and the harmonic mean t 1/2 was 10.7 hours.,Cyclosporine kinetics in renal transplantation. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3896612/),1/[h],0.065,87768,DB00091,Cyclosporine
,3896612,t 1/2,The mean (+/- SD) terminal disposition rate constant was 0.065 +/- 0.036 hours-1 and the harmonic mean t 1/2 was 10.7 hours.,Cyclosporine kinetics in renal transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3896612/),h,10.7,87769,DB00091,Cyclosporine
,3896612,total body clearance,The harmonic mean total body clearance of cyclosporine was 5.73 ml/min/kg and the mean apparent volume of distribution was 4.5 +/- 3.6 L/kg.,Cyclosporine kinetics in renal transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3896612/),[ml] / [kg·min],5.73,87770,DB00091,Cyclosporine
,3896612,apparent volume of distribution,The harmonic mean total body clearance of cyclosporine was 5.73 ml/min/kg and the mean apparent volume of distribution was 4.5 +/- 3.6 L/kg.,Cyclosporine kinetics in renal transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3896612/),[l] / [kg],4.5,87771,DB00091,Cyclosporine
,3896612,Peak blood cyclosporine concentrations,"Peak blood cyclosporine concentrations (means = 1,103 ng/ml) were reached between 1 and 8 hours after oral dosing (means = 4 hours).",Cyclosporine kinetics in renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3896612/),[ng] / [ml],"1,103",87772,DB00091,Cyclosporine
,3896612,relative bioavailability,The mean relative bioavailability was 27.6% +/- 20%.,Cyclosporine kinetics in renal transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3896612/),%,27.6,87773,DB00091,Cyclosporine
less,3896612,Oral bioavailability,Oral bioavailability was less than 10% in 17% of our subjects.,Cyclosporine kinetics in renal transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3896612/),%,10,87774,DB00091,Cyclosporine
,3896612,Oral bioavailability,Oral bioavailability was less than 10% in 17% of our subjects.,Cyclosporine kinetics in renal transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3896612/),%,17,87775,DB00091,Cyclosporine
,9269646,trough levels,Pharmacokinetic investigations were performed after establishing a stable maintenance dose with trough levels in the desired window of 5-12 ng/ml.,Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9269646/),[ng] / [ml],5-12,87786,DB00091,Cyclosporine
,9269646,trough level,Mean trough level was 7.1 +/- 2.6 ng/ml in the morning and 6.5 +/- 2.0 ng/ml in the evening.,Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9269646/),[ng] / [ml],7.1,87787,DB00091,Cyclosporine
,9269646,trough level,Mean trough level was 7.1 +/- 2.6 ng/ml in the morning and 6.5 +/- 2.0 ng/ml in the evening.,Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9269646/),[ng] / [ml],6.5,87788,DB00091,Cyclosporine
,9269646,time of maximum concentration (tmax),"Median time of maximum concentration (tmax) was 120 min after application, and the mean maximum concentration (Cmax) was 15.2 +/- 6.7 ng/ml.",Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9269646/),min,120,87789,DB00091,Cyclosporine
,9269646,maximum concentration (Cmax),"Median time of maximum concentration (tmax) was 120 min after application, and the mean maximum concentration (Cmax) was 15.2 +/- 6.7 ng/ml.",Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9269646/),[ng] / [ml],15.2,87790,DB00091,Cyclosporine
,9269646,area under the curve (AUC),"Mean area under the curve (AUC) was 104 +/- 33 ng* h/ml, with a range from 65 yo 169 ng* h/ml.",Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9269646/),[h·ng] / [ml],104,87791,DB00091,Cyclosporine
,9558129,Vs,"The one-compartment model pharmacokinetic parameter-the slope of volume to body weight (Vs) and the elimination rate constant (Kel) values found (mean values: Vs = 2.177 l/kg, Kel = 0.235 h(-1); median values: Vs = 1.559 l/kg, Kel = 0.163 h(-1); the percent coefficient of variation (Vs = 92%, Kel = 79%) appear reasonable and show the ability of NPEM2 to deal with sparse data.","A population pharmacokinetic model of cyclosporine in the early postoperative phase in patients with liver transplants, and its predictive performance with Bayesian fitting. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9558129/),[l] / [kg],2.177,88391,DB00091,Cyclosporine
,9558129,Kel,"The one-compartment model pharmacokinetic parameter-the slope of volume to body weight (Vs) and the elimination rate constant (Kel) values found (mean values: Vs = 2.177 l/kg, Kel = 0.235 h(-1); median values: Vs = 1.559 l/kg, Kel = 0.163 h(-1); the percent coefficient of variation (Vs = 92%, Kel = 79%) appear reasonable and show the ability of NPEM2 to deal with sparse data.","A population pharmacokinetic model of cyclosporine in the early postoperative phase in patients with liver transplants, and its predictive performance with Bayesian fitting. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9558129/),1/[h],0.235,88392,DB00091,Cyclosporine
,9558129,Vs,"The one-compartment model pharmacokinetic parameter-the slope of volume to body weight (Vs) and the elimination rate constant (Kel) values found (mean values: Vs = 2.177 l/kg, Kel = 0.235 h(-1); median values: Vs = 1.559 l/kg, Kel = 0.163 h(-1); the percent coefficient of variation (Vs = 92%, Kel = 79%) appear reasonable and show the ability of NPEM2 to deal with sparse data.","A population pharmacokinetic model of cyclosporine in the early postoperative phase in patients with liver transplants, and its predictive performance with Bayesian fitting. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9558129/),[l] / [kg],1.559,88393,DB00091,Cyclosporine
,9558129,Kel,"The one-compartment model pharmacokinetic parameter-the slope of volume to body weight (Vs) and the elimination rate constant (Kel) values found (mean values: Vs = 2.177 l/kg, Kel = 0.235 h(-1); median values: Vs = 1.559 l/kg, Kel = 0.163 h(-1); the percent coefficient of variation (Vs = 92%, Kel = 79%) appear reasonable and show the ability of NPEM2 to deal with sparse data.","A population pharmacokinetic model of cyclosporine in the early postoperative phase in patients with liver transplants, and its predictive performance with Bayesian fitting. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9558129/),1/[h],0.163,88394,DB00091,Cyclosporine
,11389708,trough blood levels,Mean trough blood levels of MPA ranged between 68.8 and 340 ng/mL with a median of 146.7 ng/mL.,Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11389708/),[ng] / [ml],146.7,88825,DB00091,Cyclosporine
,11389708,AUC0-12 h,The mean MPA AUC0-12 h after first dose ranged between 19349+/-5087 ng * h/mL and 25705+/-3042 ng * h/mL and correlated with the dose level of MMF.,Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11389708/),[h·ng] / [ml],19349,88826,DB00091,Cyclosporine
,11389708,AUC0-12 h,The mean MPA AUC0-12 h after first dose ranged between 19349+/-5087 ng * h/mL and 25705+/-3042 ng * h/mL and correlated with the dose level of MMF.,Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11389708/),[h·ng] / [ml],25705,88827,DB00091,Cyclosporine
,17214827,CL,The model predicted the mean CL to decrease from 35 l h(-1) (CV = 44%) in the first week after transplantation to 17 l h(-1) (CV = 38%) after 6 months.,Time-dependent clearance of mycophenolic acid in renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17214827/),[l] / [h],35,89414,DB00091,Cyclosporine
,17214827,CL,The model predicted the mean CL to decrease from 35 l h(-1) (CV = 44%) in the first week after transplantation to 17 l h(-1) (CV = 38%) after 6 months.,Time-dependent clearance of mycophenolic acid in renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17214827/),[l] / [h],17,89415,DB00091,Cyclosporine
,17214827,CL,"In a covariate model without a term for time-dependent CL, changes during the first 6 months after transplantation in creatinine clearance from 19 to 71 ml min(-1), in albumin concentration from 35 to 40 g l(-1), in haemoglobin from 9.7 to 12 g dl(-1) and in cyclosporin predose concentration from 225 to 100 ng ml(-1) corresponded with a decrease of CL from 32 to 19 l h(-1).",Time-dependent clearance of mycophenolic acid in renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17214827/),,32,89416,DB00091,Cyclosporine
,24521918,m/z,The mass transitions m/z 1203.49 → 1185.53 and m/z 814.71 → 796.67 were used to assay the analyte and IS.,Quantitative determination of cyclosporine in human whole blood by ultra-performance liquid chromatography with triple quadrupole tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521918/),,1203.49,89553,DB00091,Cyclosporine
,24521918,m/z,The mass transitions m/z 1203.49 → 1185.53 and m/z 814.71 → 796.67 were used to assay the analyte and IS.,Quantitative determination of cyclosporine in human whole blood by ultra-performance liquid chromatography with triple quadrupole tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521918/),,1185,89554,DB00091,Cyclosporine
,24521918,m/z,The mass transitions m/z 1203.49 → 1185.53 and m/z 814.71 → 796.67 were used to assay the analyte and IS.,Quantitative determination of cyclosporine in human whole blood by ultra-performance liquid chromatography with triple quadrupole tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521918/),,814.71,89555,DB00091,Cyclosporine
,24521918,m/z,The mass transitions m/z 1203.49 → 1185.53 and m/z 814.71 → 796.67 were used to assay the analyte and IS.,Quantitative determination of cyclosporine in human whole blood by ultra-performance liquid chromatography with triple quadrupole tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521918/),,796.,89556,DB00091,Cyclosporine
,8878394,mean survival time (MST),"A 14-day course of oral SRL produced dose-dependent prolongation of heart allografts: in untreated controls, 0.5 mg/kg SRL per day extended the mean survival time (MST) from 6.4+/-0.5 days to 12.3+/-3.8 days (P<0.05); SRL at 1.0 mg/kg per day prolonged the MST to 18.0+/-5.5 days (P<0.01); at 2.0 mg/kg SRL per day, MST was extended to 52.5+/-13.2 days (P<0.01); and 4.0 mg/kg SRL per day prolonged MST to 90.0+/-41.1 days (P<0.01).",Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878394/),d,6.4,89831,DB00091,Cyclosporine
,8878394,mean survival time (MST),"A 14-day course of oral SRL produced dose-dependent prolongation of heart allografts: in untreated controls, 0.5 mg/kg SRL per day extended the mean survival time (MST) from 6.4+/-0.5 days to 12.3+/-3.8 days (P<0.05); SRL at 1.0 mg/kg per day prolonged the MST to 18.0+/-5.5 days (P<0.01); at 2.0 mg/kg SRL per day, MST was extended to 52.5+/-13.2 days (P<0.01); and 4.0 mg/kg SRL per day prolonged MST to 90.0+/-41.1 days (P<0.01).",Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878394/),d,12.3,89832,DB00091,Cyclosporine
,8878394,MST,"A 14-day course of oral SRL produced dose-dependent prolongation of heart allografts: in untreated controls, 0.5 mg/kg SRL per day extended the mean survival time (MST) from 6.4+/-0.5 days to 12.3+/-3.8 days (P<0.05); SRL at 1.0 mg/kg per day prolonged the MST to 18.0+/-5.5 days (P<0.01); at 2.0 mg/kg SRL per day, MST was extended to 52.5+/-13.2 days (P<0.01); and 4.0 mg/kg SRL per day prolonged MST to 90.0+/-41.1 days (P<0.01).",Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878394/),d,18.0,89833,DB00091,Cyclosporine
,8878394,MST,"A 14-day course of oral SRL produced dose-dependent prolongation of heart allografts: in untreated controls, 0.5 mg/kg SRL per day extended the mean survival time (MST) from 6.4+/-0.5 days to 12.3+/-3.8 days (P<0.05); SRL at 1.0 mg/kg per day prolonged the MST to 18.0+/-5.5 days (P<0.01); at 2.0 mg/kg SRL per day, MST was extended to 52.5+/-13.2 days (P<0.01); and 4.0 mg/kg SRL per day prolonged MST to 90.0+/-41.1 days (P<0.01).",Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878394/),d,52.5,89834,DB00091,Cyclosporine
,8878394,MST,"A 14-day course of oral SRL produced dose-dependent prolongation of heart allografts: in untreated controls, 0.5 mg/kg SRL per day extended the mean survival time (MST) from 6.4+/-0.5 days to 12.3+/-3.8 days (P<0.05); SRL at 1.0 mg/kg per day prolonged the MST to 18.0+/-5.5 days (P<0.01); at 2.0 mg/kg SRL per day, MST was extended to 52.5+/-13.2 days (P<0.01); and 4.0 mg/kg SRL per day prolonged MST to 90.0+/-41.1 days (P<0.01).",Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878394/),d,90.0,89835,DB00091,Cyclosporine
less,8878394,oral bioavailability,Comparison of the in vivo effects after oral versus continuous intravenous SRL administration suggested that the oral bioavailability of SRL is less than 10%.,Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878394/),%,10,89836,DB00091,Cyclosporine
,8878394,ED50,"The ED50 for SRL alone is 2.4 mg/kg per day, which produces an average [SRL(WB)] of 13.2 ng/ml.",Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878394/),[mg] / [d·kg],2.4,89837,DB00091,Cyclosporine
,8878394,[,"The ED50 for SRL alone is 2.4 mg/kg per day, which produces an average [SRL(WB)] of 13.2 ng/ml.",Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878394/),[ng] / [ml],13.2,89838,DB00091,Cyclosporine
,8878394,SRL(WB)],"The ED50 for SRL alone is 2.4 mg/kg per day, which produces an average [SRL(WB)] of 13.2 ng/ml.",Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878394/),[ng] / [ml],13.2,89839,DB00091,Cyclosporine
,8878394,ED50,"The ED50 for CsA alone is 8.0 mg/kg per day, which produces an average [CsA(WB)] of 1642 ng/ml.",Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878394/),[mg] / [d·kg],8.0,89840,DB00091,Cyclosporine
,8878394,ED50,"However, when the two drugs are combined, the ED50 effect is achieved with only 0.34 mg/kg SRL per day ([SRL(WB)]=1.1 ng/ml) and 2.1 mg/kg CsA per day ([CsA(WB)] =326 ng/ml).",Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878394/),[ng] / [ml],1.1,89841,DB00091,Cyclosporine
,8878394,ED50,"However, when the two drugs are combined, the ED50 effect is achieved with only 0.34 mg/kg SRL per day ([SRL(WB)]=1.1 ng/ml) and 2.1 mg/kg CsA per day ([CsA(WB)] =326 ng/ml).",Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878394/),[ng] / [ml],326,89842,DB00091,Cyclosporine
,8878394,SRL,"Individually, 0.34 mg/kg SRL per day produces an ED9 with an average [SRL(WB)] of 0.6 ng/ml, and 2.1 mg/kg CsA per day produces an ED22 with an average [CsA(WB)] of 174 ng/ml.",Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8878394/),,0,89843,DB00091,Cyclosporine
,10342912,AUC,"For example, the AUC of cyclosporine increased significantly (33.1 versus 24.7 microg h/ml) at cyclosporine oral dose of 10 mg/kg, however, the value decreased significantly (167 versus 235 microg h/ml) at cyclosporine oral dose of 100 mg/kg.",Effects of propranolol on the pharmacokinetics of cyclosporine after intravenous and oral administration to control rats and rats with uranyl nitrate-induced acute renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10342912/),[h·μg] / [ml],33.1,89959,DB00091,Cyclosporine
,10342912,AUC,"For example, the AUC of cyclosporine increased significantly (33.1 versus 24.7 microg h/ml) at cyclosporine oral dose of 10 mg/kg, however, the value decreased significantly (167 versus 235 microg h/ml) at cyclosporine oral dose of 100 mg/kg.",Effects of propranolol on the pharmacokinetics of cyclosporine after intravenous and oral administration to control rats and rats with uranyl nitrate-induced acute renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10342912/),[h·μg] / [ml],24.7,89960,DB00091,Cyclosporine
,10342912,AUC,"For example, the AUC of cyclosporine increased significantly (33.1 versus 24.7 microg h/ml) at cyclosporine oral dose of 10 mg/kg, however, the value decreased significantly (167 versus 235 microg h/ml) at cyclosporine oral dose of 100 mg/kg.",Effects of propranolol on the pharmacokinetics of cyclosporine after intravenous and oral administration to control rats and rats with uranyl nitrate-induced acute renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10342912/),[h·μg] / [ml],167,89961,DB00091,Cyclosporine
,10342912,AUC,"For example, the AUC of cyclosporine increased significantly (33.1 versus 24.7 microg h/ml) at cyclosporine oral dose of 10 mg/kg, however, the value decreased significantly (167 versus 235 microg h/ml) at cyclosporine oral dose of 100 mg/kg.",Effects of propranolol on the pharmacokinetics of cyclosporine after intravenous and oral administration to control rats and rats with uranyl nitrate-induced acute renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10342912/),[h·μg] / [ml],235,89962,DB00091,Cyclosporine
,8085287,plasma IP,"Initial plasma IP level was 2260 ng/ml, whole blood total cyclosporine (T-CsA) concentration was 1,800 ng/ml and that of specific cyclosporine (Sp-CsA), 714 ng/ml.",Multiple drug overdose in a kidney transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085287/),[ng] / [ml],714,90235,DB00091,Cyclosporine
,8085287,concentration,"Five days after overdose, the IP concentration was 232 ng/ml, that of T-CsA 401 ng/ml, and that of Sp-CsA 96 ng/ml.",Multiple drug overdose in a kidney transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085287/),[ng] / [ml],232,90236,DB00091,Cyclosporine
,8085287,concentration,"Five days after overdose, the IP concentration was 232 ng/ml, that of T-CsA 401 ng/ml, and that of Sp-CsA 96 ng/ml.",Multiple drug overdose in a kidney transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085287/),[ng] / [ml],401,90237,DB00091,Cyclosporine
,8085287,concentration,"Five days after overdose, the IP concentration was 232 ng/ml, that of T-CsA 401 ng/ml, and that of Sp-CsA 96 ng/ml.",Multiple drug overdose in a kidney transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085287/),[ng] / [ml],96,90238,DB00091,Cyclosporine
,8085287,t1/2,"Compared to subjects on therapeutic doses, a significant prolongation of the half-life, t 1/2, was observed for both IP (t1/2, 43.4 h) and Sp-CsA (t1/2, 70.1 h).",Multiple drug overdose in a kidney transplant patient. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085287/),h,43.4,90239,DB00091,Cyclosporine
,8085287,t1/2,"Compared to subjects on therapeutic doses, a significant prolongation of the half-life, t 1/2, was observed for both IP (t1/2, 43.4 h) and Sp-CsA (t1/2, 70.1 h).",Multiple drug overdose in a kidney transplant patient. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085287/),h,70.1,90240,DB00091,Cyclosporine
,8885117,trough levels,"At withdrawal, a worsening of PASI appeared when CsA daily dose reached 2 mg/kg b.w., the mean trough levels or AUC values being, respectively, 100 and 2,200 ng/ml.hr.",Blood concentrations and clinical effect of cyclosporin in psoriasis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8885117/),[ng] / [h·ml],100,90464,DB00091,Cyclosporine
,8885117,AUC,"At withdrawal, a worsening of PASI appeared when CsA daily dose reached 2 mg/kg b.w., the mean trough levels or AUC values being, respectively, 100 and 2,200 ng/ml.hr.",Blood concentrations and clinical effect of cyclosporin in psoriasis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8885117/),[ng] / [h·ml],"2,200",90465,DB00091,Cyclosporine
,11255279,AUC,The comparison between pharmacokinetic parameters obtained in patients receiving Neoral 5 mg/kg/day or 7.5 mg/kg/day showed a proportional increase of the AUC (4776+/-1084 vs. 7746+/-2006 ng/mL h) and C(max) (1027+/-203 vs. 1514+/-231 ng/mL).,Pharmacokinetic study of the new cyclosporine-A formulation (Neoral) in adult allogeneic bone marrow transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11255279/),[ng] / [h·ml],4776,90515,DB00091,Cyclosporine
,11255279,AUC,The comparison between pharmacokinetic parameters obtained in patients receiving Neoral 5 mg/kg/day or 7.5 mg/kg/day showed a proportional increase of the AUC (4776+/-1084 vs. 7746+/-2006 ng/mL h) and C(max) (1027+/-203 vs. 1514+/-231 ng/mL).,Pharmacokinetic study of the new cyclosporine-A formulation (Neoral) in adult allogeneic bone marrow transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11255279/),[ng] / [h·ml],7746,90516,DB00091,Cyclosporine
,11255279,C(max),The comparison between pharmacokinetic parameters obtained in patients receiving Neoral 5 mg/kg/day or 7.5 mg/kg/day showed a proportional increase of the AUC (4776+/-1084 vs. 7746+/-2006 ng/mL h) and C(max) (1027+/-203 vs. 1514+/-231 ng/mL).,Pharmacokinetic study of the new cyclosporine-A formulation (Neoral) in adult allogeneic bone marrow transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11255279/),[ng] / [ml],1027,90517,DB00091,Cyclosporine
,11255279,C(max),The comparison between pharmacokinetic parameters obtained in patients receiving Neoral 5 mg/kg/day or 7.5 mg/kg/day showed a proportional increase of the AUC (4776+/-1084 vs. 7746+/-2006 ng/mL h) and C(max) (1027+/-203 vs. 1514+/-231 ng/mL).,Pharmacokinetic study of the new cyclosporine-A formulation (Neoral) in adult allogeneic bone marrow transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11255279/),[ng] / [ml],1514,90518,DB00091,Cyclosporine
above,11255279,C(trough) levels,"In all patients to whom 7.5 mg/kg/day of Neoral were given, C(trough) levels were always above the threshold of 200 ng/mL.",Pharmacokinetic study of the new cyclosporine-A formulation (Neoral) in adult allogeneic bone marrow transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11255279/),[ng] / [ml],200,90519,DB00091,Cyclosporine
,7752303,volume of distribution at steady-state,"When non-compartmental pharmacokinetic analysis of the data was performed, the resulting mean (+/- SD) pharmacokinetic parameters in woodchucks and Pekin ducks, respectively, were as follows: volume of distribution at steady-state, 2.9 (+/- 0.8) and 2.7 (+/- 0.2) L/kg; systemic clearance, 10.2 (+/- 2.8) and 28.6 (+/- 6.1) mL/kg/min; mean residence time, 4.8 (+/- 1.1) and 1.6 (+/- 0.3).",Pharmacokinetics of cyclosporine in woodchucks and Pekin ducks. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752303/),[l] / [kg],2.9,90816,DB00091,Cyclosporine
,7752303,volume of distribution at steady-state,"When non-compartmental pharmacokinetic analysis of the data was performed, the resulting mean (+/- SD) pharmacokinetic parameters in woodchucks and Pekin ducks, respectively, were as follows: volume of distribution at steady-state, 2.9 (+/- 0.8) and 2.7 (+/- 0.2) L/kg; systemic clearance, 10.2 (+/- 2.8) and 28.6 (+/- 6.1) mL/kg/min; mean residence time, 4.8 (+/- 1.1) and 1.6 (+/- 0.3).",Pharmacokinetics of cyclosporine in woodchucks and Pekin ducks. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752303/),[l] / [kg],2.7,90817,DB00091,Cyclosporine
,7752303,systemic clearance,"When non-compartmental pharmacokinetic analysis of the data was performed, the resulting mean (+/- SD) pharmacokinetic parameters in woodchucks and Pekin ducks, respectively, were as follows: volume of distribution at steady-state, 2.9 (+/- 0.8) and 2.7 (+/- 0.2) L/kg; systemic clearance, 10.2 (+/- 2.8) and 28.6 (+/- 6.1) mL/kg/min; mean residence time, 4.8 (+/- 1.1) and 1.6 (+/- 0.3).",Pharmacokinetics of cyclosporine in woodchucks and Pekin ducks. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752303/),[ml] / [kg·min],10.2,90818,DB00091,Cyclosporine
,7752303,systemic clearance,"When non-compartmental pharmacokinetic analysis of the data was performed, the resulting mean (+/- SD) pharmacokinetic parameters in woodchucks and Pekin ducks, respectively, were as follows: volume of distribution at steady-state, 2.9 (+/- 0.8) and 2.7 (+/- 0.2) L/kg; systemic clearance, 10.2 (+/- 2.8) and 28.6 (+/- 6.1) mL/kg/min; mean residence time, 4.8 (+/- 1.1) and 1.6 (+/- 0.3).",Pharmacokinetics of cyclosporine in woodchucks and Pekin ducks. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752303/),[ml] / [kg·min],28.6,90819,DB00091,Cyclosporine
,7752303,mean residence time,"When non-compartmental pharmacokinetic analysis of the data was performed, the resulting mean (+/- SD) pharmacokinetic parameters in woodchucks and Pekin ducks, respectively, were as follows: volume of distribution at steady-state, 2.9 (+/- 0.8) and 2.7 (+/- 0.2) L/kg; systemic clearance, 10.2 (+/- 2.8) and 28.6 (+/- 6.1) mL/kg/min; mean residence time, 4.8 (+/- 1.1) and 1.6 (+/- 0.3).",Pharmacokinetics of cyclosporine in woodchucks and Pekin ducks. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752303/),,4.8,90820,DB00091,Cyclosporine
,7752303,mean residence time,"When non-compartmental pharmacokinetic analysis of the data was performed, the resulting mean (+/- SD) pharmacokinetic parameters in woodchucks and Pekin ducks, respectively, were as follows: volume of distribution at steady-state, 2.9 (+/- 0.8) and 2.7 (+/- 0.2) L/kg; systemic clearance, 10.2 (+/- 2.8) and 28.6 (+/- 6.1) mL/kg/min; mean residence time, 4.8 (+/- 1.1) and 1.6 (+/- 0.3).",Pharmacokinetics of cyclosporine in woodchucks and Pekin ducks. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7752303/),,1.6,90821,DB00091,Cyclosporine
,9808668,dissociation constants (Kd),"In nonlinear model, the estimated dissociation constants (Kd) for the intracellular saturable binding ranged 0.2 to 60 ng/ml among the organs, which are comparable with values reported for cyclophilin-CyA binding in vitro.",Physiologically based pharmacokinetics of cyclosporine A: extension to tissue distribution kinetics in rats and scale-up to human. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9808668/),[ng] / [ml],0.2 to 60,91216,DB00091,Cyclosporine
,28296193,Inhibition constant (Ki ),"The predicted effects of rifampin and cyclosporine (6.58-fold and 5.07-fold increase in rosuvastatin area under the curve (AUC), respectively) were mediated primarily via inhibition of hepatic organic anion-transporting polypeptide (OATP)1B1 (Inhibition constant (Ki ) ∼1.1 and 0.014 µM, respectively) and OATP1B3 (Ki ∼0.3 and 0.007 µM, respectively), with cyclosporine also inhibiting intestinal breast cancer resistance protein (BCRP; Ki ∼0.07 µM).",Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28296193/),μM,∼1.1,92275,DB00091,Cyclosporine
,28296193,Inhibition constant (Ki ),"The predicted effects of rifampin and cyclosporine (6.58-fold and 5.07-fold increase in rosuvastatin area under the curve (AUC), respectively) were mediated primarily via inhibition of hepatic organic anion-transporting polypeptide (OATP)1B1 (Inhibition constant (Ki ) ∼1.1 and 0.014 µM, respectively) and OATP1B3 (Ki ∼0.3 and 0.007 µM, respectively), with cyclosporine also inhibiting intestinal breast cancer resistance protein (BCRP; Ki ∼0.07 µM).",Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28296193/),μM,0.014,92276,DB00091,Cyclosporine
,28296193,Ki,"The predicted effects of rifampin and cyclosporine (6.58-fold and 5.07-fold increase in rosuvastatin area under the curve (AUC), respectively) were mediated primarily via inhibition of hepatic organic anion-transporting polypeptide (OATP)1B1 (Inhibition constant (Ki ) ∼1.1 and 0.014 µM, respectively) and OATP1B3 (Ki ∼0.3 and 0.007 µM, respectively), with cyclosporine also inhibiting intestinal breast cancer resistance protein (BCRP; Ki ∼0.07 µM).",Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28296193/),μM,∼0.3,92277,DB00091,Cyclosporine
,28296193,Ki,"The predicted effects of rifampin and cyclosporine (6.58-fold and 5.07-fold increase in rosuvastatin area under the curve (AUC), respectively) were mediated primarily via inhibition of hepatic organic anion-transporting polypeptide (OATP)1B1 (Inhibition constant (Ki ) ∼1.1 and 0.014 µM, respectively) and OATP1B3 (Ki ∼0.3 and 0.007 µM, respectively), with cyclosporine also inhibiting intestinal breast cancer resistance protein (BCRP; Ki ∼0.07 µM).",Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28296193/),μM,0.007,92278,DB00091,Cyclosporine
,8161718,total blood clearance,The disposition pharmacokinetics were linear over the dose range studied; the average total blood clearance was 0.19 l g-1 kg-1.,Dose dependent absorption and linear disposition of cyclosporin A in rat. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8161718/),[l] / [g·kg],0.19,92781,DB00091,Cyclosporine
,8161718,Bioavailability,"Bioavailability was higher at higher doses; the values were 45%, 67% and 76% for the three ascending dose levels.",Dose dependent absorption and linear disposition of cyclosporin A in rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8161718/),%,45,92782,DB00091,Cyclosporine
,8161718,Bioavailability,"Bioavailability was higher at higher doses; the values were 45%, 67% and 76% for the three ascending dose levels.",Dose dependent absorption and linear disposition of cyclosporin A in rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8161718/),%,67,92783,DB00091,Cyclosporine
,8161718,Bioavailability,"Bioavailability was higher at higher doses; the values were 45%, 67% and 76% for the three ascending dose levels.",Dose dependent absorption and linear disposition of cyclosporin A in rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8161718/),%,76,92784,DB00091,Cyclosporine
,8161718,extraction,"Since the extraction of CyA in the liver is only 6%, the marked increase in bioavailability of CyA is most likely to be the result of saturated gut wall metabolism.",Dose dependent absorption and linear disposition of cyclosporin A in rat. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8161718/),%,6,92785,DB00091,Cyclosporine
,11161541,systemic clearance,"There were no statistically significant differences between regimens in any CyA pharmacokinetic parameters; there were no significant differences from baseline values, except for a higher systemic clearance of CyA with regimen A (0.40+/-0.09 vs 0.29+/-0.06 L/Kg/h, p=0.03).",Parenteral nutrition and cyclosporine: do lipids make a difference? A prospective randomized crossover trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11161541/),[l] / [h·kg],0.40,93040,DB00091,Cyclosporine
,11161541,systemic clearance,"There were no statistically significant differences between regimens in any CyA pharmacokinetic parameters; there were no significant differences from baseline values, except for a higher systemic clearance of CyA with regimen A (0.40+/-0.09 vs 0.29+/-0.06 L/Kg/h, p=0.03).",Parenteral nutrition and cyclosporine: do lipids make a difference? A prospective randomized crossover trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11161541/),[l] / [h·kg],0.29,93041,DB00091,Cyclosporine
,22584255,C-K's efflux ratio,"To define the mechanisms responsible for this low bioavailability, two P-glycoprotein (P-gp) inhibitors, verapamil and cyclosporine A, were used, and their presence substantially decreased C-K's efflux ratio in Caco-2 cells (from 26.6 to <3) and significantly increased intracellular concentrations (by as much as 40-fold).","Inhibition of P-glycoprotein leads to improved oral bioavailability of compound K, an anticancer metabolite of red ginseng extract produced by gut microflora. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22584255/),,26.6,93100,DB00091,Cyclosporine
<,22584255,C-K's efflux ratio,"To define the mechanisms responsible for this low bioavailability, two P-glycoprotein (P-gp) inhibitors, verapamil and cyclosporine A, were used, and their presence substantially decreased C-K's efflux ratio in Caco-2 cells (from 26.6 to <3) and significantly increased intracellular concentrations (by as much as 40-fold).","Inhibition of P-glycoprotein leads to improved oral bioavailability of compound K, an anticancer metabolite of red ginseng extract produced by gut microflora. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22584255/),,3,93101,DB00091,Cyclosporine
,15183289,trough concentrations,"In maintenance adult patients after conversion to a calcineurin inhibitor-free regimen, sirolimus trough concentrations of 5-10 microg/l are proposed in combination with mycophenolate mofetil.",Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15183289/),[μg] / [l],5-10,93468,DB00091,Cyclosporine
,16213292,area under the curve,"In the study group, the mean area under the curve was significantly below the average therapeutic range before (3154 ng/mL/ho) versus 5532 ng/mL/h after shifting to the single-dose regimen (which was therapeutic).",Single daily dose administration of cyclosporine in renal transplant recipients: a preliminary report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16213292/),[ng] / [ho·ml],3154,94161,DB00091,Cyclosporine
,16213292,area under the curve,"In the study group, the mean area under the curve was significantly below the average therapeutic range before (3154 ng/mL/ho) versus 5532 ng/mL/h after shifting to the single-dose regimen (which was therapeutic).",Single daily dose administration of cyclosporine in renal transplant recipients: a preliminary report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16213292/),[ng] / [h·ml],5532,94162,DB00091,Cyclosporine
,3311467,Sy/x,"RIA vs HPLC(sum of CsA + metabolites) gave the best comparison (slope = 0.931, y-intercept 14 micrograms/L, r = 0.933); but the scatter of data about the regression line remained significant (Sy/x = 132 micrograms/L).",Identification and analysis of nine metabolites of cyclosporine in whole blood by liquid chromatography. 2: Comparison of patients' results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311467/),[μg] / [l],132,94307,DB00091,Cyclosporine
,9428114,trough-level (Cmin),"The trough-level (Cmin) with Neoral was 123 +/- 39 ng/ml versus 134 +/- 29 ng/ml with Sandimmun (P = NS), the area under the time-concentration curve (AUC) was 3325 +/- 1125 ng.h/ml versus 2423 +/- 846 ng.h/ml (P < 0.001), the peak concentration (Cmax) was 650 +/- 280 ng/ml versus 337 +/- 142 ng/ ml (P < 0.001), and the median time to Cmax was 2 h (range 0.5-3 h) versus 4 h (range 1-8 h; P < 0.05).",Pharmacokinetics of cyclosporine in pediatric long-term liver transplant recipients converted from Sandimmun to Neoral. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9428114/),[ng] / [ml],123,94466,DB00091,Cyclosporine
,9428114,trough-level (Cmin),"The trough-level (Cmin) with Neoral was 123 +/- 39 ng/ml versus 134 +/- 29 ng/ml with Sandimmun (P = NS), the area under the time-concentration curve (AUC) was 3325 +/- 1125 ng.h/ml versus 2423 +/- 846 ng.h/ml (P < 0.001), the peak concentration (Cmax) was 650 +/- 280 ng/ml versus 337 +/- 142 ng/ ml (P < 0.001), and the median time to Cmax was 2 h (range 0.5-3 h) versus 4 h (range 1-8 h; P < 0.05).",Pharmacokinetics of cyclosporine in pediatric long-term liver transplant recipients converted from Sandimmun to Neoral. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9428114/),[ng] / [ml],134,94467,DB00091,Cyclosporine
,9428114,area under the time-concentration curve (AUC),"The trough-level (Cmin) with Neoral was 123 +/- 39 ng/ml versus 134 +/- 29 ng/ml with Sandimmun (P = NS), the area under the time-concentration curve (AUC) was 3325 +/- 1125 ng.h/ml versus 2423 +/- 846 ng.h/ml (P < 0.001), the peak concentration (Cmax) was 650 +/- 280 ng/ml versus 337 +/- 142 ng/ ml (P < 0.001), and the median time to Cmax was 2 h (range 0.5-3 h) versus 4 h (range 1-8 h; P < 0.05).",Pharmacokinetics of cyclosporine in pediatric long-term liver transplant recipients converted from Sandimmun to Neoral. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9428114/),[h·ng] / [ml],3325,94468,DB00091,Cyclosporine
,9428114,area under the time-concentration curve (AUC),"The trough-level (Cmin) with Neoral was 123 +/- 39 ng/ml versus 134 +/- 29 ng/ml with Sandimmun (P = NS), the area under the time-concentration curve (AUC) was 3325 +/- 1125 ng.h/ml versus 2423 +/- 846 ng.h/ml (P < 0.001), the peak concentration (Cmax) was 650 +/- 280 ng/ml versus 337 +/- 142 ng/ ml (P < 0.001), and the median time to Cmax was 2 h (range 0.5-3 h) versus 4 h (range 1-8 h; P < 0.05).",Pharmacokinetics of cyclosporine in pediatric long-term liver transplant recipients converted from Sandimmun to Neoral. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9428114/),[h·ng] / [ml],2423,94469,DB00091,Cyclosporine
,9428114,peak concentration (Cmax),"The trough-level (Cmin) with Neoral was 123 +/- 39 ng/ml versus 134 +/- 29 ng/ml with Sandimmun (P = NS), the area under the time-concentration curve (AUC) was 3325 +/- 1125 ng.h/ml versus 2423 +/- 846 ng.h/ml (P < 0.001), the peak concentration (Cmax) was 650 +/- 280 ng/ml versus 337 +/- 142 ng/ ml (P < 0.001), and the median time to Cmax was 2 h (range 0.5-3 h) versus 4 h (range 1-8 h; P < 0.05).",Pharmacokinetics of cyclosporine in pediatric long-term liver transplant recipients converted from Sandimmun to Neoral. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9428114/),[ng] / [ml],650,94470,DB00091,Cyclosporine
,9428114,peak concentration (Cmax),"The trough-level (Cmin) with Neoral was 123 +/- 39 ng/ml versus 134 +/- 29 ng/ml with Sandimmun (P = NS), the area under the time-concentration curve (AUC) was 3325 +/- 1125 ng.h/ml versus 2423 +/- 846 ng.h/ml (P < 0.001), the peak concentration (Cmax) was 650 +/- 280 ng/ml versus 337 +/- 142 ng/ ml (P < 0.001), and the median time to Cmax was 2 h (range 0.5-3 h) versus 4 h (range 1-8 h; P < 0.05).",Pharmacokinetics of cyclosporine in pediatric long-term liver transplant recipients converted from Sandimmun to Neoral. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9428114/),[ng] / [ml],337,94471,DB00091,Cyclosporine
,9428114,time to Cmax,"The trough-level (Cmin) with Neoral was 123 +/- 39 ng/ml versus 134 +/- 29 ng/ml with Sandimmun (P = NS), the area under the time-concentration curve (AUC) was 3325 +/- 1125 ng.h/ml versus 2423 +/- 846 ng.h/ml (P < 0.001), the peak concentration (Cmax) was 650 +/- 280 ng/ml versus 337 +/- 142 ng/ ml (P < 0.001), and the median time to Cmax was 2 h (range 0.5-3 h) versus 4 h (range 1-8 h; P < 0.05).",Pharmacokinetics of cyclosporine in pediatric long-term liver transplant recipients converted from Sandimmun to Neoral. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9428114/),h,2,94472,DB00091,Cyclosporine
,9428114,time to Cmax,"The trough-level (Cmin) with Neoral was 123 +/- 39 ng/ml versus 134 +/- 29 ng/ml with Sandimmun (P = NS), the area under the time-concentration curve (AUC) was 3325 +/- 1125 ng.h/ml versus 2423 +/- 846 ng.h/ml (P < 0.001), the peak concentration (Cmax) was 650 +/- 280 ng/ml versus 337 +/- 142 ng/ ml (P < 0.001), and the median time to Cmax was 2 h (range 0.5-3 h) versus 4 h (range 1-8 h; P < 0.05).",Pharmacokinetics of cyclosporine in pediatric long-term liver transplant recipients converted from Sandimmun to Neoral. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9428114/),h,4,94473,DB00091,Cyclosporine
,15752372,free fraction,"Mycophenolic acid free fraction was on average 70% higher in patients with albumin concentrations below a specified albumin cut-off concentration of 31 g l(-1)[free fraction = 7 +/- 4% for lower albumin and 4 +/- 3% for higher albumin, respectively; P = 0.001; 95% confidence interval (CI) for the difference 1.9, 4.2].",Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752372/),%,7,94667,DB00091,Cyclosporine
,15752372,free fraction,"Mycophenolic acid free fraction was on average 70% higher in patients with albumin concentrations below a specified albumin cut-off concentration of 31 g l(-1)[free fraction = 7 +/- 4% for lower albumin and 4 +/- 3% for higher albumin, respectively; P = 0.001; 95% confidence interval (CI) for the difference 1.9, 4.2].",Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752372/),%,4,94668,DB00091,Cyclosporine
,15752372,Free AUC0-6,"Free AUC0-6 was significantly higher in those patients with thrombocytopenic, leukopenic and/or infectious outcomes than in those without (mean +/- SD 1.9 +/- 0.3 mg h(-1) l(-1) and 1.1 +/- 0.1 mg h(-1) l(-1), P = 0.0043; 95% CI for the difference 0.3, 1.4).",Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752372/),[mg] / [h·l],1.9,94669,DB00091,Cyclosporine
,15752372,Free AUC0-6,"Free AUC0-6 was significantly higher in those patients with thrombocytopenic, leukopenic and/or infectious outcomes than in those without (mean +/- SD 1.9 +/- 0.3 mg h(-1) l(-1) and 1.1 +/- 0.1 mg h(-1) l(-1), P = 0.0043; 95% CI for the difference 0.3, 1.4).",Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752372/),[mg] / [h·l],1.1,94670,DB00091,Cyclosporine
,27631462,Volume of distribution,"Volume of distribution (95% confidence interval) was 34.7 L (17.3-48.0), and total apparent clearance (CL) (95% confidence interval) was correlated to body weight, tumor disease, and cyclosporine coadministration: CL = θCL × (WT/70) L/h with θCL = 3.49 (3.02-3.96), 4.66 (3.98-5.31), and 4.97 (4.42-5.41) in patients managed for hematological malignancies with or without cyclosporine coadministration and for solid malignancies, respectively.",Pediatric Patients With Solid or Hematological Tumor Disease: Vancomycin Population Pharmacokinetics and Dosage Optimization. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27631462/),l,34.7,94686,DB00091,Cyclosporine
,1889021,peak cyclosporine concentrations,"Subconjunctival administration resulted in peak cyclosporine concentrations of 718 ng/mL in the aqueous humour and 1078 ng/mL in the vitreous humour, compared with no detectable levels in the aqueous humour and a peak concentration of 292 ng/mL in the vitreous following intravenous administration.",Ocular pharmacokinetics of subconjunctivally administered cyclosporine in the rabbit. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1889021/),[ng] / [ml],718,95519,DB00091,Cyclosporine
,1889021,peak cyclosporine concentrations,"Subconjunctival administration resulted in peak cyclosporine concentrations of 718 ng/mL in the aqueous humour and 1078 ng/mL in the vitreous humour, compared with no detectable levels in the aqueous humour and a peak concentration of 292 ng/mL in the vitreous following intravenous administration.",Ocular pharmacokinetics of subconjunctivally administered cyclosporine in the rabbit. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1889021/),[ng] / [ml],1078,95520,DB00091,Cyclosporine
,1889021,peak concentration,"Subconjunctival administration resulted in peak cyclosporine concentrations of 718 ng/mL in the aqueous humour and 1078 ng/mL in the vitreous humour, compared with no detectable levels in the aqueous humour and a peak concentration of 292 ng/mL in the vitreous following intravenous administration.",Ocular pharmacokinetics of subconjunctivally administered cyclosporine in the rabbit. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1889021/),[ng] / [ml],292,95521,DB00091,Cyclosporine
,11261685,maximum concentration,"Following conversion to Neoral, the peak concentration occurred earlier (2+/-1.4 h vs 3.9+/-2.4 h), and the maximum concentration (677+/-386 ng/ml vs 488+/-265 ng/ml) and the area under the curve (3,082+/-1,536 ng/ml/h vs 2,201+/889 ng/ml/h) were higher.",A pharmacokinetic study of Neoral in childhood steroid-dependent nephrotic syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11261685/),[ng] / [ml],677,95729,DB00091,Cyclosporine
,11261685,maximum concentration,"Following conversion to Neoral, the peak concentration occurred earlier (2+/-1.4 h vs 3.9+/-2.4 h), and the maximum concentration (677+/-386 ng/ml vs 488+/-265 ng/ml) and the area under the curve (3,082+/-1,536 ng/ml/h vs 2,201+/889 ng/ml/h) were higher.",A pharmacokinetic study of Neoral in childhood steroid-dependent nephrotic syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11261685/),[ng] / [ml],488,95730,DB00091,Cyclosporine
,11261685,area under the curve,"Following conversion to Neoral, the peak concentration occurred earlier (2+/-1.4 h vs 3.9+/-2.4 h), and the maximum concentration (677+/-386 ng/ml vs 488+/-265 ng/ml) and the area under the curve (3,082+/-1,536 ng/ml/h vs 2,201+/889 ng/ml/h) were higher.",A pharmacokinetic study of Neoral in childhood steroid-dependent nephrotic syndrome. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11261685/),[ng] / [h·ml],"3,082",95731,DB00091,Cyclosporine
,11261685,area under the curve,"Following conversion to Neoral, the peak concentration occurred earlier (2+/-1.4 h vs 3.9+/-2.4 h), and the maximum concentration (677+/-386 ng/ml vs 488+/-265 ng/ml) and the area under the curve (3,082+/-1,536 ng/ml/h vs 2,201+/889 ng/ml/h) were higher.",A pharmacokinetic study of Neoral in childhood steroid-dependent nephrotic syndrome. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11261685/),[ng] / [h·ml],"2,201",95732,DB00091,Cyclosporine
greater,1406233,trough,"The daily dosing regimen resulted in greatly elevated trough CsA levels (greater than 1,600 micrograms/liter) and substantial chronic systemic toxicity, with weight loss and death in eight animals.",Chronic cyclosporin A therapy in rats. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1406233/),[μg] / [l],"1,600",96132,DB00091,Cyclosporine
,1406233,trough levels,"Alternate day dosing reduced trough levels (mean 1,311 micrograms/liter) and decreased toxicity.",Chronic cyclosporin A therapy in rats. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1406233/),[μg] / [l],"1,311",96133,DB00091,Cyclosporine
,17096765,relative bioavailability,"When comparing the dose-normalized AUCs over 24 h, every single patient demonstrated lower CyA-ME exposure on t.i.d. than on b.i.d. dosing with an average relative bioavailability that was 37.9% lower on t.i.d. than on b.i.d. dosing.",Cyclosporin twice or three times daily dosing in pediatric transplant patients - it is not the same! ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17096765/),%,37.9,96238,DB00091,Cyclosporine
,17096765,dose-normalized AUC(0-->24h),"The median dose-normalized AUC(0-->24h) dropped from 1620 ng x h x kg/mL x mg (range: 1253-4319) on b.i.d. to 1016 ng x h x kg/mL x mg (range: 712-1485, p = 0.02, Wilcoxon's matched pairs test) on t.i.d. dosing.",Cyclosporin twice or three times daily dosing in pediatric transplant patients - it is not the same! ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17096765/),[h·kg·ng] / [mg·ml],1620,96239,DB00091,Cyclosporine
,17096765,dose-normalized AUC(0-->24h),"The median dose-normalized AUC(0-->24h) dropped from 1620 ng x h x kg/mL x mg (range: 1253-4319) on b.i.d. to 1016 ng x h x kg/mL x mg (range: 712-1485, p = 0.02, Wilcoxon's matched pairs test) on t.i.d. dosing.",Cyclosporin twice or three times daily dosing in pediatric transplant patients - it is not the same! ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17096765/),[h·kg·ng] / [mg·ml],1016,96240,DB00091,Cyclosporine
,3540030,blood clearance,Cyclosporine blood clearance ranged from 29 to 203 mL/min (1.9-21.5 mL/min/kg) in children and from 253 to 680 mL/min (3.2-7.6 mL/min/kg) in adults.,Cyclosporine absorption following orthotopic liver transplantation. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3540030/),[ml] / [min],29 to 203,96285,DB00091,Cyclosporine
,3540030,blood clearance,Cyclosporine blood clearance ranged from 29 to 203 mL/min (1.9-21.5 mL/min/kg) in children and from 253 to 680 mL/min (3.2-7.6 mL/min/kg) in adults.,Cyclosporine absorption following orthotopic liver transplantation. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3540030/),[ml] / [kg·min],1.9-21.5,96286,DB00091,Cyclosporine
,3540030,blood clearance,Cyclosporine blood clearance ranged from 29 to 203 mL/min (1.9-21.5 mL/min/kg) in children and from 253 to 680 mL/min (3.2-7.6 mL/min/kg) in adults.,Cyclosporine absorption following orthotopic liver transplantation. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3540030/),[ml] / [min],253 to 680,96287,DB00091,Cyclosporine
,3540030,clearance,The mean cyclosporine clearance value was 9.3 mL/min/kg in the pediatric patients and 5.5 mL/min/kg in the adults.,Cyclosporine absorption following orthotopic liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3540030/),[ml] / [kg·min],9.3,96288,DB00091,Cyclosporine
,3540030,clearance,The mean cyclosporine clearance value was 9.3 mL/min/kg in the pediatric patients and 5.5 mL/min/kg in the adults.,Cyclosporine absorption following orthotopic liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3540030/),[ml] / [kg·min],5.5,96289,DB00091,Cyclosporine
less,3540030,bioavailability,Cyclosporine bioavailability was less than 5% in six studies on five pediatric patients in the immediate postoperative period.,Cyclosporine absorption following orthotopic liver transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3540030/),%,5,96290,DB00091,Cyclosporine
,3540030,bioavailability,"The bioavailability varied from 8% to 60% in adult liver transplant patients (mean, 27%).",Cyclosporine absorption following orthotopic liver transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3540030/),%,8,96291,DB00091,Cyclosporine
,3540030,bioavailability,"The bioavailability varied from 8% to 60% in adult liver transplant patients (mean, 27%).",Cyclosporine absorption following orthotopic liver transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3540030/),%,60,96292,DB00091,Cyclosporine
,3540030,bioavailability,"The bioavailability varied from 8% to 60% in adult liver transplant patients (mean, 27%).",Cyclosporine absorption following orthotopic liver transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3540030/),%,27,96293,DB00091,Cyclosporine
,28646274,absorption rate constant (K a),"The absorption rate constant (K a), V/F, and apparent oral clearance (CL/F) of the final population pharmacokinetic (PopPK) model of diltiazem were 1.96/h, 3550 L, and 92.4 L/h, respectively.",Population Pharmacokinetic Modeling of Diltiazem in Chinese Renal Transplant Recipients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28646274/),1/[h],1.96,96725,DB00091,Cyclosporine
,28646274,V/F,"The absorption rate constant (K a), V/F, and apparent oral clearance (CL/F) of the final population pharmacokinetic (PopPK) model of diltiazem were 1.96/h, 3550 L, and 92.4 L/h, respectively.",Population Pharmacokinetic Modeling of Diltiazem in Chinese Renal Transplant Recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28646274/),l,3550,96726,DB00091,Cyclosporine
,28646274,apparent oral clearance (CL/F),"The absorption rate constant (K a), V/F, and apparent oral clearance (CL/F) of the final population pharmacokinetic (PopPK) model of diltiazem were 1.96/h, 3550 L, and 92.4 L/h, respectively.",Population Pharmacokinetic Modeling of Diltiazem in Chinese Renal Transplant Recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28646274/),[l] / [h],92.4,96727,DB00091,Cyclosporine
,21115788,brain-to-plasma concentration ratios,"The brain uptake of colistin was low following single and multiple subcutaneous doses, with brain-to-plasma concentration ratios ranging between 0.021 and 0.037, and this was not significantly enhanced by coadministration of GF120918 or PSC833 (P > 0.05).",Impact of p-glycoprotein inhibition and lipopolysaccharide administration on blood-brain barrier transport of colistin in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21115788/),,0.021 and 0.037,97116,DB00091,Cyclosporine
,21115788,area under the brain concentration time curve (AUC(brain)),"LPS significantly increased the brain uptake of subcutaneously administered colistin with area under the brain concentration time curve (AUC(brain)) values of 11.7 ± 2.7 μg·h/g and 4.0 ± 0.3 μg·h/g for LPS- and saline-treated mice, respectively (mean ± standard deviation).",Impact of p-glycoprotein inhibition and lipopolysaccharide administration on blood-brain barrier transport of colistin in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21115788/),[h·μg] / [g],11.7,97117,DB00091,Cyclosporine
,21115788,area under the brain concentration time curve (AUC(brain)),"LPS significantly increased the brain uptake of subcutaneously administered colistin with area under the brain concentration time curve (AUC(brain)) values of 11.7 ± 2.7 μg·h/g and 4.0 ± 0.3 μg·h/g for LPS- and saline-treated mice, respectively (mean ± standard deviation).",Impact of p-glycoprotein inhibition and lipopolysaccharide administration on blood-brain barrier transport of colistin in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21115788/),[h·μg] / [g],4.0,97118,DB00091,Cyclosporine
,21115788,brain-to-perfusate,"Similarly, in situ perfusion of colistin led to higher antibiotic brain concentrations in LPS-treated animals than in saline-treated animals, with colistin brain-to-perfusate concentration ratios of 0.019 ± 0.001 and 0.014 ± 0.001, respectively.",Impact of p-glycoprotein inhibition and lipopolysaccharide administration on blood-brain barrier transport of colistin in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21115788/),,0.019,97119,DB00091,Cyclosporine
,21115788,concentration ratios,"Similarly, in situ perfusion of colistin led to higher antibiotic brain concentrations in LPS-treated animals than in saline-treated animals, with colistin brain-to-perfusate concentration ratios of 0.019 ± 0.001 and 0.014 ± 0.001, respectively.",Impact of p-glycoprotein inhibition and lipopolysaccharide administration on blood-brain barrier transport of colistin in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21115788/),,0.019,97120,DB00091,Cyclosporine
,21115788,concentration ratios,"Similarly, in situ perfusion of colistin led to higher antibiotic brain concentrations in LPS-treated animals than in saline-treated animals, with colistin brain-to-perfusate concentration ratios of 0.019 ± 0.001 and 0.014 ± 0.001, respectively.",Impact of p-glycoprotein inhibition and lipopolysaccharide administration on blood-brain barrier transport of colistin in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21115788/),,0.014,97121,DB00091,Cyclosporine
,11487715,area under the concentration-time curve (AUC),Dose escalation of paclitaxel from 60 to 300 mg/m(2) resulted in a significant decrease in the area under the concentration-time curve (AUC) of CsA from 24.4+/-9.9 to 17.6+/-2.8 mg/l.h (p=0.03) (n=28).,Pharmacokinetics of oral cyclosporin A when co-administered to enhance the oral absorption of paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11487715/),[mg] / [h·l],24.4,97393,DB00091,Cyclosporine
,11487715,area under the concentration-time curve (AUC),Dose escalation of paclitaxel from 60 to 300 mg/m(2) resulted in a significant decrease in the area under the concentration-time curve (AUC) of CsA from 24.4+/-9.9 to 17.6+/-2.8 mg/l.h (p=0.03) (n=28).,Pharmacokinetics of oral cyclosporin A when co-administered to enhance the oral absorption of paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11487715/),[mg] / [h·l],17.6,97394,DB00091,Cyclosporine
,9089419,Cmax,"The results suggest that, when malnutrition is present, the median Cmax of cyclosporine decreases by almost threefold (from 387.5 ng/mL in group I to 136.1 ng/mL in group II).",Pharmacokinetics of cyclosporine as a function of energy--protein deficiency in children with chronic renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9089419/),[ng] / [ml],387.5,97562,DB00091,Cyclosporine
,9089419,Cmax,"The results suggest that, when malnutrition is present, the median Cmax of cyclosporine decreases by almost threefold (from 387.5 ng/mL in group I to 136.1 ng/mL in group II).",Pharmacokinetics of cyclosporine as a function of energy--protein deficiency in children with chronic renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9089419/),[ng] / [ml],136.1,97563,DB00091,Cyclosporine
,9089419,AUC0-infinity,"An observed 52% reduction in AUC0-infinity (from 2,856.0 ng/mL/hr in group I to 1,481.4 ng/mL/hr in group II) was caused by the increased volume of distribution (from 4.6 L/kg in group I to 11.1 L/kg in group II).",Pharmacokinetics of cyclosporine as a function of energy--protein deficiency in children with chronic renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9089419/),[ng] / [h·ml],"2,856.0",97564,DB00091,Cyclosporine
,9089419,AUC0-infinity,"An observed 52% reduction in AUC0-infinity (from 2,856.0 ng/mL/hr in group I to 1,481.4 ng/mL/hr in group II) was caused by the increased volume of distribution (from 4.6 L/kg in group I to 11.1 L/kg in group II).",Pharmacokinetics of cyclosporine as a function of energy--protein deficiency in children with chronic renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9089419/),[ng] / [h·ml],"1,481.4",97565,DB00091,Cyclosporine
,9089419,volume of distribution,"An observed 52% reduction in AUC0-infinity (from 2,856.0 ng/mL/hr in group I to 1,481.4 ng/mL/hr in group II) was caused by the increased volume of distribution (from 4.6 L/kg in group I to 11.1 L/kg in group II).",Pharmacokinetics of cyclosporine as a function of energy--protein deficiency in children with chronic renal failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9089419/),[l] / [kg],4.6,97566,DB00091,Cyclosporine
,9089419,volume of distribution,"An observed 52% reduction in AUC0-infinity (from 2,856.0 ng/mL/hr in group I to 1,481.4 ng/mL/hr in group II) was caused by the increased volume of distribution (from 4.6 L/kg in group I to 11.1 L/kg in group II).",Pharmacokinetics of cyclosporine as a function of energy--protein deficiency in children with chronic renal failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9089419/),[l] / [kg],11.1,97567,DB00091,Cyclosporine
,9089419,elimination half-life (t1/2),"The elimination half-life (t1/2) was longer in group II compared with that of group I (12.4 hr for group II; range, 7.8-13.5 hr versus 8.9 hr for group I; range, 5.2-16.0 hr).",Pharmacokinetics of cyclosporine as a function of energy--protein deficiency in children with chronic renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9089419/),h,12.4,97568,DB00091,Cyclosporine
,9089419,elimination half-life (t1/2),"The elimination half-life (t1/2) was longer in group II compared with that of group I (12.4 hr for group II; range, 7.8-13.5 hr versus 8.9 hr for group I; range, 5.2-16.0 hr).",Pharmacokinetics of cyclosporine as a function of energy--protein deficiency in children with chronic renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9089419/),h,8.9,97569,DB00091,Cyclosporine
,15289793,steady,"In transplant recipients taking 10 mg rosuvastatin, geometric mean values and percent coefficient of variation for steady-state AUC(0-24) and Cmax were 284 ng.",Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289793/),ng,28,98031,DB00091,Cyclosporine
,15289793,association constant,"The in vitro results demonstrate that rosuvastatin is a good substrate for OATP-C-mediated hepatic uptake (association constant, 8.5 +/- 1.1 micromol/L) and that cyclosporine is an effective inhibitor of this process (50% inhibition constant, 2.2 +/- 0.4 micromol/L when the rosuvastatin concentration was 5 micromol/L).",Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289793/),[μM] / [l],8.5,98032,DB00091,Cyclosporine
,15289793,50% inhibition constant,"The in vitro results demonstrate that rosuvastatin is a good substrate for OATP-C-mediated hepatic uptake (association constant, 8.5 +/- 1.1 micromol/L) and that cyclosporine is an effective inhibitor of this process (50% inhibition constant, 2.2 +/- 0.4 micromol/L when the rosuvastatin concentration was 5 micromol/L).",Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289793/),[μM] / [l],2.2,98033,DB00091,Cyclosporine
,11073292,dose-normalized c,The mean dose-normalized cyclosporin concentration during this comedication (90% confidence interval) was 0.48 (0.43 to 0.54) ng/(ml x mg) and was constantly below the respective concentration without the herbal remedy (0.84 (0.79 to 0.89) ng/(ml x mg)).,Hazardous pharmacokinetic interaction of Saint John's wort (Hypericum perforatum) with the immunosuppressant cyclosporin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11073292/),-1·ng,0.48,98234,DB00091,Cyclosporine
,11073292,dose-normalized c,The mean dose-normalized cyclosporin concentration during this comedication (90% confidence interval) was 0.48 (0.43 to 0.54) ng/(ml x mg) and was constantly below the respective concentration without the herbal remedy (0.84 (0.79 to 0.89) ng/(ml x mg)).,Hazardous pharmacokinetic interaction of Saint John's wort (Hypericum perforatum) with the immunosuppressant cyclosporin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11073292/),[ng] / [mg·ml],0.84,98235,DB00091,Cyclosporine
,15618725,T(max),"Oral co-administration of CsA increased NFV T(max) from 2.6+/-0.9 to 3.2+/-0.8 h (p<0.05), and AUC(0-infinity) from 27.9+/-15.2 to 43.2+/-27.1 mg(*)h/mL (p=0.06).",Pharmacokinetic interactions between cyclosporine and protease inhibitors in HIV+ subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618725/),h,2.6,98370,DB00091,Cyclosporine
,15618725,T(max),"Oral co-administration of CsA increased NFV T(max) from 2.6+/-0.9 to 3.2+/-0.8 h (p<0.05), and AUC(0-infinity) from 27.9+/-15.2 to 43.2+/-27.1 mg(*)h/mL (p=0.06).",Pharmacokinetic interactions between cyclosporine and protease inhibitors in HIV+ subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618725/),h,3.2,98371,DB00091,Cyclosporine
,15618725,AUC(0-infinity),"Oral co-administration of CsA increased NFV T(max) from 2.6+/-0.9 to 3.2+/-0.8 h (p<0.05), and AUC(0-infinity) from 27.9+/-15.2 to 43.2+/-27.1 mg(*)h/mL (p=0.06).",Pharmacokinetic interactions between cyclosporine and protease inhibitors in HIV+ subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618725/),[)h·mg(] / [ml],27.9,98372,DB00091,Cyclosporine
,15618725,AUC(0-infinity),"Oral co-administration of CsA increased NFV T(max) from 2.6+/-0.9 to 3.2+/-0.8 h (p<0.05), and AUC(0-infinity) from 27.9+/-15.2 to 43.2+/-27.1 mg(*)h/mL (p=0.06).",Pharmacokinetic interactions between cyclosporine and protease inhibitors in HIV+ subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618725/),[)h·mg(] / [ml],43.2,98373,DB00091,Cyclosporine
,9403215,Sbp,Sbp decreased from 166 +/- 18 to 142 +/- 14 mmHg and Dbp decreased from 97 +/- 8 to 82 +/- 10 mmHg (mean +/- 1 SD).,Effects of isradipine on renal hemodynamics in renal transplant patients treated with cyclosporine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403215/),mmhg,166,98638,DB00091,Cyclosporine
,9403215,Sbp,Sbp decreased from 166 +/- 18 to 142 +/- 14 mmHg and Dbp decreased from 97 +/- 8 to 82 +/- 10 mmHg (mean +/- 1 SD).,Effects of isradipine on renal hemodynamics in renal transplant patients treated with cyclosporine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403215/),mmhg,142,98639,DB00091,Cyclosporine
,9403215,Dbp,Sbp decreased from 166 +/- 18 to 142 +/- 14 mmHg and Dbp decreased from 97 +/- 8 to 82 +/- 10 mmHg (mean +/- 1 SD).,Effects of isradipine on renal hemodynamics in renal transplant patients treated with cyclosporine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403215/),mmhg,97,98640,DB00091,Cyclosporine
,9403215,Dbp,Sbp decreased from 166 +/- 18 to 142 +/- 14 mmHg and Dbp decreased from 97 +/- 8 to 82 +/- 10 mmHg (mean +/- 1 SD).,Effects of isradipine on renal hemodynamics in renal transplant patients treated with cyclosporine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403215/),mmhg,82,98641,DB00091,Cyclosporine
,9403215,Renal vascular resistance,"Renal vascular resistance, calculated from mean arterial pressure and renal blood flow, decreased significantly (p < 0.002) from 0.57 +/- 0.21 to 0.41 +/- 0.12 mmHg/ml/min (mean +/- 1 SD).",Effects of isradipine on renal hemodynamics in renal transplant patients treated with cyclosporine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403215/),[mmhg] / [min·ml],0.57,98642,DB00091,Cyclosporine
,9403215,Renal vascular resistance,"Renal vascular resistance, calculated from mean arterial pressure and renal blood flow, decreased significantly (p < 0.002) from 0.57 +/- 0.21 to 0.41 +/- 0.12 mmHg/ml/min (mean +/- 1 SD).",Effects of isradipine on renal hemodynamics in renal transplant patients treated with cyclosporine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9403215/),[mmhg] / [min·ml],0.41,98643,DB00091,Cyclosporine
,12742493,trough sirolimus concentrations,High-risk recipients of black ethnicity (n = 68) were randomized to target whole-blood trough sirolimus concentrations between 8 and 12 ng/mL or 15 to 20 ng/mL.,Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742493/),[ng] / [ml],8 and 12,98662,DB00091,Cyclosporine
,12742493,trough sirolimus concentrations,High-risk recipients of black ethnicity (n = 68) were randomized to target whole-blood trough sirolimus concentrations between 8 and 12 ng/mL or 15 to 20 ng/mL.,Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742493/),[ng] / [ml],15 to 20,98663,DB00091,Cyclosporine
,12742493,late loss,"The 4-month follow-up angiography revealed no restenosis (stenosis diameter > 50%), a late loss of 0.56 +/- 0.40 mm, and a loss index of 0.33 +/- 0.30.",Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742493/),mm,0.56,98664,DB00091,Cyclosporine
,12742493,loss index,"The 4-month follow-up angiography revealed no restenosis (stenosis diameter > 50%), a late loss of 0.56 +/- 0.40 mm, and a loss index of 0.33 +/- 0.30.",Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742493/),,0.33,98665,DB00091,Cyclosporine
,12817518,oral clearance,"CsA oral clearance was significantly higher in subjects who carried at least one 3435T allele compared to homozygous wild-type individuals (40.0 +/- 2.2 vs. 26.4 +/- 3.1 L/h, p = 0.007).",The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12817518/),[l] / [h],40.0,99288,DB00091,Cyclosporine
,12817518,oral clearance,"CsA oral clearance was significantly higher in subjects who carried at least one 3435T allele compared to homozygous wild-type individuals (40.0 +/- 2.2 vs. 26.4 +/- 3.1 L/h, p = 0.007).",The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12817518/),[l] / [h],26.4,99289,DB00091,Cyclosporine
,11907637,C(max.),"Values of C(max.) and AUC(0h-24h) were higher in the patient group than in the control group (day 1, patients vs. controls, C(max.): 869.4 +/- 604.0 ng/mL vs. 211.9 +/- 113.9 ng/mL; AUC(0h-24h): 1948.8 +/- 1347.9 ng/mL*h vs. 549.4 +/- 247.4 ng/mL*h), whereas the corresponding value of CL was lower in the patient group (33.3 +/- 24.5 L/h vs. 107.9 +/- 95.8 L/h), and the values of t(max.) and t(1/2) showed no differences.",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[ng] / [ml],869.4,99577,DB00091,Cyclosporine
,11907637,C(max.),"Values of C(max.) and AUC(0h-24h) were higher in the patient group than in the control group (day 1, patients vs. controls, C(max.): 869.4 +/- 604.0 ng/mL vs. 211.9 +/- 113.9 ng/mL; AUC(0h-24h): 1948.8 +/- 1347.9 ng/mL*h vs. 549.4 +/- 247.4 ng/mL*h), whereas the corresponding value of CL was lower in the patient group (33.3 +/- 24.5 L/h vs. 107.9 +/- 95.8 L/h), and the values of t(max.) and t(1/2) showed no differences.",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[ng] / [ml],211.9,99578,DB00091,Cyclosporine
,11907637,AUC(0h-24h),"Values of C(max.) and AUC(0h-24h) were higher in the patient group than in the control group (day 1, patients vs. controls, C(max.): 869.4 +/- 604.0 ng/mL vs. 211.9 +/- 113.9 ng/mL; AUC(0h-24h): 1948.8 +/- 1347.9 ng/mL*h vs. 549.4 +/- 247.4 ng/mL*h), whereas the corresponding value of CL was lower in the patient group (33.3 +/- 24.5 L/h vs. 107.9 +/- 95.8 L/h), and the values of t(max.) and t(1/2) showed no differences.",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[ng] / [h·ml],1948.8,99579,DB00091,Cyclosporine
,11907637,AUC(0h-24h),"Values of C(max.) and AUC(0h-24h) were higher in the patient group than in the control group (day 1, patients vs. controls, C(max.): 869.4 +/- 604.0 ng/mL vs. 211.9 +/- 113.9 ng/mL; AUC(0h-24h): 1948.8 +/- 1347.9 ng/mL*h vs. 549.4 +/- 247.4 ng/mL*h), whereas the corresponding value of CL was lower in the patient group (33.3 +/- 24.5 L/h vs. 107.9 +/- 95.8 L/h), and the values of t(max.) and t(1/2) showed no differences.",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[ng] / [h·ml],549.4,99580,DB00091,Cyclosporine
,11907637,CL,"Values of C(max.) and AUC(0h-24h) were higher in the patient group than in the control group (day 1, patients vs. controls, C(max.): 869.4 +/- 604.0 ng/mL vs. 211.9 +/- 113.9 ng/mL; AUC(0h-24h): 1948.8 +/- 1347.9 ng/mL*h vs. 549.4 +/- 247.4 ng/mL*h), whereas the corresponding value of CL was lower in the patient group (33.3 +/- 24.5 L/h vs. 107.9 +/- 95.8 L/h), and the values of t(max.) and t(1/2) showed no differences.",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[l] / [h],33.3,99581,DB00091,Cyclosporine
,11907637,CL,"Values of C(max.) and AUC(0h-24h) were higher in the patient group than in the control group (day 1, patients vs. controls, C(max.): 869.4 +/- 604.0 ng/mL vs. 211.9 +/- 113.9 ng/mL; AUC(0h-24h): 1948.8 +/- 1347.9 ng/mL*h vs. 549.4 +/- 247.4 ng/mL*h), whereas the corresponding value of CL was lower in the patient group (33.3 +/- 24.5 L/h vs. 107.9 +/- 95.8 L/h), and the values of t(max.) and t(1/2) showed no differences.",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[l] / [h],107.9,99582,DB00091,Cyclosporine
,11907637,C(max.),"In addition, values of C(max.) and AUC(0h-24h) after administration of 40 mg/day fluvastatin for 4 weeks in both groups were slightly higher than at the beginning, whereas the value of CL was slightly lower (day 28, patients vs. controls, C(max.): 1530.4 +/- 960.4 ng/mL vs. 254.7 +/- 199.8 ng/mL; AUC(0h-24h): 2615.3 +/- 1379.4 ng/mL*h vs. 841.8 +/- 421.4 ng/mL*h; CL: day 28, 21.4 +/- 15.3 L/h vs. 61.5 +/- 36.6 L/h).",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[ng] / [ml],1530.4,99583,DB00091,Cyclosporine
,11907637,C(max.),"In addition, values of C(max.) and AUC(0h-24h) after administration of 40 mg/day fluvastatin for 4 weeks in both groups were slightly higher than at the beginning, whereas the value of CL was slightly lower (day 28, patients vs. controls, C(max.): 1530.4 +/- 960.4 ng/mL vs. 254.7 +/- 199.8 ng/mL; AUC(0h-24h): 2615.3 +/- 1379.4 ng/mL*h vs. 841.8 +/- 421.4 ng/mL*h; CL: day 28, 21.4 +/- 15.3 L/h vs. 61.5 +/- 36.6 L/h).",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[ng] / [ml],254.7,99584,DB00091,Cyclosporine
,11907637,AUC(0h-24h),"In addition, values of C(max.) and AUC(0h-24h) after administration of 40 mg/day fluvastatin for 4 weeks in both groups were slightly higher than at the beginning, whereas the value of CL was slightly lower (day 28, patients vs. controls, C(max.): 1530.4 +/- 960.4 ng/mL vs. 254.7 +/- 199.8 ng/mL; AUC(0h-24h): 2615.3 +/- 1379.4 ng/mL*h vs. 841.8 +/- 421.4 ng/mL*h; CL: day 28, 21.4 +/- 15.3 L/h vs. 61.5 +/- 36.6 L/h).",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[ng] / [h·ml],2615.3,99585,DB00091,Cyclosporine
,11907637,AUC(0h-24h),"In addition, values of C(max.) and AUC(0h-24h) after administration of 40 mg/day fluvastatin for 4 weeks in both groups were slightly higher than at the beginning, whereas the value of CL was slightly lower (day 28, patients vs. controls, C(max.): 1530.4 +/- 960.4 ng/mL vs. 254.7 +/- 199.8 ng/mL; AUC(0h-24h): 2615.3 +/- 1379.4 ng/mL*h vs. 841.8 +/- 421.4 ng/mL*h; CL: day 28, 21.4 +/- 15.3 L/h vs. 61.5 +/- 36.6 L/h).",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[ng] / [h·ml],841.8,99586,DB00091,Cyclosporine
,11907637,CL,"In addition, values of C(max.) and AUC(0h-24h) after administration of 40 mg/day fluvastatin for 4 weeks in both groups were slightly higher than at the beginning, whereas the value of CL was slightly lower (day 28, patients vs. controls, C(max.): 1530.4 +/- 960.4 ng/mL vs. 254.7 +/- 199.8 ng/mL; AUC(0h-24h): 2615.3 +/- 1379.4 ng/mL*h vs. 841.8 +/- 421.4 ng/mL*h; CL: day 28, 21.4 +/- 15.3 L/h vs. 61.5 +/- 36.6 L/h).",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[l] / [h],21.4,99587,DB00091,Cyclosporine
,11907637,CL,"In addition, values of C(max.) and AUC(0h-24h) after administration of 40 mg/day fluvastatin for 4 weeks in both groups were slightly higher than at the beginning, whereas the value of CL was slightly lower (day 28, patients vs. controls, C(max.): 1530.4 +/- 960.4 ng/mL vs. 254.7 +/- 199.8 ng/mL; AUC(0h-24h): 2615.3 +/- 1379.4 ng/mL*h vs. 841.8 +/- 421.4 ng/mL*h; CL: day 28, 21.4 +/- 15.3 L/h vs. 61.5 +/- 36.6 L/h).",Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907637/),[l] / [h],61.5,99588,DB00091,Cyclosporine
,12682891,plasma trough concentration (C(0)),"MPA plasma trough concentration (C(0)), maximal concentration, and AUC(0-7) values ranged 9- to 14-fold at a median of 1.81 mg/L (range, 0.4 to 3.7 mg/L), 10.5 mg/L (range, 2.8 to 40.0 mg/L), and 30.2 mg/L.hr (range, 9.3 to 80.3 mg/L.hr), respectively.",Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682891/),[mg] / [l],1.81,99872,DB00091,Cyclosporine
,12682891,maximal concentration,"MPA plasma trough concentration (C(0)), maximal concentration, and AUC(0-7) values ranged 9- to 14-fold at a median of 1.81 mg/L (range, 0.4 to 3.7 mg/L), 10.5 mg/L (range, 2.8 to 40.0 mg/L), and 30.2 mg/L.hr (range, 9.3 to 80.3 mg/L.hr), respectively.",Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682891/),[mg] / [l],10.5,99873,DB00091,Cyclosporine
,12682891,AUC(0-7),"MPA plasma trough concentration (C(0)), maximal concentration, and AUC(0-7) values ranged 9- to 14-fold at a median of 1.81 mg/L (range, 0.4 to 3.7 mg/L), 10.5 mg/L (range, 2.8 to 40.0 mg/L), and 30.2 mg/L.hr (range, 9.3 to 80.3 mg/L.hr), respectively.",Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682891/),[mg] / [h·l],30.2,99874,DB00091,Cyclosporine
,12682891,AUC(0-7),Median AUC(0-7) (29.6 v 31.4 mg/L.hr; P =.918) was similar in children comedicated with CsA or Tac.,Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682891/),[mg] / [h·l],29.6,99875,DB00091,Cyclosporine
,12682891,AUC(0-7),Median AUC(0-7) (29.6 v 31.4 mg/L.hr; P =.918) was similar in children comedicated with CsA or Tac.,Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682891/),[mg] / [h·l],31.4,99876,DB00091,Cyclosporine
,12682891,AUC(0-7),"Consequently, median AUC(0-7) was significantly lower in the CsA group when equalized for dose and body weight (2.02 v 3.85 microg/L.hr per mg of MMF dose per kg of weight; P =.002).",Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682891/),[μg] / [h·l·mg],2.02,99877,DB00091,Cyclosporine
,12682891,AUC(0-7),"Consequently, median AUC(0-7) was significantly lower in the CsA group when equalized for dose and body weight (2.02 v 3.85 microg/L.hr per mg of MMF dose per kg of weight; P =.002).",Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682891/),[μg] / [h·l·mg],3.85,99878,DB00091,Cyclosporine
,25481447,localization,Topical application of SP50 significantly increased the localization of CsA in the target skin (113.1±13.6(μg/g)/mg) compared to all other groups (p<0.01).,Topical delivery of Cyclosporine A into the skin using SPACE-peptide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25481447/),,113.1,100163,DB00091,Cyclosporine
,25481447,skin/blood ratio,"In addition, SP50 led to significantly higher skin/blood ratio (443.4±181.5) and skin/liver ratio (1059.5±110.8) of CsA compared to all other groups (p<0.01).",Topical delivery of Cyclosporine A into the skin using SPACE-peptide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25481447/),,443.4,100164,DB00091,Cyclosporine
,25481447,skin/liver ratio,"In addition, SP50 led to significantly higher skin/blood ratio (443.4±181.5) and skin/liver ratio (1059.5±110.8) of CsA compared to all other groups (p<0.01).",Topical delivery of Cyclosporine A into the skin using SPACE-peptide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25481447/),,1059.5,100165,DB00091,Cyclosporine
,8061359,AUC (0-6 h),"On the 1st study, the dose-adjusted Aza AUC (0-6 h) ranged from 8.4 to 129.1 ngh*ml-1/mg*kg-1, mean 41.4 (+/- 37.6) ngh*ml-1/mg*kg-1.",Day-to-day variability in azathioprine pharmacokinetics in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061359/),[ngh] / [kg·mg·ml],8.4 to 129.1,100723,DB00091,Cyclosporine
,8061359,AUC (0-6 h),"On the 1st study, the dose-adjusted Aza AUC (0-6 h) ranged from 8.4 to 129.1 ngh*ml-1/mg*kg-1, mean 41.4 (+/- 37.6) ngh*ml-1/mg*kg-1.",Day-to-day variability in azathioprine pharmacokinetics in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061359/),[ngh] / [kg·mg·ml],41.4,100724,DB00091,Cyclosporine
,8061359,AUC (0-6 h),"The corresponding values for the dose-adjusted 6-MP AUC (0-6 h) ranged from 37.9 to 172.0 ngh*ml-1/mg*kg-1, mean 91.7 (+/- 50.7) ngh*ml-1/mg*kg-1.",Day-to-day variability in azathioprine pharmacokinetics in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061359/),[ngh] / [kg·mg·ml],37.9 to 172.0,100725,DB00091,Cyclosporine
,8061359,AUC (0-6 h),"The corresponding values for the dose-adjusted 6-MP AUC (0-6 h) ranged from 37.9 to 172.0 ngh*ml-1/mg*kg-1, mean 91.7 (+/- 50.7) ngh*ml-1/mg*kg-1.",Day-to-day variability in azathioprine pharmacokinetics in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061359/),[ngh] / [kg·mg·ml],91.7,100726,DB00091,Cyclosporine
,8061359,half-life,The mean half-life of Aza was 1.7 h and of 6-MP 1.2 h.,Day-to-day variability in azathioprine pharmacokinetics in renal transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061359/),h,1.7,100727,DB00091,Cyclosporine
,8061359,half-life,The mean half-life of Aza was 1.7 h and of 6-MP 1.2 h.,Day-to-day variability in azathioprine pharmacokinetics in renal transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061359/),h,1.2,100728,DB00091,Cyclosporine
,2733278,bioavailability,"At the same time, the systemic clearance (CLs) of IV-CsA decreased by 43.9 +/- 8.2 per cent, the area under the concentration curve (AUC) of IV-CsA increased by 35.4 +/- 20.8 per cent and the bioavailability of CsA decreased by 26.4 +/- 14.8 per cent.",The influence of liver dysfunction on cyclosporine pharmacokinetics--a comparison between 70 per cent hepatectomy and complete bile duct ligation in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2733278/),%,26.4,100849,DB00091,Cyclosporine
,2733278,bioavailability,"During the same period, the AUC of PO-CsA decreased by 69.9 +/- 10.7 per cent and the bioavailability of CsA also decreased markedly by 73.9 +/- 15.6 per cent.",The influence of liver dysfunction on cyclosporine pharmacokinetics--a comparison between 70 per cent hepatectomy and complete bile duct ligation in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2733278/),%,73.9,100850,DB00091,Cyclosporine
,10694566,MTD,The MTD for paclitaxel with PSC 833 was 122.5 mg/m(2).,"Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10694566/),[mg] / [m(2],122.5,101073,DB00091,Cyclosporine
,9816119,area under the time versus concentration curve (AUC),Carboplatin was targeted to an area under the time versus concentration curve (AUC) of 6 mg/ml x min and was not dose escalated.,Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816119/),[mg] / [min·ml],6,101160,DB00091,Cyclosporine
,9816119,AUC,"Estimated median carboplatin AUC, based on calculated carboplatin clearance, was 7.9 mg/ml x min.",Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816119/),[mg] / [min·ml],7.9,101161,DB00091,Cyclosporine
,9816119,AUC,"Grade 3 or 4 thrombocytopenia occurred in 35% of the patients, which could be explained by the effects of carboplatin (AUC of 6 mg/ml x min) alone.",Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816119/),[mg] / [min·ml],6,101162,DB00091,Cyclosporine
,20406219,AUC(0-12),"MPA AUC(0-12) of patients with early biopsy-proven acute rejection was significantly lower compared with patients without a rejection (median MPA AUC(0-12) 28 microg*h ml(-1) (7-45) vs. 40 microg*h ml(-1) (16-130), P < 0.01), MPA AUC(0-12) of patients with recurrent infections was significantly higher compared with patients without infections (median MPA AUC(0-12) 65 microg*h ml(-1) (range 37-130) vs. 37 microg*h ml(-1) (range 7-120), P < 0.005).",Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20406219/),[h·μg] / [ml],28,101581,DB00091,Cyclosporine
,20406219,AUC(0-12),"MPA AUC(0-12) of patients with early biopsy-proven acute rejection was significantly lower compared with patients without a rejection (median MPA AUC(0-12) 28 microg*h ml(-1) (7-45) vs. 40 microg*h ml(-1) (16-130), P < 0.01), MPA AUC(0-12) of patients with recurrent infections was significantly higher compared with patients without infections (median MPA AUC(0-12) 65 microg*h ml(-1) (range 37-130) vs. 37 microg*h ml(-1) (range 7-120), P < 0.005).",Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20406219/),[h·μg] / [ml],40,101582,DB00091,Cyclosporine
,20406219,AUC(0-12),"MPA AUC(0-12) of patients with early biopsy-proven acute rejection was significantly lower compared with patients without a rejection (median MPA AUC(0-12) 28 microg*h ml(-1) (7-45) vs. 40 microg*h ml(-1) (16-130), P < 0.01), MPA AUC(0-12) of patients with recurrent infections was significantly higher compared with patients without infections (median MPA AUC(0-12) 65 microg*h ml(-1) (range 37-130) vs. 37 microg*h ml(-1) (range 7-120), P < 0.005).",Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20406219/),[h·μg] / [ml],65,101583,DB00091,Cyclosporine
,20406219,AUC(0-12),"MPA AUC(0-12) of patients with early biopsy-proven acute rejection was significantly lower compared with patients without a rejection (median MPA AUC(0-12) 28 microg*h ml(-1) (7-45) vs. 40 microg*h ml(-1) (16-130), P < 0.01), MPA AUC(0-12) of patients with recurrent infections was significantly higher compared with patients without infections (median MPA AUC(0-12) 65 microg*h ml(-1) (range 37-130) vs. 37 microg*h ml(-1) (range 7-120), P < 0.005).",Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20406219/),[h·μg] / [ml],37,101584,DB00091,Cyclosporine
,20406219,AEC(0-12),"Low 12-h IMPDH enzyme activity curve (AEC(0-12)) was associated with an increased frequency of gastrointestinal side-effects (median IMPDH AEC(0-12) 43 nmol*h mg(-1) protein h(-1)[range 12-67) vs. 75 nmol*h mg(-1) protein h(-1) (range 15-371), P < 0.01].",Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20406219/),[h·nM] / [h·mg],43,101585,DB00091,Cyclosporine
,20406219,AEC(0-12),"Low 12-h IMPDH enzyme activity curve (AEC(0-12)) was associated with an increased frequency of gastrointestinal side-effects (median IMPDH AEC(0-12) 43 nmol*h mg(-1) protein h(-1)[range 12-67) vs. 75 nmol*h mg(-1) protein h(-1) (range 15-371), P < 0.01].",Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20406219/),[h·nM] / [h·mg],75,101586,DB00091,Cyclosporine
,20406219,AUC(0-12),"Regarding adverse events, the suggested MPA-target AUC(0-12) from 30 to 60 microg*h ml(-1) seems to be appropriate in renal allograft recipients.",Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20406219/),[h·μg] / [ml],30 to 60,101587,DB00091,Cyclosporine
,11427455,c(min),"The following PK parameters were increased in the side-effects group compared with the non-side effects group: mean MPA c(min), 2.63 +/- 1.58 vs 1.75 +/- 0.82 mg/L (P = 0.016); mean c(30), 10.47 +/- 6.27 vs 7.66 +/- 8.95 mg/L (P = 0.009); mean c(60), 9.67 +/- 5.42 vs 5.83 +/- 2.6 mg/L (P = 0.0002); mean area under the MPA time-concentration curve from 0 to 12 h [MPA-AUC((0-12))], 48.38 +/- 18.5 vs 36.04 +/- 10.82 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[mg] / [l],2.63,101864,DB00091,Cyclosporine
,11427455,c(min),"The following PK parameters were increased in the side-effects group compared with the non-side effects group: mean MPA c(min), 2.63 +/- 1.58 vs 1.75 +/- 0.82 mg/L (P = 0.016); mean c(30), 10.47 +/- 6.27 vs 7.66 +/- 8.95 mg/L (P = 0.009); mean c(60), 9.67 +/- 5.42 vs 5.83 +/- 2.6 mg/L (P = 0.0002); mean area under the MPA time-concentration curve from 0 to 12 h [MPA-AUC((0-12))], 48.38 +/- 18.5 vs 36.04 +/- 10.82 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[mg] / [l],1.75,101865,DB00091,Cyclosporine
,11427455,c(30),"The following PK parameters were increased in the side-effects group compared with the non-side effects group: mean MPA c(min), 2.63 +/- 1.58 vs 1.75 +/- 0.82 mg/L (P = 0.016); mean c(30), 10.47 +/- 6.27 vs 7.66 +/- 8.95 mg/L (P = 0.009); mean c(60), 9.67 +/- 5.42 vs 5.83 +/- 2.6 mg/L (P = 0.0002); mean area under the MPA time-concentration curve from 0 to 12 h [MPA-AUC((0-12))], 48.38 +/- 18.5 vs 36.04 +/- 10.82 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[mg] / [l],10.47,101866,DB00091,Cyclosporine
,11427455,c(30),"The following PK parameters were increased in the side-effects group compared with the non-side effects group: mean MPA c(min), 2.63 +/- 1.58 vs 1.75 +/- 0.82 mg/L (P = 0.016); mean c(30), 10.47 +/- 6.27 vs 7.66 +/- 8.95 mg/L (P = 0.009); mean c(60), 9.67 +/- 5.42 vs 5.83 +/- 2.6 mg/L (P = 0.0002); mean area under the MPA time-concentration curve from 0 to 12 h [MPA-AUC((0-12))], 48.38 +/- 18.5 vs 36.04 +/- 10.82 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[mg] / [l],7.66,101867,DB00091,Cyclosporine
,11427455,c(60),"The following PK parameters were increased in the side-effects group compared with the non-side effects group: mean MPA c(min), 2.63 +/- 1.58 vs 1.75 +/- 0.82 mg/L (P = 0.016); mean c(30), 10.47 +/- 6.27 vs 7.66 +/- 8.95 mg/L (P = 0.009); mean c(60), 9.67 +/- 5.42 vs 5.83 +/- 2.6 mg/L (P = 0.0002); mean area under the MPA time-concentration curve from 0 to 12 h [MPA-AUC((0-12))], 48.38 +/- 18.5 vs 36.04 +/- 10.82 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[mg] / [l],9.67,101868,DB00091,Cyclosporine
,11427455,c(60),"The following PK parameters were increased in the side-effects group compared with the non-side effects group: mean MPA c(min), 2.63 +/- 1.58 vs 1.75 +/- 0.82 mg/L (P = 0.016); mean c(30), 10.47 +/- 6.27 vs 7.66 +/- 8.95 mg/L (P = 0.009); mean c(60), 9.67 +/- 5.42 vs 5.83 +/- 2.6 mg/L (P = 0.0002); mean area under the MPA time-concentration curve from 0 to 12 h [MPA-AUC((0-12))], 48.38 +/- 18.5 vs 36.04 +/- 10.82 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[mg] / [l],5.83,101869,DB00091,Cyclosporine
,11427455,-AUC((0-12))],"The following PK parameters were increased in the side-effects group compared with the non-side effects group: mean MPA c(min), 2.63 +/- 1.58 vs 1.75 +/- 0.82 mg/L (P = 0.016); mean c(30), 10.47 +/- 6.27 vs 7.66 +/- 8.95 mg/L (P = 0.009); mean c(60), 9.67 +/- 5.42 vs 5.83 +/- 2.6 mg/L (P = 0.0002); mean area under the MPA time-concentration curve from 0 to 12 h [MPA-AUC((0-12))], 48.38 +/- 18.5 vs 36.04 +/- 10.82 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),mg,48.38,101870,DB00091,Cyclosporine
,11427455,-AUC((0-12))],"The following PK parameters were increased in the side-effects group compared with the non-side effects group: mean MPA c(min), 2.63 +/- 1.58 vs 1.75 +/- 0.82 mg/L (P = 0.016); mean c(30), 10.47 +/- 6.27 vs 7.66 +/- 8.95 mg/L (P = 0.009); mean c(60), 9.67 +/- 5.42 vs 5.83 +/- 2.6 mg/L (P = 0.0002); mean area under the MPA time-concentration curve from 0 to 12 h [MPA-AUC((0-12))], 48.38 +/- 18.5 vs 36.04 +/- 10.82 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),mg,36.04,101871,DB00091,Cyclosporine
,11427455,dose-normalized MP,"h/L (P = 0.0006); mean dose-normalized MPA-AUC, 0.16 +/- 0.05 vs 0.12 +/- 0.04 (mg. h/L)/(mg/m(2)) (P = 0.0015).",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[h·l·mg·mg] / [m(2],0.16,101872,DB00091,Cyclosporine
,11427455,-AUC,"h/L (P = 0.0006); mean dose-normalized MPA-AUC, 0.16 +/- 0.05 vs 0.12 +/- 0.04 (mg. h/L)/(mg/m(2)) (P = 0.0015).",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[h·l·mg·mg] / [m(2],0.16,101873,DB00091,Cyclosporine
,11427455,-AUC,"h/L (P = 0.0006); mean dose-normalized MPA-AUC, 0.16 +/- 0.05 vs 0.12 +/- 0.04 (mg. h/L)/(mg/m(2)) (P = 0.0015).",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[h·l·mg·mg] / [m(2],0.12,101874,DB00091,Cyclosporine
,11427455,c(min),"For the three AR patients, MPA concentrations obtained at the time of AR revealed MPA c(min) values of 1.86, 1.76, and 3.83 mg/L, respectively, and MPA-AUC((0-12)) values of 37.7, 24.9, and 104.9 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[mg] / [l],1.86,101875,DB00091,Cyclosporine
,11427455,c(min),"For the three AR patients, MPA concentrations obtained at the time of AR revealed MPA c(min) values of 1.86, 1.76, and 3.83 mg/L, respectively, and MPA-AUC((0-12)) values of 37.7, 24.9, and 104.9 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[mg] / [l],1.76,101876,DB00091,Cyclosporine
,11427455,c(min),"For the three AR patients, MPA concentrations obtained at the time of AR revealed MPA c(min) values of 1.86, 1.76, and 3.83 mg/L, respectively, and MPA-AUC((0-12)) values of 37.7, 24.9, and 104.9 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[mg] / [l],3.83,101877,DB00091,Cyclosporine
,11427455,AUC((0-12)),"For the three AR patients, MPA concentrations obtained at the time of AR revealed MPA c(min) values of 1.86, 1.76, and 3.83 mg/L, respectively, and MPA-AUC((0-12)) values of 37.7, 24.9, and 104.9 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),mg,37.7,101878,DB00091,Cyclosporine
,11427455,AUC((0-12)),"For the three AR patients, MPA concentrations obtained at the time of AR revealed MPA c(min) values of 1.86, 1.76, and 3.83 mg/L, respectively, and MPA-AUC((0-12)) values of 37.7, 24.9, and 104.9 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),mg,24.9,101879,DB00091,Cyclosporine
,11427455,AUC((0-12)),"For the three AR patients, MPA concentrations obtained at the time of AR revealed MPA c(min) values of 1.86, 1.76, and 3.83 mg/L, respectively, and MPA-AUC((0-12)) values of 37.7, 24.9, and 104.9 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),mg,104.9,101880,DB00091,Cyclosporine
,11427455,maximum,"h/L. The threshold of toxicity was 3 mg/L (sensitivity, 38.7%; specificity, 91.5%) for c(min), 8.09 mg/L for maximum MPA concentration during the first hour (sensitivity, 77.8%; specificity, 67.4%), and 37.6 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[mg] / [l],8.,101881,DB00091,Cyclosporine
,6839005,terminal half-life,Blood CyA concentrations declined bi-exponentially with a terminal half-life of 13.1 +/- 1.8 h.,Pharmacokinetic evaluation of the blood-to-lymph transfer of cyclosporin A in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6839005/),h,13.1,102292,DB00091,Cyclosporine
,6839005,blood-to-lymph clearance rate of CyA (ClL)b,"From the slopes of graphs relating the appearance rate of CyA in the lymph to the corresponding midpoint blood drug concentration, the estimated blood-to-lymph clearance rate of CyA (ClL)b was 0.262 +/- 0.132 ml h-1.",Pharmacokinetic evaluation of the blood-to-lymph transfer of cyclosporin A in rats. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6839005/),[ml] / [h],0.262,102293,DB00091,Cyclosporine
,6839005,plasma-to-lymph clearance rate of,"On the other hand, the plasma-to-lymph clearance rate of CyA (ClL)p of 0.393 +/- 0.198 ml h-1 was positively correlated and similar to QL.",Pharmacokinetic evaluation of the blood-to-lymph transfer of cyclosporin A in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6839005/),[ml] / [h],0.393,102294,DB00091,Cyclosporine
,6839005,Lymph concentrations,Lymph concentrations of CyA were approximately 40-60 per cent of the corresponding blood concentrations.,Pharmacokinetic evaluation of the blood-to-lymph transfer of cyclosporin A in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6839005/),%,40-60,102295,DB00091,Cyclosporine
,26372815,efflux ratio,"Reduction in testosterone and DTX metabolism (twofold increase in half-life) by PPL was comparable to the standard CYP3A4 inhibitor, cyclosporine A. P-gp efflux ratio of DTX across caco-2 monolayer was reduced from 2.37 to 1.52 on co-incubation with PPL.",Piperlongumine for Enhancing Oral Bioavailability and Cytotoxicity of Docetaxel in Triple-Negative Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26372815/),,2.37,102339,DB00091,Cyclosporine
,26372815,efflux ratio,"Reduction in testosterone and DTX metabolism (twofold increase in half-life) by PPL was comparable to the standard CYP3A4 inhibitor, cyclosporine A. P-gp efflux ratio of DTX across caco-2 monolayer was reduced from 2.37 to 1.52 on co-incubation with PPL.",Piperlongumine for Enhancing Oral Bioavailability and Cytotoxicity of Docetaxel in Triple-Negative Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26372815/),,1.52,102340,DB00091,Cyclosporine
below,26372815,combination index,The IC50 value of DTX was reduced three to five times and combination index values in all the cell lines were below 0.6.,Piperlongumine for Enhancing Oral Bioavailability and Cytotoxicity of Docetaxel in Triple-Negative Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26372815/),,0.6,102341,DB00091,Cyclosporine
,9203180,time to reach Cmax,"We observed an increase in the maximum CYA concentration (Cmax) of 114%, an increase in area under the curve (AUC) of 71% and the time to reach Cmax was reduced from 1.75 h to 1.25 h with NEO, while 12-h trough levels (C12 h) did not change significantly.",Comparison of Neoral and Sandimmun cyclosporin A pharmacokinetic profiles in young renal transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9203180/),h,1.75,102528,DB00091,Cyclosporine
,9203180,time to reach Cmax,"We observed an increase in the maximum CYA concentration (Cmax) of 114%, an increase in area under the curve (AUC) of 71% and the time to reach Cmax was reduced from 1.75 h to 1.25 h with NEO, while 12-h trough levels (C12 h) did not change significantly.",Comparison of Neoral and Sandimmun cyclosporin A pharmacokinetic profiles in young renal transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9203180/),h,1.25,102529,DB00091,Cyclosporine
,2516344,CIN,Mean CIN of rats coadministered CSA and PTX (942 +/- 214 microliters/min/g KW) was similar to control rats 884 +/- 185 microliters/min/g KW); both were significantly greater than CSA alone (537 +/- 211 microliters/min/g KW; p less than .01).,Prevention of cyclosporine-induced nephrotoxicity with pentoxifylline. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2516344/),[μl] / [g·min],942,102658,DB00091,Cyclosporine
,2516344,CIN,Mean CIN of rats coadministered CSA and PTX (942 +/- 214 microliters/min/g KW) was similar to control rats 884 +/- 185 microliters/min/g KW); both were significantly greater than CSA alone (537 +/- 211 microliters/min/g KW; p less than .01).,Prevention of cyclosporine-induced nephrotoxicity with pentoxifylline. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2516344/),[μl] / [g·min],884,102659,DB00091,Cyclosporine
,2516344,CIN,Mean CIN of rats coadministered CSA and PTX (942 +/- 214 microliters/min/g KW) was similar to control rats 884 +/- 185 microliters/min/g KW); both were significantly greater than CSA alone (537 +/- 211 microliters/min/g KW; p less than .01).,Prevention of cyclosporine-induced nephrotoxicity with pentoxifylline. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2516344/),[μl] / [g·min],537,102660,DB00091,Cyclosporine
,11072195,size ratios,"Nonetheless, the final to initial size ratios ( approximately 1.5) indicated that particle size was slightly affected in both cases.","Freeze-drying of polycaprolactone and poly(D,L-lactic-glycolic) nanoparticles induce minor particle size changes affecting the oral pharmacokinetics of loaded drugs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11072195/),,1.5,102861,DB00091,Cyclosporine
,10361143,relative bioavailability,"The relative bioavailability of cyclosporin A from nanospheres was only 3%, based on comparison of the area under the blood concentration-time curve (AUC) values for the two formulations.",Nanospheres of cyclosporin A: poor oral absorption in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10361143/),%,3,103086,DB00091,Cyclosporine
,8693548,peak blood CsA concentration,"Five days after the conversion, the mean peak blood CsA concentration was higher (microemulsion: 963 ng/ml, range: 518-1864 ng/ml; conventional: 431 ng/ml, range: 98-888 ng/ml; P<0.0001) and it was reached faster (median time of peak concentration: 1.6 hr vs. 2.9 hr, range: 1.0-3.0 hr vs. 1.9-4.0 hr; P=0.0009).",Comparison of conventional oral cyclosporine and cyclosporine microemulsion formulations in children with a liver transplant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8693548/),[ng] / [ml],963,103229,DB00091,Cyclosporine
,8693548,peak blood CsA concentration,"Five days after the conversion, the mean peak blood CsA concentration was higher (microemulsion: 963 ng/ml, range: 518-1864 ng/ml; conventional: 431 ng/ml, range: 98-888 ng/ml; P<0.0001) and it was reached faster (median time of peak concentration: 1.6 hr vs. 2.9 hr, range: 1.0-3.0 hr vs. 1.9-4.0 hr; P=0.0009).",Comparison of conventional oral cyclosporine and cyclosporine microemulsion formulations in children with a liver transplant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8693548/),[ng] / [ml],431,103230,DB00091,Cyclosporine
,8693548,time of peak concentration,"Five days after the conversion, the mean peak blood CsA concentration was higher (microemulsion: 963 ng/ml, range: 518-1864 ng/ml; conventional: 431 ng/ml, range: 98-888 ng/ml; P<0.0001) and it was reached faster (median time of peak concentration: 1.6 hr vs. 2.9 hr, range: 1.0-3.0 hr vs. 1.9-4.0 hr; P=0.0009).",Comparison of conventional oral cyclosporine and cyclosporine microemulsion formulations in children with a liver transplant. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8693548/),h,1.6,103231,DB00091,Cyclosporine
,8693548,time of peak concentration,"Five days after the conversion, the mean peak blood CsA concentration was higher (microemulsion: 963 ng/ml, range: 518-1864 ng/ml; conventional: 431 ng/ml, range: 98-888 ng/ml; P<0.0001) and it was reached faster (median time of peak concentration: 1.6 hr vs. 2.9 hr, range: 1.0-3.0 hr vs. 1.9-4.0 hr; P=0.0009).",Comparison of conventional oral cyclosporine and cyclosporine microemulsion formulations in children with a liver transplant. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8693548/),h,2.9,103232,DB00091,Cyclosporine
,8693548,time of peak concentration,"Five days after the conversion, the mean peak blood CsA concentration was higher (microemulsion: 963 ng/ml, range: 518-1864 ng/ml; conventional: 431 ng/ml, range: 98-888 ng/ml; P<0.0001) and it was reached faster (median time of peak concentration: 1.6 hr vs. 2.9 hr, range: 1.0-3.0 hr vs. 1.9-4.0 hr; P=0.0009).",Comparison of conventional oral cyclosporine and cyclosporine microemulsion formulations in children with a liver transplant. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8693548/),h,1.9-4.0,103233,DB00091,Cyclosporine
,23217391,maximum plasma concentration,"The mean maximum plasma concentration, the mean time for it to reach peak (T(max)), and the mean MPA AUC were (11.38 ± 2.49) mg/L, (4.85 ± 3.32) hours, and (63.19 ± 13.54) mg×h×L(-1), respectively.",Pharmacokinetics of enteric-coated mycophenolate sodium in Chinese renal transplantation recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23217391/),[mg] / [l],11.38,103247,DB00091,Cyclosporine
,23217391,time for it to reach peak (T(max)),"The mean maximum plasma concentration, the mean time for it to reach peak (T(max)), and the mean MPA AUC were (11.38 ± 2.49) mg/L, (4.85 ± 3.32) hours, and (63.19 ± 13.54) mg×h×L(-1), respectively.",Pharmacokinetics of enteric-coated mycophenolate sodium in Chinese renal transplantation recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23217391/),h,4.85,103248,DB00091,Cyclosporine
,23217391,AUC,"The mean maximum plasma concentration, the mean time for it to reach peak (T(max)), and the mean MPA AUC were (11.38 ± 2.49) mg/L, (4.85 ± 3.32) hours, and (63.19 ± 13.54) mg×h×L(-1), respectively.",Pharmacokinetics of enteric-coated mycophenolate sodium in Chinese renal transplantation recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23217391/),[h·mg] / [l],63.19,103249,DB00091,Cyclosporine
,17175302,trough level (C0),At study entry tacrolimus trough level (C0) was 7.9 +/- 3.9 ng/mL and area under the curve over a dosing interval (AUC) was 132 +/- 56 ng x h/mL.,Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[ng] / [ml],7.9,103909,DB00091,Cyclosporine
,17175302,area under the curve over a dosing interval (AUC),At study entry tacrolimus trough level (C0) was 7.9 +/- 3.9 ng/mL and area under the curve over a dosing interval (AUC) was 132 +/- 56 ng x h/mL.,Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[h·ng] / [ml],132,103910,DB00091,Cyclosporine
,17175302,C0,"The addition of everolimus in period 1 did not change tacrolimus exposure: C0 8.4 +/- 4.0 ng/mL, AUC 134 +/- 70 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[ng] / [ml],8.4,103911,DB00091,Cyclosporine
,17175302,AUC,"The addition of everolimus in period 1 did not change tacrolimus exposure: C0 8.4 +/- 4.0 ng/mL, AUC 134 +/- 70 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[h·ng] / [ml],134,103912,DB00091,Cyclosporine
,17175302,C0,"Everolimus pharmacokinetics in the presence of tacrolimus in period 1 were: C0 3.3 +/- 1.2 ng/mL, Cmax 10.4 +/- 5.1 ng/mL, AUC 58 +/- 20 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[ng] / [ml],3.3,103913,DB00091,Cyclosporine
,17175302,Cmax,"Everolimus pharmacokinetics in the presence of tacrolimus in period 1 were: C0 3.3 +/- 1.2 ng/mL, Cmax 10.4 +/- 5.1 ng/mL, AUC 58 +/- 20 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[ng] / [ml],10.4,103914,DB00091,Cyclosporine
,17175302,AUC,"Everolimus pharmacokinetics in the presence of tacrolimus in period 1 were: C0 3.3 +/- 1.2 ng/mL, Cmax 10.4 +/- 5.1 ng/mL, AUC 58 +/- 20 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[h·ng] / [ml],58,103915,DB00091,Cyclosporine
,17175302,C0,"After tacrolimus dose reduction in period 2, there was no clinically relevant change in everolimus exposure: C0 3.0 +/- 1.1 ng/mL, Cmax 8.2 +/- 1.3 ng/mL, AUC 49 +/- 10 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[ng] / [ml],3.0,103916,DB00091,Cyclosporine
,17175302,Cmax,"After tacrolimus dose reduction in period 2, there was no clinically relevant change in everolimus exposure: C0 3.0 +/- 1.1 ng/mL, Cmax 8.2 +/- 1.3 ng/mL, AUC 49 +/- 10 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[ng] / [ml],8.2,103917,DB00091,Cyclosporine
,17175302,AUC,"After tacrolimus dose reduction in period 2, there was no clinically relevant change in everolimus exposure: C0 3.0 +/- 1.1 ng/mL, Cmax 8.2 +/- 1.3 ng/mL, AUC 49 +/- 10 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[h·ng] / [ml],49,103918,DB00091,Cyclosporine
,9384468,maximum dose,"Eight stable kidney transplant recipients maintained on cyclosporin but not taking diltiazem, were given increasing doses of diltiazem to a maximum dose of 180 mg day(-1).",Diltiazem-cyclosporin pharmacokinetic interaction--dose-response relationship. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9384468/),[mg] / [day],180,104420,DB00091,Cyclosporine
,12810356,area under the curve of the first 4 h (AUC(0-4)),"The area under the curve of the first 4 h (AUC(0-4)), trough (C(0)) and 2 h (C(2)) levels showed median values of 1655 ng x h/ml, 114 ng/ml and 384 ng/ml, respectively.",Pharmacokinetic and pharmacodynamic correlations of cyclosporine therapy in stable renal transplant patients: evaluation of long-term target C(2). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12810356/),[h·ng] / [ml],1655,104496,DB00091,Cyclosporine
,12810356,trough (C(0)),"The area under the curve of the first 4 h (AUC(0-4)), trough (C(0)) and 2 h (C(2)) levels showed median values of 1655 ng x h/ml, 114 ng/ml and 384 ng/ml, respectively.",Pharmacokinetic and pharmacodynamic correlations of cyclosporine therapy in stable renal transplant patients: evaluation of long-term target C(2). ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12810356/),[ng] / [ml],114,104497,DB00091,Cyclosporine
,12810356,2 h (C(2)),"The area under the curve of the first 4 h (AUC(0-4)), trough (C(0)) and 2 h (C(2)) levels showed median values of 1655 ng x h/ml, 114 ng/ml and 384 ng/ml, respectively.",Pharmacokinetic and pharmacodynamic correlations of cyclosporine therapy in stable renal transplant patients: evaluation of long-term target C(2). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12810356/),[ng] / [ml],384,104498,DB00091,Cyclosporine
,12810356,IL-2,"IL-2 production was 349 pg/ml at 0 h and 276.35 pg/ml at 2 h; both results were significantly lower (reductions of 44.5% and 56.1%, respectively; p=0.04 and 0.005) than the controls of 629.1 pg/ml.",Pharmacokinetic and pharmacodynamic correlations of cyclosporine therapy in stable renal transplant patients: evaluation of long-term target C(2). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12810356/),[pg] / [ml],349,104499,DB00091,Cyclosporine
,12810356,IL-2,"IL-2 production was 349 pg/ml at 0 h and 276.35 pg/ml at 2 h; both results were significantly lower (reductions of 44.5% and 56.1%, respectively; p=0.04 and 0.005) than the controls of 629.1 pg/ml.",Pharmacokinetic and pharmacodynamic correlations of cyclosporine therapy in stable renal transplant patients: evaluation of long-term target C(2). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12810356/),[pg] / [ml],276.35,104500,DB00091,Cyclosporine
,12810356,production,"IL-2 production was 349 pg/ml at 0 h and 276.35 pg/ml at 2 h; both results were significantly lower (reductions of 44.5% and 56.1%, respectively; p=0.04 and 0.005) than the controls of 629.1 pg/ml.",Pharmacokinetic and pharmacodynamic correlations of cyclosporine therapy in stable renal transplant patients: evaluation of long-term target C(2). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12810356/),[pg] / [ml],349,104501,DB00091,Cyclosporine
,12810356,production,"IL-2 production was 349 pg/ml at 0 h and 276.35 pg/ml at 2 h; both results were significantly lower (reductions of 44.5% and 56.1%, respectively; p=0.04 and 0.005) than the controls of 629.1 pg/ml.",Pharmacokinetic and pharmacodynamic correlations of cyclosporine therapy in stable renal transplant patients: evaluation of long-term target C(2). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12810356/),[pg] / [ml],276.35,104502,DB00091,Cyclosporine
,12810356,IFN-gamma,"IFN-gamma at 2 h post-dose (8.16 UI/ml) was significantly lower (72.1% reduction, p=0.005) than in controls (29.2 UI/ml).",Pharmacokinetic and pharmacodynamic correlations of cyclosporine therapy in stable renal transplant patients: evaluation of long-term target C(2). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12810356/),[ui] / [ml],8.16,104503,DB00091,Cyclosporine
,12810356,IFN-gamma,"IFN-gamma at 2 h post-dose (8.16 UI/ml) was significantly lower (72.1% reduction, p=0.005) than in controls (29.2 UI/ml).",Pharmacokinetic and pharmacodynamic correlations of cyclosporine therapy in stable renal transplant patients: evaluation of long-term target C(2). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12810356/),u,29.2,104504,DB00091,Cyclosporine
,12810356,C(2),"In treated patients, the Emax inhibitory sigmoidal model showed that a C(2) of 279 ng/ml was needed to achieve a 50% inhibition (EC50) of IL-2 and INF-gamma production.",Pharmacokinetic and pharmacodynamic correlations of cyclosporine therapy in stable renal transplant patients: evaluation of long-term target C(2). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12810356/),[ng] / [ml],279,104505,DB00091,Cyclosporine
,12810356,C(2),"A median C(2) value of 384 ng/ml was associated with a good degree of inhibition of CNa and IL-2 and IFN-gamma synthesis, and the lack of rejection episodes and relevant toxicity.",Pharmacokinetic and pharmacodynamic correlations of cyclosporine therapy in stable renal transplant patients: evaluation of long-term target C(2). ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12810356/),[ng] / [ml],384,104506,DB00091,Cyclosporine
,10071349,Cmax,"Mean peak cyclosporine levels were higher and were achieved significantly sooner with Neoral (Cmax 790.5 +/- 216.5 ng/mL, P =.06; Tmax 1.8 +/- 1.0 hr, P =.01) than with Sandimmune (Cmax 589.4 +/- 313 ng/mL, Tmax 2.5 +/- 1.7 hr), implying more rapid and better absorption.",Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071349/),[ng] / [ml],790.5,104602,DB00091,Cyclosporine
,10071349,Tmax,"Mean peak cyclosporine levels were higher and were achieved significantly sooner with Neoral (Cmax 790.5 +/- 216.5 ng/mL, P =.06; Tmax 1.8 +/- 1.0 hr, P =.01) than with Sandimmune (Cmax 589.4 +/- 313 ng/mL, Tmax 2.5 +/- 1.7 hr), implying more rapid and better absorption.",Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071349/),h,1.8,104603,DB00091,Cyclosporine
,10071349,Cmax,"Mean peak cyclosporine levels were higher and were achieved significantly sooner with Neoral (Cmax 790.5 +/- 216.5 ng/mL, P =.06; Tmax 1.8 +/- 1.0 hr, P =.01) than with Sandimmune (Cmax 589.4 +/- 313 ng/mL, Tmax 2.5 +/- 1.7 hr), implying more rapid and better absorption.",Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071349/),[ng] / [ml],589.4,104604,DB00091,Cyclosporine
,10071349,Tmax,"Mean peak cyclosporine levels were higher and were achieved significantly sooner with Neoral (Cmax 790.5 +/- 216.5 ng/mL, P =.06; Tmax 1.8 +/- 1.0 hr, P =.01) than with Sandimmune (Cmax 589.4 +/- 313 ng/mL, Tmax 2.5 +/- 1.7 hr), implying more rapid and better absorption.",Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071349/),h,2.5,104605,DB00091,Cyclosporine
,11139311,area under the plasma concentration-time curve (AUC),The mean area under the plasma concentration-time curve (AUC) of paclitaxel after oral drug administration in combination with GF120918 was 3.27 +/- 1.67 microM x h.,Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11139311/),h·μM,3.27,104794,DB00091,Cyclosporine
,11139311,AUC,In our previously performed study of 120 mg/m(2)oral paclitaxel in combination with CsA the mean AUC of paclitaxel was 2.55 +/- 2.29 microM x h.,Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11139311/),h·μM,2.55,104795,DB00091,Cyclosporine
,11139311,AUC,After i.v. administration of paclitaxel the mean AUC was 15.92( )+/- 2.46 microM x h.,Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11139311/),h·μM,15.92,104796,DB00091,Cyclosporine
,20161984,C(max),"The results of a pharmacokinetic study in beagle dogs showed improved absorption of CyA from cubic nanoparticles as compared to microemulsion-based Neoral((R)); higher C(max) (1371.18 +/- 37.34 vs 969.68 +/- 176.3 ng mL(-1)), higher AUC(0-t) (7757.21 +/- 1093.64 vs 4739.52 +/- 806.30 ng h mL(-1)) and AUC(0-infinity) (9004.77 +/- 1090.38 vs 5462.31 +/- 930.76 ng h mL(-1)).",Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20161984/),[ng] / [ml],1371.18,105009,DB00091,Cyclosporine
,20161984,C(max),"The results of a pharmacokinetic study in beagle dogs showed improved absorption of CyA from cubic nanoparticles as compared to microemulsion-based Neoral((R)); higher C(max) (1371.18 +/- 37.34 vs 969.68 +/- 176.3 ng mL(-1)), higher AUC(0-t) (7757.21 +/- 1093.64 vs 4739.52 +/- 806.30 ng h mL(-1)) and AUC(0-infinity) (9004.77 +/- 1090.38 vs 5462.31 +/- 930.76 ng h mL(-1)).",Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20161984/),[ng] / [ml],969.68,105010,DB00091,Cyclosporine
,20161984,AUC(0-t),"The results of a pharmacokinetic study in beagle dogs showed improved absorption of CyA from cubic nanoparticles as compared to microemulsion-based Neoral((R)); higher C(max) (1371.18 +/- 37.34 vs 969.68 +/- 176.3 ng mL(-1)), higher AUC(0-t) (7757.21 +/- 1093.64 vs 4739.52 +/- 806.30 ng h mL(-1)) and AUC(0-infinity) (9004.77 +/- 1090.38 vs 5462.31 +/- 930.76 ng h mL(-1)).",Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20161984/),[h·ng] / [ml],7757.21,105011,DB00091,Cyclosporine
,20161984,AUC(0-t),"The results of a pharmacokinetic study in beagle dogs showed improved absorption of CyA from cubic nanoparticles as compared to microemulsion-based Neoral((R)); higher C(max) (1371.18 +/- 37.34 vs 969.68 +/- 176.3 ng mL(-1)), higher AUC(0-t) (7757.21 +/- 1093.64 vs 4739.52 +/- 806.30 ng h mL(-1)) and AUC(0-infinity) (9004.77 +/- 1090.38 vs 5462.31 +/- 930.76 ng h mL(-1)).",Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20161984/),[h·ng] / [ml],4739.52,105012,DB00091,Cyclosporine
,20161984,AUC(0-infinity),"The results of a pharmacokinetic study in beagle dogs showed improved absorption of CyA from cubic nanoparticles as compared to microemulsion-based Neoral((R)); higher C(max) (1371.18 +/- 37.34 vs 969.68 +/- 176.3 ng mL(-1)), higher AUC(0-t) (7757.21 +/- 1093.64 vs 4739.52 +/- 806.30 ng h mL(-1)) and AUC(0-infinity) (9004.77 +/- 1090.38 vs 5462.31 +/- 930.76 ng h mL(-1)).",Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20161984/),[h·ng] / [ml],9004.77,105013,DB00091,Cyclosporine
,20161984,AUC(0-infinity),"The results of a pharmacokinetic study in beagle dogs showed improved absorption of CyA from cubic nanoparticles as compared to microemulsion-based Neoral((R)); higher C(max) (1371.18 +/- 37.34 vs 969.68 +/- 176.3 ng mL(-1)), higher AUC(0-t) (7757.21 +/- 1093.64 vs 4739.52 +/- 806.30 ng h mL(-1)) and AUC(0-infinity) (9004.77 +/- 1090.38 vs 5462.31 +/- 930.76 ng h mL(-1)).",Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20161984/),[h·ng] / [ml],5462.31,105014,DB00091,Cyclosporine
,20161984,relative oral bioavailability,The relative oral bioavailability of CyA cubic nanoparticles calculated on the basis of AUC(0-infinity) was about 178% as compared to Neoral((R)).,Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20161984/),%,178,105015,DB00091,Cyclosporine
,22182476,time to platelet recovery,RAD001/CsA caused a more pronounced reduction of platelet counts to median 2 × 10(9)/L (range: 0-21 × 10(9)/L) and longer time to platelet recovery of 21 days (range: 14-24 days) compared with MMF/CsA.,Everolimus in combination with cyclosporin a as pre- and posttransplantation immunosuppressive therapy in nonmyeloablative allogeneic hematopoietic stem cell transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22182476/),d,21,105054,DB00091,Cyclosporine
,9402690,Cmin,"However, patients receiving tacrolimus and MMF displayed significantly higher levels (Cmin and area under the curve) of mycophenolic acid (MPA) than those receiving CsA (Sandimmune or Neoral) and the same dose of MMF (50.2 +/- 16.5 vs 32.1 +/- 16.7 micrograms h/ml AUC, p < 0.02).","Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402690/),[h·μg] / [ml],50.2,105168,DB00091,Cyclosporine
,9402690,area under the curve,"However, patients receiving tacrolimus and MMF displayed significantly higher levels (Cmin and area under the curve) of mycophenolic acid (MPA) than those receiving CsA (Sandimmune or Neoral) and the same dose of MMF (50.2 +/- 16.5 vs 32.1 +/- 16.7 micrograms h/ml AUC, p < 0.02).","Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402690/),[h·μg] / [ml],32.1,105169,DB00091,Cyclosporine
,9402690,AUC,"However, patients receiving tacrolimus and MMF displayed significantly higher levels (Cmin and area under the curve) of mycophenolic acid (MPA) than those receiving CsA (Sandimmune or Neoral) and the same dose of MMF (50.2 +/- 16.5 vs 32.1 +/- 16.7 micrograms h/ml AUC, p < 0.02).","Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402690/),[h·μg] / [ml],50.2,105170,DB00091,Cyclosporine
,9402690,AUC,"However, patients receiving tacrolimus and MMF displayed significantly higher levels (Cmin and area under the curve) of mycophenolic acid (MPA) than those receiving CsA (Sandimmune or Neoral) and the same dose of MMF (50.2 +/- 16.5 vs 32.1 +/- 16.7 micrograms h/ml AUC, p < 0.02).","Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402690/),[h·μg] / [ml],32.1,105171,DB00091,Cyclosporine
,9402690,AUC,"There were also significantly lower levels of the glucuronide metabolite of MPA (MPAG) (755 +/- 280 vs 1230 +/- 250 micrograms h/ml AUC, p = 0.02), suggesting a specific inhibition (either direct or indirect) of the conversion of MPA to MPAG in tacrolimus patients, as opposed to those receiving CsA.","Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402690/),[h·μg] / [ml],755,105172,DB00091,Cyclosporine
,9402690,AUC,"There were also significantly lower levels of the glucuronide metabolite of MPA (MPAG) (755 +/- 280 vs 1230 +/- 250 micrograms h/ml AUC, p = 0.02), suggesting a specific inhibition (either direct or indirect) of the conversion of MPA to MPAG in tacrolimus patients, as opposed to those receiving CsA.","Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402690/),[h·μg] / [ml],1230,105173,DB00091,Cyclosporine
,9402690,AUC,"There were also significantly lower levels of the glucuronide metabolite of MPA (MPAG) (755 +/- 280 vs 1230 +/- 250 micrograms h/ml AUC, p = 0.02), suggesting a specific inhibition (either direct or indirect) of the conversion of MPA to MPAG in tacrolimus patients, as opposed to those receiving CsA.","Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402690/),[h·μg] / [ml],250,105174,DB00091,Cyclosporine
,9402690,trough concentrations,Culture media containing MPA and tacrolimus equal to clinical therapeutic trough concentrations (10 ng/ml) were significantly more MLC inhibitory than CsA at equivalent clinical therapeutic trough concentrations (200 ng/ml) with equivalent MPA levels.,"Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402690/),[ng] / [ml],10,105175,DB00091,Cyclosporine
,9402690,trough concentrations,Culture media containing MPA and tacrolimus equal to clinical therapeutic trough concentrations (10 ng/ml) were significantly more MLC inhibitory than CsA at equivalent clinical therapeutic trough concentrations (200 ng/ml) with equivalent MPA levels.,"Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402690/),[ng] / [ml],200,105176,DB00091,Cyclosporine
,3125755,Peak plasma concentrations,"Peak plasma concentrations ranged from 435 to 1,542 ng/ml and were attained at between 2 and 6 hours in the apancreatic dogs, and concentrations from 602 to 4,414 ng/ml were attained at between 1 and 6 hours in the control dogs.",Cyclosporine absorption in apancreatic dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3125755/),[ng] / [ml],"435 to 1,542",105497,DB00091,Cyclosporine
,3125755,Peak plasma concentrations,"Peak plasma concentrations ranged from 435 to 1,542 ng/ml and were attained at between 2 and 6 hours in the apancreatic dogs, and concentrations from 602 to 4,414 ng/ml were attained at between 1 and 6 hours in the control dogs.",Cyclosporine absorption in apancreatic dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3125755/),[ng] / [ml],"602 to 4,414",105498,DB00091,Cyclosporine
,7819002,clearances,"At 48 months post transplant, the iothalamate clearances (mean +/- SD) were 57.9 +/- 26.8 ml/min per 1.73 m2 in the CSA group and 68.5 +/- 20.2 in the Pred/AZA group (P > 0.05).",Effect of cyclosporine A on long-term allograft function in pediatric renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7819002/),[ml] / [1.73·m2·min],57.9,105531,DB00091,Cyclosporine
,7819002,clearances,"At 48 months post transplant, the iothalamate clearances (mean +/- SD) were 57.9 +/- 26.8 ml/min per 1.73 m2 in the CSA group and 68.5 +/- 20.2 in the Pred/AZA group (P > 0.05).",Effect of cyclosporine A on long-term allograft function in pediatric renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7819002/),[ml] / [1.73·m2·min],68.5,105532,DB00091,Cyclosporine
,3541320,serum trough radio,The CsA serum trough radioimmunoassay (RIA) was relatively high among hepatotoxic patients with a mean value of 225 +/- 17 ng/ml.,Hepatobiliary and pancreatic complications of cyclosporine therapy in 466 renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3541320/),[ng] / [ml],225,105552,DB00091,Cyclosporine
,7747714,peak whole-blood CsA level,"Mean peak whole-blood CsA level at the highest CsA dose level was 919 ng/ml (range: 414-1,827) with a trough prior to Vbl injection of 451 ng/ml (range: 128-1,229).",Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7747714/),[ng] / [ml],919,105670,DB00091,Cyclosporine
,7747714,trough prior to Vbl injection,"Mean peak whole-blood CsA level at the highest CsA dose level was 919 ng/ml (range: 414-1,827) with a trough prior to Vbl injection of 451 ng/ml (range: 128-1,229).",Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7747714/),[ng] / [ml],451,105671,DB00091,Cyclosporine
,18492124,CL,"Pharmacokinetics was described adequately with a two-compartment model with lag time (population estimates: CL = 11.3 l h(-1); V(c) = 16.5 l; V(p) = 59.9 l; t(1/2) absorption = 0.78 h, t(lag) = 0.6 h).",Ciclosporin kinetics in children after stem cell transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18492124/),[l] / [h],11.3,106028,DB00091,Cyclosporine
,18492124,V(c),"Pharmacokinetics was described adequately with a two-compartment model with lag time (population estimates: CL = 11.3 l h(-1); V(c) = 16.5 l; V(p) = 59.9 l; t(1/2) absorption = 0.78 h, t(lag) = 0.6 h).",Ciclosporin kinetics in children after stem cell transplantation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18492124/),l,16.5,106029,DB00091,Cyclosporine
,18492124,V(p),"Pharmacokinetics was described adequately with a two-compartment model with lag time (population estimates: CL = 11.3 l h(-1); V(c) = 16.5 l; V(p) = 59.9 l; t(1/2) absorption = 0.78 h, t(lag) = 0.6 h).",Ciclosporin kinetics in children after stem cell transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18492124/),l,59.9,106030,DB00091,Cyclosporine
,18492124,t(1/2) absorption,"Pharmacokinetics was described adequately with a two-compartment model with lag time (population estimates: CL = 11.3 l h(-1); V(c) = 16.5 l; V(p) = 59.9 l; t(1/2) absorption = 0.78 h, t(lag) = 0.6 h).",Ciclosporin kinetics in children after stem cell transplantation. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18492124/),h,0.78,106031,DB00091,Cyclosporine
,18492124,t(lag),"Pharmacokinetics was described adequately with a two-compartment model with lag time (population estimates: CL = 11.3 l h(-1); V(c) = 16.5 l; V(p) = 59.9 l; t(1/2) absorption = 0.78 h, t(lag) = 0.6 h).",Ciclosporin kinetics in children after stem cell transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18492124/),h,0.6,106032,DB00091,Cyclosporine
,25708713,half-lives,"Cyclosporine and tacrolimus half-lives increased from 7 to 25 h and 32 to 232 h, respectively.","Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25708713/),h,7 to 25,106418,DB00091,Cyclosporine
,25708713,half-lives,"Cyclosporine and tacrolimus half-lives increased from 7 to 25 h and 32 to 232 h, respectively.","Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25708713/),h,32 to 232,106419,DB00091,Cyclosporine
,16936114,drug-loading,"The CyS-PLGA-MS was produced, with drug-loading ranging from 11% to 16% and a high entrapment efficiency from 86% to 98%.",Cyclosporine-loaded microspheres for treatment of uveitis: in vitro characterization and in vivo pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16936114/),%,11,106564,DB00091,Cyclosporine
,16936114,drug-loading,"The CyS-PLGA-MS was produced, with drug-loading ranging from 11% to 16% and a high entrapment efficiency from 86% to 98%.",Cyclosporine-loaded microspheres for treatment of uveitis: in vitro characterization and in vivo pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16936114/),%,16,106565,DB00091,Cyclosporine
,16936114,en,"The CyS-PLGA-MS was produced, with drug-loading ranging from 11% to 16% and a high entrapment efficiency from 86% to 98%.",Cyclosporine-loaded microspheres for treatment of uveitis: in vitro characterization and in vivo pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16936114/),,86,106566,DB00091,Cyclosporine
,16936114,en,"The CyS-PLGA-MS was produced, with drug-loading ranging from 11% to 16% and a high entrapment efficiency from 86% to 98%.",Cyclosporine-loaded microspheres for treatment of uveitis: in vitro characterization and in vivo pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16936114/),,98,106567,DB00091,Cyclosporine
<,18758392,AUC0-12,"Presuming a therapeutic window of 30-60 mg h/L, 15 (60%) of 25 patients at day 7 had an MPA-AUC0-12 <30 mg h/L, indicating potential underexposure, whereas the proportion of patients with an MPA-AUC0-12 <30 mg h/L between months 3 and 36 was low (5%-17%).",Long-term pharmacokinetics of mycophenolic acid in pediatric renal transplant recipients over 3 years posttransplant. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18758392/),[h·mg] / [l],30,106622,DB00091,Cyclosporine
,9695721,central distribution volume,The central distribution volume was 5.6 +/- 1.7 L with a steady-state volume of 7.5 +/- 2.5 L.,Disposition and immunodynamics of basiliximab in liver allograft recipients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9695721/),l,5.6,106930,DB00091,Cyclosporine
,9695721,steady-state volume,The central distribution volume was 5.6 +/- 1.7 L with a steady-state volume of 7.5 +/- 2.5 L.,Disposition and immunodynamics of basiliximab in liver allograft recipients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9695721/),l,7.5,106931,DB00091,Cyclosporine
,9695721,total body clearance,It was cleared slowly with a total body clearance of 75 +/- 24 ml/hr and an elimination half-life of 4.1 +/- 2.1 days.,Disposition and immunodynamics of basiliximab in liver allograft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9695721/),[ml] / [h],75,106932,DB00091,Cyclosporine
,9695721,elimination half-life,It was cleared slowly with a total body clearance of 75 +/- 24 ml/hr and an elimination half-life of 4.1 +/- 2.1 days.,Disposition and immunodynamics of basiliximab in liver allograft recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9695721/),d,4.1,106933,DB00091,Cyclosporine
,9695721,duration of receptor saturation,"The duration of receptor saturation was 23 +/- 7 days after transplantation (range, 13 to 41 days).",Disposition and immunodynamics of basiliximab in liver allograft recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9695721/),d,23,106934,DB00091,Cyclosporine
,10232563,trough CsA level,"Dose adjustments were made daily, or as needed, to reach a target trough CsA level of 350 ng/ml in both groups.","Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8). ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10232563/),ng,350,107041,DB00091,Cyclosporine
,9243357,Maximum concentration (Cmax),"Maximum concentration (Cmax) ranged from 528 ng/mL to 2,689 ng/mL, area under the concentration-time curve (AUC) ranged from 6,550 ng.hr/mL to 18,562 ng.hr/mL, and time to reach Cmax (tmax) ranged from 1 to 8 hours.",Bioavailability of oral cyclosporine in healthy Mexican volunteers: evidence for interethnic variability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9243357/),[ng] / [ml],528,107465,DB00091,Cyclosporine
,9243357,Maximum concentration (Cmax),"Maximum concentration (Cmax) ranged from 528 ng/mL to 2,689 ng/mL, area under the concentration-time curve (AUC) ranged from 6,550 ng.hr/mL to 18,562 ng.hr/mL, and time to reach Cmax (tmax) ranged from 1 to 8 hours.",Bioavailability of oral cyclosporine in healthy Mexican volunteers: evidence for interethnic variability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9243357/),[ng] / [ml],"2,689",107466,DB00091,Cyclosporine
,9243357,area under the concentration-time curve (AUC),"Maximum concentration (Cmax) ranged from 528 ng/mL to 2,689 ng/mL, area under the concentration-time curve (AUC) ranged from 6,550 ng.hr/mL to 18,562 ng.hr/mL, and time to reach Cmax (tmax) ranged from 1 to 8 hours.",Bioavailability of oral cyclosporine in healthy Mexican volunteers: evidence for interethnic variability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9243357/),[h·ng] / [ml],"6,550",107467,DB00091,Cyclosporine
,9243357,area under the concentration-time curve (AUC),"Maximum concentration (Cmax) ranged from 528 ng/mL to 2,689 ng/mL, area under the concentration-time curve (AUC) ranged from 6,550 ng.hr/mL to 18,562 ng.hr/mL, and time to reach Cmax (tmax) ranged from 1 to 8 hours.",Bioavailability of oral cyclosporine in healthy Mexican volunteers: evidence for interethnic variability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9243357/),[h·ng] / [ml],"18,562",107468,DB00091,Cyclosporine
,9243357,time to reach Cmax (tmax),"Maximum concentration (Cmax) ranged from 528 ng/mL to 2,689 ng/mL, area under the concentration-time curve (AUC) ranged from 6,550 ng.hr/mL to 18,562 ng.hr/mL, and time to reach Cmax (tmax) ranged from 1 to 8 hours.",Bioavailability of oral cyclosporine in healthy Mexican volunteers: evidence for interethnic variability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9243357/),h,1 to 8,107469,DB00091,Cyclosporine
,9243357,Half-life (t1/2),"Half-life (t1/2) exhibited less important variations, ranging from 4.4 to 9.1 hours.",Bioavailability of oral cyclosporine in healthy Mexican volunteers: evidence for interethnic variability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9243357/),h,4.4 to 9.1,107470,DB00091,Cyclosporine
,22595383,AUC,Median MPA AUC was constantly within the therapeutic window of 30 - 60 mg/l × h throughout the three months of evaluation.,Mycophenolate sodium dosing in combination with tacrolimus: pharmacokinetic evaluation of a novel regimen in de novo tacrolimus-treated kidney transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22595383/),[mg] / [h·l],30 - 60,107762,DB00091,Cyclosporine
above,22595383,AUC,More than 75% of patients had a MPA AUC above 30 mg/l × h at Day 2 and Day 7 post-transplant.,Mycophenolate sodium dosing in combination with tacrolimus: pharmacokinetic evaluation of a novel regimen in de novo tacrolimus-treated kidney transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22595383/),[mg] / [h·l],30,107763,DB00091,Cyclosporine
,12829916,C(min) (trough level),"Steady-state pharmacokinetic parameters were as follows (median, range): C(min) (trough level), 4.7 (2.3- 9.5) ng/mL; peak concentration, 13.5 (5.9-22.2) ng/mL; area under the concentration-time curve (AUC), 77 (53-147) ng x hr/mL; and apparent oral clearance, 10.2 (5.5-15.6) L/hr/m2.",Everolimus in pediatric de nova renal transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12829916/),[ng] / [ml],4.7,107786,DB00091,Cyclosporine
,12829916,peak concentration,"Steady-state pharmacokinetic parameters were as follows (median, range): C(min) (trough level), 4.7 (2.3- 9.5) ng/mL; peak concentration, 13.5 (5.9-22.2) ng/mL; area under the concentration-time curve (AUC), 77 (53-147) ng x hr/mL; and apparent oral clearance, 10.2 (5.5-15.6) L/hr/m2.",Everolimus in pediatric de nova renal transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12829916/),[ng] / [ml],13.5,107787,DB00091,Cyclosporine
,12829916,area under the concentration-time curve (AUC),"Steady-state pharmacokinetic parameters were as follows (median, range): C(min) (trough level), 4.7 (2.3- 9.5) ng/mL; peak concentration, 13.5 (5.9-22.2) ng/mL; area under the concentration-time curve (AUC), 77 (53-147) ng x hr/mL; and apparent oral clearance, 10.2 (5.5-15.6) L/hr/m2.",Everolimus in pediatric de nova renal transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12829916/),[h·ng] / [ml],77,107788,DB00091,Cyclosporine
,12829916,apparent oral clearance,"Steady-state pharmacokinetic parameters were as follows (median, range): C(min) (trough level), 4.7 (2.3- 9.5) ng/mL; peak concentration, 13.5 (5.9-22.2) ng/mL; area under the concentration-time curve (AUC), 77 (53-147) ng x hr/mL; and apparent oral clearance, 10.2 (5.5-15.6) L/hr/m2.",Everolimus in pediatric de nova renal transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12829916/),[l] / [h·m2],10.2,107789,DB00091,Cyclosporine
,12829916,C(min),"Everolimus C(min) were stable over time with median values of 3.9, 3.4, and 3.1 ng/mL at months 1, 3, and 6, respectively.",Everolimus in pediatric de nova renal transplant patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12829916/),[ng] / [ml],3.9,107790,DB00091,Cyclosporine
,12829916,C(min),"Everolimus C(min) were stable over time with median values of 3.9, 3.4, and 3.1 ng/mL at months 1, 3, and 6, respectively.",Everolimus in pediatric de nova renal transplant patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12829916/),[ng] / [ml],3.4,107791,DB00091,Cyclosporine
,12829916,C(min),"Everolimus C(min) were stable over time with median values of 3.9, 3.4, and 3.1 ng/mL at months 1, 3, and 6, respectively.",Everolimus in pediatric de nova renal transplant patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12829916/),[ng] / [ml],3.1,107792,DB00091,Cyclosporine
,12829916,C(min),"The concurrent median cyclosporine C(min) were generally at the lower end of conventional target ranges: 156, 83, and 69 ng/mL at months 1, 3, and 6, respectively.",Everolimus in pediatric de nova renal transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12829916/),[ng] / [ml],156,107793,DB00091,Cyclosporine
,12829916,C(min),"The concurrent median cyclosporine C(min) were generally at the lower end of conventional target ranges: 156, 83, and 69 ng/mL at months 1, 3, and 6, respectively.",Everolimus in pediatric de nova renal transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12829916/),[ng] / [ml],83,107794,DB00091,Cyclosporine
,12829916,C(min),"The concurrent median cyclosporine C(min) were generally at the lower end of conventional target ranges: 156, 83, and 69 ng/mL at months 1, 3, and 6, respectively.",Everolimus in pediatric de nova renal transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12829916/),[ng] / [ml],69,107795,DB00091,Cyclosporine
,1713626,"total plasma clearance, CLtot","After the i.v. injection of FK at 1.0 and 5.0 mg/kg, the total plasma clearance, CLtot, was 7.028 +/- 0.076 (mean +/- S.E.) and 7.651 +/- 0.755 ml/min, steady-state distribution volume, Vd.ss, was 4623 +/- 28 and 4201 +/- 529 ml/kg, elimination half-life at the terminal elimination phase, t1/2 beta, was 2.36 +/- 0.25 and 2.54 +/- 0.29 h, and the volume of the initial distribution space, V1, was 1336 +/- 150 and 1065 +/- 115 ml/kg, respectively.","Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1713626/),[ml] / [min],7.028,108215,DB00091,Cyclosporine
,1713626,"total plasma clearance, CLtot","After the i.v. injection of FK at 1.0 and 5.0 mg/kg, the total plasma clearance, CLtot, was 7.028 +/- 0.076 (mean +/- S.E.) and 7.651 +/- 0.755 ml/min, steady-state distribution volume, Vd.ss, was 4623 +/- 28 and 4201 +/- 529 ml/kg, elimination half-life at the terminal elimination phase, t1/2 beta, was 2.36 +/- 0.25 and 2.54 +/- 0.29 h, and the volume of the initial distribution space, V1, was 1336 +/- 150 and 1065 +/- 115 ml/kg, respectively.","Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1713626/),[ml] / [min],7.651,108216,DB00091,Cyclosporine
,1713626,"steady-state distribution volume, Vd.ss","After the i.v. injection of FK at 1.0 and 5.0 mg/kg, the total plasma clearance, CLtot, was 7.028 +/- 0.076 (mean +/- S.E.) and 7.651 +/- 0.755 ml/min, steady-state distribution volume, Vd.ss, was 4623 +/- 28 and 4201 +/- 529 ml/kg, elimination half-life at the terminal elimination phase, t1/2 beta, was 2.36 +/- 0.25 and 2.54 +/- 0.29 h, and the volume of the initial distribution space, V1, was 1336 +/- 150 and 1065 +/- 115 ml/kg, respectively.","Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1713626/),[ml] / [kg],4623,108217,DB00091,Cyclosporine
,1713626,"steady-state distribution volume, Vd.ss","After the i.v. injection of FK at 1.0 and 5.0 mg/kg, the total plasma clearance, CLtot, was 7.028 +/- 0.076 (mean +/- S.E.) and 7.651 +/- 0.755 ml/min, steady-state distribution volume, Vd.ss, was 4623 +/- 28 and 4201 +/- 529 ml/kg, elimination half-life at the terminal elimination phase, t1/2 beta, was 2.36 +/- 0.25 and 2.54 +/- 0.29 h, and the volume of the initial distribution space, V1, was 1336 +/- 150 and 1065 +/- 115 ml/kg, respectively.","Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1713626/),[ml] / [kg],4201,108218,DB00091,Cyclosporine
,1713626,"elimination half-life at the terminal elimination phase, t1/2 beta","After the i.v. injection of FK at 1.0 and 5.0 mg/kg, the total plasma clearance, CLtot, was 7.028 +/- 0.076 (mean +/- S.E.) and 7.651 +/- 0.755 ml/min, steady-state distribution volume, Vd.ss, was 4623 +/- 28 and 4201 +/- 529 ml/kg, elimination half-life at the terminal elimination phase, t1/2 beta, was 2.36 +/- 0.25 and 2.54 +/- 0.29 h, and the volume of the initial distribution space, V1, was 1336 +/- 150 and 1065 +/- 115 ml/kg, respectively.","Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1713626/),h,2.36,108219,DB00091,Cyclosporine
,1713626,"elimination half-life at the terminal elimination phase, t1/2 beta","After the i.v. injection of FK at 1.0 and 5.0 mg/kg, the total plasma clearance, CLtot, was 7.028 +/- 0.076 (mean +/- S.E.) and 7.651 +/- 0.755 ml/min, steady-state distribution volume, Vd.ss, was 4623 +/- 28 and 4201 +/- 529 ml/kg, elimination half-life at the terminal elimination phase, t1/2 beta, was 2.36 +/- 0.25 and 2.54 +/- 0.29 h, and the volume of the initial distribution space, V1, was 1336 +/- 150 and 1065 +/- 115 ml/kg, respectively.","Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1713626/),h,2.54,108220,DB00091,Cyclosporine
,1713626,"volume of the initial distribution space, V1","After the i.v. injection of FK at 1.0 and 5.0 mg/kg, the total plasma clearance, CLtot, was 7.028 +/- 0.076 (mean +/- S.E.) and 7.651 +/- 0.755 ml/min, steady-state distribution volume, Vd.ss, was 4623 +/- 28 and 4201 +/- 529 ml/kg, elimination half-life at the terminal elimination phase, t1/2 beta, was 2.36 +/- 0.25 and 2.54 +/- 0.29 h, and the volume of the initial distribution space, V1, was 1336 +/- 150 and 1065 +/- 115 ml/kg, respectively.","Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1713626/),[ml] / [kg],1336,108221,DB00091,Cyclosporine
,1713626,"volume of the initial distribution space, V1","After the i.v. injection of FK at 1.0 and 5.0 mg/kg, the total plasma clearance, CLtot, was 7.028 +/- 0.076 (mean +/- S.E.) and 7.651 +/- 0.755 ml/min, steady-state distribution volume, Vd.ss, was 4623 +/- 28 and 4201 +/- 529 ml/kg, elimination half-life at the terminal elimination phase, t1/2 beta, was 2.36 +/- 0.25 and 2.54 +/- 0.29 h, and the volume of the initial distribution space, V1, was 1336 +/- 150 and 1065 +/- 115 ml/kg, respectively.","Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1713626/),[ml] / [kg],1065,108222,DB00091,Cyclosporine
,1713626,percentage,"The mean percentage of FK transferred into the thoracic lymphatics over 6 h were 0.09 +/- 0.02% (1.0 mg/kg) and 0.16 +/- 0.02% (5.0 mg/kg), respectively.","Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1713626/),%,0.09,108223,DB00091,Cyclosporine
,1713626,percentage,"The mean percentage of FK transferred into the thoracic lymphatics over 6 h were 0.09 +/- 0.02% (1.0 mg/kg) and 0.16 +/- 0.02% (5.0 mg/kg), respectively.","Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1713626/),%,0.16,108224,DB00091,Cyclosporine
,23444283,AUC*,"Significant R × D was identified for MPA AUC* for EC-MPS (AA, 0.056 ± 0.029 [mg·h/L]/mg; C, 0.080 ± 0.044 [mg·h/L]/mg) compared with MMF (AA, 0.053 ± 0.019 [mg·h/L]/mg; C, 0.060 ± 0.025 [mg·h/L]/mg), P = .022.",Race and drug formulation influence on mycophenolic acid pharmacokinetics in stable renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23444283/),[h·mg] / [l],0.056,108525,DB00091,Cyclosporine
,23444283,AUC*,"Significant R × D was identified for MPA AUC* for EC-MPS (AA, 0.056 ± 0.029 [mg·h/L]/mg; C, 0.080 ± 0.044 [mg·h/L]/mg) compared with MMF (AA, 0.053 ± 0.019 [mg·h/L]/mg; C, 0.060 ± 0.025 [mg·h/L]/mg), P = .022.",Race and drug formulation influence on mycophenolic acid pharmacokinetics in stable renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23444283/),[h·mg] / [l],0.080,108526,DB00091,Cyclosporine
,23444283,AUC*,"Significant R × D was identified for MPA AUC* for EC-MPS (AA, 0.056 ± 0.029 [mg·h/L]/mg; C, 0.080 ± 0.044 [mg·h/L]/mg) compared with MMF (AA, 0.053 ± 0.019 [mg·h/L]/mg; C, 0.060 ± 0.025 [mg·h/L]/mg), P = .022.",Race and drug formulation influence on mycophenolic acid pharmacokinetics in stable renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23444283/),[h·mg] / [l],0.053,108527,DB00091,Cyclosporine
,23444283,AUC*,"Significant R × D was identified for MPA AUC* for EC-MPS (AA, 0.056 ± 0.029 [mg·h/L]/mg; C, 0.080 ± 0.044 [mg·h/L]/mg) compared with MMF (AA, 0.053 ± 0.019 [mg·h/L]/mg; C, 0.060 ± 0.025 [mg·h/L]/mg), P = .022.",Race and drug formulation influence on mycophenolic acid pharmacokinetics in stable renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23444283/),[h·mg] / [l],0.060,108528,DB00091,Cyclosporine
,10075604,bioavailabilities,"Pharmacokinetic studies revealed bioavailabilities of 2% and 6% respectively, while D-xylose and B12 absorption were found to be within normal limits and fecal fat was only slightly increased, suggesting that there was a selective absorptive defect for these drugs.",Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10075604/),%,2,108902,DB00091,Cyclosporine
,10075604,bioavailabilities,"Pharmacokinetic studies revealed bioavailabilities of 2% and 6% respectively, while D-xylose and B12 absorption were found to be within normal limits and fecal fat was only slightly increased, suggesting that there was a selective absorptive defect for these drugs.",Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10075604/),%,6,108903,DB00091,Cyclosporine
up to,33086102,encapsulation efficiency,"nMIC and nFIB displayed good CsA encapsulation efficiency (up to 4.5 and 2 mg/mL, respectively in aqueous solution), superior to many other solubilization methods, and provided sustained release (>14 and > 7 days for the nMIC and nFIB) without compromising CsA's pharmacological activity.",Drug-Integrating Amphiphilic Nanomaterial Assemblies: 1. Spatiotemporal control of cyclosporine delivery and activity using nanomicelles and nanofibrils. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33086102/),[mg] / [ml],4.5,109495,DB00091,Cyclosporine
,33086102,encapsulation efficiency,"nMIC and nFIB displayed good CsA encapsulation efficiency (up to 4.5 and 2 mg/mL, respectively in aqueous solution), superior to many other solubilization methods, and provided sustained release (>14 and > 7 days for the nMIC and nFIB) without compromising CsA's pharmacological activity.",Drug-Integrating Amphiphilic Nanomaterial Assemblies: 1. Spatiotemporal control of cyclosporine delivery and activity using nanomicelles and nanofibrils. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33086102/),[mg] / [ml],2,109496,DB00091,Cyclosporine
,12234272,time after transplantation,"The median time after transplantation was 540 (range: 247-1,358) days.",A strategy to calculate cyclosporin A area under the time-concentration curve in pediatric renal transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12234272/),d,540,109499,DB00091,Cyclosporine
,7575761,time to reach maximum concentration,"According to these data it is concluded that the preparations are bioequivalent; a time to reach maximum concentration was slightly shorter for test preparation (2.5 and 3.2 h, respectively), but not statistically significant.",Bioequivalence of two oral cyclosporine preparations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7575761/),h,2.5,110428,DB00091,Cyclosporine
,7575761,time to reach maximum concentration,"According to these data it is concluded that the preparations are bioequivalent; a time to reach maximum concentration was slightly shorter for test preparation (2.5 and 3.2 h, respectively), but not statistically significant.",Bioequivalence of two oral cyclosporine preparations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7575761/),h,3.2,110429,DB00091,Cyclosporine
,7575761,areas under the concentration curves,"There are no significant differences between the areas under the concentration curves (1667 and 1665 ng.h/ml, respectively).",Bioequivalence of two oral cyclosporine preparations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7575761/),[h·ng] / [ml],1667,110430,DB00091,Cyclosporine
,7575761,areas under the concentration curves,"There are no significant differences between the areas under the concentration curves (1667 and 1665 ng.h/ml, respectively).",Bioequivalence of two oral cyclosporine preparations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7575761/),[h·ng] / [ml],1665,110431,DB00091,Cyclosporine
,7575761,areas under concentration curves,"After the calculation of pharmacokinetic parameters of concentration data measured by a non-specific method a significant difference for areas under concentration curves was seen (3709 and 4600 ng.h/ml, respectively).",Bioequivalence of two oral cyclosporine preparations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7575761/),[h·ng] / [ml],3709,110432,DB00091,Cyclosporine
,7575761,areas under concentration curves,"After the calculation of pharmacokinetic parameters of concentration data measured by a non-specific method a significant difference for areas under concentration curves was seen (3709 and 4600 ng.h/ml, respectively).",Bioequivalence of two oral cyclosporine preparations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7575761/),[h·ng] / [ml],4600,110433,DB00091,Cyclosporine
,32739890,absolute bioavailability,The absolute bioavailability for fevipiprant was approximately 0.3 to 0.4 in the absence and 0.5 in the presence of cyclosporine.,A Study of the Effect of Cyclosporine on Fevipiprant Pharmacokinetics and its Absolute Bioavailability Using an Intravenous Microdose Approach. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32739890/),,0.3 to 0.4,110899,DB00091,Cyclosporine
,32739890,absolute bioavailability,The absolute bioavailability for fevipiprant was approximately 0.3 to 0.4 in the absence and 0.5 in the presence of cyclosporine.,A Study of the Effect of Cyclosporine on Fevipiprant Pharmacokinetics and its Absolute Bioavailability Using an Intravenous Microdose Approach. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32739890/),,0.5,110900,DB00091,Cyclosporine
,15848555,C0,Predose levels (C0) increased significantly during the first 6 months after transplantation: C0 at 6 and 180 days after transplantation was 0.8 +/- 0.6 and 1.9 +/- 1.1 microg/mL (P < .0001).,Mycophenolate mofetil pharmacokinetic monitoring in pediatric kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848555/),[μg] / [ml],0.8,111154,DB00091,Cyclosporine
,15848555,C0,Predose levels (C0) increased significantly during the first 6 months after transplantation: C0 at 6 and 180 days after transplantation was 0.8 +/- 0.6 and 1.9 +/- 1.1 microg/mL (P < .0001).,Mycophenolate mofetil pharmacokinetic monitoring in pediatric kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848555/),[μg] / [ml],1.9,111155,DB00091,Cyclosporine
,15848555,AUC(0-12),A significant time-dependent increase in the AUC of MPA was also observed during the first 6 posttransplant months: AUC(0-12) at 6 and 180 days after transplantation was 23.3 +/- 10.8 and 40 +/- 11.6 mg*h/L (P = .003).,Mycophenolate mofetil pharmacokinetic monitoring in pediatric kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848555/),[h·mg] / [l],23.3,111156,DB00091,Cyclosporine
,15848555,AUC(0-12),A significant time-dependent increase in the AUC of MPA was also observed during the first 6 posttransplant months: AUC(0-12) at 6 and 180 days after transplantation was 23.3 +/- 10.8 and 40 +/- 11.6 mg*h/L (P = .003).,Mycophenolate mofetil pharmacokinetic monitoring in pediatric kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848555/),[h·mg] / [l],40,111157,DB00091,Cyclosporine
,26242764,time to neutrophil engraftment,"Median (range) time to neutrophil engraftment (>500 cells/µL) and platelet engraftment (>20,000/mm(3) ) were 15 (12-28) and 25 (17-30) days, respectively.",Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26242764/),d,15,111482,DB00091,Cyclosporine
,26242764,time to neutrophil engraftment,"Median (range) time to neutrophil engraftment (>500 cells/µL) and platelet engraftment (>20,000/mm(3) ) were 15 (12-28) and 25 (17-30) days, respectively.",Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26242764/),d,25,111483,DB00091,Cyclosporine
,12636164,Peak blood concentrations,"Peak blood concentrations of CsA after aerosol administration ranged from 119-402 ng/ml, and concentrations at 24 h ranged from 9-48 ng/ml.",Lung deposition and pharmacokinetics of cyclosporine after aerosolization in lung transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12636164/),[ng] / [ml],119-402,111912,DB00091,Cyclosporine
,12636164,concentrations,"Peak blood concentrations of CsA after aerosol administration ranged from 119-402 ng/ml, and concentrations at 24 h ranged from 9-48 ng/ml.",Lung deposition and pharmacokinetics of cyclosporine after aerosolization in lung transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12636164/),[ng] / [ml],9-48,111913,DB00091,Cyclosporine
,12636164,Terminal disposition half life (t 1/2 lambda(z)),"Terminal disposition half life (t 1/2 lambda(z)) values ranged from 4.1-9.9 h (mean 6.5 h) following IV administration and from 23.1 to 65.2 h (mean 40.7 h) following pulmonary administration, suggesting that drug absorption occurred throughout the 24-h sampling period following pulmonary administration.",Lung deposition and pharmacokinetics of cyclosporine after aerosolization in lung transplant patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12636164/),h,4.1-9.9,111914,DB00091,Cyclosporine
,12636164,Terminal disposition half life (t 1/2 lambda(z)),"Terminal disposition half life (t 1/2 lambda(z)) values ranged from 4.1-9.9 h (mean 6.5 h) following IV administration and from 23.1 to 65.2 h (mean 40.7 h) following pulmonary administration, suggesting that drug absorption occurred throughout the 24-h sampling period following pulmonary administration.",Lung deposition and pharmacokinetics of cyclosporine after aerosolization in lung transplant patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12636164/),h,6.5,111915,DB00091,Cyclosporine
,12636164,Terminal disposition half life (t 1/2 lambda(z)),"Terminal disposition half life (t 1/2 lambda(z)) values ranged from 4.1-9.9 h (mean 6.5 h) following IV administration and from 23.1 to 65.2 h (mean 40.7 h) following pulmonary administration, suggesting that drug absorption occurred throughout the 24-h sampling period following pulmonary administration.",Lung deposition and pharmacokinetics of cyclosporine after aerosolization in lung transplant patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12636164/),h,23.1 to 65.2,111916,DB00091,Cyclosporine
,12636164,Terminal disposition half life (t 1/2 lambda(z)),"Terminal disposition half life (t 1/2 lambda(z)) values ranged from 4.1-9.9 h (mean 6.5 h) following IV administration and from 23.1 to 65.2 h (mean 40.7 h) following pulmonary administration, suggesting that drug absorption occurred throughout the 24-h sampling period following pulmonary administration.",Lung deposition and pharmacokinetics of cyclosporine after aerosolization in lung transplant patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12636164/),h,40.7,111917,DB00091,Cyclosporine
,12636164,absorption half-life,"Deconvolution analysis indicated biphasic absorption of CsA from the lung in all patients, characterized by rapid initial absorption (absorption half-life 0.73 +/- 0.38 h) over the first 4 to 6 h followed by slower, sustained absorption throughout the remainder of the sampling period (absorption half-life 16.2 +/- 13.2 h).",Lung deposition and pharmacokinetics of cyclosporine after aerosolization in lung transplant patients. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12636164/),h,0.73,111918,DB00091,Cyclosporine
,12636164,absorption half-life,"Deconvolution analysis indicated biphasic absorption of CsA from the lung in all patients, characterized by rapid initial absorption (absorption half-life 0.73 +/- 0.38 h) over the first 4 to 6 h followed by slower, sustained absorption throughout the remainder of the sampling period (absorption half-life 16.2 +/- 13.2 h).",Lung deposition and pharmacokinetics of cyclosporine after aerosolization in lung transplant patients. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12636164/),h,16.2,111919,DB00091,Cyclosporine
,12636164,absolute bioavailability,The absolute bioavailability of CsA after aerosol administration ranged from 5.4-11.2% (mean 8.2%) of the dose placed in the nebulizer.,Lung deposition and pharmacokinetics of cyclosporine after aerosolization in lung transplant patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12636164/),%,8.2,111920,DB00091,Cyclosporine
,23023401,concentration maximum (C max),"Single-dose PK data demonstrated that NOVA22007 0.1% and 0.05% delivered higher CsA concentrations to the cornea than Restasis [concentration maximum (C max): 2692, 1372, and 748 ng/g, respectively] and have a better exposition (area under the curve).",Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23023401/),[ng] / [g],2692,112486,DB00091,Cyclosporine
,23023401,concentration maximum (C max),"Single-dose PK data demonstrated that NOVA22007 0.1% and 0.05% delivered higher CsA concentrations to the cornea than Restasis [concentration maximum (C max): 2692, 1372, and 748 ng/g, respectively] and have a better exposition (area under the curve).",Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23023401/),[ng] / [g],1372,112487,DB00091,Cyclosporine
,23023401,concentration maximum (C max),"Single-dose PK data demonstrated that NOVA22007 0.1% and 0.05% delivered higher CsA concentrations to the cornea than Restasis [concentration maximum (C max): 2692, 1372, and 748 ng/g, respectively] and have a better exposition (area under the curve).",Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23023401/),[ng] / [g],748,112488,DB00091,Cyclosporine
,23023401,Cmax,"Conjunctival Cmax values were 1914, 696, and 849 ng/g and area under the curve values were 3984, 2796, and 2515 ng/g · h, for either dose of the cationic emulsions and Restasis, respectively.",Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23023401/),[ng] / [g],1914,112489,DB00091,Cyclosporine
,23023401,Cmax,"Conjunctival Cmax values were 1914, 696, and 849 ng/g and area under the curve values were 3984, 2796, and 2515 ng/g · h, for either dose of the cationic emulsions and Restasis, respectively.",Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23023401/),[ng] / [g],696,112490,DB00091,Cyclosporine
,23023401,Cmax,"Conjunctival Cmax values were 1914, 696, and 849 ng/g and area under the curve values were 3984, 2796, and 2515 ng/g · h, for either dose of the cationic emulsions and Restasis, respectively.",Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23023401/),[ng] / [g],849,112491,DB00091,Cyclosporine
,23023401,area under the curve,"Conjunctival Cmax values were 1914, 696, and 849 ng/g and area under the curve values were 3984, 2796, and 2515 ng/g · h, for either dose of the cationic emulsions and Restasis, respectively.",Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23023401/),[ng] / [g·h],3984,112492,DB00091,Cyclosporine
,23023401,area under the curve,"Conjunctival Cmax values were 1914, 696, and 849 ng/g and area under the curve values were 3984, 2796, and 2515 ng/g · h, for either dose of the cationic emulsions and Restasis, respectively.",Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23023401/),[ng] / [g·h],2796,112493,DB00091,Cyclosporine
,23023401,area under the curve,"Conjunctival Cmax values were 1914, 696, and 849 ng/g and area under the curve values were 3984, 2796, and 2515 ng/g · h, for either dose of the cationic emulsions and Restasis, respectively.",Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23023401/),[ng] / [g·h],2515,112494,DB00091,Cyclosporine
,12042653,Elimination half-life,Elimination half-life of the antibody was 99 hr with a total body clearance of 57 ml/hr.,"Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12042653/),h,99,112977,DB00091,Cyclosporine
,12042653,total body clearance,Elimination half-life of the antibody was 99 hr with a total body clearance of 57 ml/hr.,"Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12042653/),[ml] / [h],57,112978,DB00091,Cyclosporine
,8616954,elimination half-life (t0.5e),"The washout phase of ATG elimination was analysed over 0-300 days; results were well-fitted by a single exponential decay (r2 > 0.95) giving a mean elimination half-life (t0.5e) of 29.8 days (range 14.3-45.0, n = 9).",The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616954/),d,29.8,113057,DB00091,Cyclosporine
,8616954,apparent volume of distribution of ATG (Vd),"Data for the first 4 days of treatment were analysed with linear regression to obtain a mean value for the apparent volume of distribution of ATG (Vd) of 0.12 l/kg body weight (range 0.07 to 0.17, n = 5).",The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8616954/),[l] / [body·kg·weight],0.12,113058,DB00091,Cyclosporine
<,9231509,steady state AUC0-12 h plasma levels,"To date, all available data are assessed and more particularly:--the doses of 1 or 1.5 g administered twice daily,--a pilot, open-label multicentre study which showed a decreased incidence of acute rejection episodes in patients with steady state AUC0-12 h plasma levels < 40 micrograms.","[Mycophenolate mofetil, a new immunosuppressive agent. Is pharmacokinetic monitoring justified?]. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9231509/),μg,40,113229,DB00091,Cyclosporine
,9055138,absolute bioavailability,The absolute bioavailability of PSC 833 was 34% but ranged from 3% to 58% of the administered dose.,"Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9055138/),%,34,113744,DB00091,Cyclosporine
,9055138,absolute bioavailability,The absolute bioavailability of PSC 833 was 34% but ranged from 3% to 58% of the administered dose.,"Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9055138/),%,3,113745,DB00091,Cyclosporine
,9055138,absolute bioavailability,The absolute bioavailability of PSC 833 was 34% but ranged from 3% to 58% of the administered dose.,"Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9055138/),%,58,113746,DB00091,Cyclosporine
>,9163863,average,Patients in the CyA-ME group reached the 1st month target average concentration (Cav) values (> or = 550 ng/ml) earlier than those in the CyA-GC group and required significantly lower daily CyA doses (P = 0.018).,A pharmacokinetic comparison of the corn oil versus microemulsion gelcap formulation of cyclosporin used de novo after renal transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9163863/),[ng] / [ml],550,113810,DB00091,Cyclosporine
>,9163863,concentration (Cav),Patients in the CyA-ME group reached the 1st month target average concentration (Cav) values (> or = 550 ng/ml) earlier than those in the CyA-GC group and required significantly lower daily CyA doses (P = 0.018).,A pharmacokinetic comparison of the corn oil versus microemulsion gelcap formulation of cyclosporin used de novo after renal transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9163863/),[ng] / [ml],550,113811,DB00091,Cyclosporine
,22169469,area under the curve (AUC),"When co-administered, the area under the curve (AUC) of spinosin in blood, bile and brain increased from 205.70 to 673.51 mg min/L, 7.77 × 10(4) to 1.25 × 10(5) mg min/L, and 2.09 to 5.58 mg min/L, respectively.","In vivo microdialysis with LC-MS for analysis of spinosin and its interaction with cyclosporin A in rat brain, blood and bile. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22169469/),[mg·min] / [l],205,113941,DB00091,Cyclosporine
,22169469,area under the curve (AUC),"When co-administered, the area under the curve (AUC) of spinosin in blood, bile and brain increased from 205.70 to 673.51 mg min/L, 7.77 × 10(4) to 1.25 × 10(5) mg min/L, and 2.09 to 5.58 mg min/L, respectively.","In vivo microdialysis with LC-MS for analysis of spinosin and its interaction with cyclosporin A in rat brain, blood and bile. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22169469/),[mg·min] / [l],7.77 × 10(4,113942,DB00091,Cyclosporine
,22169469,area under the curve (AUC),"When co-administered, the area under the curve (AUC) of spinosin in blood, bile and brain increased from 205.70 to 673.51 mg min/L, 7.77 × 10(4) to 1.25 × 10(5) mg min/L, and 2.09 to 5.58 mg min/L, respectively.","In vivo microdialysis with LC-MS for analysis of spinosin and its interaction with cyclosporin A in rat brain, blood and bile. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22169469/),[mg·min] / [l],1.25 × 10(5,113943,DB00091,Cyclosporine
,22169469,area under the curve (AUC),"When co-administered, the area under the curve (AUC) of spinosin in blood, bile and brain increased from 205.70 to 673.51 mg min/L, 7.77 × 10(4) to 1.25 × 10(5) mg min/L, and 2.09 to 5.58 mg min/L, respectively.","In vivo microdialysis with LC-MS for analysis of spinosin and its interaction with cyclosporin A in rat brain, blood and bile. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22169469/),[mg·min] / [l],2,113944,DB00091,Cyclosporine
,22169469,t(1/2),"The t(1/2) values of spinosin in blood, bile and brain also changed from 48.07 to 95.04 min, from 97.20 to 152.21 and from 42.18 to 73.83 min, respectively.","In vivo microdialysis with LC-MS for analysis of spinosin and its interaction with cyclosporin A in rat brain, blood and bile. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22169469/),min,48.07 to 95.04,113945,DB00091,Cyclosporine
,22169469,t(1/2),"The t(1/2) values of spinosin in blood, bile and brain also changed from 48.07 to 95.04 min, from 97.20 to 152.21 and from 42.18 to 73.83 min, respectively.","In vivo microdialysis with LC-MS for analysis of spinosin and its interaction with cyclosporin A in rat brain, blood and bile. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22169469/),min,97.20 to 152.21,113946,DB00091,Cyclosporine
,22169469,t(1/2),"The t(1/2) values of spinosin in blood, bile and brain also changed from 48.07 to 95.04 min, from 97.20 to 152.21 and from 42.18 to 73.83 min, respectively.","In vivo microdialysis with LC-MS for analysis of spinosin and its interaction with cyclosporin A in rat brain, blood and bile. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22169469/),min,42.18 to 73.83,113947,DB00091,Cyclosporine
,22286813,AUC(0-24),"Pharmacokinetic assessment showed AUC(0-24) 3009.66 ± 1449.78 ng/ml.h and C(max) 827.84 ± 425.84 after administration of a single dose of CSA, AUC(0-24) 3698.50 ± 2147 ng/ml.h and C(max) 741 ± 493 ng/ml after repeated dose.","Single-dose and steady state pharmacokinetics of CSA and two main primary metabolites, AM1 and AM4n in patients with rheumatic/autoimmune diseases. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22286813/),[ng] / [h·ml],3009.66,114111,DB00091,Cyclosporine
,22286813,C(max),"Pharmacokinetic assessment showed AUC(0-24) 3009.66 ± 1449.78 ng/ml.h and C(max) 827.84 ± 425.84 after administration of a single dose of CSA, AUC(0-24) 3698.50 ± 2147 ng/ml.h and C(max) 741 ± 493 ng/ml after repeated dose.","Single-dose and steady state pharmacokinetics of CSA and two main primary metabolites, AM1 and AM4n in patients with rheumatic/autoimmune diseases. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22286813/),,827.84,114112,DB00091,Cyclosporine
,22286813,AUC(0-24),"Pharmacokinetic assessment showed AUC(0-24) 3009.66 ± 1449.78 ng/ml.h and C(max) 827.84 ± 425.84 after administration of a single dose of CSA, AUC(0-24) 3698.50 ± 2147 ng/ml.h and C(max) 741 ± 493 ng/ml after repeated dose.","Single-dose and steady state pharmacokinetics of CSA and two main primary metabolites, AM1 and AM4n in patients with rheumatic/autoimmune diseases. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22286813/),[ng] / [h·ml],3698.50,114113,DB00091,Cyclosporine
,22286813,C(max),"Pharmacokinetic assessment showed AUC(0-24) 3009.66 ± 1449.78 ng/ml.h and C(max) 827.84 ± 425.84 after administration of a single dose of CSA, AUC(0-24) 3698.50 ± 2147 ng/ml.h and C(max) 741 ± 493 ng/ml after repeated dose.","Single-dose and steady state pharmacokinetics of CSA and two main primary metabolites, AM1 and AM4n in patients with rheumatic/autoimmune diseases. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22286813/),[ng] / [ml],741,114114,DB00091,Cyclosporine
,8600892,half-life,"After the 10-microgram injection, the half-life was longer (10.8 hours vs. 4.2 hours) and the distribution volume was smaller (1.7 mL vs 3.2 mL) than after the 1-microgram injection.",Evaluation of a delivery system providing long-term release of cyclosporine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8600892/),h,10.8,114551,DB00091,Cyclosporine
,8600892,half-life,"After the 10-microgram injection, the half-life was longer (10.8 hours vs. 4.2 hours) and the distribution volume was smaller (1.7 mL vs 3.2 mL) than after the 1-microgram injection.",Evaluation of a delivery system providing long-term release of cyclosporine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8600892/),h,4.2,114552,DB00091,Cyclosporine
,8600892,distribution volume,"After the 10-microgram injection, the half-life was longer (10.8 hours vs. 4.2 hours) and the distribution volume was smaller (1.7 mL vs 3.2 mL) than after the 1-microgram injection.",Evaluation of a delivery system providing long-term release of cyclosporine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8600892/),ml,1.7,114553,DB00091,Cyclosporine
,8600892,distribution volume,"After the 10-microgram injection, the half-life was longer (10.8 hours vs. 4.2 hours) and the distribution volume was smaller (1.7 mL vs 3.2 mL) than after the 1-microgram injection.",Evaluation of a delivery system providing long-term release of cyclosporine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8600892/),ml,3.2,114554,DB00091,Cyclosporine
,25166216,ɛ,"Genotype was found to significantly affect peg-IFN effectiveness (ɛ = 86.3 and 99.1% for genotypes 1/4 and genotypes 2/3, respectively, P < 10(-7)) and the loss rate of infected cells (δ = 0.22 vs.",A pharmacokinetic-viral kinetic model describes the effect of alisporivir as monotherapy or in combination with peg-IFN on hepatitis C virologic response. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25166216/),%,86.3,114563,DB00091,Cyclosporine
,25166216,ɛ,"Genotype was found to significantly affect peg-IFN effectiveness (ɛ = 86.3 and 99.1% for genotypes 1/4 and genotypes 2/3, respectively, P < 10(-7)) and the loss rate of infected cells (δ = 0.22 vs.",A pharmacokinetic-viral kinetic model describes the effect of alisporivir as monotherapy or in combination with peg-IFN on hepatitis C virologic response. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25166216/),%,99.1,114564,DB00091,Cyclosporine
,2781141,systemic clearance,Ketoconazole decreased the systemic clearance of cyclosporine from 7.0 ml/min/kg to 2.5 ml/min/kg.,Pharmacokinetics of the cyclosporine-ketoconazole interaction in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2781141/),[ml] / [kg·min],7.0,114731,DB00091,Cyclosporine
,2781141,systemic clearance,Ketoconazole decreased the systemic clearance of cyclosporine from 7.0 ml/min/kg to 2.5 ml/min/kg.,Pharmacokinetics of the cyclosporine-ketoconazole interaction in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2781141/),[ml] / [kg·min],2.5,114732,DB00091,Cyclosporine
,2781141,terminal disposition rate constant,The terminal disposition rate constant was also decreased significantly from 0.0794 to 0.0354 hrs-1.,Pharmacokinetics of the cyclosporine-ketoconazole interaction in dogs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2781141/),1/[h],0.0794,114733,DB00091,Cyclosporine
,2781141,terminal disposition rate constant,The terminal disposition rate constant was also decreased significantly from 0.0794 to 0.0354 hrs-1.,Pharmacokinetics of the cyclosporine-ketoconazole interaction in dogs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2781141/),1/[h],0.0354,114734,DB00091,Cyclosporine
,22624503,area under the blood concentration-time curve from time zero to 12 hours (AUC(12)),Everolimus blood concentrations were analysed in whole blood using liquid chromatography-tandem mass spectrometry during routine therapeutic drug monitoring targeting an area under the blood concentration-time curve from time zero to 12 hours (AUC(12)) of 120 μg · h/L.,Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22624503/),[h·μg] / [l],120,114932,DB00091,Cyclosporine
,22624503,AUC(12),Maintaining everolimus systemic exposure at an AUC(12) of 120 μg · h/L resulted in low rejection rates but considerable numbers of adverse events and toxicity.,Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22624503/),[h·μg] / [l],120,114933,DB00091,Cyclosporine
,22624503,oral clearance,Everolimus pharmacokinetics were best described by a two-compartment model with lag-time (oral clearance = 17.9 L/h; volume of distribution of the central compartment after oral administration [V(1)/F] = 148 L and first-order absorption rate constant [k(a)] = 7.36 h-1).,Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22624503/),[l] / [h],17.9,114934,DB00091,Cyclosporine
,22624503,volume of distribution of the central compartment after oral administration [V(1)/F],Everolimus pharmacokinetics were best described by a two-compartment model with lag-time (oral clearance = 17.9 L/h; volume of distribution of the central compartment after oral administration [V(1)/F] = 148 L and first-order absorption rate constant [k(a)] = 7.36 h-1).,Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22624503/),l,148,114935,DB00091,Cyclosporine
,22624503,first-order absorption rate constant [k(a)],Everolimus pharmacokinetics were best described by a two-compartment model with lag-time (oral clearance = 17.9 L/h; volume of distribution of the central compartment after oral administration [V(1)/F] = 148 L and first-order absorption rate constant [k(a)] = 7.36 h-1).,Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22624503/),1/[h],7.36,114936,DB00091,Cyclosporine
,15987748,Cockcroft calculated clearance,Renal function was improved in the MMF group compared with the CsA group (Cockcroft calculated clearance 64.7 +/- 18.7 versus 56.5 +/- 18.0 ml/min; P = 0.023).,"Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15987748/),[ml] / [min],64.7,114965,DB00091,Cyclosporine
,15987748,Cockcroft calculated clearance,Renal function was improved in the MMF group compared with the CsA group (Cockcroft calculated clearance 64.7 +/- 18.7 versus 56.5 +/- 18.0 ml/min; P = 0.023).,"Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15987748/),[ml] / [min],56.5,114966,DB00091,Cyclosporine
,15987748,area under the curve,"The 10 patients who developed acute rejection after CsA withdrawal had a significantly higher incidence of borderline changes on the randomization biopsy than the 44 rejection-free patients (five of 10 versus eight of 44; P = 0.034), and they displayed a lower area under the curve of mycophenolic acid (43 +/- 9 versus 58 +/- 22 mg/h per L; P = 0.045).","Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15987748/),[mg] / [h·l],43,114967,DB00091,Cyclosporine
,15987748,area under the curve,"The 10 patients who developed acute rejection after CsA withdrawal had a significantly higher incidence of borderline changes on the randomization biopsy than the 44 rejection-free patients (five of 10 versus eight of 44; P = 0.034), and they displayed a lower area under the curve of mycophenolic acid (43 +/- 9 versus 58 +/- 22 mg/h per L; P = 0.045).","Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15987748/),[mg] / [h·l],58,114968,DB00091,Cyclosporine
,14501869,AUC(0-2),"In contrast, the combination of amlodipine significantly increased CsA AUC(0-2)/dose/kg (706.2 microg x hr/L to 819.2 microg x hr/L, P<0.05).","Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14501869/),[h·μg] / [l],706.2,115163,DB00091,Cyclosporine
,14501869,AUC(0-2),"In contrast, the combination of amlodipine significantly increased CsA AUC(0-2)/dose/kg (706.2 microg x hr/L to 819.2 microg x hr/L, P<0.05).","Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14501869/),[h·μg] / [l],819.2,115164,DB00091,Cyclosporine
,23503472,trough concentration (C0),"The dose-adjusted trough concentration (C0) of cyclosporine in ABCB1 2677 TT carriers was significantly higher than that in GG carriers together with GT carriers [90.4±24.5 vs 67.8±26.8 (ng/mL)/(mg/kg), P=0.001].","Associations of ABCB1, NFKB1, CYP3A, and NR1I2 polymorphisms with cyclosporine trough concentrations in Chinese renal transplant recipients. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23503472/),[ml·ng] / [kg·mg],90.4,115274,DB00091,Cyclosporine
,23503472,trough concentration (C0),"The dose-adjusted trough concentration (C0) of cyclosporine in ABCB1 2677 TT carriers was significantly higher than that in GG carriers together with GT carriers [90.4±24.5 vs 67.8±26.8 (ng/mL)/(mg/kg), P=0.001].","Associations of ABCB1, NFKB1, CYP3A, and NR1I2 polymorphisms with cyclosporine trough concentrations in Chinese renal transplant recipients. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23503472/),[ml·ng] / [kg·mg],67.8,115275,DB00091,Cyclosporine
,23503472,dose-adjusted,"ABCB1 3435 TT carriers had a significantly higher dose-adjusted C0 of cyclosporine than CC carriers together with CT carriers [92.0±24.0 vs 68.4±26.5 (ng/mL)/(mg/kg), P=0.002].","Associations of ABCB1, NFKB1, CYP3A, and NR1I2 polymorphisms with cyclosporine trough concentrations in Chinese renal transplant recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23503472/),[ml·ng] / [kg·mg],92.0,115276,DB00091,Cyclosporine
,23503472,dose-adjusted,"ABCB1 3435 TT carriers had a significantly higher dose-adjusted C0 of cyclosporine than CC carriers together with CT carriers [92.0±24.0 vs 68.4±26.5 (ng/mL)/(mg/kg), P=0.002].","Associations of ABCB1, NFKB1, CYP3A, and NR1I2 polymorphisms with cyclosporine trough concentrations in Chinese renal transplant recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23503472/),[ml·ng] / [kg·mg],68.4,115277,DB00091,Cyclosporine
,23503472,C0,"ABCB1 3435 TT carriers had a significantly higher dose-adjusted C0 of cyclosporine than CC carriers together with CT carriers [92.0±24.0 vs 68.4±26.5 (ng/mL)/(mg/kg), P=0.002].","Associations of ABCB1, NFKB1, CYP3A, and NR1I2 polymorphisms with cyclosporine trough concentrations in Chinese renal transplant recipients. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23503472/),[ml·ng] / [kg·mg],92.0,115278,DB00091,Cyclosporine
,23503472,C0,"ABCB1 3435 TT carriers had a significantly higher dose-adjusted C0 of cyclosporine than CC carriers together with CT carriers [92.0±24.0 vs 68.4±26.5 (ng/mL)/(mg/kg), P=0.002].","Associations of ABCB1, NFKB1, CYP3A, and NR1I2 polymorphisms with cyclosporine trough concentrations in Chinese renal transplant recipients. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23503472/),[ml·ng] / [kg·mg],68.4,115279,DB00091,Cyclosporine
,23503472,C0/D,"Carriers of the ABCB1 1236TT-2677TT-3435TT haplotype had a considerably higher CsA C0/D than carriers of other genotypes [97.2±21.8 vs 68.7±26.9 (ng/mL)/(mg/kg), P=0.001].","Associations of ABCB1, NFKB1, CYP3A, and NR1I2 polymorphisms with cyclosporine trough concentrations in Chinese renal transplant recipients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23503472/),[ml·ng] / [kg·mg],97.2,115280,DB00091,Cyclosporine
,23503472,C0/D,"Carriers of the ABCB1 1236TT-2677TT-3435TT haplotype had a considerably higher CsA C0/D than carriers of other genotypes [97.2±21.8 vs 68.7±26.9 (ng/mL)/(mg/kg), P=0.001].","Associations of ABCB1, NFKB1, CYP3A, and NR1I2 polymorphisms with cyclosporine trough concentrations in Chinese renal transplant recipients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23503472/),[ml·ng] / [kg·mg],68.7,115281,DB00091,Cyclosporine
,23503472,C0,"Among non-carriers of the ABCB1 2677 TT and 3435 TT genotypes, patients with the NFKB1 -94 ATTG ins/ins genotype had a significantly higher dose-adjusted C0 than those with the -94 ATTG del/del genotype [75.9±32.9 vs 55.1±15.1 (ng/mL)/(mg/kg), P=0.026].","Associations of ABCB1, NFKB1, CYP3A, and NR1I2 polymorphisms with cyclosporine trough concentrations in Chinese renal transplant recipients. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23503472/),[ml·ng] / [kg·mg],75.9,115282,DB00091,Cyclosporine
,23503472,C0,"Among non-carriers of the ABCB1 2677 TT and 3435 TT genotypes, patients with the NFKB1 -94 ATTG ins/ins genotype had a significantly higher dose-adjusted C0 than those with the -94 ATTG del/del genotype [75.9±32.9 vs 55.1±15.1 (ng/mL)/(mg/kg), P=0.026].","Associations of ABCB1, NFKB1, CYP3A, and NR1I2 polymorphisms with cyclosporine trough concentrations in Chinese renal transplant recipients. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23503472/),[ml·ng] / [kg·mg],55.1,115283,DB00091,Cyclosporine
,2391396,Blood,"Blood and plasma clearances of cyclosporine were calculated to be 0.36 and 0.47 L hr-1 Kg-1, respectively, and volume of distribution at steady state was calculated to be 1.21 L Kg-1, when cyclosporine was administered without a high fat meal.",Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391396/),[l] / [h·kg],0.36,115423,DB00091,Cyclosporine
,2391396,plasma clearances,"Blood and plasma clearances of cyclosporine were calculated to be 0.36 and 0.47 L hr-1 Kg-1, respectively, and volume of distribution at steady state was calculated to be 1.21 L Kg-1, when cyclosporine was administered without a high fat meal.",Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391396/),[l] / [h·kg],0.47,115424,DB00091,Cyclosporine
,2391396,volume of distribution at steady state,"Blood and plasma clearances of cyclosporine were calculated to be 0.36 and 0.47 L hr-1 Kg-1, respectively, and volume of distribution at steady state was calculated to be 1.21 L Kg-1, when cyclosporine was administered without a high fat meal.",Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391396/),[l] / [kg],1.21,115425,DB00091,Cyclosporine
,2391396,oral bioavailability,"Using plasma analysis, the oral bioavailability of cyclosporine was estimated to be 21 and 79%, when administered without and with a high fat meal, respectively.",Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391396/),%,21,115426,DB00091,Cyclosporine
,2391396,oral bioavailability,"Using plasma analysis, the oral bioavailability of cyclosporine was estimated to be 21 and 79%, when administered without and with a high fat meal, respectively.",Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391396/),%,79,115427,DB00091,Cyclosporine
,2391396,Blood,"Blood and plasma clearances of cyclosporine were 0.44 and 0.70 L hr-1 Kg-1, respectively, when cyclosporine was administered along with a high fat meal.",Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391396/),[l] / [h·kg],0.44,115428,DB00091,Cyclosporine
,2391396,plasma clearances,"Blood and plasma clearances of cyclosporine were 0.44 and 0.70 L hr-1 Kg-1, respectively, when cyclosporine was administered along with a high fat meal.",Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2391396/),[l] / [h·kg],0.70,115429,DB00091,Cyclosporine
,9855321,"Cmax,b","Lack of a pharmacokinetic drug-drug interaction with respect to valspodar was conclusively demonstrated for both Cmax,b (2.3+/-0.4 vs 2.4+/-0.5 microg/ml) and AUCb (19.8+/-4.8 vs 19.6+/-4.9 microg x hr/ml) inasmuch as bioequivalence criteria were satisfied when comparing administration alone with coadministration, respectively.","Pharmacokinetics of dexamethasone and valspodar, a P-glycoprotein (mdr1) modulator: implications for coadministration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855321/),[μg] / [ml],2.3,115655,DB00091,Cyclosporine
,9855321,"Cmax,b","Lack of a pharmacokinetic drug-drug interaction with respect to valspodar was conclusively demonstrated for both Cmax,b (2.3+/-0.4 vs 2.4+/-0.5 microg/ml) and AUCb (19.8+/-4.8 vs 19.6+/-4.9 microg x hr/ml) inasmuch as bioequivalence criteria were satisfied when comparing administration alone with coadministration, respectively.","Pharmacokinetics of dexamethasone and valspodar, a P-glycoprotein (mdr1) modulator: implications for coadministration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855321/),[μg] / [ml],2.4,115656,DB00091,Cyclosporine
,9855321,AUCb,"Lack of a pharmacokinetic drug-drug interaction with respect to valspodar was conclusively demonstrated for both Cmax,b (2.3+/-0.4 vs 2.4+/-0.5 microg/ml) and AUCb (19.8+/-4.8 vs 19.6+/-4.9 microg x hr/ml) inasmuch as bioequivalence criteria were satisfied when comparing administration alone with coadministration, respectively.","Pharmacokinetics of dexamethasone and valspodar, a P-glycoprotein (mdr1) modulator: implications for coadministration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855321/),[h·μg] / [ml],19.8,115657,DB00091,Cyclosporine
,9855321,AUCb,"Lack of a pharmacokinetic drug-drug interaction with respect to valspodar was conclusively demonstrated for both Cmax,b (2.3+/-0.4 vs 2.4+/-0.5 microg/ml) and AUCb (19.8+/-4.8 vs 19.6+/-4.9 microg x hr/ml) inasmuch as bioequivalence criteria were satisfied when comparing administration alone with coadministration, respectively.","Pharmacokinetics of dexamethasone and valspodar, a P-glycoprotein (mdr1) modulator: implications for coadministration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855321/),[h·μg] / [ml],19.6,115658,DB00091,Cyclosporine
,9855321,Cmax,"Although no changes in the rate of dexamethasone absorption were noted on coadministration with valspodar (Cmax 88+/-23 vs 91+/-20 ng/ml), overall exposure was significantly increased by 24% on average (AUC 400+/-87 vs 494+/-90 ng x hr/ml).","Pharmacokinetics of dexamethasone and valspodar, a P-glycoprotein (mdr1) modulator: implications for coadministration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855321/),[ng] / [ml],88,115659,DB00091,Cyclosporine
,9855321,Cmax,"Although no changes in the rate of dexamethasone absorption were noted on coadministration with valspodar (Cmax 88+/-23 vs 91+/-20 ng/ml), overall exposure was significantly increased by 24% on average (AUC 400+/-87 vs 494+/-90 ng x hr/ml).","Pharmacokinetics of dexamethasone and valspodar, a P-glycoprotein (mdr1) modulator: implications for coadministration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855321/),[ng] / [ml],91,115660,DB00091,Cyclosporine
,9855321,AUC,"Although no changes in the rate of dexamethasone absorption were noted on coadministration with valspodar (Cmax 88+/-23 vs 91+/-20 ng/ml), overall exposure was significantly increased by 24% on average (AUC 400+/-87 vs 494+/-90 ng x hr/ml).","Pharmacokinetics of dexamethasone and valspodar, a P-glycoprotein (mdr1) modulator: implications for coadministration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855321/),[h·ng] / [ml],400,115661,DB00091,Cyclosporine
,9855321,AUC,"Although no changes in the rate of dexamethasone absorption were noted on coadministration with valspodar (Cmax 88+/-23 vs 91+/-20 ng/ml), overall exposure was significantly increased by 24% on average (AUC 400+/-87 vs 494+/-90 ng x hr/ml).","Pharmacokinetics of dexamethasone and valspodar, a P-glycoprotein (mdr1) modulator: implications for coadministration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9855321/),[h·ng] / [ml],494,115662,DB00091,Cyclosporine
,22179400,survival time (MST),"STN monotherapy at 50 mg/kg once daily prolonged recipient survival times to the predefined endpoint of 29 days (n=2); when given at 25 mg/kg twice daily, the median survival time (MST) was 27 days (n=4).",Sotrastaurin (AEB071) alone and in combination with cyclosporine A prolongs survival times of non-human primate recipients of life-supporting kidney allografts. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22179400/),d,27,116165,DB00091,Cyclosporine
more,22179400,MST,"By combining lower once-daily doses of STN (7 or 2 mg/kg) with CsA (20 mg/kg), MST was more than 100 (n=3) and 22 days (n=2), respectively.",Sotrastaurin (AEB071) alone and in combination with cyclosporine A prolongs survival times of non-human primate recipients of life-supporting kidney allografts. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22179400/),d,100,116166,DB00091,Cyclosporine
,22179400,MST,"By combining lower once-daily doses of STN (7 or 2 mg/kg) with CsA (20 mg/kg), MST was more than 100 (n=3) and 22 days (n=2), respectively.",Sotrastaurin (AEB071) alone and in combination with cyclosporine A prolongs survival times of non-human primate recipients of life-supporting kidney allografts. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22179400/),d,22,116167,DB00091,Cyclosporine
,15866686,S-Crea,"The study included 13 adolescents (mean posttransplantation time, 3.5 +/- 2.55 years) with stable renal transplant function (S-Crea 121 +/- 40 micromol/L).",Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866686/),μ,121,116558,DB00091,Cyclosporine
,15866686,C2,"Whereas C2 (mean 743.2 +/- 221.8 ng/mL) was the single point with the closest correlation to AUC(0-6h) (r2 = 0.86; P < .001), C0 (mean 120.5 +/- 35.2 ng/mL) showed the weakest correlation (r2 = 0.61, P = .002).",Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866686/),[ng] / [ml],743.2,116559,DB00091,Cyclosporine
,15866686,C0,"Whereas C2 (mean 743.2 +/- 221.8 ng/mL) was the single point with the closest correlation to AUC(0-6h) (r2 = 0.86; P < .001), C0 (mean 120.5 +/- 35.2 ng/mL) showed the weakest correlation (r2 = 0.61, P = .002).",Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866686/),[ng] / [ml],120.5,116560,DB00091,Cyclosporine
,16252067,area under concentration-time curve,"Accordingly, the area under concentration-time curve in serum and brain was higher in CsA co-treated rats (13.5 vs.",Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16252067/),,13.5,116658,DB00091,Cyclosporine
,19702545,AUC up to infinity,"There were no differences in PK profiles after i.v. administration of CyA between RIR and control rats; however, AUC up to infinity (1.81+/-0.18 microg.h/ml) in RIR rats after i.d. administration was significantly lower than in control rats (5.01+/-1.78 microg.h/ml).",Comparison of pharmacokinetics of cyclosporine A in cadaveric and living-related renal transplant recipients and in an experimental rat model of renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19702545/),[h·μg] / [ml],1.81,116886,DB00091,Cyclosporine
,19702545,AUC up to infinity,"There were no differences in PK profiles after i.v. administration of CyA between RIR and control rats; however, AUC up to infinity (1.81+/-0.18 microg.h/ml) in RIR rats after i.d. administration was significantly lower than in control rats (5.01+/-1.78 microg.h/ml).",Comparison of pharmacokinetics of cyclosporine A in cadaveric and living-related renal transplant recipients and in an experimental rat model of renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19702545/),[h·μg] / [ml],5.01,116887,DB00091,Cyclosporine
,10071350,bioavailability,"On conversion to the microemulsion formulation of cyclosporine, black and nonblack patients experienced increases in cyclosporine bioavailability of 102% and 39%, respectively (P =.009 and P =.001).",Improved cyclosporine bioavailability in black pediatric liver transplant recipients after administration of the microemulsion formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071350/),%,102,117283,DB00091,Cyclosporine
,10071350,bioavailability,"On conversion to the microemulsion formulation of cyclosporine, black and nonblack patients experienced increases in cyclosporine bioavailability of 102% and 39%, respectively (P =.009 and P =.001).",Improved cyclosporine bioavailability in black pediatric liver transplant recipients after administration of the microemulsion formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071350/),%,39,117284,DB00091,Cyclosporine
,1932609,terminal elimination half-life (t1/2),The terminal elimination half-life (t1/2) of CyA was significantly lower with Intralipid administration (191 +/- 25 min) than control (298 +/- 59 min).,Effect of co-administration of Intralipid on the pharmacokinetics of cyclosporine in the rabbit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932609/),min,191,117517,DB00091,Cyclosporine
,1932609,terminal elimination half-life (t1/2),The terminal elimination half-life (t1/2) of CyA was significantly lower with Intralipid administration (191 +/- 25 min) than control (298 +/- 59 min).,Effect of co-administration of Intralipid on the pharmacokinetics of cyclosporine in the rabbit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932609/),min,298,117518,DB00091,Cyclosporine
,1932609,free fraction,"The free fraction of CyA in plasma with and without Intralipid administration was estimated to be 0.05 +/- 0.01 and 0.17 +/- 0.06, respectively.",Effect of co-administration of Intralipid on the pharmacokinetics of cyclosporine in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932609/),,0.05,117519,DB00091,Cyclosporine
,1932609,free fraction,"The free fraction of CyA in plasma with and without Intralipid administration was estimated to be 0.05 +/- 0.01 and 0.17 +/- 0.06, respectively.",Effect of co-administration of Intralipid on the pharmacokinetics of cyclosporine in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932609/),,0.17,117520,DB00091,Cyclosporine
,16969354,overall response rate,"In intention to treat analysis, the overall response rate was 52%, the median time to progression was 6.5 months and overall survival was 16 months.",Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16969354/),%,52,117578,DB00091,Cyclosporine
,16969354,time to progression,"In intention to treat analysis, the overall response rate was 52%, the median time to progression was 6.5 months and overall survival was 16 months.",Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16969354/),month,6.5,117579,DB00091,Cyclosporine
,16969354,overall survival,"In intention to treat analysis, the overall response rate was 52%, the median time to progression was 6.5 months and overall survival was 16 months.",Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16969354/),month,16,117580,DB00091,Cyclosporine
,10935703,trough concentration,"The mean Mycophenolic acid (MPA) trough concentration was 4.0 +/- 2.0 microg/ml, range 1.4-7.9 microg/ml.",Effect of adding Mycophenolate mofetil in paediatric renal transplant recipients with chronical cyclosporine nephrotoxicity. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10935703/),[μg] / [ml],4.0,117816,DB00091,Cyclosporine
,10935703,AUC,Mean 12 h MPA AUC was 70.6 +/- 28.1 (range 31.9-127) microg x h/ml.,Effect of adding Mycophenolate mofetil in paediatric renal transplant recipients with chronical cyclosporine nephrotoxicity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10935703/),[h·μg] / [ml],70.6,117817,DB00091,Cyclosporine
,8055680,terminal elimination half-life,The terminal elimination half-life is between 20 and 50 hours.,Clinical pharmacokinetics of ticlopidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8055680/),h,20 and 50,118182,DB00091,Cyclosporine
,18084333,AUC,"Using a twice daily MMF regimen, we conclude that an AUC of 30-60 mug/ml h as recommended for SOT cannot be reached in HSCT.",Pharmacokinetics of oral mycophenolate mofetil in combination with CsA in dogs after nonmyeloablative allogeneic hematopoietic stem cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18084333/),[μg] / [h·ml],30-60,118647,DB00091,Cyclosporine
,23089581,AUC(0-24h),"In vivo study in rats showed that the optimized NC(50/125) and NC(100/125) released the drug in controlled way as well as enhanced the bioavailability significantly with AUC(0-24h) values of 14880.3±1470.6 and 12657.8±754.5 ng h/ml, respectively, compared to that of SEDDS-core solution (9878.9±409.6 ng h/ml).",Polymeric nanocapsules with SEDDS oil-core for the controlled and enhanced oral absorption of cyclosporine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23089581/),[h·ng] / [ml],14880.3,118751,DB00091,Cyclosporine
,23089581,AUC(0-24h),"In vivo study in rats showed that the optimized NC(50/125) and NC(100/125) released the drug in controlled way as well as enhanced the bioavailability significantly with AUC(0-24h) values of 14880.3±1470.6 and 12657.8±754.5 ng h/ml, respectively, compared to that of SEDDS-core solution (9878.9±409.6 ng h/ml).",Polymeric nanocapsules with SEDDS oil-core for the controlled and enhanced oral absorption of cyclosporine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23089581/),[h·ng] / [ml],12657.8,118752,DB00091,Cyclosporine
,23089581,AUC(0-24h),"In vivo study in rats showed that the optimized NC(50/125) and NC(100/125) released the drug in controlled way as well as enhanced the bioavailability significantly with AUC(0-24h) values of 14880.3±1470.6 and 12657.8±754.5 ng h/ml, respectively, compared to that of SEDDS-core solution (9878.9±409.6 ng h/ml).",Polymeric nanocapsules with SEDDS oil-core for the controlled and enhanced oral absorption of cyclosporine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23089581/),[h·ng] / [ml],9878.9,118753,DB00091,Cyclosporine
,12021639,area under the concentration-time curve (AUC),"The 12-hour area under the concentration-time curve (AUC) values for MPA and its major metabolite the phenolic glucuronide MPAG were 55.1 mg.h/L and 800 mg.h/L, respectively.",Atypical pharmacokinetics and metabolism of mycophenolic acid in a young kidney transplant recipient with impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021639/),[h·mg] / [l],55.1,120123,DB00091,Cyclosporine
,12021639,area under the concentration-time curve (AUC),"The 12-hour area under the concentration-time curve (AUC) values for MPA and its major metabolite the phenolic glucuronide MPAG were 55.1 mg.h/L and 800 mg.h/L, respectively.",Atypical pharmacokinetics and metabolism of mycophenolic acid in a young kidney transplant recipient with impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021639/),[h·mg] / [l],800,120124,DB00091,Cyclosporine
,12021639,12-h,"An unusually high concentration (12-h AUC, 165 mg.h/L) of the phenolic glucose conjugate of MPA was found.",Atypical pharmacokinetics and metabolism of mycophenolic acid in a young kidney transplant recipient with impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021639/),[h·mg] / [l],165,120125,DB00091,Cyclosporine
,12021639,AUC,"An unusually high concentration (12-h AUC, 165 mg.h/L) of the phenolic glucose conjugate of MPA was found.",Atypical pharmacokinetics and metabolism of mycophenolic acid in a young kidney transplant recipient with impaired renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021639/),[h·mg] / [l],165,120126,DB00091,Cyclosporine
,12021639,apparent renal clearance,The apparent renal clearance of MPAG was only 2.2 mL/min.,Atypical pharmacokinetics and metabolism of mycophenolic acid in a young kidney transplant recipient with impaired renal function. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021639/),[ml] / [min],2.2,120127,DB00091,Cyclosporine
,7711283,free fraction,"The free fraction of cyclosporine in the rabbits and the heart transplant patients was 0.0122 and 0.14, respectively.",The estimation of the plasma free fraction of cyclosporine in rabbits and heart transplant patients: the application of a physiological model of renal clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711283/),,0.0122,120624,DB00091,Cyclosporine
,7711283,free fraction,"The free fraction of cyclosporine in the rabbits and the heart transplant patients was 0.0122 and 0.14, respectively.",The estimation of the plasma free fraction of cyclosporine in rabbits and heart transplant patients: the application of a physiological model of renal clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711283/),,0.14,120625,DB00091,Cyclosporine
,1330397,bioavailability (F),"Major findings were as follows: The bioavailability (F) of cyclosporine was significantly lower in black patients than in white patients (mean values of 30.9% +/- 12.3% and 39.5% +/- 16.5%, respectively; p < 0.001).",Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1330397/),%,30.9,120627,DB00091,Cyclosporine
,1330397,bioavailability (F),"Major findings were as follows: The bioavailability (F) of cyclosporine was significantly lower in black patients than in white patients (mean values of 30.9% +/- 12.3% and 39.5% +/- 16.5%, respectively; p < 0.001).",Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1330397/),%,39.5,120628,DB00091,Cyclosporine
,23070347,trough levels,We present a prospective study of a microemulsion of cyclosporin to treat idiopathic nephrotic syndrome in ten children with normal renal function who presented cyclosporin trough levels between 50 and 150 ng/ml and achieved complete remission with cyclosporin.,Pharmacokinetics of cyclosporin--a microemulsion in children with idiopathic nephrotic syndrome. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23070347/),[ng] / [ml],50 and 150,121237,DB00091,Cyclosporine
,16490808,Tmax,Tmax (approximately 1.3 hours) was similar with and without EZE (P >.200).,Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490808/),h,1.3,121284,DB00091,Cyclosporine
,10971308,Emax,"Compared with PSC alone, morphine elicited an increase in reaction time (Emax 48 ms, compared with the predose absolute reaction time of 644 ms), which was not detected by the alertness-drowsiness score, indicating only slight sedation.",Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10971308/),ms,48,121815,DB00091,Cyclosporine
,10971308,absolute reaction time,"Compared with PSC alone, morphine elicited an increase in reaction time (Emax 48 ms, compared with the predose absolute reaction time of 644 ms), which was not detected by the alertness-drowsiness score, indicating only slight sedation.",Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10971308/),ms,644,121816,DB00091,Cyclosporine
,10971308,Emax,"In contrast, morphine caused a significant increase in PCO2 (Emax 0.69 kPa) compared to PSC alone, indicating slight respiratory depression.",Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10971308/),kpa,0.69,121817,DB00091,Cyclosporine
,9278195,C(max),Neoral had a higher C(max) and AUC(C(max): 943 +/- 176 ng ml(-1); AUC: 4612 +/- 785 ng ml(-1) h) than those of the CsA capsules (C(max): 697 +/- 187 ng ml(-1); AUC: 3483 +/- 873 ng ml(-1) h; P < 0.05).,Cyclosporin pharmacokinetics following administration of capsules and Neoral in paediatric patients with lupus nephritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278195/),[ng] / [ml],943,121897,DB00091,Cyclosporine
,9278195,AUC,Neoral had a higher C(max) and AUC(C(max): 943 +/- 176 ng ml(-1); AUC: 4612 +/- 785 ng ml(-1) h) than those of the CsA capsules (C(max): 697 +/- 187 ng ml(-1); AUC: 3483 +/- 873 ng ml(-1) h; P < 0.05).,Cyclosporin pharmacokinetics following administration of capsules and Neoral in paediatric patients with lupus nephritis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278195/),[h·ng] / [ml],4612,121898,DB00091,Cyclosporine
,9278195,C(max),Neoral had a higher C(max) and AUC(C(max): 943 +/- 176 ng ml(-1); AUC: 4612 +/- 785 ng ml(-1) h) than those of the CsA capsules (C(max): 697 +/- 187 ng ml(-1); AUC: 3483 +/- 873 ng ml(-1) h; P < 0.05).,Cyclosporin pharmacokinetics following administration of capsules and Neoral in paediatric patients with lupus nephritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278195/),[ng] / [ml],697,121899,DB00091,Cyclosporine
,9278195,AUC,Neoral had a higher C(max) and AUC(C(max): 943 +/- 176 ng ml(-1); AUC: 4612 +/- 785 ng ml(-1) h) than those of the CsA capsules (C(max): 697 +/- 187 ng ml(-1); AUC: 3483 +/- 873 ng ml(-1) h; P < 0.05).,Cyclosporin pharmacokinetics following administration of capsules and Neoral in paediatric patients with lupus nephritis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278195/),[h·ng] / [ml],3483,121900,DB00091,Cyclosporine
,2655690,bioavailability,"2. Blood and plasma CyA concentrations and blood concentrations of metabolite 17 were measured by h.p.l.c. 3. Erythromycin produced almost a two-fold increase in bioavailability, from 36% to 60%; with a small (13%) decrease in clearance of CyA. 4.",Cyclosporin-erythromycin interaction in renal transplant patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2655690/),%,36,121924,DB00091,Cyclosporine
,2655690,bioavailability,"2. Blood and plasma CyA concentrations and blood concentrations of metabolite 17 were measured by h.p.l.c. 3. Erythromycin produced almost a two-fold increase in bioavailability, from 36% to 60%; with a small (13%) decrease in clearance of CyA. 4.",Cyclosporin-erythromycin interaction in renal transplant patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2655690/),%,60,121925,DB00091,Cyclosporine
,22116269,blood concentration at 2 h post-dose (C2),The doses of CyA administered were adjusted such that the target value for blood concentration at 2 h post-dose (C2) was 400-450 ng/ml.,Age effect on whole blood cyclosporine concentrations following oral administration in children with nephrotic syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22116269/),[ng] / [ml],400-450,122369,DB00091,Cyclosporine
,9300138,trough levels,"In clinical adaptation for renal transplant patients, the steady-state concentration of CsA (Css) based on the AUC0-8 predictive model was significantly decreased during acute gastroenteritis or before acute rejection, whereas nephrotoxicity was increased, even though CsA trough levels were within a normal therapeutic range (100-200 ng/ml).",A predictive model for area under the concentration versus time curve of cyclosporin A using several routine monitoring results in renal transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9300138/),[ng] / [ml],100-200,122470,DB00091,Cyclosporine
,17686907,Km,"CP-671,305 was a substrate of human OATP2B1 with a high affinity (Km = 4 microM) but not a substrate for human OATP1B1 or OATP1B3.","Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid in rat and human. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17686907/),μM,4,122906,DB00091,Cyclosporine
,17686907,Km,"Upon examination as a substrate for major rat hepatic Oatps, CP-671,305 displayed high affinity (Km = 12 microM) for Oatp1a4.","Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid in rat and human. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17686907/),μM,12,122907,DB00091,Cyclosporine
,18793723,self-diffusion coefficient (D),"Utilizing nuclear magnetic resonance spectroscopy (NMR), the self-diffusion coefficient (D) of PAC in CM, LBM and CPM containing 10% of deuterium oxide (D(2)O) was 2.24x10(-11), 1.97x10(-11) and 0.51x10(-11) m(2)/s, respectively.",Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793723/),[m(2] / [s],2.24x10(-11),123149,DB00091,Cyclosporine
,18793723,self-diffusion coefficient (D),"Utilizing nuclear magnetic resonance spectroscopy (NMR), the self-diffusion coefficient (D) of PAC in CM, LBM and CPM containing 10% of deuterium oxide (D(2)O) was 2.24x10(-11), 1.97x10(-11) and 0.51x10(-11) m(2)/s, respectively.",Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793723/),[m(2] / [s],1.97x10(-11),123150,DB00091,Cyclosporine
,18793723,self-diffusion coefficient (D),"Utilizing nuclear magnetic resonance spectroscopy (NMR), the self-diffusion coefficient (D) of PAC in CM, LBM and CPM containing 10% of deuterium oxide (D(2)O) was 2.24x10(-11), 1.97x10(-11) and 0.51x10(-11) m(2)/s, respectively.",Oral microemulsions of paclitaxel: in situ and pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793723/),[m(2] / [s],0.51x10(-11),123151,DB00091,Cyclosporine
,3318898,clearance,"4 Following the 72 h infusion, a plateau was reached by 24 h and clearance was 0.60 l h-1 kg-1.",Pharmacokinetics of cyclosporin: influence of rate of constant intravenous infusion in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3318898/),[l] / [h·kg],0.60,123735,DB00091,Cyclosporine
,3318898,Clearance,5 Clearance associated with the 10 mg kg-1 day-1 infusion rate (0.43 l h-1 kg-1) was estimated to be lower than that following the 4 and 7 mg kg-1 day-1 rates (0.52 and 0.54 l h-1 kg-1 respectively) but the difference is unlikely to be of clinical significance.,Pharmacokinetics of cyclosporin: influence of rate of constant intravenous infusion in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3318898/),[l] / [h·kg],0.43,123736,DB00091,Cyclosporine
,3318898,Clearance,5 Clearance associated with the 10 mg kg-1 day-1 infusion rate (0.43 l h-1 kg-1) was estimated to be lower than that following the 4 and 7 mg kg-1 day-1 rates (0.52 and 0.54 l h-1 kg-1 respectively) but the difference is unlikely to be of clinical significance.,Pharmacokinetics of cyclosporin: influence of rate of constant intravenous infusion in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3318898/),[l] / [h·kg],0.52,123737,DB00091,Cyclosporine
,3318898,Clearance,5 Clearance associated with the 10 mg kg-1 day-1 infusion rate (0.43 l h-1 kg-1) was estimated to be lower than that following the 4 and 7 mg kg-1 day-1 rates (0.52 and 0.54 l h-1 kg-1 respectively) but the difference is unlikely to be of clinical significance.,Pharmacokinetics of cyclosporin: influence of rate of constant intravenous infusion in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3318898/),[l] / [h·kg],0.54,123738,DB00091,Cyclosporine
,16827636,concentration,"In the days immediately after transplantation, we found a correlation between the concentration/dose ratio and the exon 26 MDR single nucleotide polymorphisms (33.3+/-15.24 microg mg/L/kg in the CT group vs 44.1+/-28.4 microg mg/L/kg in the TT group, P=.019).",Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16827636/),,33,124801,DB00091,Cyclosporine
,3895624,peak,The administration of cyclosporine with food resulted in a significant increase in the peak (1465 ng/ml versus 1120 ng/ml) and trough (267 ng/ml versus 228 ng/ml) blood concentrations as well as the area under the blood concentration versus time curve (11430 ng . hr/ml versus 7881 ng . hr/ml).,The effect of food on cyclosporine absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3895624/),[ng] / [ml],1465,124937,DB00091,Cyclosporine
,3895624,peak,The administration of cyclosporine with food resulted in a significant increase in the peak (1465 ng/ml versus 1120 ng/ml) and trough (267 ng/ml versus 228 ng/ml) blood concentrations as well as the area under the blood concentration versus time curve (11430 ng . hr/ml versus 7881 ng . hr/ml).,The effect of food on cyclosporine absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3895624/),[ng] / [ml],1120,124938,DB00091,Cyclosporine
,3895624,trough,The administration of cyclosporine with food resulted in a significant increase in the peak (1465 ng/ml versus 1120 ng/ml) and trough (267 ng/ml versus 228 ng/ml) blood concentrations as well as the area under the blood concentration versus time curve (11430 ng . hr/ml versus 7881 ng . hr/ml).,The effect of food on cyclosporine absorption. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3895624/),[ng] / [ml],267,124939,DB00091,Cyclosporine
,3895624,trough,The administration of cyclosporine with food resulted in a significant increase in the peak (1465 ng/ml versus 1120 ng/ml) and trough (267 ng/ml versus 228 ng/ml) blood concentrations as well as the area under the blood concentration versus time curve (11430 ng . hr/ml versus 7881 ng . hr/ml).,The effect of food on cyclosporine absorption. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3895624/),[ng] / [ml],228,124940,DB00091,Cyclosporine
,3895624,area under the blood concentration versus time curve,The administration of cyclosporine with food resulted in a significant increase in the peak (1465 ng/ml versus 1120 ng/ml) and trough (267 ng/ml versus 228 ng/ml) blood concentrations as well as the area under the blood concentration versus time curve (11430 ng . hr/ml versus 7881 ng . hr/ml).,The effect of food on cyclosporine absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3895624/),[h·ng] / [ml],11430,124941,DB00091,Cyclosporine
,3895624,area under the blood concentration versus time curve,The administration of cyclosporine with food resulted in a significant increase in the peak (1465 ng/ml versus 1120 ng/ml) and trough (267 ng/ml versus 228 ng/ml) blood concentrations as well as the area under the blood concentration versus time curve (11430 ng . hr/ml versus 7881 ng . hr/ml).,The effect of food on cyclosporine absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3895624/),[h·ng] / [ml],7881,124942,DB00091,Cyclosporine
,11250882,brain-to-blood coefficient of distribution,"2. Following pefloxacin administration, the brain-to-blood coefficient of distribution was 0.036.","Pharmacokinetics of pefloxacin and its interaction with cyclosporin A, a P-glycoprotein modulator, in rat blood, brain and bile, using simultaneous microdialysis. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11250882/),,0.036,125115,DB00091,Cyclosporine
,11250882,coefficient of distribution (k,The bile-to-blood coefficient of distribution (k=AUC(bile)/AUC(blood)) was 1.53.,"Pharmacokinetics of pefloxacin and its interaction with cyclosporin A, a P-glycoprotein modulator, in rat blood, brain and bile, using simultaneous microdialysis. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11250882/),,1.53,125116,DB00091,Cyclosporine
,9286770,area-under-the-curve,Conversion to Neoral resulted in a 24% increase in area-under-the-curve in spite of no significant changes in cyclosporine trough levels (165 +/- 48 [Sandimmune] vs 169 +/- 32 nmol/L; p = 0.26).,"Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9286770/),[nM] / [l],165,125127,DB00091,Cyclosporine
,9286770,area-under-the-curve,Conversion to Neoral resulted in a 24% increase in area-under-the-curve in spite of no significant changes in cyclosporine trough levels (165 +/- 48 [Sandimmune] vs 169 +/- 32 nmol/L; p = 0.26).,"Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9286770/),[nM] / [l],169,125128,DB00091,Cyclosporine
,9286770,trough levels,Conversion to Neoral resulted in a 24% increase in area-under-the-curve in spite of no significant changes in cyclosporine trough levels (165 +/- 48 [Sandimmune] vs 169 +/- 32 nmol/L; p = 0.26).,"Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9286770/),[nM] / [l],165,125129,DB00091,Cyclosporine
,9286770,trough levels,Conversion to Neoral resulted in a 24% increase in area-under-the-curve in spite of no significant changes in cyclosporine trough levels (165 +/- 48 [Sandimmune] vs 169 +/- 32 nmol/L; p = 0.26).,"Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9286770/),[nM] / [l],169,125130,DB00091,Cyclosporine
,24673713,maximum plasma concentrations (Cmax ),"The mean maximum plasma concentrations (Cmax ) of MPA in the CsA and Tac groups were 11.365 ± 9.522 and 9.748 ± 7.523 μg/ml, respectively (p = 0.137).",Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673713/),[μg] / [ml],11.365,125813,DB00091,Cyclosporine
,24673713,maximum plasma concentrations (Cmax ),"The mean maximum plasma concentrations (Cmax ) of MPA in the CsA and Tac groups were 11.365 ± 9.522 and 9.748 ± 7.523 μg/ml, respectively (p = 0.137).",Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673713/),[μg] / [ml],9.748,125814,DB00091,Cyclosporine
,24673713,maximum times to Cmax (Tmax ),"The maximum times to Cmax (Tmax ) were 2.54 ± 1.53 and 2.67 ± 1.08 h, respectively (p = 0.341).",Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673713/),h,2.54,125815,DB00091,Cyclosporine
,24673713,maximum times to Cmax (Tmax ),"The maximum times to Cmax (Tmax ) were 2.54 ± 1.53 and 2.67 ± 1.08 h, respectively (p = 0.341).",Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673713/),h,2.67,125816,DB00091,Cyclosporine
,24673713,areas under the curve (MPA-AUC0-12 h ),The mean MPA 12-h areas under the curve (MPA-AUC0-12 h ) were 59.463 ± 16.252 and 77.535 ± 33.615 μg h/ml (p = 0.003) and the mean residence times (MRT) were 3.71 ± 0.829 and 3.928 ± 0.923 h (p = 0.038).,Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673713/),[h·μg] / [ml],59.463,125817,DB00091,Cyclosporine
,24673713,areas under the curve (MPA-AUC0-12 h ),The mean MPA 12-h areas under the curve (MPA-AUC0-12 h ) were 59.463 ± 16.252 and 77.535 ± 33.615 μg h/ml (p = 0.003) and the mean residence times (MRT) were 3.71 ± 0.829 and 3.928 ± 0.923 h (p = 0.038).,Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673713/),[h·μg] / [ml],77.535,125818,DB00091,Cyclosporine
,24673713,mean residence times (MRT),The mean MPA 12-h areas under the curve (MPA-AUC0-12 h ) were 59.463 ± 16.252 and 77.535 ± 33.615 μg h/ml (p = 0.003) and the mean residence times (MRT) were 3.71 ± 0.829 and 3.928 ± 0.923 h (p = 0.038).,Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673713/),h,3.71,125819,DB00091,Cyclosporine
,24673713,mean residence times (MRT),The mean MPA 12-h areas under the curve (MPA-AUC0-12 h ) were 59.463 ± 16.252 and 77.535 ± 33.615 μg h/ml (p = 0.003) and the mean residence times (MRT) were 3.71 ± 0.829 and 3.928 ± 0.923 h (p = 0.038).,Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673713/),h,3.928,125820,DB00091,Cyclosporine
,14749545,mean absorption time (MAT),"The ""Erlang"" model best described the data, with mean absorption time (MAT), apparent clearance (CL/F), and apparent volume of the central compartment (Vc/F) of 0.78 hours, 26.3 L/h, and 76 L, respectively (interindividual variability CV = 33, 30, and 48%).",Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749545/),h,0.78,125991,DB00091,Cyclosporine
,14749545,apparent clearance (CL/F),"The ""Erlang"" model best described the data, with mean absorption time (MAT), apparent clearance (CL/F), and apparent volume of the central compartment (Vc/F) of 0.78 hours, 26.3 L/h, and 76 L, respectively (interindividual variability CV = 33, 30, and 48%).",Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749545/),[l] / [h],26.3,125992,DB00091,Cyclosporine
,14749545,apparent volume of the central compartment (Vc/F),"The ""Erlang"" model best described the data, with mean absorption time (MAT), apparent clearance (CL/F), and apparent volume of the central compartment (Vc/F) of 0.78 hours, 26.3 L/h, and 76 L, respectively (interindividual variability CV = 33, 30, and 48%).",Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749545/),l,76,125993,DB00091,Cyclosporine
,19857744,acute rejection rate,The biopsy-proved acute rejection rate was 65% at 3 months post-OLT.,Rationale for monitoring cyclosporine concentration at 2 hours after administration in infants posttransplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19857744/),%,65,126154,DB00091,Cyclosporine
,23676788,trough concentration,"The target trough concentration of sirolimus and cyclosporine was set to around 15 ng/mL and 180 ng/mL, respectively.",Effectiveness of sirolimus in combination with cyclosporine against chronic rejection in a pediatric liver transplant patient. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23676788/),[ng] / [ml],15,126304,DB00091,Cyclosporine
,23676788,trough concentration,"The target trough concentration of sirolimus and cyclosporine was set to around 15 ng/mL and 180 ng/mL, respectively.",Effectiveness of sirolimus in combination with cyclosporine against chronic rejection in a pediatric liver transplant patient. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23676788/),[ng] / [ml],180,126305,DB00091,Cyclosporine
,23676788,T-bil,"Thereafter, the levels of AST and ALT as well as the T-bil were successfully decreased to 73 U/L, 83 U/L, and 3.0 mg/dL, respectively.",Effectiveness of sirolimus in combination with cyclosporine against chronic rejection in a pediatric liver transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23676788/),[mg] / [dl],3.0,126306,DB00091,Cyclosporine
,9884251,duration of,"The median duration of the initial episode of i.v. cyclosporine was 4.0 days for Neoral, compared to 6.5 days for Sandimmun (P<0.001).",Randomized trial of cyclosporine microemulsion (neoral) versus conventional cyclosporine in liver transplantation: MILTON study. Multicentre International Study in Liver Transplantation of Neoral. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884251/),d,4.0,126663,DB00091,Cyclosporine
,9884251,duration of,"The median duration of the initial episode of i.v. cyclosporine was 4.0 days for Neoral, compared to 6.5 days for Sandimmun (P<0.001).",Randomized trial of cyclosporine microemulsion (neoral) versus conventional cyclosporine in liver transplantation: MILTON study. Multicentre International Study in Liver Transplantation of Neoral. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884251/),d,6.5,126664,DB00091,Cyclosporine
,9649150,area under the concentration time for etoposide curve,Cyclosporin levels ranged from 1359 to 4835 ng ml(-1) and cyclosporin increased the median area under the concentration time for etoposide curve from 7.2 to 12.5 mg ml(-1) min.,High-dose cyclosporin with etoposide--toxicity and pharmacokinetic interaction in children with solid tumours. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9649150/),[mg·min] / [ml],7,126710,DB00091,Cyclosporine
,16130744,flow rate,"Samples were eluted with a mobile phase containing methanol-1% diethylamine (pH 7.15) in water (75:25, v/v) and the flow rate of the mobile phase was 0.7 ml/min.",Measurement and pharmacokinetics of vincamine in rat blood and brain using microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16130744/),[ml] / [min],0.7,127286,DB00091,Cyclosporine
>,17326777,Cmax,"While only 2 (28.6%) of seven pigs with Cmax > 3 microg/ml during the first 2 weeks had AMR, 7 (87.5%) of eight pigs with Cmax < 3 microg/ml elicited anti-donor Abs and experienced AMR (P = 0.0406).",Prophylactic treatment of antibody-mediated rejection with high-dose mizoribine and pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17326777/),[μg] / [ml],3,127304,DB00091,Cyclosporine
<,17326777,Cmax,"While only 2 (28.6%) of seven pigs with Cmax > 3 microg/ml during the first 2 weeks had AMR, 7 (87.5%) of eight pigs with Cmax < 3 microg/ml elicited anti-donor Abs and experienced AMR (P = 0.0406).",Prophylactic treatment of antibody-mediated rejection with high-dose mizoribine and pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17326777/),[μg] / [ml],3,127305,DB00091,Cyclosporine
over,17326777,Cmax,Effective Cmax seemed to be over 3 microg/ml at minimum.,Prophylactic treatment of antibody-mediated rejection with high-dose mizoribine and pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17326777/),[μg] / [ml],3,127306,DB00091,Cyclosporine
,24929057,Absolute recoveries,"Absolute recoveries of DLM, CIS and TRANS ranged from 86 to 95%.",Measurement of plasma protein and lipoprotein binding of pyrethroids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24929057/),%,86 to 95,127507,DB00091,Cyclosporine
,16476117,area under the curve (AUC),"Despite a comparable MMF dose, a large inter-patient variability in both MPA area under the curve (AUC) from 0 to 12 h (range 10.03-135.4 microg h/mL) and in predose concentrations (0.31-6.09 microg/mL) was observed.",Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16476117/),[h·μg] / [ml],10.03-135.4,127533,DB00091,Cyclosporine
>,16476117,AUC,Patients with AUC > 35 microg h/mL showed better (P < 0.1) renal function than patients with AUC < 20 microg h/mL (mean creatinine concentration 1.48 +/- 0.12 vs. 3.35 +/- 0.4 mg/dL respectively).,Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16476117/),[h·μg] / [ml],35,127534,DB00091,Cyclosporine
<,16476117,AUC,Patients with AUC > 35 microg h/mL showed better (P < 0.1) renal function than patients with AUC < 20 microg h/mL (mean creatinine concentration 1.48 +/- 0.12 vs. 3.35 +/- 0.4 mg/dL respectively).,Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16476117/),[h·μg] / [ml],20,127535,DB00091,Cyclosporine
,16476117,trough level,A higher trough level of the metabolite MPA glucuronide (MPAG) in the 1 week after transplantation was found when compared with the 3-month level (mean 150.1 +/- 146.7; range 17.1 to 560 vs. 75.8 +/- 40.0; range 27.3 to 174.2 microg/mL).,Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16476117/),[μg] / [ml],150.1,127536,DB00091,Cyclosporine
,16476117,trough level,A higher trough level of the metabolite MPA glucuronide (MPAG) in the 1 week after transplantation was found when compared with the 3-month level (mean 150.1 +/- 146.7; range 17.1 to 560 vs. 75.8 +/- 40.0; range 27.3 to 174.2 microg/mL).,Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16476117/),[μg] / [ml],75.8,127537,DB00091,Cyclosporine
,15848556,AUC0-9 level,MPA AUC0-9 level was significantly higher among the AR-negative group (n = 33; 34.2 +/- 16.8 ng.hr/mL) compared with AR-positive group (n = 3; 28.2 +/- 1.9 ng.hr/mL; P = .04085) over the 2 weeks after transplantation.,Therapeutic drug monitoring of mycophenolic acid in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848556/),[h·ng] / [ml],34.2,128192,DB00091,Cyclosporine
,15848556,AUC0-9 level,MPA AUC0-9 level was significantly higher among the AR-negative group (n = 33; 34.2 +/- 16.8 ng.hr/mL) compared with AR-positive group (n = 3; 28.2 +/- 1.9 ng.hr/mL; P = .04085) over the 2 weeks after transplantation.,Therapeutic drug monitoring of mycophenolic acid in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848556/),[h·ng] / [ml],28.2,128193,DB00091,Cyclosporine
,15848556,AUC0-9 level,MPA AUC0-9 level was higher among the adverse event (AE-positive) group (n = 15; 39.2 +/- 22.8 ng.hr/mL) compared with the negative group (n = 21; 30.1 +/- 8.0 ng.hr/mL; P = .08772) within 2 weeks after transplantation.,Therapeutic drug monitoring of mycophenolic acid in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848556/),[h·ng] / [ml],39.2,128194,DB00091,Cyclosporine
,15848556,AUC0-9 level,MPA AUC0-9 level was higher among the adverse event (AE-positive) group (n = 15; 39.2 +/- 22.8 ng.hr/mL) compared with the negative group (n = 21; 30.1 +/- 8.0 ng.hr/mL; P = .08772) within 2 weeks after transplantation.,Therapeutic drug monitoring of mycophenolic acid in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848556/),[h·ng] / [ml],30.1,128195,DB00091,Cyclosporine
,15848556,AUC0-9,The possible target level of MPA AUC0-9 would be approximately 30 ng.hr/mL using the present immunosuppressive regimen.,Therapeutic drug monitoring of mycophenolic acid in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848556/),[h·ng] / [ml],30,128196,DB00091,Cyclosporine
,3193363,terminal half-life,"Nonlinear disposition is suggested by the significant increase of the terminal half-life from 8.9 +/- 4.9 hr to 11.9 +/- 4.9 hr (mean +/- SD) after a 350 mg and a 1400 mg dose, respectively.",On the dose dependency of cyclosporin A absorption and disposition in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3193363/),h,8.9,128218,DB00091,Cyclosporine
,3193363,terminal half-life,"Nonlinear disposition is suggested by the significant increase of the terminal half-life from 8.9 +/- 4.9 hr to 11.9 +/- 4.9 hr (mean +/- SD) after a 350 mg and a 1400 mg dose, respectively.",On the dose dependency of cyclosporin A absorption and disposition in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3193363/),h,11.9,128219,DB00091,Cyclosporine
,3193363,lag time,The lag time (0.2-0.8 hr) was independent of dose.,On the dose dependency of cyclosporin A absorption and disposition in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3193363/),h,0.2-0.8,128220,DB00091,Cyclosporine
,3193363,duration of absorption,The duration of absorption for 11 of 12 subjects was in the range 2.5-3.5 hr over all doses and agrees well with the small intestine transit time.,On the dose dependency of cyclosporin A absorption and disposition in healthy volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3193363/),h,2.5-3.5,128221,DB00091,Cyclosporine
,20720518,clearance,"Median clearance was 30.2, 45.6, and 10.7 L/h in RTx, HSCTx, and AID patients, respectively.","Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20720518/),[l] / [h],30.2,128319,DB00091,Cyclosporine
,20720518,clearance,"Median clearance was 30.2, 45.6, and 10.7 L/h in RTx, HSCTx, and AID patients, respectively.","Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20720518/),[l] / [h],45.6,128320,DB00091,Cyclosporine
,20720518,clearance,"Median clearance was 30.2, 45.6, and 10.7 L/h in RTx, HSCTx, and AID patients, respectively.","Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20720518/),[l] / [h],10.7,128321,DB00091,Cyclosporine
,14603484,oral bioavailability (F,The paclitaxel S-SEDDS formulation shows approximately 10-fold higher maximum concentration (C(max)) and five-fold higher oral bioavailability (F approximately 9.5%) compared with that of the orally dosed Taxol formulation (F approximately 2.0%) and the SEDDS formulation without HPMC (F approximately 1%).,Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14603484/),%,9.5,128322,DB00091,Cyclosporine
,14603484,F,The paclitaxel S-SEDDS formulation shows approximately 10-fold higher maximum concentration (C(max)) and five-fold higher oral bioavailability (F approximately 9.5%) compared with that of the orally dosed Taxol formulation (F approximately 2.0%) and the SEDDS formulation without HPMC (F approximately 1%).,Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14603484/),%,2.0,128323,DB00091,Cyclosporine
,14603484,F,The paclitaxel S-SEDDS formulation shows approximately 10-fold higher maximum concentration (C(max)) and five-fold higher oral bioavailability (F approximately 9.5%) compared with that of the orally dosed Taxol formulation (F approximately 2.0%) and the SEDDS formulation without HPMC (F approximately 1%).,Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14603484/),%,1,128324,DB00091,Cyclosporine
,14603484,oral bioavailability (F,"Coadministration of cyclosporin A (CsA), an inhibitor of P-glycoprotein and CYP 3A4 enzyme, at a dose of 5 mg/kg with the S-SEDDS formulation further increased the oral bioavailability (F approximately 22.6%).",Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14603484/),%,22.6,128325,DB00091,Cyclosporine
,19533049,half-life,"Pharmacokinetic half-life of prednisolone is 2-3 h, indicating short pharmacodynamic effect duration.",Twice daily fractionated dose administration of prednisolone compared to standard once daily administration to patients with glomerulonephritis or with kidney transplants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19533049/),h,2-3,128507,DB00091,Cyclosporine
,2886315,t 1/2 alpha,"In blood, kidney, liver, and lymph nodes, t 1/2 alpha of cyclosporine ranged from 6-10 hr.","Tissue distribution, disposition, and metabolism of cyclosporine in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2886315/),h,6-10,129141,DB00091,Cyclosporine
,2886315,terminal half-life,"Elimination of radioactivity from the systemic circulation was multiphasic, with a terminal half-life of 20-30 hr.","Tissue distribution, disposition, and metabolism of cyclosporine in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2886315/),h,20-30,129142,DB00091,Cyclosporine
,11920222,complete response rate,The complete response rate was 49% overall and similar in both cohorts.,Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920222/),%,49,129252,DB00091,Cyclosporine
,11920222,overall survival,The median overall survival of patients was 333 days in cohort 1 compared to 98 days in cohort 2.,Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920222/),d,333,129253,DB00091,Cyclosporine
,11920222,overall survival,The median overall survival of patients was 333 days in cohort 1 compared to 98 days in cohort 2.,Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920222/),d,98,129254,DB00091,Cyclosporine
,11920222,maximum tolerated dose,The maximum tolerated dose of DNR was established as 35 mg/m(2).,Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920222/),[mg] / [m],35,129255,DB00091,Cyclosporine
,15491107,relative bioavailability,"The relative bioavailability of CyA-HP50 and CyA-HP55 nanoparticles calculated by the AUC0-72 were 82.3% and 119.6%, bioequivalent to the reference of Neoral.",[Relative bioavailability of cyclosporine A-loaded hydroxypropyl methylcellulose phthalate nanoparticles for oral administration in rats]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15491107/),%,82.3,129676,DB00091,Cyclosporine
,15491107,relative bioavailability,"The relative bioavailability of CyA-HP50 and CyA-HP55 nanoparticles calculated by the AUC0-72 were 82.3% and 119.6%, bioequivalent to the reference of Neoral.",[Relative bioavailability of cyclosporine A-loaded hydroxypropyl methylcellulose phthalate nanoparticles for oral administration in rats]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15491107/),%,119.6,129677,DB00091,Cyclosporine
,15491107,relative bioavailability,The relative bioavailability of CyA-HP55 nanoparticles was 145.3% of CyA-HP50 nanoparticles.,[Relative bioavailability of cyclosporine A-loaded hydroxypropyl methylcellulose phthalate nanoparticles for oral administration in rats]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15491107/),%,145.3,129678,DB00091,Cyclosporine
,29475007,net efflux ratio,The net efflux ratio of afatinib was 2.3 across vector-/MDR1-MDCKII cell monolayers and was decreased by P-gp inhibitor.,P-gp is involved in the intestinal absorption and biliary excretion of afatinib in vitro and in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29475007/),,2.3,129722,DB00091,Cyclosporine
,29475007,Km,"The activity of P-gp ATPase was induced by afatinib and the Km and Vmax were 1.05μM and 59.88nmol ATP/mg hP-gp/min, respectively.",P-gp is involved in the intestinal absorption and biliary excretion of afatinib in vitro and in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29475007/),μM,1.05,129723,DB00091,Cyclosporine
,29475007,Vmax,"The activity of P-gp ATPase was induced by afatinib and the Km and Vmax were 1.05μM and 59.88nmol ATP/mg hP-gp/min, respectively.",P-gp is involved in the intestinal absorption and biliary excretion of afatinib in vitro and in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29475007/),[atp·nM] / [h·mg],59.88,129724,DB00091,Cyclosporine
,14703954,C2hour,"In maintenance patients, C2hour values between 500 and 600 ng/ml are effective and safe for providing effective rejection prophylaxis.",Cyclosporin C2hour monitoring after renal transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14703954/),[ng] / [ml],500 and 600,129778,DB00091,Cyclosporine
,25017487,trough concentration,Everolimus exposure is unaffected when tacrolimus exposure is down-titrated within the trough concentration range of 1.5-7 ng/mL.,The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25017487/),[ng] / [ml],1.5-7,130074,DB00091,Cyclosporine
below,21709602,AUC0-12,MPA exposure significantly increased when CsA AUC0-12 was below 2000 ng hr/mL.,Renal graft function and low-dose cyclosporine affect mycophenolic acid pharmacokinetics in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21709602/),[h·ng] / [ml],2000,130430,DB00091,Cyclosporine
,21709602,AUC0-12,Stratification of MPA profiles according to stages of renal dysfunction showed that dose-adjusted MPA AUC0-12 was higher (P<0.001) in patients with severe (stage 4: 70.37±27.93 μg hr/mL/g MMF) than in those with mild (stage 2: 47.46±11.66 μg hr/mL/g MMF) or moderate (stage 3; 47.48±15.22 μg hr/mL/g MMF) renal insufficiency.,Renal graft function and low-dose cyclosporine affect mycophenolic acid pharmacokinetics in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21709602/),[h·μg] / [g·ml],70.37,130431,DB00091,Cyclosporine
,21709602,AUC0-12,Stratification of MPA profiles according to stages of renal dysfunction showed that dose-adjusted MPA AUC0-12 was higher (P<0.001) in patients with severe (stage 4: 70.37±27.93 μg hr/mL/g MMF) than in those with mild (stage 2: 47.46±11.66 μg hr/mL/g MMF) or moderate (stage 3; 47.48±15.22 μg hr/mL/g MMF) renal insufficiency.,Renal graft function and low-dose cyclosporine affect mycophenolic acid pharmacokinetics in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21709602/),[h·μg] / [g·ml],47.46,130432,DB00091,Cyclosporine
,21709602,AUC0-12,Stratification of MPA profiles according to stages of renal dysfunction showed that dose-adjusted MPA AUC0-12 was higher (P<0.001) in patients with severe (stage 4: 70.37±27.93 μg hr/mL/g MMF) than in those with mild (stage 2: 47.46±11.66 μg hr/mL/g MMF) or moderate (stage 3; 47.48±15.22 μg hr/mL/g MMF) renal insufficiency.,Renal graft function and low-dose cyclosporine affect mycophenolic acid pharmacokinetics in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21709602/),[h·μg] / [g·ml],47.48,130433,DB00091,Cyclosporine
,17545536,clearance,"There was no difference in the geometric mean docetaxel clearance between African-American patients [40.3 L/h; 95% confidence interval (95% CI), 19.3-84.1] and Caucasian patients (41.8 L/h; 95% CI, 22.0-79.7; P = 0.6).",A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17545536/),[l] / [h],40.3,131058,DB00091,Cyclosporine
,17545536,clearance,"There was no difference in the geometric mean docetaxel clearance between African-American patients [40.3 L/h; 95% confidence interval (95% CI), 19.3-84.1] and Caucasian patients (41.8 L/h; 95% CI, 22.0-79.7; P = 0.6).",A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17545536/),[l] / [h],41.8,131059,DB00091,Cyclosporine
,15518751,AUC,The median MPA AUC was 34.3 ug.h/mL (range 14.1-65.4).,The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15518751/),[h·ug] / [ml],34.3,131352,DB00091,Cyclosporine
,15518751,AUC,"Thirty-one of 45 (68.9%) patients had a MPA AUC within 20 to 40 ug.h/mL, which is the most reasonable risk: benefit ratio in terms of preventing acute rejection episodes.",The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15518751/),[h·ug] / [ml],20 to 40,131353,DB00091,Cyclosporine
,15518751,AUC,"Forty-one of 45 (91.1%) patients had MPA AUC within 20 to 60 ug.h/mL, which is the MPA therapeutic range.",The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15518751/),[h·ug] / [ml],20 to 60,131354,DB00091,Cyclosporine
,6723928,maximum values,"After a single oral dose of cyclosporin A (82 mg/kg) in rats, tissue (kidneys liver and brain) and blood levels reached maximum values (approximately 80 micrograms/g and 3.5 micrograms/ml) between 3 and 7 h after drug administration.",Blood and tissue distribution of cyclosporin A after a single oral dose in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723928/),[μg] / [g],80,131488,DB00091,Cyclosporine
,6723928,maximum values,"After a single oral dose of cyclosporin A (82 mg/kg) in rats, tissue (kidneys liver and brain) and blood levels reached maximum values (approximately 80 micrograms/g and 3.5 micrograms/ml) between 3 and 7 h after drug administration.",Blood and tissue distribution of cyclosporin A after a single oral dose in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723928/),[μg] / [ml],3.5,131489,DB00091,Cyclosporine
,6723928,urine,The 24-h urine and bile elimination was 2% for each.,Blood and tissue distribution of cyclosporin A after a single oral dose in the rat. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723928/),%,2,131490,DB00091,Cyclosporine
,6723928,bile elimination,The 24-h urine and bile elimination was 2% for each.,Blood and tissue distribution of cyclosporin A after a single oral dose in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723928/),%,2,131491,DB00091,Cyclosporine
,1617860,hepatic blood flow,Mean hepatic blood flow was estimated to be 0.89 (95% CI: 0.62 to 1.23) L/h/kg and intrinsic cyclosporin clearance as 0.60 (95% CI: 0.49 to 0.72) L/h/kg.,Evaluation of hepatic function using the pharmacokinetics of a therapeutically administered drug. Application to the immunosuppressant cyclosporin. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1617860/),[l] / [h·kg],0.89,131940,DB00091,Cyclosporine
,1617860,intrinsic cyclosporin clearance,Mean hepatic blood flow was estimated to be 0.89 (95% CI: 0.62 to 1.23) L/h/kg and intrinsic cyclosporin clearance as 0.60 (95% CI: 0.49 to 0.72) L/h/kg.,Evaluation of hepatic function using the pharmacokinetics of a therapeutically administered drug. Application to the immunosuppressant cyclosporin. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1617860/),[l] / [h·kg],0.60,131941,DB00091,Cyclosporine
,15385835,AUC,"The mean AUC (ng x h/mL) of CsA for the 3 genotype groups were 4962 +/- 1074 (A/A), 6677 +/- 1153 (G/G), and 5416 +/- 1817 (A/G), (A/A versus G/G, P = 0.03), and the mean CL/F (mL/min/kg) were 15.6 +/- 3.1 (A/A), 12.0 +/- 2.3 (G/G), and 14.7 +/- 5.9 (A/G), (A/A versus G/G, P = 0.04).",CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385835/),[h·ng] / [ml],4962,132015,DB00091,Cyclosporine
,15385835,AUC,"The mean AUC (ng x h/mL) of CsA for the 3 genotype groups were 4962 +/- 1074 (A/A), 6677 +/- 1153 (G/G), and 5416 +/- 1817 (A/G), (A/A versus G/G, P = 0.03), and the mean CL/F (mL/min/kg) were 15.6 +/- 3.1 (A/A), 12.0 +/- 2.3 (G/G), and 14.7 +/- 5.9 (A/G), (A/A versus G/G, P = 0.04).",CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385835/),[h·ng] / [ml],6677,132016,DB00091,Cyclosporine
,15385835,AUC,"The mean AUC (ng x h/mL) of CsA for the 3 genotype groups were 4962 +/- 1074 (A/A), 6677 +/- 1153 (G/G), and 5416 +/- 1817 (A/G), (A/A versus G/G, P = 0.03), and the mean CL/F (mL/min/kg) were 15.6 +/- 3.1 (A/A), 12.0 +/- 2.3 (G/G), and 14.7 +/- 5.9 (A/G), (A/A versus G/G, P = 0.04).",CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385835/),[h·ng] / [ml],5416,132017,DB00091,Cyclosporine
,15385835,CL/F,"The mean AUC (ng x h/mL) of CsA for the 3 genotype groups were 4962 +/- 1074 (A/A), 6677 +/- 1153 (G/G), and 5416 +/- 1817 (A/G), (A/A versus G/G, P = 0.03), and the mean CL/F (mL/min/kg) were 15.6 +/- 3.1 (A/A), 12.0 +/- 2.3 (G/G), and 14.7 +/- 5.9 (A/G), (A/A versus G/G, P = 0.04).",CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385835/),[ml] / [kg·min],15.6,132018,DB00091,Cyclosporine
,15385835,CL/F,"The mean AUC (ng x h/mL) of CsA for the 3 genotype groups were 4962 +/- 1074 (A/A), 6677 +/- 1153 (G/G), and 5416 +/- 1817 (A/G), (A/A versus G/G, P = 0.03), and the mean CL/F (mL/min/kg) were 15.6 +/- 3.1 (A/A), 12.0 +/- 2.3 (G/G), and 14.7 +/- 5.9 (A/G), (A/A versus G/G, P = 0.04).",CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385835/),[ml] / [kg·min],12.0,132019,DB00091,Cyclosporine
,15385835,CL/F,"The mean AUC (ng x h/mL) of CsA for the 3 genotype groups were 4962 +/- 1074 (A/A), 6677 +/- 1153 (G/G), and 5416 +/- 1817 (A/G), (A/A versus G/G, P = 0.03), and the mean CL/F (mL/min/kg) were 15.6 +/- 3.1 (A/A), 12.0 +/- 2.3 (G/G), and 14.7 +/- 5.9 (A/G), (A/A versus G/G, P = 0.04).",CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15385835/),[ml] / [kg·min],14.7,132020,DB00091,Cyclosporine
,17632584,area under the curve of blood CsA versus time (AUCiv),The area under the curve of blood CsA versus time (AUCiv) increased from 27.7 +/- 5.3 to 60.6 +/- 13.8 mug.h.,Increased cyclosporine bioavailability induced by experimental nephrotic syndrome in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632584/),h·μg,27.7,132099,DB00091,Cyclosporine
,17632584,area under the curve of blood CsA versus time (AUCiv),The area under the curve of blood CsA versus time (AUCiv) increased from 27.7 +/- 5.3 to 60.6 +/- 13.8 mug.h.,Increased cyclosporine bioavailability induced by experimental nephrotic syndrome in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632584/),h·μg,60.6,132100,DB00091,Cyclosporine
,17632584,total body clearance,"On the other hand, the total body clearance was significantly lower (0.38 +/- 0.06 vs. 0.17 +/- 0.03 L.(kg body mass)-1.h-1) and the volume of distribution at steady state (3.70 +/- 0.52 vs. 2.85 +/- 0.32 L/kg) was significantly smaller in nephrotic rats as compared with control.",Increased cyclosporine bioavailability induced by experimental nephrotic syndrome in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632584/),[l] / [body·h·kg·mass],0.38,132101,DB00091,Cyclosporine
,17632584,total body clearance,"On the other hand, the total body clearance was significantly lower (0.38 +/- 0.06 vs. 0.17 +/- 0.03 L.(kg body mass)-1.h-1) and the volume of distribution at steady state (3.70 +/- 0.52 vs. 2.85 +/- 0.32 L/kg) was significantly smaller in nephrotic rats as compared with control.",Increased cyclosporine bioavailability induced by experimental nephrotic syndrome in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632584/),[l] / [body·h·kg·mass],0.17,132102,DB00091,Cyclosporine
,17632584,volume of distribution at steady state,"On the other hand, the total body clearance was significantly lower (0.38 +/- 0.06 vs. 0.17 +/- 0.03 L.(kg body mass)-1.h-1) and the volume of distribution at steady state (3.70 +/- 0.52 vs. 2.85 +/- 0.32 L/kg) was significantly smaller in nephrotic rats as compared with control.",Increased cyclosporine bioavailability induced by experimental nephrotic syndrome in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632584/),[l] / [kg],3.70,132103,DB00091,Cyclosporine
,17632584,volume of distribution at steady state,"On the other hand, the total body clearance was significantly lower (0.38 +/- 0.06 vs. 0.17 +/- 0.03 L.(kg body mass)-1.h-1) and the volume of distribution at steady state (3.70 +/- 0.52 vs. 2.85 +/- 0.32 L/kg) was significantly smaller in nephrotic rats as compared with control.",Increased cyclosporine bioavailability induced by experimental nephrotic syndrome in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632584/),[l] / [kg],2.85,132104,DB00091,Cyclosporine
,17632584,terminal half-life,These pharmacokinetic changes lead to a longer terminal half-life of CsA in P-NS rats (11.8 +/- 1.6 vs. 6.9 +/- 0.91 h).,Increased cyclosporine bioavailability induced by experimental nephrotic syndrome in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632584/),h,11.8,132105,DB00091,Cyclosporine
,17632584,terminal half-life,These pharmacokinetic changes lead to a longer terminal half-life of CsA in P-NS rats (11.8 +/- 1.6 vs. 6.9 +/- 0.91 h).,Increased cyclosporine bioavailability induced by experimental nephrotic syndrome in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17632584/),h,6.9,132106,DB00091,Cyclosporine
,3058372,peak drug concentrations,"Despite peak drug concentrations of 1463 +/- 754 ng/ml during the infusion period, no adverse pulmonary effects were noted; renal function, urine output, and mean arterial pressure also appeared to have been unaffected.",Pharmacokinetics and clinical tolerance of intravenous and oral cyclosporine in the immediate postoperative period. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3058372/),[ng] / [ml],1463,132480,DB00091,Cyclosporine
,3058372,trough cyclosporine concentration,"The mean trough cyclosporine concentration was 141 +/- 50 ng/ml; however, two patients had trough values below sensitivity.",Pharmacokinetics and clinical tolerance of intravenous and oral cyclosporine in the immediate postoperative period. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3058372/),[ng] / [ml],141,132481,DB00091,Cyclosporine
,3058372,total body clearance,"Kinetic analysis after the third dose of intravenous cyclosporine revealed a mean total body clearance of 0.31 +/- 0.1 L/min and a volume of distribution of 2.88 +/- 1.1 L/kg, whereas the elimination half-life was 12.8 +/- 3.8 hours and the mean residence time was 9.5 +/- 5.1 hours.",Pharmacokinetics and clinical tolerance of intravenous and oral cyclosporine in the immediate postoperative period. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3058372/),[l] / [min],0.31,132482,DB00091,Cyclosporine
,3058372,volume of distribution,"Kinetic analysis after the third dose of intravenous cyclosporine revealed a mean total body clearance of 0.31 +/- 0.1 L/min and a volume of distribution of 2.88 +/- 1.1 L/kg, whereas the elimination half-life was 12.8 +/- 3.8 hours and the mean residence time was 9.5 +/- 5.1 hours.",Pharmacokinetics and clinical tolerance of intravenous and oral cyclosporine in the immediate postoperative period. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3058372/),[l] / [kg],2.88,132483,DB00091,Cyclosporine
,3058372,elimination half-life,"Kinetic analysis after the third dose of intravenous cyclosporine revealed a mean total body clearance of 0.31 +/- 0.1 L/min and a volume of distribution of 2.88 +/- 1.1 L/kg, whereas the elimination half-life was 12.8 +/- 3.8 hours and the mean residence time was 9.5 +/- 5.1 hours.",Pharmacokinetics and clinical tolerance of intravenous and oral cyclosporine in the immediate postoperative period. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3058372/),h,12.8,132484,DB00091,Cyclosporine
,3058372,mean residence time,"Kinetic analysis after the third dose of intravenous cyclosporine revealed a mean total body clearance of 0.31 +/- 0.1 L/min and a volume of distribution of 2.88 +/- 1.1 L/kg, whereas the elimination half-life was 12.8 +/- 3.8 hours and the mean residence time was 9.5 +/- 5.1 hours.",Pharmacokinetics and clinical tolerance of intravenous and oral cyclosporine in the immediate postoperative period. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3058372/),h,9.5,132485,DB00091,Cyclosporine
,3058372,bioavailability,"After conversion to oral therapy the bioavailability ranged from 0.11 to 0.47, with a mean value of 0.27.",Pharmacokinetics and clinical tolerance of intravenous and oral cyclosporine in the immediate postoperative period. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3058372/),,0.11 to 0.47,132486,DB00091,Cyclosporine
,3058372,bioavailability,"After conversion to oral therapy the bioavailability ranged from 0.11 to 0.47, with a mean value of 0.27.",Pharmacokinetics and clinical tolerance of intravenous and oral cyclosporine in the immediate postoperative period. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3058372/),,0.27,132487,DB00091,Cyclosporine
,3058372,bioavailability,"Subsequently there was an unpredictable pattern of bioavailability within patients, with mean values of 0.27 +/- 0.13 and 0.30 +/- 0.25 during the second and third oral study periods, respectively.",Pharmacokinetics and clinical tolerance of intravenous and oral cyclosporine in the immediate postoperative period. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3058372/),,0.27,132488,DB00091,Cyclosporine
,3058372,bioavailability,"Subsequently there was an unpredictable pattern of bioavailability within patients, with mean values of 0.27 +/- 0.13 and 0.30 +/- 0.25 during the second and third oral study periods, respectively.",Pharmacokinetics and clinical tolerance of intravenous and oral cyclosporine in the immediate postoperative period. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3058372/),,0.30,132489,DB00091,Cyclosporine
more,2191442,oral bioavailability,"The pharmacokinetic profile of fluconazole clearly distinguishes it from other antifungal agents; oral bioavailability is more than 90%, and plasma protein binding is 12%.",The clinical pharmacology of fluconazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2191442/),%,90,132916,DB00091,Cyclosporine
,2191442,plasma protein binding,"The pharmacokinetic profile of fluconazole clearly distinguishes it from other antifungal agents; oral bioavailability is more than 90%, and plasma protein binding is 12%.",The clinical pharmacology of fluconazole. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2191442/),%,12,132917,DB00091,Cyclosporine
,2191442,elimination half-life,The mean elimination half-life is approximately 30 hours.,The clinical pharmacology of fluconazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2191442/),h,30,132918,DB00091,Cyclosporine
,16044096,C0,"Mean +/- SD values for CsA dose, C0, and C2 were 4.8 +/- 1.4 mg/kg/d, 240 +/- 62 microg/L, and 1319 +/- 469 microg/L, respectively.",Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044096/),[μg] / [l],240,133047,DB00091,Cyclosporine
,16044096,C2,"Mean +/- SD values for CsA dose, C0, and C2 were 4.8 +/- 1.4 mg/kg/d, 240 +/- 62 microg/L, and 1319 +/- 469 microg/L, respectively.",Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044096/),[μg] / [l],1319,133048,DB00091,Cyclosporine
,16044096,C0,"The mean +/- SD values for C0 (microg/L) and C2 (microg/L) for rejectors (n = 3) were 215 +/- 68 and 949 +/- 204 versus 242 +/- 62 and 1359 +/- 474 for the nonrejectors (P = 0.66 and 0.12, respectively).",Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044096/),[μg] / [l],215,133049,DB00091,Cyclosporine
,16044096,C2,"The mean +/- SD values for C0 (microg/L) and C2 (microg/L) for rejectors (n = 3) were 215 +/- 68 and 949 +/- 204 versus 242 +/- 62 and 1359 +/- 474 for the nonrejectors (P = 0.66 and 0.12, respectively).",Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044096/),[μg] / [l],215,133050,DB00091,Cyclosporine
,16044096,C2,"The mean +/- SD values for C0 (microg/L) and C2 (microg/L) for rejectors (n = 3) were 215 +/- 68 and 949 +/- 204 versus 242 +/- 62 and 1359 +/- 474 for the nonrejectors (P = 0.66 and 0.12, respectively).",Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044096/),[μg] / [l],949,133051,DB00091,Cyclosporine
,16044096,C2,"The mean +/- SD values for C0 (microg/L) and C2 (microg/L) for rejectors (n = 3) were 215 +/- 68 and 949 +/- 204 versus 242 +/- 62 and 1359 +/- 474 for the nonrejectors (P = 0.66 and 0.12, respectively).",Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044096/),[μg] / [l],242,133052,DB00091,Cyclosporine
,16044096,C2,"The mean +/- SD values for C0 (microg/L) and C2 (microg/L) for rejectors (n = 3) were 215 +/- 68 and 949 +/- 204 versus 242 +/- 62 and 1359 +/- 474 for the nonrejectors (P = 0.66 and 0.12, respectively).",Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044096/),[μg] / [l],1359,133053,DB00091,Cyclosporine
,16044096,C0,"Fisher exact test P values using the median as threshold value for C0 and C2 (234 microg/L and 1251 microg/L, respectively) were 0.6 and 0.1.",Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044096/),[μg] / [l],234,133054,DB00091,Cyclosporine
,16044096,C2,"Fisher exact test P values using the median as threshold value for C0 and C2 (234 microg/L and 1251 microg/L, respectively) were 0.6 and 0.1.",Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044096/),[μg] / [l],1251,133055,DB00091,Cyclosporine
,18367972,Sir AUC,The average Sir AUC was 64.9 +/- 29.7 ng*h/mL.,Pharmacokinetics of mycophenolate mofetil and sirolimus in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18367972/),[h·ng] / [ml],64.9,133309,DB00091,Cyclosporine
,18367972,AUC,"The median (range) AUC for each metabolite was as follows: 12-hydroxy-Sir, 7.6 (0.2-18.8); 46-hydroxy-Sir, 3.1 (0.0-12.4); 24-hydroxy-Sir, 4.3 (0.0-12.6); piperidine-hydroxy-Sir, 3.5 (0.0-8.3); 39-desmethyl-Sir, 3.6 (0.0-11.3); 16-desmethyl-Sir, 5.0 (0.1-9.9); and di-hydroxy-Sir, 4.3 (0.0-32.5) ng*h/mL.",Pharmacokinetics of mycophenolate mofetil and sirolimus in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18367972/),[h·ng] / [ml],7.6,133310,DB00091,Cyclosporine
,18367972,AUC,"The median (range) AUC for each metabolite was as follows: 12-hydroxy-Sir, 7.6 (0.2-18.8); 46-hydroxy-Sir, 3.1 (0.0-12.4); 24-hydroxy-Sir, 4.3 (0.0-12.6); piperidine-hydroxy-Sir, 3.5 (0.0-8.3); 39-desmethyl-Sir, 3.6 (0.0-11.3); 16-desmethyl-Sir, 5.0 (0.1-9.9); and di-hydroxy-Sir, 4.3 (0.0-32.5) ng*h/mL.",Pharmacokinetics of mycophenolate mofetil and sirolimus in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18367972/),[h·ng] / [ml],3.1,133311,DB00091,Cyclosporine
,18367972,AUC,"The median (range) AUC for each metabolite was as follows: 12-hydroxy-Sir, 7.6 (0.2-18.8); 46-hydroxy-Sir, 3.1 (0.0-12.4); 24-hydroxy-Sir, 4.3 (0.0-12.6); piperidine-hydroxy-Sir, 3.5 (0.0-8.3); 39-desmethyl-Sir, 3.6 (0.0-11.3); 16-desmethyl-Sir, 5.0 (0.1-9.9); and di-hydroxy-Sir, 4.3 (0.0-32.5) ng*h/mL.",Pharmacokinetics of mycophenolate mofetil and sirolimus in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18367972/),[h·ng] / [ml],4.3,133312,DB00091,Cyclosporine
,18367972,AUC,"The median (range) AUC for each metabolite was as follows: 12-hydroxy-Sir, 7.6 (0.2-18.8); 46-hydroxy-Sir, 3.1 (0.0-12.4); 24-hydroxy-Sir, 4.3 (0.0-12.6); piperidine-hydroxy-Sir, 3.5 (0.0-8.3); 39-desmethyl-Sir, 3.6 (0.0-11.3); 16-desmethyl-Sir, 5.0 (0.1-9.9); and di-hydroxy-Sir, 4.3 (0.0-32.5) ng*h/mL.",Pharmacokinetics of mycophenolate mofetil and sirolimus in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18367972/),[h·ng] / [ml],3.5,133313,DB00091,Cyclosporine
,18367972,AUC,"The median (range) AUC for each metabolite was as follows: 12-hydroxy-Sir, 7.6 (0.2-18.8); 46-hydroxy-Sir, 3.1 (0.0-12.4); 24-hydroxy-Sir, 4.3 (0.0-12.6); piperidine-hydroxy-Sir, 3.5 (0.0-8.3); 39-desmethyl-Sir, 3.6 (0.0-11.3); 16-desmethyl-Sir, 5.0 (0.1-9.9); and di-hydroxy-Sir, 4.3 (0.0-32.5) ng*h/mL.",Pharmacokinetics of mycophenolate mofetil and sirolimus in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18367972/),[h·ng] / [ml],3.6,133314,DB00091,Cyclosporine
,18367972,AUC,"The median (range) AUC for each metabolite was as follows: 12-hydroxy-Sir, 7.6 (0.2-18.8); 46-hydroxy-Sir, 3.1 (0.0-12.4); 24-hydroxy-Sir, 4.3 (0.0-12.6); piperidine-hydroxy-Sir, 3.5 (0.0-8.3); 39-desmethyl-Sir, 3.6 (0.0-11.3); 16-desmethyl-Sir, 5.0 (0.1-9.9); and di-hydroxy-Sir, 4.3 (0.0-32.5) ng*h/mL.",Pharmacokinetics of mycophenolate mofetil and sirolimus in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18367972/),[h·ng] / [ml],5.0,133315,DB00091,Cyclosporine
,18367972,AUC,"The median (range) AUC for each metabolite was as follows: 12-hydroxy-Sir, 7.6 (0.2-18.8); 46-hydroxy-Sir, 3.1 (0.0-12.4); 24-hydroxy-Sir, 4.3 (0.0-12.6); piperidine-hydroxy-Sir, 3.5 (0.0-8.3); 39-desmethyl-Sir, 3.6 (0.0-11.3); 16-desmethyl-Sir, 5.0 (0.1-9.9); and di-hydroxy-Sir, 4.3 (0.0-32.5) ng*h/mL.",Pharmacokinetics of mycophenolate mofetil and sirolimus in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18367972/),[h·ng] / [ml],4.3,133316,DB00091,Cyclosporine
,30195818,survival times (MSTs),"In MMF monotherapy, oral administration of 20 or 40 mg/kg/day prolonged graft survival with median survival times (MSTs) of 16.5 days and 33 days, respectively, whereas untreated animals showed MST of 6 days.","Replacement of mycophenolate mofetil with a JAK inhibitor, AS2553627, in combination with low-dose tacrolimus, for renal allograft rejection in non-human primates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30195818/),d,16.5,133331,DB00091,Cyclosporine
,30195818,survival times (MSTs),"In MMF monotherapy, oral administration of 20 or 40 mg/kg/day prolonged graft survival with median survival times (MSTs) of 16.5 days and 33 days, respectively, whereas untreated animals showed MST of 6 days.","Replacement of mycophenolate mofetil with a JAK inhibitor, AS2553627, in combination with low-dose tacrolimus, for renal allograft rejection in non-human primates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30195818/),d,33,133332,DB00091,Cyclosporine
,30195818,MST,"In MMF monotherapy, oral administration of 20 or 40 mg/kg/day prolonged graft survival with median survival times (MSTs) of 16.5 days and 33 days, respectively, whereas untreated animals showed MST of 6 days.","Replacement of mycophenolate mofetil with a JAK inhibitor, AS2553627, in combination with low-dose tacrolimus, for renal allograft rejection in non-human primates. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30195818/),d,6,133333,DB00091,Cyclosporine
,23624757,CL/F,"The estimated CL/F was 15.1, which was lower than those of children receiving stem cell or kidney transplant reported in the West (16.9-29.3).","Population pharmacokinetics of ciclosporin in Chinese children with aplastic anemia: effects of weight, renal function and stanozolol administration. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23624757/),,15.1,133337,DB00091,Cyclosporine
,23624757,weight normalized CL/F,The weight normalized CL/F was 0.45 (range: 0.27-0.70) Lh(-1)·kg(-1).,"Population pharmacokinetics of ciclosporin in Chinese children with aplastic anemia: effects of weight, renal function and stanozolol administration. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23624757/),1/[kg·lh],0.45,133338,DB00091,Cyclosporine
,8165192,relative bioavailability,"The relative bioavailability of cyclosporine from Sandimmune Neoral ranged from 174 to 239% compared to Sandimmune, depending on the dose level.",Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8165192/),%,174,133429,DB00091,Cyclosporine
,8165192,relative bioavailability,"The relative bioavailability of cyclosporine from Sandimmune Neoral ranged from 174 to 239% compared to Sandimmune, depending on the dose level.",Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8165192/),%,239,133430,DB00091,Cyclosporine
,30171280,t1/2,"The geometric mean t1/2 was ≈ 21, ≈ 24, and ≈ 26 h, respectively, in cyclosporine 200 mg + eltrombopag, cyclosporine 600 mg + eltrombopag and eltrombopag alone groups.",Effect of cyclosporine coadministration on the pharmacokinetics of eltrombopag in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30171280/),h,21,133454,DB00091,Cyclosporine
,30171280,t1/2,"The geometric mean t1/2 was ≈ 21, ≈ 24, and ≈ 26 h, respectively, in cyclosporine 200 mg + eltrombopag, cyclosporine 600 mg + eltrombopag and eltrombopag alone groups.",Effect of cyclosporine coadministration on the pharmacokinetics of eltrombopag in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30171280/),h,24,133455,DB00091,Cyclosporine
,30171280,t1/2,"The geometric mean t1/2 was ≈ 21, ≈ 24, and ≈ 26 h, respectively, in cyclosporine 200 mg + eltrombopag, cyclosporine 600 mg + eltrombopag and eltrombopag alone groups.",Effect of cyclosporine coadministration on the pharmacokinetics of eltrombopag in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30171280/),h,26,133456,DB00091,Cyclosporine
,17205304,C (max),"The median C (max) of paclitaxel was 0.42 (0.23-0.96), 0.48 (0.08-0.59), and 0.39 (0.11-1.03) microg/ml and the area under the plasma concentration-time curve was 2.83 (1.69-5.12), 2.01 (1.57-3.04), and 2.67 (1.05-3.61) mug h/ml following administration of formulations 1, 2B, and 2C, respectively.",Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17205304/),[μg] / [ml],0.42,133533,DB00091,Cyclosporine
,17205304,C (max),"The median C (max) of paclitaxel was 0.42 (0.23-0.96), 0.48 (0.08-0.59), and 0.39 (0.11-1.03) microg/ml and the area under the plasma concentration-time curve was 2.83 (1.69-5.12), 2.01 (1.57-3.04), and 2.67 (1.05-3.61) mug h/ml following administration of formulations 1, 2B, and 2C, respectively.",Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17205304/),[μg] / [ml],0.48,133534,DB00091,Cyclosporine
,17205304,C (max),"The median C (max) of paclitaxel was 0.42 (0.23-0.96), 0.48 (0.08-0.59), and 0.39 (0.11-1.03) microg/ml and the area under the plasma concentration-time curve was 2.83 (1.69-5.12), 2.01 (1.57-3.04), and 2.67 (1.05-3.61) mug h/ml following administration of formulations 1, 2B, and 2C, respectively.",Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17205304/),[μg] / [ml],0.39,133535,DB00091,Cyclosporine
,17205304,area under the plasma concentration-time curve,"The median C (max) of paclitaxel was 0.42 (0.23-0.96), 0.48 (0.08-0.59), and 0.39 (0.11-1.03) microg/ml and the area under the plasma concentration-time curve was 2.83 (1.69-5.12), 2.01 (1.57-3.04), and 2.67 (1.05-3.61) mug h/ml following administration of formulations 1, 2B, and 2C, respectively.",Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17205304/),[h·μg] / [ml],2.83,133536,DB00091,Cyclosporine
,17205304,area under the plasma concentration-time curve,"The median C (max) of paclitaxel was 0.42 (0.23-0.96), 0.48 (0.08-0.59), and 0.39 (0.11-1.03) microg/ml and the area under the plasma concentration-time curve was 2.83 (1.69-5.12), 2.01 (1.57-3.04), and 2.67 (1.05-3.61) mug h/ml following administration of formulations 1, 2B, and 2C, respectively.",Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17205304/),[h·μg] / [ml],2.01,133537,DB00091,Cyclosporine
,17205304,area under the plasma concentration-time curve,"The median C (max) of paclitaxel was 0.42 (0.23-0.96), 0.48 (0.08-0.59), and 0.39 (0.11-1.03) microg/ml and the area under the plasma concentration-time curve was 2.83 (1.69-5.12), 2.01 (1.57-3.04), and 2.67 (1.05-3.61) mug h/ml following administration of formulations 1, 2B, and 2C, respectively.",Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17205304/),[h·μg] / [ml],2.67,133538,DB00091,Cyclosporine
,3680581,distribution half-life,"The harmonic mean distribution half-life based on HPLC data was 0.45 hours, and the harmonic mean terminal disposition half-life was 6.2 hours.",Cyclosporine kinetics in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680581/),h,0.45,134073,DB00091,Cyclosporine
,3680581,terminal disposition half-life,"The harmonic mean distribution half-life based on HPLC data was 0.45 hours, and the harmonic mean terminal disposition half-life was 6.2 hours.",Cyclosporine kinetics in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680581/),h,6.2,134074,DB00091,Cyclosporine
,3680581,clearance,"The clearance of cyclosporine based on HPLC cyclosporine concentrations was 3.9 mL/min/kg, and the volume of distribution at steady state of cyclosporine was 1.23 L/kg.",Cyclosporine kinetics in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680581/),[ml] / [kg·min],3.9,134075,DB00091,Cyclosporine
,3680581,volume of distribution at steady state,"The clearance of cyclosporine based on HPLC cyclosporine concentrations was 3.9 mL/min/kg, and the volume of distribution at steady state of cyclosporine was 1.23 L/kg.",Cyclosporine kinetics in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3680581/),[l] / [kg],1.23,134076,DB00091,Cyclosporine
,15919452,IC50 ratio,The mean IC50 ratio of CyA and Tac (CyA/Tac of IC50) was 25.1.,Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15919452/),,25.1,134145,DB00091,Cyclosporine
,15919452,area under the concentration-time curve (AUC) ratio (CyA/Tac of AUC,"The mean area under the concentration-time curve (AUC) ratio (CyA/Tac of AUC) was 25.5, the mean trough level (C(min)) ratio (CyA/Tac of C(min)) was 13.2, and the mean dose per body weight ratio was 25.2.",Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15919452/),,25.5,134146,DB00091,Cyclosporine
,15919452,trough level (C(min)) ratio (CyA/Tac of C(min),"The mean area under the concentration-time curve (AUC) ratio (CyA/Tac of AUC) was 25.5, the mean trough level (C(min)) ratio (CyA/Tac of C(min)) was 13.2, and the mean dose per body weight ratio was 25.2.",Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15919452/),,13.2,134147,DB00091,Cyclosporine
,15283470,h,"The prodrug was decomposed in human liver homogenate to produce the active material, CsA, and the hydrolysis half-life (t(1/2)) of the prodrug, KI-306 was 2.2 minutes at 37 degrees C.",Water soluble cyclosporine monomethoxy poly(ethyleneglycol) conjugates as potential prodrugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15283470/),min,2.2,134543,DB00091,Cyclosporine
,15283470,half-life (t(1/2)),"However, a demonstration of non-enzymatic conversion in pH 7.4 phosphate buffer was provided by the fact that the half-life (t(1/2)) is 21 hours at 37 degrees C.",Water soluble cyclosporine monomethoxy poly(ethyleneglycol) conjugates as potential prodrugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15283470/),h,21,134544,DB00091,Cyclosporine
,15283470,half-life (t(1/2)),"The hydrolysis was seen with half-life (t(1/2)) of about 9.9, 65.0, 14.2, 3.4, 2.1 9.5, and 1.6 minutes for KI-306, 309, 312, 313, 315, 316, and 317, respectively.",Water soluble cyclosporine monomethoxy poly(ethyleneglycol) conjugates as potential prodrugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15283470/),min,9.9,134545,DB00091,Cyclosporine
,15283470,half-life (t(1/2)),"The hydrolysis was seen with half-life (t(1/2)) of about 9.9, 65.0, 14.2, 3.4, 2.1 9.5, and 1.6 minutes for KI-306, 309, 312, 313, 315, 316, and 317, respectively.",Water soluble cyclosporine monomethoxy poly(ethyleneglycol) conjugates as potential prodrugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15283470/),min,65.0,134546,DB00091,Cyclosporine
,15283470,half-life (t(1/2)),"The hydrolysis was seen with half-life (t(1/2)) of about 9.9, 65.0, 14.2, 3.4, 2.1 9.5, and 1.6 minutes for KI-306, 309, 312, 313, 315, 316, and 317, respectively.",Water soluble cyclosporine monomethoxy poly(ethyleneglycol) conjugates as potential prodrugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15283470/),min,14.2,134547,DB00091,Cyclosporine
,15283470,half-life (t(1/2)),"The hydrolysis was seen with half-life (t(1/2)) of about 9.9, 65.0, 14.2, 3.4, 2.1 9.5, and 1.6 minutes for KI-306, 309, 312, 313, 315, 316, and 317, respectively.",Water soluble cyclosporine monomethoxy poly(ethyleneglycol) conjugates as potential prodrugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15283470/),min,3.4,134548,DB00091,Cyclosporine
,15283470,half-life (t(1/2)),"The hydrolysis was seen with half-life (t(1/2)) of about 9.9, 65.0, 14.2, 3.4, 2.1 9.5, and 1.6 minutes for KI-306, 309, 312, 313, 315, 316, and 317, respectively.",Water soluble cyclosporine monomethoxy poly(ethyleneglycol) conjugates as potential prodrugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15283470/),min,2.1,134549,DB00091,Cyclosporine
,15283470,half-life (t(1/2)),"The hydrolysis was seen with half-life (t(1/2)) of about 9.9, 65.0, 14.2, 3.4, 2.1 9.5, and 1.6 minutes for KI-306, 309, 312, 313, 315, 316, and 317, respectively.",Water soluble cyclosporine monomethoxy poly(ethyleneglycol) conjugates as potential prodrugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15283470/),min,9.5,134550,DB00091,Cyclosporine
,15283470,half-life (t(1/2)),"The hydrolysis was seen with half-life (t(1/2)) of about 9.9, 65.0, 14.2, 3.4, 2.1 9.5, and 1.6 minutes for KI-306, 309, 312, 313, 315, 316, and 317, respectively.",Water soluble cyclosporine monomethoxy poly(ethyleneglycol) conjugates as potential prodrugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15283470/),min,1.6,134551,DB00091,Cyclosporine
,15283470,Tmax,"The kinetic value was also seen with Tmax of about 1.43 and 2.44 hours for KI-306 and Neoral, respectively.",Water soluble cyclosporine monomethoxy poly(ethyleneglycol) conjugates as potential prodrugs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15283470/),h,1.43,134552,DB00091,Cyclosporine
,15283470,Tmax,"The kinetic value was also seen with Tmax of about 1.43 and 2.44 hours for KI-306 and Neoral, respectively.",Water soluble cyclosporine monomethoxy poly(ethyleneglycol) conjugates as potential prodrugs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15283470/),h,2.44,134553,DB00091,Cyclosporine
,11049011,absorption lag time,"There was an absorption lag time of about 35 min with SAN, but zero lag time with NEO.",Factors affecting oral cyclosporin disposition after heart transplantation: bootstrap validation of a population pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11049011/),min,35,134785,DB00091,Cyclosporine
,22664010,AUC,"AUC was 4.3, 5.9, and 8.3 in the 200-mg/d dose group on days 3, 7, and 21, respectively.",Pharmacokinetics of mizoribine in adult living donor liver transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22664010/),,4.3,135308,DB00091,Cyclosporine
,22664010,AUC,"AUC was 4.3, 5.9, and 8.3 in the 200-mg/d dose group on days 3, 7, and 21, respectively.",Pharmacokinetics of mizoribine in adult living donor liver transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22664010/),,5.9,135309,DB00091,Cyclosporine
,22664010,AUC,"AUC was 4.3, 5.9, and 8.3 in the 200-mg/d dose group on days 3, 7, and 21, respectively.",Pharmacokinetics of mizoribine in adult living donor liver transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22664010/),,8.3,135310,DB00091,Cyclosporine
,20197016,half-life,"In regard to the time course of changes of the serum basiliximab concentration, after the peak serum concentration was reached, basiliximab was gradually eliminated from the blood with a mean half-life of 7.06 days.",Pharmacokinetics and pharmacodynamics of basiliximab in Japanese pediatric renal transplant patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20197016/),d,7.06,135471,DB00091,Cyclosporine
,15684491,clearance ratio,"Without pretreatment with CsA or KCZ, the clearance ratio of Clbile relative to the total body clearances of Rho123, NFV and EM was 10.5, 0.07 and 31.1%, respectively.",In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15684491/),%,10.5,135601,DB00091,Cyclosporine
,15684491,clearance ratio,"Without pretreatment with CsA or KCZ, the clearance ratio of Clbile relative to the total body clearances of Rho123, NFV and EM was 10.5, 0.07 and 31.1%, respectively.",In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15684491/),%,0.07,135602,DB00091,Cyclosporine
,15684491,clearance ratio,"Without pretreatment with CsA or KCZ, the clearance ratio of Clbile relative to the total body clearances of Rho123, NFV and EM was 10.5, 0.07 and 31.1%, respectively.",In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15684491/),%,31.1,135603,DB00091,Cyclosporine
,24727337,IC50,The overall relationship between MPA concentration and IMPDH activity was described by a direct inhibitory maximum effect model with an IC50 of 3.23 mg/L total MPA and 57.3 ng/mL unbound MPA.,Pharmacokinetic and pharmacodynamic analysis of inosine monophosphate dehydrogenase activity in hematopoietic cell transplantation recipients treated with mycophenolate mofetil. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24727337/),[mg] / [l],3.23,135633,DB00091,Cyclosporine
,24727337,IC50,The overall relationship between MPA concentration and IMPDH activity was described by a direct inhibitory maximum effect model with an IC50 of 3.23 mg/L total MPA and 57.3 ng/mL unbound MPA.,Pharmacokinetic and pharmacodynamic analysis of inosine monophosphate dehydrogenase activity in hematopoietic cell transplantation recipients treated with mycophenolate mofetil. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24727337/),[ng] / [ml],57.3,135634,DB00091,Cyclosporine
,26041408,oral bioavailability,Dose-proportional systemic exposure to canagliflozin has been observed over a wide dose range (50-1600 mg) with an oral bioavailability of 65 %.,"Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26041408/),%,65,135780,DB00091,Cyclosporine
,26041408,half-life,"The half-life of orally administered canagliflozin 100 or 300 mg in healthy participants is 10.6 and 13.1 h, respectively.","Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26041408/),h,10.6,135781,DB00091,Cyclosporine
,26041408,half-life,"The half-life of orally administered canagliflozin 100 or 300 mg in healthy participants is 10.6 and 13.1 h, respectively.","Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26041408/),h,13.1,135782,DB00091,Cyclosporine
,9869848,level (C0),Whole blood through CsA level (C0) did not differ after conversion (SIM: 136.2 +/- 33 ng/ml and NEO: 142.6 +/- 34 ng/ml).,Higher exposure to cyclosporine A with unchanged tolerability in patients converted from Sandimmun to Sandimmun Neoral. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869848/),[ng] / [ml],136.2,135999,DB00091,Cyclosporine
,9869848,level (C0),Whole blood through CsA level (C0) did not differ after conversion (SIM: 136.2 +/- 33 ng/ml and NEO: 142.6 +/- 34 ng/ml).,Higher exposure to cyclosporine A with unchanged tolerability in patients converted from Sandimmun to Sandimmun Neoral. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869848/),[ng] / [ml],142.6,136000,DB00091,Cyclosporine
,9869848,peak blood concentration (Cmax),During therapy with NEO peak blood concentration (Cmax) was significantly higher (935.6 +/- 368 ng/ml) and occurred earlier (Tmax 1 hr.,Higher exposure to cyclosporine A with unchanged tolerability in patients converted from Sandimmun to Sandimmun Neoral. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869848/),[ng] / [ml],935.6,136001,DB00091,Cyclosporine
,9869848,Tmax,During therapy with NEO peak blood concentration (Cmax) was significantly higher (935.6 +/- 368 ng/ml) and occurred earlier (Tmax 1 hr.,Higher exposure to cyclosporine A with unchanged tolerability in patients converted from Sandimmun to Sandimmun Neoral. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869848/),h,1,136002,DB00091,Cyclosporine
,9869848,Cmax,"+/- 30 min) as compared to the period on SIM (Cmax 598 +/- 309 ng/ml, p = 0.01), Tmax = 3 hr.",Higher exposure to cyclosporine A with unchanged tolerability in patients converted from Sandimmun to Sandimmun Neoral. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869848/),[ng] / [ml],598,136003,DB00091,Cyclosporine
,9869848,Tmax,"+/- 30 min) as compared to the period on SIM (Cmax 598 +/- 309 ng/ml, p = 0.01), Tmax = 3 hr.",Higher exposure to cyclosporine A with unchanged tolerability in patients converted from Sandimmun to Sandimmun Neoral. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869848/),h,3,136004,DB00091,Cyclosporine
,9869848,AUC,AUC increased from 2975.4 +/- 1020 ngxhr/ml to 4236.1 +/- 1188 ngxhr/ml (p < 0.0001).,Higher exposure to cyclosporine A with unchanged tolerability in patients converted from Sandimmun to Sandimmun Neoral. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869848/),[h·ng] / [ml],2975.4,136005,DB00091,Cyclosporine
,9869848,AUC,AUC increased from 2975.4 +/- 1020 ngxhr/ml to 4236.1 +/- 1188 ngxhr/ml (p < 0.0001).,Higher exposure to cyclosporine A with unchanged tolerability in patients converted from Sandimmun to Sandimmun Neoral. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869848/),[h·ng] / [ml],4236.1,136006,DB00091,Cyclosporine
,3305823,Area under curve,(Area under curve = 7776 +/- 1437 for Cremophor 15 mg/kg vs 1837 +/- 726 for Miglyol 15 mg/kg; 2579 +/- 694 for Cremophor 10 vs 1123 +/- 393 for Miglyol 10.),Role of the carrier solution in cyclosporine pharmacokinetics in the baboon. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3305823/),,7776,136140,DB00091,Cyclosporine
,3305823,Area under curve,(Area under curve = 7776 +/- 1437 for Cremophor 15 mg/kg vs 1837 +/- 726 for Miglyol 15 mg/kg; 2579 +/- 694 for Cremophor 10 vs 1123 +/- 393 for Miglyol 10.),Role of the carrier solution in cyclosporine pharmacokinetics in the baboon. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3305823/),,1837,136141,DB00091,Cyclosporine
,3305823,Area under curve,(Area under curve = 7776 +/- 1437 for Cremophor 15 mg/kg vs 1837 +/- 726 for Miglyol 15 mg/kg; 2579 +/- 694 for Cremophor 10 vs 1123 +/- 393 for Miglyol 10.),Role of the carrier solution in cyclosporine pharmacokinetics in the baboon. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3305823/),,2579,136142,DB00091,Cyclosporine
,3305823,Area under curve,(Area under curve = 7776 +/- 1437 for Cremophor 15 mg/kg vs 1837 +/- 726 for Miglyol 15 mg/kg; 2579 +/- 694 for Cremophor 10 vs 1123 +/- 393 for Miglyol 10.),Role of the carrier solution in cyclosporine pharmacokinetics in the baboon. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3305823/),,1123,136143,DB00091,Cyclosporine
,3305823,serum trough level,Long-term daily intramuscular administration of Cremophor provides a sustained drug serum trough level with wide variability between individual animals (80 to 825 ng/ml).,Role of the carrier solution in cyclosporine pharmacokinetics in the baboon. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3305823/),[ng] / [ml],80 to 825,136144,DB00091,Cyclosporine
,10551636,half-life,"The drug was absorbed within 2 hr and displayed a 16-19-hr half-life, which is shorter than that of rapamycin.",A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10551636/),h,16-19-,136171,DB00091,Cyclosporine
,18089380,area under the concentration time curve (AUC(0-infinity)),The pharmacokinetic parameter area under the concentration time curve (AUC(0-infinity)) of CsA after intravenous administration was significantly lower (2903 ng*h*mL(-1)) than that after oral administration (4344 ng*h*mL(-1); P=.01).,A prospective cross-over study comparing the pharmacokinetics of cyclosporine A and its metabolites after oral versus short-time intravenous cyclosporine A administration in pre-heart transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18089380/),[h·ng] / [ml],2903,136962,DB00091,Cyclosporine
,18089380,area under the concentration time curve (AUC(0-infinity)),The pharmacokinetic parameter area under the concentration time curve (AUC(0-infinity)) of CsA after intravenous administration was significantly lower (2903 ng*h*mL(-1)) than that after oral administration (4344 ng*h*mL(-1); P=.01).,A prospective cross-over study comparing the pharmacokinetics of cyclosporine A and its metabolites after oral versus short-time intravenous cyclosporine A administration in pre-heart transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18089380/),[h·ng] / [ml],4344,136963,DB00091,Cyclosporine
,3530588,CL,"Mean (+/- SE) cyclosporine CL was 82 +/- 21, 45 +/- 5, 38 +/- 9, 44 +/- 8, and 20 +/- 3 ml/min/kg and mean cyclosporine Vss was 34 +/- 11, 28 +/- 10, 15 +/- 4, 14 +/- 5, and 4.7 +/- 0.7 L/kg in patients 0 to 10 (n = 12), 11 to 20 (n = 19), 21 to 30 (n = 12), 31 to 40 (n = 17), and greater than 40 (n = 9) years old, respectively.",Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3530588/),[ml] / [kg·min],82,137560,DB00091,Cyclosporine
,3530588,CL,"Mean (+/- SE) cyclosporine CL was 82 +/- 21, 45 +/- 5, 38 +/- 9, 44 +/- 8, and 20 +/- 3 ml/min/kg and mean cyclosporine Vss was 34 +/- 11, 28 +/- 10, 15 +/- 4, 14 +/- 5, and 4.7 +/- 0.7 L/kg in patients 0 to 10 (n = 12), 11 to 20 (n = 19), 21 to 30 (n = 12), 31 to 40 (n = 17), and greater than 40 (n = 9) years old, respectively.",Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3530588/),[ml] / [kg·min],45,137561,DB00091,Cyclosporine
,3530588,CL,"Mean (+/- SE) cyclosporine CL was 82 +/- 21, 45 +/- 5, 38 +/- 9, 44 +/- 8, and 20 +/- 3 ml/min/kg and mean cyclosporine Vss was 34 +/- 11, 28 +/- 10, 15 +/- 4, 14 +/- 5, and 4.7 +/- 0.7 L/kg in patients 0 to 10 (n = 12), 11 to 20 (n = 19), 21 to 30 (n = 12), 31 to 40 (n = 17), and greater than 40 (n = 9) years old, respectively.",Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3530588/),[ml] / [kg·min],38,137562,DB00091,Cyclosporine
,3530588,CL,"Mean (+/- SE) cyclosporine CL was 82 +/- 21, 45 +/- 5, 38 +/- 9, 44 +/- 8, and 20 +/- 3 ml/min/kg and mean cyclosporine Vss was 34 +/- 11, 28 +/- 10, 15 +/- 4, 14 +/- 5, and 4.7 +/- 0.7 L/kg in patients 0 to 10 (n = 12), 11 to 20 (n = 19), 21 to 30 (n = 12), 31 to 40 (n = 17), and greater than 40 (n = 9) years old, respectively.",Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3530588/),[ml] / [kg·min],44,137563,DB00091,Cyclosporine
,3530588,CL,"Mean (+/- SE) cyclosporine CL was 82 +/- 21, 45 +/- 5, 38 +/- 9, 44 +/- 8, and 20 +/- 3 ml/min/kg and mean cyclosporine Vss was 34 +/- 11, 28 +/- 10, 15 +/- 4, 14 +/- 5, and 4.7 +/- 0.7 L/kg in patients 0 to 10 (n = 12), 11 to 20 (n = 19), 21 to 30 (n = 12), 31 to 40 (n = 17), and greater than 40 (n = 9) years old, respectively.",Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3530588/),[ml] / [kg·min],20,137564,DB00091,Cyclosporine
,3530588,Vss,"Mean (+/- SE) cyclosporine CL was 82 +/- 21, 45 +/- 5, 38 +/- 9, 44 +/- 8, and 20 +/- 3 ml/min/kg and mean cyclosporine Vss was 34 +/- 11, 28 +/- 10, 15 +/- 4, 14 +/- 5, and 4.7 +/- 0.7 L/kg in patients 0 to 10 (n = 12), 11 to 20 (n = 19), 21 to 30 (n = 12), 31 to 40 (n = 17), and greater than 40 (n = 9) years old, respectively.",Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3530588/),[l] / [kg],34,137565,DB00091,Cyclosporine
,3530588,Vss,"Mean (+/- SE) cyclosporine CL was 82 +/- 21, 45 +/- 5, 38 +/- 9, 44 +/- 8, and 20 +/- 3 ml/min/kg and mean cyclosporine Vss was 34 +/- 11, 28 +/- 10, 15 +/- 4, 14 +/- 5, and 4.7 +/- 0.7 L/kg in patients 0 to 10 (n = 12), 11 to 20 (n = 19), 21 to 30 (n = 12), 31 to 40 (n = 17), and greater than 40 (n = 9) years old, respectively.",Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3530588/),[l] / [kg],28,137566,DB00091,Cyclosporine
,3530588,Vss,"Mean (+/- SE) cyclosporine CL was 82 +/- 21, 45 +/- 5, 38 +/- 9, 44 +/- 8, and 20 +/- 3 ml/min/kg and mean cyclosporine Vss was 34 +/- 11, 28 +/- 10, 15 +/- 4, 14 +/- 5, and 4.7 +/- 0.7 L/kg in patients 0 to 10 (n = 12), 11 to 20 (n = 19), 21 to 30 (n = 12), 31 to 40 (n = 17), and greater than 40 (n = 9) years old, respectively.",Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3530588/),[l] / [kg],15,137567,DB00091,Cyclosporine
,3530588,Vss,"Mean (+/- SE) cyclosporine CL was 82 +/- 21, 45 +/- 5, 38 +/- 9, 44 +/- 8, and 20 +/- 3 ml/min/kg and mean cyclosporine Vss was 34 +/- 11, 28 +/- 10, 15 +/- 4, 14 +/- 5, and 4.7 +/- 0.7 L/kg in patients 0 to 10 (n = 12), 11 to 20 (n = 19), 21 to 30 (n = 12), 31 to 40 (n = 17), and greater than 40 (n = 9) years old, respectively.",Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3530588/),[l] / [kg],14,137568,DB00091,Cyclosporine
,3530588,Vss,"Mean (+/- SE) cyclosporine CL was 82 +/- 21, 45 +/- 5, 38 +/- 9, 44 +/- 8, and 20 +/- 3 ml/min/kg and mean cyclosporine Vss was 34 +/- 11, 28 +/- 10, 15 +/- 4, 14 +/- 5, and 4.7 +/- 0.7 L/kg in patients 0 to 10 (n = 12), 11 to 20 (n = 19), 21 to 30 (n = 12), 31 to 40 (n = 17), and greater than 40 (n = 9) years old, respectively.",Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3530588/),[l] / [kg],4.7,137569,DB00091,Cyclosporine
,8937932,trough levels,Tacrolimus trough levels were adjusted to a therapeutic window of 5-8 ng/ml.,Clinical pharmacokinetics of tacrolimus in rescue therapy after renal transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8937932/),[ng] / [ml],5-8,137955,DB00091,Cyclosporine
>,8937932,trough levels,"Overall, 82 adverse events were noted, of which 29 (35%) were associated with high trough levels (> 10 ng/ml).",Clinical pharmacokinetics of tacrolimus in rescue therapy after renal transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8937932/),[ng] / [ml],10,137956,DB00091,Cyclosporine
<,8937932,trough levels,"In contrast, 3 patients with trough levels < 4 ng/ml had ongoing rejection.",Clinical pharmacokinetics of tacrolimus in rescue therapy after renal transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8937932/),[ng] / [ml],4,137957,DB00091,Cyclosporine
,8937932,trough levels,We conclude: Tacrolimus conversion for rescue therapy after renal transplantation is efficient and safe with target trough levels between 5 -8 ng/ml.,Clinical pharmacokinetics of tacrolimus in rescue therapy after renal transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8937932/),[ng] / [ml],5 -8,137958,DB00091,Cyclosporine
,14742751,AUC,Atorvastatin coadministration increased the cyclosporine AUC by 9% (range 0-20.6%; 3018 vs 3290 ng.h/mL; p = 0.04).,Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14742751/),[h·ng] / [ml],3018,138469,DB00091,Cyclosporine
,14742751,AUC,Atorvastatin coadministration increased the cyclosporine AUC by 9% (range 0-20.6%; 3018 vs 3290 ng.h/mL; p = 0.04).,Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14742751/),[h·ng] / [ml],3290,138470,DB00091,Cyclosporine
,8060468,tmax,Median tmax did not change significantly after UDCA (3.0 vs 4.0 h without UDCA) and only 7 of 12 patients (58%) showed a rise in the amount of cyclosporin absorbed over 24 h with the AUC not having changed significantly (median 4527 vs 4979 micrograms.h.l-1 without UDCA).,Variable effect of ursodeoxycholic acid on cyclosporin absorption after orthotopic liver transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8060468/),h,3.0,138639,DB00091,Cyclosporine
,8060468,tmax,Median tmax did not change significantly after UDCA (3.0 vs 4.0 h without UDCA) and only 7 of 12 patients (58%) showed a rise in the amount of cyclosporin absorbed over 24 h with the AUC not having changed significantly (median 4527 vs 4979 micrograms.h.l-1 without UDCA).,Variable effect of ursodeoxycholic acid on cyclosporin absorption after orthotopic liver transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8060468/),h,4.0,138640,DB00091,Cyclosporine
,8060468,AUC,Median tmax did not change significantly after UDCA (3.0 vs 4.0 h without UDCA) and only 7 of 12 patients (58%) showed a rise in the amount of cyclosporin absorbed over 24 h with the AUC not having changed significantly (median 4527 vs 4979 micrograms.h.l-1 without UDCA).,Variable effect of ursodeoxycholic acid on cyclosporin absorption after orthotopic liver transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8060468/),[h·μg] / [l],4527,138641,DB00091,Cyclosporine
,8060468,AUC,Median tmax did not change significantly after UDCA (3.0 vs 4.0 h without UDCA) and only 7 of 12 patients (58%) showed a rise in the amount of cyclosporin absorbed over 24 h with the AUC not having changed significantly (median 4527 vs 4979 micrograms.h.l-1 without UDCA).,Variable effect of ursodeoxycholic acid on cyclosporin absorption after orthotopic liver transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8060468/),[h·μg] / [l],4979,138642,DB00091,Cyclosporine
,8060468,Cmax,"Median Cmax and C24 also increased only marginally following UDCA administration (616 vs 587 micrograms.l-1 and 87 vs 58 micrograms.l-1 without UDCA, respectively).",Variable effect of ursodeoxycholic acid on cyclosporin absorption after orthotopic liver transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8060468/),[μg] / [l],616,138643,DB00091,Cyclosporine
,8060468,Cmax,"Median Cmax and C24 also increased only marginally following UDCA administration (616 vs 587 micrograms.l-1 and 87 vs 58 micrograms.l-1 without UDCA, respectively).",Variable effect of ursodeoxycholic acid on cyclosporin absorption after orthotopic liver transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8060468/),[μg] / [l],587,138644,DB00091,Cyclosporine
,8060468,C24,"Median Cmax and C24 also increased only marginally following UDCA administration (616 vs 587 micrograms.l-1 and 87 vs 58 micrograms.l-1 without UDCA, respectively).",Variable effect of ursodeoxycholic acid on cyclosporin absorption after orthotopic liver transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8060468/),[μg] / [l],87,138645,DB00091,Cyclosporine
,8060468,C24,"Median Cmax and C24 also increased only marginally following UDCA administration (616 vs 587 micrograms.l-1 and 87 vs 58 micrograms.l-1 without UDCA, respectively).",Variable effect of ursodeoxycholic acid on cyclosporin absorption after orthotopic liver transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8060468/),[μg] / [l],58,138646,DB00091,Cyclosporine
,8060468,AUC,"In the cholestatic patients, median AUC was 50% smaller (3223 vs 6439 micrograms.",Variable effect of ursodeoxycholic acid on cyclosporin absorption after orthotopic liver transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8060468/),μg,3223,138647,DB00091,Cyclosporine
,8060468,AUC,"In the cholestatic patients, median AUC was 50% smaller (3223 vs 6439 micrograms.",Variable effect of ursodeoxycholic acid on cyclosporin absorption after orthotopic liver transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8060468/),μg,6439,138648,DB00091,Cyclosporine
,8060468,t1/2 a,h.l-1) and median t1/2 a was 100% longer (1.58 vs 0.8 h) than in patients without cholestasis.,Variable effect of ursodeoxycholic acid on cyclosporin absorption after orthotopic liver transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8060468/),h,1.58,138649,DB00091,Cyclosporine
,8060468,t1/2 a,h.l-1) and median t1/2 a was 100% longer (1.58 vs 0.8 h) than in patients without cholestasis.,Variable effect of ursodeoxycholic acid on cyclosporin absorption after orthotopic liver transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8060468/),h,0.8,138650,DB00091,Cyclosporine
,3229899,half-life,We found that the half-life of free cyclosporine was about 6 hours and that of liposome-bound cyclosporine was about 3 days.,Liposome-bound cyclosporine: clearance after intravitreal injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3229899/),h,6,138714,DB00091,Cyclosporine
,3229899,half-life,We found that the half-life of free cyclosporine was about 6 hours and that of liposome-bound cyclosporine was about 3 days.,Liposome-bound cyclosporine: clearance after intravitreal injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3229899/),d,3,138715,DB00091,Cyclosporine
,8573949,times to maximum cy,"The average times to maximum cyclosporine concentrations were similar between baseline (3.2 h), cimetidine (2.9 h), and famotidine (3.6 h) dosing periods.",Evaluation of the pharmacokinetic interaction between cimetidine or famotidine and cyclosporine in healthy men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8573949/),h,3.2,139511,DB00091,Cyclosporine
,8573949,times to maximum cy,"The average times to maximum cyclosporine concentrations were similar between baseline (3.2 h), cimetidine (2.9 h), and famotidine (3.6 h) dosing periods.",Evaluation of the pharmacokinetic interaction between cimetidine or famotidine and cyclosporine in healthy men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8573949/),h,2.9,139512,DB00091,Cyclosporine
,8573949,times to maximum cy,"The average times to maximum cyclosporine concentrations were similar between baseline (3.2 h), cimetidine (2.9 h), and famotidine (3.6 h) dosing periods.",Evaluation of the pharmacokinetic interaction between cimetidine or famotidine and cyclosporine in healthy men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8573949/),h,3.6,139513,DB00091,Cyclosporine
,21068646,apparent clearance (CL/F),"Population parameters of apparent clearance (CL/F) and volume of distribution were estimated as 23.1 L/h and 105 L, respectively.",Population pharmacokinetic study of cyclosporine based on NONMEM in Chinese liver transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21068646/),[l] / [h],23.1,139526,DB00091,Cyclosporine
,21068646,volume of distribution,"Population parameters of apparent clearance (CL/F) and volume of distribution were estimated as 23.1 L/h and 105 L, respectively.",Population pharmacokinetic study of cyclosporine based on NONMEM in Chinese liver transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21068646/),l,105,139527,DB00091,Cyclosporine
,24243422,oral clearance (CL/F),"Population mean estimates (relative standard error, rse) for oral clearance (CL/F) and first compartment volume of distribution (V1), were 717 mL min(-1) (35%) and 2010 mL (17%), respectively.",Population PKPD of voclosporin in renal allograft patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24243422/),[ml] / [min],717,139811,DB00091,Cyclosporine
,24243422,first compartment volume of distribution (V1),"Population mean estimates (relative standard error, rse) for oral clearance (CL/F) and first compartment volume of distribution (V1), were 717 mL min(-1) (35%) and 2010 mL (17%), respectively.",Population PKPD of voclosporin in renal allograft patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24243422/),ml,2010,139812,DB00091,Cyclosporine
,24243422,Maximum CNa Inhibition (Imax),"Maximum CNa Inhibition (Imax), effective concentration (C50), and baseline immunosuppression (S0) were 0.87 pmol/min/mg (8.0%), 123 ng/mL (10%), and 1.15 pmol/min/mg (4.0%), respectively.",Population PKPD of voclosporin in renal allograft patients. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24243422/),[pM] / [mg·min],0.87,139813,DB00091,Cyclosporine
,24243422,effective concentration (C50),"Maximum CNa Inhibition (Imax), effective concentration (C50), and baseline immunosuppression (S0) were 0.87 pmol/min/mg (8.0%), 123 ng/mL (10%), and 1.15 pmol/min/mg (4.0%), respectively.",Population PKPD of voclosporin in renal allograft patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24243422/),[ng] / [ml],123,139814,DB00091,Cyclosporine
,24243422,baseline,"Maximum CNa Inhibition (Imax), effective concentration (C50), and baseline immunosuppression (S0) were 0.87 pmol/min/mg (8.0%), 123 ng/mL (10%), and 1.15 pmol/min/mg (4.0%), respectively.",Population PKPD of voclosporin in renal allograft patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24243422/),[ng] / [ml],123,139815,DB00091,Cyclosporine
,12164891,AUC0-12h,"Despite that the MMF dose did not change significantly with time, dose-normalized MPA AUC0-12h was lower during the first month (triple therapy, high doses of steroids) than at month 6 post-surgery (triple therapy, low maintenance dose of steroids (32.94 +/- 10.98 vs. 50.87 +/- 22.37 microg/mL. h; P < 0.01).",Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12164891/),[μg] / [h·ml],32.94,139829,DB00091,Cyclosporine
,12164891,AUC0-12h,"Despite that the MMF dose did not change significantly with time, dose-normalized MPA AUC0-12h was lower during the first month (triple therapy, high doses of steroids) than at month 6 post-surgery (triple therapy, low maintenance dose of steroids (32.94 +/- 10.98 vs. 50.87 +/- 22.37 microg/mL. h; P < 0.01).",Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12164891/),[μg] / [h·ml],50.87,139830,DB00091,Cyclosporine
<,10701434,run times,"The method has a lower limit of quantification (LLOQ) adequate for sensitive pharmacokinetic studies ( < or = 0.05 microg/ml), has run times of < or = 15 min, and uses aliquot volumes adequate for pediatric studies (0.25 ml).","A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701434/),min,15,140499,DB00091,Cyclosporine
,10701434,lambda(ex),Detection and quantification of ganciclovir is by fluorescence (lambda(ex) = 278 nm; lambda(em) = 380 nm).,"A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701434/),,278,140500,DB00091,Cyclosporine
,10701434,lambda(em),Detection and quantification of ganciclovir is by fluorescence (lambda(ex) = 278 nm; lambda(em) = 380 nm).,"A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701434/),,380,140501,DB00091,Cyclosporine
<,10701434,% C.V.,All intra- and inter-assay % C.V. values were < 8%; all recoveries (accuracy) were within 7% of nominal values.,"A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701434/),%,8,140502,DB00091,Cyclosporine
,11309548,clearance,"Basiliximab clearance was 55 +/- 26 mL/h, the distribution volume was 9.7 +/- 4.2 L, and the half-life was 8.7 +/- 6.7 days.",A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11309548/),[ml] / [h],55,140513,DB00091,Cyclosporine
,11309548,distribution volume,"Basiliximab clearance was 55 +/- 26 mL/h, the distribution volume was 9.7 +/- 4.2 L, and the half-life was 8.7 +/- 6.7 days.",A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11309548/),l,9.7,140514,DB00091,Cyclosporine
,11309548,half-life,"Basiliximab clearance was 55 +/- 26 mL/h, the distribution volume was 9.7 +/- 4.2 L, and the half-life was 8.7 +/- 6.7 days.",A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11309548/),d,8.7,140515,DB00091,Cyclosporine
,18043470,area under the curve(0-12),"Median (range) of MPA area under the curve(0-12) was 36.7 (range, 16.4-116.4) mg*h/L in diabetic and 48.2 (range, 34.9-80.1) mg*h/L in nondiabetic patients (P=0.49).",Effect of diabetes mellitus on mycophenolate sodium pharmacokinetics and inosine monophosphate dehydrogenase activity in stable kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043470/),[h·mg] / [l],36.7,140632,DB00091,Cyclosporine
,18043470,area under the curve(0-12),"Median (range) of MPA area under the curve(0-12) was 36.7 (range, 16.4-116.4) mg*h/L in diabetic and 48.2 (range, 34.9-80.1) mg*h/L in nondiabetic patients (P=0.49).",Effect of diabetes mellitus on mycophenolate sodium pharmacokinetics and inosine monophosphate dehydrogenase activity in stable kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043470/),[h·mg] / [l],48.2,140633,DB00091,Cyclosporine
,18043470,activity,"In contrast, IMPDH activity was 17.5+/-2.8 versus 46.6+/-2.5 nmol XMP/h/microg protein in diabetics and nondiabetics, respectively (P<0.0001) and was significantly lower in the diabetics irrespective of concomitant therapy with cyclosporine or tacrolimus.",Effect of diabetes mellitus on mycophenolate sodium pharmacokinetics and inosine monophosphate dehydrogenase activity in stable kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043470/),[Mp·nM] / [h·μg],17.5,140634,DB00091,Cyclosporine
,18043470,activity,"In contrast, IMPDH activity was 17.5+/-2.8 versus 46.6+/-2.5 nmol XMP/h/microg protein in diabetics and nondiabetics, respectively (P<0.0001) and was significantly lower in the diabetics irrespective of concomitant therapy with cyclosporine or tacrolimus.",Effect of diabetes mellitus on mycophenolate sodium pharmacokinetics and inosine monophosphate dehydrogenase activity in stable kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043470/),[Mp·nM] / [h·μg],46.6,140635,DB00091,Cyclosporine
,4023419,lower detection limit,The lower detection limit is 100 ng/ml in human blood (from 1.0 ml) and 500 ng/ml in the rat plasma or lymph (from 0.2 ml).,High performance liquid chromatographic determination of cyclosporin A in body fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4023419/),[ng] / [ml],100,140764,DB00091,Cyclosporine
,4023419,lower detection limit,The lower detection limit is 100 ng/ml in human blood (from 1.0 ml) and 500 ng/ml in the rat plasma or lymph (from 0.2 ml).,High performance liquid chromatographic determination of cyclosporin A in body fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4023419/),[ng] / [ml],500,140765,DB00091,Cyclosporine
,8070508,maximum blood concentration,The mean maximum blood concentration of CsA for the oral dose was 776 ng.,Cyclosporin pharmacokinetics in heart-lung transplant recipients with cystic fibrosis. Effects of pancreatic enzymes and ranitidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070508/),ng,776,141552,DB00091,Cyclosporine
,8070508,peak values,"ml-1 for the 7 CF subjects, which was comparable with the mean peak values of 789 ng.",Cyclosporin pharmacokinetics in heart-lung transplant recipients with cystic fibrosis. Effects of pancreatic enzymes and ranitidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070508/),ng,789,141553,DB00091,Cyclosporine
,8070508,bioavailability,Poor enteral absorption of CsA probably accounts for the significantly lower mean bioavailability in the 7 CF subjects (14.9%) compared with the 3 non-CF control subjects (39.4%).,Cyclosporin pharmacokinetics in heart-lung transplant recipients with cystic fibrosis. Effects of pancreatic enzymes and ranitidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070508/),%,14.9,141554,DB00091,Cyclosporine
,8070508,bioavailability,Poor enteral absorption of CsA probably accounts for the significantly lower mean bioavailability in the 7 CF subjects (14.9%) compared with the 3 non-CF control subjects (39.4%).,Cyclosporin pharmacokinetics in heart-lung transplant recipients with cystic fibrosis. Effects of pancreatic enzymes and ranitidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070508/),%,39.4,141555,DB00091,Cyclosporine
>,9527407,Cmax,"Administration of the predicted oral dose of CsA-ME produced a Cmax > 700 ng/ml in 90% of patients from days 2 to 4, and in 97% from days 5 to 7, whereas administration of the predicted oral dose of CsA-GC produced a Cmax > 700 ng/ml in only 64 and 82% of patients during these same time periods, respectively (both P < 0.05).",Pretransplant test-dose pharmacokinetic profiles: cyclosporine microemulsion versus corn oil-based soft gel capsule formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527407/),[ng] / [ml],700,142102,DB00091,Cyclosporine
,19675788,C2,"Mean C2 value before switchover was 894 +/- 208 ng/ml, which was not significantly different from the mean values of C2 after switchover therapy (P>0.30).",Clinical evaluation of efficacy and safety of cyclosporine (Imusporin) in renal transplant patients with stable graft function maintained on neoral or bioral. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19675788/),[ng] / [ml],894,142259,DB00091,Cyclosporine
<,9249946,bioavailability,"After excluding poor compliance, drug interactions and analytical problems and identifying poor bioavailability (< 2.6%) and rapid clearance (4.2 l/h), fluconazole (100 mg/day) was initiated to inhibit tacrolimus metabolism and consistent therapeutic blood levels of tacrolimus were achieved.",Tacrolimus (FK506) malabsorption: management with fluconazole coadministration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9249946/),%,2.6,143611,DB00091,Cyclosporine
,9249946,clearance,"After excluding poor compliance, drug interactions and analytical problems and identifying poor bioavailability (< 2.6%) and rapid clearance (4.2 l/h), fluconazole (100 mg/day) was initiated to inhibit tacrolimus metabolism and consistent therapeutic blood levels of tacrolimus were achieved.",Tacrolimus (FK506) malabsorption: management with fluconazole coadministration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9249946/),[l] / [h],4.2,143612,DB00091,Cyclosporine
,15795639,absorption rate constants,The absorption rate constants were fixed at 0.25 L/h for Sandimmune and 1.35 L/h for Neoral formulations.,Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795639/),[l] / [h],0.25,143668,DB00091,Cyclosporine
,15795639,absorption rate constants,The absorption rate constants were fixed at 0.25 L/h for Sandimmune and 1.35 L/h for Neoral formulations.,Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795639/),[l] / [h],1.35,143669,DB00091,Cyclosporine
,15795639,Oral clearance (CL/F),Oral clearance (CL/F) was estimated to be 22.1 L/h (95% confidence intervals [CI] 19.5-24.7 L/h).,Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795639/),[l] / [h],22.1,143670,DB00091,Cyclosporine
,15795639,relative oral bioavailability,The relative oral bioavailability of Sandimmune to Neoral was 0.82.,Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795639/),,0.82,143671,DB00091,Cyclosporine
,3658087,T6,"To show the results in a prospective study utilizing the T6 as a monitoring tool and with dose adjustments disregarding concomitant serum creatinine levels, with the aim of maintaining a therapeutic T6 (range 150-250 ng/ml).","[Plasma levels of cyclosporin 6 hours after its oral administration, T6: key to the surveillance of the treatment]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3658087/),ng,150-250,143788,DB00091,Cyclosporine
,17044449,C2 concentration,"The first predicted dose was estimated by using C2 concentration of 1,700 ng/mL.",Study of cyclosporine level at 2 hours after administration in preoperative kidney transplant recipients for prediction of postoperative optimal cyclosporine dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17044449/),[ng] / [ml],"1,700",143829,DB00091,Cyclosporine
,11861816,apparent oral clearance,"The apparent oral clearance of grepafloxacin was decreased to 33% of the control, and the bioavailability of grepafloxacin was increased to 95% by cyclosporin A from 53% in the controls.",Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11861816/),,33,144031,DB00091,Cyclosporine
,11861816,bioavailability,"The apparent oral clearance of grepafloxacin was decreased to 33% of the control, and the bioavailability of grepafloxacin was increased to 95% by cyclosporin A from 53% in the controls.",Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11861816/),,95,144032,DB00091,Cyclosporine
,11861816,bioavailability,"The apparent oral clearance of grepafloxacin was decreased to 33% of the control, and the bioavailability of grepafloxacin was increased to 95% by cyclosporin A from 53% in the controls.",Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11861816/),%,53,144033,DB00091,Cyclosporine
,28353583,AUC(0-12),"The patients treated with a higher mean dose of CsA displayed higher MPA AUC(0-12) exposure in the low-dose MMF group (1000 mg/day) (40.50 ± 10.97 vs 28.08 ± 11.03 h mg/L; rs = 0.497, P < 0.05), medium-dose MMF group (2000 mg/day) (43.00 ± 6.27 vs 28.85 ± 11.08 h mg/L; rs = 0.437, P < 0.01), and high-dose MMF group (3000 mg/day) (56.75 ± 16.78 vs 36.20 ± 3.70 h mg/L; rs = 0.608, P < 0.05).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[h·mg] / [l],40.50,144481,DB00091,Cyclosporine
,28353583,AUC(0-12),"The patients treated with a higher mean dose of CsA displayed higher MPA AUC(0-12) exposure in the low-dose MMF group (1000 mg/day) (40.50 ± 10.97 vs 28.08 ± 11.03 h mg/L; rs = 0.497, P < 0.05), medium-dose MMF group (2000 mg/day) (43.00 ± 6.27 vs 28.85 ± 11.08 h mg/L; rs = 0.437, P < 0.01), and high-dose MMF group (3000 mg/day) (56.75 ± 16.78 vs 36.20 ± 3.70 h mg/L; rs = 0.608, P < 0.05).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[h·mg] / [l],28.08,144482,DB00091,Cyclosporine
,28353583,AUC(0-12),"The patients treated with a higher mean dose of CsA displayed higher MPA AUC(0-12) exposure in the low-dose MMF group (1000 mg/day) (40.50 ± 10.97 vs 28.08 ± 11.03 h mg/L; rs = 0.497, P < 0.05), medium-dose MMF group (2000 mg/day) (43.00 ± 6.27 vs 28.85 ± 11.08 h mg/L; rs = 0.437, P < 0.01), and high-dose MMF group (3000 mg/day) (56.75 ± 16.78 vs 36.20 ± 3.70 h mg/L; rs = 0.608, P < 0.05).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[h·mg] / [l],43.00,144483,DB00091,Cyclosporine
,28353583,AUC(0-12),"The patients treated with a higher mean dose of CsA displayed higher MPA AUC(0-12) exposure in the low-dose MMF group (1000 mg/day) (40.50 ± 10.97 vs 28.08 ± 11.03 h mg/L; rs = 0.497, P < 0.05), medium-dose MMF group (2000 mg/day) (43.00 ± 6.27 vs 28.85 ± 11.08 h mg/L; rs = 0.437, P < 0.01), and high-dose MMF group (3000 mg/day) (56.75 ± 16.78 vs 36.20 ± 3.70 h mg/L; rs = 0.608, P < 0.05).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[h·mg] / [l],28.85,144484,DB00091,Cyclosporine
,28353583,AUC(0-12),"The patients treated with a higher mean dose of CsA displayed higher MPA AUC(0-12) exposure in the low-dose MMF group (1000 mg/day) (40.50 ± 10.97 vs 28.08 ± 11.03 h mg/L; rs = 0.497, P < 0.05), medium-dose MMF group (2000 mg/day) (43.00 ± 6.27 vs 28.85 ± 11.08 h mg/L; rs = 0.437, P < 0.01), and high-dose MMF group (3000 mg/day) (56.75 ± 16.78 vs 36.20 ± 3.70 h mg/L; rs = 0.608, P < 0.05).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[h·mg] / [l],56.75,144485,DB00091,Cyclosporine
,28353583,AUC(0-12),"The patients treated with a higher mean dose of CsA displayed higher MPA AUC(0-12) exposure in the low-dose MMF group (1000 mg/day) (40.50 ± 10.97 vs 28.08 ± 11.03 h mg/L; rs = 0.497, P < 0.05), medium-dose MMF group (2000 mg/day) (43.00 ± 6.27 vs 28.85 ± 11.08 h mg/L; rs = 0.437, P < 0.01), and high-dose MMF group (3000 mg/day) (56.75 ± 16.78 vs 36.20 ± 3.70 h mg/L; rs = 0.608, P < 0.05).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[h·mg] / [l],36.20,144486,DB00091,Cyclosporine
,28353583,Cmax,"A positive correlation was also observed between the mean CsA dose and the MPA Cmax in the low-dose MMF group (Cmax 22.83 ± 10.82 vs 12.08 ± 5.59 mg/L; rs = 0.507, P < 0.05) and in the medium-dose MMF group (22.77 ± 8.86 vs 13.00 ± 6.82 mg/L; rs = 0.414, P < 0.01).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[mg] / [l],22.83,144487,DB00091,Cyclosporine
,28353583,Cmax,"A positive correlation was also observed between the mean CsA dose and the MPA Cmax in the low-dose MMF group (Cmax 22.83 ± 10.82 vs 12.08 ± 5.59 mg/L; rs = 0.507, P < 0.05) and in the medium-dose MMF group (22.77 ± 8.86 vs 13.00 ± 6.82 mg/L; rs = 0.414, P < 0.01).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[mg] / [l],12.08,144488,DB00091,Cyclosporine
,28353583,Cmax,"A positive correlation was also observed between the mean CsA dose and the MPA Cmax in the low-dose MMF group (Cmax 22.83 ± 10.82 vs 12.08 ± 5.59 mg/L; rs = 0.507, P < 0.05) and in the medium-dose MMF group (22.77 ± 8.86 vs 13.00 ± 6.82 mg/L; rs = 0.414, P < 0.01).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[mg] / [l],22.77,144489,DB00091,Cyclosporine
,28353583,Cmax,"A positive correlation was also observed between the mean CsA dose and the MPA Cmax in the low-dose MMF group (Cmax 22.83 ± 10.82 vs 12.08 ± 5.59 mg/L; rs = 0.507, P < 0.05) and in the medium-dose MMF group (22.77 ± 8.86 vs 13.00 ± 6.82 mg/L; rs = 0.414, P < 0.01).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[mg] / [l],13.00,144490,DB00091,Cyclosporine
,10336506,concentration ratios,"In marked contrast to previous results with i.a. cyclosporin A infusion, only a minimal regional advantage of local FK506 delivery (mean right/left concentration ratios 1.0-1.4) was obtained in all forearm tissues over the dose range studied.",Pharmacokinetics of intra-arterial delivery of tacrolimus to vascularly isolated rabbit forelimb. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10336506/),,1.0-1.4,144610,DB00091,Cyclosporine
,9691165,bioavailabilities,"The bioavailabilities of acyclovir for neonatal control and CyA-treated rats after oral administration were significantly different at 15.6 and 22.0%, respectively, but those for the adult control and CyA-treated rats were the same at 15.6 and 14.0%, respectively.",Effect of cyclosporine A on the gastrointestinal absorption of acyclovir in neonatal and adult rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9691165/),%,15.6,144775,DB00091,Cyclosporine
,9691165,bioavailabilities,"The bioavailabilities of acyclovir for neonatal control and CyA-treated rats after oral administration were significantly different at 15.6 and 22.0%, respectively, but those for the adult control and CyA-treated rats were the same at 15.6 and 14.0%, respectively.",Effect of cyclosporine A on the gastrointestinal absorption of acyclovir in neonatal and adult rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9691165/),%,22.0,144776,DB00091,Cyclosporine
,9691165,bioavailabilities,"The bioavailabilities of acyclovir for neonatal control and CyA-treated rats after oral administration were significantly different at 15.6 and 22.0%, respectively, but those for the adult control and CyA-treated rats were the same at 15.6 and 14.0%, respectively.",Effect of cyclosporine A on the gastrointestinal absorption of acyclovir in neonatal and adult rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9691165/),%,14.0,144777,DB00091,Cyclosporine
,18520601,trough whole blood level,This was repeated during the period that CsA was administered and a steady-state concentration of CsA was achieved (trough whole blood level 200-400 ng/mL).,Effects of cyclosporine a on single-dose pharmacokinetics of intravenous itraconazole in patients with hematologic malignancies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520601/),[ng] / [ml],200-400,145051,DB00091,Cyclosporine
,1522483,K12,"A nonlinear mixed effects model was used to obtain the following parameter estimates (percent relative standard error): K12 = 0.111 day-1 (10.0), k21 = 0.0109 day-1 (12.6), ka = 0.0807 day-1 (11.8), CL/F = 14.6 L/day/kg (3.8), and Vd/F = 1.52 L/kg (13.4), where k12 and k21 are intercompartmental rate constants between sc compartments, ka is the absorption rate constant into the sampling compartment, CL/F is the apparent blood clearance of CyA from the body (F is bioavailability), and Vd/F is the apparent volume of distribution of CyA.",Pharmacokinetic model for subcutaneous absorption of cyclosporine in the rabbit during chronic treatment. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1522483/),1/[d],0.111,145120,DB00091,Cyclosporine
,1522483,k21,"A nonlinear mixed effects model was used to obtain the following parameter estimates (percent relative standard error): K12 = 0.111 day-1 (10.0), k21 = 0.0109 day-1 (12.6), ka = 0.0807 day-1 (11.8), CL/F = 14.6 L/day/kg (3.8), and Vd/F = 1.52 L/kg (13.4), where k12 and k21 are intercompartmental rate constants between sc compartments, ka is the absorption rate constant into the sampling compartment, CL/F is the apparent blood clearance of CyA from the body (F is bioavailability), and Vd/F is the apparent volume of distribution of CyA.",Pharmacokinetic model for subcutaneous absorption of cyclosporine in the rabbit during chronic treatment. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1522483/),1/[d],0.0109,145121,DB00091,Cyclosporine
,1522483,ka,"A nonlinear mixed effects model was used to obtain the following parameter estimates (percent relative standard error): K12 = 0.111 day-1 (10.0), k21 = 0.0109 day-1 (12.6), ka = 0.0807 day-1 (11.8), CL/F = 14.6 L/day/kg (3.8), and Vd/F = 1.52 L/kg (13.4), where k12 and k21 are intercompartmental rate constants between sc compartments, ka is the absorption rate constant into the sampling compartment, CL/F is the apparent blood clearance of CyA from the body (F is bioavailability), and Vd/F is the apparent volume of distribution of CyA.",Pharmacokinetic model for subcutaneous absorption of cyclosporine in the rabbit during chronic treatment. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1522483/),1/[d],0.0807,145122,DB00091,Cyclosporine
,1522483,CL/F,"A nonlinear mixed effects model was used to obtain the following parameter estimates (percent relative standard error): K12 = 0.111 day-1 (10.0), k21 = 0.0109 day-1 (12.6), ka = 0.0807 day-1 (11.8), CL/F = 14.6 L/day/kg (3.8), and Vd/F = 1.52 L/kg (13.4), where k12 and k21 are intercompartmental rate constants between sc compartments, ka is the absorption rate constant into the sampling compartment, CL/F is the apparent blood clearance of CyA from the body (F is bioavailability), and Vd/F is the apparent volume of distribution of CyA.",Pharmacokinetic model for subcutaneous absorption of cyclosporine in the rabbit during chronic treatment. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1522483/),[l] / [d·kg],14.6,145123,DB00091,Cyclosporine
,1522483,Vd/F,"A nonlinear mixed effects model was used to obtain the following parameter estimates (percent relative standard error): K12 = 0.111 day-1 (10.0), k21 = 0.0109 day-1 (12.6), ka = 0.0807 day-1 (11.8), CL/F = 14.6 L/day/kg (3.8), and Vd/F = 1.52 L/kg (13.4), where k12 and k21 are intercompartmental rate constants between sc compartments, ka is the absorption rate constant into the sampling compartment, CL/F is the apparent blood clearance of CyA from the body (F is bioavailability), and Vd/F is the apparent volume of distribution of CyA.",Pharmacokinetic model for subcutaneous absorption of cyclosporine in the rabbit during chronic treatment. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1522483/),[l] / [kg],1.52,145124,DB00091,Cyclosporine
,19566116,time to peak concentration,There was a rapid rise in MPA concentrations (median time to peak concentration 0.72-1.25 hours).,Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566116/),h,0.72-1.25,145318,DB00091,Cyclosporine
,11019845,AUC,"Drug exposure was substantially lower in children than adults, with an AUC of 861+/-805 vs 2629+/-1487 micromg x h/l (P = 0.001), respectively, and absorption was delayed and diminished in both groups by comparison with solid organ recipients.",Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11019845/),[h·μmg] / [l],861,145391,DB00091,Cyclosporine
,11019845,AUC,"Drug exposure was substantially lower in children than adults, with an AUC of 861+/-805 vs 2629+/-1487 micromg x h/l (P = 0.001), respectively, and absorption was delayed and diminished in both groups by comparison with solid organ recipients.",Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11019845/),[h·μmg] / [l],2629,145392,DB00091,Cyclosporine
,11019845,AUC,"In adults, gastrointestinal (GI) inflammation due to either mucositis or GVHD resulted in a higher AUC of 3077+/-1551 microg x h/l compared to 1795+/-973 microg x h/l (P = 0.02), and a similar trend was observed in children.",Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11019845/),[h·μg] / [l],3077,145393,DB00091,Cyclosporine
,11019845,AUC,"In adults, gastrointestinal (GI) inflammation due to either mucositis or GVHD resulted in a higher AUC of 3077+/-1551 microg x h/l compared to 1795+/-973 microg x h/l (P = 0.02), and a similar trend was observed in children.",Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11019845/),[h·μg] / [l],1795,145394,DB00091,Cyclosporine
,2231321,bioavailability,"The bioavailability and clearance were estimated to be 0.24 +/- 0.10 and 21 +/- 8 L/hr, respectively.",Comparison of methods to calculate cyclosporine A bioavailability from consecutive oral and intravenous doses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2231321/),[l] / [h],0.24,145531,DB00091,Cyclosporine
,2231321,clearance,"The bioavailability and clearance were estimated to be 0.24 +/- 0.10 and 21 +/- 8 L/hr, respectively.",Comparison of methods to calculate cyclosporine A bioavailability from consecutive oral and intravenous doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2231321/),[l] / [h],21,145532,DB00091,Cyclosporine
,2231321,bioavailabilities,"Markedly higher bioavailabilities (0.34 +/- 0.13) were obtained when a model-independent AUC correction procedure, commonly used to calculate CyA bioavailability, was used.",Comparison of methods to calculate cyclosporine A bioavailability from consecutive oral and intravenous doses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2231321/),,0.34,145533,DB00091,Cyclosporine
,9834211,t1/2,"Pharmacokinetic sampling was performed in 10 patients; the t1/2 +/- SE was 9.1 +/- 1.3 hours, the Cmax was 2,549 +/- 291 ng/mL, the Vd was 3.97 +/- 0.95 L, and the Vd/kg was 0. 05 +/- 0.01 L/kg.","A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834211/),h,9.1,146337,DB00091,Cyclosporine
,9834211,Cmax,"Pharmacokinetic sampling was performed in 10 patients; the t1/2 +/- SE was 9.1 +/- 1.3 hours, the Cmax was 2,549 +/- 291 ng/mL, the Vd was 3.97 +/- 0.95 L, and the Vd/kg was 0. 05 +/- 0.01 L/kg.","A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834211/),[ng] / [ml],"2,549",146338,DB00091,Cyclosporine
,9834211,Vd,"Pharmacokinetic sampling was performed in 10 patients; the t1/2 +/- SE was 9.1 +/- 1.3 hours, the Cmax was 2,549 +/- 291 ng/mL, the Vd was 3.97 +/- 0.95 L, and the Vd/kg was 0. 05 +/- 0.01 L/kg.","A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834211/),l,3.97,146339,DB00091,Cyclosporine
,9834211,Vd/kg,"Pharmacokinetic sampling was performed in 10 patients; the t1/2 +/- SE was 9.1 +/- 1.3 hours, the Cmax was 2,549 +/- 291 ng/mL, the Vd was 3.97 +/- 0.95 L, and the Vd/kg was 0. 05 +/- 0.01 L/kg.","A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834211/),[l] / [kg],0. 05,146340,DB00091,Cyclosporine
,9834211,total response rate,"At the end of treatment (day 11), there were six patients with complete responses and five with a reduction in grade of GVHD for a total response rate of 55% (95% confidence interval [CI], 32% to 77%).","A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834211/),%,55,146341,DB00091,Cyclosporine
,15561259,AUC,"Comparing the AUC/mg dose, PK-1 was much lower than PK-2 (25.2 +/- 11.4 ng x h/mg x mL vs 45.4 +/- 12.9 ng x h/mg x mL; P = .0005 using paired t test).",A limited sampling strategy for the estimation of 12-hour cyclosporine neoral area under the curve in Chinese cardiac transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561259/),[h·ng] / [mg·ml],25.2,147140,DB00091,Cyclosporine
,15561259,AUC,"Comparing the AUC/mg dose, PK-1 was much lower than PK-2 (25.2 +/- 11.4 ng x h/mg x mL vs 45.4 +/- 12.9 ng x h/mg x mL; P = .0005 using paired t test).",A limited sampling strategy for the estimation of 12-hour cyclosporine neoral area under the curve in Chinese cardiac transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561259/),[h·ng] / [mg·ml],45.4,147141,DB00091,Cyclosporine
,11269572,absolute bioavailability,"The absolute bioavailability of CsA was 21% lower in African American subjects compared with Caucasian subjects when it was given with water (p = 0.048), but these differences disappeared when it was given with GJ (p = 0.6).",Effect of grapefruit juice on pharmacokinetics of microemulsion cyclosporine in African American subjects compared with Caucasian subjects: does ethnic difference matter? ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11269572/),%,21,147592,DB00091,Cyclosporine
,31341257,clearance (CL),"The typical values for clearance (CL) and volume of distribution (V) were 42.3 L/h and 3100 L, respectively.",Population pharmacokinetics of cyclosporine in Chinese children receiving hematopoietic stem cell transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31341257/),[l] / [h],42.3,148473,DB00091,Cyclosporine
,31341257,volume of distribution (V),"The typical values for clearance (CL) and volume of distribution (V) were 42.3 L/h and 3100 L, respectively.",Population pharmacokinetics of cyclosporine in Chinese children receiving hematopoietic stem cell transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31341257/),l,3100,148474,DB00091,Cyclosporine
,16386613,trough level (C(0)),"Mean CsA trough level (C(0)) measured at first week posttransplant was significantly lower in the rejection than the no-rejection group (125.17 +/- 56.9 ng/mL versus 169.33 +/- 48.27 ng/mL, P = .001).",Relationship between pharmacokinetic parameters of cyclosporin and the incidence of acute rejection after heart transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386613/),[ng] / [ml],125.17,148675,DB00091,Cyclosporine
,16386613,trough level (C(0)),"Mean CsA trough level (C(0)) measured at first week posttransplant was significantly lower in the rejection than the no-rejection group (125.17 +/- 56.9 ng/mL versus 169.33 +/- 48.27 ng/mL, P = .001).",Relationship between pharmacokinetic parameters of cyclosporin and the incidence of acute rejection after heart transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386613/),[ng] / [ml],169.33,148676,DB00091,Cyclosporine
,16386613,C(0),ROC analysis showed that C(0) of 150 ng/mL provided the optimal cutoff.,Relationship between pharmacokinetic parameters of cyclosporin and the incidence of acute rejection after heart transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386613/),[ng] / [ml],150,148677,DB00091,Cyclosporine
>,16386613,C(0),"Patients with mean C(0) >150 ng/mL over the first week had less incidence of acute rejection than patients with levels <150 ng/mL (30.3% versus 64.9%) (P = .009, Cochran-Mantel-Haenszel test).",Relationship between pharmacokinetic parameters of cyclosporin and the incidence of acute rejection after heart transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386613/),[ng] / [ml],150,148678,DB00091,Cyclosporine
above,16386613,early trough levels,"In conclusion, our data suggest that in heart transplant patients it may be crucial to target early trough levels above 150 ng/mL during the first days postsurgery to avoid rejection.",Relationship between pharmacokinetic parameters of cyclosporin and the incidence of acute rejection after heart transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386613/),[ng] / [ml],150,148679,DB00091,Cyclosporine
,12100864,detection limit,The detection limit of fluconazole was 50 ng/ml.,Hepatobiliary excretion of fluconazole and its interaction with cyclosporin A in rat blood and bile using microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100864/),[ng] / [ml],50,149022,DB00091,Cyclosporine
,18192894,oral bioavailability,"In the whole population, the mean+/-SD cyclosporine oral bioavailability was 0.38+/-0.09, volume of distribution was 2.3+/-0.54 l/kg, and systemic clearance normalized by allometric body weight was 0.88+/-0.16 l/h/kg3/4.",Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192894/),,0.38,149244,DB00091,Cyclosporine
,18192894,volume of distribution,"In the whole population, the mean+/-SD cyclosporine oral bioavailability was 0.38+/-0.09, volume of distribution was 2.3+/-0.54 l/kg, and systemic clearance normalized by allometric body weight was 0.88+/-0.16 l/h/kg3/4.",Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192894/),[l] / [kg],2.3,149245,DB00091,Cyclosporine
,18192894,systemic clearance,"In the whole population, the mean+/-SD cyclosporine oral bioavailability was 0.38+/-0.09, volume of distribution was 2.3+/-0.54 l/kg, and systemic clearance normalized by allometric body weight was 0.88+/-0.16 l/h/kg3/4.",Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192894/),[l] / [4·h·kg3],0.88,149246,DB00091,Cyclosporine
,18192894,prehepatic extraction ratio,"The prehepatic extraction ratio was 0.51+/-0.13, and the hepatic extraction ratio was 0.24+/-0.04, the former explaining 95% of the variability in oral bioavailability (P<0.0001).",Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192894/),,0.51,149247,DB00091,Cyclosporine
,18192894,hepatic extraction ratio,"The prehepatic extraction ratio was 0.51+/-0.13, and the hepatic extraction ratio was 0.24+/-0.04, the former explaining 95% of the variability in oral bioavailability (P<0.0001).",Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192894/),,0.24,149248,DB00091,Cyclosporine
,18192894,pre-hepatic extraction,"In children older than 8 years, the pre-hepatic extraction was 0.64+/-0.09 in those with the ABCB1 c.2677GG genotype, 0.52+/-0.11 in those with the c.2677GT genotype, and 0.41+/-0.03 in those with the c.2677TT genotype (P=0.021, r2=0.334), leading to corresponding differences in oral bioavailability (0.28+/-0.07, 0.36+/-0.07, and 0.44+/-0.04, respectively; P=0.012, r2=0.372).",Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192894/),,0.64,149249,DB00091,Cyclosporine
,18192894,pre-hepatic extraction,"In children older than 8 years, the pre-hepatic extraction was 0.64+/-0.09 in those with the ABCB1 c.2677GG genotype, 0.52+/-0.11 in those with the c.2677GT genotype, and 0.41+/-0.03 in those with the c.2677TT genotype (P=0.021, r2=0.334), leading to corresponding differences in oral bioavailability (0.28+/-0.07, 0.36+/-0.07, and 0.44+/-0.04, respectively; P=0.012, r2=0.372).",Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192894/),,0.52,149250,DB00091,Cyclosporine
,18192894,pre-hepatic extraction,"In children older than 8 years, the pre-hepatic extraction was 0.64+/-0.09 in those with the ABCB1 c.2677GG genotype, 0.52+/-0.11 in those with the c.2677GT genotype, and 0.41+/-0.03 in those with the c.2677TT genotype (P=0.021, r2=0.334), leading to corresponding differences in oral bioavailability (0.28+/-0.07, 0.36+/-0.07, and 0.44+/-0.04, respectively; P=0.012, r2=0.372).",Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192894/),,0.41,149251,DB00091,Cyclosporine
,18192894,oral bioavailability,"In children older than 8 years, the pre-hepatic extraction was 0.64+/-0.09 in those with the ABCB1 c.2677GG genotype, 0.52+/-0.11 in those with the c.2677GT genotype, and 0.41+/-0.03 in those with the c.2677TT genotype (P=0.021, r2=0.334), leading to corresponding differences in oral bioavailability (0.28+/-0.07, 0.36+/-0.07, and 0.44+/-0.04, respectively; P=0.012, r2=0.372).",Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192894/),,0.28,149252,DB00091,Cyclosporine
,18192894,oral bioavailability,"In children older than 8 years, the pre-hepatic extraction was 0.64+/-0.09 in those with the ABCB1 c.2677GG genotype, 0.52+/-0.11 in those with the c.2677GT genotype, and 0.41+/-0.03 in those with the c.2677TT genotype (P=0.021, r2=0.334), leading to corresponding differences in oral bioavailability (0.28+/-0.07, 0.36+/-0.07, and 0.44+/-0.04, respectively; P=0.012, r2=0.372).",Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192894/),,0.36,149253,DB00091,Cyclosporine
,18192894,oral bioavailability,"In children older than 8 years, the pre-hepatic extraction was 0.64+/-0.09 in those with the ABCB1 c.2677GG genotype, 0.52+/-0.11 in those with the c.2677GT genotype, and 0.41+/-0.03 in those with the c.2677TT genotype (P=0.021, r2=0.334), leading to corresponding differences in oral bioavailability (0.28+/-0.07, 0.36+/-0.07, and 0.44+/-0.04, respectively; P=0.012, r2=0.372).",Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192894/),,0.44,149254,DB00091,Cyclosporine
,3544377,maximum blood concentration,Coadministration of cyclosporine with metoclopramide resulted in a significant increase in mean maximum blood concentration (567 ng/ml versus 388 ng/ml) and mean area under the blood-concentration-versus-time curve (4120 ng X hr/ml versus 3370 ng X hr/ml); and a significant decrease in mean time to reach maximum concentration.,The effect of oral metoclopramide on the absorption of cyclosporine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3544377/),[ng] / [ml],567,149318,DB00091,Cyclosporine
,3544377,maximum blood concentration,Coadministration of cyclosporine with metoclopramide resulted in a significant increase in mean maximum blood concentration (567 ng/ml versus 388 ng/ml) and mean area under the blood-concentration-versus-time curve (4120 ng X hr/ml versus 3370 ng X hr/ml); and a significant decrease in mean time to reach maximum concentration.,The effect of oral metoclopramide on the absorption of cyclosporine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3544377/),[ng] / [ml],388,149319,DB00091,Cyclosporine
,3544377,area under the blood-concentration-versus-time curve,Coadministration of cyclosporine with metoclopramide resulted in a significant increase in mean maximum blood concentration (567 ng/ml versus 388 ng/ml) and mean area under the blood-concentration-versus-time curve (4120 ng X hr/ml versus 3370 ng X hr/ml); and a significant decrease in mean time to reach maximum concentration.,The effect of oral metoclopramide on the absorption of cyclosporine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3544377/),[h·ng] / [ml],4120,149320,DB00091,Cyclosporine
,3544377,area under the blood-concentration-versus-time curve,Coadministration of cyclosporine with metoclopramide resulted in a significant increase in mean maximum blood concentration (567 ng/ml versus 388 ng/ml) and mean area under the blood-concentration-versus-time curve (4120 ng X hr/ml versus 3370 ng X hr/ml); and a significant decrease in mean time to reach maximum concentration.,The effect of oral metoclopramide on the absorption of cyclosporine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3544377/),[h·ng] / [ml],3370,149321,DB00091,Cyclosporine
,24120885,in,"An in situ intestinal perfusion study in rats showed that verapamil co-perfusion caused a significant increase in the intestinal permeability of AC, from 0.22×10(-5) to 2.85×10(-5) cm/s.","P-glycoprotein is responsible for the poor intestinal absorption and low toxicity of oral aconitine: in vitro, in situ, in vivo and in silico studies. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24120885/),[cm] / [s],0.22×10(-5),149527,DB00091,Cyclosporine
,24120885,permeability,"An in situ intestinal perfusion study in rats showed that verapamil co-perfusion caused a significant increase in the intestinal permeability of AC, from 0.22×10(-5) to 2.85×10(-5) cm/s.","P-glycoprotein is responsible for the poor intestinal absorption and low toxicity of oral aconitine: in vitro, in situ, in vivo and in silico studies. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24120885/),[cm] / [s],0.22×10(-5),149528,DB00091,Cyclosporine
,24120885,permeability,"An in situ intestinal perfusion study in rats showed that verapamil co-perfusion caused a significant increase in the intestinal permeability of AC, from 0.22×10(-5) to 2.85×10(-5) cm/s.","P-glycoprotein is responsible for the poor intestinal absorption and low toxicity of oral aconitine: in vitro, in situ, in vivo and in silico studies. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24120885/),[cm] / [s],2.85×10(-5),149529,DB00091,Cyclosporine
,24120885,maximum plasma concentration (Cmax),"With pre-treatment of verapamil, the maximum plasma concentration (Cmax) of AC increased sharply, from 39.43 to 1490.7 ng/ml.","P-glycoprotein is responsible for the poor intestinal absorption and low toxicity of oral aconitine: in vitro, in situ, in vivo and in silico studies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24120885/),[ng] / [ml],39.43,149530,DB00091,Cyclosporine
,24120885,maximum plasma concentration (Cmax),"With pre-treatment of verapamil, the maximum plasma concentration (Cmax) of AC increased sharply, from 39.43 to 1490.7 ng/ml.","P-glycoprotein is responsible for the poor intestinal absorption and low toxicity of oral aconitine: in vitro, in situ, in vivo and in silico studies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24120885/),[ng] / [ml],1490.7,149531,DB00091,Cyclosporine
,14550821,Cmins,Everolimus Cmins averaged 5.2 +/- 3.8 ng/ml and 9.4 +/- 6.3 ng/ml at the lower and upper dose levels.,"Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14550821/),[ng] / [ml],5.2,149623,DB00091,Cyclosporine
,14550821,Cmins,Everolimus Cmins averaged 5.2 +/- 3.8 ng/ml and 9.4 +/- 6.3 ng/ml at the lower and upper dose levels.,"Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14550821/),[ng] / [ml],9.4,149624,DB00091,Cyclosporine
<,14550821,trough levels,"We observed a significantly increased risk of acute rejection at everolimus trough levels <3 ng/ml, which constitutes the lower therapeutic concentration limit when everolimus is used with conventionally dosed cyclosporine.","Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14550821/),[ng] / [ml],3,149625,DB00091,Cyclosporine
,14550821,troughs,Everolimus-related adverse events were manageable up to the highest troughs (22 ng/ml) observed in this population.,"Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14550821/),[ng] / [ml],22,149626,DB00091,Cyclosporine
,9217274,unbound col,The SDZ PSC 833 treatment resulted in important modifications of colchicine blood pharmacokinetics: the unbound colchicine blood concentration at steady-state was enhanced from 149.6 +/- 9.9 to 333.5 +/- 81.7 ng/ml indicating a two-fold decrease in colchicine clearance.,"Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9217274/),[ng] / [ml],149.6,150215,DB00091,Cyclosporine
,9217274,blood concentration at steady-state,The SDZ PSC 833 treatment resulted in important modifications of colchicine blood pharmacokinetics: the unbound colchicine blood concentration at steady-state was enhanced from 149.6 +/- 9.9 to 333.5 +/- 81.7 ng/ml indicating a two-fold decrease in colchicine clearance.,"Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9217274/),[ng] / [ml],149.6,150216,DB00091,Cyclosporine
,9217274,blood concentration at steady-state,The SDZ PSC 833 treatment resulted in important modifications of colchicine blood pharmacokinetics: the unbound colchicine blood concentration at steady-state was enhanced from 149.6 +/- 9.9 to 333.5 +/- 81.7 ng/ml indicating a two-fold decrease in colchicine clearance.,"Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9217274/),[ng] / [ml],333.5,150217,DB00091,Cyclosporine
,2338629,terminal disposition half-life of,The terminal disposition half-life of CsA (t1/2 beta) ranged from 400 to 475 min and was not statistically different among the three groups.,Pharmacokinetics of two alternative dosage forms for cyclosporine: liposomes and intralipid. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338629/),min,400 to 475,150517,DB00091,Cyclosporine
,2338629,volume of distribution of CsA at steady state (Vdss),The volume of distribution of CsA at steady state (Vdss) in Sandimmune was 2.7 +/- 0.2 L/kg and was significantly lower than that of either Intralipid (10.6 +/- 2.7 L/kg) or liposomes (7.4 +/- 2.3 L/kg).,Pharmacokinetics of two alternative dosage forms for cyclosporine: liposomes and intralipid. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338629/),[l] / [kg],2.7,150518,DB00091,Cyclosporine
,2338629,volume of distribution of CsA at steady state (Vdss),The volume of distribution of CsA at steady state (Vdss) in Sandimmune was 2.7 +/- 0.2 L/kg and was significantly lower than that of either Intralipid (10.6 +/- 2.7 L/kg) or liposomes (7.4 +/- 2.3 L/kg).,Pharmacokinetics of two alternative dosage forms for cyclosporine: liposomes and intralipid. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338629/),[l] / [kg],10.6,150519,DB00091,Cyclosporine
,2338629,volume of distribution of CsA at steady state (Vdss),The volume of distribution of CsA at steady state (Vdss) in Sandimmune was 2.7 +/- 0.2 L/kg and was significantly lower than that of either Intralipid (10.6 +/- 2.7 L/kg) or liposomes (7.4 +/- 2.3 L/kg).,Pharmacokinetics of two alternative dosage forms for cyclosporine: liposomes and intralipid. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338629/),[l] / [kg],7.4,150520,DB00091,Cyclosporine
,2338629,total body clearance (TBC),A significantly lower total body clearance (TBC) of CsA also was seen for Sandimmune (12.7 +/- 0.3 mL/min/kg) as compared with that of either Intralipid (24.4 +/- 8.2 mL/min/kg) or liposomes (18.9 +/- 3.9 mL/min/kg).,Pharmacokinetics of two alternative dosage forms for cyclosporine: liposomes and intralipid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338629/),[ml] / [kg·min],12.7,150521,DB00091,Cyclosporine
,2338629,total body clearance (TBC),A significantly lower total body clearance (TBC) of CsA also was seen for Sandimmune (12.7 +/- 0.3 mL/min/kg) as compared with that of either Intralipid (24.4 +/- 8.2 mL/min/kg) or liposomes (18.9 +/- 3.9 mL/min/kg).,Pharmacokinetics of two alternative dosage forms for cyclosporine: liposomes and intralipid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338629/),[ml] / [kg·min],24.4,150522,DB00091,Cyclosporine
,2338629,total body clearance (TBC),A significantly lower total body clearance (TBC) of CsA also was seen for Sandimmune (12.7 +/- 0.3 mL/min/kg) as compared with that of either Intralipid (24.4 +/- 8.2 mL/min/kg) or liposomes (18.9 +/- 3.9 mL/min/kg).,Pharmacokinetics of two alternative dosage forms for cyclosporine: liposomes and intralipid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338629/),[ml] / [kg·min],18.9,150523,DB00091,Cyclosporine
>,10966158,plasma trough level,"At plasma trough level > 4 microg/ml some serious toxic effects were observed, whereas at Cmin < 2 microg/ml, there were some cases of interstitial rejection.",Pharmacokinetic monitoring of mycophenolate mofetil in kidney transplanted patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10966158/),[μg] / [ml],4,150678,DB00091,Cyclosporine
<,10966158,Cmin,"At plasma trough level > 4 microg/ml some serious toxic effects were observed, whereas at Cmin < 2 microg/ml, there were some cases of interstitial rejection.",Pharmacokinetic monitoring of mycophenolate mofetil in kidney transplanted patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10966158/),[μg] / [ml],2,150679,DB00091,Cyclosporine
,16102443,AUC(0-4),"Mean AUC(0-4) was 3,700 ng . h/ml during Year 1 post-transplant, 2,400 ng . h/ml during Years 1 to 3, and 1,500 ng . h/ml thereafter.",Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16102443/),[h·ng] / [ml],"3,700",151304,DB00091,Cyclosporine
,16102443,AUC(0-4),"Mean AUC(0-4) was 3,700 ng . h/ml during Year 1 post-transplant, 2,400 ng . h/ml during Years 1 to 3, and 1,500 ng . h/ml thereafter.",Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16102443/),[h·ng] / [ml],"2,400",151305,DB00091,Cyclosporine
,16102443,AUC(0-4),"Mean AUC(0-4) was 3,700 ng . h/ml during Year 1 post-transplant, 2,400 ng . h/ml during Years 1 to 3, and 1,500 ng . h/ml thereafter.",Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16102443/),[h·ng] / [ml],"1,500",151306,DB00091,Cyclosporine
,16102443,C(2),"Mean C(2) values were 1.2 microg/ml during Year 1, 0.8 microg/ml during Years 1 to 3, and 0.5 microg/ml thereafter.",Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16102443/),[μg] / [ml],1.2,151307,DB00091,Cyclosporine
,16102443,C(2),"Mean C(2) values were 1.2 microg/ml during Year 1, 0.8 microg/ml during Years 1 to 3, and 0.5 microg/ml thereafter.",Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16102443/),[μg] / [ml],0.8,151308,DB00091,Cyclosporine
,16102443,C(2),"Mean C(2) values were 1.2 microg/ml during Year 1, 0.8 microg/ml during Years 1 to 3, and 0.5 microg/ml thereafter.",Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16102443/),[μg] / [ml],0.5,151309,DB00091,Cyclosporine
,18365668,C2,"In the group C2, target C2/AUC(0-4) (C2 1700 ng/ml, AUC(0-4) 4400 ng h/ml) on the sixth day was achieved in 36.3%, and on day 14 in 76% of the patients.",[Efficacy of therapeutic monitoring of cyclosporine through C2 and AUC(0-4) during the first 24 months following kidney transplantation]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18365668/),[ng] / [ml],1700,151315,DB00091,Cyclosporine
,18365668,AUC(0-4),"In the group C2, target C2/AUC(0-4) (C2 1700 ng/ml, AUC(0-4) 4400 ng h/ml) on the sixth day was achieved in 36.3%, and on day 14 in 76% of the patients.",[Efficacy of therapeutic monitoring of cyclosporine through C2 and AUC(0-4) during the first 24 months following kidney transplantation]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18365668/),[h·ng] / [ml],4400,151316,DB00091,Cyclosporine
,18365668,C2,"In the group C2, all five patients with AR had lower C2 during AR: the average C2 at the moment of AR was 933.8 ng/ml, and in the patients without rejections was 1364.2 ng/ml (p = 0.008).",[Efficacy of therapeutic monitoring of cyclosporine through C2 and AUC(0-4) during the first 24 months following kidney transplantation]. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18365668/),[ng] / [ml],933.8,151317,DB00091,Cyclosporine
,18365668,C2,"In the group C2, all five patients with AR had lower C2 during AR: the average C2 at the moment of AR was 933.8 ng/ml, and in the patients without rejections was 1364.2 ng/ml (p = 0.008).",[Efficacy of therapeutic monitoring of cyclosporine through C2 and AUC(0-4) during the first 24 months following kidney transplantation]. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18365668/),[ng] / [ml],1364.2,151318,DB00091,Cyclosporine
,18365668,C0,"In the same group, the average C0 at the moment of AR was 263.2 ng/ml, and 240.0 ng/ml (p = 0.486) in the patients without AR.",[Efficacy of therapeutic monitoring of cyclosporine through C2 and AUC(0-4) during the first 24 months following kidney transplantation]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18365668/),[ng] / [ml],263.2,151319,DB00091,Cyclosporine
,18365668,C0,"In the same group, the average C0 at the moment of AR was 263.2 ng/ml, and 240.0 ng/ml (p = 0.486) in the patients without AR.",[Efficacy of therapeutic monitoring of cyclosporine through C2 and AUC(0-4) during the first 24 months following kidney transplantation]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18365668/),[ng] / [ml],240.0,151320,DB00091,Cyclosporine
,18365668,C0 concentration,"In the C0 group, average C0 concentration at the moment of AR was 227.1 ng/ml, while in the patients without AR it was 227.7 ng/ml (p = 0.95).",[Efficacy of therapeutic monitoring of cyclosporine through C2 and AUC(0-4) during the first 24 months following kidney transplantation]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18365668/),[ng] / [ml],227.1,151321,DB00091,Cyclosporine
,18365668,C0 concentration,"In the C0 group, average C0 concentration at the moment of AR was 227.1 ng/ml, while in the patients without AR it was 227.7 ng/ml (p = 0.95).",[Efficacy of therapeutic monitoring of cyclosporine through C2 and AUC(0-4) during the first 24 months following kidney transplantation]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18365668/),[ng] / [ml],227.7,151322,DB00091,Cyclosporine
,2658209,total body clearance,"Intravenous kinetic analysis yielded a mean total body clearance of 0.24 +/- 0.2 L/min (RIA) and 0.31 +/- 0.1 L/min (HPLC) (p greater than 0.05), the mean volume of distribution was 2.17 +/- 0.6 L/kg (RIA) and 2.75 +/- 1.2 L/kg (HPLC) (p greater than 0.05), and a mean half-life was 11.7 +/- 4.4 h (RIA) and 12.8 +/- 3.8 h (HPLC) (p greater than 0.05).",Comparison of cyclosporine assay methodology in the immediate postoperative period of renal transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2658209/),[l] / [min],0.24,151430,DB00091,Cyclosporine
,2658209,total body clearance,"Intravenous kinetic analysis yielded a mean total body clearance of 0.24 +/- 0.2 L/min (RIA) and 0.31 +/- 0.1 L/min (HPLC) (p greater than 0.05), the mean volume of distribution was 2.17 +/- 0.6 L/kg (RIA) and 2.75 +/- 1.2 L/kg (HPLC) (p greater than 0.05), and a mean half-life was 11.7 +/- 4.4 h (RIA) and 12.8 +/- 3.8 h (HPLC) (p greater than 0.05).",Comparison of cyclosporine assay methodology in the immediate postoperative period of renal transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2658209/),[l] / [min],0.31,151431,DB00091,Cyclosporine
,2658209,volume of distribution,"Intravenous kinetic analysis yielded a mean total body clearance of 0.24 +/- 0.2 L/min (RIA) and 0.31 +/- 0.1 L/min (HPLC) (p greater than 0.05), the mean volume of distribution was 2.17 +/- 0.6 L/kg (RIA) and 2.75 +/- 1.2 L/kg (HPLC) (p greater than 0.05), and a mean half-life was 11.7 +/- 4.4 h (RIA) and 12.8 +/- 3.8 h (HPLC) (p greater than 0.05).",Comparison of cyclosporine assay methodology in the immediate postoperative period of renal transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2658209/),[l] / [kg],2.17,151432,DB00091,Cyclosporine
,2658209,volume of distribution,"Intravenous kinetic analysis yielded a mean total body clearance of 0.24 +/- 0.2 L/min (RIA) and 0.31 +/- 0.1 L/min (HPLC) (p greater than 0.05), the mean volume of distribution was 2.17 +/- 0.6 L/kg (RIA) and 2.75 +/- 1.2 L/kg (HPLC) (p greater than 0.05), and a mean half-life was 11.7 +/- 4.4 h (RIA) and 12.8 +/- 3.8 h (HPLC) (p greater than 0.05).",Comparison of cyclosporine assay methodology in the immediate postoperative period of renal transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2658209/),[l] / [kg],2.75,151433,DB00091,Cyclosporine
,2658209,half-life,"Intravenous kinetic analysis yielded a mean total body clearance of 0.24 +/- 0.2 L/min (RIA) and 0.31 +/- 0.1 L/min (HPLC) (p greater than 0.05), the mean volume of distribution was 2.17 +/- 0.6 L/kg (RIA) and 2.75 +/- 1.2 L/kg (HPLC) (p greater than 0.05), and a mean half-life was 11.7 +/- 4.4 h (RIA) and 12.8 +/- 3.8 h (HPLC) (p greater than 0.05).",Comparison of cyclosporine assay methodology in the immediate postoperative period of renal transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2658209/),h,11.7,151434,DB00091,Cyclosporine
,2658209,half-life,"Intravenous kinetic analysis yielded a mean total body clearance of 0.24 +/- 0.2 L/min (RIA) and 0.31 +/- 0.1 L/min (HPLC) (p greater than 0.05), the mean volume of distribution was 2.17 +/- 0.6 L/kg (RIA) and 2.75 +/- 1.2 L/kg (HPLC) (p greater than 0.05), and a mean half-life was 11.7 +/- 4.4 h (RIA) and 12.8 +/- 3.8 h (HPLC) (p greater than 0.05).",Comparison of cyclosporine assay methodology in the immediate postoperative period of renal transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2658209/),h,12.8,151435,DB00091,Cyclosporine
,2658209,bioavailability,The mean bioavailability was 0.36 +/- 0.23 (RIA) and 0.28 +/- 0.15 (HPLC) (p greater than 0.05).,Comparison of cyclosporine assay methodology in the immediate postoperative period of renal transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2658209/),,0.36,151436,DB00091,Cyclosporine
,2658209,bioavailability,The mean bioavailability was 0.36 +/- 0.23 (RIA) and 0.28 +/- 0.15 (HPLC) (p greater than 0.05).,Comparison of cyclosporine assay methodology in the immediate postoperative period of renal transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2658209/),,0.28,151437,DB00091,Cyclosporine
,26555803,Cmax,"The Cmax, Tmax and AUC0-24 of CsA pellets from the in vivo pharmacokinetics evaluation was 268.22 ± 15.99 ng/ml, 6 ± 0 h and 3205.00 ± 149.55 ng·h/ml, respectively.","Sustained-release of Cyclosporin A pellets: preparation, in vitro release, pharmacokinetic studies and in vitro-in vivo correlation in beagle dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26555803/),[ng] / [ml],268.22,151668,DB00091,Cyclosporine
,26555803,Tmax,"The Cmax, Tmax and AUC0-24 of CsA pellets from the in vivo pharmacokinetics evaluation was 268.22 ± 15.99 ng/ml, 6 ± 0 h and 3205.00 ± 149.55 ng·h/ml, respectively.","Sustained-release of Cyclosporin A pellets: preparation, in vitro release, pharmacokinetic studies and in vitro-in vivo correlation in beagle dogs. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26555803/),h,6,151669,DB00091,Cyclosporine
,26555803,AUC0-24,"The Cmax, Tmax and AUC0-24 of CsA pellets from the in vivo pharmacokinetics evaluation was 268.22 ± 15.99 ng/ml, 6 ± 0 h and 3205.00 ± 149.55 ng·h/ml, respectively.","Sustained-release of Cyclosporin A pellets: preparation, in vitro release, pharmacokinetic studies and in vitro-in vivo correlation in beagle dogs. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26555803/),[h·ng] / [ml],3205.00,151670,DB00091,Cyclosporine
,26555803,relative bioavailability,The relative bioavailability of CsA pellets was 125.68 ± 5.37% that of Neoral®.,"Sustained-release of Cyclosporin A pellets: preparation, in vitro release, pharmacokinetic studies and in vitro-in vivo correlation in beagle dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26555803/),%,125.68,151671,DB00091,Cyclosporine
,20224513,AUC,"Cyclosporine doses ranged from 250 mg to 430 mg/day, AUC from 3.85 to 8.39 mg.h/L, clearance from 19.1 to 48.1 L/h, and elimination half-life from 3.7 to 15.5 hours.",Prediction of intravenous cyclosporine area under the concentration-time curve after allogeneic stem cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20224513/),[h·mg] / [l],3.85 to 8.39,151765,DB00091,Cyclosporine
,20224513,clearance,"Cyclosporine doses ranged from 250 mg to 430 mg/day, AUC from 3.85 to 8.39 mg.h/L, clearance from 19.1 to 48.1 L/h, and elimination half-life from 3.7 to 15.5 hours.",Prediction of intravenous cyclosporine area under the concentration-time curve after allogeneic stem cell transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20224513/),[l] / [h],19.1 to 48.1,151766,DB00091,Cyclosporine
,20224513,elimination half-life,"Cyclosporine doses ranged from 250 mg to 430 mg/day, AUC from 3.85 to 8.39 mg.h/L, clearance from 19.1 to 48.1 L/h, and elimination half-life from 3.7 to 15.5 hours.",Prediction of intravenous cyclosporine area under the concentration-time curve after allogeneic stem cell transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20224513/),h,3.7 to 15.5,151767,DB00091,Cyclosporine
,9337435,Vd,"Mean pharmacokinetic parameters were Vd 0.32 +/- 0.07 L/kg, t1/2 2.32 +/- 0.65 h, Cl 1.71 +/- 0.53 mL/min/kg, and Cl 86.2 +/- 24.5 mL/min/1.73 m2.",Gentamicin and tobramycin pharmacokinetics in pediatric bone marrow transplant patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9337435/),[l] / [kg],0.32,151882,DB00091,Cyclosporine
,9337435,t1/2,"Mean pharmacokinetic parameters were Vd 0.32 +/- 0.07 L/kg, t1/2 2.32 +/- 0.65 h, Cl 1.71 +/- 0.53 mL/min/kg, and Cl 86.2 +/- 24.5 mL/min/1.73 m2.",Gentamicin and tobramycin pharmacokinetics in pediatric bone marrow transplant patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9337435/),h,2.32,151883,DB00091,Cyclosporine
,9337435,Cl,"Mean pharmacokinetic parameters were Vd 0.32 +/- 0.07 L/kg, t1/2 2.32 +/- 0.65 h, Cl 1.71 +/- 0.53 mL/min/kg, and Cl 86.2 +/- 24.5 mL/min/1.73 m2.",Gentamicin and tobramycin pharmacokinetics in pediatric bone marrow transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9337435/),[ml] / [kg·min],1.71,151884,DB00091,Cyclosporine
,9337435,Cl,"Mean pharmacokinetic parameters were Vd 0.32 +/- 0.07 L/kg, t1/2 2.32 +/- 0.65 h, Cl 1.71 +/- 0.53 mL/min/kg, and Cl 86.2 +/- 24.5 mL/min/1.73 m2.",Gentamicin and tobramycin pharmacokinetics in pediatric bone marrow transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9337435/),[ml] / [1.73·m2·min],86.2,151885,DB00091,Cyclosporine
,21753749,Systemic,"Systemic and apparent oral midazolam clearance were 24% (269 ± 73 vs. 354 ± 102 ml/min, P = 0.022) and 31% (479 ± 190 vs. 688 ± 265 ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20).",In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21753749/),[ml] / [min],269,152160,DB00091,Cyclosporine
,21753749,Systemic,"Systemic and apparent oral midazolam clearance were 24% (269 ± 73 vs. 354 ± 102 ml/min, P = 0.022) and 31% (479 ± 190 vs. 688 ± 265 ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20).",In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21753749/),[ml] / [min],354,152161,DB00091,Cyclosporine
,21753749,apparent oral midazolam clearance,"Systemic and apparent oral midazolam clearance were 24% (269 ± 73 vs. 354 ± 102 ml/min, P = 0.022) and 31% (479 ± 190 vs. 688 ± 265 ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20).",In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21753749/),[ml] / [min],354,152162,DB00091,Cyclosporine
,21753749,apparent oral midazolam clearance,"Systemic and apparent oral midazolam clearance were 24% (269 ± 73 vs. 354 ± 102 ml/min, P = 0.022) and 31% (479 ± 190 vs. 688 ± 265 ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20).",In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21753749/),[ml] / [min],31,152163,DB00091,Cyclosporine
,21753749,apparent oral midazolam clearance,"Systemic and apparent oral midazolam clearance were 24% (269 ± 73 vs. 354 ± 102 ml/min, P = 0.022) and 31% (479 ± 190 vs. 688 ± 265 ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20).",In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21753749/),[ml] / [min],479,152164,DB00091,Cyclosporine
,21753749,apparent oral midazolam clearance,"Systemic and apparent oral midazolam clearance were 24% (269 ± 73 vs. 354 ± 102 ml/min, P = 0.022) and 31% (479 ± 190 vs. 688 ± 265 ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20).",In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21753749/),[ml] / [min],688,152165,DB00091,Cyclosporine
,7576013,clearances,"Specifically in period I on the market formulation, clearances decreased from a baseline of 71.7 +/- 20.6 to a minimum of 51.1 +/- 17.9 ml/min per 1.73 m2 (similar values in period III) and from 76.8 +/- 24.8 to 53.5 +/- 17.5 ml/min 1.73 m2 in period II on the microemulsion.",Acute effect of cyclosporin on renal function following the initial changeover to a microemulsion formulation in stable kidney transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7576013/),[ml] / [1.73·m2·min],71.7,152253,DB00091,Cyclosporine
,7576013,clearances,"Specifically in period I on the market formulation, clearances decreased from a baseline of 71.7 +/- 20.6 to a minimum of 51.1 +/- 17.9 ml/min per 1.73 m2 (similar values in period III) and from 76.8 +/- 24.8 to 53.5 +/- 17.5 ml/min 1.73 m2 in period II on the microemulsion.",Acute effect of cyclosporin on renal function following the initial changeover to a microemulsion formulation in stable kidney transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7576013/),[ml] / [1.73·m2·min],51.1,152254,DB00091,Cyclosporine
,7576013,clearances,"Specifically in period I on the market formulation, clearances decreased from a baseline of 71.7 +/- 20.6 to a minimum of 51.1 +/- 17.9 ml/min per 1.73 m2 (similar values in period III) and from 76.8 +/- 24.8 to 53.5 +/- 17.5 ml/min 1.73 m2 in period II on the microemulsion.",Acute effect of cyclosporin on renal function following the initial changeover to a microemulsion formulation in stable kidney transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7576013/),[ml] / [1.73·m2·min],76.8,152255,DB00091,Cyclosporine
,7576013,clearances,"Specifically in period I on the market formulation, clearances decreased from a baseline of 71.7 +/- 20.6 to a minimum of 51.1 +/- 17.9 ml/min per 1.73 m2 (similar values in period III) and from 76.8 +/- 24.8 to 53.5 +/- 17.5 ml/min 1.73 m2 in period II on the microemulsion.",Acute effect of cyclosporin on renal function following the initial changeover to a microemulsion formulation in stable kidney transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7576013/),[ml] / [1.73·m2·min],53.5,152256,DB00091,Cyclosporine
,27310199,Ctrough,"Estimated tacrolimus Ctrough values (median; interquartile range) before and during 3D treatment were comparable (5.7 ng/mL; 4.9-6.5 ng/mL versus 5.2 ng/mL; 4.2-6.3 ng/mL, respectively).",Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27310199/),[ng] / [ml],5.7,152910,DB00091,Cyclosporine
,27310199,Ctrough,"Estimated tacrolimus Ctrough values (median; interquartile range) before and during 3D treatment were comparable (5.7 ng/mL; 4.9-6.5 ng/mL versus 5.2 ng/mL; 4.2-6.3 ng/mL, respectively).",Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27310199/),[ng] / [ml],5.2,152911,DB00091,Cyclosporine
,27310199,Ctrough,"Based on simulations, in a patient with a starting Ctrough of 6 ng/mL, 0.5 mg tacrolimus every 7 or 14 days or 0.2 mg tacrolimus every 3 days will result in Ctrough levels of 6-9 ng/mL, 4-6 ng/mL, and 6-10 ng/mL, respectively, during 3D treatment.",Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27310199/),[ng] / [ml],6,152912,DB00091,Cyclosporine
,27310199,Ctrough,"Based on simulations, in a patient with a starting Ctrough of 6 ng/mL, 0.5 mg tacrolimus every 7 or 14 days or 0.2 mg tacrolimus every 3 days will result in Ctrough levels of 6-9 ng/mL, 4-6 ng/mL, and 6-10 ng/mL, respectively, during 3D treatment.",Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27310199/),[ng] / [ml],6-9,152913,DB00091,Cyclosporine
,27310199,Ctrough,"Based on simulations, in a patient with a starting Ctrough of 6 ng/mL, 0.5 mg tacrolimus every 7 or 14 days or 0.2 mg tacrolimus every 3 days will result in Ctrough levels of 6-9 ng/mL, 4-6 ng/mL, and 6-10 ng/mL, respectively, during 3D treatment.",Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27310199/),[ng] / [ml],4-6,152914,DB00091,Cyclosporine
,27310199,Ctrough,"Based on simulations, in a patient with a starting Ctrough of 6 ng/mL, 0.5 mg tacrolimus every 7 or 14 days or 0.2 mg tacrolimus every 3 days will result in Ctrough levels of 6-9 ng/mL, 4-6 ng/mL, and 6-10 ng/mL, respectively, during 3D treatment.",Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27310199/),[ng] / [ml],6-10,152915,DB00091,Cyclosporine
,27310199,Ctrough,"For CSA, Ctrough values (median; interquartile range) before and during 3D treatment were comparable (126 ng/mL; 94-140 ng/mL versus 104 ng/mL; 82-140 ng/mL).",Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27310199/),[ng] / [ml],126,152916,DB00091,Cyclosporine
,27310199,Ctrough,"For CSA, Ctrough values (median; interquartile range) before and during 3D treatment were comparable (126 ng/mL; 94-140 ng/mL versus 104 ng/mL; 82-140 ng/mL).",Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27310199/),[ng] / [ml],104,152917,DB00091,Cyclosporine
,29135906,overall dose-adjusted predose concentration (C0/dose,"CYP3A5 nonexpressers had higher overall dose-adjusted predose concentration (C0/dose; ng/mL per mg/kg) compared with expressers (31.48 ± 12.75 versus 22.44 ± 7.12, P = 0.01).","Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29135906/),[ng] / [kg·mg·ml],31.48,153106,DB00091,Cyclosporine
,29135906,overall dose-adjusted predose concentration (C0/dose,"CYP3A5 nonexpressers had higher overall dose-adjusted predose concentration (C0/dose; ng/mL per mg/kg) compared with expressers (31.48 ± 12.75 versus 22.44 ± 7.12, P = 0.01).","Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29135906/),[ng] / [kg·mg·ml],22.44,153107,DB00091,Cyclosporine
,29135906,overall dose-adjusted concentration (C2/dose),"CYP3A5 nonexpressers carrying POR*28 allele had a lower overall dose-adjusted concentration (C2/dose) than those with POR*1/*1 genotype (165.54 ± 70.40 versus 210.55 ± 79.98, P = 0.02), with age as covariate.","Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29135906/),,165.54,153108,DB00091,Cyclosporine
,29135906,overall dose-adjusted concentration (C2/dose),"CYP3A5 nonexpressers carrying POR*28 allele had a lower overall dose-adjusted concentration (C2/dose) than those with POR*1/*1 genotype (165.54 ± 70.40 versus 210.55 ± 79.98, P = 0.02), with age as covariate.","Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29135906/),,210.55,153109,DB00091,Cyclosporine
,29135906,overall C0/dose,"Children aged 6 years and younger had a lower overall C0/dose (18.82 ± 4.72 versus 34.19 ± 11.89, P = 0.001) and C2/dose (106.75 ± 26.99 versus 209.20 ± 71.57, P < 0.001) compared with older children.","Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29135906/),,18.82,153110,DB00091,Cyclosporine
,29135906,overall C0/dose,"Children aged 6 years and younger had a lower overall C0/dose (18.82 ± 4.72 versus 34.19 ± 11.89, P = 0.001) and C2/dose (106.75 ± 26.99 versus 209.20 ± 71.57, P < 0.001) compared with older children.","Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29135906/),,34.19,153111,DB00091,Cyclosporine
,29135906,C2/dose,"Children aged 6 years and younger had a lower overall C0/dose (18.82 ± 4.72 versus 34.19 ± 11.89, P = 0.001) and C2/dose (106.75 ± 26.99 versus 209.20 ± 71.57, P < 0.001) compared with older children.","Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29135906/),,106.75,153112,DB00091,Cyclosporine
,29135906,C2/dose,"Children aged 6 years and younger had a lower overall C0/dose (18.82 ± 4.72 versus 34.19 ± 11.89, P = 0.001) and C2/dose (106.75 ± 26.99 versus 209.20 ± 71.57, P < 0.001) compared with older children.","Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29135906/),,209.20,153113,DB00091,Cyclosporine
,10594471,elimination half-life,The elimination half-life ranged from 24 to 35 h across the five highest dose groups.,Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594471/),h,24 to 35,153257,DB00091,Cyclosporine
>,9503554,Cav,"Patients with an initial Cav > or = 550 ng/ml had higher 1-year (88%) and 6-year (66%) graft survival rates than patients with Cav < 550 ng/ml, who had 1- and 6-year graft survival rates of 80% and 59%, respectively (P = NS).",Impact of early cyclosporin average blood concentration on early kidney transplant failure. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9503554/),[ng] / [ml],550,154189,DB00091,Cyclosporine
<,9503554,Cav,"Patients with an initial Cav > or = 550 ng/ml had higher 1-year (88%) and 6-year (66%) graft survival rates than patients with Cav < 550 ng/ml, who had 1- and 6-year graft survival rates of 80% and 59%, respectively (P = NS).",Impact of early cyclosporin average blood concentration on early kidney transplant failure. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9503554/),[ng] / [ml],550,154190,DB00091,Cyclosporine
<,9503554,Cav,"Statistically significant differences were observed in graft survival rates between patients with Cav < 550 versus Cav > or = 550 ng/ml at 30 (88% vs 96%; P < 0.02), 60 (85% vs 94%; P < 0.007), 90 (85% vs 94%; P < 0.02), and 180 (83% vs 92%; P < 0.05) days.",Impact of early cyclosporin average blood concentration on early kidney transplant failure. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9503554/),,550,154191,DB00091,Cyclosporine
>,9503554,Cav,"Statistically significant differences were observed in graft survival rates between patients with Cav < 550 versus Cav > or = 550 ng/ml at 30 (88% vs 96%; P < 0.02), 60 (85% vs 94%; P < 0.007), 90 (85% vs 94%; P < 0.02), and 180 (83% vs 92%; P < 0.05) days.",Impact of early cyclosporin average blood concentration on early kidney transplant failure. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9503554/),[ng] / [ml],550,154192,DB00091,Cyclosporine
<,9503554,Cav,"Moreover, patients with Cav < 550 ng/ml displayed more severe rejection episodes, as judged by Banff classification, than patients who displayed Cav > or = 550 ng/ml (grades II and III; 71% vs 50%; P = 0.036).",Impact of early cyclosporin average blood concentration on early kidney transplant failure. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9503554/),[ng] / [ml],550,154193,DB00091,Cyclosporine
> or =,9503554,Cav,"Moreover, patients with Cav < 550 ng/ml displayed more severe rejection episodes, as judged by Banff classification, than patients who displayed Cav > or = 550 ng/ml (grades II and III; 71% vs 50%; P = 0.036).",Impact of early cyclosporin average blood concentration on early kidney transplant failure. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9503554/),[ng] / [ml],550,154194,DB00091,Cyclosporine
,7965755,clearance,The mean MDZ clearance predicted from in vitro 1'-hydroxylation data was identical to the mean clearance observed in vivo (0.60 +/- 0.24 versus 0.59 +/- 0.25 liter/min).,Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965755/),[l] / [min],0.60,154888,DB00091,Cyclosporine
,7965755,clearance,The mean MDZ clearance predicted from in vitro 1'-hydroxylation data was identical to the mean clearance observed in vivo (0.60 +/- 0.24 versus 0.59 +/- 0.25 liter/min).,Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965755/),[l] / [min],0.59,154889,DB00091,Cyclosporine
,18812562,steady-state minimum concentration (C(min)),Satisfactory steady-state minimum concentration (C(min)) of everolimus was achieved (approximately 5 ng/mL).,Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18812562/),[ng] / [ml],5,154970,DB00091,Cyclosporine
,18812562,C(min),"At that time, the everolimus C(min) averaged approximately 3 ng/mL.",Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18812562/),[ng] / [ml],3,154971,DB00091,Cyclosporine
,18812562,concentration/dose ratio,"The concentration/dose ratio of everolimus (ie, C(min) reached at steady-state for each milligram per kilogram of drug administered) was markedly lower during fluconazole versus voriconazole cotreatment (mean +/- SD, 3.49 +/- 0.29 vs 11.05 +/- 0.81 ng/mL per mg/kg/daily; p < 0.001).",Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18812562/),[ng] / [daily·kg·mg·ml],3.49,154972,DB00091,Cyclosporine
,18812562,concentration/dose ratio,"The concentration/dose ratio of everolimus (ie, C(min) reached at steady-state for each milligram per kilogram of drug administered) was markedly lower during fluconazole versus voriconazole cotreatment (mean +/- SD, 3.49 +/- 0.29 vs 11.05 +/- 0.81 ng/mL per mg/kg/daily; p < 0.001).",Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18812562/),[ng] / [daily·kg·mg·ml],11.05,154973,DB00091,Cyclosporine
,18812562,C(min),"The concentration/dose ratio of everolimus (ie, C(min) reached at steady-state for each milligram per kilogram of drug administered) was markedly lower during fluconazole versus voriconazole cotreatment (mean +/- SD, 3.49 +/- 0.29 vs 11.05 +/- 0.81 ng/mL per mg/kg/daily; p < 0.001).",Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18812562/),[ng] / [daily·kg·mg·ml],3.49,154974,DB00091,Cyclosporine
,18812562,C(min),"The concentration/dose ratio of everolimus (ie, C(min) reached at steady-state for each milligram per kilogram of drug administered) was markedly lower during fluconazole versus voriconazole cotreatment (mean +/- SD, 3.49 +/- 0.29 vs 11.05 +/- 0.81 ng/mL per mg/kg/daily; p < 0.001).",Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18812562/),[ng] / [daily·kg·mg·ml],11.05,154975,DB00091,Cyclosporine
>,22563974,bioavailability,"Pharmacokinetic results show that FLAP has high bioavailability (> 75%), long T1/2 (> 260 min), and short peak time (<20 min).",Disposition of orally administered a promising chemotherapeutic agent flavopiridol in the intestine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22563974/),%,75,155259,DB00091,Cyclosporine
>,22563974,T1/2,"Pharmacokinetic results show that FLAP has high bioavailability (> 75%), long T1/2 (> 260 min), and short peak time (<20 min).",Disposition of orally administered a promising chemotherapeutic agent flavopiridol in the intestine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22563974/),min,260,155260,DB00091,Cyclosporine
<,22563974,peak time,"Pharmacokinetic results show that FLAP has high bioavailability (> 75%), long T1/2 (> 260 min), and short peak time (<20 min).",Disposition of orally administered a promising chemotherapeutic agent flavopiridol in the intestine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22563974/),min,20,155261,DB00091,Cyclosporine
,22563974,permeability,"In the Caco-2 cell culture model, the bidirectional permeability of FLAP was 0.47 × 10(-5) cm/s to 1.53 × 10(-5) cm/s and the efflux ratios were 3.27 and 2.17 at 10 and 30 μM, respectively.",Disposition of orally administered a promising chemotherapeutic agent flavopiridol in the intestine. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22563974/),[cm] / [s],0.47 × 10(-5),155262,DB00091,Cyclosporine
,22563974,permeability,"In the Caco-2 cell culture model, the bidirectional permeability of FLAP was 0.47 × 10(-5) cm/s to 1.53 × 10(-5) cm/s and the efflux ratios were 3.27 and 2.17 at 10 and 30 μM, respectively.",Disposition of orally administered a promising chemotherapeutic agent flavopiridol in the intestine. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22563974/),[cm] / [s],1.53 × 10(-5),155263,DB00091,Cyclosporine
,22563974,efflux ratios,"In the Caco-2 cell culture model, the bidirectional permeability of FLAP was 0.47 × 10(-5) cm/s to 1.53 × 10(-5) cm/s and the efflux ratios were 3.27 and 2.17 at 10 and 30 μM, respectively.",Disposition of orally administered a promising chemotherapeutic agent flavopiridol in the intestine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22563974/),,3.27,155264,DB00091,Cyclosporine
,22563974,efflux ratios,"In the Caco-2 cell culture model, the bidirectional permeability of FLAP was 0.47 × 10(-5) cm/s to 1.53 × 10(-5) cm/s and the efflux ratios were 3.27 and 2.17 at 10 and 30 μM, respectively.",Disposition of orally administered a promising chemotherapeutic agent flavopiridol in the intestine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22563974/),,2.17,155265,DB00091,Cyclosporine
,22563974,biliary excretions,"In the four-site model, 10 and 40 μM FLAP perfusions were well absorbed at various regions of the intestine, and the biliary excretions of FLAP glucuronides were 1.60-2.84 nmol and 12.47-17.33 nmol, respectively.",Disposition of orally administered a promising chemotherapeutic agent flavopiridol in the intestine. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22563974/),nM,1.60-2.84,155266,DB00091,Cyclosporine
,22563974,biliary excretions,"In the four-site model, 10 and 40 μM FLAP perfusions were well absorbed at various regions of the intestine, and the biliary excretions of FLAP glucuronides were 1.60-2.84 nmol and 12.47-17.33 nmol, respectively.",Disposition of orally administered a promising chemotherapeutic agent flavopiridol in the intestine. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22563974/),nM,12.47-17.33,155267,DB00091,Cyclosporine
,17097975,AUC,"The maximum mean values of MPA AUC and predose concentration (C0h) (20.8 +/- 11.8 and 2.3 +/- 1.8, respectively) were reached on the third day.",Pharmacokinetic evaluation of mycophenolic acid profiles during the period immediately following an orthotopic liver transplant. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17097975/),,20.8,155609,DB00091,Cyclosporine
,17097975,predose,"The maximum mean values of MPA AUC and predose concentration (C0h) (20.8 +/- 11.8 and 2.3 +/- 1.8, respectively) were reached on the third day.",Pharmacokinetic evaluation of mycophenolic acid profiles during the period immediately following an orthotopic liver transplant. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17097975/),,20.8,155610,DB00091,Cyclosporine
,17097975,concentration (C0h),"The maximum mean values of MPA AUC and predose concentration (C0h) (20.8 +/- 11.8 and 2.3 +/- 1.8, respectively) were reached on the third day.",Pharmacokinetic evaluation of mycophenolic acid profiles during the period immediately following an orthotopic liver transplant. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17097975/),,2.3,155611,DB00091,Cyclosporine
>/=,17097975,tmax,The single sample showing the greatest correlation with the MPA AUC was the one collected after 3 hours (r(2) = 0.575); 59.1% of profiles displayed a single peak with more than half showing a tmax >/= 3 hours.,Pharmacokinetic evaluation of mycophenolic acid profiles during the period immediately following an orthotopic liver transplant. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17097975/),h,3,155612,DB00091,Cyclosporine
,1884727,clearance,"Cyclosporine clearance was smaller by PARIA than HPLC (mean 7.3 versus 3.3 ml.min-1.kg-1, respectively, before clamping).",Cyclosporine pharmacokinetics in liver transplant recipients: evaluation of results using both polyclonal radioimmunoassay and liquid chromatographic analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884727/),[ml] / [kg·min],7.3,155748,DB00091,Cyclosporine
,1884727,clearance,"Cyclosporine clearance was smaller by PARIA than HPLC (mean 7.3 versus 3.3 ml.min-1.kg-1, respectively, before clamping).",Cyclosporine pharmacokinetics in liver transplant recipients: evaluation of results using both polyclonal radioimmunoassay and liquid chromatographic analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884727/),[ml] / [kg·min],3.3,155749,DB00091,Cyclosporine
,1884727,distribution,"Both values decreased by 25% after clamping (to 5.5 and 2.4 ml.min-1.kg-1, respectively), although there was no significant change in distribution or elimination half-lives (around 0.5 and 8 h, respectively).",Cyclosporine pharmacokinetics in liver transplant recipients: evaluation of results using both polyclonal radioimmunoassay and liquid chromatographic analysis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884727/),h,0.5,155750,DB00091,Cyclosporine
,1884727,elimination half-lives,"Both values decreased by 25% after clamping (to 5.5 and 2.4 ml.min-1.kg-1, respectively), although there was no significant change in distribution or elimination half-lives (around 0.5 and 8 h, respectively).",Cyclosporine pharmacokinetics in liver transplant recipients: evaluation of results using both polyclonal radioimmunoassay and liquid chromatographic analysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884727/),h,8,155751,DB00091,Cyclosporine
,1884727,bioavailability,The mean bioavailability of oral cyclosporine increased significantly after clamping in 9 patients (from 10.6% to 28.1% by HPLC and from 14.8 to 35.1% by PARIA) but in two patients who developed the vanishing bile duct syndrome values fell to less than 10% and the proportional overestimation of cyclosporine concentrations by PARIA increased.,Cyclosporine pharmacokinetics in liver transplant recipients: evaluation of results using both polyclonal radioimmunoassay and liquid chromatographic analysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884727/),%,10.6,155752,DB00091,Cyclosporine
,1884727,bioavailability,The mean bioavailability of oral cyclosporine increased significantly after clamping in 9 patients (from 10.6% to 28.1% by HPLC and from 14.8 to 35.1% by PARIA) but in two patients who developed the vanishing bile duct syndrome values fell to less than 10% and the proportional overestimation of cyclosporine concentrations by PARIA increased.,Cyclosporine pharmacokinetics in liver transplant recipients: evaluation of results using both polyclonal radioimmunoassay and liquid chromatographic analysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884727/),%,28.1,155753,DB00091,Cyclosporine
,1884727,bioavailability,The mean bioavailability of oral cyclosporine increased significantly after clamping in 9 patients (from 10.6% to 28.1% by HPLC and from 14.8 to 35.1% by PARIA) but in two patients who developed the vanishing bile duct syndrome values fell to less than 10% and the proportional overestimation of cyclosporine concentrations by PARIA increased.,Cyclosporine pharmacokinetics in liver transplant recipients: evaluation of results using both polyclonal radioimmunoassay and liquid chromatographic analysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884727/),%,14.8,155754,DB00091,Cyclosporine
,1884727,bioavailability,The mean bioavailability of oral cyclosporine increased significantly after clamping in 9 patients (from 10.6% to 28.1% by HPLC and from 14.8 to 35.1% by PARIA) but in two patients who developed the vanishing bile duct syndrome values fell to less than 10% and the proportional overestimation of cyclosporine concentrations by PARIA increased.,Cyclosporine pharmacokinetics in liver transplant recipients: evaluation of results using both polyclonal radioimmunoassay and liquid chromatographic analysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884727/),%,35.1,155755,DB00091,Cyclosporine
less,1884727,bioavailability,The mean bioavailability of oral cyclosporine increased significantly after clamping in 9 patients (from 10.6% to 28.1% by HPLC and from 14.8 to 35.1% by PARIA) but in two patients who developed the vanishing bile duct syndrome values fell to less than 10% and the proportional overestimation of cyclosporine concentrations by PARIA increased.,Cyclosporine pharmacokinetics in liver transplant recipients: evaluation of results using both polyclonal radioimmunoassay and liquid chromatographic analysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884727/),%,10,155756,DB00091,Cyclosporine
,1884727,Vz,Clamping had no singificant effect on the mean apparent volumes of distribution but values of Vz were approximately twice those of Vss (around 2.6 and 1.31.kg-1 by PARIA and HPLC respectively).,Cyclosporine pharmacokinetics in liver transplant recipients: evaluation of results using both polyclonal radioimmunoassay and liquid chromatographic analysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884727/),1/[kg],2.6,155757,DB00091,Cyclosporine
,1884727,Vz,Clamping had no singificant effect on the mean apparent volumes of distribution but values of Vz were approximately twice those of Vss (around 2.6 and 1.31.kg-1 by PARIA and HPLC respectively).,Cyclosporine pharmacokinetics in liver transplant recipients: evaluation of results using both polyclonal radioimmunoassay and liquid chromatographic analysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884727/),1/[kg],1.31,155758,DB00091,Cyclosporine
,1884727,Vss,Clamping had no singificant effect on the mean apparent volumes of distribution but values of Vz were approximately twice those of Vss (around 2.6 and 1.31.kg-1 by PARIA and HPLC respectively).,Cyclosporine pharmacokinetics in liver transplant recipients: evaluation of results using both polyclonal radioimmunoassay and liquid chromatographic analysis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884727/),1/[kg],2.6,155759,DB00091,Cyclosporine
,1884727,Vss,Clamping had no singificant effect on the mean apparent volumes of distribution but values of Vz were approximately twice those of Vss (around 2.6 and 1.31.kg-1 by PARIA and HPLC respectively).,Cyclosporine pharmacokinetics in liver transplant recipients: evaluation of results using both polyclonal radioimmunoassay and liquid chromatographic analysis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884727/),1/[kg],1.31,155760,DB00091,Cyclosporine
,1884727,t 1/2 lambda 2,Mean half lives after clamping were shorter following oral than intravenous cyclosporine (t 1/2 lambda 2 around 15 h enterally versus 8 h parenterally).,Cyclosporine pharmacokinetics in liver transplant recipients: evaluation of results using both polyclonal radioimmunoassay and liquid chromatographic analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884727/),h,15,155761,DB00091,Cyclosporine
,1884727,t 1/2 lambda 2,Mean half lives after clamping were shorter following oral than intravenous cyclosporine (t 1/2 lambda 2 around 15 h enterally versus 8 h parenterally).,Cyclosporine pharmacokinetics in liver transplant recipients: evaluation of results using both polyclonal radioimmunoassay and liquid chromatographic analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884727/),h,8,155762,DB00091,Cyclosporine
,1425874,Cy trough levels,"Fenofibrate 200 mg once daily significantly reduced blood lipids (cholesterol 6.5 vs 7.7 mmol/l; apoprotein B 1.2 vs 1.6 g/l) but did not modify mean whole blood Cy trough levels (113 before fenofibrate vs 103 ng.ml-1), Cmax (812 ng.","Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425874/),[ng] / [ml],113,156044,DB00091,Cyclosporine
,1425874,Cy trough levels,"Fenofibrate 200 mg once daily significantly reduced blood lipids (cholesterol 6.5 vs 7.7 mmol/l; apoprotein B 1.2 vs 1.6 g/l) but did not modify mean whole blood Cy trough levels (113 before fenofibrate vs 103 ng.ml-1), Cmax (812 ng.","Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425874/),[ng] / [ml],103,156045,DB00091,Cyclosporine
,1425874,Cmax,"Fenofibrate 200 mg once daily significantly reduced blood lipids (cholesterol 6.5 vs 7.7 mmol/l; apoprotein B 1.2 vs 1.6 g/l) but did not modify mean whole blood Cy trough levels (113 before fenofibrate vs 103 ng.ml-1), Cmax (812 ng.","Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425874/),ng,812,156046,DB00091,Cyclosporine
,1425874,tmax,"ml-1 by HPLC before fenofibrate versus 865 and 741 respectively, during fenofibrate); tmax (1.6 and 1.7 h before fenofibrate versus 1.4 and 1.4 h respectively), and t1/2 (13.9 and 11.1 h versus 9.5 and 10.7 h).","Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425874/),h,1.6,156047,DB00091,Cyclosporine
,1425874,tmax,"ml-1 by HPLC before fenofibrate versus 865 and 741 respectively, during fenofibrate); tmax (1.6 and 1.7 h before fenofibrate versus 1.4 and 1.4 h respectively), and t1/2 (13.9 and 11.1 h versus 9.5 and 10.7 h).","Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425874/),h,1.7,156048,DB00091,Cyclosporine
,1425874,tmax,"ml-1 by HPLC before fenofibrate versus 865 and 741 respectively, during fenofibrate); tmax (1.6 and 1.7 h before fenofibrate versus 1.4 and 1.4 h respectively), and t1/2 (13.9 and 11.1 h versus 9.5 and 10.7 h).","Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425874/),h,1.4,156049,DB00091,Cyclosporine
,1425874,t1/2,"ml-1 by HPLC before fenofibrate versus 865 and 741 respectively, during fenofibrate); tmax (1.6 and 1.7 h before fenofibrate versus 1.4 and 1.4 h respectively), and t1/2 (13.9 and 11.1 h versus 9.5 and 10.7 h).","Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425874/),h,13.9,156050,DB00091,Cyclosporine
,1425874,t1/2,"ml-1 by HPLC before fenofibrate versus 865 and 741 respectively, during fenofibrate); tmax (1.6 and 1.7 h before fenofibrate versus 1.4 and 1.4 h respectively), and t1/2 (13.9 and 11.1 h versus 9.5 and 10.7 h).","Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425874/),h,11.1,156051,DB00091,Cyclosporine
,1425874,t1/2,"ml-1 by HPLC before fenofibrate versus 865 and 741 respectively, during fenofibrate); tmax (1.6 and 1.7 h before fenofibrate versus 1.4 and 1.4 h respectively), and t1/2 (13.9 and 11.1 h versus 9.5 and 10.7 h).","Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425874/),h,9.5,156052,DB00091,Cyclosporine
,1425874,t1/2,"ml-1 by HPLC before fenofibrate versus 865 and 741 respectively, during fenofibrate); tmax (1.6 and 1.7 h before fenofibrate versus 1.4 and 1.4 h respectively), and t1/2 (13.9 and 11.1 h versus 9.5 and 10.7 h).","Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425874/),h,10.7,156053,DB00091,Cyclosporine
,11153448,Km,"Clearance, essentially hepatic, and described by the well-stirred model, was also adequately characterized by Michaelis-Menten kinetics, Km 0.60 microgram/ml.",Physiologically based pharmacokinetics of cyclosporine A: reevaluation of dose-nonlinear kinetics in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11153448/),[μg] / [ml],0.60,156131,DB00091,Cyclosporine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,28.0,156443,DB00091,Cyclosporine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,5.1,156444,DB00091,Cyclosporine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,9.9,156445,DB00091,Cyclosporine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,2.8,156446,DB00091,Cyclosporine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,22. 9,156447,DB00091,Cyclosporine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,14.7,156448,DB00091,Cyclosporine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,22.3,156449,DB00091,Cyclosporine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,11.1,156450,DB00091,Cyclosporine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,39.6,156451,DB00091,Cyclosporine
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,26,156452,DB00091,Cyclosporine
,16504926,AUC,"B-CsA reached peak in median at 0.90 and 0.96 h (633 and 914 ng/ml) in the 15 and 30 mg/kg/day groups, respectively, and median AUC was 5055 and 6275 h ng/ml, respectively.",The pharmacokinetics and acute renal effects of oral microemulsion ciclosporin A in normal pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16504926/),[h·ng] / [ml],5055,156822,DB00091,Cyclosporine
,16504926,AUC,"B-CsA reached peak in median at 0.90 and 0.96 h (633 and 914 ng/ml) in the 15 and 30 mg/kg/day groups, respectively, and median AUC was 5055 and 6275 h ng/ml, respectively.",The pharmacokinetics and acute renal effects of oral microemulsion ciclosporin A in normal pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16504926/),[h·ng] / [ml],6275,156823,DB00091,Cyclosporine
,16504926,Trough levels,Trough levels were 338 and 475 ng/ml.,The pharmacokinetics and acute renal effects of oral microemulsion ciclosporin A in normal pigs. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16504926/),[ng] / [ml],338,156824,DB00091,Cyclosporine
,16504926,Trough levels,Trough levels were 338 and 475 ng/ml.,The pharmacokinetics and acute renal effects of oral microemulsion ciclosporin A in normal pigs. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16504926/),[ng] / [ml],475,156825,DB00091,Cyclosporine
,3073383,maximum binding capacity,The average maximum binding capacity is 2560 micrograms CyA/liter of packed erythrocytes; the unbound CyA concentration associated with 50% saturation of the binding site is 67 micrograms/liter.,Saturable binding of cyclosporin A to erythrocytes: estimation of binding parameters in renal transplant patients and implications for bioavailability assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3073383/),[cya·μg] / [l],2560,157108,DB00091,Cyclosporine
,3073383,unbound CyA concentration,The average maximum binding capacity is 2560 micrograms CyA/liter of packed erythrocytes; the unbound CyA concentration associated with 50% saturation of the binding site is 67 micrograms/liter.,Saturable binding of cyclosporin A to erythrocytes: estimation of binding parameters in renal transplant patients and implications for bioavailability assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3073383/),[μg] / [l],67,157109,DB00091,Cyclosporine
,20600721,area under curve (AUC),"For brain pharmacokinetics, the CsA pretreatment raised significantly the area under curve (AUC) of BU (24.0+/-5.9 vs. 14.6+/-4.4min microg/mL, p=0.015).",Effects of a P-glycoprotein modulator on the pharmacokinetics and distribution of free levobupivacaine and bupivacaine in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20600721/),[min·μg] / [ml],24.0,157122,DB00091,Cyclosporine
,20600721,area under curve (AUC),"For brain pharmacokinetics, the CsA pretreatment raised significantly the area under curve (AUC) of BU (24.0+/-5.9 vs. 14.6+/-4.4min microg/mL, p=0.015).",Effects of a P-glycoprotein modulator on the pharmacokinetics and distribution of free levobupivacaine and bupivacaine in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20600721/),[min·μg] / [ml],14.6,157123,DB00091,Cyclosporine
,20600721,AUC,"For bile pharmacokinetics, LB and BU went through hepatobiliary excretion, and the AUC of BU was significantly higher than that of the LB group (6.6+/-1.0 vs. 4.6+/-0.6min microg/mL, p=0.005).",Effects of a P-glycoprotein modulator on the pharmacokinetics and distribution of free levobupivacaine and bupivacaine in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20600721/),[min·μg] / [ml],6.6,157124,DB00091,Cyclosporine
,20600721,AUC,"For bile pharmacokinetics, LB and BU went through hepatobiliary excretion, and the AUC of BU was significantly higher than that of the LB group (6.6+/-1.0 vs. 4.6+/-0.6min microg/mL, p=0.005).",Effects of a P-glycoprotein modulator on the pharmacokinetics and distribution of free levobupivacaine and bupivacaine in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20600721/),[min·μg] / [ml],4.6,157125,DB00091,Cyclosporine
,20600721,AUC,"In addition, the pretreatment of CsA significantly reduced the hepatobiliary excretion of BU in terms of AUC (4.4+/-0.8 vs. 6.6+/-1.0minmicrog/mL, p=0.003).",Effects of a P-glycoprotein modulator on the pharmacokinetics and distribution of free levobupivacaine and bupivacaine in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20600721/),[minμg] / [ml],4.4,157126,DB00091,Cyclosporine
,20600721,AUC,"In addition, the pretreatment of CsA significantly reduced the hepatobiliary excretion of BU in terms of AUC (4.4+/-0.8 vs. 6.6+/-1.0minmicrog/mL, p=0.003).",Effects of a P-glycoprotein modulator on the pharmacokinetics and distribution of free levobupivacaine and bupivacaine in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20600721/),[minμg] / [ml],6.6,157127,DB00091,Cyclosporine
,20600721,maximum concentration (C(max)),"Furthermore, the maximum concentration (C(max)) of BU diminished significantly as a result of the CsA pretreatment (0.10+/-0.03 vs. 0.20+/-0.05microg/mL, p=0.002).",Effects of a P-glycoprotein modulator on the pharmacokinetics and distribution of free levobupivacaine and bupivacaine in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20600721/),[μg] / [ml],0.10,157128,DB00091,Cyclosporine
,20600721,maximum concentration (C(max)),"Furthermore, the maximum concentration (C(max)) of BU diminished significantly as a result of the CsA pretreatment (0.10+/-0.03 vs. 0.20+/-0.05microg/mL, p=0.002).",Effects of a P-glycoprotein modulator on the pharmacokinetics and distribution of free levobupivacaine and bupivacaine in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20600721/),[μg] / [ml],0.20,157129,DB00091,Cyclosporine
,25473029,AUC,"The AUC over a 6 day period (IQR) for a typical patient on 200 mg every 48 h or 300 mg every 72 h resulted in 348 mg · h/L (310.6-386.7) and 359 mg · h/L (319.1-400.9), respectively, comparable to the licensed regimen [397.0 mg · h/L (352.4-440.5)].",A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25473029/),[h·mg] / [l],348,157617,DB00091,Cyclosporine
,25473029,AUC,"The AUC over a 6 day period (IQR) for a typical patient on 200 mg every 48 h or 300 mg every 72 h resulted in 348 mg · h/L (310.6-386.7) and 359 mg · h/L (319.1-400.9), respectively, comparable to the licensed regimen [397.0 mg · h/L (352.4-440.5)].",A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25473029/),[h·mg] / [l],359,157618,DB00091,Cyclosporine
,25473029,AUC,"The AUC over a 6 day period (IQR) for a typical patient on 200 mg every 48 h or 300 mg every 72 h resulted in 348 mg · h/L (310.6-386.7) and 359 mg · h/L (319.1-400.9), respectively, comparable to the licensed regimen [397.0 mg · h/L (352.4-440.5)].",A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25473029/),[h·mg] / [l],397.0,157619,DB00091,Cyclosporine
,16120063,clearance,"Using this model, no statistically significant difference was observed in clearance of MPA between TACR and CsA co-administration (11.9 and 14.1 l h(-1), respectively).",Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120063/),[l] / [h],11.9,157933,DB00091,Cyclosporine
,16120063,clearance,"Using this model, no statistically significant difference was observed in clearance of MPA between TACR and CsA co-administration (11.9 and 14.1 l h(-1), respectively).",Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120063/),[l] / [h],14.1,157934,DB00091,Cyclosporine
,16120063,Total clearance,"Total clearance of MPAG was lower in case of CsA co-administration (1.45 and 0.92 l h(-1), respectively), while there was no difference in renal clearance of MPAG (1.09 and 0.92 l h(-1), respectively).",Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120063/),[l] / [h],1.45,157935,DB00091,Cyclosporine
,16120063,Total clearance,"Total clearance of MPAG was lower in case of CsA co-administration (1.45 and 0.92 l h(-1), respectively), while there was no difference in renal clearance of MPAG (1.09 and 0.92 l h(-1), respectively).",Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120063/),[l] / [h],0.92,157936,DB00091,Cyclosporine
,16120063,renal clearance,"Total clearance of MPAG was lower in case of CsA co-administration (1.45 and 0.92 l h(-1), respectively), while there was no difference in renal clearance of MPAG (1.09 and 0.92 l h(-1), respectively).",Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120063/),[l] / [h],1.09,157937,DB00091,Cyclosporine
,16120063,renal clearance,"Total clearance of MPAG was lower in case of CsA co-administration (1.45 and 0.92 l h(-1), respectively), while there was no difference in renal clearance of MPAG (1.09 and 0.92 l h(-1), respectively).",Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120063/),[l] / [h],0.92,157938,DB00091,Cyclosporine
,24861133,AUC(,Co-administration of cyclosporine with ticagrelor significantly increased AR-C124910XX AUC(∞) (1.33 [1.23-1.42]) and decreased C(max) (0.85 [0.76-0.94]).,Pharmacokinetic interaction study of ticagrelor and cyclosporine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861133/),,1,157947,DB00091,Cyclosporine
,16778713,bioavailability,"The bioavailability of SIM compared with NEO was 54% to 71%, in agreement with previous results.",Comparative bioavailability of the microemulsion formulation of cyclosporine (Neoral) with a generic dispersion formulation (Cicloral) in young healthy male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778713/),%,54,158024,DB00091,Cyclosporine
,16778713,bioavailability,"The bioavailability of SIM compared with NEO was 54% to 71%, in agreement with previous results.",Comparative bioavailability of the microemulsion formulation of cyclosporine (Neoral) with a generic dispersion formulation (Cicloral) in young healthy male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778713/),%,71,158025,DB00091,Cyclosporine
,17093994,C (max),"The mean C (max) and AUC(0-12h) of total and free MPA were 9.4 +/- 3.4 mg/L, 20.2 +/- 6.5 mg x h/L and 0.4 +/- 0.4 mg/L, 0.7 +/- 0.5 mg x h/L, respectively, whereas mean C (max) and AUC(0-12h) of total and free MPAG were 97.3 +/- 32.6 mg/L, 656.0 +/- 148.0 mg.h/L and 29.9 +/- 8.5 mg/L, 222.0 +/- 58.1 mg x h/L respectively.",Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17093994/),[mg] / [l],9.4,159212,DB00091,Cyclosporine
,17093994,AUC(0-12h),"The mean C (max) and AUC(0-12h) of total and free MPA were 9.4 +/- 3.4 mg/L, 20.2 +/- 6.5 mg x h/L and 0.4 +/- 0.4 mg/L, 0.7 +/- 0.5 mg x h/L, respectively, whereas mean C (max) and AUC(0-12h) of total and free MPAG were 97.3 +/- 32.6 mg/L, 656.0 +/- 148.0 mg.h/L and 29.9 +/- 8.5 mg/L, 222.0 +/- 58.1 mg x h/L respectively.",Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17093994/),[h·mg] / [l],0.7,159213,DB00091,Cyclosporine
,17093994,C (max),"The mean C (max) and AUC(0-12h) of total and free MPA were 9.4 +/- 3.4 mg/L, 20.2 +/- 6.5 mg x h/L and 0.4 +/- 0.4 mg/L, 0.7 +/- 0.5 mg x h/L, respectively, whereas mean C (max) and AUC(0-12h) of total and free MPAG were 97.3 +/- 32.6 mg/L, 656.0 +/- 148.0 mg.h/L and 29.9 +/- 8.5 mg/L, 222.0 +/- 58.1 mg x h/L respectively.",Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17093994/),[mg] / [l],97.3,159214,DB00091,Cyclosporine
,17093994,AUC(0-12h),"The mean C (max) and AUC(0-12h) of total and free MPA were 9.4 +/- 3.4 mg/L, 20.2 +/- 6.5 mg x h/L and 0.4 +/- 0.4 mg/L, 0.7 +/- 0.5 mg x h/L, respectively, whereas mean C (max) and AUC(0-12h) of total and free MPAG were 97.3 +/- 32.6 mg/L, 656.0 +/- 148.0 mg.h/L and 29.9 +/- 8.5 mg/L, 222.0 +/- 58.1 mg x h/L respectively.",Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17093994/),[h·mg] / [l],656.0,159215,DB00091,Cyclosporine
,17093994,AUC(0-12h),"The mean C (max) and AUC(0-12h) of total and free MPA were 9.4 +/- 3.4 mg/L, 20.2 +/- 6.5 mg x h/L and 0.4 +/- 0.4 mg/L, 0.7 +/- 0.5 mg x h/L, respectively, whereas mean C (max) and AUC(0-12h) of total and free MPAG were 97.3 +/- 32.6 mg/L, 656.0 +/- 148.0 mg.h/L and 29.9 +/- 8.5 mg/L, 222.0 +/- 58.1 mg x h/L respectively.",Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17093994/),[mg] / [l],29.9,159216,DB00091,Cyclosporine
,17093994,AUC(0-12h),"The mean C (max) and AUC(0-12h) of total and free MPA were 9.4 +/- 3.4 mg/L, 20.2 +/- 6.5 mg x h/L and 0.4 +/- 0.4 mg/L, 0.7 +/- 0.5 mg x h/L, respectively, whereas mean C (max) and AUC(0-12h) of total and free MPAG were 97.3 +/- 32.6 mg/L, 656.0 +/- 148.0 mg.h/L and 29.9 +/- 8.5 mg/L, 222.0 +/- 58.1 mg x h/L respectively.",Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17093994/),[h·mg] / [l],222.0,159217,DB00091,Cyclosporine
,17093994,fractions,"The mean fractions of free MPA and MPAG were 3.5 +/- 2.0 and 34.6 +/- 8.0%, respectively.",Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17093994/),%,3.5,159218,DB00091,Cyclosporine
,17093994,fractions,"The mean fractions of free MPA and MPAG were 3.5 +/- 2.0 and 34.6 +/- 8.0%, respectively.",Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17093994/),%,34.6,159219,DB00091,Cyclosporine
,9156373,time to peak blood concentration,"Mean values for the pharmacokinetic parameters of sirolimus calculated in all dose groups were as follows: time to peak blood concentration, 1.4 +/- 1.2 hours; terminal half-life, 62 +/- 16 hours; oral dose clearance, 208 +/- 95 mL/h/kg; apparent oral steady-state volume of distribution, 12 +/- 5 L/kg; and blood/plasma ratio, 38 +/- 13.",Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156373/),h,1.4,159990,DB00091,Cyclosporine
,9156373,terminal half-life,"Mean values for the pharmacokinetic parameters of sirolimus calculated in all dose groups were as follows: time to peak blood concentration, 1.4 +/- 1.2 hours; terminal half-life, 62 +/- 16 hours; oral dose clearance, 208 +/- 95 mL/h/kg; apparent oral steady-state volume of distribution, 12 +/- 5 L/kg; and blood/plasma ratio, 38 +/- 13.",Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156373/),h,62,159991,DB00091,Cyclosporine
,9156373,oral dose clearance,"Mean values for the pharmacokinetic parameters of sirolimus calculated in all dose groups were as follows: time to peak blood concentration, 1.4 +/- 1.2 hours; terminal half-life, 62 +/- 16 hours; oral dose clearance, 208 +/- 95 mL/h/kg; apparent oral steady-state volume of distribution, 12 +/- 5 L/kg; and blood/plasma ratio, 38 +/- 13.",Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156373/),[ml] / [h·kg],208,159992,DB00091,Cyclosporine
,9156373,apparent oral steady-state volume of distribution,"Mean values for the pharmacokinetic parameters of sirolimus calculated in all dose groups were as follows: time to peak blood concentration, 1.4 +/- 1.2 hours; terminal half-life, 62 +/- 16 hours; oral dose clearance, 208 +/- 95 mL/h/kg; apparent oral steady-state volume of distribution, 12 +/- 5 L/kg; and blood/plasma ratio, 38 +/- 13.",Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156373/),[l] / [kg],12,159993,DB00091,Cyclosporine
,9156373,blood/plasma ratio,"Mean values for the pharmacokinetic parameters of sirolimus calculated in all dose groups were as follows: time to peak blood concentration, 1.4 +/- 1.2 hours; terminal half-life, 62 +/- 16 hours; oral dose clearance, 208 +/- 95 mL/h/kg; apparent oral steady-state volume of distribution, 12 +/- 5 L/kg; and blood/plasma ratio, 38 +/- 13.",Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9156373/),,38,159994,DB00091,Cyclosporine
,11475470,peak plasma drug concentration (Cmax),"In the range of doses employed, the average peak plasma drug concentration (Cmax) and area under the concentration-time curve to 12 hours tended to increase linearly with the dose (from 782.35 to 1,607.98 microg/L and from 3,612 to 7,221 microg x h/L for doses of 200 mg and 400 mg, respectively), whereas the time to Cmax (tmax) and elimination half-life (t 1/2beta) ranged between 78 and 95.2 min and 85.5 and 162 min, respectively, and did not appear to change with the dose.",Pharmacokinetics of cyclosporin microemulsion in patients with inflammatory bowel disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11475470/),μ,"782.35 to 1,607.98",160084,DB00091,Cyclosporine
,11475470,area under the concentration-time curve to 12 hours,"In the range of doses employed, the average peak plasma drug concentration (Cmax) and area under the concentration-time curve to 12 hours tended to increase linearly with the dose (from 782.35 to 1,607.98 microg/L and from 3,612 to 7,221 microg x h/L for doses of 200 mg and 400 mg, respectively), whereas the time to Cmax (tmax) and elimination half-life (t 1/2beta) ranged between 78 and 95.2 min and 85.5 and 162 min, respectively, and did not appear to change with the dose.",Pharmacokinetics of cyclosporin microemulsion in patients with inflammatory bowel disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11475470/),[h·μg] / [l],"3,612 to 7,221",160085,DB00091,Cyclosporine
,11475470,time to Cmax (tmax),"In the range of doses employed, the average peak plasma drug concentration (Cmax) and area under the concentration-time curve to 12 hours tended to increase linearly with the dose (from 782.35 to 1,607.98 microg/L and from 3,612 to 7,221 microg x h/L for doses of 200 mg and 400 mg, respectively), whereas the time to Cmax (tmax) and elimination half-life (t 1/2beta) ranged between 78 and 95.2 min and 85.5 and 162 min, respectively, and did not appear to change with the dose.",Pharmacokinetics of cyclosporin microemulsion in patients with inflammatory bowel disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11475470/),min,78 and 95.2,160086,DB00091,Cyclosporine
,11475470,elimination half-life (t 1/2beta),"In the range of doses employed, the average peak plasma drug concentration (Cmax) and area under the concentration-time curve to 12 hours tended to increase linearly with the dose (from 782.35 to 1,607.98 microg/L and from 3,612 to 7,221 microg x h/L for doses of 200 mg and 400 mg, respectively), whereas the time to Cmax (tmax) and elimination half-life (t 1/2beta) ranged between 78 and 95.2 min and 85.5 and 162 min, respectively, and did not appear to change with the dose.",Pharmacokinetics of cyclosporin microemulsion in patients with inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11475470/),min,85.,160087,DB00091,Cyclosporine
,11475470,elimination half-life (t 1/2beta),"In the range of doses employed, the average peak plasma drug concentration (Cmax) and area under the concentration-time curve to 12 hours tended to increase linearly with the dose (from 782.35 to 1,607.98 microg/L and from 3,612 to 7,221 microg x h/L for doses of 200 mg and 400 mg, respectively), whereas the time to Cmax (tmax) and elimination half-life (t 1/2beta) ranged between 78 and 95.2 min and 85.5 and 162 min, respectively, and did not appear to change with the dose.",Pharmacokinetics of cyclosporin microemulsion in patients with inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11475470/),min,162,160088,DB00091,Cyclosporine
,11475470,tmax,"After dose-normalisation by transformation of data into percentage increase over baseline (trough) concentration for each patient, single kinetic parameters for the whole study population (n = 58) could be calculated (Cmax 620% vs baseline. tmax 86.5 min, t 1/2 115 min).",Pharmacokinetics of cyclosporin microemulsion in patients with inflammatory bowel disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11475470/),min,86.5,160089,DB00091,Cyclosporine
,11475470,t 1/2,"After dose-normalisation by transformation of data into percentage increase over baseline (trough) concentration for each patient, single kinetic parameters for the whole study population (n = 58) could be calculated (Cmax 620% vs baseline. tmax 86.5 min, t 1/2 115 min).",Pharmacokinetics of cyclosporin microemulsion in patients with inflammatory bowel disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11475470/),min,115,160090,DB00091,Cyclosporine
,9263380,blood/ plasma ratio,Blood and plasma sirolimus concentrations were analyzed by an electrospray-high performance liquid/mass spectrophotometric (ESP-HPLC/MS) method Sirolimus showed an extensive red blood cell distribution with a mean blood/ plasma ratio of 49.1.,Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9263380/),,49.1,160379,DB00091,Cyclosporine
,9263380,elimination half-life,The elimination half-life ranged from 43.8 to 86.5 hours (mean 56.9 hours).,Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9263380/),h,56.9,160380,DB00091,Cyclosporine
,9263380,oral dose clearance,The oral dose clearance ranged from 42 to 339 ml/h.kg.,Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9263380/),[ml] / [h·kg],42 to 339,160381,DB00091,Cyclosporine
,17954018,P app,"Even though, AT1002 appeared to increase the P app of CsA in each treatment (CsA/AT1002, 1.54+/-0.13 x 10(-6)cm/s and CsA/PI/AT1002, 1.76+/-0.05 x 10(-6)cm/s) compared to each control (CsA and CsA/PI), respectively.",Effect of the six-mer synthetic peptide (AT1002) fragment of zonula occludens toxin on the intestinal absorption of cyclosporin A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17954018/),[cm] / [s],1.54,160412,DB00091,Cyclosporine
,17954018,P app,"Even though, AT1002 appeared to increase the P app of CsA in each treatment (CsA/AT1002, 1.54+/-0.13 x 10(-6)cm/s and CsA/PI/AT1002, 1.76+/-0.05 x 10(-6)cm/s) compared to each control (CsA and CsA/PI), respectively.",Effect of the six-mer synthetic peptide (AT1002) fragment of zonula occludens toxin on the intestinal absorption of cyclosporin A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17954018/),[cm] / [s],1.76,160413,DB00091,Cyclosporine
,17954018,AUC 0-120 min,"Also, AUC 0-120 min of CsA over a range of 1.64-2.14 and the Cmax of CsA over a range of 1.77-2.56 was statistically and significantly increased at 10 and 40 mg/kg of AT1002 after the intraduodenal administration of CsA/PI/BC/AT1002 to Sprague-Dawley rats.",Effect of the six-mer synthetic peptide (AT1002) fragment of zonula occludens toxin on the intestinal absorption of cyclosporin A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17954018/),,1.64-2.14,160414,DB00091,Cyclosporine
,17954018,Cmax,"Also, AUC 0-120 min of CsA over a range of 1.64-2.14 and the Cmax of CsA over a range of 1.77-2.56 was statistically and significantly increased at 10 and 40 mg/kg of AT1002 after the intraduodenal administration of CsA/PI/BC/AT1002 to Sprague-Dawley rats.",Effect of the six-mer synthetic peptide (AT1002) fragment of zonula occludens toxin on the intestinal absorption of cyclosporin A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17954018/),,1.77-2.56,160415,DB00091,Cyclosporine
,11368437,maximum tolerated dose,The maximum tolerated dose of mitoxantrone was defined as 4.5 mg/m2/day.,"Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11368437/),[mg] / [d·m2],4.5,161135,DB00091,Cyclosporine
,11368437,overall survival,The median overall survival was 4 months.,"Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11368437/),month,4,161136,DB00091,Cyclosporine
,16678035,AUC,Only 9 of 52 LTx patients had a prednisolone AUC within the previously reported reference range for healthy adult control subjects (170 to 260 nmol x hr/liter/milligram prednisolone).,Therapeutic drug monitoring of prednisolone after lung transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16678035/),[h·nM] / [l·milligram],170 to 260,162032,DB00091,Cyclosporine
,16678035,AUC,"Prednisolone AUC was higher in patients with CF compared with non-CF patients (511 +/- 82 vs 349 +/- 27 nmol x hr/liter/milligram, p < 0.02) and 70% of LTx recipients had measurable prednisolone levels at baseline (26.5 +/- 4.5 nmol/liter), unlike normal controls.",Therapeutic drug monitoring of prednisolone after lung transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16678035/),[h·nM] / [l·milligram],511,162033,DB00091,Cyclosporine
,16678035,AUC,"Prednisolone AUC was higher in patients with CF compared with non-CF patients (511 +/- 82 vs 349 +/- 27 nmol x hr/liter/milligram, p < 0.02) and 70% of LTx recipients had measurable prednisolone levels at baseline (26.5 +/- 4.5 nmol/liter), unlike normal controls.",Therapeutic drug monitoring of prednisolone after lung transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16678035/),[h·nM] / [l·milligram],349,162034,DB00091,Cyclosporine
,24923538,platelet nadir,"Median platelet nadir amounted in all dogs to 0 × 10(9)/L (median, day +10; duration <50 × 10(9)/L, 22 days) and median leukocyte nadir was 1.0 × 10(9)/L (range, .1 to 2.5 × 10(9)/L; median, day +13).",Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24923538/),,0 × 10(9),162089,DB00091,Cyclosporine
,24923538,leukocyte nadir,"Median platelet nadir amounted in all dogs to 0 × 10(9)/L (median, day +10; duration <50 × 10(9)/L, 22 days) and median leukocyte nadir was 1.0 × 10(9)/L (range, .1 to 2.5 × 10(9)/L; median, day +13).",Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24923538/),,1.0 × 10(9),162090,DB00091,Cyclosporine
,24923538,trough levels,"Pharmacokinetics of RAD001 and MMF showed median trough levels of 19.1 (range, 10.5 to 43.2) μg/L and .3 (.1 to 1.3) mg/L, respectively.",Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24923538/),[μg] / [l],19.1,162091,DB00091,Cyclosporine
,24923538,trough levels,"Pharmacokinetics of RAD001 and MMF showed median trough levels of 19.1 (range, 10.5 to 43.2) μg/L and .3 (.1 to 1.3) mg/L, respectively.",Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24923538/),[mg] / [l],.3,162092,DB00091,Cyclosporine
,24923538,area under the curve,"The median area under the curve was 325 (range, 178 to 593) μg/L × hour for RAD001 and 29.6 (range, 7.9 to 40.5) ng/L × hour for MMF.",Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24923538/),[μg] / [h·l],325,162093,DB00091,Cyclosporine
,24923538,area under the curve,"The median area under the curve was 325 (range, 178 to 593) μg/L × hour for RAD001 and 29.6 (range, 7.9 to 40.5) ng/L × hour for MMF.",Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24923538/),[ng] / [h·l],29.6,162094,DB00091,Cyclosporine
,10589373,oral bioavailability,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),%,52 to 55,162570,DB00091,Cyclosporine
,10589373,maximum concentrations,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[mg] / [l],1.01 to 1.52,162571,DB00091,Cyclosporine
,10589373,maximum concentrations,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[mg] / [l],2.41 to 2.85,162572,DB00091,Cyclosporine
,10589373,elimination half-life,"The pharmacokinetic advantages that clarithromycin has over erythromycin include increased oral bioavailability (52 to 55%), increased plasma concentrations (mean maximum concentrations ranged from 1.01 to 1.52 mg/L and 2.41 to 2.85 mg/L after multiple 250 and 500 mg doses, respectively), and a longer elimination half-life (3.3 to 4.9 hours) to allow twice daily administration.",Clinical pharmacokinetics of clarithromycin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),h,3.3 to 4.9,162573,DB00091,Cyclosporine
,10589373,total body clearance,"The reported mean values of total body clearance and renal clearance in adults have ranged from 29.2 to 58.1 L/h and 6.7 to 12.8 L/h, respectively.",Clinical pharmacokinetics of clarithromycin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[l] / [h],29.2 to 58.1,162574,DB00091,Cyclosporine
,10589373,renal clearance,"The reported mean values of total body clearance and renal clearance in adults have ranged from 29.2 to 58.1 L/h and 6.7 to 12.8 L/h, respectively.",Clinical pharmacokinetics of clarithromycin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589373/),[l] / [h],6.7 to 12.8,162575,DB00091,Cyclosporine
,22764568,recovered amounts,The recovered amounts of quinidine 30 min after administration were 21.1% of dose in control rats and 94.7% in ranitidine-treated rats.,"Characterization of intestinal absorption of quinidine, a P-glycoprotein substrate, given as a powder in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22764568/),%,21.1,162642,DB00091,Cyclosporine
,22764568,recovered amounts,The recovered amounts of quinidine 30 min after administration were 21.1% of dose in control rats and 94.7% in ranitidine-treated rats.,"Characterization of intestinal absorption of quinidine, a P-glycoprotein substrate, given as a powder in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22764568/),%,94.7,162643,DB00091,Cyclosporine
,11782899,maximum concentration (C(max)),Peppermint oil (100 mg/kg) tripled the mean cyclosporine maximum concentration (C(max)) from 0.60 to 1.6 microg/mL and increased the area under the concentration versus time curve (AUC(0-infinity)) from 8.3 to 24.3 microg x h/mL.,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),[μg] / [ml],0.60 to 1.6,162836,DB00091,Cyclosporine
,11782899,area under the concentration versus time curve (AUC(0-infinity)),Peppermint oil (100 mg/kg) tripled the mean cyclosporine maximum concentration (C(max)) from 0.60 to 1.6 microg/mL and increased the area under the concentration versus time curve (AUC(0-infinity)) from 8.3 to 24.3 microg x h/mL.,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),[h·μg] / [ml],8,162837,DB00091,Cyclosporine
,11782899,area under the concentration versus time curve (AUC(0-infinity)),Peppermint oil (100 mg/kg) tripled the mean cyclosporine maximum concentration (C(max)) from 0.60 to 1.6 microg/mL and increased the area under the concentration versus time curve (AUC(0-infinity)) from 8.3 to 24.3 microg x h/mL.,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),[h·μg] / [ml],24,162838,DB00091,Cyclosporine
,11782899,time to reach C(max) (t(max)),The median time to reach C(max) (t(max)) was increased from 2 to 6 h.,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),h,2,162839,DB00091,Cyclosporine
,11782899,time to reach C(max) (t(max)),The median time to reach C(max) (t(max)) was increased from 2 to 6 h.,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),h,6,162840,DB00091,Cyclosporine
,11782899,Terminal half-life,Terminal half-life (10 h) and mean residence time (MRT; 15 h) were unaffected.,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),h,10,162841,DB00091,Cyclosporine
,11782899,mean residence time (MRT,Terminal half-life (10 h) and mean residence time (MRT; 15 h) were unaffected.,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),h,15,162842,DB00091,Cyclosporine
,11782899,C(max),Coadministration of TPGS (50 mg/kg) with cyclosporine in a saline vehicle doubled cyclosporine C(max) from 1.3 to 2.9 microg/mL and increased AUC(0-infinity) from 28.5 to 59.7 microg x h/mL.,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),[μg] / [ml],1.3,162843,DB00091,Cyclosporine
,11782899,C(max),Coadministration of TPGS (50 mg/kg) with cyclosporine in a saline vehicle doubled cyclosporine C(max) from 1.3 to 2.9 microg/mL and increased AUC(0-infinity) from 28.5 to 59.7 microg x h/mL.,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),[μg] / [ml],2,162844,DB00091,Cyclosporine
,11782899,AUC(0-infinity),Coadministration of TPGS (50 mg/kg) with cyclosporine in a saline vehicle doubled cyclosporine C(max) from 1.3 to 2.9 microg/mL and increased AUC(0-infinity) from 28.5 to 59.7 microg x h/mL.,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),[h·μg] / [ml],28,162845,DB00091,Cyclosporine
,11782899,t(max),The t(max) was unchanged (3 h).,Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),h,3,162846,DB00091,Cyclosporine
,11782899,Terminal half-life,"Terminal half-life and MRT were increased by 44% (15.4 versus 10.7 h) and 24% (19.9 versus 16.0 h), respectively.",Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),h,15.4,162847,DB00091,Cyclosporine
,11782899,Terminal half-life,"Terminal half-life and MRT were increased by 44% (15.4 versus 10.7 h) and 24% (19.9 versus 16.0 h), respectively.",Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),h,10.7,162848,DB00091,Cyclosporine
,11782899,MRT,"Terminal half-life and MRT were increased by 44% (15.4 versus 10.7 h) and 24% (19.9 versus 16.0 h), respectively.",Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),h,10.7,162849,DB00091,Cyclosporine
,11782899,MRT,"Terminal half-life and MRT were increased by 44% (15.4 versus 10.7 h) and 24% (19.9 versus 16.0 h), respectively.",Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),h,19.9,162850,DB00091,Cyclosporine
,11782899,MRT,"Terminal half-life and MRT were increased by 44% (15.4 versus 10.7 h) and 24% (19.9 versus 16.0 h), respectively.",Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11782899/),h,16.0,162851,DB00091,Cyclosporine
,11861442,AUC,"According to ROC analysis, an AUC value of 33.8 mg x h/L for MPA from t(0) to t(12h) (MPA-AUC(0-12)) determined by HPLC had a diagnostic sensitivity of 80% and a diagnostic specificity of 57%.",Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11861442/),[h·mg] / [l],33.8,163321,DB00091,Cyclosporine
,11861442,Emit,The corresponding value of the Emit was 36.1 mg x h/L.,Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11861442/),[h·mg] / [l],36.1,163322,DB00091,Cyclosporine
,9707972,dose at,Mean Neoral dose at conversion was 3.8 mg/kg/day (range: 2.1-5.7).,Advantages of Neoral conversion in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9707972/),[mg] / [d·kg],3.8,163323,DB00091,Cyclosporine
,2651227,bioavailability,"After T-tube clamping, cyclosporin A absorption was faster and more complete with the mean time of peak concentration, tmax, reduced to around three hours from around six hours and mean bioavailability rising from only 16.6% (n = 13) to 30% in the entire group (n = 11 after clamping) or to 35% after excluding two patients who developed severe cholestasis after the preclamping study.",Cyclosporin A pharmacokinetics in liver transplant recipients in relation to biliary T-tube clamping and liver dysfunction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2651227/),%,16.6,163539,DB00091,Cyclosporine
,2651227,bioavailability,"After T-tube clamping, cyclosporin A absorption was faster and more complete with the mean time of peak concentration, tmax, reduced to around three hours from around six hours and mean bioavailability rising from only 16.6% (n = 13) to 30% in the entire group (n = 11 after clamping) or to 35% after excluding two patients who developed severe cholestasis after the preclamping study.",Cyclosporin A pharmacokinetics in liver transplant recipients in relation to biliary T-tube clamping and liver dysfunction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2651227/),%,30,163540,DB00091,Cyclosporine
,2651227,bioavailability,"After T-tube clamping, cyclosporin A absorption was faster and more complete with the mean time of peak concentration, tmax, reduced to around three hours from around six hours and mean bioavailability rising from only 16.6% (n = 13) to 30% in the entire group (n = 11 after clamping) or to 35% after excluding two patients who developed severe cholestasis after the preclamping study.",Cyclosporin A pharmacokinetics in liver transplant recipients in relation to biliary T-tube clamping and liver dysfunction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2651227/),%,35,163541,DB00091,Cyclosporine
below,2651227,Bioavailability,Bioavailability in these two patients fell below 8% and to around 1% in a further patient with severe graft dysfunction.,Cyclosporin A pharmacokinetics in liver transplant recipients in relation to biliary T-tube clamping and liver dysfunction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2651227/),%,8,163542,DB00091,Cyclosporine
,2651227,Bioavailability,Bioavailability in these two patients fell below 8% and to around 1% in a further patient with severe graft dysfunction.,Cyclosporin A pharmacokinetics in liver transplant recipients in relation to biliary T-tube clamping and liver dysfunction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2651227/),%,1,163543,DB00091,Cyclosporine
,2651227,metabolic clearance,Clamping reduced the metabolic clearance of cyclosporin A by only 25% from a mean before clamping of 2.9 ml/min/kg to 2.3 ml/min/kg (n = 11).,Cyclosporin A pharmacokinetics in liver transplant recipients in relation to biliary T-tube clamping and liver dysfunction. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2651227/),[ml] / [kg·min],2.9,163544,DB00091,Cyclosporine
,2651227,metabolic clearance,Clamping reduced the metabolic clearance of cyclosporin A by only 25% from a mean before clamping of 2.9 ml/min/kg to 2.3 ml/min/kg (n = 11).,Cyclosporin A pharmacokinetics in liver transplant recipients in relation to biliary T-tube clamping and liver dysfunction. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2651227/),[ml] / [kg·min],2.3,163545,DB00091,Cyclosporine
,18978521,area under the concentration-time curve (AUC0-12),"The area under the concentration-time curve (AUC0-12) of MPA normalized to mycophenolate mofetil (MMF) dose (mg/kg) was significantly lower in LN patients and CyA-treated KT recipients than in Tac-treated KT recipients [median (range), 2.19 (0.87-4.23), 2.36 (1.13-5.74), and 4.86 (3.25-6.75) microg x h/mL per mg/kg, P < 0.05 and P < 0.01, respectively].",Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18978521/),[h·μg] / [kg·mg·ml],2.19,163570,DB00091,Cyclosporine
,18978521,area under the concentration-time curve (AUC0-12),"The area under the concentration-time curve (AUC0-12) of MPA normalized to mycophenolate mofetil (MMF) dose (mg/kg) was significantly lower in LN patients and CyA-treated KT recipients than in Tac-treated KT recipients [median (range), 2.19 (0.87-4.23), 2.36 (1.13-5.74), and 4.86 (3.25-6.75) microg x h/mL per mg/kg, P < 0.05 and P < 0.01, respectively].",Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18978521/),[h·μg] / [kg·mg·ml],2.36,163571,DB00091,Cyclosporine
,18978521,area under the concentration-time curve (AUC0-12),"The area under the concentration-time curve (AUC0-12) of MPA normalized to mycophenolate mofetil (MMF) dose (mg/kg) was significantly lower in LN patients and CyA-treated KT recipients than in Tac-treated KT recipients [median (range), 2.19 (0.87-4.23), 2.36 (1.13-5.74), and 4.86 (3.25-6.75) microg x h/mL per mg/kg, P < 0.05 and P < 0.01, respectively].",Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18978521/),[h·μg] / [kg·mg·ml],4.86,163572,DB00091,Cyclosporine
,18978521,AUC0-12,"Dose-normalized MPAG AUC0-12 was significantly lower in LN patients and slightly lower in Tac-treated KT recipients than in CyA-treated KT recipients [median (range), 35.0 (8.34-69.8), 51.6 (34.4-94.8), and 84.1 (34.7-152) microg x h/mL per mg/kg, P < 0.05 and P = 0.13, respectively].",Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18978521/),[h·μg] / [kg·mg·ml],35.0,163573,DB00091,Cyclosporine
,18978521,AUC0-12,"Dose-normalized MPAG AUC0-12 was significantly lower in LN patients and slightly lower in Tac-treated KT recipients than in CyA-treated KT recipients [median (range), 35.0 (8.34-69.8), 51.6 (34.4-94.8), and 84.1 (34.7-152) microg x h/mL per mg/kg, P < 0.05 and P = 0.13, respectively].",Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18978521/),[h·μg] / [kg·mg·ml],51.6,163574,DB00091,Cyclosporine
,18978521,AUC0-12,"Dose-normalized MPAG AUC0-12 was significantly lower in LN patients and slightly lower in Tac-treated KT recipients than in CyA-treated KT recipients [median (range), 35.0 (8.34-69.8), 51.6 (34.4-94.8), and 84.1 (34.7-152) microg x h/mL per mg/kg, P < 0.05 and P = 0.13, respectively].",Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18978521/),[h·μg] / [kg·mg·ml],84.1,163575,DB00091,Cyclosporine
,12639706,blood-to-bile distribution ratios (k = AUC(bile) / AUC(blood)),"The area under the concentration versus time curves (AUC's) for sinomenine in the bile were significantly greater than those in the blood at dosages of 3, 10, and 30 mg/kg with the blood-to-bile distribution ratios (k = AUC(bile) / AUC(blood)) being 3.85 +/- 0.29 and 3.52 +/- 0.28 at 10 and 30 mg/kg, respectively, indicating active hepatobiliary excretion.",Regulation of hepatobiliary excretion of sinomenine by P-glycoprotein in Sprague-Dawley rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12639706/),,3.85,163743,DB00091,Cyclosporine
,12639706,blood-to-bile distribution ratios (k = AUC(bile) / AUC(blood)),"The area under the concentration versus time curves (AUC's) for sinomenine in the bile were significantly greater than those in the blood at dosages of 3, 10, and 30 mg/kg with the blood-to-bile distribution ratios (k = AUC(bile) / AUC(blood)) being 3.85 +/- 0.29 and 3.52 +/- 0.28 at 10 and 30 mg/kg, respectively, indicating active hepatobiliary excretion.",Regulation of hepatobiliary excretion of sinomenine by P-glycoprotein in Sprague-Dawley rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12639706/),,3.52,163744,DB00091,Cyclosporine
,12639706,bile/blood distribution ratio,"Coadministration with 20 mg/kg of cyclosporin A 10 min prior to sinomenine administration resulted in a significant reduction of the bile AUC's for the dosages of 10 and 30 mg/kg., resulting in the bile/blood distribution ratio being significantly reduced to 0.47 +/- 0.05 and 0.49 +/- 0.05, respectively.",Regulation of hepatobiliary excretion of sinomenine by P-glycoprotein in Sprague-Dawley rats. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12639706/),,0.47,163745,DB00091,Cyclosporine
,12639706,bile/blood distribution ratio,"Coadministration with 20 mg/kg of cyclosporin A 10 min prior to sinomenine administration resulted in a significant reduction of the bile AUC's for the dosages of 10 and 30 mg/kg., resulting in the bile/blood distribution ratio being significantly reduced to 0.47 +/- 0.05 and 0.49 +/- 0.05, respectively.",Regulation of hepatobiliary excretion of sinomenine by P-glycoprotein in Sprague-Dawley rats. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12639706/),,0.49,163746,DB00091,Cyclosporine
,10867245,encapsulation ratio,"The mean diameter of cyclosporin A stearic acid nanoparticles was 316.1 nm, while the encapsulation ratio of cyclosporin A to stearic acid nanoparticles reached to 88.36%.",Studies on the cyclosporin A loaded stearic acid nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10867245/),%,88.36,163975,DB00091,Cyclosporine
,10867245,relative bioavailability,"The relative bioavailability of cyclosporin A stearic acid nanoparticles over reference was nearly 80%, and the time to reach maximum concentration (T(max)) of cyclosporin A after oral administration of cyclosporin A stearic acid nanoparticles was delayed significantly than the reference, suggesting an obvious sustained release effect.",Studies on the cyclosporin A loaded stearic acid nanoparticles. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10867245/),%,80,163976,DB00091,Cyclosporine
,8366177,steady-state concentrations,"The steady-state concentrations of AZN observed in these patients ranged from 6 to 583 micrograms/L, and the interday coefficients of variation of the concentration in three randomly selected patients were 38%, 12%, and 4.6%.",Pharmacokinetics of azathioprine after repeated oral and single intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8366177/),[μg] / [l],6 to 583,164031,DB00091,Cyclosporine
,8366177,TCLor,The frequency distribution pattern of the apparent oral clearance (TCLor) of AZN separates the patients almost equally into poor (TCLor = 0.126 to 4 L/hour.kg) and extensive metabolizers (TCLor = 5 to 12 L/hour.kg).,Pharmacokinetics of azathioprine after repeated oral and single intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8366177/),[l] / [h·kg],0.126 to 4,164032,DB00091,Cyclosporine
,8366177,TCLor,The frequency distribution pattern of the apparent oral clearance (TCLor) of AZN separates the patients almost equally into poor (TCLor = 0.126 to 4 L/hour.kg) and extensive metabolizers (TCLor = 5 to 12 L/hour.kg).,Pharmacokinetics of azathioprine after repeated oral and single intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8366177/),[l] / [h·kg],5 to 12,164033,DB00091,Cyclosporine
,8366177,alpha,"The data obtained from the IV administration displayed the two-compartment model characteristics with mean (standard error of the mean) of alpha, beta, Vc, and total body clearance of 15.3 (2)/hour, 2.38 (.64)/hour, 1.05 (.3) L/kg, and 8.12 (1.26) L/hour.kg, respectively.",Pharmacokinetics of azathioprine after repeated oral and single intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8366177/),1/[h],15.3,164034,DB00091,Cyclosporine
,8366177,total body clearance,"The data obtained from the IV administration displayed the two-compartment model characteristics with mean (standard error of the mean) of alpha, beta, Vc, and total body clearance of 15.3 (2)/hour, 2.38 (.64)/hour, 1.05 (.3) L/kg, and 8.12 (1.26) L/hour.kg, respectively.",Pharmacokinetics of azathioprine after repeated oral and single intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8366177/),[l] / [h·kg],8.12,164035,DB00091,Cyclosporine
,2340843,trough level,The mean whole blood CyA trough level determined by HPLC rose from 117 ng.,Pharmacokinetic interaction between cyclosporin and diltiazem. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340843/),ng,117,164418,DB00091,Cyclosporine
,2340843,trough level,"ml-1 after one week on diltiazem, and the mean trough level of metabolite 17 rose similarly from 184 ng.",Pharmacokinetic interaction between cyclosporin and diltiazem. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340843/),ng,184,164419,DB00091,Cyclosporine
,19933691,AUC(0-12),Median AUC(0-12) of voriconazole on the day of HSCT was 33.81 mg.h/L [interquartile range (IQR) 20.59-39.39] and 25.61 mg.h/L (IQR 22.48-38.65) 1 week later.,Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19933691/),[h·mg] / [l],33.81,165090,DB00091,Cyclosporine
,19933691,AUC(0-12),Median AUC(0-12) of voriconazole on the day of HSCT was 33.81 mg.h/L [interquartile range (IQR) 20.59-39.39] and 25.61 mg.h/L (IQR 22.48-38.65) 1 week later.,Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19933691/),[h·mg] / [l],25.61,165091,DB00091,Cyclosporine
<,19933691,Trough levels,Trough levels were <1.0 mg/L for 3 of 10 patients on the day of HSCT and for 4 of 10 patients 1 week later.,Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19933691/),[mg] / [l],1.0,165092,DB00091,Cyclosporine
,19859566,total body clearance,"Diabetic dogs showed a significant increase in total body clearance of cyclosporine compared to healthy controls (0.457 L hr(-1)Kg(-1) versus 0.201 L hr(-1)Kg(-1), P = .0019) and a decrease in its biological half-life (9.32 hours versus 22.56 hours, P = .0125).",Influence of overt diabetes mellitus on cyclosporine pharmacokinetics in a canine model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19859566/),[l] / [hr],0.457,165858,DB00091,Cyclosporine
,19859566,total body clearance,"Diabetic dogs showed a significant increase in total body clearance of cyclosporine compared to healthy controls (0.457 L hr(-1)Kg(-1) versus 0.201 L hr(-1)Kg(-1), P = .0019) and a decrease in its biological half-life (9.32 hours versus 22.56 hours, P = .0125).",Influence of overt diabetes mellitus on cyclosporine pharmacokinetics in a canine model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19859566/),[l] / [hr],0.201,165859,DB00091,Cyclosporine
,19859566,biological half-life,"Diabetic dogs showed a significant increase in total body clearance of cyclosporine compared to healthy controls (0.457 L hr(-1)Kg(-1) versus 0.201 L hr(-1)Kg(-1), P = .0019) and a decrease in its biological half-life (9.32 hours versus 22.56 hours, P = .0125).",Influence of overt diabetes mellitus on cyclosporine pharmacokinetics in a canine model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19859566/),h,9.32,165860,DB00091,Cyclosporine
,19859566,biological half-life,"Diabetic dogs showed a significant increase in total body clearance of cyclosporine compared to healthy controls (0.457 L hr(-1)Kg(-1) versus 0.201 L hr(-1)Kg(-1), P = .0019) and a decrease in its biological half-life (9.32 hours versus 22.56 hours, P = .0125).",Influence of overt diabetes mellitus on cyclosporine pharmacokinetics in a canine model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19859566/),h,22.56,165861,DB00091,Cyclosporine
,3044424,dose-normalized area under the blood concentration vs time curve (AUC),3. The mean (+/- s.d.) dose-normalized area under the blood concentration vs time curve (AUC) over a dosing interval was 5.23 (+/- 3.22) ng ml-1 h during the pre clamping period and 15.79 +/- 7.92 ng ml-1 h during the post clamping period.,Effect of bile on cyclosporin absorption in liver transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3044424/),[h·ng] / [ml],5.23,166741,DB00091,Cyclosporine
,3044424,dose-normalized area under the blood concentration vs time curve (AUC),3. The mean (+/- s.d.) dose-normalized area under the blood concentration vs time curve (AUC) over a dosing interval was 5.23 (+/- 3.22) ng ml-1 h during the pre clamping period and 15.79 +/- 7.92 ng ml-1 h during the post clamping period.,Effect of bile on cyclosporin absorption in liver transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3044424/),[h·ng] / [ml],15.79,166742,DB00091,Cyclosporine
,29051147,Michaelis-Menten constant,"We initially investigated the active transport of rosuvastatin into PXB cells, and found concentration-dependent uptake with a Michaelis-Menten constant value of 4.0 μmol/l and a Vmax value of 4.63 pmol/min per 106 cells.",Organic Anion-Transporting Polypeptide (OATP)-Mediated Drug-Drug Interaction Study between Rosuvastatin and Cyclosporine A in Chimeric Mice with Humanized Liver. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29051147/),[μM] / [l],4.0,166789,DB00091,Cyclosporine
,29051147,Vmax,"We initially investigated the active transport of rosuvastatin into PXB cells, and found concentration-dependent uptake with a Michaelis-Menten constant value of 4.0 μmol/l and a Vmax value of 4.63 pmol/min per 106 cells.",Organic Anion-Transporting Polypeptide (OATP)-Mediated Drug-Drug Interaction Study between Rosuvastatin and Cyclosporine A in Chimeric Mice with Humanized Liver. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29051147/),[pM] / [106·cells·min],4.63,166790,DB00091,Cyclosporine
,29051147,IC50,Cyclosporine A inhibited the uptake of rosuvastatin with an IC50 value of 0.21 μmol/l.,Organic Anion-Transporting Polypeptide (OATP)-Mediated Drug-Drug Interaction Study between Rosuvastatin and Cyclosporine A in Chimeric Mice with Humanized Liver. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29051147/),[μM] / [l],0.21,166791,DB00091,Cyclosporine
,12548141,lambda(1),"The PK model developed reliably described the individual PK of Neoral in lung transplant patients with and without CF, and the values of the first and second half-lives were different in these two populations (lambda(1) = 4.14 +/- 3.01 vs.",Bayesian forecasting of oral cyclosporin pharmacokinetics in stable lung transplant recipients with and without cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12548141/),,4.14,166851,DB00091,Cyclosporine
,12548141,lambda(2),"2.16 +/- 1.75 h(-1); P < 0.01; lambda(2) = 0.36 +/- 0.11 vs. 0.49 +/- 0.12 h(-1); P < 0.01), while the mean absorption time and standard deviation of absorption time tended to be less in patients with cystic fibrosis (P < 0.1).",Bayesian forecasting of oral cyclosporin pharmacokinetics in stable lung transplant recipients with and without cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12548141/),1/[h],0.36,166852,DB00091,Cyclosporine
,12548141,lambda(2),"2.16 +/- 1.75 h(-1); P < 0.01; lambda(2) = 0.36 +/- 0.11 vs. 0.49 +/- 0.12 h(-1); P < 0.01), while the mean absorption time and standard deviation of absorption time tended to be less in patients with cystic fibrosis (P < 0.1).",Bayesian forecasting of oral cyclosporin pharmacokinetics in stable lung transplant recipients with and without cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12548141/),1/[h],0.49,166853,DB00091,Cyclosporine
,8610430,steady state c,"The mean steady state cyclosporine and tacrolimus concentrations without fluconazole were 320.3 and 18.2 ng/ml and increased to 389.2 and 21.2 ng/ml, respectively, after the addition of fluconazole, corresponding to a 21% (P=0.031) and 16% (P=0.125) increase.",Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610430/),[ng] / [ml],320.3,168869,DB00091,Cyclosporine
,8610430,steady state c,"The mean steady state cyclosporine and tacrolimus concentrations without fluconazole were 320.3 and 18.2 ng/ml and increased to 389.2 and 21.2 ng/ml, respectively, after the addition of fluconazole, corresponding to a 21% (P=0.031) and 16% (P=0.125) increase.",Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610430/),[ng] / [ml],18.2,168870,DB00091,Cyclosporine
,8610430,steady state c,"The mean steady state cyclosporine and tacrolimus concentrations without fluconazole were 320.3 and 18.2 ng/ml and increased to 389.2 and 21.2 ng/ml, respectively, after the addition of fluconazole, corresponding to a 21% (P=0.031) and 16% (P=0.125) increase.",Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610430/),[ng] / [ml],389.2,168871,DB00091,Cyclosporine
,8610430,steady state c,"The mean steady state cyclosporine and tacrolimus concentrations without fluconazole were 320.3 and 18.2 ng/ml and increased to 389.2 and 21.2 ng/ml, respectively, after the addition of fluconazole, corresponding to a 21% (P=0.031) and 16% (P=0.125) increase.",Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610430/),[ng] / [ml],21.2,168872,DB00091,Cyclosporine
,8610430,concentrations,"The mean steady state cyclosporine and tacrolimus concentrations without fluconazole were 320.3 and 18.2 ng/ml and increased to 389.2 and 21.2 ng/ml, respectively, after the addition of fluconazole, corresponding to a 21% (P=0.031) and 16% (P=0.125) increase.",Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610430/),[ng] / [ml],320.3,168873,DB00091,Cyclosporine
,8610430,concentrations,"The mean steady state cyclosporine and tacrolimus concentrations without fluconazole were 320.3 and 18.2 ng/ml and increased to 389.2 and 21.2 ng/ml, respectively, after the addition of fluconazole, corresponding to a 21% (P=0.031) and 16% (P=0.125) increase.",Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610430/),[ng] / [ml],18.2,168874,DB00091,Cyclosporine
,8610430,concentrations,"The mean steady state cyclosporine and tacrolimus concentrations without fluconazole were 320.3 and 18.2 ng/ml and increased to 389.2 and 21.2 ng/ml, respectively, after the addition of fluconazole, corresponding to a 21% (P=0.031) and 16% (P=0.125) increase.",Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610430/),[ng] / [ml],389.2,168875,DB00091,Cyclosporine
,8610430,concentrations,"The mean steady state cyclosporine and tacrolimus concentrations without fluconazole were 320.3 and 18.2 ng/ml and increased to 389.2 and 21.2 ng/ml, respectively, after the addition of fluconazole, corresponding to a 21% (P=0.031) and 16% (P=0.125) increase.",Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610430/),[ng] / [ml],21.2,168876,DB00091,Cyclosporine
,8610430,steady state clearance,"The mean steady state clearance of cyclosporine and tacrolimus without fluconazole was 6.82 and 1.28 ml/min/kg, which decreased to 5.57 and 1.10 ml/min/kg with fluconazole, corresponding to a 21% (P=0.031) and 16% (P=0.125) decrease, respectively.",Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610430/),[ml] / [kg·min],6.82,168877,DB00091,Cyclosporine
,8610430,steady state clearance,"The mean steady state clearance of cyclosporine and tacrolimus without fluconazole was 6.82 and 1.28 ml/min/kg, which decreased to 5.57 and 1.10 ml/min/kg with fluconazole, corresponding to a 21% (P=0.031) and 16% (P=0.125) decrease, respectively.",Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610430/),[ml] / [kg·min],1.28,168878,DB00091,Cyclosporine
,8610430,steady state clearance,"The mean steady state clearance of cyclosporine and tacrolimus without fluconazole was 6.82 and 1.28 ml/min/kg, which decreased to 5.57 and 1.10 ml/min/kg with fluconazole, corresponding to a 21% (P=0.031) and 16% (P=0.125) decrease, respectively.",Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610430/),[ml] / [kg·min],5.57,168879,DB00091,Cyclosporine
,8610430,steady state clearance,"The mean steady state clearance of cyclosporine and tacrolimus without fluconazole was 6.82 and 1.28 ml/min/kg, which decreased to 5.57 and 1.10 ml/min/kg with fluconazole, corresponding to a 21% (P=0.031) and 16% (P=0.125) decrease, respectively.",Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610430/),[ml] / [kg·min],1.10,168880,DB00091,Cyclosporine
,2556239,plasma half-life,It has a plasma half-life of approximately 25-30 hr and approximately 70% of dose is excreted in the urine unchanged.,Review of fluconazole: a new triazole antifungal agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2556239/),h,25-30,169591,DB00091,Cyclosporine
,15230340,maximum concentration (Cmax),Mean CsA maximum concentration (Cmax) decreased from 0.4 +/- 0.1 microg/ml to 0.1 +/- 0.0 microg/mL in rats pretreated with 90 mg/kg diltiazem (p<0.05).,The interaction of the diltiazem with oral and intravenous cyclosporine in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15230340/),[μg] / [ml],0.4,170099,DB00091,Cyclosporine
,15230340,maximum concentration (Cmax),Mean CsA maximum concentration (Cmax) decreased from 0.4 +/- 0.1 microg/ml to 0.1 +/- 0.0 microg/mL in rats pretreated with 90 mg/kg diltiazem (p<0.05).,The interaction of the diltiazem with oral and intravenous cyclosporine in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15230340/),[μg] / [ml],0.1,170100,DB00091,Cyclosporine
,15230340,absolute bioavailability after oral administration (F,The absolute bioavailability after oral administration (F(p.o.)) in the 60 or 90 mg/kg diltiazem groups were lower than the control group (9.6% and 8.5% versus 22.6%).,The interaction of the diltiazem with oral and intravenous cyclosporine in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15230340/),%,9.6,170101,DB00091,Cyclosporine
,15230340,absolute bioavailability after oral administration (F,The absolute bioavailability after oral administration (F(p.o.)) in the 60 or 90 mg/kg diltiazem groups were lower than the control group (9.6% and 8.5% versus 22.6%).,The interaction of the diltiazem with oral and intravenous cyclosporine in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15230340/),%,8.5,170102,DB00091,Cyclosporine
,15230340,absolute bioavailability after oral administration (F,The absolute bioavailability after oral administration (F(p.o.)) in the 60 or 90 mg/kg diltiazem groups were lower than the control group (9.6% and 8.5% versus 22.6%).,The interaction of the diltiazem with oral and intravenous cyclosporine in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15230340/),%,22.6,170103,DB00091,Cyclosporine
,1733057,elimination half-life,"Mean +/- SD elimination half-life was 3.02 +/- 0.81 hr, and the transplanted kidney removed as much as 47-59% (mean 56%) of locally infused MZB.",Mizoribine pharmacokinetics and pharmacodynamics in a canine renal allograft model of local immunosuppression. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1733057/),h,3.02,170984,DB00091,Cyclosporine
,1733057,survival time [MST],A dose of 3.0 mg/kg/day MZB did not significantly prolong survival of renal allograft recipients over that of untreated controls (median survival time [MST] = 8 days) when administered either locally (MST = 9 days) or systemically (MST = 12 days).,Mizoribine pharmacokinetics and pharmacodynamics in a canine renal allograft model of local immunosuppression. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1733057/),d,8,170985,DB00091,Cyclosporine
,1733057,survival time [MST],A dose of 3.0 mg/kg/day MZB did not significantly prolong survival of renal allograft recipients over that of untreated controls (median survival time [MST] = 8 days) when administered either locally (MST = 9 days) or systemically (MST = 12 days).,Mizoribine pharmacokinetics and pharmacodynamics in a canine renal allograft model of local immunosuppression. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1733057/),,9,170986,DB00091,Cyclosporine
,1733057,survival time [MST],A dose of 3.0 mg/kg/day MZB did not significantly prolong survival of renal allograft recipients over that of untreated controls (median survival time [MST] = 8 days) when administered either locally (MST = 9 days) or systemically (MST = 12 days).,Mizoribine pharmacokinetics and pharmacodynamics in a canine renal allograft model of local immunosuppression. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1733057/),,12,170987,DB00091,Cyclosporine
,1733057,MST,"All dogs receiving 4.0 mg/kg/day MZB i.a. died from rejection, and a survival advantage was still not realized (MST = 7 days).",Mizoribine pharmacokinetics and pharmacodynamics in a canine renal allograft model of local immunosuppression. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1733057/),d,7,170988,DB00091,Cyclosporine
,2655218,trough level,"When dosed according to ABW, obese recipients of renal allografts had a mean serum RIA trough level of 227 ng/ml as compared to 121 ng/ml in nonobese recipients on day 7.",The impact of body weight on cyclosporine pharmacokinetics in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2655218/),[ng] / [ml],227,171594,DB00091,Cyclosporine
,2655218,trough level,"When dosed according to ABW, obese recipients of renal allografts had a mean serum RIA trough level of 227 ng/ml as compared to 121 ng/ml in nonobese recipients on day 7.",The impact of body weight on cyclosporine pharmacokinetics in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2655218/),[ng] / [ml],121,171595,DB00091,Cyclosporine
,11245398,LD50,"Male Wistar rats were administered either water or two different doses of parathion (1/100 LD50, 1/25 LD50; LD50 = 14 mg/kg) by gavage for 6 wk.",Effects of subchronic parathion exposure on cyclosporine pharmacokinetics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11245398/),[mg] / [kg],14,171596,DB00091,Cyclosporine
,9850449,trough CsA concentration,"Whole blood trough CsA concentration was not altered by glipizide treatment, 256 +/- 76 micrograms/L off and 242 +/- 73 micrograms/L (mean +/- SD) with glipizide coadministration.",Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850449/),[μg] / [l],256,171804,DB00091,Cyclosporine
,9850449,trough CsA concentration,"Whole blood trough CsA concentration was not altered by glipizide treatment, 256 +/- 76 micrograms/L off and 242 +/- 73 micrograms/L (mean +/- SD) with glipizide coadministration.",Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850449/),[μg] / [l],242,171805,DB00091,Cyclosporine
,9850449,area under the curve (AUC),"The area under the curve (AUC) and terminal half-life of CsA remained unchanged with glipizide treatment: 6391 +/- 1483 micrograms/L per h and 7.3 +/- 1.5 h without; and 6279 +/- 1601 micrograms/L per h and 7.1 +/- 1.8 h with glipizide, respectively.",Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850449/),[μg] / [h·l],6391,171806,DB00091,Cyclosporine
,9850449,area under the curve (AUC),"The area under the curve (AUC) and terminal half-life of CsA remained unchanged with glipizide treatment: 6391 +/- 1483 micrograms/L per h and 7.3 +/- 1.5 h without; and 6279 +/- 1601 micrograms/L per h and 7.1 +/- 1.8 h with glipizide, respectively.",Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850449/),[μg] / [h·l],6279,171807,DB00091,Cyclosporine
,9850449,terminal half-life,"The area under the curve (AUC) and terminal half-life of CsA remained unchanged with glipizide treatment: 6391 +/- 1483 micrograms/L per h and 7.3 +/- 1.5 h without; and 6279 +/- 1601 micrograms/L per h and 7.1 +/- 1.8 h with glipizide, respectively.",Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850449/),h,7.3,171808,DB00091,Cyclosporine
,9850449,terminal half-life,"The area under the curve (AUC) and terminal half-life of CsA remained unchanged with glipizide treatment: 6391 +/- 1483 micrograms/L per h and 7.3 +/- 1.5 h without; and 6279 +/- 1601 micrograms/L per h and 7.1 +/- 1.8 h with glipizide, respectively.",Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850449/),h,7.1,171809,DB00091,Cyclosporine
,9850449,peak concentration (Cmax),No change in the CsA peak concentration (Cmax) was observed: 1507 +/- 406 micrograms/L without and 1469 +/- 538 micrograms/L with glipizide coadministration.,Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850449/),[μg] / [l],1507,171810,DB00091,Cyclosporine
,9850449,peak concentration (Cmax),No change in the CsA peak concentration (Cmax) was observed: 1507 +/- 406 micrograms/L without and 1469 +/- 538 micrograms/L with glipizide coadministration.,Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850449/),[μg] / [l],1469,171811,DB00091,Cyclosporine
<,22549498,AUC,"Similarly, the number of patients underexposed to MPA (AUC < 30 ng·h/mL) was higher at most periods in the PPI group but again not statistically significant.",Diminished mycophenolic acid exposure caused by omeprazole may be clinically relevant in the first week posttransplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22549498/),[h·ng] / [ml],30,171979,DB00091,Cyclosporine
,7667170,trough C,"Even though the mean daily dosage of CsA was consistently higher in the carbamazepine group than in the control group (16.2 mg/kg/24 hrs vs 10.8 mg/kg/24 hrs, respectively), the predose trough CsA blood concentrations were significantly lower in the carbamazepine group (57 ng/ml vs 162 ng/ml, respectively; p = 0.0023).",Effects of carbamazepine on cyclosporine metabolism in pediatric renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7667170/),[ng] / [ml],57,172083,DB00091,Cyclosporine
,7667170,trough C,"Even though the mean daily dosage of CsA was consistently higher in the carbamazepine group than in the control group (16.2 mg/kg/24 hrs vs 10.8 mg/kg/24 hrs, respectively), the predose trough CsA blood concentrations were significantly lower in the carbamazepine group (57 ng/ml vs 162 ng/ml, respectively; p = 0.0023).",Effects of carbamazepine on cyclosporine metabolism in pediatric renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7667170/),[ng] / [ml],162,172084,DB00091,Cyclosporine
,7667170,blood concentrations,"Even though the mean daily dosage of CsA was consistently higher in the carbamazepine group than in the control group (16.2 mg/kg/24 hrs vs 10.8 mg/kg/24 hrs, respectively), the predose trough CsA blood concentrations were significantly lower in the carbamazepine group (57 ng/ml vs 162 ng/ml, respectively; p = 0.0023).",Effects of carbamazepine on cyclosporine metabolism in pediatric renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7667170/),[ng] / [ml],57,172085,DB00091,Cyclosporine
,7667170,blood concentrations,"Even though the mean daily dosage of CsA was consistently higher in the carbamazepine group than in the control group (16.2 mg/kg/24 hrs vs 10.8 mg/kg/24 hrs, respectively), the predose trough CsA blood concentrations were significantly lower in the carbamazepine group (57 ng/ml vs 162 ng/ml, respectively; p = 0.0023).",Effects of carbamazepine on cyclosporine metabolism in pediatric renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7667170/),[ng] / [ml],162,172086,DB00091,Cyclosporine
,10385211,area under the blood cyclosporin concentration-time curve after oral administration (AUCpo),The area under the blood cyclosporin concentration-time curve after oral administration (AUCpo) were 4.976+/-0.847 mghL(-1) for ARF rats and 9.684+/-1.100 mghL(-1) for control rats; AUCpo in ARF was significantly reduced in a manner dependent on renal function.,Influence of glycerol-induced acute renal failure on the pharmacokinetics of cyclosporin in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10385211/),1/[mghl],4.976,172087,DB00091,Cyclosporine
,10385211,area under the blood cyclosporin concentration-time curve after oral administration (AUCpo),The area under the blood cyclosporin concentration-time curve after oral administration (AUCpo) were 4.976+/-0.847 mghL(-1) for ARF rats and 9.684+/-1.100 mghL(-1) for control rats; AUCpo in ARF was significantly reduced in a manner dependent on renal function.,Influence of glycerol-induced acute renal failure on the pharmacokinetics of cyclosporin in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10385211/),1/[mghl],9.684,172088,DB00091,Cyclosporine
,10385211,oral clearance,"The oral clearance of cyclosporin in ARF and control rats was 1.172+/-0.207 and 0.544+/-0.062Lh(-1) kg(-1), respectively, whereas total body clearance in ARF and control rats was 0.151+/-0.008 and 0.183+/-0.010Lh(-1)kg(-1), respectively.",Influence of glycerol-induced acute renal failure on the pharmacokinetics of cyclosporin in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10385211/),1/[kg·lh],1.172,172089,DB00091,Cyclosporine
,10385211,oral clearance,"The oral clearance of cyclosporin in ARF and control rats was 1.172+/-0.207 and 0.544+/-0.062Lh(-1) kg(-1), respectively, whereas total body clearance in ARF and control rats was 0.151+/-0.008 and 0.183+/-0.010Lh(-1)kg(-1), respectively.",Influence of glycerol-induced acute renal failure on the pharmacokinetics of cyclosporin in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10385211/),1/[kg·lh],0.544,172090,DB00091,Cyclosporine
,10385211,total body clearance,"The oral clearance of cyclosporin in ARF and control rats was 1.172+/-0.207 and 0.544+/-0.062Lh(-1) kg(-1), respectively, whereas total body clearance in ARF and control rats was 0.151+/-0.008 and 0.183+/-0.010Lh(-1)kg(-1), respectively.",Influence of glycerol-induced acute renal failure on the pharmacokinetics of cyclosporin in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10385211/),1/[lh],0.151,172091,DB00091,Cyclosporine
,10385211,total body clearance,"The oral clearance of cyclosporin in ARF and control rats was 1.172+/-0.207 and 0.544+/-0.062Lh(-1) kg(-1), respectively, whereas total body clearance in ARF and control rats was 0.151+/-0.008 and 0.183+/-0.010Lh(-1)kg(-1), respectively.",Influence of glycerol-induced acute renal failure on the pharmacokinetics of cyclosporin in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10385211/),1/[lh],0.183,172092,DB00091,Cyclosporine
,10385211,relative bioavailability,"The relative bioavailability of cyclosporin in ARF and control rats was 0.118 and 0.336, respectively.",Influence of glycerol-induced acute renal failure on the pharmacokinetics of cyclosporin in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10385211/),,0.118,172093,DB00091,Cyclosporine
,10385211,relative bioavailability,"The relative bioavailability of cyclosporin in ARF and control rats was 0.118 and 0.336, respectively.",Influence of glycerol-induced acute renal failure on the pharmacokinetics of cyclosporin in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10385211/),,0.336,172094,DB00091,Cyclosporine
,18641543,AUC,"The mean MPA AUC as well as the standard deviation was much greater in the SRL group, 56.4 +/- 23.5 mg.h/L, compared with 30.4 +/- 11.0 mg.h/L in the cyclosporine group (P < 0.001).",Development of a predictive limited sampling strategy for estimation of mycophenolic acid area under the concentration time curve in patients receiving concomitant sirolimus or cyclosporine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641543/),[h·mg] / [l],56.4,172406,DB00091,Cyclosporine
,18641543,AUC,"The mean MPA AUC as well as the standard deviation was much greater in the SRL group, 56.4 +/- 23.5 mg.h/L, compared with 30.4 +/- 11.0 mg.h/L in the cyclosporine group (P < 0.001).",Development of a predictive limited sampling strategy for estimation of mycophenolic acid area under the concentration time curve in patients receiving concomitant sirolimus or cyclosporine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641543/),[h·mg] / [l],30.4,172407,DB00091,Cyclosporine
,18641543,maximum concentration,Mean maximum concentration was also greater in the SRL group: 16.4 +/- 7.7 mg/L versus 11.7 +/- 7.1mg/L (P < 0.005).,Development of a predictive limited sampling strategy for estimation of mycophenolic acid area under the concentration time curve in patients receiving concomitant sirolimus or cyclosporine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641543/),[mg] / [l],16.4,172408,DB00091,Cyclosporine
,18641543,maximum concentration,Mean maximum concentration was also greater in the SRL group: 16.4 +/- 7.7 mg/L versus 11.7 +/- 7.1mg/L (P < 0.005).,Development of a predictive limited sampling strategy for estimation of mycophenolic acid area under the concentration time curve in patients receiving concomitant sirolimus or cyclosporine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641543/),[mg] / [l],11.7,172409,DB00091,Cyclosporine
,10684356,trough concentration,"We recently published pharmacokinetic (PK) profiles of MMF in combination with tacrolimus (FK506): in order to keep the mycophenolic acid (MPA) pre-dose trough concentration between 2 and 5 microg/ml and to avoid side effects, mean MMF doses were reduced to 300 mg/m(2) b.i.d.",Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684356/),[μg] / [ml],2 and 5,173014,DB00091,Cyclosporine
,10684356,area under the curve (AUC),Mean area under the curve (AUC) in all PK profiles was 61.9+/-23.8 microgxh/ml.,Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684356/),[h·μg] / [ml],61.9,173015,DB00091,Cyclosporine
,25540593,AUC,"The mean AUC was 39.49 mg-h/L (28.39-89.58 mg-h/L), which was in the therapeutic range.",Mycophenolic acid AUC in Thai kidney transplant recipients receiving low dose mycophenolate and its association with UGT2B7 polymorphisms. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25540593/),[mg-h] / [l],39.49,173022,DB00091,Cyclosporine
,18547379,area under the curve from 0-12 h (AUC(0-12)),"Co-administration of orange juice with CsA compared with water did not significantly increase the area under the curve from 0-12 h (AUC(0-12)) of CsA (orange juice 2833 +/- 553, water 3053 +/- 1532, p > 0.05).",Serum cyclosporine level and orange juice in pediatric renal-transplanted patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18547379/),,2833,173245,DB00091,Cyclosporine
,18547379,area under the curve from 0-12 h (AUC(0-12)),"Co-administration of orange juice with CsA compared with water did not significantly increase the area under the curve from 0-12 h (AUC(0-12)) of CsA (orange juice 2833 +/- 553, water 3053 +/- 1532, p > 0.05).",Serum cyclosporine level and orange juice in pediatric renal-transplanted patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18547379/),,3053,173246,DB00091,Cyclosporine
,33928146,absorption constant (ka),"Population estimates for the absorption constant (ka) and lag time were 0.523 h-1 and 0.512 h, respectively; apparent clearance (CL/F) was 30.3 L/h (relative standard error [RSE] ± 8.25%) with an interindividual variability of 39.8% and interoccasion variability of 38.0%; meanwhile, apparent clearance of distribution (Q/F) was 17.0 L/h (RSE ± 12.1%) with and interindividual variability of 53.2%.",Development of a Population Pharmacokinetic Model for Cyclosporine from Therapeutic Drug Monitoring Data. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33928146/),1/[h],0.523,173262,DB00091,Cyclosporine
,33928146,lag time,"Population estimates for the absorption constant (ka) and lag time were 0.523 h-1 and 0.512 h, respectively; apparent clearance (CL/F) was 30.3 L/h (relative standard error [RSE] ± 8.25%) with an interindividual variability of 39.8% and interoccasion variability of 38.0%; meanwhile, apparent clearance of distribution (Q/F) was 17.0 L/h (RSE ± 12.1%) with and interindividual variability of 53.2%.",Development of a Population Pharmacokinetic Model for Cyclosporine from Therapeutic Drug Monitoring Data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33928146/),h,0.512,173263,DB00091,Cyclosporine
,33928146,apparent clearance (CL/F),"Population estimates for the absorption constant (ka) and lag time were 0.523 h-1 and 0.512 h, respectively; apparent clearance (CL/F) was 30.3 L/h (relative standard error [RSE] ± 8.25%) with an interindividual variability of 39.8% and interoccasion variability of 38.0%; meanwhile, apparent clearance of distribution (Q/F) was 17.0 L/h (RSE ± 12.1%) with and interindividual variability of 53.2%.",Development of a Population Pharmacokinetic Model for Cyclosporine from Therapeutic Drug Monitoring Data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33928146/),[l] / [h],30.3,173264,DB00091,Cyclosporine
,33928146,apparent clearance of distribution (Q/F),"Population estimates for the absorption constant (ka) and lag time were 0.523 h-1 and 0.512 h, respectively; apparent clearance (CL/F) was 30.3 L/h (relative standard error [RSE] ± 8.25%) with an interindividual variability of 39.8% and interoccasion variability of 38.0%; meanwhile, apparent clearance of distribution (Q/F) was 17.0 L/h (RSE ± 12.1%) with and interindividual variability of 53.2%.",Development of a Population Pharmacokinetic Model for Cyclosporine from Therapeutic Drug Monitoring Data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33928146/),[l] / [h],17.0,173265,DB00091,Cyclosporine
,1958443,oral availability,3. The mean oral availability of cyclosporine was 20.6% (range 10.8-34.1%).,Evidence for pre-hepatic metabolism of oral cyclosporine in children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1958443/),%,20.6,173501,DB00091,Cyclosporine
,20209646,maximum tolerated dose (MTD),"The maximum tolerated dose (MTD) of valspodar was 12.5 mg/kg/day, combined with 50% dose-reduced mitoxantrone and etoposide.",Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20209646/),[mg] / [d·kg],12.5,173804,DB00091,Cyclosporine
,22404324,dose-normalized C(max),"For levofloxacin, the mean values for dose-normalized C(max) and AUC(last) with the two doses were as follows: therapeutic dose, 15.2 ± 4.6 ng/ml/mg and 103.6 ± 15.5 ng·h/ml/mg, respectively; low dose, 17.1 ± 6.5 ng/ml/mg and 72.6 ± 8.7 ng·h/ml/mg, respectively.",Assessment of pharmacokinetic proportionality of levofloxacin and cyclosporine over a 100-fold dose range in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22404324/),[ng] / [mg·ml],15.2,173962,DB00091,Cyclosporine
,22404324,dose-normalized C(max),"For levofloxacin, the mean values for dose-normalized C(max) and AUC(last) with the two doses were as follows: therapeutic dose, 15.2 ± 4.6 ng/ml/mg and 103.6 ± 15.5 ng·h/ml/mg, respectively; low dose, 17.1 ± 6.5 ng/ml/mg and 72.6 ± 8.7 ng·h/ml/mg, respectively.",Assessment of pharmacokinetic proportionality of levofloxacin and cyclosporine over a 100-fold dose range in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22404324/),[ng] / [mg·ml],17.1,173963,DB00091,Cyclosporine
,22404324,AUC(last),"For levofloxacin, the mean values for dose-normalized C(max) and AUC(last) with the two doses were as follows: therapeutic dose, 15.2 ± 4.6 ng/ml/mg and 103.6 ± 15.5 ng·h/ml/mg, respectively; low dose, 17.1 ± 6.5 ng/ml/mg and 72.6 ± 8.7 ng·h/ml/mg, respectively.",Assessment of pharmacokinetic proportionality of levofloxacin and cyclosporine over a 100-fold dose range in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22404324/),[h·ng] / [mg·ml],103.6,173964,DB00091,Cyclosporine
,22404324,AUC(last),"For levofloxacin, the mean values for dose-normalized C(max) and AUC(last) with the two doses were as follows: therapeutic dose, 15.2 ± 4.6 ng/ml/mg and 103.6 ± 15.5 ng·h/ml/mg, respectively; low dose, 17.1 ± 6.5 ng/ml/mg and 72.6 ± 8.7 ng·h/ml/mg, respectively.",Assessment of pharmacokinetic proportionality of levofloxacin and cyclosporine over a 100-fold dose range in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22404324/),[ng] / [mg·ml],17.1,173965,DB00091,Cyclosporine
,22404324,AUC(last),"For levofloxacin, the mean values for dose-normalized C(max) and AUC(last) with the two doses were as follows: therapeutic dose, 15.2 ± 4.6 ng/ml/mg and 103.6 ± 15.5 ng·h/ml/mg, respectively; low dose, 17.1 ± 6.5 ng/ml/mg and 72.6 ± 8.7 ng·h/ml/mg, respectively.",Assessment of pharmacokinetic proportionality of levofloxacin and cyclosporine over a 100-fold dose range in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22404324/),[h·ng] / [mg·ml],72.6,173966,DB00091,Cyclosporine
,22404324,dose-normalized C(max),"For cyclosporine, the mean values for dose-normalized C(max) and AUC(last) were as follows: therapeutic dose, 4.9 ± 1.5 ng/ml/mg and 15.4 ± 4.9 ng·h/ml/mg, respectively; low dose, 1.6 ± 0.6 ng/ml/mg and 9.3 ± 7.3 ng·h/ml/mg, respectively.",Assessment of pharmacokinetic proportionality of levofloxacin and cyclosporine over a 100-fold dose range in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22404324/),[ng] / [mg·ml],4.9,173967,DB00091,Cyclosporine
,22404324,dose-normalized C(max),"For cyclosporine, the mean values for dose-normalized C(max) and AUC(last) were as follows: therapeutic dose, 4.9 ± 1.5 ng/ml/mg and 15.4 ± 4.9 ng·h/ml/mg, respectively; low dose, 1.6 ± 0.6 ng/ml/mg and 9.3 ± 7.3 ng·h/ml/mg, respectively.",Assessment of pharmacokinetic proportionality of levofloxacin and cyclosporine over a 100-fold dose range in healthy human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22404324/),[ng] / [mg·ml],1.6,173968,DB00091,Cyclosporine
,22404324,AUC(last),"For cyclosporine, the mean values for dose-normalized C(max) and AUC(last) were as follows: therapeutic dose, 4.9 ± 1.5 ng/ml/mg and 15.4 ± 4.9 ng·h/ml/mg, respectively; low dose, 1.6 ± 0.6 ng/ml/mg and 9.3 ± 7.3 ng·h/ml/mg, respectively.",Assessment of pharmacokinetic proportionality of levofloxacin and cyclosporine over a 100-fold dose range in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22404324/),[ng] / [mg·ml],4.9,173969,DB00091,Cyclosporine
,22404324,AUC(last),"For cyclosporine, the mean values for dose-normalized C(max) and AUC(last) were as follows: therapeutic dose, 4.9 ± 1.5 ng/ml/mg and 15.4 ± 4.9 ng·h/ml/mg, respectively; low dose, 1.6 ± 0.6 ng/ml/mg and 9.3 ± 7.3 ng·h/ml/mg, respectively.",Assessment of pharmacokinetic proportionality of levofloxacin and cyclosporine over a 100-fold dose range in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22404324/),[h·ng] / [mg·ml],15.4,173970,DB00091,Cyclosporine
,22404324,AUC(last),"For cyclosporine, the mean values for dose-normalized C(max) and AUC(last) were as follows: therapeutic dose, 4.9 ± 1.5 ng/ml/mg and 15.4 ± 4.9 ng·h/ml/mg, respectively; low dose, 1.6 ± 0.6 ng/ml/mg and 9.3 ± 7.3 ng·h/ml/mg, respectively.",Assessment of pharmacokinetic proportionality of levofloxacin and cyclosporine over a 100-fold dose range in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22404324/),[ng] / [mg·ml],1.6,173971,DB00091,Cyclosporine
,22404324,AUC(last),"For cyclosporine, the mean values for dose-normalized C(max) and AUC(last) were as follows: therapeutic dose, 4.9 ± 1.5 ng/ml/mg and 15.4 ± 4.9 ng·h/ml/mg, respectively; low dose, 1.6 ± 0.6 ng/ml/mg and 9.3 ± 7.3 ng·h/ml/mg, respectively.",Assessment of pharmacokinetic proportionality of levofloxacin and cyclosporine over a 100-fold dose range in healthy human volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22404324/),[h·ng] / [mg·ml],9.3,173972,DB00091,Cyclosporine
,22616181,T1/2,"After receiving single dose of 400 mg of Cyclosporine A, the pharmacokinetic parameters of T1/2, Cmax, Tmax, and AUC0-t, of Cyclosporin A were (10.114 +/- 6.329) h and (9.717 +/- 4.076) h, (2021.235 +/- 298.581) ng x ml(-1) and (1992.192 +/- 1286.923) ng x ml(-1) (1.729 +/- 0.361) h and (1.813 +/- 0.323) h, (9824.811 +/- 1633.026) ng x h x ml(-1) and (10316.514 +/- 1395.955) ng x h x ml(-1) for test preparation and reference preparation, respectively.",[Bioequivalence research of cyclosporin soft capsules]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22616181/),h,10.114,174462,DB00091,Cyclosporine
,22616181,Cmax,"After receiving single dose of 400 mg of Cyclosporine A, the pharmacokinetic parameters of T1/2, Cmax, Tmax, and AUC0-t, of Cyclosporin A were (10.114 +/- 6.329) h and (9.717 +/- 4.076) h, (2021.235 +/- 298.581) ng x ml(-1) and (1992.192 +/- 1286.923) ng x ml(-1) (1.729 +/- 0.361) h and (1.813 +/- 0.323) h, (9824.811 +/- 1633.026) ng x h x ml(-1) and (10316.514 +/- 1395.955) ng x h x ml(-1) for test preparation and reference preparation, respectively.",[Bioequivalence research of cyclosporin soft capsules]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22616181/),[ng] / [ml],2021.235,174463,DB00091,Cyclosporine
,22616181,AUC0-t,"After receiving single dose of 400 mg of Cyclosporine A, the pharmacokinetic parameters of T1/2, Cmax, Tmax, and AUC0-t, of Cyclosporin A were (10.114 +/- 6.329) h and (9.717 +/- 4.076) h, (2021.235 +/- 298.581) ng x ml(-1) and (1992.192 +/- 1286.923) ng x ml(-1) (1.729 +/- 0.361) h and (1.813 +/- 0.323) h, (9824.811 +/- 1633.026) ng x h x ml(-1) and (10316.514 +/- 1395.955) ng x h x ml(-1) for test preparation and reference preparation, respectively.",[Bioequivalence research of cyclosporin soft capsules]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22616181/),h,1.729,174464,DB00091,Cyclosporine
,22616181,AUC0-t,"After receiving single dose of 400 mg of Cyclosporine A, the pharmacokinetic parameters of T1/2, Cmax, Tmax, and AUC0-t, of Cyclosporin A were (10.114 +/- 6.329) h and (9.717 +/- 4.076) h, (2021.235 +/- 298.581) ng x ml(-1) and (1992.192 +/- 1286.923) ng x ml(-1) (1.729 +/- 0.361) h and (1.813 +/- 0.323) h, (9824.811 +/- 1633.026) ng x h x ml(-1) and (10316.514 +/- 1395.955) ng x h x ml(-1) for test preparation and reference preparation, respectively.",[Bioequivalence research of cyclosporin soft capsules]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22616181/),h,1.813,174465,DB00091,Cyclosporine
,22616181,AUC0-t,"After receiving single dose of 400 mg of Cyclosporine A, the pharmacokinetic parameters of T1/2, Cmax, Tmax, and AUC0-t, of Cyclosporin A were (10.114 +/- 6.329) h and (9.717 +/- 4.076) h, (2021.235 +/- 298.581) ng x ml(-1) and (1992.192 +/- 1286.923) ng x ml(-1) (1.729 +/- 0.361) h and (1.813 +/- 0.323) h, (9824.811 +/- 1633.026) ng x h x ml(-1) and (10316.514 +/- 1395.955) ng x h x ml(-1) for test preparation and reference preparation, respectively.",[Bioequivalence research of cyclosporin soft capsules]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22616181/),[h·ng] / [ml],9824.811,174466,DB00091,Cyclosporine
,22616181,AUC0-t,"After receiving single dose of 400 mg of Cyclosporine A, the pharmacokinetic parameters of T1/2, Cmax, Tmax, and AUC0-t, of Cyclosporin A were (10.114 +/- 6.329) h and (9.717 +/- 4.076) h, (2021.235 +/- 298.581) ng x ml(-1) and (1992.192 +/- 1286.923) ng x ml(-1) (1.729 +/- 0.361) h and (1.813 +/- 0.323) h, (9824.811 +/- 1633.026) ng x h x ml(-1) and (10316.514 +/- 1395.955) ng x h x ml(-1) for test preparation and reference preparation, respectively.",[Bioequivalence research of cyclosporin soft capsules]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22616181/),[h·ng] / [ml],10316.514,174467,DB00091,Cyclosporine
,16580159,encapsulation rate,The encapsulation rate of SLN was found to be 96.1%.,Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580159/),%,96.1,174594,DB00091,Cyclosporine
above,16580159,plasma peak,"The blood profiles observed after oral administration of the commercial microemulsion Sandimmun revealed a fast absorption of drug leading to the observation of a plasma peak above 1,000 ng/ml within the first 2 h.",Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16580159/),[ng] / [ml],1,174595,DB00091,Cyclosporine
,26114223,clearance,Tacrolimus clearance decreased gradually throughout the entire first year but only in CYP3A5*3/*3 homozygous recipients (25.6 ± 11.1 l h(-1) at day 7; 17 ± 9.1 l h(-1) at month 12; P < 0.001).,Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26114223/),[l] / [h],25.6,174693,DB00091,Cyclosporine
,26114223,clearance,Tacrolimus clearance decreased gradually throughout the entire first year but only in CYP3A5*3/*3 homozygous recipients (25.6 ± 11.1 l h(-1) at day 7; 17 ± 9.1 l h(-1) at month 12; P < 0.001).,Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26114223/),[l] / [h],17,174694,DB00091,Cyclosporine
,26114223,apparent oral MDZ clearance,"In mixed model analysis, decreasing CYP3A4 activity, measured by apparent oral MDZ clearance (924 ± 443 ml min(-1) at day 7 vs.",Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26114223/),[ml] / [min],924,174695,DB00091,Cyclosporine
,24649882,plasma concentrations,"Median (range) telaprevir plasma concentrations of TW 4, 8 and 12 were 3970 (1980-4430) ng/ml and 2520 (1870-8730) ng/ml in patients after OLT and ciclosporin- or tacrolimus-based IS, respectively, as compared to 2790 (1870-3140) in non-OLT patients (P = 0.3).",Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24649882/),[ng] / [ml],3970,175021,DB00091,Cyclosporine
,24649882,plasma concentrations,"Median (range) telaprevir plasma concentrations of TW 4, 8 and 12 were 3970 (1980-4430) ng/ml and 2520 (1870-8730) ng/ml in patients after OLT and ciclosporin- or tacrolimus-based IS, respectively, as compared to 2790 (1870-3140) in non-OLT patients (P = 0.3).",Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24649882/),[ng] / [ml],2520,175022,DB00091,Cyclosporine
,24649882,plasma concentrations,"Median (range) telaprevir plasma concentrations of TW 4, 8 and 12 were 3970 (1980-4430) ng/ml and 2520 (1870-8730) ng/ml in patients after OLT and ciclosporin- or tacrolimus-based IS, respectively, as compared to 2790 (1870-3140) in non-OLT patients (P = 0.3).",Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24649882/),,2790,175023,DB00091,Cyclosporine
,19034006,C2,"Elderly patients achieved target C2 levels with lower CsA doses than the younger patients (4.3+/-0.8 vs. 6.1+/-2.1 mg/day/kg, P=0.025) because of lower clearance of CsA (22.7+/-5.1 vs. 30.5+/-11.1 L/hr, P=0.031).",Reduced elimination of cyclosporine A in elderly (>65 years) kidney transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034006/),[mg] / [d·kg],4.3,175051,DB00091,Cyclosporine
,19034006,C2,"Elderly patients achieved target C2 levels with lower CsA doses than the younger patients (4.3+/-0.8 vs. 6.1+/-2.1 mg/day/kg, P=0.025) because of lower clearance of CsA (22.7+/-5.1 vs. 30.5+/-11.1 L/hr, P=0.031).",Reduced elimination of cyclosporine A in elderly (>65 years) kidney transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034006/),[mg] / [d·kg],6.1,175052,DB00091,Cyclosporine
,19034006,clearance,"Elderly patients achieved target C2 levels with lower CsA doses than the younger patients (4.3+/-0.8 vs. 6.1+/-2.1 mg/day/kg, P=0.025) because of lower clearance of CsA (22.7+/-5.1 vs. 30.5+/-11.1 L/hr, P=0.031).",Reduced elimination of cyclosporine A in elderly (>65 years) kidney transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034006/),[l] / [h],22.7,175053,DB00091,Cyclosporine
,19034006,clearance,"Elderly patients achieved target C2 levels with lower CsA doses than the younger patients (4.3+/-0.8 vs. 6.1+/-2.1 mg/day/kg, P=0.025) because of lower clearance of CsA (22.7+/-5.1 vs. 30.5+/-11.1 L/hr, P=0.031).",Reduced elimination of cyclosporine A in elderly (>65 years) kidney transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034006/),[l] / [h],30.5,175054,DB00091,Cyclosporine
,8900303,trough level,While on therapy with the standard formulation at a mean daily dose+/-SD of 231+/-101.8 mg patients had a mean cyclosporine trough level of 188.7+/-51.4 ng/ml.,Conversion and pharmacokinetic studies of a microemulsion formulation of cyclosporine in pediatric liver transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8900303/),[ng] / [ml],188.7,175669,DB00091,Cyclosporine
,8900303,trough level,The mean cyclosporine trough level at this point was 221.5+/-69.7 ng/ml.,Conversion and pharmacokinetic studies of a microemulsion formulation of cyclosporine in pediatric liver transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8900303/),[ng] / [ml],221.5,175670,DB00091,Cyclosporine
,8900303,maximum concentration,"The pharmacokinetic study of the microemulsion in 11 patients showed a monophasic curve, with an early absorption at 30 min and maximum concentration+/-SD of 880.8+/-72.8 ng/ml and time to maximum concentration of 1.5+/-0.12 hr.",Conversion and pharmacokinetic studies of a microemulsion formulation of cyclosporine in pediatric liver transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8900303/),[ng] / [ml],880.8,175671,DB00091,Cyclosporine
,8900303,time to maximum concentration,"The pharmacokinetic study of the microemulsion in 11 patients showed a monophasic curve, with an early absorption at 30 min and maximum concentration+/-SD of 880.8+/-72.8 ng/ml and time to maximum concentration of 1.5+/-0.12 hr.",Conversion and pharmacokinetic studies of a microemulsion formulation of cyclosporine in pediatric liver transplant patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8900303/),h,1.5,175672,DB00091,Cyclosporine
,3254764,plasma magnesium concentration,"2. After 7 days of cyclosporin treatment, plasma magnesium concentration was 1.04 +/- 0.01 mmol/l in control rats compared with 0.85 +/- 0.01 mmol/l in group II and 0.81 +/- 0.02 mmol/l in group III.",Cyclosporin-induced hypomagnesaemia and renal magnesium wasting in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3254764/),[mM] / [l],1.04,175718,DB00091,Cyclosporine
,3254764,plasma magnesium concentration,"2. After 7 days of cyclosporin treatment, plasma magnesium concentration was 1.04 +/- 0.01 mmol/l in control rats compared with 0.85 +/- 0.01 mmol/l in group II and 0.81 +/- 0.02 mmol/l in group III.",Cyclosporin-induced hypomagnesaemia and renal magnesium wasting in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3254764/),[mM] / [l],0.85,175719,DB00091,Cyclosporine
,3254764,plasma magnesium concentration,"2. After 7 days of cyclosporin treatment, plasma magnesium concentration was 1.04 +/- 0.01 mmol/l in control rats compared with 0.85 +/- 0.01 mmol/l in group II and 0.81 +/- 0.02 mmol/l in group III.",Cyclosporin-induced hypomagnesaemia and renal magnesium wasting in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3254764/),[mM] / [l],0.81,175720,DB00091,Cyclosporine
,7617533,terminal elimination half life,"The terminal elimination half life from these tissues was 45 hr and 30 hr, respectively, providing evidence that these tissues could act as a reservoir for the drug.",A compartmental model for the ocular pharmacokinetics of cyclosporine in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7617533/),h,45,175738,DB00091,Cyclosporine
,7617533,terminal elimination half life,"The terminal elimination half life from these tissues was 45 hr and 30 hr, respectively, providing evidence that these tissues could act as a reservoir for the drug.",A compartmental model for the ocular pharmacokinetics of cyclosporine in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7617533/),h,30,175739,DB00091,Cyclosporine
,3891122,clearance,"The clearance (10.4 +/- 5.41 1/h), half-life (26.4 +/- 14.6 h), and bioavailability (16% +/- 10%) calculated directly from experimental data showed wide interindividual variations.",Clinical pharmacokinetics of ciclosporin A in bone marrow transplantation patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3891122/),[1] / [h],10.4,176512,DB00091,Cyclosporine
,3891122,half-life,"The clearance (10.4 +/- 5.41 1/h), half-life (26.4 +/- 14.6 h), and bioavailability (16% +/- 10%) calculated directly from experimental data showed wide interindividual variations.",Clinical pharmacokinetics of ciclosporin A in bone marrow transplantation patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3891122/),h,26.4,176513,DB00091,Cyclosporine
,3891122,bioavailability,"The clearance (10.4 +/- 5.41 1/h), half-life (26.4 +/- 14.6 h), and bioavailability (16% +/- 10%) calculated directly from experimental data showed wide interindividual variations.",Clinical pharmacokinetics of ciclosporin A in bone marrow transplantation patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3891122/),%,16,176514,DB00091,Cyclosporine
,23736966,EC50,PKPD correlation indicated an EC50 of 78.3 ± 6.8 ng/mL.,Voclosporin food effect and single oral ascending dose pharmacokinetic and pharmacodynamic studies in healthy human subjects. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23736966/),[ng] / [ml],78.3,176549,DB00091,Cyclosporine
,9871094,plasma clearance,"The mean plasma clearance of 99mTc-DACH was significantly greater than that of 51Cr-EDTA in volunteers (109.4¿19.7 ml/min versus 86.6 +/- 13.7 ml/min, P<0.05).",Evaluation of renal function in low-dose cyclosporine-treated patients using technetium-99m diaminocyclohexane: a cationic tubular excretion agent. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871094/),[ml] / [min],109.4,176556,DB00091,Cyclosporine
,9871094,plasma clearance,"The mean plasma clearance of 99mTc-DACH was significantly greater than that of 51Cr-EDTA in volunteers (109.4¿19.7 ml/min versus 86.6 +/- 13.7 ml/min, P<0.05).",Evaluation of renal function in low-dose cyclosporine-treated patients using technetium-99m diaminocyclohexane: a cationic tubular excretion agent. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871094/),[ml] / [min],86.6,176557,DB00091,Cyclosporine
,9871094,urinary excretion,"However, the urinary excretion of 99mTc-DACH at 90 min was significantly lower than that of 51Cr-EDTA (46.1% +/- 9.3% versus 53.1% +/- 8.6%, P<0.05), most probably due to its partial parenchymal retention.",Evaluation of renal function in low-dose cyclosporine-treated patients using technetium-99m diaminocyclohexane: a cationic tubular excretion agent. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871094/),%,46.1,176558,DB00091,Cyclosporine
,9871094,urinary excretion,"However, the urinary excretion of 99mTc-DACH at 90 min was significantly lower than that of 51Cr-EDTA (46.1% +/- 9.3% versus 53.1% +/- 8.6%, P<0.05), most probably due to its partial parenchymal retention.",Evaluation of renal function in low-dose cyclosporine-treated patients using technetium-99m diaminocyclohexane: a cationic tubular excretion agent. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871094/),%,53.1,176559,DB00091,Cyclosporine
,3313841,clearance,In 38 patients on Aza-Po treatment the mean clearance for prednisolone was 0.17 +/- 0.04 1/kg/hr (range 0.11-0.27) and in 39 patients on CsA-Po the mean prednisolone clearance was 0.12 +/- 0.02 (0.07-0.17) (P less than 0.001).,Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),[1] / [h·kg],0.17,176633,DB00091,Cyclosporine
,3313841,clearance,In 38 patients on Aza-Po treatment the mean clearance for prednisolone was 0.17 +/- 0.04 1/kg/hr (range 0.11-0.27) and in 39 patients on CsA-Po the mean prednisolone clearance was 0.12 +/- 0.02 (0.07-0.17) (P less than 0.001).,Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),,0.12,176634,DB00091,Cyclosporine
,3313841,clearance,"Eight patients on CsA-Po were tested on three occasions; prednisolone clearance at 2-4 weeks was 0.13 +/- 0.02 (range 0.11-0.17), at 3-6 months 0.11 +/- 0.01 (0.10-0.12) and at 2-5 years 0.11 +/- 0.02 (0.09-0.14).",Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),,0.13,176635,DB00091,Cyclosporine
,3313841,clearance,"Eight patients on CsA-Po were tested on three occasions; prednisolone clearance at 2-4 weeks was 0.13 +/- 0.02 (range 0.11-0.17), at 3-6 months 0.11 +/- 0.01 (0.10-0.12) and at 2-5 years 0.11 +/- 0.02 (0.09-0.14).",Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),,0.11,176636,DB00091,Cyclosporine
,3313841,clearance,"Eight patients on CsA-Po were tested on three occasions; prednisolone clearance at 2-4 weeks was 0.13 +/- 0.02 (range 0.11-0.17), at 3-6 months 0.11 +/- 0.01 (0.10-0.12) and at 2-5 years 0.11 +/- 0.02 (0.09-0.14).",Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),,0.11,176637,DB00091,Cyclosporine
,3313841,clearance,The prednisolone clearance then decreased from 0.18 +/- 0.05 1/kg/hr (range 0.13-0.27) to 0.12 +/- 0.03 (0.10-0.16) (P less than 0.001).,Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),[1] / [h·kg],0.18,176638,DB00091,Cyclosporine
,3313841,clearance,The prednisolone clearance then decreased from 0.18 +/- 0.05 1/kg/hr (range 0.13-0.27) to 0.12 +/- 0.03 (0.10-0.16) (P less than 0.001).,Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),[1] / [h·kg],0.12,176639,DB00091,Cyclosporine
,3313841,clearance,"When the treatment was changed from CsA-Po to Aza-Po in 2 patients the prednisolone clearance increased from 0.12 and 0.10 to 0.17 and 0.12 1/kg/hr, respectively.",Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),[1] / [h·kg],0.12,176640,DB00091,Cyclosporine
,3313841,clearance,"When the treatment was changed from CsA-Po to Aza-Po in 2 patients the prednisolone clearance increased from 0.12 and 0.10 to 0.17 and 0.12 1/kg/hr, respectively.",Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),[1] / [h·kg],0.10,176641,DB00091,Cyclosporine
,3313841,clearance,"When the treatment was changed from CsA-Po to Aza-Po in 2 patients the prednisolone clearance increased from 0.12 and 0.10 to 0.17 and 0.12 1/kg/hr, respectively.",Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3313841/),[1] / [h·kg],0.17,176642,DB00091,Cyclosporine
,11249778,oral bioavailability,A new formulation of the drug has recently been developed with better oral bioavailability (60%) and less interindividual variability.,"Technology evaluation: Valspodar, Novartis AG. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11249778/),%,60,176839,DB00091,Cyclosporine
,20959500,clearance,"In 6 patients with cancer, vinblastine increased the median (95% CI) clearance of the CYP3A4 phenotyping probe midazolam from 21.7 L/h (12.6 to 28.1) to 32.3 L/h (17.3 to 53.9) (p = 0.0156, Wilcoxon signed-rank test).",Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20959500/),[l] / [h],21.7,177346,DB00091,Cyclosporine
,20959500,clearance,"In 6 patients with cancer, vinblastine increased the median (95% CI) clearance of the CYP3A4 phenotyping probe midazolam from 21.7 L/h (12.6 to 28.1) to 32.3 L/h (17.3 to 53.9) (p = 0.0156, Wilcoxon signed-rank test).",Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20959500/),[l] / [h],32.3,177347,DB00091,Cyclosporine
>,17006328,EC50,"While FTY720-P activated both S1P1 and S1P3 receptors, KRP-203-P selectively activated S1P1, but not the S1P3 receptor (EC50:>1000 nM).","Use of sphingosine-1-phosphate 1 receptor agonist, KRP-203, in combination with a subtherapeutic dose of cyclosporine A for rat renal transplantation. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17006328/),nM,1000,177486,DB00091,Cyclosporine
,17006328,survival time,"With a low dose of CsA (1 mg/kg/day), KRP-203 (0.3 mg/kg/day) significantly prolonged renal allograft survival (P<0.05, survival time: 9.8 days (CsA) vs. >27.4 days (CsA+KRP)).","Use of sphingosine-1-phosphate 1 receptor agonist, KRP-203, in combination with a subtherapeutic dose of cyclosporine A for rat renal transplantation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17006328/),d,9.8,177487,DB00091,Cyclosporine
>,17006328,survival time,"With a low dose of CsA (1 mg/kg/day), KRP-203 (0.3 mg/kg/day) significantly prolonged renal allograft survival (P<0.05, survival time: 9.8 days (CsA) vs. >27.4 days (CsA+KRP)).","Use of sphingosine-1-phosphate 1 receptor agonist, KRP-203, in combination with a subtherapeutic dose of cyclosporine A for rat renal transplantation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17006328/),d,27.4,177488,DB00091,Cyclosporine
,1474170,Cmax,The Cmax for CsA was achieved over a period ranging from 2 to 6 hours (mean/median = 4.7/4.0) during the day 7 and the day 21 studies.,Optimization of sampling time for cyclosporine monitoring in transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1474170/),h,2 to 6,177849,DB00091,Cyclosporine
,1474170,Cmax,The Cmax for CsA was achieved over a period ranging from 2 to 6 hours (mean/median = 4.7/4.0) during the day 7 and the day 21 studies.,Optimization of sampling time for cyclosporine monitoring in transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1474170/),h,4,177850,DB00091,Cyclosporine
,1474170,half-life,"The mean (+/- SD) half-life was 3.2 (1.0) hours on day 7 and 2.9 (1.1) hours on day 21, (P > 0.05); the mean apparent oral clearance was 276 (117) L/hr on the day 7 and 269 (209) L/hr on day 21, (P > 0.05).",Optimization of sampling time for cyclosporine monitoring in transplant patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1474170/),h,3.2,177851,DB00091,Cyclosporine
,1474170,half-life,"The mean (+/- SD) half-life was 3.2 (1.0) hours on day 7 and 2.9 (1.1) hours on day 21, (P > 0.05); the mean apparent oral clearance was 276 (117) L/hr on the day 7 and 269 (209) L/hr on day 21, (P > 0.05).",Optimization of sampling time for cyclosporine monitoring in transplant patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1474170/),h,2.9,177852,DB00091,Cyclosporine
,1474170,apparent oral clearance,"The mean (+/- SD) half-life was 3.2 (1.0) hours on day 7 and 2.9 (1.1) hours on day 21, (P > 0.05); the mean apparent oral clearance was 276 (117) L/hr on the day 7 and 269 (209) L/hr on day 21, (P > 0.05).",Optimization of sampling time for cyclosporine monitoring in transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1474170/),[l] / [h],276,177853,DB00091,Cyclosporine
,1474170,apparent oral clearance,"The mean (+/- SD) half-life was 3.2 (1.0) hours on day 7 and 2.9 (1.1) hours on day 21, (P > 0.05); the mean apparent oral clearance was 276 (117) L/hr on the day 7 and 269 (209) L/hr on day 21, (P > 0.05).",Optimization of sampling time for cyclosporine monitoring in transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1474170/),[l] / [h],269,177854,DB00091,Cyclosporine
,27498124,area under the concentration-time curve from 0 to 12 hours,Mean (± SD) area under the concentration-time curve from 0 to 12 hours was 4805 ± 3265 hour * ng/mL on day 0 and 5917 ± 4048 hour * ng/mL on day +10.,A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27498124/),[h·ng] / [ml],4805,177950,DB00091,Cyclosporine
,27498124,area under the concentration-time curve from 0 to 12 hours,Mean (± SD) area under the concentration-time curve from 0 to 12 hours was 4805 ± 3265 hour * ng/mL on day 0 and 5917 ± 4048 hour * ng/mL on day +10.,A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27498124/),[h·ng] / [ml],5917,177951,DB00091,Cyclosporine
,11335792,time above the threshold concentrations,Dose reduction of CsA from 10 to 5 mg/kg resulted in a statistically significant decrease in the area under the plasma concentration-time curve (AUC) and time above the threshold concentrations of 0.1 microM (T>0.1 microM) of oral paclitaxel.,The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11335792/),μM,0.1,177953,DB00091,Cyclosporine
>,11335792,T,Dose reduction of CsA from 10 to 5 mg/kg resulted in a statistically significant decrease in the area under the plasma concentration-time curve (AUC) and time above the threshold concentrations of 0.1 microM (T>0.1 microM) of oral paclitaxel.,The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11335792/),μM,0.1,177954,DB00091,Cyclosporine
,11335792,AUC,"The mean (+/-SD) AUC and T>0.1 microM values of oral paclitaxel with CsA 10 mg/kg were 4.29+/-0.88 microM x h and 12.0+/-2.1 h, respectively.",The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11335792/),h·μM,4.29,177955,DB00091,Cyclosporine
,11335792,T>0.1,"The mean (+/-SD) AUC and T>0.1 microM values of oral paclitaxel with CsA 10 mg/kg were 4.29+/-0.88 microM x h and 12.0+/-2.1 h, respectively.",The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11335792/),h·μM,4.29,177956,DB00091,Cyclosporine
,11335792,T>0.1,"The mean (+/-SD) AUC and T>0.1 microM values of oral paclitaxel with CsA 10 mg/kg were 4.29+/-0.88 microM x h and 12.0+/-2.1 h, respectively.",The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11335792/),h,12.0,177957,DB00091,Cyclosporine
>,11335792,T,"Because CsA 10 mg/kg resulted in similar paclitaxel AUC and T>0.1 microM values compared to CsA 15 mg/kg (data which we have published previously), the minimally effective dose of CsA is determined at 10 mg/kg.",The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11335792/),μM,0.1,177958,DB00091,Cyclosporine
,7791036,equilibrium blood cell/plasma ratio,"Accumulation of IMM in blood cell is high (equilibrium blood cell/plasma ratio = 8), although the kinetics of drug transference between plasma and blood cell is moderately slow, taking approximately 10 min to reach equilibrium, implying a membrane-limited distribution into blood cells.","Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791036/),,8,177974,DB00091,Cyclosporine
,15592326,absorption rate constant,"For a typical 70-kg white patient, the following parameters were estimated: absorption rate constant, 1.27 h -1; absorption time lag, 0.47 hour; oral volume of distribution of the central and peripheral compartment, 56.3 and 185.0 L, respectively; oral clearance (Cl/F), 30.7 L/h; and oral intercompartmental clearance, 31.7 L/h.","Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592326/),-1·h,1.27,178737,DB00091,Cyclosporine
,15592326,absorption time lag,"For a typical 70-kg white patient, the following parameters were estimated: absorption rate constant, 1.27 h -1; absorption time lag, 0.47 hour; oral volume of distribution of the central and peripheral compartment, 56.3 and 185.0 L, respectively; oral clearance (Cl/F), 30.7 L/h; and oral intercompartmental clearance, 31.7 L/h.","Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592326/),h,0.47,178738,DB00091,Cyclosporine
,15592326,oral volume of distribution of the central,"For a typical 70-kg white patient, the following parameters were estimated: absorption rate constant, 1.27 h -1; absorption time lag, 0.47 hour; oral volume of distribution of the central and peripheral compartment, 56.3 and 185.0 L, respectively; oral clearance (Cl/F), 30.7 L/h; and oral intercompartmental clearance, 31.7 L/h.","Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592326/),l,56.3,178739,DB00091,Cyclosporine
,15592326,oral volume of distribution of the central,"For a typical 70-kg white patient, the following parameters were estimated: absorption rate constant, 1.27 h -1; absorption time lag, 0.47 hour; oral volume of distribution of the central and peripheral compartment, 56.3 and 185.0 L, respectively; oral clearance (Cl/F), 30.7 L/h; and oral intercompartmental clearance, 31.7 L/h.","Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592326/),l,185.0,178740,DB00091,Cyclosporine
,15592326,oral clearance (Cl/F),"For a typical 70-kg white patient, the following parameters were estimated: absorption rate constant, 1.27 h -1; absorption time lag, 0.47 hour; oral volume of distribution of the central and peripheral compartment, 56.3 and 185.0 L, respectively; oral clearance (Cl/F), 30.7 L/h; and oral intercompartmental clearance, 31.7 L/h.","Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592326/),[l] / [h],30.7,178741,DB00091,Cyclosporine
,15592326,oral intercompartmental clearance,"For a typical 70-kg white patient, the following parameters were estimated: absorption rate constant, 1.27 h -1; absorption time lag, 0.47 hour; oral volume of distribution of the central and peripheral compartment, 56.3 and 185.0 L, respectively; oral clearance (Cl/F), 30.7 L/h; and oral intercompartmental clearance, 31.7 L/h.","Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592326/),[l] / [h],31.7,178742,DB00091,Cyclosporine
,30088322,efflux ratio (B-A/A-B),"7-Hydroxymitragynine showed a tendency to efflux, with efflux ratio (B-A/A-B) of 1.39.",Rate and extent of mitragynine and 7-hydroxymitragynine blood-brain barrier transport and their intra-brain distribution: the missing link in pharmacodynamic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30088322/),,1.39,178827,DB00091,Cyclosporine
,8130357,AUC,"The best model predictive of AUC curves used three time points at 2, 6, and 24 h postdose: AUC predicted = 8.6 x (24 h) + 1.4 x (2 h) + 6.2 x (6 h) + 1.57 mg x h/L; r2 = 0.986, P = 0.00001.",Efficacy of area under the curve cyclosporine monitoring in renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8130357/),h,8.6,179375,DB00091,Cyclosporine
,8130357,AUC,"The best model predictive of AUC curves used three time points at 2, 6, and 24 h postdose: AUC predicted = 8.6 x (24 h) + 1.4 x (2 h) + 6.2 x (6 h) + 1.57 mg x h/L; r2 = 0.986, P = 0.00001.",Efficacy of area under the curve cyclosporine monitoring in renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8130357/),h,24,179376,DB00091,Cyclosporine
,8130357,AUC,"The best model predictive of AUC curves used three time points at 2, 6, and 24 h postdose: AUC predicted = 8.6 x (24 h) + 1.4 x (2 h) + 6.2 x (6 h) + 1.57 mg x h/L; r2 = 0.986, P = 0.00001.",Efficacy of area under the curve cyclosporine monitoring in renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8130357/),h,1.4,179377,DB00091,Cyclosporine
,8130357,AUC,"The best model predictive of AUC curves used three time points at 2, 6, and 24 h postdose: AUC predicted = 8.6 x (24 h) + 1.4 x (2 h) + 6.2 x (6 h) + 1.57 mg x h/L; r2 = 0.986, P = 0.00001.",Efficacy of area under the curve cyclosporine monitoring in renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8130357/),h,2,179378,DB00091,Cyclosporine
,8130357,AUC,"The best model predictive of AUC curves used three time points at 2, 6, and 24 h postdose: AUC predicted = 8.6 x (24 h) + 1.4 x (2 h) + 6.2 x (6 h) + 1.57 mg x h/L; r2 = 0.986, P = 0.00001.",Efficacy of area under the curve cyclosporine monitoring in renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8130357/),h,6.2,179379,DB00091,Cyclosporine
,8130357,AUC,"The best model predictive of AUC curves used three time points at 2, 6, and 24 h postdose: AUC predicted = 8.6 x (24 h) + 1.4 x (2 h) + 6.2 x (6 h) + 1.57 mg x h/L; r2 = 0.986, P = 0.00001.",Efficacy of area under the curve cyclosporine monitoring in renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8130357/),h,6,179380,DB00091,Cyclosporine
,8130357,AUC,"The best model predictive of AUC curves used three time points at 2, 6, and 24 h postdose: AUC predicted = 8.6 x (24 h) + 1.4 x (2 h) + 6.2 x (6 h) + 1.57 mg x h/L; r2 = 0.986, P = 0.00001.",Efficacy of area under the curve cyclosporine monitoring in renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8130357/),[h·mg] / [l],1,179381,DB00091,Cyclosporine
more,8130357,AUC,"An AUC of more than 13 mg x h/L correlated with nephrotoxicity, whereas a value of 8 mg x h/L correlated with protection from rejection in first-transplant recipients.",Efficacy of area under the curve cyclosporine monitoring in renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8130357/),[h·mg] / [l],13,179382,DB00091,Cyclosporine
,8130357,AUC,"An AUC of more than 13 mg x h/L correlated with nephrotoxicity, whereas a value of 8 mg x h/L correlated with protection from rejection in first-transplant recipients.",Efficacy of area under the curve cyclosporine monitoring in renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8130357/),[h·mg] / [l],8,179383,DB00091,Cyclosporine
,19858252,apparent clearance,"A one-compartment model with first-order absorption and elimination as the basic structural model appropriately described the data, with the apparent clearance being 75.8 liters/h (95% confidence interval [CI], 65.2 to 86.4 liters/h) and the apparent volume being distribution of 835 liters (95% CI, 559 to 1,111 liters).",Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19858252/),[l] / [h],75.8,179515,DB00091,Cyclosporine
,19858252,apparent volume being distribution,"A one-compartment model with first-order absorption and elimination as the basic structural model appropriately described the data, with the apparent clearance being 75.8 liters/h (95% confidence interval [CI], 65.2 to 86.4 liters/h) and the apparent volume being distribution of 835 liters (95% CI, 559 to 1,111 liters).",Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19858252/),l,835,179516,DB00091,Cyclosporine
,19858252,volume of distribution,"Among the covariates tested, significant effects were found for age (decrease in the volume of distribution of 123 liters per year of age) and the presence of diarrhea (59% loss of bioavailability).",Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19858252/),l,123,179517,DB00091,Cyclosporine
,16601778,C(max),"At identical dosing, the new formulation was found to have geometric means of C(max) 717 ng/ml and AUCtau 3108 ng/ml.h, while corresponding results of comparator were 725 ng/ml and AUCtau 3039 ng/ml.h, respectively.",Pharmacokinetic conversion study of a new cyclosporine formulation in stable adult renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16601778/),[ng] / [ml],717,179636,DB00091,Cyclosporine
,16601778,AUCtau,"At identical dosing, the new formulation was found to have geometric means of C(max) 717 ng/ml and AUCtau 3108 ng/ml.h, while corresponding results of comparator were 725 ng/ml and AUCtau 3039 ng/ml.h, respectively.",Pharmacokinetic conversion study of a new cyclosporine formulation in stable adult renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16601778/),[ng] / [h·ml],3108,179637,DB00091,Cyclosporine
,16601778,AUCtau,"At identical dosing, the new formulation was found to have geometric means of C(max) 717 ng/ml and AUCtau 3108 ng/ml.h, while corresponding results of comparator were 725 ng/ml and AUCtau 3039 ng/ml.h, respectively.",Pharmacokinetic conversion study of a new cyclosporine formulation in stable adult renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16601778/),[ng] / [h·ml],3039,179638,DB00091,Cyclosporine
,7676504,area under the concentration-time curve,"Specifically, the area under the concentration-time curve was 943 +/- 400 vs.",Bile-independent absorption of cyclosporine from a microemulsion formulation in liver transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7676504/),,943,179676,DB00091,Cyclosporine
,7676504,bioavailability,"2378 +/- 911 ng.hr/ml, indicating an average 156% higher bioavailability from the microemulsion compared with the currently marketed formulation in liver transplant patients in the absence of bile.",Bile-independent absorption of cyclosporine from a microemulsion formulation in liver transplant patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7676504/),[h·ng] / [ml],2378,179677,DB00091,Cyclosporine
,2379521,clearance,The pharmacokinetic parameters after intravenous administration were (mean +/- SD; n = 4): clearance = 327 +/- 21 ml/h/kg; volume of distribution = 7.2 +/- 2.8 liters/kg.,Bioavailability of intramuscular ciclosporin in the pig. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379521/),[ml] / [h·kg],327,179967,DB00091,Cyclosporine
,2379521,volume of distribution,The pharmacokinetic parameters after intravenous administration were (mean +/- SD; n = 4): clearance = 327 +/- 21 ml/h/kg; volume of distribution = 7.2 +/- 2.8 liters/kg.,Bioavailability of intramuscular ciclosporin in the pig. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379521/),[l] / [kg],7.2,179968,DB00091,Cyclosporine
,2379521,clearance,The same parameters after intramuscular dosing were: clearance = 326 +/- 59 ml/h/kg; volume of distribution = 6.9 +/- 2.1 liters/kg.,Bioavailability of intramuscular ciclosporin in the pig. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379521/),[ml] / [h·kg],326,179969,DB00091,Cyclosporine
,2379521,volume of distribution,The same parameters after intramuscular dosing were: clearance = 326 +/- 59 ml/h/kg; volume of distribution = 6.9 +/- 2.1 liters/kg.,Bioavailability of intramuscular ciclosporin in the pig. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379521/),[l] / [kg],6.9,179970,DB00091,Cyclosporine
,2379521,percent bioavailability,The percent bioavailability of intramuscular CS was 101.9 +/- 13.3 with a mean absorption time of 10.6 +/- 2.7 h.,Bioavailability of intramuscular ciclosporin in the pig. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379521/),,101.9,179971,DB00091,Cyclosporine
,2379521,mean absorption time,The percent bioavailability of intramuscular CS was 101.9 +/- 13.3 with a mean absorption time of 10.6 +/- 2.7 h.,Bioavailability of intramuscular ciclosporin in the pig. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379521/),h,10.6,179972,DB00091,Cyclosporine
,21299636,AUC(12h),Only six of 24 patients had an MPA-AUC(12h) within the putative therapeutic range of 40-60 mg/L·h.,Pharmacokinetics and pharmacodynamics of mycophenolate sodium (EC-MPS) co-administered with cyclosporine in the early-phase post-kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21299636/),[mg] / [h·l],40-60,180132,DB00091,Cyclosporine
,23429854,en,"The drug content and encapsulation efficiency of the cyclosporin A-loaded, PEGylated chitosan-modified nanoparticles were 37.04% and 69.22%, respectively.","Preparation and in vitro and in vivo characterization of cyclosporin A-loaded, PEGylated chitosan-modified, lipid-based nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23429854/),,37,180347,DB00091,Cyclosporine
,23429854,en,"The drug content and encapsulation efficiency of the cyclosporin A-loaded, PEGylated chitosan-modified nanoparticles were 37.04% and 69.22%, respectively.","Preparation and in vitro and in vivo characterization of cyclosporin A-loaded, PEGylated chitosan-modified, lipid-based nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23429854/),%,69,180348,DB00091,Cyclosporine
,15013306,AUC,"The mean AUC for Neoral and Equoral was 2856 and 2892, respectively.",The pharmacokinetics of equoral versus neoral in stable renal transplant patients: a multinational multicenter study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15013306/),,2856,180641,DB00091,Cyclosporine
,15013306,AUC,"The mean AUC for Neoral and Equoral was 2856 and 2892, respectively.",The pharmacokinetics of equoral versus neoral in stable renal transplant patients: a multinational multicenter study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15013306/),,2892,180642,DB00091,Cyclosporine
,12886389,through levels,The average CsA through levels in the first month were higher (551 +/- 280 ng/ml) in the 23 cases as compared to the 31 controls (418 +/- 228 ng/ml; p< 0.05).,[Elevated cyclosporine A trough levels in HCV positive kidney transplant recipients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12886389/),[ng] / [ml],551,180760,DB00091,Cyclosporine
,12886389,through levels,The average CsA through levels in the first month were higher (551 +/- 280 ng/ml) in the 23 cases as compared to the 31 controls (418 +/- 228 ng/ml; p< 0.05).,[Elevated cyclosporine A trough levels in HCV positive kidney transplant recipients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12886389/),[ng] / [ml],418,180761,DB00091,Cyclosporine
,15175422,Rate of elimination (k(10)),"Rate of elimination (k(10)) for erythromycin and those with inhibitors was found to be similar (141 +/- 23 min), suggesting that elimination pathways were not altered.",Pharmacokinetics of erythromycin in rabbit corneas after single-dose infusion: role of P-glycoprotein as a barrier to in vivo ocular drug absorption. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15175422/),min,141,181611,DB00091,Cyclosporine
,8347899,clearances,Mean methylprednisolone clearances were similar in both groups: 405 +/- 205 (double-drug) and 373 +/- 365 mL/h/kg (triple-drug) (p > 0.05).,Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347899/),[ml] / [h·kg],405,181655,DB00091,Cyclosporine
,8347899,clearances,Mean methylprednisolone clearances were similar in both groups: 405 +/- 205 (double-drug) and 373 +/- 365 mL/h/kg (triple-drug) (p > 0.05).,Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347899/),[ml] / [h·kg],373,181656,DB00091,Cyclosporine
,8347899,steady-state volume of distribution,Mean steady-state volume of distribution was 1.5 +/- 0.8 L/kg in the double-drug group and 1.3 +/- 0.8 L/kg in the triple-drug group (p > 0.05).,Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347899/),[l] / [kg],1.5,181657,DB00091,Cyclosporine
,8347899,steady-state volume of distribution,Mean steady-state volume of distribution was 1.5 +/- 0.8 L/kg in the double-drug group and 1.3 +/- 0.8 L/kg in the triple-drug group (p > 0.05).,Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347899/),[l] / [kg],1.3,181658,DB00091,Cyclosporine
,8347899,Plasma half-life,Plasma half-life ranged from 1.7 to 4.3 h (mean 2.7) in the double-drug group versus 1.4 to 3.4 h (mean 2.6) in the triple-drug group (p > 0.05).,Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347899/),h,2.7,181659,DB00091,Cyclosporine
,8347899,Plasma half-life,Plasma half-life ranged from 1.7 to 4.3 h (mean 2.7) in the double-drug group versus 1.4 to 3.4 h (mean 2.6) in the triple-drug group (p > 0.05).,Comparative methylprednisolone pharmacokinetics in renal transplant patients receiving double- or triple-drug immunosuppression. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8347899/),h,2.6,181660,DB00091,Cyclosporine
,3047931,CL,"Cyclosporine CL significantly differed among nonobese patients in different age groups; patients less than or equal to 10 years old had a higher mean CL (13.1 ml/min/kg) than patients 11-20, 21-30, 31-40, or greater than 40 years old (mean CL: 8.5-10.3 ml/min/kg) (P less than 0.05).","Blood cyclosporine pharmacokinetics in patients undergoing marrow transplantation. Influence of age, obesity, and hematocrit. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3047931/),[ml] / [kg·min],13.1,181791,DB00091,Cyclosporine
,3047931,CL,"Cyclosporine CL significantly differed among nonobese patients in different age groups; patients less than or equal to 10 years old had a higher mean CL (13.1 ml/min/kg) than patients 11-20, 21-30, 31-40, or greater than 40 years old (mean CL: 8.5-10.3 ml/min/kg) (P less than 0.05).","Blood cyclosporine pharmacokinetics in patients undergoing marrow transplantation. Influence of age, obesity, and hematocrit. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3047931/),[ml] / [kg·min],8.5-10.3,181792,DB00091,Cyclosporine
,22947591,clearance,"The final estimate of mean clearance was 56 L/h, and the mean volume of distribution was 4650 L.",CYP3A5 polymorphism effect on cyclosporine pharmacokinetics in living donor renal transplant recipients: analysis by population pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22947591/),[l] / [h],56,182026,DB00091,Cyclosporine
,22947591,volume of distribution,"The final estimate of mean clearance was 56 L/h, and the mean volume of distribution was 4650 L.",CYP3A5 polymorphism effect on cyclosporine pharmacokinetics in living donor renal transplant recipients: analysis by population pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22947591/),l,4650,182027,DB00091,Cyclosporine
,14632536,AUC,"Drug exposure as evaluated by AUC was 39.95 +/- 44.86, 25.24 +/- 25.68, and 43.96 +/- 38.67 micro g*h/mL during sampling periods 1, 2, and 3, respectively, (p > 0.05).",Mycophenolate pharmacokinetics in early period following lung or heart transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14632536/),[h·μg] / [ml],39.95,182275,DB00091,Cyclosporine
,14632536,AUC,"Drug exposure as evaluated by AUC was 39.95 +/- 44.86, 25.24 +/- 25.68, and 43.96 +/- 38.67 micro g*h/mL during sampling periods 1, 2, and 3, respectively, (p > 0.05).",Mycophenolate pharmacokinetics in early period following lung or heart transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14632536/),[h·μg] / [ml],25.24,182276,DB00091,Cyclosporine
,14632536,AUC,"Drug exposure as evaluated by AUC was 39.95 +/- 44.86, 25.24 +/- 25.68, and 43.96 +/- 38.67 micro g*h/mL during sampling periods 1, 2, and 3, respectively, (p > 0.05).",Mycophenolate pharmacokinetics in early period following lung or heart transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14632536/),[h·μg] / [ml],43.96,182277,DB00091,Cyclosporine
,20003043,survival,"In the DA to LEW model, combining a nonefficacious dose of AEB (10 mg/kg b.i.d.) with a nonefficacious dose of cyclosporine, everolimus or FTY720 led to prolonged median survival times (26 days, >68 days and >68 days, respectively).","Effects of the novel protein kinase C inhibitor AEB071 (Sotrastaurin) on rat cardiac allograft survival using single agent treatment or combination therapy with cyclosporine, everolimus or FTY720. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20003043/),d,26,182384,DB00091,Cyclosporine
>,20003043,survival,"In the DA to LEW model, combining a nonefficacious dose of AEB (10 mg/kg b.i.d.) with a nonefficacious dose of cyclosporine, everolimus or FTY720 led to prolonged median survival times (26 days, >68 days and >68 days, respectively).","Effects of the novel protein kinase C inhibitor AEB071 (Sotrastaurin) on rat cardiac allograft survival using single agent treatment or combination therapy with cyclosporine, everolimus or FTY720. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20003043/),d,68,182385,DB00091,Cyclosporine
,25536375,C0 /D,"Subgroup analysis by ethnicity demonstrated that C0 /D was lower in Asian CC versus TT genotype carriers (WMD = 10.32 (ng ml(-1))/(mg kg(-1)), 95% CIs: 4.78-15.85, p = 0.0003) but did not vary by genotype for Caucasian recipients.",The Effect of ABCB1 C3435T Polymorphism on Cyclosporine Dose Requirements in Kidney Transplant Recipients: A Meta-Analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25536375/),[mg·ng] / [kg·ml],10,182475,DB00091,Cyclosporine
below,3765052,serum trough concentrations,"Following 7 daily oral doses of commercial cyclosporine (CsA) (20 mg/kg) the Cs serum trough concentrations of the pancreatectomized dogs were consistently below 100 ng/ml, while those of the normal dogs were above 400 ng/ml.",Cyclosporine pharmacokinetics in normal and pancreatectomized dogs. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3765052/),[ng] / [ml],100,182630,DB00091,Cyclosporine
above,3765052,serum trough concentrations,"Following 7 daily oral doses of commercial cyclosporine (CsA) (20 mg/kg) the Cs serum trough concentrations of the pancreatectomized dogs were consistently below 100 ng/ml, while those of the normal dogs were above 400 ng/ml.",Cyclosporine pharmacokinetics in normal and pancreatectomized dogs. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3765052/),[ng] / [ml],400,182631,DB00091,Cyclosporine
,21720508,relative oral bioavailability,"The relative oral bioavailability of CyA-loaded SPC/SDC and SPC/Chol liposomes was 120.3% and 98.6%, respectively, with Sandimmun Neoral as the reference.",Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21720508/),%,120.3,182966,DB00091,Cyclosporine
,21720508,relative oral bioavailability,"The relative oral bioavailability of CyA-loaded SPC/SDC and SPC/Chol liposomes was 120.3% and 98.6%, respectively, with Sandimmun Neoral as the reference.",Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21720508/),%,98.6,182967,DB00091,Cyclosporine
,10582742,systemic,KC significantly decreased the mean systemic CsA clearance from 2.73 mL/min/kg to 1.22 mL/min/kg resulting in an increase in the terminal phase half-life from 10.7 to 22.2 hours.,The effects of ketoconazole on the pharmacokinetics of cyclosporine A in cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582742/),[ml] / [kg·min],2.73,183205,DB00091,Cyclosporine
,10582742,systemic,KC significantly decreased the mean systemic CsA clearance from 2.73 mL/min/kg to 1.22 mL/min/kg resulting in an increase in the terminal phase half-life from 10.7 to 22.2 hours.,The effects of ketoconazole on the pharmacokinetics of cyclosporine A in cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582742/),[ml] / [kg·min],1.22,183206,DB00091,Cyclosporine
,10582742,terminal phase half-life,KC significantly decreased the mean systemic CsA clearance from 2.73 mL/min/kg to 1.22 mL/min/kg resulting in an increase in the terminal phase half-life from 10.7 to 22.2 hours.,The effects of ketoconazole on the pharmacokinetics of cyclosporine A in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582742/),h,10.7,183207,DB00091,Cyclosporine
,10582742,terminal phase half-life,KC significantly decreased the mean systemic CsA clearance from 2.73 mL/min/kg to 1.22 mL/min/kg resulting in an increase in the terminal phase half-life from 10.7 to 22.2 hours.,The effects of ketoconazole on the pharmacokinetics of cyclosporine A in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582742/),h,22.2,183208,DB00091,Cyclosporine
,7768070,peak concentration,"After oral administration, grapefruit juice significantly increased peak concentration (936 versus 1340 ng/ml), as well as area under the curve (6722 versus 10,730 ng . hr/ml) but had no effect on elimination half-life.",Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768070/),[ng] / [ml],936,183662,DB00091,Cyclosporine
,7768070,peak concentration,"After oral administration, grapefruit juice significantly increased peak concentration (936 versus 1340 ng/ml), as well as area under the curve (6722 versus 10,730 ng . hr/ml) but had no effect on elimination half-life.",Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768070/),[ng] / [ml],1340,183663,DB00091,Cyclosporine
,7768070,area under the curve,"After oral administration, grapefruit juice significantly increased peak concentration (936 versus 1340 ng/ml), as well as area under the curve (6722 versus 10,730 ng . hr/ml) but had no effect on elimination half-life.",Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768070/),[h·ng] / [ml],6722,183664,DB00091,Cyclosporine
,7768070,area under the curve,"After oral administration, grapefruit juice significantly increased peak concentration (936 versus 1340 ng/ml), as well as area under the curve (6722 versus 10,730 ng . hr/ml) but had no effect on elimination half-life.",Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768070/),[h·ng] / [ml],"10,730",183665,DB00091,Cyclosporine
,7768070,Absolute bioavailability,"Absolute bioavailability of cyclosporine was increased from 0.22 to 0.36 (average increase, 62%) by grapefruit juice.",Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768070/),,0.22,183666,DB00091,Cyclosporine
,7768070,Absolute bioavailability,"Absolute bioavailability of cyclosporine was increased from 0.22 to 0.36 (average increase, 62%) by grapefruit juice.",Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768070/),,0.36,183667,DB00091,Cyclosporine
,7768070,Absolute bioavailability,"Absolute bioavailability of cyclosporine was increased from 0.22 to 0.36 (average increase, 62%) by grapefruit juice.",Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768070/),%,62,183668,DB00091,Cyclosporine
,21244766,overall bioavailability,"The overall bioavailability for Sandimmun® versus the microemulsion formulation Sandimmun Neoral® was 76 percent, with upper CI limits lower than 80 percent in some cases.",Bioavailability of Sandimmun® versus Sandimmun Neoral®: a meta-analysis of published studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21244766/),%,76,184059,DB00091,Cyclosporine
lower,21244766,overall bioavailability,"The overall bioavailability for Sandimmun® versus the microemulsion formulation Sandimmun Neoral® was 76 percent, with upper CI limits lower than 80 percent in some cases.",Bioavailability of Sandimmun® versus Sandimmun Neoral®: a meta-analysis of published studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21244766/),%,80,184060,DB00091,Cyclosporine
,7787866,Bioavailability,Bioavailability ranged between 18% and 68% (RIE-MoSP) and were overestimated when calculated using RIE-MoNP (38% to 100%) owing to extensive cyclosporine metabolization during the first passage through the intestine and the liver.,[Pharmacokinetics of cyclosporine and its metabolites in patients undergoing kidney transplantation]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7787866/),%,18,185001,DB00091,Cyclosporine
,7787866,Bioavailability,Bioavailability ranged between 18% and 68% (RIE-MoSP) and were overestimated when calculated using RIE-MoNP (38% to 100%) owing to extensive cyclosporine metabolization during the first passage through the intestine and the liver.,[Pharmacokinetics of cyclosporine and its metabolites in patients undergoing kidney transplantation]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7787866/),%,68,185002,DB00091,Cyclosporine
,7787866,Bioavailability,Bioavailability ranged between 18% and 68% (RIE-MoSP) and were overestimated when calculated using RIE-MoNP (38% to 100%) owing to extensive cyclosporine metabolization during the first passage through the intestine and the liver.,[Pharmacokinetics of cyclosporine and its metabolites in patients undergoing kidney transplantation]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7787866/),%,38,185003,DB00091,Cyclosporine
,7787866,Bioavailability,Bioavailability ranged between 18% and 68% (RIE-MoSP) and were overestimated when calculated using RIE-MoNP (38% to 100%) owing to extensive cyclosporine metabolization during the first passage through the intestine and the liver.,[Pharmacokinetics of cyclosporine and its metabolites in patients undergoing kidney transplantation]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7787866/),%,100,185004,DB00091,Cyclosporine
,7787866,trough levels,"The correlation between one sample obtained at any time after cyclosporine administration and the AUC were unsatisfactory, even the trough levels of 12 and 24 hours.",[Pharmacokinetics of cyclosporine and its metabolites in patients undergoing kidney transplantation]. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7787866/),h,12,185005,DB00091,Cyclosporine
,7787866,trough levels,"The correlation between one sample obtained at any time after cyclosporine administration and the AUC were unsatisfactory, even the trough levels of 12 and 24 hours.",[Pharmacokinetics of cyclosporine and its metabolites in patients undergoing kidney transplantation]. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7787866/),h,24,185006,DB00091,Cyclosporine
,7624915,bioavailability,"In 39 patients who were on stable doses of cyclosporine 1 month after transplantation, the bioavailability of N-SIM was higher than that of SIM under both fasting (+64%, p = 0.001) and fed (+37%, p = 0.004) conditions.",Pharmacokinetics of a new oral formulation of cyclosporine in liver transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7624915/),%,64,185118,DB00091,Cyclosporine
,7624915,bioavailability,"In 39 patients who were on stable doses of cyclosporine 1 month after transplantation, the bioavailability of N-SIM was higher than that of SIM under both fasting (+64%, p = 0.001) and fed (+37%, p = 0.004) conditions.",Pharmacokinetics of a new oral formulation of cyclosporine in liver transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7624915/),%,37,185119,DB00091,Cyclosporine
,16995869,AUC(0-9 h),"The mean mycophenolic acid AUC(0-9 h) in the sirolimus group was 44.9 mg h(-1) L(-1) (95% CI: 34.7-55.1), vs. 30.5 mg h(-1) L(-1) (95% CI: 25.4-35.6) in the ciclosporin group, corresponding to 1.5-fold dose-normalized difference (95% CI: 1.1-1.9; P < 0.05).",A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995869/),[mg] / [h·l],44.9,185175,DB00091,Cyclosporine
,16995869,AUC(0-9 h),"The mean mycophenolic acid AUC(0-9 h) in the sirolimus group was 44.9 mg h(-1) L(-1) (95% CI: 34.7-55.1), vs. 30.5 mg h(-1) L(-1) (95% CI: 25.4-35.6) in the ciclosporin group, corresponding to 1.5-fold dose-normalized difference (95% CI: 1.1-1.9; P < 0.05).",A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995869/),[mg] / [h·l],30.5,185176,DB00091,Cyclosporine
,16415090,pseudo steady-state C,"Under isoflurane anesthesia, male Sprague-Dawley rats were administered i.v. CsA to achieve pseudo steady-state CsA blood concentrations ranging from 0 to approximately 12 microM.","Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415090/),μM,0 to,185380,DB00091,Cyclosporine
,16415090,blood concentrations,"Under isoflurane anesthesia, male Sprague-Dawley rats were administered i.v. CsA to achieve pseudo steady-state CsA blood concentrations ranging from 0 to approximately 12 microM.","Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415090/),μM,0 to,185381,DB00091,Cyclosporine
,16415090,E(max),"The percentage increase in the brain/blood (3)H radioactivity (relative to 0 microM CsA) was described by the Hill equation with E(max), 1290%; EC(50), 7.2 microM; and gamma, 3.8.","Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415090/),%,1290,185382,DB00091,Cyclosporine
,16415090,EC(50),"The percentage increase in the brain/blood (3)H radioactivity (relative to 0 microM CsA) was described by the Hill equation with E(max), 1290%; EC(50), 7.2 microM; and gamma, 3.8.","Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415090/),μM,7.2,185383,DB00091,Cyclosporine
,16415090,gamma,"The percentage increase in the brain/blood (3)H radioactivity (relative to 0 microM CsA) was described by the Hill equation with E(max), 1290%; EC(50), 7.2 microM; and gamma, 3.8.","Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415090/),,3.8,185384,DB00091,Cyclosporine
,8513657,Vmax,The following parameters with interindividual variation in parenthesis were estimated: Vmax = 852 mg/24 hr (43%) and Km at 114 days after transplantation = 349 ng/ml (117%).,Michaelis-Menten kinetics determine cyclosporine steady-state concentrations: a population analysis in kidney transplant patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513657/),[mg] / [24·h],852,185570,DB00091,Cyclosporine
,8513657,Km,The following parameters with interindividual variation in parenthesis were estimated: Vmax = 852 mg/24 hr (43%) and Km at 114 days after transplantation = 349 ng/ml (117%).,Michaelis-Menten kinetics determine cyclosporine steady-state concentrations: a population analysis in kidney transplant patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513657/),[ng] / [ml],349,185571,DB00091,Cyclosporine
,29511796,AUC0 - tau,"The MPA AUC0 - tau was 31.9 ± 3.4, 26.2 ± 2.4, and 21.0 ± 2.2 µg*h/mL, the mean Ctrough was 0.25, 0.35, and 0.37 µg/mL, and the Cmax was 10.8, 9.2, and 5.5 µg/mL on days 2, 9, and 16, respectively.",Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511796/),[h·μg] / [ml],31.9,186291,DB00091,Cyclosporine
,29511796,AUC0 - tau,"The MPA AUC0 - tau was 31.9 ± 3.4, 26.2 ± 2.4, and 21.0 ± 2.2 µg*h/mL, the mean Ctrough was 0.25, 0.35, and 0.37 µg/mL, and the Cmax was 10.8, 9.2, and 5.5 µg/mL on days 2, 9, and 16, respectively.",Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511796/),[h·μg] / [ml],26.2,186292,DB00091,Cyclosporine
,29511796,AUC0 - tau,"The MPA AUC0 - tau was 31.9 ± 3.4, 26.2 ± 2.4, and 21.0 ± 2.2 µg*h/mL, the mean Ctrough was 0.25, 0.35, and 0.37 µg/mL, and the Cmax was 10.8, 9.2, and 5.5 µg/mL on days 2, 9, and 16, respectively.",Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511796/),[h·μg] / [ml],21.0,186293,DB00091,Cyclosporine
,29511796,Ctrough,"The MPA AUC0 - tau was 31.9 ± 3.4, 26.2 ± 2.4, and 21.0 ± 2.2 µg*h/mL, the mean Ctrough was 0.25, 0.35, and 0.37 µg/mL, and the Cmax was 10.8, 9.2, and 5.5 µg/mL on days 2, 9, and 16, respectively.",Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511796/),[μg] / [ml],0.25,186294,DB00091,Cyclosporine
,29511796,Ctrough,"The MPA AUC0 - tau was 31.9 ± 3.4, 26.2 ± 2.4, and 21.0 ± 2.2 µg*h/mL, the mean Ctrough was 0.25, 0.35, and 0.37 µg/mL, and the Cmax was 10.8, 9.2, and 5.5 µg/mL on days 2, 9, and 16, respectively.",Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511796/),[μg] / [ml],0.35,186295,DB00091,Cyclosporine
,29511796,Ctrough,"The MPA AUC0 - tau was 31.9 ± 3.4, 26.2 ± 2.4, and 21.0 ± 2.2 µg*h/mL, the mean Ctrough was 0.25, 0.35, and 0.37 µg/mL, and the Cmax was 10.8, 9.2, and 5.5 µg/mL on days 2, 9, and 16, respectively.",Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511796/),[μg] / [ml],0.37,186296,DB00091,Cyclosporine
,29511796,Cmax,"The MPA AUC0 - tau was 31.9 ± 3.4, 26.2 ± 2.4, and 21.0 ± 2.2 µg*h/mL, the mean Ctrough was 0.25, 0.35, and 0.37 µg/mL, and the Cmax was 10.8, 9.2, and 5.5 µg/mL on days 2, 9, and 16, respectively.",Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511796/),[μg] / [ml],10.8,186297,DB00091,Cyclosporine
,29511796,Cmax,"The MPA AUC0 - tau was 31.9 ± 3.4, 26.2 ± 2.4, and 21.0 ± 2.2 µg*h/mL, the mean Ctrough was 0.25, 0.35, and 0.37 µg/mL, and the Cmax was 10.8, 9.2, and 5.5 µg/mL on days 2, 9, and 16, respectively.",Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511796/),[μg] / [ml],9.2,186298,DB00091,Cyclosporine
,29511796,Cmax,"The MPA AUC0 - tau was 31.9 ± 3.4, 26.2 ± 2.4, and 21.0 ± 2.2 µg*h/mL, the mean Ctrough was 0.25, 0.35, and 0.37 µg/mL, and the Cmax was 10.8, 9.2, and 5.5 µg/mL on days 2, 9, and 16, respectively.",Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511796/),[μg] / [ml],5.5,186299,DB00091,Cyclosporine
above,10755319,AUC,"The fitted parameter-estimates suggested that at equivalent unbound etoposide AUC values above 10 microg x h/ml, the sigmoid Emax model predicted a 5% greater WBC count suppression when CsA was added to the treatment regimen.",Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10755319/),[h·μg] / [ml],10,186323,DB00091,Cyclosporine
,16979996,levels,"Mean CsA levels (ng/mL) during the first month were 1419.1 +/- 213.6 and 1460.5 +/- 290.7 and at 3 months, 1296.3 +/- 227.8 and 1342.4 +/- 303.4 in the two groups, respectively (P = NS).",Comparison of generic cyclosporine microemulsion versus neoral in de novo renal transplant recipients managed by 2-hour postdose monitoring. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16979996/),[ng] / [ml],1419.1,186526,DB00091,Cyclosporine
,16979996,levels,"Mean CsA levels (ng/mL) during the first month were 1419.1 +/- 213.6 and 1460.5 +/- 290.7 and at 3 months, 1296.3 +/- 227.8 and 1342.4 +/- 303.4 in the two groups, respectively (P = NS).",Comparison of generic cyclosporine microemulsion versus neoral in de novo renal transplant recipients managed by 2-hour postdose monitoring. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16979996/),[ng] / [ml],1460.5,186527,DB00091,Cyclosporine
,16979996,levels,"Mean CsA levels (ng/mL) during the first month were 1419.1 +/- 213.6 and 1460.5 +/- 290.7 and at 3 months, 1296.3 +/- 227.8 and 1342.4 +/- 303.4 in the two groups, respectively (P = NS).",Comparison of generic cyclosporine microemulsion versus neoral in de novo renal transplant recipients managed by 2-hour postdose monitoring. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16979996/),[ng] / [ml],129,186528,DB00091,Cyclosporine
,16979996,levels,"Mean CsA levels (ng/mL) during the first month were 1419.1 +/- 213.6 and 1460.5 +/- 290.7 and at 3 months, 1296.3 +/- 227.8 and 1342.4 +/- 303.4 in the two groups, respectively (P = NS).",Comparison of generic cyclosporine microemulsion versus neoral in de novo renal transplant recipients managed by 2-hour postdose monitoring. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16979996/),[ng] / [ml],1342,186529,DB00091,Cyclosporine
,14756266,AUC(0-8),"The concomitant administration of daclizumab and MMF had no effect on the pharmacokinetics of MPA: AUC(0-8) values (microg h/mL +/- SD) on day 28 were 30.1 +/- 13.3 for daclizumab-treat patients vs. 31.1 +/- 12.4 for placebo and on day 56, 37.7 +/- 18.2 for daclizumab-treated patients vs. 35.7 +/- 14.0 for placebo.",Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756266/),[h·μg] / [ml],30.1,186660,DB00091,Cyclosporine
,14756266,AUC(0-8),"The concomitant administration of daclizumab and MMF had no effect on the pharmacokinetics of MPA: AUC(0-8) values (microg h/mL +/- SD) on day 28 were 30.1 +/- 13.3 for daclizumab-treat patients vs. 31.1 +/- 12.4 for placebo and on day 56, 37.7 +/- 18.2 for daclizumab-treated patients vs. 35.7 +/- 14.0 for placebo.",Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756266/),[h·μg] / [ml],31.1,186661,DB00091,Cyclosporine
,14756266,AUC(0-8),"The concomitant administration of daclizumab and MMF had no effect on the pharmacokinetics of MPA: AUC(0-8) values (microg h/mL +/- SD) on day 28 were 30.1 +/- 13.3 for daclizumab-treat patients vs. 31.1 +/- 12.4 for placebo and on day 56, 37.7 +/- 18.2 for daclizumab-treated patients vs. 35.7 +/- 14.0 for placebo.",Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756266/),[h·μg] / [ml],37.7,186662,DB00091,Cyclosporine
,14756266,AUC(0-8),"The concomitant administration of daclizumab and MMF had no effect on the pharmacokinetics of MPA: AUC(0-8) values (microg h/mL +/- SD) on day 28 were 30.1 +/- 13.3 for daclizumab-treat patients vs. 31.1 +/- 12.4 for placebo and on day 56, 37.7 +/- 18.2 for daclizumab-treated patients vs. 35.7 +/- 14.0 for placebo.",Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756266/),[h·μg] / [ml],35.7,186663,DB00091,Cyclosporine
,15114410,plasma clearance,"Infusion of CyA (1 mg/h) in rats treated with an i.v. bolus of etoposide caused a decrease in the plasma clearance (5.4+/-2.1 vs 9.3+/-2.4 ml/min), and an increase in plasma and tissue concentrations of etoposide, but the tissue-to-plasma concentration ratios of etoposide were not affected.",Effect of cyclosporine A on the tissue distribution and pharmacokinetics of etoposide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114410/),[ml] / [min],5.4,186964,DB00091,Cyclosporine
,15114410,plasma clearance,"Infusion of CyA (1 mg/h) in rats treated with an i.v. bolus of etoposide caused a decrease in the plasma clearance (5.4+/-2.1 vs 9.3+/-2.4 ml/min), and an increase in plasma and tissue concentrations of etoposide, but the tissue-to-plasma concentration ratios of etoposide were not affected.",Effect of cyclosporine A on the tissue distribution and pharmacokinetics of etoposide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114410/),[ml] / [min],9.3,186965,DB00091,Cyclosporine
,15114410,plasma clearance,"When etoposide was infused at a constant rate to reach a steady-state plasma level, coinfusion of CyA (10 mg/h) also caused a decrease in the plasma clearance (4.8+/-1.5 vs 9.8+/-4.7 ml/min), and an increase in plasma and tissue concentrations of etoposide.",Effect of cyclosporine A on the tissue distribution and pharmacokinetics of etoposide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114410/),[ml] / [min],4.8,186966,DB00091,Cyclosporine
,15114410,plasma clearance,"When etoposide was infused at a constant rate to reach a steady-state plasma level, coinfusion of CyA (10 mg/h) also caused a decrease in the plasma clearance (4.8+/-1.5 vs 9.8+/-4.7 ml/min), and an increase in plasma and tissue concentrations of etoposide.",Effect of cyclosporine A on the tissue distribution and pharmacokinetics of etoposide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15114410/),[ml] / [min],9.8,186967,DB00091,Cyclosporine
,22527344,CL,"The population mean estimate and interindividual variability from the final model for CL, Ka, Tlag, V1, V2, and Q were 25.4 L/h (CV = 38.72 %), 0.214 h(-1)(CV = 28.5 %), 0.382 h, 10.9 L (85.73 %), 496 L, and 5 L/h, respectively.",Population pharmacokinetics and Bayesian estimation of cyclosporine in a Tunisian population of hematopoietic stem cell transplant recipient. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22527344/),[l] / [h],25.4,187206,DB00091,Cyclosporine
,22527344,Q,"The population mean estimate and interindividual variability from the final model for CL, Ka, Tlag, V1, V2, and Q were 25.4 L/h (CV = 38.72 %), 0.214 h(-1)(CV = 28.5 %), 0.382 h, 10.9 L (85.73 %), 496 L, and 5 L/h, respectively.",Population pharmacokinetics and Bayesian estimation of cyclosporine in a Tunisian population of hematopoietic stem cell transplant recipient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22527344/),[l] / [h],5,187207,DB00091,Cyclosporine
,32802109,area under concentration - time curve (AUC),"Of pharmacokinetic parameters mean ± SD area under concentration - time curve (AUC), clearance, and half-life were estimated to be 5492 ± 1596 ng.h/mL, 19.44 ± 6.61 L/h, and 11.8 ± 5.4 h for IV and 7637.7 ± 2739.8 ng.h/mL, 19.42 ± 6.62 L/h, and 11.16 ± 5.9 h for oral administration, respectively.","Evaluation of Cyclosporine Pharmacokinetic, Monitoring, and Dosing Parameters for GVHD Prophylaxis in Hematopoietic Stem Cell Transplant (HSCT) Recipients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32802109/),[h·ng] / [ml],5492,187431,DB00091,Cyclosporine
,32802109,clearance,"Of pharmacokinetic parameters mean ± SD area under concentration - time curve (AUC), clearance, and half-life were estimated to be 5492 ± 1596 ng.h/mL, 19.44 ± 6.61 L/h, and 11.8 ± 5.4 h for IV and 7637.7 ± 2739.8 ng.h/mL, 19.42 ± 6.62 L/h, and 11.16 ± 5.9 h for oral administration, respectively.","Evaluation of Cyclosporine Pharmacokinetic, Monitoring, and Dosing Parameters for GVHD Prophylaxis in Hematopoietic Stem Cell Transplant (HSCT) Recipients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32802109/),[l] / [h],19.44,187432,DB00091,Cyclosporine
,32802109,clearance,"Of pharmacokinetic parameters mean ± SD area under concentration - time curve (AUC), clearance, and half-life were estimated to be 5492 ± 1596 ng.h/mL, 19.44 ± 6.61 L/h, and 11.8 ± 5.4 h for IV and 7637.7 ± 2739.8 ng.h/mL, 19.42 ± 6.62 L/h, and 11.16 ± 5.9 h for oral administration, respectively.","Evaluation of Cyclosporine Pharmacokinetic, Monitoring, and Dosing Parameters for GVHD Prophylaxis in Hematopoietic Stem Cell Transplant (HSCT) Recipients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32802109/),[h·ng] / [ml],7637.7,187433,DB00091,Cyclosporine
,32802109,clearance,"Of pharmacokinetic parameters mean ± SD area under concentration - time curve (AUC), clearance, and half-life were estimated to be 5492 ± 1596 ng.h/mL, 19.44 ± 6.61 L/h, and 11.8 ± 5.4 h for IV and 7637.7 ± 2739.8 ng.h/mL, 19.42 ± 6.62 L/h, and 11.16 ± 5.9 h for oral administration, respectively.","Evaluation of Cyclosporine Pharmacokinetic, Monitoring, and Dosing Parameters for GVHD Prophylaxis in Hematopoietic Stem Cell Transplant (HSCT) Recipients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32802109/),[l] / [h],19.42,187434,DB00091,Cyclosporine
,32802109,half-life,"Of pharmacokinetic parameters mean ± SD area under concentration - time curve (AUC), clearance, and half-life were estimated to be 5492 ± 1596 ng.h/mL, 19.44 ± 6.61 L/h, and 11.8 ± 5.4 h for IV and 7637.7 ± 2739.8 ng.h/mL, 19.42 ± 6.62 L/h, and 11.16 ± 5.9 h for oral administration, respectively.","Evaluation of Cyclosporine Pharmacokinetic, Monitoring, and Dosing Parameters for GVHD Prophylaxis in Hematopoietic Stem Cell Transplant (HSCT) Recipients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32802109/),h,11.8,187435,DB00091,Cyclosporine
,32802109,half-life,"Of pharmacokinetic parameters mean ± SD area under concentration - time curve (AUC), clearance, and half-life were estimated to be 5492 ± 1596 ng.h/mL, 19.44 ± 6.61 L/h, and 11.8 ± 5.4 h for IV and 7637.7 ± 2739.8 ng.h/mL, 19.42 ± 6.62 L/h, and 11.16 ± 5.9 h for oral administration, respectively.","Evaluation of Cyclosporine Pharmacokinetic, Monitoring, and Dosing Parameters for GVHD Prophylaxis in Hematopoietic Stem Cell Transplant (HSCT) Recipients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32802109/),h,11.16,187436,DB00091,Cyclosporine
,15550721,steady-state blood concentration,The steady-state plasma concentration of CER increased 1.4-fold when coadministered with CsA up to a steady-state blood concentration of 4 microM.,In vitro and in vivo correlation of the inhibitory effect of cyclosporin A on the transporter-mediated hepatic uptake of cerivastatin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15550721/),μM,4,187603,DB00091,Cyclosporine
,15550721,Ki,CsA competitively inhibited the uptake of [14C]CER with a Ki of 0.3 microM.,In vitro and in vivo correlation of the inhibitory effect of cyclosporin A on the transporter-mediated hepatic uptake of cerivastatin in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15550721/),μM,0.3,187604,DB00091,Cyclosporine
,15550721,IC50,"The IC50 for the uptake of [14C]CER in the absence and presence of rat plasma was 0.2 and 2.3 microM, respectively.",In vitro and in vivo correlation of the inhibitory effect of cyclosporin A on the transporter-mediated hepatic uptake of cerivastatin in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15550721/),μM,0.2,187605,DB00091,Cyclosporine
,15550721,IC50,"The IC50 for the uptake of [14C]CER in the absence and presence of rat plasma was 0.2 and 2.3 microM, respectively.",In vitro and in vivo correlation of the inhibitory effect of cyclosporin A on the transporter-mediated hepatic uptake of cerivastatin in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15550721/),μM,2.3,187606,DB00091,Cyclosporine
,16404634,EC(50),"The EC(50) values of cyclosporin A, tacrolimus and sirolimus for inhibition of BCRP-mediated pheophorbide A efflux were 4.3 +/- 1.9 microM, 3.6 +/- 1.8 microM and 1.9 +/- 0.4 microM, respectively.","Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16404634/),μM,4.3,188010,DB00091,Cyclosporine
,16404634,EC(50),"The EC(50) values of cyclosporin A, tacrolimus and sirolimus for inhibition of BCRP-mediated pheophorbide A efflux were 4.3 +/- 1.9 microM, 3.6 +/- 1.8 microM and 1.9 +/- 0.4 microM, respectively.","Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16404634/),μM,3.6,188011,DB00091,Cyclosporine
,16404634,EC(50),"The EC(50) values of cyclosporin A, tacrolimus and sirolimus for inhibition of BCRP-mediated pheophorbide A efflux were 4.3 +/- 1.9 microM, 3.6 +/- 1.8 microM and 1.9 +/- 0.4 microM, respectively.","Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16404634/),μM,1.9,188012,DB00091,Cyclosporine
,15518745,dose-normalized C(0),The mean dose-normalized C(0) was 2.13 +/- 0.91 ng/mL/mg.,Pharmacokinetic variability of sirolimus in Taiwanese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15518745/),[ng] / [mg·ml],2.13,188527,DB00091,Cyclosporine
,15871634,terminal half-life,The estimated terminal half-life of ezetimibe and ezetimibe-glucuronide is approximately 22 hours.,"Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871634/),h,22,188555,DB00091,Cyclosporine
,8013274,absolute bioavailability,The absolute bioavailability of 53% observed after a single oral dose of 10 mg/kg was variable and similar to that observed with cyclosporine A.,"Absorption and disposition of SDZ IMM 125, a new cyclosporine derivative, in rats after single and repeated administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8013274/),%,53,188664,DB00091,Cyclosporine
,8013274,volume of distribution,"The tissue distribution of SDZ IMM 125 is lower than that of cyclosporine A; the volume of distribution of this drug (2.6 liters/kg) is roughly half that of cyclosporine A, which is consistent with the lower lipophilicity of this compound.","Absorption and disposition of SDZ IMM 125, a new cyclosporine derivative, in rats after single and repeated administration. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8013274/),[l] / [kg],2.6,188665,DB00091,Cyclosporine
,8013274,systemic clearance,The systemic clearance of SDZ IMM 125 is relatively low (1.3 ml/min) and comparable to that of cyclosporine A.,"Absorption and disposition of SDZ IMM 125, a new cyclosporine derivative, in rats after single and repeated administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8013274/),[ml] / [min],1.3,188666,DB00091,Cyclosporine
,19560537,relative oral bioavailability (F(r)),"The relative oral bioavailability (F(r)) of DHA-ME in comparison to Neoral was determined to be 114%, while the F(r) of VE-ME was only 60%.",Improvement of cyclosporine A bioavailability by incorporating ethyl docosahexaenoate in the microemulsion as an oil excipient. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19560537/),%,114,189010,DB00091,Cyclosporine
,19560537,F(r),"The relative oral bioavailability (F(r)) of DHA-ME in comparison to Neoral was determined to be 114%, while the F(r) of VE-ME was only 60%.",Improvement of cyclosporine A bioavailability by incorporating ethyl docosahexaenoate in the microemulsion as an oil excipient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19560537/),%,60,189011,DB00091,Cyclosporine
,17220566,C/D ratio,"The dose of metoprolol and patient age were significantly higher in the MET group when compared with the MET+AMD group (1.00+/-0.480 versus 0.767+/-0.418 mg/kg/day, p<0.050; 68.6+/-10.6 versus 57.6+/-14.1 years, p<0.001, respectively), but the C/D ratio was significantly lower in the MET group than in the MET+AMD group (90.8+/-64.0 versus 136+/-97.8, p<0.01).",Effect of amiodarone on the serum concentration/dose ratio of metoprolol in patients with cardiac arrhythmia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220566/),,90.8,189038,DB00091,Cyclosporine
,17220566,C/D ratio,"The dose of metoprolol and patient age were significantly higher in the MET group when compared with the MET+AMD group (1.00+/-0.480 versus 0.767+/-0.418 mg/kg/day, p<0.050; 68.6+/-10.6 versus 57.6+/-14.1 years, p<0.001, respectively), but the C/D ratio was significantly lower in the MET group than in the MET+AMD group (90.8+/-64.0 versus 136+/-97.8, p<0.01).",Effect of amiodarone on the serum concentration/dose ratio of metoprolol in patients with cardiac arrhythmia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220566/),,136,189039,DB00091,Cyclosporine
>or=,16981000,C2,C2 levels >or=800 microg/l were also achieved for 20 out of 24 (83%) of cases after the 2 h infusion of CsA without any increase of CsA-related toxicity but for only three of the 23 patients (13%) after continuous infusion.,Cyclosporine short infusion and C2 monitoring in haematopoietic stem cell transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16981000/),[μg] / [l],800,189124,DB00091,Cyclosporine
>,16981000,C2,"Therefore, we recommend CsA infusions in 2 h during transplant and perform C2 monitoring to obtain therapeutic C2 levels >or=800 microg/l.",Cyclosporine short infusion and C2 monitoring in haematopoietic stem cell transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16981000/),[μg] / [l],800,189125,DB00091,Cyclosporine
,14600407,maximum concentration,"Although the pharmacokinetics of cyclosporin A was unchanged after intravenous administration, maximum concentration of cyclosporin A in ARF rats was significantly reduced to 608+/-62 and 999+/-189 ng/ml compared with 1720+/-142 and 1832+/-250 ng/ml in controls after oral administration of MEPC and completely dissolved formulations, respectively.",Decreased cyclosporin A concentrations in the absorption phase using microemulsion preconcentrate formulation in rats with cisplatin-induced acute renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14600407/),[ng] / [ml],608,189158,DB00091,Cyclosporine
,14600407,maximum concentration,"Although the pharmacokinetics of cyclosporin A was unchanged after intravenous administration, maximum concentration of cyclosporin A in ARF rats was significantly reduced to 608+/-62 and 999+/-189 ng/ml compared with 1720+/-142 and 1832+/-250 ng/ml in controls after oral administration of MEPC and completely dissolved formulations, respectively.",Decreased cyclosporin A concentrations in the absorption phase using microemulsion preconcentrate formulation in rats with cisplatin-induced acute renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14600407/),[ng] / [ml],999,189159,DB00091,Cyclosporine
,14600407,maximum concentration,"Although the pharmacokinetics of cyclosporin A was unchanged after intravenous administration, maximum concentration of cyclosporin A in ARF rats was significantly reduced to 608+/-62 and 999+/-189 ng/ml compared with 1720+/-142 and 1832+/-250 ng/ml in controls after oral administration of MEPC and completely dissolved formulations, respectively.",Decreased cyclosporin A concentrations in the absorption phase using microemulsion preconcentrate formulation in rats with cisplatin-induced acute renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14600407/),[ng] / [ml],1720,189160,DB00091,Cyclosporine
,14600407,maximum concentration,"Although the pharmacokinetics of cyclosporin A was unchanged after intravenous administration, maximum concentration of cyclosporin A in ARF rats was significantly reduced to 608+/-62 and 999+/-189 ng/ml compared with 1720+/-142 and 1832+/-250 ng/ml in controls after oral administration of MEPC and completely dissolved formulations, respectively.",Decreased cyclosporin A concentrations in the absorption phase using microemulsion preconcentrate formulation in rats with cisplatin-induced acute renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14600407/),[ng] / [ml],1832,189161,DB00091,Cyclosporine
,16430377,area under the curve,"Mean area under the curve and predicted maximal blood concentration increased with each dosing cohort (I = 9840 h*microg/L, 398 microg/L; II = 18300 h*microg/L, 645 microg/L; III = 32500 h*microg/L, 1300 microg/L).",Cyclosporin A disposition following acute traumatic brain injury. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16430377/),[h·μg] / [l],9840,189387,DB00091,Cyclosporine
,16430377,area under the curve,"Mean area under the curve and predicted maximal blood concentration increased with each dosing cohort (I = 9840 h*microg/L, 398 microg/L; II = 18300 h*microg/L, 645 microg/L; III = 32500 h*microg/L, 1300 microg/L).",Cyclosporin A disposition following acute traumatic brain injury. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16430377/),[μg] / [l],398,189388,DB00091,Cyclosporine
,16430377,area under the curve,"Mean area under the curve and predicted maximal blood concentration increased with each dosing cohort (I = 9840 h*microg/L, 398 microg/L; II = 18300 h*microg/L, 645 microg/L; III = 32500 h*microg/L, 1300 microg/L).",Cyclosporin A disposition following acute traumatic brain injury. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16430377/),[h·μg] / [l],18300,189389,DB00091,Cyclosporine
,16430377,area under the curve,"Mean area under the curve and predicted maximal blood concentration increased with each dosing cohort (I = 9840 h*microg/L, 398 microg/L; II = 18300 h*microg/L, 645 microg/L; III = 32500 h*microg/L, 1300 microg/L).",Cyclosporin A disposition following acute traumatic brain injury. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16430377/),[h·μg] / [l],32500,189390,DB00091,Cyclosporine
,16430377,maximal blood concentration,"Mean area under the curve and predicted maximal blood concentration increased with each dosing cohort (I = 9840 h*microg/L, 398 microg/L; II = 18300 h*microg/L, 645 microg/L; III = 32500 h*microg/L, 1300 microg/L).",Cyclosporin A disposition following acute traumatic brain injury. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16430377/),[μg] / [l],645,189391,DB00091,Cyclosporine
,16430377,maximal blood concentration,"Mean area under the curve and predicted maximal blood concentration increased with each dosing cohort (I = 9840 h*microg/L, 398 microg/L; II = 18300 h*microg/L, 645 microg/L; III = 32500 h*microg/L, 1300 microg/L).",Cyclosporin A disposition following acute traumatic brain injury. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16430377/),[h·μg] / [l],32500,189392,DB00091,Cyclosporine
,16430377,maximal blood concentration,"Mean area under the curve and predicted maximal blood concentration increased with each dosing cohort (I = 9840 h*microg/L, 398 microg/L; II = 18300 h*microg/L, 645 microg/L; III = 32500 h*microg/L, 1300 microg/L).",Cyclosporin A disposition following acute traumatic brain injury. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16430377/),[μg] / [l],1300,189393,DB00091,Cyclosporine
,16430377,Whole blood clearance,"Whole blood clearance, steady state volume of distribution, and beta half-life were independent of dose and higher than published reports from other populations: 0.420 L/h/kg, 5.91 L/kg, and 17.3 h, respectively.",Cyclosporin A disposition following acute traumatic brain injury. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16430377/),[l] / [h·kg],0.420,189394,DB00091,Cyclosporine
,16430377,steady state volume of distribution,"Whole blood clearance, steady state volume of distribution, and beta half-life were independent of dose and higher than published reports from other populations: 0.420 L/h/kg, 5.91 L/kg, and 17.3 h, respectively.",Cyclosporin A disposition following acute traumatic brain injury. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16430377/),[l] / [kg],5.91,189395,DB00091,Cyclosporine
,16430377,beta half-life,"Whole blood clearance, steady state volume of distribution, and beta half-life were independent of dose and higher than published reports from other populations: 0.420 L/h/kg, 5.91 L/kg, and 17.3 h, respectively.",Cyclosporin A disposition following acute traumatic brain injury. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16430377/),h,17.3,189396,DB00091,Cyclosporine
,17044476,Time to maximum concentration (Tmax),Time to maximum concentration (Tmax) of CsA was at 1.5 hr (1.5-4.0 hr) [median (range)].,Effect of diltiazem on the pharmacokinetics of microemulsion cyclosporine A in renal transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17044476/),h,1.5,190811,DB00091,Cyclosporine
,17044476,Tmax,Tmax of CsA was at 1.5 hr (1.5-4.0 hr) [median (range)].,Effect of diltiazem on the pharmacokinetics of microemulsion cyclosporine A in renal transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17044476/),h,1.5,190812,DB00091,Cyclosporine
,11714218,whole blood,His oral cyclosporine dosage for the past 2 years was stabilized at 100 mg twice/day; his cyclosporine whole blood trough levels 15 days earlier and on the day he was admitted were both 178 ng/ml.,Possible interaction between intravenous azithromycin and oral cyclosporine. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11714218/),[ng] / [ml],178,190868,DB00091,Cyclosporine
,11714218,trough levels,His oral cyclosporine dosage for the past 2 years was stabilized at 100 mg twice/day; his cyclosporine whole blood trough levels 15 days earlier and on the day he was admitted were both 178 ng/ml.,Possible interaction between intravenous azithromycin and oral cyclosporine. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11714218/),[ng] / [ml],178,190869,DB00091,Cyclosporine
,11714218,trough level,"On hospital day 3, his cyclosporine trough level rose to 400 ng/ml and his dosage was reduced by 50%.",Possible interaction between intravenous azithromycin and oral cyclosporine. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11714218/),[ng] / [ml],400,190870,DB00091,Cyclosporine
,11714218,Trough levels,"Trough levels were 181 ng/ml and 175 ng/ml on hospital days 6 and 9, respectively On hospital day 9, the patient stopped receiving azithromycin.",Possible interaction between intravenous azithromycin and oral cyclosporine. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11714218/),[ng] / [ml],181,190871,DB00091,Cyclosporine
,11714218,Trough levels,"Trough levels were 181 ng/ml and 175 ng/ml on hospital days 6 and 9, respectively On hospital day 9, the patient stopped receiving azithromycin.",Possible interaction between intravenous azithromycin and oral cyclosporine. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11714218/),[ng] / [ml],175,190872,DB00091,Cyclosporine
,11714218,trough level,"On hospital day 14, his cyclosporine trough level dropped to 76 ng/ml, and his cyclosporine dosage was increased back to 100 mg twice/day.",Possible interaction between intravenous azithromycin and oral cyclosporine. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11714218/),[ng] / [ml],76,190873,DB00091,Cyclosporine
,11714218,trough level,"The patient was discharged on day 20, and a follow-up cyclosporine trough level determined 3 weeks later was 175 ng/ml.",Possible interaction between intravenous azithromycin and oral cyclosporine. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11714218/),[ng] / [ml],175,190874,DB00091,Cyclosporine
,11936566,clearance,The median (range) valspodar clearance was 0.40 ml/min/kg (0.07-1.40 ml/min/kg).,Pharmacokinetic study of infusional valspodar. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11936566/),[ml] / [kg·min],0.40,190992,DB00091,Cyclosporine
,15802827,apparent absolute bioavailability,"The apparent oral bioavailability of CsA in P-gp knockout mice was 1.55-fold larger than in wild-type mice, leading to an apparent absolute bioavailability of 41.8%.",Limited role of P-glycoprotein in the intestinal absorption of cyclosporin A. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15802827/),%,41.8,191153,DB00091,Cyclosporine
,9850444,AUC0-infinity,"In a cross-over study involving 36 healthy male volunteers, single 500 mg cyclosporine doses of Sang-35 (AUC0-infinity: 13,900 +/- 2470 micrograms.",Development of Sang-35: a cyclosporine formulation bioequivalent to Neoral. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850444/),μg,"13,900",191531,DB00091,Cyclosporine
,9850444,AUC0-infinity,"h.L-1, mean +/- standard deviation (SD)) and of Neoral (AUC0-infinity: 14,000 +/- 2900 micrograms.h.L-1) resulted in equal areas-under-the-time-concentration curve (AUC0-infinity).",Development of Sang-35: a cyclosporine formulation bioequivalent to Neoral. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850444/),[h·μg] / [l],"14,000",191532,DB00091,Cyclosporine
,9850444,AUC0-12 h,"In stable kidney transplant patients (n = 12) receiving a mean (+/- SD) cyclosporine dose of mg/d (3.6 +/- 1.6 mg/kg/d), AUC0-12 h after Sang-35 was, as expected, significantly higher than that after Sandimmune (4550 +/- 1858 vs 3468 +/- 1402 micrograms.h.L-1, p < 0.01).",Development of Sang-35: a cyclosporine formulation bioequivalent to Neoral. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850444/),[h·μg] / [l],4550,191533,DB00091,Cyclosporine
,9850444,AUC0-12 h,"In stable kidney transplant patients (n = 12) receiving a mean (+/- SD) cyclosporine dose of mg/d (3.6 +/- 1.6 mg/kg/d), AUC0-12 h after Sang-35 was, as expected, significantly higher than that after Sandimmune (4550 +/- 1858 vs 3468 +/- 1402 micrograms.h.L-1, p < 0.01).",Development of Sang-35: a cyclosporine formulation bioequivalent to Neoral. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850444/),[h·μg] / [l],3468,191534,DB00091,Cyclosporine
,9850444,AUC0-12 h,"Sang-35 and Neoral resulted in equivalent cyclosporine AUC0-12 h values (4120 +/- 1508 and 4377 +/- 1579 micrograms.h.L-1, respectively) in stable kidney transplant patients (dose: 293 +/- 114 mg/d or 3.7 +/- 1.5 mg/kg/d, n = 32).",Development of Sang-35: a cyclosporine formulation bioequivalent to Neoral. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850444/),[h·μg] / [l],4120,191535,DB00091,Cyclosporine
,9850444,AUC0-12 h,"Sang-35 and Neoral resulted in equivalent cyclosporine AUC0-12 h values (4120 +/- 1508 and 4377 +/- 1579 micrograms.h.L-1, respectively) in stable kidney transplant patients (dose: 293 +/- 114 mg/d or 3.7 +/- 1.5 mg/kg/d, n = 32).",Development of Sang-35: a cyclosporine formulation bioequivalent to Neoral. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850444/),[h·μg] / [l],4377,191536,DB00091,Cyclosporine
,25378925,particle,The particle size of PLGA NPs (182.2 ± 12.8 nm) was larger than that of NLCs (89.7 ± 9.0 nm) and SMEDDS (26.9 ± 1.9 nm).,Enhancement of oral bioavailability of cyclosporine A: comparison of various nanoscale drug-delivery systems. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25378925/),,182.2,191649,DB00091,Cyclosporine
,25378925,particle,The particle size of PLGA NPs (182.2 ± 12.8 nm) was larger than that of NLCs (89.7 ± 9.0 nm) and SMEDDS (26.9 ± 1.9 nm).,Enhancement of oral bioavailability of cyclosporine A: comparison of various nanoscale drug-delivery systems. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25378925/),,89.7,191650,DB00091,Cyclosporine
,25378925,entrapment efficiency,"The entrapment efficiency of PLGA NPs and NLCs was 87.6%± 1.6% and 80.3%± 0.6%, respectively.",Enhancement of oral bioavailability of cyclosporine A: comparison of various nanoscale drug-delivery systems. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25378925/),%,87.6,191651,DB00091,Cyclosporine
,25378925,entrapment efficiency,"The entrapment efficiency of PLGA NPs and NLCs was 87.6%± 1.6% and 80.3%± 0.6%, respectively.",Enhancement of oral bioavailability of cyclosporine A: comparison of various nanoscale drug-delivery systems. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25378925/),%,80.3,191652,DB00091,Cyclosporine
lower,25378925,cumulative release,"In vitro release tests indicated that the cumulative release of CyA was lower than 4% from all vehicles, including Sandimmun Neoral(®), according to the dialysis method.",Enhancement of oral bioavailability of cyclosporine A: comparison of various nanoscale drug-delivery systems. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25378925/),%,4,191653,DB00091,Cyclosporine
,25378925,relative oral bioavailability,"Both NLCs and SMEDDS showed high relative oral bioavailability, 111.8% and 73.6%, respectively, after oral gavage administration to beagle dogs, which was not statistically different from commercial Sandimmun Neoral(®).",Enhancement of oral bioavailability of cyclosporine A: comparison of various nanoscale drug-delivery systems. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25378925/),%,111.8,191654,DB00091,Cyclosporine
,25378925,relative oral bioavailability,"Both NLCs and SMEDDS showed high relative oral bioavailability, 111.8% and 73.6%, respectively, after oral gavage administration to beagle dogs, which was not statistically different from commercial Sandimmun Neoral(®).",Enhancement of oral bioavailability of cyclosporine A: comparison of various nanoscale drug-delivery systems. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25378925/),%,73.6,191655,DB00091,Cyclosporine
,25378925,relative bioavailability,"However, PLGA NPs failed to achieve efficient absorption, with relative bioavailability of about 22.7%.",Enhancement of oral bioavailability of cyclosporine A: comparison of various nanoscale drug-delivery systems. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25378925/),%,22.7,191656,DB00091,Cyclosporine
,16386526,AUC(0-12 h),"The renal insufficiency group showed a significantly increased AUC(0-12 h) for MPAG (1550 +/- 392 vs 3527 +/- 1130 microg.h/mL, P < .001) and increased trough and AUC(0-12 h) values for f-MPA (0.023 +/- 0.02 vs 0.094 +/- 0.07 microg/mL, P = .003, and 0.87 +/- 0.3 vs 1.52 +/- 0.8 microg . h/mL, P = .016, respectively).",Pharmacokinetics of mycophenolate mofetil in kidney transplant patients with renal insufficiency. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386526/),[h·μg] / [ml],1550,191709,DB00091,Cyclosporine
,16386526,AUC(0-12 h),"The renal insufficiency group showed a significantly increased AUC(0-12 h) for MPAG (1550 +/- 392 vs 3527 +/- 1130 microg.h/mL, P < .001) and increased trough and AUC(0-12 h) values for f-MPA (0.023 +/- 0.02 vs 0.094 +/- 0.07 microg/mL, P = .003, and 0.87 +/- 0.3 vs 1.52 +/- 0.8 microg . h/mL, P = .016, respectively).",Pharmacokinetics of mycophenolate mofetil in kidney transplant patients with renal insufficiency. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386526/),[h·μg] / [ml],3527,191710,DB00091,Cyclosporine
,16386526,trough,"The renal insufficiency group showed a significantly increased AUC(0-12 h) for MPAG (1550 +/- 392 vs 3527 +/- 1130 microg.h/mL, P < .001) and increased trough and AUC(0-12 h) values for f-MPA (0.023 +/- 0.02 vs 0.094 +/- 0.07 microg/mL, P = .003, and 0.87 +/- 0.3 vs 1.52 +/- 0.8 microg . h/mL, P = .016, respectively).",Pharmacokinetics of mycophenolate mofetil in kidney transplant patients with renal insufficiency. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386526/),[μg] / [ml],0.023,191711,DB00091,Cyclosporine
,16386526,AUC(0-12 h),"The renal insufficiency group showed a significantly increased AUC(0-12 h) for MPAG (1550 +/- 392 vs 3527 +/- 1130 microg.h/mL, P < .001) and increased trough and AUC(0-12 h) values for f-MPA (0.023 +/- 0.02 vs 0.094 +/- 0.07 microg/mL, P = .003, and 0.87 +/- 0.3 vs 1.52 +/- 0.8 microg . h/mL, P = .016, respectively).",Pharmacokinetics of mycophenolate mofetil in kidney transplant patients with renal insufficiency. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386526/),[μg] / [ml],0.094,191712,DB00091,Cyclosporine
,16386526,AUC(0-12 h),"The renal insufficiency group showed a significantly increased AUC(0-12 h) for MPAG (1550 +/- 392 vs 3527 +/- 1130 microg.h/mL, P < .001) and increased trough and AUC(0-12 h) values for f-MPA (0.023 +/- 0.02 vs 0.094 +/- 0.07 microg/mL, P = .003, and 0.87 +/- 0.3 vs 1.52 +/- 0.8 microg . h/mL, P = .016, respectively).",Pharmacokinetics of mycophenolate mofetil in kidney transplant patients with renal insufficiency. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386526/),[h·μg] / [ml],0.87,191713,DB00091,Cyclosporine
,16386526,AUC(0-12 h),"The renal insufficiency group showed a significantly increased AUC(0-12 h) for MPAG (1550 +/- 392 vs 3527 +/- 1130 microg.h/mL, P < .001) and increased trough and AUC(0-12 h) values for f-MPA (0.023 +/- 0.02 vs 0.094 +/- 0.07 microg/mL, P = .003, and 0.87 +/- 0.3 vs 1.52 +/- 0.8 microg . h/mL, P = .016, respectively).",Pharmacokinetics of mycophenolate mofetil in kidney transplant patients with renal insufficiency. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386526/),[h·μg] / [ml],1.52,191714,DB00091,Cyclosporine
,11271189,Blood concentrations,"Blood concentrations ranged from 0.5 to 391 ng/ml and from 0.5 to 616 ng/ml after intravenous and oral doses, respectively.",Pharmacokinetic interpretation of FK 506 levels in blood and in plasma during a European randomised study in primary liver transplant patients. The FK 506 European Study Group. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11271189/),[ng] / [ml],0.5 to 391,191983,DB00091,Cyclosporine
,11271189,Blood concentrations,"Blood concentrations ranged from 0.5 to 391 ng/ml and from 0.5 to 616 ng/ml after intravenous and oral doses, respectively.",Pharmacokinetic interpretation of FK 506 levels in blood and in plasma during a European randomised study in primary liver transplant patients. The FK 506 European Study Group. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11271189/),[ng] / [ml],0.5 to 616,191984,DB00091,Cyclosporine
,9625273,tmax,Grapefruit juice postponed the tmax of diazepam from 1.50 h to 2.06 h (P < 0.01).,Interaction between grapefruit juice and diazepam in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9625273/),h,1.50,192764,DB00091,Cyclosporine
,9625273,tmax,Grapefruit juice postponed the tmax of diazepam from 1.50 h to 2.06 h (P < 0.01).,Interaction between grapefruit juice and diazepam in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9625273/),h,2.06,192765,DB00091,Cyclosporine
,7715295,Area-under-the-curve (AUC),"Area-under-the-curve (AUC) was significantly higher with grapefruit juice than with water or orange juice (means 7057, 4871, and 4932 ng h/mL, respectively; p < 0.0001).",Effect of grapefruit juice on blood cyclosporin concentration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7715295/),[h·ng] / [ml],7057,192829,DB00091,Cyclosporine
,7715295,Area-under-the-curve (AUC),"Area-under-the-curve (AUC) was significantly higher with grapefruit juice than with water or orange juice (means 7057, 4871, and 4932 ng h/mL, respectively; p < 0.0001).",Effect of grapefruit juice on blood cyclosporin concentration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7715295/),[h·ng] / [ml],4871,192830,DB00091,Cyclosporine
,7715295,Area-under-the-curve (AUC),"Area-under-the-curve (AUC) was significantly higher with grapefruit juice than with water or orange juice (means 7057, 4871, and 4932 ng h/mL, respectively; p < 0.0001).",Effect of grapefruit juice on blood cyclosporin concentration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7715295/),[h·ng] / [ml],4932,192831,DB00091,Cyclosporine
,17164687,tmax,Sirolimus also had a significant effect on the FPIA/LC-MS ratio at 12 hour in studies with tmax at 2 hours (P = 0.042) but not 4 hours (P = 0.735).,12-hour area under the curve cyclosporine concentrations determined by a validated liquid chromatography-mass spectrometry procedure compared with fluorescence polarization immunoassay reveals sirolimus effect on cyclosporine pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17164687/),h,2,193007,DB00091,Cyclosporine
,17164687,tmax,Sirolimus also had a significant effect on the FPIA/LC-MS ratio at 12 hour in studies with tmax at 2 hours (P = 0.042) but not 4 hours (P = 0.735).,12-hour area under the curve cyclosporine concentrations determined by a validated liquid chromatography-mass spectrometry procedure compared with fluorescence polarization immunoassay reveals sirolimus effect on cyclosporine pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17164687/),h,4,193008,DB00091,Cyclosporine
,3308718,peak CyA concentration,"The peak blood CyA concentration appeared at about 2.5 h after oral administration of CyA 180-360 mg, and the mean peak CyA concentration was 582 +/- 238 (SD) ng/ml.",A preliminary pharmacokinetic study of cyclosporine A in 10 Japanese renal transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3308718/),[ng] / [ml],582,193038,DB00091,Cyclosporine
,3308718,apparent clearance,The apparent clearance was 39.9 +/- 16.9 (SD) ml/min/kg which is almost the same as reported in European transplant patients.,A preliminary pharmacokinetic study of cyclosporine A in 10 Japanese renal transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3308718/),[ml] / [kg·min],39.9,193039,DB00091,Cyclosporine
,3308718,apparent distribution volume,The apparent distribution volume was 5.34 +/- 3.05 (SD) l/kg.,A preliminary pharmacokinetic study of cyclosporine A in 10 Japanese renal transplant patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3308718/),[l] / [kg],5.34,193040,DB00091,Cyclosporine
,12454106,time to progression,"The median time to progression was 3.5 months (95% CI, 1.2 to 3.9 months), and median overall survival was 6.0 months (95% CI, 2.3 months to not available).",Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12454106/),month,3.5,193238,DB00091,Cyclosporine
,12454106,overall survival,"The median time to progression was 3.5 months (95% CI, 1.2 to 3.9 months), and median overall survival was 6.0 months (95% CI, 2.3 months to not available).",Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12454106/),month,6.0,193239,DB00091,Cyclosporine
,12454106,area under the concentration-time curve (AUC),"Pharmacokinetics revealed that the mean area under the concentration-time curve (AUC) of oral paclitaxel was 5.0 +/- 2.3 micro mol/L/h in week 1 and 4.6 +/- 2.0 micro mol/L/h in week 2, with interpatient variabilities (coefficient of variation [%CV]) of 45% and 42%, respectively.",Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12454106/),[μmol] / [h·l],5.0,193240,DB00091,Cyclosporine
,12454106,area under the concentration-time curve (AUC),"Pharmacokinetics revealed that the mean area under the concentration-time curve (AUC) of oral paclitaxel was 5.0 +/- 2.3 micro mol/L/h in week 1 and 4.6 +/- 2.0 micro mol/L/h in week 2, with interpatient variabilities (coefficient of variation [%CV]) of 45% and 42%, respectively.",Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12454106/),[μmol] / [h·l],4.6,193241,DB00091,Cyclosporine
,16299163,Km,"The Km, Vmax, and Ki values were 25.5 microM, 2.45 nmol/min/mg protein, and 5.52 microM, respectively.",Demonstration of docosahexaenoic acid as a bioavailability enhancer for CYP3A substrates: in vitro and in vivo evidence using cyclosporin in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16299163/),μM,25.5,193543,DB00091,Cyclosporine
,16299163,Vmax,"The Km, Vmax, and Ki values were 25.5 microM, 2.45 nmol/min/mg protein, and 5.52 microM, respectively.",Demonstration of docosahexaenoic acid as a bioavailability enhancer for CYP3A substrates: in vitro and in vivo evidence using cyclosporin in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16299163/),[nM] / [mg·min],2.45,193544,DB00091,Cyclosporine
,16299163,Vmax,"The Km, Vmax, and Ki values were 25.5 microM, 2.45 nmol/min/mg protein, and 5.52 microM, respectively.",Demonstration of docosahexaenoic acid as a bioavailability enhancer for CYP3A substrates: in vitro and in vivo evidence using cyclosporin in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16299163/),μM,5.52,193545,DB00091,Cyclosporine
,16299163,Ki,"The Km, Vmax, and Ki values were 25.5 microM, 2.45 nmol/min/mg protein, and 5.52 microM, respectively.",Demonstration of docosahexaenoic acid as a bioavailability enhancer for CYP3A substrates: in vitro and in vivo evidence using cyclosporin in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16299163/),μM,5.52,193546,DB00091,Cyclosporine
,12826143,dose-normalized AUC(0-4),"The mean dose-normalized AUC(0-4) values changed by less than 2.5%, namely, 557 versus 545 ng x h/mL per unit dose, respectively.",Comparison of cyclosporine absorption profiles over a 12-month period in stable pediatric renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12826143/),[h·ng] / [ml·unit],557,193665,DB00091,Cyclosporine
,12826143,dose-normalized AUC(0-4),"The mean dose-normalized AUC(0-4) values changed by less than 2.5%, namely, 557 versus 545 ng x h/mL per unit dose, respectively.",Comparison of cyclosporine absorption profiles over a 12-month period in stable pediatric renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12826143/),[h·ng] / [ml·unit],545,193666,DB00091,Cyclosporine
,16003227,area under the curve,"Subjects using protease inhibitors and cyclosporine had a threefold increase in cyclosporine area under the curve (4,190+/-2,180-11,900+/-1,600 ng*hr/mL, P<0.01), necessitating an 85% reduction in cyclosporine dose over a 2-year period (1.3+/-1.5-0.2+/-0.0 mg/kg/dose), leading to a progressive increase in oral cyclosporine bioavailability (R=0.92, P<0.02).",Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16003227/),[h·ng] / [ml],"4,190",194290,DB00091,Cyclosporine
,16003227,area under the curve,"Subjects using protease inhibitors and cyclosporine had a threefold increase in cyclosporine area under the curve (4,190+/-2,180-11,900+/-1,600 ng*hr/mL, P<0.01), necessitating an 85% reduction in cyclosporine dose over a 2-year period (1.3+/-1.5-0.2+/-0.0 mg/kg/dose), leading to a progressive increase in oral cyclosporine bioavailability (R=0.92, P<0.02).",Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16003227/),[h·ng] / [ml],"11,900",194291,DB00091,Cyclosporine
,19660003,apparent clearance (CL/F),"The typical values with interindividual variability for apparent clearance (CL/F) and apparent volume of distribution (V/F) were 10.1 l h(-1) (23.8%) and 3670 l (56.7%), respectively.",Population pharmacokinetics of sirolimus in de novo Chinese adult renal transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19660003/),[l] / [h],10.1,194447,DB00091,Cyclosporine
,19660003,apparent volume of distribution (V/F),"The typical values with interindividual variability for apparent clearance (CL/F) and apparent volume of distribution (V/F) were 10.1 l h(-1) (23.8%) and 3670 l (56.7%), respectively.",Population pharmacokinetics of sirolimus in de novo Chinese adult renal transplant patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19660003/),l,3670,194448,DB00091,Cyclosporine
,15012174,half-life stabilization time,"In the final model, the Dmax parameter is affected by plasmatic urea values and shows a half-life stabilization time of 90.90 days (95% CI: 52.60 to 250 days).",[Cyclosporin pharmacokinetic modeling in renal transplant patients]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15012174/),d,90.90,194572,DB00091,Cyclosporine
,15012174,Dmax,"Plasmatic urea values of 50 mg/dL are related to an initial Dmax value of 3 mg/kg daily (95% CI: 1.81 to 4.19 mg/kg daily) which decreases exponentially throughout the post-transplant period until it reaches a constant value of 2.16 mg/kg daily (95% CI: 1.41 to 2.91 mg/kg daily) In the same way, the Km parameter presents a central tendency value of 93.60 ng/mL (95% CI: 28.60 to 158.60 ng/mL) and the half-life necessary for its stabilization is 12.70 days (95% CI: 9.80 to 17.90 days).",[Cyclosporin pharmacokinetic modeling in renal transplant patients]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15012174/),[mg] / [kg],3,194573,DB00091,Cyclosporine
,15012174,Km,"Plasmatic urea values of 50 mg/dL are related to an initial Dmax value of 3 mg/kg daily (95% CI: 1.81 to 4.19 mg/kg daily) which decreases exponentially throughout the post-transplant period until it reaches a constant value of 2.16 mg/kg daily (95% CI: 1.41 to 2.91 mg/kg daily) In the same way, the Km parameter presents a central tendency value of 93.60 ng/mL (95% CI: 28.60 to 158.60 ng/mL) and the half-life necessary for its stabilization is 12.70 days (95% CI: 9.80 to 17.90 days).",[Cyclosporin pharmacokinetic modeling in renal transplant patients]. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15012174/),[ng] / [ml],93.60,194574,DB00091,Cyclosporine
,15012174,half-life,"Plasmatic urea values of 50 mg/dL are related to an initial Dmax value of 3 mg/kg daily (95% CI: 1.81 to 4.19 mg/kg daily) which decreases exponentially throughout the post-transplant period until it reaches a constant value of 2.16 mg/kg daily (95% CI: 1.41 to 2.91 mg/kg daily) In the same way, the Km parameter presents a central tendency value of 93.60 ng/mL (95% CI: 28.60 to 158.60 ng/mL) and the half-life necessary for its stabilization is 12.70 days (95% CI: 9.80 to 17.90 days).",[Cyclosporin pharmacokinetic modeling in renal transplant patients]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15012174/),d,12.70,194575,DB00091,Cyclosporine
greater,21695772,area under the plasma concentration-time curve from 0 to 12 hours (AUC(0-12) ),The aim of this study was to determine the MMF dosage required for pediatric liver transplant recipients to achieve an area under the plasma concentration-time curve from 0 to 12 hours (AUC(0-12) ) for mycophenolic acid (MPA) greater than 30 mg hour/L.,Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21695772/),[h·mg] / [l],30,194863,DB00091,Cyclosporine
less,21695772,AUC(0-12),Thirteen of the 15 patients had an MPA AUC(0-12) value less than 30 mg hour/L.,Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21695772/),[h·mg] / [l],30,194864,DB00091,Cyclosporine
greater,21695772,AUC(0-12),The MMF dosage required to reach an MPA AUC(0-12) value greater than the defined target of 30 mg hour/L ranged from 371 to 1014 mg/m(2) /day.,Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21695772/),[h·mg] / [l],30,194865,DB00091,Cyclosporine
,21695772,AUC(0-12),The MMF dosage required to reach an MPA AUC(0-12) value greater than the defined target of 30 mg hour/L ranged from 371 to 1014 mg/m(2) /day.,Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21695772/),[mg] / [·d·m(2)],371 to 1014,194866,DB00091,Cyclosporine
greater,21695772,AUC(0-12),"In conclusion, an initial MMF dose of 600 mg/m(2) twice a day led to MPA AUC(0-12) values greater than the 30 mg hour/L threshold except when rifampin was coadministered.",Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21695772/),[h·mg] / [l],30,194867,DB00091,Cyclosporine
,15032307,zeta potential,"Following 1:10 aqueous dilution of optimal paclitaxel SMEDDS, the droplet size of resulting microemulsions was 2.0 +/- 0.4 nm, and the zeta potential was -45.5 +/- 0.5 mV.",Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15032307/),m,-,195658,DB00091,Cyclosporine
,15032307,zeta potential,"Following 1:10 aqueous dilution of optimal paclitaxel SMEDDS, the droplet size of resulting microemulsions was 2.0 +/- 0.4 nm, and the zeta potential was -45.5 +/- 0.5 mV.",Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15032307/),m,45.5,195659,DB00091,Cyclosporine
,15032307,oral bioavailability,"Compared to Taxol, the oral bioavailability of paclitaxel SMEDDS increased by 28.6% to 52.7% at various doses.",Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15032307/),,52,195660,DB00091,Cyclosporine
,15032307,time above therapeutic level,There was a significant improvement in area under the curve (AUC) and time above therapeutic level (0.1 microM) of paclitaxel SMEDDS as compared to those of Taxol following coadministration of both formulations with 40 mg cyclosporin A (CsA)/kg.,Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15032307/),,0,195661,DB00091,Cyclosporine
,30139426,Cmax,"However, the Cmax of CyA-loaded PEO-b-PCL micelles was significantly (p < 0.05) higher than that obtained with Neoral® (2.10 ± 0.41 versus 1.40 ± 0.25 µg/mL, respectively).",Pharmacokinetics of Orally Administered Poly(Ethylene Oxide)-block-Poly(ε-Caprolactone) Micelles of Cyclosporine A in Rats: Comparison with Neoral®. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30139426/),[μg] / [ml],2.10,195945,DB00091,Cyclosporine
,30139426,Cmax,"However, the Cmax of CyA-loaded PEO-b-PCL micelles was significantly (p < 0.05) higher than that obtained with Neoral® (2.10 ± 0.41 versus 1.40 ± 0.25 µg/mL, respectively).",Pharmacokinetics of Orally Administered Poly(Ethylene Oxide)-block-Poly(ε-Caprolactone) Micelles of Cyclosporine A in Rats: Comparison with Neoral®. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30139426/),[μg] / [ml],1.40,195946,DB00091,Cyclosporine
,25913040,dAUC,"MMF + PAN intake led to a lowest mean dAUC for MPA of 41.46 ng h ml(-1) mg(-1) [95% confidence interval (CI) 32.38, 50.54], while MPA exposure was highest for EC-MPS + PAN [dAUC: 46.30 ng h ml(-1) mg(-1) (95% CI 37.11, 55.49)].",No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25913040/),[h·ng] / [mg·ml],41.46,196144,DB00091,Cyclosporine
,25913040,dAUC,"MMF + PAN intake led to a lowest mean dAUC for MPA of 41.46 ng h ml(-1) mg(-1) [95% confidence interval (CI) 32.38, 50.54], while MPA exposure was highest for EC-MPS + PAN [dAUC: 46.30 ng h ml(-1) mg(-1) (95% CI 37.11, 55.49)].",No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25913040/),[h·ng] / [mg·ml],46.30,196145,DB00091,Cyclosporine
,25913040,dAUC,"Only for MMF [dAUC: 41.46 ng h ml(-1) mg(-1) (95% CI 32.38, 50.54)] and EC-MPS [dAUC: 43.39 ng h ml(-1) mg(-1) (95% CI 33.44, 53.34)] bioequivalence was established for dAUC [geometric mean ratio: 101.25% (90% CI 84.60, 121.17)].",No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25913040/),[h·ng] / [mg·ml],41.46,196146,DB00091,Cyclosporine
,25913040,dAUC,"Only for MMF [dAUC: 41.46 ng h ml(-1) mg(-1) (95% CI 32.38, 50.54)] and EC-MPS [dAUC: 43.39 ng h ml(-1) mg(-1) (95% CI 33.44, 53.34)] bioequivalence was established for dAUC [geometric mean ratio: 101.25% (90% CI 84.60, 121.17)].",No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25913040/),[h·ng] / [mg·ml],43.39,196147,DB00091,Cyclosporine
,25913040,time to Cmax (tmax),Simultaneous EC-MPS + PAN intake led to an earlier time to Cmax (tmax) [median: 2.0 h (min-max: 0.5-10.0)] than EC-MPS intake alone [3 h (1.5-12.0); P = 0.037].,No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25913040/),h,2.0,196148,DB00091,Cyclosporine
,25913040,time to Cmax (tmax),Simultaneous EC-MPS + PAN intake led to an earlier time to Cmax (tmax) [median: 2.0 h (min-max: 0.5-10.0)] than EC-MPS intake alone [3 h (1.5-12.0); P = 0.037].,No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25913040/),h,3,196149,DB00091,Cyclosporine
,25913040,Tmax,"Tmax was not affected for MMF [1.0 h (0.5-5.0)] ± pantoprazole [1.0 h (0.5-6.0), P = 0.928).",No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25913040/),h,1.0,196150,DB00091,Cyclosporine
,25913040,Tmax,"Tmax was not affected for MMF [1.0 h (0.5-5.0)] ± pantoprazole [1.0 h (0.5-6.0), P = 0.928).",No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25913040/),h,1.0,196151,DB00091,Cyclosporine
,1292968,AUC,"For example, the mean AUC +/- sd values were 5,247 +/- 2,255 (D-1) vs 5,317 +/- 1,675 (D+13) microgram.",Lack of effect of isradipine on cyclosporin pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1292968/),μg,"5,247",196992,DB00091,Cyclosporine
,1292968,AUC,"For example, the mean AUC +/- sd values were 5,247 +/- 2,255 (D-1) vs 5,317 +/- 1,675 (D+13) microgram.",Lack of effect of isradipine on cyclosporin pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1292968/),μg,"5,317",196993,DB00091,Cyclosporine
over,23011175,peak concentration,"To establish the conversion ratio and the best strategy of twice-daily administration of CyA, the authors investigated the serial changes in the blood CyA concentration during the switch from twice-daily intravenous infusion to oral administration while maintaining high-peak concentration (over 1000 ng/mL) and calculated the bioavailability of Neoral, a micro emulsion cyclosporine, in 11 patients.",Pharmacokinetics of cyclosporine a conversion from twice-daily infusion to oral administration in allogeneic hematopoietic stem cell transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23011175/),[ng] / [ml],1000,197639,DB00091,Cyclosporine
,23011175,total area under the concentration-time curve during oral administration (AUCpo),"The total area under the concentration-time curve during oral administration (AUCpo) was nearly the same as AUC during intravenous infusion (AUCiv) (mean ± SD, 7206 ± 1557 ng·h·mL and 7783 ± 897.7 ng·h·mL, respectively).",Pharmacokinetics of cyclosporine a conversion from twice-daily infusion to oral administration in allogeneic hematopoietic stem cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23011175/),h·ml·ng,7206,197640,DB00091,Cyclosporine
,23011175,bioavailability,"The bioavailability of Neoral, defined as F = AUCpo × DOSEiv/AUCiv × DOSEpo was 0.58 ± 0.15 (mean ± SD, range: 0.41-0.94).",Pharmacokinetics of cyclosporine a conversion from twice-daily infusion to oral administration in allogeneic hematopoietic stem cell transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23011175/),,0.58,197641,DB00091,Cyclosporine
greater,6865770,trough Cy serum levels,"Thus, Cy prevents diabetes mellitus in the BB rat when trough Cy serum levels greater than 100 ng/mL are achieved.","Cyclosporine: action, pharmacokinetics, and effect in the BB rat model. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6865770/),[ng] / [ml],100,197718,DB00091,Cyclosporine
,19379322,Bioavailability,"Bioavailability of DT alone and DT combined with cyclosporine was 1.3 and 82%, respectively, in rats.",Enhanced bioavailability of oral docetaxel by co-administration of cyclosporin A in dogs and rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19379322/),%,1.3,197826,DB00091,Cyclosporine
,19379322,Bioavailability,"Bioavailability of DT alone and DT combined with cyclosporine was 1.3 and 82%, respectively, in rats.",Enhanced bioavailability of oral docetaxel by co-administration of cyclosporin A in dogs and rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19379322/),%,82,197827,DB00091,Cyclosporine
,19379322,Bioavailability,Bioavailability of DT alone was 18 +/- 16% and statistically exceeded 100% (251 +/- 104%) when combined with cyclosporine in dogs.,Enhanced bioavailability of oral docetaxel by co-administration of cyclosporin A in dogs and rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19379322/),%,18,197828,DB00091,Cyclosporine
,19379322,Bioavailability,Bioavailability of DT alone was 18 +/- 16% and statistically exceeded 100% (251 +/- 104%) when combined with cyclosporine in dogs.,Enhanced bioavailability of oral docetaxel by co-administration of cyclosporin A in dogs and rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19379322/),%,100,197829,DB00091,Cyclosporine
,19379322,Bioavailability,Bioavailability of DT alone was 18 +/- 16% and statistically exceeded 100% (251 +/- 104%) when combined with cyclosporine in dogs.,Enhanced bioavailability of oral docetaxel by co-administration of cyclosporin A in dogs and rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19379322/),%,251,197830,DB00091,Cyclosporine
,16272406,partial clearance,"There was no difference in the half-life, hepatic extraction ratio (E(H)), clearance or partial clearance of MPA to MPAGe, but there was a difference in partial clearance to MPAGa between control and CsA groups (0.9 +/- 0.4 versus 0.5 +/- 0.1 ml/min).",Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16272406/),[ml] / [min],0.9,197985,DB00091,Cyclosporine
,16272406,partial clearance,"There was no difference in the half-life, hepatic extraction ratio (E(H)), clearance or partial clearance of MPA to MPAGe, but there was a difference in partial clearance to MPAGa between control and CsA groups (0.9 +/- 0.4 versus 0.5 +/- 0.1 ml/min).",Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16272406/),[ml] / [min],0.5,197986,DB00091,Cyclosporine
,16272406,E(H),"TR- rats had a lower E(H) (0.59 +/- 0.30 versus 0.95 +/- 0.30), a lower clearance (18 +/- 8 versus 29 +/- 7 ml/min), and a longer half-life (19.5 +/- 10.3 versus 10.1 +/- 2.4 min) than controls.",Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16272406/),,0.59,197987,DB00091,Cyclosporine
,16272406,E(H),"TR- rats had a lower E(H) (0.59 +/- 0.30 versus 0.95 +/- 0.30), a lower clearance (18 +/- 8 versus 29 +/- 7 ml/min), and a longer half-life (19.5 +/- 10.3 versus 10.1 +/- 2.4 min) than controls.",Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16272406/),[ml] / [min],0.95,197988,DB00091,Cyclosporine
,16272406,clearance,"TR- rats had a lower E(H) (0.59 +/- 0.30 versus 0.95 +/- 0.30), a lower clearance (18 +/- 8 versus 29 +/- 7 ml/min), and a longer half-life (19.5 +/- 10.3 versus 10.1 +/- 2.4 min) than controls.",Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16272406/),[ml] / [min],18,197989,DB00091,Cyclosporine
,16272406,clearance,"TR- rats had a lower E(H) (0.59 +/- 0.30 versus 0.95 +/- 0.30), a lower clearance (18 +/- 8 versus 29 +/- 7 ml/min), and a longer half-life (19.5 +/- 10.3 versus 10.1 +/- 2.4 min) than controls.",Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16272406/),[ml] / [min],29,197990,DB00091,Cyclosporine
,16272406,half-life,"TR- rats had a lower E(H) (0.59 +/- 0.30 versus 0.95 +/- 0.30), a lower clearance (18 +/- 8 versus 29 +/- 7 ml/min), and a longer half-life (19.5 +/- 10.3 versus 10.1 +/- 2.4 min) than controls.",Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16272406/),min,19.5,197991,DB00091,Cyclosporine
,16272406,half-life,"TR- rats had a lower E(H) (0.59 +/- 0.30 versus 0.95 +/- 0.30), a lower clearance (18 +/- 8 versus 29 +/- 7 ml/min), and a longer half-life (19.5 +/- 10.3 versus 10.1 +/- 2.4 min) than controls.",Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16272406/),min,10.1,197992,DB00091,Cyclosporine
,9428817,serum half-life,"The serum half-life of daclizumab was 20 days, and its administration resulted in prolonged saturation of interleukin-2alpha receptors on circulating lymphocytes.",Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9428817/),d,20,198235,DB00091,Cyclosporine
,19903013,plasma unbound fraction,Its plasma unbound fraction was around 15% in the Cremophor EL formulation used in the study.,Pharmacokinetics of PSC 833 (valspodar) in its Cremophor EL formulation in rat. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19903013/),%,15,198638,DB00091,Cyclosporine
,19903013,maximal plasma concentration,After 10 mg kg(-1) orally it was rapidly absorbed with an average maximal plasma concentration of 1.48 mg l(-1) within approximately 2 h.,Pharmacokinetics of PSC 833 (valspodar) in its Cremophor EL formulation in rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19903013/),[mg] / [l],1.48,198639,DB00091,Cyclosporine
,19903013,bioavailability,The mean bioavailability of valspodar was 42.8%.,Pharmacokinetics of PSC 833 (valspodar) in its Cremophor EL formulation in rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19903013/),%,42.8,198640,DB00091,Cyclosporine
,15570185,Tmax,"However, in diabetic patients Tmax (time of Cmax, 1.59 hours) was higher than for nondiabetic patients (0.67 hours) on day 11 (P = 0.04).",Mycophenolic acid in diabetic renal transplant recipients: pharmacokinetics and application of a limited sampling strategy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15570185/),h,1.59,199867,DB00091,Cyclosporine
,15570185,Tmax,"However, in diabetic patients Tmax (time of Cmax, 1.59 hours) was higher than for nondiabetic patients (0.67 hours) on day 11 (P = 0.04).",Mycophenolic acid in diabetic renal transplant recipients: pharmacokinetics and application of a limited sampling strategy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15570185/),h,0.67,199868,DB00091,Cyclosporine
,15570185,time of Cmax,"However, in diabetic patients Tmax (time of Cmax, 1.59 hours) was higher than for nondiabetic patients (0.67 hours) on day 11 (P = 0.04).",Mycophenolic acid in diabetic renal transplant recipients: pharmacokinetics and application of a limited sampling strategy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15570185/),h,1.59,199869,DB00091,Cyclosporine
,15570185,time of Cmax,"However, in diabetic patients Tmax (time of Cmax, 1.59 hours) was higher than for nondiabetic patients (0.67 hours) on day 11 (P = 0.04).",Mycophenolic acid in diabetic renal transplant recipients: pharmacokinetics and application of a limited sampling strategy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15570185/),h,0.67,199870,DB00091,Cyclosporine
,1836548,Para-aminohippurate clearance (CPAH),"Para-aminohippurate clearance (CPAH) increased from 256.4 +/- 21.5 to 291.5 +/- 26.3 ml/min (P less than 0.05), renal vascular resistance was reduced by 21.5% (P less than 0.01) and inulin clearance (CIn) was unchanged.",Effects of isradipine on renal function in cyclosporin-treated renal transplanted patients. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1836548/),[ml] / [min],256.4,200248,DB00091,Cyclosporine
,1836548,Para-aminohippurate clearance (CPAH),"Para-aminohippurate clearance (CPAH) increased from 256.4 +/- 21.5 to 291.5 +/- 26.3 ml/min (P less than 0.05), renal vascular resistance was reduced by 21.5% (P less than 0.01) and inulin clearance (CIn) was unchanged.",Effects of isradipine on renal function in cyclosporin-treated renal transplanted patients. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1836548/),[ml] / [min],291.5,200249,DB00091,Cyclosporine
,11932959,C(max),"Comparing a 15 mg/kg dose, cyclosporine C(max) (mean+/-SD 1.12+/-0.16 microg/ml) and AUC(0-6) (5.34+/-0.71 microg h/ml) were 50% lower when propylene glycol was used as gavage vehicle instead of saline (2.19+/-0.94 microg/ml and 9.52+/-2.52 microg h/ml, respectively).",Minimal effect of ketoconazole on cyclosporine (SangCyA) oral absorption and first-pass metabolism in rats: evidence of a significant vehicle effect on SangCyA absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11932959/),[μg] / [ml],1.12,200255,DB00091,Cyclosporine
,11932959,AUC(0-6),"Comparing a 15 mg/kg dose, cyclosporine C(max) (mean+/-SD 1.12+/-0.16 microg/ml) and AUC(0-6) (5.34+/-0.71 microg h/ml) were 50% lower when propylene glycol was used as gavage vehicle instead of saline (2.19+/-0.94 microg/ml and 9.52+/-2.52 microg h/ml, respectively).",Minimal effect of ketoconazole on cyclosporine (SangCyA) oral absorption and first-pass metabolism in rats: evidence of a significant vehicle effect on SangCyA absorption. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11932959/),[h·μg] / [ml],5.34,200256,DB00091,Cyclosporine
,11932959,AUC(0-6),"Comparing a 15 mg/kg dose, cyclosporine C(max) (mean+/-SD 1.12+/-0.16 microg/ml) and AUC(0-6) (5.34+/-0.71 microg h/ml) were 50% lower when propylene glycol was used as gavage vehicle instead of saline (2.19+/-0.94 microg/ml and 9.52+/-2.52 microg h/ml, respectively).",Minimal effect of ketoconazole on cyclosporine (SangCyA) oral absorption and first-pass metabolism in rats: evidence of a significant vehicle effect on SangCyA absorption. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11932959/),[μg] / [ml],2.19,200257,DB00091,Cyclosporine
,11932959,AUC(0-6),"Comparing a 15 mg/kg dose, cyclosporine C(max) (mean+/-SD 1.12+/-0.16 microg/ml) and AUC(0-6) (5.34+/-0.71 microg h/ml) were 50% lower when propylene glycol was used as gavage vehicle instead of saline (2.19+/-0.94 microg/ml and 9.52+/-2.52 microg h/ml, respectively).",Minimal effect of ketoconazole on cyclosporine (SangCyA) oral absorption and first-pass metabolism in rats: evidence of a significant vehicle effect on SangCyA absorption. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11932959/),[h·μg] / [ml],9.52,200258,DB00091,Cyclosporine
,11932959,T(max),"Ketoconazole increased cyclosporine C(max) and AUC(0-6) by 50-60%, regardless of the vehicle or the cyclosporine dose, without altering T(max) (2-3 h).",Minimal effect of ketoconazole on cyclosporine (SangCyA) oral absorption and first-pass metabolism in rats: evidence of a significant vehicle effect on SangCyA absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11932959/),h,2-3,200259,DB00091,Cyclosporine
,15099443,half-life,The difference between the in-vivo and in-vitro inhibitory behaviours of MP was attributed to the rapid elimination of MP after biotransformation from MPS because the plasma MP concentration decreased with a half-life of 15 min immediately after reaching a level close to the inhibition constant for the triazolam 4-hydroxylation reaction (32.4 microM).,Influence of intravenous methylprednisolone pulse treatment on the disposition of ciclosporin and hepatic CYP3A activity in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15099443/),min,15,200702,DB00091,Cyclosporine
,15099443,inhibition constant,The difference between the in-vivo and in-vitro inhibitory behaviours of MP was attributed to the rapid elimination of MP after biotransformation from MPS because the plasma MP concentration decreased with a half-life of 15 min immediately after reaching a level close to the inhibition constant for the triazolam 4-hydroxylation reaction (32.4 microM).,Influence of intravenous methylprednisolone pulse treatment on the disposition of ciclosporin and hepatic CYP3A activity in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15099443/),μM,32.4,200703,DB00091,Cyclosporine
,14697925,peak,Mean peak and trough itraconazole levels were 1.64 +/- 0.82 and 1.23 +/- 0.90 microg/mL respectively.,Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14697925/),[μg] / [ml],1.64,200851,DB00091,Cyclosporine
,14697925,trough itraconazole levels,Mean peak and trough itraconazole levels were 1.64 +/- 0.82 and 1.23 +/- 0.90 microg/mL respectively.,Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14697925/),[μg] / [ml],1.23,200852,DB00091,Cyclosporine
,14697925,peak,"Mean peak and trough hydroxy-itraconazole levels were 2.37 +/- 1.55 and 2.20 +/- 1.48 microg/mL, respectively.",Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14697925/),[μg] / [ml],2.37,200853,DB00091,Cyclosporine
,14697925,trough hydroxy,"Mean peak and trough hydroxy-itraconazole levels were 2.37 +/- 1.55 and 2.20 +/- 1.48 microg/mL, respectively.",Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14697925/),[μg] / [ml],2.20,200854,DB00091,Cyclosporine
,11591896,area under the concentration-time curve (AUC),"As the majority of patients were treated with low doses of cyclosporine after adding MMF, the area under the concentration-time curve (AUC) for cyclosporine showed a wide scatter ranging from 296 to 6400 ng x h/mL.",Effect of cyclosporine on mycophenolic acid area under the concentration-time curve in pediatric kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11591896/),[h·ng] / [ml],296 to 6400,201483,DB00091,Cyclosporine
greater,11591896,AUC,"When dividing the MPA profiles into two groups (11 and 12 patients) with a CyA AUC less than or greater than 1600 ng x h/mL, there was a significantly higher 8-hour concentration in the patients with the lower CyA AUC, secondary to a higher second peak.",Effect of cyclosporine on mycophenolic acid area under the concentration-time curve in pediatric kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11591896/),[h·ng] / [ml],1600,201484,DB00091,Cyclosporine
,10616974,retention,The retention of pulmonary CsA delivered by liposome aerosol is approximately 120 min in this model.,Pharmacokinetics of liposomal aerosolized cyclosporine A for pulmonary immunosuppression. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10616974/),min,120,201639,DB00091,Cyclosporine
,1738928,steady-state concentration (Css),"Target values were 400 ng/ml steady-state concentration (Css) during continuous intravenous infusion, and 500 ng/ml average drug concentration (Cavss = AUC/dosing interval) after oral administration, based upon measurements with the specific monoclonal antibody 3H-tracer radioimmunoassay.",The ability of pretransplant test-dose pharmacokinetic profiles to reduce early adverse events after renal transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1738928/),[ng] / [ml],400,201849,DB00091,Cyclosporine
greater,1738928,peak concentration,"Administration of the predicted oral dose produced a peak concentration of greater than or equal to 700 ng/ml drug absorption in 60% of recipients at 3 days, 90% at 5 days, and 98% at 7 days.",The ability of pretransplant test-dose pharmacokinetic profiles to reduce early adverse events after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1738928/),[ng] / [ml],700,201850,DB00091,Cyclosporine
,19898510,area under the concentration-time curve during oral administration (AUC(PO)),"The area under the concentration-time curve during oral administration (AUC(PO)) was significantly higher than the AUC during intravenous infusion (AUC(IV)) (median 7508 vs 6705 ng/ml x h, P=0.050).",Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19898510/),[ng] / [h·ml],7508,202024,DB00091,Cyclosporine
,19898510,AU,"The area under the concentration-time curve during oral administration (AUC(PO)) was significantly higher than the AUC during intravenous infusion (AUC(IV)) (median 7508 vs 6705 ng/ml x h, P=0.050).",Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19898510/),[ng] / [h·ml],7508,202025,DB00091,Cyclosporine
,19898510,AUC(IV)),"The area under the concentration-time curve during oral administration (AUC(PO)) was significantly higher than the AUC during intravenous infusion (AUC(IV)) (median 7508 vs 6705 ng/ml x h, P=0.050).",Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19898510/),[ng] / [h·ml],6705,202026,DB00091,Cyclosporine
,19898510,bioavailability,"The median bioavailability of Neoral, defined as (AUC(PO)/DOSE(PO)) divided by (AUC(IV)/DOSE(IV)), was 0.685 (range, 0.45-1.04).",Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19898510/),,0.685,202027,DB00091,Cyclosporine
,19898510,bioavailability,"Concomitant administration of oral voriconazole (n=4) significantly increased the bioavailability of Neoral (median 0.87 vs 0.54, P=0.017), probably due to the inhibition of gut CYP3A4 by voriconazole.",Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19898510/),,0.87,202028,DB00091,Cyclosporine
,19898510,bioavailability,"Concomitant administration of oral voriconazole (n=4) significantly increased the bioavailability of Neoral (median 0.87 vs 0.54, P=0.017), probably due to the inhibition of gut CYP3A4 by voriconazole.",Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19898510/),,0.54,202029,DB00091,Cyclosporine
,25785492,brain/blood exposure ratios,"The brain/blood exposure ratios of 4.49, 0.01, 0.33, and 0.03 for CsA-NE (IN), CsA-NE (IV), CsA-S (IN), and CsA-S (IV), respectively, indicated that CsA-NE is capable of direct nose-to-brain transport, bypassing the blood-brain barrier.",Comparative Biodistribution and Pharmacokinetic Analysis of Cyclosporine-A in the Brain upon Intranasal or Intravenous Administration in an Oil-in-Water Nanoemulsion Formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25785492/),,4.49,202101,DB00091,Cyclosporine
,25785492,brain/blood exposure ratios,"The brain/blood exposure ratios of 4.49, 0.01, 0.33, and 0.03 for CsA-NE (IN), CsA-NE (IV), CsA-S (IN), and CsA-S (IV), respectively, indicated that CsA-NE is capable of direct nose-to-brain transport, bypassing the blood-brain barrier.",Comparative Biodistribution and Pharmacokinetic Analysis of Cyclosporine-A in the Brain upon Intranasal or Intravenous Administration in an Oil-in-Water Nanoemulsion Formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25785492/),,0.01,202102,DB00091,Cyclosporine
,25785492,brain/blood exposure ratios,"The brain/blood exposure ratios of 4.49, 0.01, 0.33, and 0.03 for CsA-NE (IN), CsA-NE (IV), CsA-S (IN), and CsA-S (IV), respectively, indicated that CsA-NE is capable of direct nose-to-brain transport, bypassing the blood-brain barrier.",Comparative Biodistribution and Pharmacokinetic Analysis of Cyclosporine-A in the Brain upon Intranasal or Intravenous Administration in an Oil-in-Water Nanoemulsion Formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25785492/),,0.33,202103,DB00091,Cyclosporine
,25785492,brain/blood exposure ratios,"The brain/blood exposure ratios of 4.49, 0.01, 0.33, and 0.03 for CsA-NE (IN), CsA-NE (IV), CsA-S (IN), and CsA-S (IV), respectively, indicated that CsA-NE is capable of direct nose-to-brain transport, bypassing the blood-brain barrier.",Comparative Biodistribution and Pharmacokinetic Analysis of Cyclosporine-A in the Brain upon Intranasal or Intravenous Administration in an Oil-in-Water Nanoemulsion Formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25785492/),,0.03,202104,DB00091,Cyclosporine
,20137760,C(0)/C(2),"Mean levels at C(0)/C(2) were CsA-RIA 82/612, CsA-HPLC 89/425, AM1 121/179, AM9 4.1/81.4, AM4N 9.5/21.0 ng/ml.",Significant discrepancy in cyclosporin A post-dose concentrations when analyzed with specific RIA and HPLC method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137760/),[ng] / [ml],82,202186,DB00091,Cyclosporine
,20137760,C(0)/C(2),"Mean levels at C(0)/C(2) were CsA-RIA 82/612, CsA-HPLC 89/425, AM1 121/179, AM9 4.1/81.4, AM4N 9.5/21.0 ng/ml.",Significant discrepancy in cyclosporin A post-dose concentrations when analyzed with specific RIA and HPLC method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137760/),[ng] / [ml],89,202187,DB00091,Cyclosporine
,20137760,C(0)/C(2),"Mean levels at C(0)/C(2) were CsA-RIA 82/612, CsA-HPLC 89/425, AM1 121/179, AM9 4.1/81.4, AM4N 9.5/21.0 ng/ml.",Significant discrepancy in cyclosporin A post-dose concentrations when analyzed with specific RIA and HPLC method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137760/),[ng] / [ml],121,202188,DB00091,Cyclosporine
,20137760,C(0)/C(2),"Mean levels at C(0)/C(2) were CsA-RIA 82/612, CsA-HPLC 89/425, AM1 121/179, AM9 4.1/81.4, AM4N 9.5/21.0 ng/ml.",Significant discrepancy in cyclosporin A post-dose concentrations when analyzed with specific RIA and HPLC method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137760/),[ng] / [ml],4.1/,202189,DB00091,Cyclosporine
,20137760,C(0)/C(2),"Mean levels at C(0)/C(2) were CsA-RIA 82/612, CsA-HPLC 89/425, AM1 121/179, AM9 4.1/81.4, AM4N 9.5/21.0 ng/ml.",Significant discrepancy in cyclosporin A post-dose concentrations when analyzed with specific RIA and HPLC method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137760/),[ng] / [ml],81.4,202190,DB00091,Cyclosporine
,20137760,C(0)/C(2),"Mean levels at C(0)/C(2) were CsA-RIA 82/612, CsA-HPLC 89/425, AM1 121/179, AM9 4.1/81.4, AM4N 9.5/21.0 ng/ml.",Significant discrepancy in cyclosporin A post-dose concentrations when analyzed with specific RIA and HPLC method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137760/),[ng] / [ml],9.5,202191,DB00091,Cyclosporine
,20137760,C(0)/C(2),"Mean levels at C(0)/C(2) were CsA-RIA 82/612, CsA-HPLC 89/425, AM1 121/179, AM9 4.1/81.4, AM4N 9.5/21.0 ng/ml.",Significant discrepancy in cyclosporin A post-dose concentrations when analyzed with specific RIA and HPLC method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20137760/),[ng] / [ml],21.0,202192,DB00091,Cyclosporine
,23382105,clearance (CL),"The median MPA clearance (CL) and volume of the central compartment were 24.2 L/hour and 36.4 L, respectively, for a 70 kg patient receiving tacrolimus with a serum albumin of 3.4 g/dL.",Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23382105/),[l] / [h],24.2,202474,DB00091,Cyclosporine
,23382105,volume of the central compartment,"The median MPA clearance (CL) and volume of the central compartment were 24.2 L/hour and 36.4 L, respectively, for a 70 kg patient receiving tacrolimus with a serum albumin of 3.4 g/dL.",Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23382105/),l,36.4,202475,DB00091,Cyclosporine
,18840028,"time to the peak blood ciclosporin concentration at steady state (t(max)(,ss))","In diabetic patients, the time to the peak blood ciclosporin concentration at steady state (t(max)(,ss)) was prolonged (128 minutes vs 93 minutes in nondiabetic patients, p < 0.01) and, on average, the paracetamol t(max) was prolonged by 30 minutes.",Blood and plasma pharmacokinetics of ciclosporin in diabetic kidney transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18840028/),min,128,202643,DB00091,Cyclosporine
,18840028,"time to the peak blood ciclosporin concentration at steady state (t(max)(,ss))","In diabetic patients, the time to the peak blood ciclosporin concentration at steady state (t(max)(,ss)) was prolonged (128 minutes vs 93 minutes in nondiabetic patients, p < 0.01) and, on average, the paracetamol t(max) was prolonged by 30 minutes.",Blood and plasma pharmacokinetics of ciclosporin in diabetic kidney transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18840028/),min,93,202644,DB00091,Cyclosporine
,18840028,f(u),"The ciclosporin f(u) was numerically higher in diabetic patients (1.20 +/- 0.65% vs 0.72 +/- 0.28% in nondiabetic patients, p = 0.066); however, the unbound concentration values were essentially similar in the two groups (0.58 +/- 0.76 microg/L in diabetic patients and 0.52 +/- 0.48 microg/L in nondiabetic patients; p = 0.59).",Blood and plasma pharmacokinetics of ciclosporin in diabetic kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18840028/),%,1.20,202645,DB00091,Cyclosporine
,18840028,f(u),"The ciclosporin f(u) was numerically higher in diabetic patients (1.20 +/- 0.65% vs 0.72 +/- 0.28% in nondiabetic patients, p = 0.066); however, the unbound concentration values were essentially similar in the two groups (0.58 +/- 0.76 microg/L in diabetic patients and 0.52 +/- 0.48 microg/L in nondiabetic patients; p = 0.59).",Blood and plasma pharmacokinetics of ciclosporin in diabetic kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18840028/),%,0.72,202646,DB00091,Cyclosporine
,18840028,unbound concentration,"The ciclosporin f(u) was numerically higher in diabetic patients (1.20 +/- 0.65% vs 0.72 +/- 0.28% in nondiabetic patients, p = 0.066); however, the unbound concentration values were essentially similar in the two groups (0.58 +/- 0.76 microg/L in diabetic patients and 0.52 +/- 0.48 microg/L in nondiabetic patients; p = 0.59).",Blood and plasma pharmacokinetics of ciclosporin in diabetic kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18840028/),[μg] / [l],0.58,202647,DB00091,Cyclosporine
,18840028,unbound concentration,"The ciclosporin f(u) was numerically higher in diabetic patients (1.20 +/- 0.65% vs 0.72 +/- 0.28% in nondiabetic patients, p = 0.066); however, the unbound concentration values were essentially similar in the two groups (0.58 +/- 0.76 microg/L in diabetic patients and 0.52 +/- 0.48 microg/L in nondiabetic patients; p = 0.59).",Blood and plasma pharmacokinetics of ciclosporin in diabetic kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18840028/),[μg] / [l],0.52,202648,DB00091,Cyclosporine
,10223652,Cmax,"After a single dose, cyclosporin A was rapidly absorbed into the conjunctiva (Cmax: dogs, 1490 ng/g; rabbits, 1340 ng/g) and cornea (Cmax: dogs, 311 ng/g; rabbits, 955 ng/g).",Distribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223652/),[ng] / [g],1490,202651,DB00091,Cyclosporine
,10223652,Cmax,"After a single dose, cyclosporin A was rapidly absorbed into the conjunctiva (Cmax: dogs, 1490 ng/g; rabbits, 1340 ng/g) and cornea (Cmax: dogs, 311 ng/g; rabbits, 955 ng/g).",Distribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223652/),[ng] / [g],1340,202652,DB00091,Cyclosporine
,10223652,Cmax,"After a single dose, cyclosporin A was rapidly absorbed into the conjunctiva (Cmax: dogs, 1490 ng/g; rabbits, 1340 ng/g) and cornea (Cmax: dogs, 311 ng/g; rabbits, 955 ng/g).",Distribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223652/),[ng] / [g],311,202653,DB00091,Cyclosporine
,10223652,Cmax,"After a single dose, cyclosporin A was rapidly absorbed into the conjunctiva (Cmax: dogs, 1490 ng/g; rabbits, 1340 ng/g) and cornea (Cmax: dogs, 311 ng/g; rabbits, 955 ng/g).",Distribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223652/),[ng] / [g],955,202654,DB00091,Cyclosporine
,16715103,bioavailability (F),"The mean+/-s.d. value of bioavailability (F), maximum concentration (C(max)), half-life (t(1/2)) of CsA were 43.1+/-14.4%, 1135.3+/-340.6 ng/ml and 3.1+/-1.2 h, respectively.",Assessment of converting from intravenous to oral administration of cyclosporin A in pediatric allogeneic hematopoietic stem cell transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715103/),%,43.1,203849,DB00091,Cyclosporine
,16715103,maximum concentration (C(max)),"The mean+/-s.d. value of bioavailability (F), maximum concentration (C(max)), half-life (t(1/2)) of CsA were 43.1+/-14.4%, 1135.3+/-340.6 ng/ml and 3.1+/-1.2 h, respectively.",Assessment of converting from intravenous to oral administration of cyclosporin A in pediatric allogeneic hematopoietic stem cell transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715103/),[ng] / [ml],1135.3,203850,DB00091,Cyclosporine
,16715103,half-life (t(1/2)),"The mean+/-s.d. value of bioavailability (F), maximum concentration (C(max)), half-life (t(1/2)) of CsA were 43.1+/-14.4%, 1135.3+/-340.6 ng/ml and 3.1+/-1.2 h, respectively.",Assessment of converting from intravenous to oral administration of cyclosporin A in pediatric allogeneic hematopoietic stem cell transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715103/),h,3.1,203851,DB00091,Cyclosporine
,16715103,clearance (CL),"Mean clearance (CL)+/-s.d. was 480.9+/-103.7, 414.9+/-137.1 and 320+/-51.8 ml/h/kg in patients <20, 20-40 and >40 kg of body weight, respectively.",Assessment of converting from intravenous to oral administration of cyclosporin A in pediatric allogeneic hematopoietic stem cell transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715103/),[ml] / [h·kg],480.9,203852,DB00091,Cyclosporine
,16715103,clearance (CL),"Mean clearance (CL)+/-s.d. was 480.9+/-103.7, 414.9+/-137.1 and 320+/-51.8 ml/h/kg in patients <20, 20-40 and >40 kg of body weight, respectively.",Assessment of converting from intravenous to oral administration of cyclosporin A in pediatric allogeneic hematopoietic stem cell transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715103/),[ml] / [h·kg],414.9,203853,DB00091,Cyclosporine
,16715103,clearance (CL),"Mean clearance (CL)+/-s.d. was 480.9+/-103.7, 414.9+/-137.1 and 320+/-51.8 ml/h/kg in patients <20, 20-40 and >40 kg of body weight, respectively.",Assessment of converting from intravenous to oral administration of cyclosporin A in pediatric allogeneic hematopoietic stem cell transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715103/),[ml] / [h·kg],320,203854,DB00091,Cyclosporine
,19632311,solubility,"The solubility of CsA in aqueous alpha-CD solution (14%) increased with decreasing temperature; the solubility of CsA at room temperature, +5 and +1 degrees C was 1.2, 12 and 19mg/ml, respectively.","Cyclodextrins and chitosan derivatives in sublingual delivery of low solubility peptides: A study using cyclosporin A, alpha-cyclodextrin and quaternary chitosan N-betainate. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19632311/),%,14,204090,DB00091,Cyclosporine
,19632311,solubility,"The solubility of CsA in aqueous alpha-CD solution (14%) increased with decreasing temperature; the solubility of CsA at room temperature, +5 and +1 degrees C was 1.2, 12 and 19mg/ml, respectively.","Cyclodextrins and chitosan derivatives in sublingual delivery of low solubility peptides: A study using cyclosporin A, alpha-cyclodextrin and quaternary chitosan N-betainate. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19632311/),[mg] / [ml],1.2,204091,DB00091,Cyclosporine
,19632311,solubility,"The solubility of CsA in aqueous alpha-CD solution (14%) increased with decreasing temperature; the solubility of CsA at room temperature, +5 and +1 degrees C was 1.2, 12 and 19mg/ml, respectively.","Cyclodextrins and chitosan derivatives in sublingual delivery of low solubility peptides: A study using cyclosporin A, alpha-cyclodextrin and quaternary chitosan N-betainate. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19632311/),[mg] / [ml],12,204092,DB00091,Cyclosporine
,19632311,solubility,"The solubility of CsA in aqueous alpha-CD solution (14%) increased with decreasing temperature; the solubility of CsA at room temperature, +5 and +1 degrees C was 1.2, 12 and 19mg/ml, respectively.","Cyclodextrins and chitosan derivatives in sublingual delivery of low solubility peptides: A study using cyclosporin A, alpha-cyclodextrin and quaternary chitosan N-betainate. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19632311/),[mg] / [ml],19,204093,DB00091,Cyclosporine
,19632311,bioavailability,"The bioavailability of CsA after administration of plain CsA, solid CsA/alpha-CD and solid CsA/alpha-CD/CH (0.6+/-0.5, 1.4+/-0.7 and 1.7+/-0.8%, respectively; mean+/-S.D.) was further increased when solid CsA/alpha-CD was administered together with CH solution (3.2+/-2.2%).","Cyclodextrins and chitosan derivatives in sublingual delivery of low solubility peptides: A study using cyclosporin A, alpha-cyclodextrin and quaternary chitosan N-betainate. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19632311/),%,0.6,204094,DB00091,Cyclosporine
,19632311,bioavailability,"The bioavailability of CsA after administration of plain CsA, solid CsA/alpha-CD and solid CsA/alpha-CD/CH (0.6+/-0.5, 1.4+/-0.7 and 1.7+/-0.8%, respectively; mean+/-S.D.) was further increased when solid CsA/alpha-CD was administered together with CH solution (3.2+/-2.2%).","Cyclodextrins and chitosan derivatives in sublingual delivery of low solubility peptides: A study using cyclosporin A, alpha-cyclodextrin and quaternary chitosan N-betainate. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19632311/),%,1.4,204095,DB00091,Cyclosporine
,19632311,bioavailability,"The bioavailability of CsA after administration of plain CsA, solid CsA/alpha-CD and solid CsA/alpha-CD/CH (0.6+/-0.5, 1.4+/-0.7 and 1.7+/-0.8%, respectively; mean+/-S.D.) was further increased when solid CsA/alpha-CD was administered together with CH solution (3.2+/-2.2%).","Cyclodextrins and chitosan derivatives in sublingual delivery of low solubility peptides: A study using cyclosporin A, alpha-cyclodextrin and quaternary chitosan N-betainate. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19632311/),%,1.7,204096,DB00091,Cyclosporine
,19632311,bioavailability,"The bioavailability of CsA after administration of plain CsA, solid CsA/alpha-CD and solid CsA/alpha-CD/CH (0.6+/-0.5, 1.4+/-0.7 and 1.7+/-0.8%, respectively; mean+/-S.D.) was further increased when solid CsA/alpha-CD was administered together with CH solution (3.2+/-2.2%).","Cyclodextrins and chitosan derivatives in sublingual delivery of low solubility peptides: A study using cyclosporin A, alpha-cyclodextrin and quaternary chitosan N-betainate. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19632311/),%,3.2,204097,DB00091,Cyclosporine
,2363351,peak concentration (Cmax),The peak concentration (Cmax) was 664.9 +/- 87.5 ng/ml; peak time was 3.27 +/- 1.07 h; slow elimination phase t1/2 beta was 13.53 (6.13-43.3) h.,[Oral cyclosporine pharmacokinetics in renal transplantation patients]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363351/),[ng] / [ml],664.9,204172,DB00091,Cyclosporine
,2363351,peak time,The peak concentration (Cmax) was 664.9 +/- 87.5 ng/ml; peak time was 3.27 +/- 1.07 h; slow elimination phase t1/2 beta was 13.53 (6.13-43.3) h.,[Oral cyclosporine pharmacokinetics in renal transplantation patients]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363351/),h,3.27,204173,DB00091,Cyclosporine
,2363351,slow elimination phase t1/2 beta,The peak concentration (Cmax) was 664.9 +/- 87.5 ng/ml; peak time was 3.27 +/- 1.07 h; slow elimination phase t1/2 beta was 13.53 (6.13-43.3) h.,[Oral cyclosporine pharmacokinetics in renal transplantation patients]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363351/),h,13.53,204174,DB00091,Cyclosporine
,25448562,relative bioavailability,The results of comparative pharmacokinetic study showed that the optimized nanomatrix had a relative bioavailability of 90.8% with Neoral(®) but a lower Cmax than that of Neoral(®).,Sylysia 350/Eudragit S100 solid nanomatrix as a promising system for oral delivery of cyclosporine A. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25448562/),%,90.8,205141,DB00091,Cyclosporine
,19416778,AUC(0-48),"In the pharmacokinetics study, AUC(0-48) values in blood for iCsA and oral CsA were similar (47,790 +/- 1,739 and 46,987 +/- 2,439 ng h ml(-1), respectively).",Efficacy of a new pulmonary cyclosporine a powder formulation for prevention of transplant rejection in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19416778/),[h·ng] / [ml],"47,790",205417,DB00091,Cyclosporine
,19416778,AUC(0-48),"In the pharmacokinetics study, AUC(0-48) values in blood for iCsA and oral CsA were similar (47,790 +/- 1,739 and 46,987 +/- 2,439 ng h ml(-1), respectively).",Efficacy of a new pulmonary cyclosporine a powder formulation for prevention of transplant rejection in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19416778/),[h·ng] / [ml],"46,987",205418,DB00091,Cyclosporine
,19416778,AUC,"In contrast, iCsA levels in lung tissue were much higher than oral CsA levels (AUC: 9,152,977 +/- 698,920 vs 84,149 +/- 8,134 ng h g(-1), respectively), showing the effectiveness of the pulmonary administration.",Efficacy of a new pulmonary cyclosporine a powder formulation for prevention of transplant rejection in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19416778/),[h·ng] / [g],"9,152,977",205419,DB00091,Cyclosporine
,19416778,AUC,"In contrast, iCsA levels in lung tissue were much higher than oral CsA levels (AUC: 9,152,977 +/- 698,920 vs 84,149 +/- 8,134 ng h g(-1), respectively), showing the effectiveness of the pulmonary administration.",Efficacy of a new pulmonary cyclosporine a powder formulation for prevention of transplant rejection in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19416778/),[h·ng] / [g],"84,149",205420,DB00091,Cyclosporine
,15801719,solubility,The largest solubility was found to be 5.42 +/- 0.16 mg/ml.,Solubilization and pharmacokinetic behaviors of sodium cholate/lecithin-mixed micelles containing cyclosporine A. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801719/),[mg] / [ml],5.42,205921,DB00091,Cyclosporine
,15801719,leakage,The leakage of mixed micelles in 5% glucose (5.84%) was much less than that in saline solution (36.7%).,Solubilization and pharmacokinetic behaviors of sodium cholate/lecithin-mixed micelles containing cyclosporine A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801719/),%,5.84,205922,DB00091,Cyclosporine
,15801719,leakage,The leakage of mixed micelles in 5% glucose (5.84%) was much less than that in saline solution (36.7%).,Solubilization and pharmacokinetic behaviors of sodium cholate/lecithin-mixed micelles containing cyclosporine A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801719/),%,36.7,205923,DB00091,Cyclosporine
,15801719,relative bioavailability,"The relative bioavailability of mixed micelles versus Sandimmun was 112 +/- 20%, and statistical analysis demonstrated both preparations were bioequivalent.",Solubilization and pharmacokinetic behaviors of sodium cholate/lecithin-mixed micelles containing cyclosporine A. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15801719/),%,112,205924,DB00091,Cyclosporine
,2743495,Cmax,"One of the HP-55 preparations gave the highest plasma CiA level, Cmax = 0.99 +/- 0.20 (S.E., n = 4) micrograms/ml, and also showed the highest lymphatic availability, the percentage of dose delivered to the lymphatics in 6 h was 1.98 +/- 0.10% and the maximum lymph CiA level was 76.8 +/- 12.86 micrograms/ml.",Enteric solid dispersion of ciclosporin A (CiA) having potential to deliver CiA into lymphatics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743495/),[μg] / [ml],0.99,206179,DB00091,Cyclosporine
,2743495,percentage of dose,"One of the HP-55 preparations gave the highest plasma CiA level, Cmax = 0.99 +/- 0.20 (S.E., n = 4) micrograms/ml, and also showed the highest lymphatic availability, the percentage of dose delivered to the lymphatics in 6 h was 1.98 +/- 0.10% and the maximum lymph CiA level was 76.8 +/- 12.86 micrograms/ml.",Enteric solid dispersion of ciclosporin A (CiA) having potential to deliver CiA into lymphatics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743495/),%,1.98,206180,DB00091,Cyclosporine
,2743495,maximum lymph CiA level,"One of the HP-55 preparations gave the highest plasma CiA level, Cmax = 0.99 +/- 0.20 (S.E., n = 4) micrograms/ml, and also showed the highest lymphatic availability, the percentage of dose delivered to the lymphatics in 6 h was 1.98 +/- 0.10% and the maximum lymph CiA level was 76.8 +/- 12.86 micrograms/ml.",Enteric solid dispersion of ciclosporin A (CiA) having potential to deliver CiA into lymphatics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743495/),[μg] / [ml],76.8,206181,DB00091,Cyclosporine
,2743495,Lymphatic availability,Lymphatic availability of CiA from Sandimmun was 0.78 +/- 0.11% and the peak plasma CiA level was 0.46 +/- 0.10 microgram/ml.(ABSTRACT TRUNCATED AT 250 WORDS),Enteric solid dispersion of ciclosporin A (CiA) having potential to deliver CiA into lymphatics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743495/),%,0.78,206182,DB00091,Cyclosporine
,2743495,peak plasma CiA level,Lymphatic availability of CiA from Sandimmun was 0.78 +/- 0.11% and the peak plasma CiA level was 0.46 +/- 0.10 microgram/ml.(ABSTRACT TRUNCATED AT 250 WORDS),Enteric solid dispersion of ciclosporin A (CiA) having potential to deliver CiA into lymphatics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2743495/),[μg] / [ml],0.46,206183,DB00091,Cyclosporine
,3538563,rate of mean drug clearance,"Pediatric compared with adult renal recipients showed a threefold increased rate of mean drug clearance, namely 39.6 mL/min/kg in children v 12.3 mL/min/kg in adults, which may explain the almost 50% reduction in area under the plasma concentration curve v the time curve.",Analysis of pharmacokinetic profiles in 232 renal and 87 cardiac allograft recipients treated with cyclosporine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3538563/),[ml] / [kg·min],39.6,206258,DB00091,Cyclosporine
,3538563,rate of mean drug clearance,"Pediatric compared with adult renal recipients showed a threefold increased rate of mean drug clearance, namely 39.6 mL/min/kg in children v 12.3 mL/min/kg in adults, which may explain the almost 50% reduction in area under the plasma concentration curve v the time curve.",Analysis of pharmacokinetic profiles in 232 renal and 87 cardiac allograft recipients treated with cyclosporine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3538563/),[ml] / [kg·min],12.3,206259,DB00091,Cyclosporine
,4081308,Peak plasma concentrations,Peak plasma concentrations ranging from 411.8 to 1735.0 ng/ml were attained between post-administration times of 1 and 2.5 hours.,The plasma time course of orally-administered cyclosporine in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4081308/),[ng] / [ml],411.8 to 1735.0,206487,DB00091,Cyclosporine
,4081308,Areas under plasma concentration time course curves (AUC,"Areas under plasma concentration time course curves (AUC = 4.63 +/- 5.60 micrograms/ml X hr, mean +/- SD) suggest that systemic availability is highly variable between animals.",The plasma time course of orally-administered cyclosporine in the dog. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4081308/),[μg] / [h·ml],4.63,206488,DB00091,Cyclosporine
,19773540,biliary recoveries,"The biliary recoveries of the administered rosuvastatin dose were 9.0 +/- 3.5 and 35.7 +/- 15.6% in TI and TIV, respectively.",Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19773540/),%,9.0,206726,DB00091,Cyclosporine
,19773540,biliary recoveries,"The biliary recoveries of the administered rosuvastatin dose were 9.0 +/- 3.5 and 35.7 +/- 15.6% in TI and TIV, respectively.",Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19773540/),%,35.7,206727,DB00091,Cyclosporine
,19773540,AUC(bile)/AUC(VH) ratio,"Rosuvastatin was highly transported into bile as shown by the median AUC(bile)/AUC(VH) ratio in TI of 1770 (1640-11,300).",Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19773540/),,1770,206728,DB00091,Cyclosporine
,19773540,hepatic,"However, cyclosporine significantly reduced the hepatic extraction of rosuvastatin (TI, 0.89 +/- 0.06; TII, 0.46 +/- 0.13) and increased the AUC(VP) and AUC(VH) by 1.6- and 9.1-fold, respectively.",Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19773540/),,0.89,206729,DB00091,Cyclosporine
,19773540,hepatic,"However, cyclosporine significantly reduced the hepatic extraction of rosuvastatin (TI, 0.89 +/- 0.06; TII, 0.46 +/- 0.13) and increased the AUC(VP) and AUC(VH) by 1.6- and 9.1-fold, respectively.",Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19773540/),,0.46,206730,DB00091,Cyclosporine
,28651341,Cmin,The median Cmin (IQR) was 11.3 μg/mL (6.2-27.8) and the median Cmax was 13.4 μg/mL (6.0-28.3).,Plasma concentrations of atovaquone given to immunocompromised patients to prevent Pneumocystis jirovecii. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28651341/),[μg] / [ml],11.3,207131,DB00091,Cyclosporine
,28651341,Cmax,The median Cmin (IQR) was 11.3 μg/mL (6.2-27.8) and the median Cmax was 13.4 μg/mL (6.0-28.3).,Plasma concentrations of atovaquone given to immunocompromised patients to prevent Pneumocystis jirovecii. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28651341/),[μg] / [ml],13.4,207132,DB00091,Cyclosporine
<,28651341,Cmin,"Nineteen of the 33 (58%) patients had Cmin <15 μg/mL, a threshold associated with a low rate of clinical response in PCP treatment.",Plasma concentrations of atovaquone given to immunocompromised patients to prevent Pneumocystis jirovecii. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28651341/),[μg] / [ml],15,207133,DB00091,Cyclosporine
,30537048,clearance,The clearance of MPA was 12.3 ± 1.14 L/h.,Population Pharmacokinetics and Bayesian Estimation of Mycophenolic Acid Exposure in Chinese Renal Allograft Recipients After Administration of EC-MPS. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30537048/),[l] / [h],12.3,207244,DB00091,Cyclosporine
,21209244,clearance,MPA clearance in African American males was 26.5 ± 14.4 L/h versus 17.9 ± 6.1 L/h in Caucasian males (P = .035) and 16.1 ± 4.6 L/h in Caucasian females (P = .024) with no difference noted in MPA troughs.,Mycophenolic acid pharmacokinetics during maintenance immunosuppression in African American and Caucasian renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21209244/),[l] / [h],26.5,207271,DB00091,Cyclosporine
,21209244,clearance,MPA clearance in African American males was 26.5 ± 14.4 L/h versus 17.9 ± 6.1 L/h in Caucasian males (P = .035) and 16.1 ± 4.6 L/h in Caucasian females (P = .024) with no difference noted in MPA troughs.,Mycophenolic acid pharmacokinetics during maintenance immunosuppression in African American and Caucasian renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21209244/),[l] / [h],17.9,207272,DB00091,Cyclosporine
,21209244,clearance,MPA clearance in African American males was 26.5 ± 14.4 L/h versus 17.9 ± 6.1 L/h in Caucasian males (P = .035) and 16.1 ± 4.6 L/h in Caucasian females (P = .024) with no difference noted in MPA troughs.,Mycophenolic acid pharmacokinetics during maintenance immunosuppression in African American and Caucasian renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21209244/),[l] / [h],16.1,207273,DB00091,Cyclosporine
,2898348,area under the blood concentration versus time curve,The mean area under the blood concentration versus time curve of CyA (HPLC measurements) was lower in pigs than in humans after oral (67 +/- 31 micrograms/ml x min vs. 296 +/- 101 micrograms/ml x min) and after iv (358 +/- 71 micrograms/ml x min vs. 858 +/- 292 micrograms/ml x min) doses of CyA.,Marked interspecies differences between humans and pigs in cyclosporine and prednisolone disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898348/),[μg] / [min·ml],67,207360,DB00091,Cyclosporine
,2898348,area under the blood concentration versus time curve,The mean area under the blood concentration versus time curve of CyA (HPLC measurements) was lower in pigs than in humans after oral (67 +/- 31 micrograms/ml x min vs. 296 +/- 101 micrograms/ml x min) and after iv (358 +/- 71 micrograms/ml x min vs. 858 +/- 292 micrograms/ml x min) doses of CyA.,Marked interspecies differences between humans and pigs in cyclosporine and prednisolone disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898348/),[μg] / [min·ml],296,207361,DB00091,Cyclosporine
,2898348,area under the blood concentration versus time curve,The mean area under the blood concentration versus time curve of CyA (HPLC measurements) was lower in pigs than in humans after oral (67 +/- 31 micrograms/ml x min vs. 296 +/- 101 micrograms/ml x min) and after iv (358 +/- 71 micrograms/ml x min vs. 858 +/- 292 micrograms/ml x min) doses of CyA.,Marked interspecies differences between humans and pigs in cyclosporine and prednisolone disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898348/),[μg] / [min·ml],358,207362,DB00091,Cyclosporine
,2898348,area under the blood concentration versus time curve,The mean area under the blood concentration versus time curve of CyA (HPLC measurements) was lower in pigs than in humans after oral (67 +/- 31 micrograms/ml x min vs. 296 +/- 101 micrograms/ml x min) and after iv (358 +/- 71 micrograms/ml x min vs. 858 +/- 292 micrograms/ml x min) doses of CyA.,Marked interspecies differences between humans and pigs in cyclosporine and prednisolone disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2898348/),[μg] / [min·ml],858,207363,DB00091,Cyclosporine
,27941326,area under the concentration-time curve,"The mean CsA area under the concentration-time curve increased slightly after switching from Neoral to Ciqorin (p = 0.03), but did not change significantly after Neoral was reintroduced (Neoral 1: 2,234 ± 783, Ciqorin: 2,452 ± 767, Neoral 2: 2,472 ± 784 ng × h/mL).",Conversion from Brand-Name Neoral to the Generic Ciqorin in Stable Renal Transplant Recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27941326/),[h·ng] / [ml],"2,234",207906,DB00091,Cyclosporine
,27941326,area under the concentration-time curve,"The mean CsA area under the concentration-time curve increased slightly after switching from Neoral to Ciqorin (p = 0.03), but did not change significantly after Neoral was reintroduced (Neoral 1: 2,234 ± 783, Ciqorin: 2,452 ± 767, Neoral 2: 2,472 ± 784 ng × h/mL).",Conversion from Brand-Name Neoral to the Generic Ciqorin in Stable Renal Transplant Recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27941326/),[h·ng] / [ml],"2,452",207907,DB00091,Cyclosporine
,27941326,area under the concentration-time curve,"The mean CsA area under the concentration-time curve increased slightly after switching from Neoral to Ciqorin (p = 0.03), but did not change significantly after Neoral was reintroduced (Neoral 1: 2,234 ± 783, Ciqorin: 2,452 ± 767, Neoral 2: 2,472 ± 784 ng × h/mL).",Conversion from Brand-Name Neoral to the Generic Ciqorin in Stable Renal Transplant Recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27941326/),[h·ng] / [ml],"2,472",207908,DB00091,Cyclosporine
,2298719,half-time of elimination,The results with or without PE were not significantly different: half-time of elimination 3 vs.,Acyclovir pharmacokinetics in plasmapheresis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2298719/),,3,208003,DB00091,Cyclosporine
,2298719,volume of distribution,"2.3 h, volume of distribution 1.8 vs.",Acyclovir pharmacokinetics in plasmapheresis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2298719/),,1.8,208004,DB00091,Cyclosporine
,2298719,total clearance,"1.14 liter/kg, and total clearance 404 vs. 314 ml/min.",Acyclovir pharmacokinetics in plasmapheresis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2298719/),[ml] / [min],404,208005,DB00091,Cyclosporine
,2298719,total clearance,"1.14 liter/kg, and total clearance 404 vs. 314 ml/min.",Acyclovir pharmacokinetics in plasmapheresis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2298719/),[ml] / [min],314,208006,DB00091,Cyclosporine
,2298719,clearance,"The clearance and the fraction of elimination due to PE were 5.27 ml/min and 2.5%, respectively.",Acyclovir pharmacokinetics in plasmapheresis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2298719/),[ml] / [min],5.27,208007,DB00091,Cyclosporine
,2298719,fraction of elimination,"The clearance and the fraction of elimination due to PE were 5.27 ml/min and 2.5%, respectively.",Acyclovir pharmacokinetics in plasmapheresis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2298719/),%,2.5,208008,DB00091,Cyclosporine
,15661261,MTD,The MTD of idarubicin in this combination was 8 mg/(m(2) day) with a DLT of oral mucositis.,"A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15661261/),[mg] / [d·m(2)],8,208630,DB00091,Cyclosporine
,15661261,complete remission rate,"The complete remission rate (on an intent-to-treat basis) for this regimen was 33%, with a median duration of 6 months.","A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15661261/),%,33,208631,DB00091,Cyclosporine
,15661261,clearance,"The clearance of idarubicin was 140 +/- 200 and 181 +/- 94.3 l/h for idarubicin alone and with PSC-833, respectively.","A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15661261/),[l] / [h],140,208632,DB00091,Cyclosporine
,15661261,clearance,"The clearance of idarubicin was 140 +/- 200 and 181 +/- 94.3 l/h for idarubicin alone and with PSC-833, respectively.","A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15661261/),[l] / [h],181,208633,DB00091,Cyclosporine
,15661261,volume of distribution of the central compartment,"The volume of distribution of the central compartment was 423 +/- 443 and 337 +/- 394 l for idarubicin alone and in combination with PSC-833, respectively.","A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15661261/),l,423,208634,DB00091,Cyclosporine
,15661261,volume of distribution of the central compartment,"The volume of distribution of the central compartment was 423 +/- 443 and 337 +/- 394 l for idarubicin alone and in combination with PSC-833, respectively.","A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15661261/),l,337,208635,DB00091,Cyclosporine
,12954187,intestinal clearance,"The intestinal clearance of ABZSO was 0.106+/-0.010 ml/min, exhibiting a stereoselective intestinal elimination to (-)ABZSO form.",Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12954187/),[ml] / [min],0.106,208940,DB00091,Cyclosporine
,12954187,intestinal elimination,"Oxfendazole, ampicillin and cyclosporine significantly reduced the intestinal elimination of ABZSO to 0.079+/-0.008, 0.069+/-0.009 and 0.065+/-0.012 ml/min, respectively.",Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12954187/),[ml] / [min],0.079,208941,DB00091,Cyclosporine
,12954187,intestinal elimination,"Oxfendazole, ampicillin and cyclosporine significantly reduced the intestinal elimination of ABZSO to 0.079+/-0.008, 0.069+/-0.009 and 0.065+/-0.012 ml/min, respectively.",Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12954187/),[ml] / [min],0.069,208942,DB00091,Cyclosporine
,12954187,intestinal elimination,"Oxfendazole, ampicillin and cyclosporine significantly reduced the intestinal elimination of ABZSO to 0.079+/-0.008, 0.069+/-0.009 and 0.065+/-0.012 ml/min, respectively.",Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12954187/),[ml] / [min],0.065,208943,DB00091,Cyclosporine
,18721002,maximum plasma concentrations (C(max)),"Mean (standard deviation) midazolam maximum plasma concentrations (C(max)) and area under the plasma concentration-time curve from time zero to infinity (AUC(infinity)) were 9.31 (3.09) ng/mL and 24.1 (7.7) ng . h/mL, respectively, when administered in combination with cinacalcet, compared with 9.76 (2.81) ng/mL and 22.8 (6.1) ng . h/mL when administered alone.","Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18721002/),[ng] / [ml],9.31,209092,DB00091,Cyclosporine
,18721002,maximum plasma concentrations (C(max)),"Mean (standard deviation) midazolam maximum plasma concentrations (C(max)) and area under the plasma concentration-time curve from time zero to infinity (AUC(infinity)) were 9.31 (3.09) ng/mL and 24.1 (7.7) ng . h/mL, respectively, when administered in combination with cinacalcet, compared with 9.76 (2.81) ng/mL and 22.8 (6.1) ng . h/mL when administered alone.","Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18721002/),[ng] / [ml],9.76,209093,DB00091,Cyclosporine
,18721002,area under the plasma concentration-time curve from time zero to infinity (AUC(infinity)),"Mean (standard deviation) midazolam maximum plasma concentrations (C(max)) and area under the plasma concentration-time curve from time zero to infinity (AUC(infinity)) were 9.31 (3.09) ng/mL and 24.1 (7.7) ng . h/mL, respectively, when administered in combination with cinacalcet, compared with 9.76 (2.81) ng/mL and 22.8 (6.1) ng . h/mL when administered alone.","Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18721002/),[h·ng] / [ml],24.1,209094,DB00091,Cyclosporine
,18721002,area under the plasma concentration-time curve from time zero to infinity (AUC(infinity)),"Mean (standard deviation) midazolam maximum plasma concentrations (C(max)) and area under the plasma concentration-time curve from time zero to infinity (AUC(infinity)) were 9.31 (3.09) ng/mL and 24.1 (7.7) ng . h/mL, respectively, when administered in combination with cinacalcet, compared with 9.76 (2.81) ng/mL and 22.8 (6.1) ng . h/mL when administered alone.","Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18721002/),[h·ng] / [ml],22.8,209095,DB00091,Cyclosporine
,15171925,flow-rate,"Separation was performed using a reversed phase ODS-2 microbore column 150 mm x 1 mm i.d., particle size 5 microm with mobile phase of acetonitrile-0.1M ammonium acetate (30:70, v/v) at flow-rate of 0.05 ml/min.",Determination of extracellular hesperidin in blood and bile of anaesthetized rats by microdialysis with high-performance liquid chromatography: a pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15171925/),[ml] / [min],0.05,209128,DB00091,Cyclosporine
,15171925,blood-to-bile distribution ratio (k,The blood-to-bile distribution ratio (k = AUC(bile)/AUC(blood)) was 8.9 +/- 2.5 for hesperidin at 30 mg/kg.,Determination of extracellular hesperidin in blood and bile of anaesthetized rats by microdialysis with high-performance liquid chromatography: a pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15171925/),,8.9,209129,DB00091,Cyclosporine
,15171925,distribution ratio,"Following cyclosporin A treatment, the distribution ratio was reduced to 3.2 +/- 0.6.",Determination of extracellular hesperidin in blood and bile of anaesthetized rats by microdialysis with high-performance liquid chromatography: a pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15171925/),,3.2,209130,DB00091,Cyclosporine
,18622423,AUC(inf),The i.v. CYA dose predicted to achieve an AUC(inf) of 4200 microg x h/l was calculated for each patient and expressed as a function of each patient's actual weight and body surface area (BSA).,Determination of initial i.v. CYA dosage to achieve target AUC values in pediatric hematopoietic stem cell transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622423/),[h·μg] / [l],4200,209660,DB00091,Cyclosporine
,18622423,AUC,"CYA dose predicted to achieve the target AUC was 2.6+/-0.94 and 2.1+/-1.21 mg/kg, respectively.",Determination of initial i.v. CYA dosage to achieve target AUC values in pediatric hematopoietic stem cell transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622423/),[mg] / [kg],2.6,209661,DB00091,Cyclosporine
,18622423,AUC,"CYA dose predicted to achieve the target AUC was 2.6+/-0.94 and 2.1+/-1.21 mg/kg, respectively.",Determination of initial i.v. CYA dosage to achieve target AUC values in pediatric hematopoietic stem cell transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622423/),[mg] / [kg],2.1,209662,DB00091,Cyclosporine
,18622423,AUC(inf),"In children 0.5-17 years of age undergoing HSCT, we recommend an initial i.v. CYA dose of 65 mg/m(2) infused over 2 h to achieve an AUC(inf) of approximately 4200 microg x h/l.",Determination of initial i.v. CYA dosage to achieve target AUC values in pediatric hematopoietic stem cell transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18622423/),[h·μg] / [l],4200,209663,DB00091,Cyclosporine
up to,15237382,elimination half-lives,"Under ritonavir-boosted HAART, cyclosporine A levels showed markedly altered absorption/elimination characteristics with more or less constant blood-levels throughout the dosing interval and prolonged elimination half-lives up to 38 hours.",Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15237382/),h,38,210328,DB00091,Cyclosporine
,3803418,terminal half-life,"According to zero order absorption the mean of the following PK parameters was determined: terminal half-life = 12.1 +/- 5.0 h, apparent volume of distribution at steady-state = 5.6 +/- 2.11 X kg-1, apparent clearance = 0.51 +/- 0.11 l X h-1 X kg-1.",Pharmacokinetics of oral cyclosporin A (Sandimmun) in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803418/),h,12.1,211375,DB00091,Cyclosporine
,3803418,apparent volume of distribution at steady-state,"According to zero order absorption the mean of the following PK parameters was determined: terminal half-life = 12.1 +/- 5.0 h, apparent volume of distribution at steady-state = 5.6 +/- 2.11 X kg-1, apparent clearance = 0.51 +/- 0.11 l X h-1 X kg-1.",Pharmacokinetics of oral cyclosporin A (Sandimmun) in healthy subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803418/),1/[kg],5.6,211376,DB00091,Cyclosporine
,3803418,apparent clearance,"According to zero order absorption the mean of the following PK parameters was determined: terminal half-life = 12.1 +/- 5.0 h, apparent volume of distribution at steady-state = 5.6 +/- 2.11 X kg-1, apparent clearance = 0.51 +/- 0.11 l X h-1 X kg-1.",Pharmacokinetics of oral cyclosporin A (Sandimmun) in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803418/),[l] / [h·kg],0.51,211377,DB00091,Cyclosporine
,3803418,time lag,"The time lag between drug ingestion and first blood level was short, 0.38 +/- 0.11 h.",Pharmacokinetics of oral cyclosporin A (Sandimmun) in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803418/),h,0.38,211378,DB00091,Cyclosporine
,28536776,area under the concentration-time curve from 0 to 12 h (AUC0-12),Simulations using the final model showed that a 70-kg subject with a creatinine clearance of 90 mL/min receiving concomitant CsA would require 1.25 g of MMF twice daily while a similar subject who did not receive concomitant CsA would require 0.75 g twice daily to achieve a MPA area under the concentration-time curve from 0 to 12 h (AUC0-12) of 45 mg·h/L.,Development of Improved Dosing Regimens for Mycophenolate Mofetil Based on Population Pharmacokinetic Analyses in Adults with Lupus Nephritis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28536776/),[h·mg] / [l],45,211465,DB00091,Cyclosporine
,9692659,AUC12,"The AUC12 for Neoral and cyclosporine were 4164+/-1467 and 5318+/-1670 microg x L/hour (p=0.09), respectively.",Pharmacokinetic profile and variability of cyclosporine versus neoral in patients with cystic fibrosis after lung transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9692659/),[l·μg] / [h],4164,211808,DB00091,Cyclosporine
,9692659,AUC12,"The AUC12 for Neoral and cyclosporine were 4164+/-1467 and 5318+/-1670 microg x L/hour (p=0.09), respectively.",Pharmacokinetic profile and variability of cyclosporine versus neoral in patients with cystic fibrosis after lung transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9692659/),[l·μg] / [h],5318,211809,DB00091,Cyclosporine
,9692659,Cmax,Respective Cmax were 613+/-242 and 931 +/-458 microg/L (p=0.08) and relative Cmax and AUC12 were 1.91 and 1.47 (p<0.05).,Pharmacokinetic profile and variability of cyclosporine versus neoral in patients with cystic fibrosis after lung transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9692659/),[μg] / [l],613,211810,DB00091,Cyclosporine
,9692659,Cmax,Respective Cmax were 613+/-242 and 931 +/-458 microg/L (p=0.08) and relative Cmax and AUC12 were 1.91 and 1.47 (p<0.05).,Pharmacokinetic profile and variability of cyclosporine versus neoral in patients with cystic fibrosis after lung transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9692659/),[μg] / [l],931,211811,DB00091,Cyclosporine
,15740555,AUC(0-infinity),"Both EC-MPS doses delivered bioequivalent mean MPA exposure (AUC(0-infinity)) compared with 1000 mg MMF: 60.7 microg h/mL for 640 mg EC-MPS, 66.5 microg h/mL for 720 mg EC-MPS, and 63.7 microg h/mL for 1000 mg MMF.",Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15740555/),[h·μg] / [ml],60.7,211901,DB00091,Cyclosporine
,15740555,AUC(0-infinity),"Both EC-MPS doses delivered bioequivalent mean MPA exposure (AUC(0-infinity)) compared with 1000 mg MMF: 60.7 microg h/mL for 640 mg EC-MPS, 66.5 microg h/mL for 720 mg EC-MPS, and 63.7 microg h/mL for 1000 mg MMF.",Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15740555/),[h·μg] / [ml],66.5,211902,DB00091,Cyclosporine
,15740555,AUC(0-infinity),"Both EC-MPS doses delivered bioequivalent mean MPA exposure (AUC(0-infinity)) compared with 1000 mg MMF: 60.7 microg h/mL for 640 mg EC-MPS, 66.5 microg h/mL for 720 mg EC-MPS, and 63.7 microg h/mL for 1000 mg MMF.",Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15740555/),[h·μg] / [ml],63.7,211903,DB00091,Cyclosporine
,15740555,t(max),"Median t(max) was significantly delayed for both EC-MPS doses compared with MMF (2.0 h vs. 0.75 h, respectively; p < 0.01), consistent with a functional enteric coating of EC-MPS.",Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15740555/),h,2.0,211904,DB00091,Cyclosporine
,15740555,t(max),"Median t(max) was significantly delayed for both EC-MPS doses compared with MMF (2.0 h vs. 0.75 h, respectively; p < 0.01), consistent with a functional enteric coating of EC-MPS.",Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15740555/),h,0.75,211905,DB00091,Cyclosporine
,6743782,F,F increased from 0.13 after the 6 mg kg-1 dose to 0.22 with the 18 and 23 mg kg-1 doses (p less than 0.05).,Apparent dose-dependent oral absorption of cyclosporin A in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6743782/),,0.13,211977,DB00091,Cyclosporine
,6743782,F,F increased from 0.13 after the 6 mg kg-1 dose to 0.22 with the 18 and 23 mg kg-1 doses (p less than 0.05).,Apparent dose-dependent oral absorption of cyclosporin A in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6743782/),,0.22,211978,DB00091,Cyclosporine
,6743782,duration of drug absorption (T),"In the present investigation, the observed values for the duration of drug absorption (T), terminal first-order rate constant (beta) and corresponding elimination half-life (T 1/2 beta) of approximately 4-5 h, 0.030 h-1 and 21-28 h, respectively, were similar for all CyA doses.",Apparent dose-dependent oral absorption of cyclosporin A in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6743782/),h,4-5,211979,DB00091,Cyclosporine
,6743782,terminal first-order rate constant (beta),"In the present investigation, the observed values for the duration of drug absorption (T), terminal first-order rate constant (beta) and corresponding elimination half-life (T 1/2 beta) of approximately 4-5 h, 0.030 h-1 and 21-28 h, respectively, were similar for all CyA doses.",Apparent dose-dependent oral absorption of cyclosporin A in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6743782/),1/[h],0.030,211980,DB00091,Cyclosporine
,6743782,elimination half-life (T 1/2 beta),"In the present investigation, the observed values for the duration of drug absorption (T), terminal first-order rate constant (beta) and corresponding elimination half-life (T 1/2 beta) of approximately 4-5 h, 0.030 h-1 and 21-28 h, respectively, were similar for all CyA doses.",Apparent dose-dependent oral absorption of cyclosporin A in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6743782/),h,21-28,211981,DB00091,Cyclosporine
,6743782,Absorption lag times,Absorption lag times of 1-2 h were found.,Apparent dose-dependent oral absorption of cyclosporin A in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6743782/),h,1-2,211982,DB00091,Cyclosporine
,11075307,effective half-life,Steady-state ADI628 concentrations reflected an effective half-life of 7.0 to 12.5 hours.,"Pharmacokinetics, pharmacodynamics, and safety of inhaled cyclosporin A (ADI628) after single and repeated administration in healthy male and female subjects and asthmatic patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11075307/),h,7.0 to 12.5,212027,DB00091,Cyclosporine
less,30472978,maximum drug load,The maximum drug load for the SERIES 1 formulations was less than 40 mg/ml.,"Development, Characterization, and Pharmacokinetic Evaluation of a CRV431 Loaded Self-Microemulsifying Drug Delivery System. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30472978/),[mg] / [ml],40,212439,DB00091,Cyclosporine
,21166111,C2,"CsA was targeted to C2 of 700 to 1400 ng/mL, and Tac ER was targeted to C0 of 5 to 10 ng/mL.",A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21166111/),[ng] / [ml],700 to 1400,212609,DB00091,Cyclosporine
,21166111,C0,"CsA was targeted to C2 of 700 to 1400 ng/mL, and Tac ER was targeted to C0 of 5 to 10 ng/mL.",A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21166111/),[ng] / [ml],5 to 10,212610,DB00091,Cyclosporine
,21166111,C(o) Tac,"The achieved mean C(o) Tac and CsA were 6.4 +/- 1.16 and 201 +/- 57 ng/mL, respectively.",A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21166111/),[ng] / [ml],6.4,212611,DB00091,Cyclosporine
,21166111,C(o) Tac,"The achieved mean C(o) Tac and CsA were 6.4 +/- 1.16 and 201 +/- 57 ng/mL, respectively.",A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21166111/),[ng] / [ml],201,212612,DB00091,Cyclosporine
,21166111,AUC (PD 0-6) h,"The ERPF and GFR AUC (PD 0-6) hr were 3645 +/- 887 vs. 3210 +/- 582 mL/1.73 m2 (P=0.027) and 604 +/- 98 vs. 543+/- 79 mL/1.73 m2(P=0.023) for Tac ER versus CsA, respectively.",A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21166111/),[ml] / [1.73·m2],3645,212613,DB00091,Cyclosporine
,21166111,AUC (PD 0-6) h,"The ERPF and GFR AUC (PD 0-6) hr were 3645 +/- 887 vs. 3210 +/- 582 mL/1.73 m2 (P=0.027) and 604 +/- 98 vs. 543+/- 79 mL/1.73 m2(P=0.023) for Tac ER versus CsA, respectively.",A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21166111/),[ml] / [1.73·m2],3210,212614,DB00091,Cyclosporine
,21166111,AUC (PD 0-6) h,"The ERPF and GFR AUC (PD 0-6) hr were 3645 +/- 887 vs. 3210 +/- 582 mL/1.73 m2 (P=0.027) and 604 +/- 98 vs. 543+/- 79 mL/1.73 m2(P=0.023) for Tac ER versus CsA, respectively.",A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21166111/),[ml] / [1.73·m2],604,212615,DB00091,Cyclosporine
,21166111,AUC (PD 0-6) h,"The ERPF and GFR AUC (PD 0-6) hr were 3645 +/- 887 vs. 3210 +/- 582 mL/1.73 m2 (P=0.027) and 604 +/- 98 vs. 543+/- 79 mL/1.73 m2(P=0.023) for Tac ER versus CsA, respectively.",A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21166111/),[ml] / [1.73·m2],543,212616,DB00091,Cyclosporine
,10435879,AUC,"CsA AUC increased from 2887 +/- 1729 ng.h/ml on day 0 to 3842 +/- 1975 ng.h/ml on day 2 (P < 0.05), 4750 +/- 1718 ng.h/ml on day 4 (P< 0.01) and then decreased to 4052 +/- 1687 ng.h/ml on day 7 (P<0.01).",Unpredictable cyclosporin--fluconazole interaction in renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435879/),[h·ng] / [ml],2887,212757,DB00091,Cyclosporine
,10435879,AUC,"CsA AUC increased from 2887 +/- 1729 ng.h/ml on day 0 to 3842 +/- 1975 ng.h/ml on day 2 (P < 0.05), 4750 +/- 1718 ng.h/ml on day 4 (P< 0.01) and then decreased to 4052 +/- 1687 ng.h/ml on day 7 (P<0.01).",Unpredictable cyclosporin--fluconazole interaction in renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435879/),[h·ng] / [ml],3842,212758,DB00091,Cyclosporine
,10435879,AUC,"CsA AUC increased from 2887 +/- 1729 ng.h/ml on day 0 to 3842 +/- 1975 ng.h/ml on day 2 (P < 0.05), 4750 +/- 1718 ng.h/ml on day 4 (P< 0.01) and then decreased to 4052 +/- 1687 ng.h/ml on day 7 (P<0.01).",Unpredictable cyclosporin--fluconazole interaction in renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435879/),[h·ng] / [ml],4750,212759,DB00091,Cyclosporine
,10435879,AUC,"CsA AUC increased from 2887 +/- 1729 ng.h/ml on day 0 to 3842 +/- 1975 ng.h/ml on day 2 (P < 0.05), 4750 +/- 1718 ng.h/ml on day 4 (P< 0.01) and then decreased to 4052 +/- 1687 ng.h/ml on day 7 (P<0.01).",Unpredictable cyclosporin--fluconazole interaction in renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435879/),[h·ng] / [ml],4052,212760,DB00091,Cyclosporine
,10435879,AUC,"Following CsA dose reduction by 50%, the mean AUC decreased significantly to 2330 +/- 1602 ng x h/ml (P<0.01).",Unpredictable cyclosporin--fluconazole interaction in renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435879/),[h·ng] / [ml],2330,212761,DB00091,Cyclosporine
,10435879,Cmax,"The Cmax showed a significant increase from 701 +/- 345 ng/ml on day 0 to 941 +/- 326 ng/ml (P < 0.01) on day 4 but decreased from 768 +/- 292 ng/ml on day 7 to 498 +/- 289 ng/ml on day 14, P<0.01.",Unpredictable cyclosporin--fluconazole interaction in renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435879/),[ng] / [ml],701,212762,DB00091,Cyclosporine
,10435879,Cmax,"The Cmax showed a significant increase from 701 +/- 345 ng/ml on day 0 to 941 +/- 326 ng/ml (P < 0.01) on day 4 but decreased from 768 +/- 292 ng/ml on day 7 to 498 +/- 289 ng/ml on day 14, P<0.01.",Unpredictable cyclosporin--fluconazole interaction in renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435879/),[ng] / [ml],941,212763,DB00091,Cyclosporine
,10435879,Cmax,"The Cmax showed a significant increase from 701 +/- 345 ng/ml on day 0 to 941 +/- 326 ng/ml (P < 0.01) on day 4 but decreased from 768 +/- 292 ng/ml on day 7 to 498 +/- 289 ng/ml on day 14, P<0.01.",Unpredictable cyclosporin--fluconazole interaction in renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435879/),[ng] / [ml],768,212764,DB00091,Cyclosporine
,10435879,Cmax,"The Cmax showed a significant increase from 701 +/- 345 ng/ml on day 0 to 941 +/- 326 ng/ml (P < 0.01) on day 4 but decreased from 768 +/- 292 ng/ml on day 7 to 498 +/- 289 ng/ml on day 14, P<0.01.",Unpredictable cyclosporin--fluconazole interaction in renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435879/),[ng] / [ml],498,212765,DB00091,Cyclosporine
,10435879,Cmin,The mean Cmin increased from 207 +/- 138 ng/ml on day 0 to 274 +/- 168 ng/ml on day 4.,Unpredictable cyclosporin--fluconazole interaction in renal transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435879/),[ng] / [ml],207,212766,DB00091,Cyclosporine
,10435879,Cmin,The mean Cmin increased from 207 +/- 138 ng/ml on day 0 to 274 +/- 168 ng/ml on day 4.,Unpredictable cyclosporin--fluconazole interaction in renal transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10435879/),[ng] / [ml],274,212767,DB00091,Cyclosporine
,11274802,entrapment efficiency,"Results showed CyA vesicles were spherical particles, with content of 3.137+/-0.060% mg/ml, entrapment efficiency of 98.91+/-0.80%, particle size of 63.89+/-4.75 nm, polydispersity of 43.2+/-6.1% and Zeta potential of -13 mV.",Pharmacokinetic behavior of cyclosporin A in rabbits by oral administration of lecithin vesicle and Sandimmun Neoral. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11274802/),%,98.91,212782,DB00091,Cyclosporine
,11274802,polydispersity,"Results showed CyA vesicles were spherical particles, with content of 3.137+/-0.060% mg/ml, entrapment efficiency of 98.91+/-0.80%, particle size of 63.89+/-4.75 nm, polydispersity of 43.2+/-6.1% and Zeta potential of -13 mV.",Pharmacokinetic behavior of cyclosporin A in rabbits by oral administration of lecithin vesicle and Sandimmun Neoral. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11274802/),%,43.2,212783,DB00091,Cyclosporine
,11274802,Zeta potential,"Results showed CyA vesicles were spherical particles, with content of 3.137+/-0.060% mg/ml, entrapment efficiency of 98.91+/-0.80%, particle size of 63.89+/-4.75 nm, polydispersity of 43.2+/-6.1% and Zeta potential of -13 mV.",Pharmacokinetic behavior of cyclosporin A in rabbits by oral administration of lecithin vesicle and Sandimmun Neoral. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11274802/),mv,-,212784,DB00091,Cyclosporine
,11274802,Zeta potential,"Results showed CyA vesicles were spherical particles, with content of 3.137+/-0.060% mg/ml, entrapment efficiency of 98.91+/-0.80%, particle size of 63.89+/-4.75 nm, polydispersity of 43.2+/-6.1% and Zeta potential of -13 mV.",Pharmacokinetic behavior of cyclosporin A in rabbits by oral administration of lecithin vesicle and Sandimmun Neoral. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11274802/),mv,13,212785,DB00091,Cyclosporine
,11274802,relative bioavailability,The relative bioavailability of CsA-VES versus CsA-NEO was 105+/-21% (n=6) and statistical analysis demonstrated both preparations were bioequivalent.,Pharmacokinetic behavior of cyclosporin A in rabbits by oral administration of lecithin vesicle and Sandimmun Neoral. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11274802/),%,105,212786,DB00091,Cyclosporine
,16860172,AUCs,"In patients receiving CsA/MMF, MPA AUCs ranged from 19.67 to 81.80 mg/h.L (mean [SD], 41.92 [14.14] mg/h.L).",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [h·l],19.67 to 81.80,213191,DB00091,Cyclosporine
,16860172,AUCs,"In patients receiving CsA/MMF, MPA AUCs ranged from 19.67 to 81.80 mg/h.L (mean [SD], 41.92 [14.14] mg/h.L).",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [h·l],41.92,213192,DB00091,Cyclosporine
<,16860172,AUCs,"Co levels of 0.5 and 1.6 mg/L were correlated with AUCs of <30 and <40 mg/h.L, respectively.",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [h·l],30,213193,DB00091,Cyclosporine
<,16860172,AUCs,"Co levels of 0.5 and 1.6 mg/L were correlated with AUCs of <30 and <40 mg/h.L, respectively.",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [h·l],40,213194,DB00091,Cyclosporine
,16860172,AUCs,"In patients receiving RAPA/MMF, MPA AUCs ranged from 34.40 to 87.60 mg/h.L (mean, 51.07 [15.80] mg/h.L).",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [h·l],51.07,213195,DB00091,Cyclosporine
,16860172,C0,"MPA C0 levels of 1.0 and 2.3 mg/L were correlated with AUCs of 30 and 40 mg/h.L, respectively.",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [l],1.0,213196,DB00091,Cyclosporine
,16860172,C0,"MPA C0 levels of 1.0 and 2.3 mg/L were correlated with AUCs of 30 and 40 mg/h.L, respectively.",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [l],2.3,213197,DB00091,Cyclosporine
,16860172,AUCs,"MPA C0 levels of 1.0 and 2.3 mg/L were correlated with AUCs of 30 and 40 mg/h.L, respectively.",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [h·l],30,213198,DB00091,Cyclosporine
,16860172,AUCs,"MPA C0 levels of 1.0 and 2.3 mg/L were correlated with AUCs of 30 and 40 mg/h.L, respectively.",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [h·l],40,213199,DB00091,Cyclosporine
,16860172,AUC,"Statistically significant differences between RAPA/MMF and CsA/MMF were noted in the mean MMF dosage (1.90 [0.71] vs 2.87 [0.78] g/d, respectively; P<0.001), the mean dose-adjusted MPA AUC (60.95 [27.42] vs 31.92 [16.12] mg/h.L.g MMF; P<0.001), and mean dose-adjusted MPA C0 levels (5.10 [3.41] vs 1.41 [0.95] mg/L.g; P<0.001).",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [g·h·l],60.95,213200,DB00091,Cyclosporine
,16860172,AUC,"Statistically significant differences between RAPA/MMF and CsA/MMF were noted in the mean MMF dosage (1.90 [0.71] vs 2.87 [0.78] g/d, respectively; P<0.001), the mean dose-adjusted MPA AUC (60.95 [27.42] vs 31.92 [16.12] mg/h.L.g MMF; P<0.001), and mean dose-adjusted MPA C0 levels (5.10 [3.41] vs 1.41 [0.95] mg/L.g; P<0.001).",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [g·h·l],31.92,213201,DB00091,Cyclosporine
,16860172,C0,"Statistically significant differences between RAPA/MMF and CsA/MMF were noted in the mean MMF dosage (1.90 [0.71] vs 2.87 [0.78] g/d, respectively; P<0.001), the mean dose-adjusted MPA AUC (60.95 [27.42] vs 31.92 [16.12] mg/h.L.g MMF; P<0.001), and mean dose-adjusted MPA C0 levels (5.10 [3.41] vs 1.41 [0.95] mg/L.g; P<0.001).",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [g·l],5.10,213202,DB00091,Cyclosporine
,16860172,C0,"Statistically significant differences between RAPA/MMF and CsA/MMF were noted in the mean MMF dosage (1.90 [0.71] vs 2.87 [0.78] g/d, respectively; P<0.001), the mean dose-adjusted MPA AUC (60.95 [27.42] vs 31.92 [16.12] mg/h.L.g MMF; P<0.001), and mean dose-adjusted MPA C0 levels (5.10 [3.41] vs 1.41 [0.95] mg/L.g; P<0.001).",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [g·l],1.41,213203,DB00091,Cyclosporine
,8451783,bioavailability,"Clamping the bile drain increased the bioavailability (9.6% vs. 7%, p < 0.05), but even then it was considerably lower than the value of approximately 30% generally reported in literature.",Pharmacokinetics of cyclosporine A after intravenous and oral administration in liver transplant patients measured with high-performance liquid chromatography. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8451783/),%,9.6,213361,DB00091,Cyclosporine
,8451783,bioavailability,"Clamping the bile drain increased the bioavailability (9.6% vs. 7%, p < 0.05), but even then it was considerably lower than the value of approximately 30% generally reported in literature.",Pharmacokinetics of cyclosporine A after intravenous and oral administration in liver transplant patients measured with high-performance liquid chromatography. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8451783/),%,7,213362,DB00091,Cyclosporine
,8451783,bioavailability,"Clamping the bile drain increased the bioavailability (9.6% vs. 7%, p < 0.05), but even then it was considerably lower than the value of approximately 30% generally reported in literature.",Pharmacokinetics of cyclosporine A after intravenous and oral administration in liver transplant patients measured with high-performance liquid chromatography. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8451783/),%,30,213363,DB00091,Cyclosporine
,8786246,AUC,"At the eighth week (before crossover), AUC and Cmax values for Neoral and Sandimmune were 5618 +/- 1705 versus 3202 +/- 596 ng.h/mL and 1283 +/- 337 versus 623 +/- 173 ng/mL, respectively.",Efficacy and pharmacokinetics of two formulations of cyclosporine A in patients with psoriasis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786246/),[h·ng] / [ml],5618,213477,DB00091,Cyclosporine
,8786246,Cmax,"At the eighth week (before crossover), AUC and Cmax values for Neoral and Sandimmune were 5618 +/- 1705 versus 3202 +/- 596 ng.h/mL and 1283 +/- 337 versus 623 +/- 173 ng/mL, respectively.",Efficacy and pharmacokinetics of two formulations of cyclosporine A in patients with psoriasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786246/),[h·ng] / [ml],3202,213478,DB00091,Cyclosporine
,8786246,Cmax,"At the eighth week (before crossover), AUC and Cmax values for Neoral and Sandimmune were 5618 +/- 1705 versus 3202 +/- 596 ng.h/mL and 1283 +/- 337 versus 623 +/- 173 ng/mL, respectively.",Efficacy and pharmacokinetics of two formulations of cyclosporine A in patients with psoriasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786246/),[ng] / [ml],1283,213479,DB00091,Cyclosporine
,8786246,Cmax,"At the eighth week (before crossover), AUC and Cmax values for Neoral and Sandimmune were 5618 +/- 1705 versus 3202 +/- 596 ng.h/mL and 1283 +/- 337 versus 623 +/- 173 ng/mL, respectively.",Efficacy and pharmacokinetics of two formulations of cyclosporine A in patients with psoriasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786246/),[ng] / [ml],623,213480,DB00091,Cyclosporine
,10081632,distribution volume,"The basiliximab distribution volume was 7.5 +/- 1.7 L, the half-life 7.5 +/- 2.5 d and the clearance 33 +/- 12 mL/h.",Screening for basiliximab exposure-response relationships in renal allotransplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10081632/),l,7.5,213919,DB00091,Cyclosporine
,10081632,half-life,"The basiliximab distribution volume was 7.5 +/- 1.7 L, the half-life 7.5 +/- 2.5 d and the clearance 33 +/- 12 mL/h.",Screening for basiliximab exposure-response relationships in renal allotransplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10081632/),d,7.5,213920,DB00091,Cyclosporine
,10081632,clearance,"The basiliximab distribution volume was 7.5 +/- 1.7 L, the half-life 7.5 +/- 2.5 d and the clearance 33 +/- 12 mL/h.",Screening for basiliximab exposure-response relationships in renal allotransplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10081632/),[ml] / [h],33,213921,DB00091,Cyclosporine
,23668548,total deposited dose,The average total deposited dose was 53.7 ± 12.7 mg.,Lung deposition and pharmacokinetics of nebulized cyclosporine in lung transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23668548/),mg,53.7,214322,DB00091,Cyclosporine
,23668548,stomach deposition,Predose coaching with five of 10 patients reduced stomach deposition (22.6 ± 11.2 vs. 8.3 ± 5.2 mg; p=0.03).,Lung deposition and pharmacokinetics of nebulized cyclosporine in lung transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23668548/),,22.6,214323,DB00091,Cyclosporine
,23668548,stomach deposition,Predose coaching with five of 10 patients reduced stomach deposition (22.6 ± 11.2 vs. 8.3 ± 5.2 mg; p=0.03).,Lung deposition and pharmacokinetics of nebulized cyclosporine in lung transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23668548/),,8.3,214324,DB00091,Cyclosporine
,23668548,Blood concentrations,Blood concentrations declined quickly from a maximum of 372 ± 140 ng/mL to 15.3 ± 9.7 ng/mL at 24 hr post dose.,Lung deposition and pharmacokinetics of nebulized cyclosporine in lung transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23668548/),[ng] / [ml],372,214325,DB00091,Cyclosporine
,23668548,Blood concentrations,Blood concentrations declined quickly from a maximum of 372 ± 140 ng/mL to 15.3 ± 9.7 ng/mL at 24 hr post dose.,Lung deposition and pharmacokinetics of nebulized cyclosporine in lung transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23668548/),[ng] / [ml],15.3,214326,DB00091,Cyclosporine
,23668548,AUC(0-24),"Levels of AUC(0-24) [area under the concentration vs. time curve from 0 to 24 hr] averaged 1,493 ± 746 ng hr/mL.",Lung deposition and pharmacokinetics of nebulized cyclosporine in lung transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23668548/),[h·ng] / [ml],"1,493",214327,DB00091,Cyclosporine
,23668548,area under the concentration vs. time curve from 0 to 24 hr,"Levels of AUC(0-24) [area under the concentration vs. time curve from 0 to 24 hr] averaged 1,493 ± 746 ng hr/mL.",Lung deposition and pharmacokinetics of nebulized cyclosporine in lung transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23668548/),[h·ng] / [ml],"1,493",214328,DB00091,Cyclosporine
,11707060,elimination half-life (t1/2beta),"The corticosteroids have a short elimination half-life (t1/2beta) of 1.5 to 4 hours, but their biological half-lives are much longer (12 to 36 hours).",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,1.5 to 4,214390,DB00091,Cyclosporine
,11707060,biological half-lives,"The corticosteroids have a short elimination half-life (t1/2beta) of 1.5 to 4 hours, but their biological half-lives are much longer (12 to 36 hours).",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,12 to 36,214391,DB00091,Cyclosporine
,11707060,t1/2beta,"Rapid acetylation in the intestinal wall and liver (t1/2beta 0.5 to 2 hours) and transport probably by P-glycoprotein affect mucosal concentrations of mesalazine, which apparently determine clinical response.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,0.5 to 2,214392,DB00091,Cyclosporine
,11707060,oral bioavailability,"Metronidazole has high (approximately 90%) oral bioavailability, with hepatic elimination characterised by a t1/2beta of 6 to 10 hours and a total clearance of about 4 L/h/kg.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),%,90,214393,DB00091,Cyclosporine
,11707060,t1/2beta,"Metronidazole has high (approximately 90%) oral bioavailability, with hepatic elimination characterised by a t1/2beta of 6 to 10 hours and a total clearance of about 4 L/h/kg.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,6 to 10,214394,DB00091,Cyclosporine
,11707060,total clearance,"Metronidazole has high (approximately 90%) oral bioavailability, with hepatic elimination characterised by a t1/2beta of 6 to 10 hours and a total clearance of about 4 L/h/kg.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),[l] / [h·kg],4,214395,DB00091,Cyclosporine
,11707060,t1/2beta,"Ciprofloxacin is largely excreted unchanged both renally (about 45% of dose) and extrarenally (25%), with a relatively short t1/2beta (3.5 to 7 hours).",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,3.5 to 7,214396,DB00091,Cyclosporine
,11707060,t1/2beta,"Both mercaptopurine and azathioprine have a short t1/2beta (1 to 2 hours), but the t1/2beta of 6-TGN ranges from 3 to 13 days.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,1 to 2,214397,DB00091,Cyclosporine
,11707060,t1/2beta,"Both mercaptopurine and azathioprine have a short t1/2beta (1 to 2 hours), but the t1/2beta of 6-TGN ranges from 3 to 13 days.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),d,3 to 13,214398,DB00091,Cyclosporine
up to,11707060,t1/2beta,"Almost complete bioavailability has been observed after intramuscular and subcutaneous administration of methotrexate, which is predominantly (85%) excreted as unchanged drug with a t1/2beta of up to 50 hours.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,50,214399,DB00091,Cyclosporine
,11707060,t1/2beta,"It is extensively metabolised by CYP3A4/5 in the liver and intestine (median t1/2beta and clearance 7.9 hours and 0.46 L/h/kg, respectively), and inhibitors and inducers of CYP3A4 can modify response and toxicity.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,7.9,214400,DB00091,Cyclosporine
,11707060,clearance,"It is extensively metabolised by CYP3A4/5 in the liver and intestine (median t1/2beta and clearance 7.9 hours and 0.46 L/h/kg, respectively), and inhibitors and inducers of CYP3A4 can modify response and toxicity.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),h,7.9,214401,DB00091,Cyclosporine
,11707060,clearance,"It is extensively metabolised by CYP3A4/5 in the liver and intestine (median t1/2beta and clearance 7.9 hours and 0.46 L/h/kg, respectively), and inhibitors and inducers of CYP3A4 can modify response and toxicity.",Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),[l] / [h·kg],0.46,214402,DB00091,Cyclosporine
,11707060,t1/2beta,Infliximab is predominantly distributed to the vascular compartment and eliminated with a t1/2beta between 10 and 14 days.,Pharmacokinetic considerations in the treatment of inflammatory bowel disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707060/),d,10 and 14,214403,DB00091,Cyclosporine
,11692216,Cmax,"For oral administration, mean values ( +/- SD) of Cmax, 24-h area-under-the curve (AUC) and 24-h trough level, all normalized for a 1 mg/kg dose, were 20 +/- 9 ng x kg/mg x ml, 210 +/- 70 ng x h x kg/mg x ml and 2.6 +/- 0.9 ng x kg/mg x ml, respectively.",Pharmacokinetics of cyclosporine in monkeys after oral and intramuscular administration: relation to efficacy in kidney allografting. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11692216/),[kg·ng] / [mg·ml],20,214411,DB00091,Cyclosporine
,11692216,24-h area-under-the curve (AUC),"For oral administration, mean values ( +/- SD) of Cmax, 24-h area-under-the curve (AUC) and 24-h trough level, all normalized for a 1 mg/kg dose, were 20 +/- 9 ng x kg/mg x ml, 210 +/- 70 ng x h x kg/mg x ml and 2.6 +/- 0.9 ng x kg/mg x ml, respectively.",Pharmacokinetics of cyclosporine in monkeys after oral and intramuscular administration: relation to efficacy in kidney allografting. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11692216/),[h·kg·ng] / [mg·ml],210,214412,DB00091,Cyclosporine
,11692216,24-h trough level,"For oral administration, mean values ( +/- SD) of Cmax, 24-h area-under-the curve (AUC) and 24-h trough level, all normalized for a 1 mg/kg dose, were 20 +/- 9 ng x kg/mg x ml, 210 +/- 70 ng x h x kg/mg x ml and 2.6 +/- 0.9 ng x kg/mg x ml, respectively.",Pharmacokinetics of cyclosporine in monkeys after oral and intramuscular administration: relation to efficacy in kidney allografting. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11692216/),[kg·ng] / [mg·ml],2.6,214413,DB00091,Cyclosporine
above,11692216,24-h,Rejection-free kidney allograft survival could be achieved using oral cyclosporine monotherapy with average 24-h trough concentrations above 100 ng/ml during maintenance treatment.,Pharmacokinetics of cyclosporine in monkeys after oral and intramuscular administration: relation to efficacy in kidney allografting. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11692216/),[ng] / [ml],100,214414,DB00091,Cyclosporine
above,11692216,trough concentrations,Rejection-free kidney allograft survival could be achieved using oral cyclosporine monotherapy with average 24-h trough concentrations above 100 ng/ml during maintenance treatment.,Pharmacokinetics of cyclosporine in monkeys after oral and intramuscular administration: relation to efficacy in kidney allografting. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11692216/),[ng] / [ml],100,214415,DB00091,Cyclosporine
,11692216,trough levels,"Typically, daily oral doses of 100 mg/kg-150 mg/kg during the first two weeks post-transplantation, followed by daily 30 mg/kg-100 mg/kg dose levels during subsequent maintenance can result in long-term allograft survival, with 24-h average trough levels in individual animals during maintenance between 110 ng/ml and 700 ng/ml.",Pharmacokinetics of cyclosporine in monkeys after oral and intramuscular administration: relation to efficacy in kidney allografting. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11692216/),[ng] / [ml],110,214416,DB00091,Cyclosporine
,11692216,trough levels,"Typically, daily oral doses of 100 mg/kg-150 mg/kg during the first two weeks post-transplantation, followed by daily 30 mg/kg-100 mg/kg dose levels during subsequent maintenance can result in long-term allograft survival, with 24-h average trough levels in individual animals during maintenance between 110 ng/ml and 700 ng/ml.",Pharmacokinetics of cyclosporine in monkeys after oral and intramuscular administration: relation to efficacy in kidney allografting. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11692216/),[ng] / [ml],700,214417,DB00091,Cyclosporine
,10784627,remission rate,The remission rate was 35% (n = 23 of 66).,"Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10784627/),%,35,214903,DB00091,Cyclosporine
,17445555,area under the curve (AUC 0-6),"The area under the curve (AUC 0-6) of MPA was 52.68 +/- 17.5 microg/mL*hr, with 61.5% of basal determinations (Co) under 5 microg/mL (4.08 +/- 0.74).",Converting to a generic formulation of mycophenolate mofetil in stable kidney transplant recipients: 1 year of drug surveillance and outcome. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17445555/),[μg] / [h·ml],52.68,215239,DB00091,Cyclosporine
,17445555,area under the curve (AUC 0-6),"The area under the curve (AUC 0-6) of MPA was 52.68 +/- 17.5 microg/mL*hr, with 61.5% of basal determinations (Co) under 5 microg/mL (4.08 +/- 0.74).",Converting to a generic formulation of mycophenolate mofetil in stable kidney transplant recipients: 1 year of drug surveillance and outcome. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17445555/),,4,215240,DB00091,Cyclosporine
,12352931,trough levels,"Co-medication with CsA demanded higher MPA mofetil (MMF) doses to achieve equivalent trough levels than Tac (362 vs. 178 mg per mg/L, P= 0.004).",Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352931/),[mg] / [l·mg],362,215557,DB00091,Cyclosporine
,12352931,trough levels,"Co-medication with CsA demanded higher MPA mofetil (MMF) doses to achieve equivalent trough levels than Tac (362 vs. 178 mg per mg/L, P= 0.004).",Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352931/),[mg] / [l·mg],178,215558,DB00091,Cyclosporine
,12352931,C(0),"Median MPA C(0) (range) was significantly lower during CsA co-therapy when corrected for MMF dose (2.8 vs. 5.6 mg MPA/L for Tac, P= 0.006).",Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352931/),[Mpa·mg] / [l],2.8,215559,DB00091,Cyclosporine
,12352931,C(0),"Median MPA C(0) (range) was significantly lower during CsA co-therapy when corrected for MMF dose (2.8 vs. 5.6 mg MPA/L for Tac, P= 0.006).",Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352931/),[Mpa·mg] / [l],5.6,215560,DB00091,Cyclosporine
,12352931,AUC,"The AUC of MPAG was correspondingly higher during CsA co-medication (229 vs. 94 mg/L/h for Tac, P = 0.012) with the MPA-to-MPAG ratio at C(0) correspondingly lower (0.10 vs. 0.14, respectively, P = 0.04).",Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352931/),[mg] / [h·l],229,215561,DB00091,Cyclosporine
,12352931,AUC,"The AUC of MPAG was correspondingly higher during CsA co-medication (229 vs. 94 mg/L/h for Tac, P = 0.012) with the MPA-to-MPAG ratio at C(0) correspondingly lower (0.10 vs. 0.14, respectively, P = 0.04).",Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352931/),[mg] / [h·l],94,215562,DB00091,Cyclosporine
,12352931,ratio at C(0),"The AUC of MPAG was correspondingly higher during CsA co-medication (229 vs. 94 mg/L/h for Tac, P = 0.012) with the MPA-to-MPAG ratio at C(0) correspondingly lower (0.10 vs. 0.14, respectively, P = 0.04).",Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352931/),,0.10,215563,DB00091,Cyclosporine
,12352931,ratio at C(0),"The AUC of MPAG was correspondingly higher during CsA co-medication (229 vs. 94 mg/L/h for Tac, P = 0.012) with the MPA-to-MPAG ratio at C(0) correspondingly lower (0.10 vs. 0.14, respectively, P = 0.04).",Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352931/),,0.14,215564,DB00091,Cyclosporine
,12352931,trough levels,"Children with elevated aspartate transaminase (AST; but with no evidence of rejection on liver biopsy, n = 7) had significantly lower MPA trough levels compared with those in whom AST was normal (0. 77 vs. 1.76 mg/L, P = 0.05), but there was no difference in the MMF dose per body weight.",Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352931/),[mg] / [l],0. 77,215565,DB00091,Cyclosporine
,12352931,trough levels,"Children with elevated aspartate transaminase (AST; but with no evidence of rejection on liver biopsy, n = 7) had significantly lower MPA trough levels compared with those in whom AST was normal (0. 77 vs. 1.76 mg/L, P = 0.05), but there was no difference in the MMF dose per body weight.",Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352931/),[mg] / [l],1.76,215566,DB00091,Cyclosporine
,22638872,passive diffusion,"SCHH studies suggested active uptake, passive diffusion and efflux intrinsic clearance values of 1.9, 0.5 and 1.2 μL/min/10(6)cells, respectively, for pravastatin.",Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22638872/),[min·μl] / [10(6)cells],0.5,215573,DB00091,Cyclosporine
,22638872,efflux intrinsic clearance,"SCHH studies suggested active uptake, passive diffusion and efflux intrinsic clearance values of 1.9, 0.5 and 1.2 μL/min/10(6)cells, respectively, for pravastatin.",Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22638872/),[min·μl] / [10(6)cells],1.2,215574,DB00091,Cyclosporine
,22638872,AUC ratio,"However, pravastatin-cyclosporine DDI was underpredicted (AUC ratio 4.4 Vs ~10).",Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22638872/),,4.4,215575,DB00091,Cyclosporine
,22638872,Vs,"However, pravastatin-cyclosporine DDI was underpredicted (AUC ratio 4.4 Vs ~10).",Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22638872/),,10,215576,DB00091,Cyclosporine
,17048505,absorption constant,The absorption constant for liposomal product was much greater (10.26 h(-1)) than for free drug solution (1.2 h(-1)) or the marketed sample of microemulsion (2.51 h(-1)) and the volume of distribution was found to be less for liposomes (7629.88 ml/kg) than that of the free drug solution (10971.92 ml/kg) and marketed microemulsion (9012.07 ml/kg).,"Preparation, characterization and in vivo studies of proliposomes containing Cyclosporine A. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048505/),1/[h],10.26,216055,DB00091,Cyclosporine
,17048505,absorption constant,The absorption constant for liposomal product was much greater (10.26 h(-1)) than for free drug solution (1.2 h(-1)) or the marketed sample of microemulsion (2.51 h(-1)) and the volume of distribution was found to be less for liposomes (7629.88 ml/kg) than that of the free drug solution (10971.92 ml/kg) and marketed microemulsion (9012.07 ml/kg).,"Preparation, characterization and in vivo studies of proliposomes containing Cyclosporine A. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048505/),1/[h],1.2,216056,DB00091,Cyclosporine
,17048505,absorption constant,The absorption constant for liposomal product was much greater (10.26 h(-1)) than for free drug solution (1.2 h(-1)) or the marketed sample of microemulsion (2.51 h(-1)) and the volume of distribution was found to be less for liposomes (7629.88 ml/kg) than that of the free drug solution (10971.92 ml/kg) and marketed microemulsion (9012.07 ml/kg).,"Preparation, characterization and in vivo studies of proliposomes containing Cyclosporine A. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048505/),1/[h],2.51,216057,DB00091,Cyclosporine
,17048505,volume of distribution,The absorption constant for liposomal product was much greater (10.26 h(-1)) than for free drug solution (1.2 h(-1)) or the marketed sample of microemulsion (2.51 h(-1)) and the volume of distribution was found to be less for liposomes (7629.88 ml/kg) than that of the free drug solution (10971.92 ml/kg) and marketed microemulsion (9012.07 ml/kg).,"Preparation, characterization and in vivo studies of proliposomes containing Cyclosporine A. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048505/),[ml] / [kg],7629.88,216058,DB00091,Cyclosporine
,17048505,volume of distribution,The absorption constant for liposomal product was much greater (10.26 h(-1)) than for free drug solution (1.2 h(-1)) or the marketed sample of microemulsion (2.51 h(-1)) and the volume of distribution was found to be less for liposomes (7629.88 ml/kg) than that of the free drug solution (10971.92 ml/kg) and marketed microemulsion (9012.07 ml/kg).,"Preparation, characterization and in vivo studies of proliposomes containing Cyclosporine A. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048505/),[ml] / [kg],10971.92,216059,DB00091,Cyclosporine
,17048505,volume of distribution,The absorption constant for liposomal product was much greater (10.26 h(-1)) than for free drug solution (1.2 h(-1)) or the marketed sample of microemulsion (2.51 h(-1)) and the volume of distribution was found to be less for liposomes (7629.88 ml/kg) than that of the free drug solution (10971.92 ml/kg) and marketed microemulsion (9012.07 ml/kg).,"Preparation, characterization and in vivo studies of proliposomes containing Cyclosporine A. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048505/),[ml] / [kg],9012.07,216060,DB00091,Cyclosporine
,15845749,area under the plasma concentration versus time curve (AUC),"The area under the plasma concentration versus time curve (AUC) of intravenously administered midazolam (30 mg/kg) was 2.2-fold decreased in the transgenic mice compared with wild-type (5.45 +/- 0.21 versus 11.7 +/- 0.46 microg . h ml(-1); P < 0.01), and early formation of the primary metabolite 1-hydroxymidazolam was about 2-fold increased, demonstrating the functionality of CYP3A4 in the liver.",Midazolam and cyclosporin a metabolism in transgenic mice with liver-specific expression of human CYP3A4. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15845749/),[h·μg] / [ml],5.45,216180,DB00091,Cyclosporine
,15845749,area under the plasma concentration versus time curve (AUC),"The area under the plasma concentration versus time curve (AUC) of intravenously administered midazolam (30 mg/kg) was 2.2-fold decreased in the transgenic mice compared with wild-type (5.45 +/- 0.21 versus 11.7 +/- 0.46 microg . h ml(-1); P < 0.01), and early formation of the primary metabolite 1-hydroxymidazolam was about 2-fold increased, demonstrating the functionality of CYP3A4 in the liver.",Midazolam and cyclosporin a metabolism in transgenic mice with liver-specific expression of human CYP3A4. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15845749/),[h·μg] / [ml],11.7,216181,DB00091,Cyclosporine
,15845749,plasma AUC,"Similarly, following intravenous administration of cyclosporin A (20 mg/kg), CYP3A4 transgenic mice displayed a reduced plasma AUC compared with wild-type (24.3 +/- 0.66 versus 35.8 +/- 0.53 microg . h ml(-) (1); P < 0.01).",Midazolam and cyclosporin a metabolism in transgenic mice with liver-specific expression of human CYP3A4. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15845749/),(1)·h·ml(-)·μg,24.3,216182,DB00091,Cyclosporine
,15845749,plasma AUC,"Similarly, following intravenous administration of cyclosporin A (20 mg/kg), CYP3A4 transgenic mice displayed a reduced plasma AUC compared with wild-type (24.3 +/- 0.66 versus 35.8 +/- 0.53 microg . h ml(-) (1); P < 0.01).",Midazolam and cyclosporin a metabolism in transgenic mice with liver-specific expression of human CYP3A4. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15845749/),(1)·h·ml(-)·μg,35.8,216183,DB00091,Cyclosporine
,29893406,absolute bioavailability,The absolute bioavailability was 93% for SC injection and 30% for the oral route.,Pharmacokinetics of low-dose methotrexate in healthy beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29893406/),%,93,217095,DB00091,Cyclosporine
,29893406,absolute bioavailability,The absolute bioavailability was 93% for SC injection and 30% for the oral route.,Pharmacokinetics of low-dose methotrexate in healthy beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29893406/),%,30,217096,DB00091,Cyclosporine
,8196271,clearance,"This could be explained by a higher CsG clearance (6.4 vs. 4.3 ml/min/kg in CsA, P < 0.0001) resulting in smaller CsG area under the curve.","Experimental nephrotoxicity, hepatotoxicity and pharmacokinetics of cyclosporin G versus cyclosporin A. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8196271/),[ml] / [kg·min],6.4,217281,DB00091,Cyclosporine
,8196271,clearance,"This could be explained by a higher CsG clearance (6.4 vs. 4.3 ml/min/kg in CsA, P < 0.0001) resulting in smaller CsG area under the curve.","Experimental nephrotoxicity, hepatotoxicity and pharmacokinetics of cyclosporin G versus cyclosporin A. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8196271/),[ml] / [kg·min],4.3,217282,DB00091,Cyclosporine
,8196271,urinary excretion,"CsA induced a dramatic decrease in GFR, 0.14 in CsA versus 0.67 ml/min/100 g in control, P < 0.001, and increased urinary excretion of N-acetyl beta-D-glucosaminidase (NAG), 21 in CsA versus 13 IU/gCr in control rats, P < 0.001.","Experimental nephrotoxicity, hepatotoxicity and pharmacokinetics of cyclosporin G versus cyclosporin A. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8196271/),[iu] / [g],21,217283,DB00091,Cyclosporine
,8196271,urinary excretion,"CsA induced a dramatic decrease in GFR, 0.14 in CsA versus 0.67 ml/min/100 g in control, P < 0.001, and increased urinary excretion of N-acetyl beta-D-glucosaminidase (NAG), 21 in CsA versus 13 IU/gCr in control rats, P < 0.001.","Experimental nephrotoxicity, hepatotoxicity and pharmacokinetics of cyclosporin G versus cyclosporin A. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8196271/),[iu] / [g],13,217284,DB00091,Cyclosporine
,29967572,hepatobiliary clearance,The modelling revealed a significant reduction in [11C]MT107 hepatobiliary clearance from 35.2 ± 10.9 to 17.1 ± 5.6 μl/min after cyclosporine administration.,Physiologically Based Pharmacokinetic Modelling with Dynamic PET Data to Study the In Vivo Effects of Transporter Inhibition on Hepatobiliary Clearance in Mice. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29967572/),[μl] / [min],35.2,217495,DB00091,Cyclosporine
,29967572,hepatobiliary clearance,The modelling revealed a significant reduction in [11C]MT107 hepatobiliary clearance from 35.2 ± 10.9 to 17.1 ± 5.6 μl/min after cyclosporine administration.,Physiologically Based Pharmacokinetic Modelling with Dynamic PET Data to Study the In Vivo Effects of Transporter Inhibition on Hepatobiliary Clearance in Mice. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29967572/),[μl] / [min],17.1,217496,DB00091,Cyclosporine
,27011383,Km,"The uptake studies of (14)C-labeled M-I into rat and human hepatocytes indicated that the uptakes of M-I were concentrative, temperature-dependent and saturable in both species with Km values of 4.7 and 2.8 μmol/L, respectively.","Characterization of Transporters in the Hepatic Uptake of TAK-475 M-I, a Squalene Synthase Inhibitor, in Rats and Humans. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27011383/),[μM] / [l],4.7,218012,DB00091,Cyclosporine
,27011383,Km,"The uptake studies of (14)C-labeled M-I into rat and human hepatocytes indicated that the uptakes of M-I were concentrative, temperature-dependent and saturable in both species with Km values of 4.7 and 2.8 μmol/L, respectively.","Characterization of Transporters in the Hepatic Uptake of TAK-475 M-I, a Squalene Synthase Inhibitor, in Rats and Humans. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27011383/),[μM] / [l],2.8,218013,DB00091,Cyclosporine
,27011383,Km,Uptake studies using human transporter-expressing cells revealed the saturable uptake of M-I for OATP1B3 with a Km of 2.13 μmol/L.,"Characterization of Transporters in the Hepatic Uptake of TAK-475 M-I, a Squalene Synthase Inhibitor, in Rats and Humans. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27011383/),[μM] / [l],2.13,218014,DB00091,Cyclosporine
>,20047618,C0 h,High MPA C0 h levels>10 μg/mL were rarely observed with both EC-MPS (1.8%) and MMF (0.6%).,Randomized crossover study to assess the inter- and intrasubject variability of morning mycophenolic acid concentrations from enteric-coated mycophenolate sodium and mycophenolate mofetil in stable renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20047618/),[μg] / [ml],10,218423,DB00091,Cyclosporine
,12826188,C0,"During the first 2 weeks posttransplant, C2 AM mean levels were significantly higher than C2 PM levels (542 +/- 241 vs 383 +/- 182 ng/mL, P =.005), while the C0 AM mean level was not statistically different from the C0 PM (285 +/- 174 vs 223 +/- 124 ng/mL, P =.367).",Circadian variations in cyclosporine C2 concentrations during the first 2 weeks after liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12826188/),[ng] / [ml],285,218570,DB00091,Cyclosporine
,12826188,C0,"During the first 2 weeks posttransplant, C2 AM mean levels were significantly higher than C2 PM levels (542 +/- 241 vs 383 +/- 182 ng/mL, P =.005), while the C0 AM mean level was not statistically different from the C0 PM (285 +/- 174 vs 223 +/- 124 ng/mL, P =.367).",Circadian variations in cyclosporine C2 concentrations during the first 2 weeks after liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12826188/),[ng] / [ml],223,218571,DB00091,Cyclosporine
,8885119,areas under the concentration curve (AUCs),"The patients without recurrent rejection had significantly higher areas under the concentration curve (AUCs) than did patients with recurrent rejection: 4,663 +/- 1,460 vs. 2,454 +/- 1,717 ng-h/ml (p < 0.05) by HPLC and 6,669 +/- 2,556 vs. 3,661 +/- 1,956 ng-h/ml (p < 0.05) by TDX.",Cyclosporine pharmacokinetics and risk of recurrent rejection in recipients of simultaneous pancreas/kidney transplants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8885119/),[ng-h] / [ml],"4,663",218778,DB00091,Cyclosporine
,8885119,areas under the concentration curve (AUCs),"The patients without recurrent rejection had significantly higher areas under the concentration curve (AUCs) than did patients with recurrent rejection: 4,663 +/- 1,460 vs. 2,454 +/- 1,717 ng-h/ml (p < 0.05) by HPLC and 6,669 +/- 2,556 vs. 3,661 +/- 1,956 ng-h/ml (p < 0.05) by TDX.",Cyclosporine pharmacokinetics and risk of recurrent rejection in recipients of simultaneous pancreas/kidney transplants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8885119/),[ng-h] / [ml],"2,454",218779,DB00091,Cyclosporine
,8885119,areas under the concentration curve (AUCs),"The patients without recurrent rejection had significantly higher areas under the concentration curve (AUCs) than did patients with recurrent rejection: 4,663 +/- 1,460 vs. 2,454 +/- 1,717 ng-h/ml (p < 0.05) by HPLC and 6,669 +/- 2,556 vs. 3,661 +/- 1,956 ng-h/ml (p < 0.05) by TDX.",Cyclosporine pharmacokinetics and risk of recurrent rejection in recipients of simultaneous pancreas/kidney transplants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8885119/),[ng-h] / [ml],"6,669",218780,DB00091,Cyclosporine
,8885119,areas under the concentration curve (AUCs),"The patients without recurrent rejection had significantly higher areas under the concentration curve (AUCs) than did patients with recurrent rejection: 4,663 +/- 1,460 vs. 2,454 +/- 1,717 ng-h/ml (p < 0.05) by HPLC and 6,669 +/- 2,556 vs. 3,661 +/- 1,956 ng-h/ml (p < 0.05) by TDX.",Cyclosporine pharmacokinetics and risk of recurrent rejection in recipients of simultaneous pancreas/kidney transplants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8885119/),[ng-h] / [ml],"3,661",218781,DB00091,Cyclosporine
,12110798,survival,FK778 at 4 mg/kg prolonged median survival of the control animals from 10 days to 30.5 days.,"A novel leflunomide derivative, FK778, for immunosuppression after kidney transplantation in dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110798/),d,10,218966,DB00091,Cyclosporine
,12110798,trough levels,"In combined treatments, trough levels of FK778 at 4 mg/kg ranged between 40 microg/mL and 100 microg/mL after 1 month.","A novel leflunomide derivative, FK778, for immunosuppression after kidney transplantation in dogs. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110798/),[μg] / [ml],40,218967,DB00091,Cyclosporine
,12110798,trough levels,"In combined treatments, trough levels of FK778 at 4 mg/kg ranged between 40 microg/mL and 100 microg/mL after 1 month.","A novel leflunomide derivative, FK778, for immunosuppression after kidney transplantation in dogs. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110798/),[μg] / [ml],100,218968,DB00091,Cyclosporine
,27310200,half maximal inhibitory concentration,"Cyclosporine predominantly inhibited CYP3A4 (half maximal inhibitory concentration = 0.71 µM) rather than CYP3A5 (>5 µM), whereas tacrolimus showed similar inhibition for CYP3A4 (0.29 µM) and CYP3A5 (0.41 µM).",Risk Assessment of Drug-Drug Interactions of Calcineurin Inhibitors Affecting Sirolimus Pharmacokinetics in Renal Transplant Patients. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27310200/),μM,0.71,219176,DB00091,Cyclosporine
>,27310200,half maximal inhibitory concentration,"Cyclosporine predominantly inhibited CYP3A4 (half maximal inhibitory concentration = 0.71 µM) rather than CYP3A5 (>5 µM), whereas tacrolimus showed similar inhibition for CYP3A4 (0.29 µM) and CYP3A5 (0.41 µM).",Risk Assessment of Drug-Drug Interactions of Calcineurin Inhibitors Affecting Sirolimus Pharmacokinetics in Renal Transplant Patients. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27310200/),,5,219177,DB00091,Cyclosporine
,29753157,relapse,One-year relapse was 38% for AML and 13% for MDS.,"Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29753157/),%,38,219180,DB00091,Cyclosporine
,29753157,relapse,One-year relapse was 38% for AML and 13% for MDS.,"Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29753157/),,13,219181,DB00091,Cyclosporine
,19111511,flow-rate,"The analytes were separated by a C18 column (150 x 4.6 mm I.D., 5 microm) with a mobile phase of acetonitrile-water (50:50, v/v) at a flow-rate of 1 mL/min.",Pharmacokinetics of kadsurenone and its interaction with cyclosporin A in rats using a combined HPLC and microdialysis system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19111511/),[ml] / [min],1,219309,DB00091,Cyclosporine
,19111511,limit of detection,"The limit of detection and the limit of quantification were 0.01 and 0.05 microg/mL, respectively.",Pharmacokinetics of kadsurenone and its interaction with cyclosporin A in rats using a combined HPLC and microdialysis system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19111511/),[μg] / [ml],0.01,219310,DB00091,Cyclosporine
,19111511,limit of quantification,"The limit of detection and the limit of quantification were 0.01 and 0.05 microg/mL, respectively.",Pharmacokinetics of kadsurenone and its interaction with cyclosporin A in rats using a combined HPLC and microdialysis system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19111511/),[μg] / [ml],0.05,219311,DB00091,Cyclosporine
,19111511,hepatobiliary excretion ratio,"The results indicated that the hepatobiliary excretion ratio of kadsurenone on the CsA treated-group was 1.2+/-0.1, which was not significantly different from the group of kadsurenone alone (1.3+/-0.2).",Pharmacokinetics of kadsurenone and its interaction with cyclosporin A in rats using a combined HPLC and microdialysis system. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19111511/),,1.2,219312,DB00091,Cyclosporine
,19111511,hepatobiliary excretion ratio,"The results indicated that the hepatobiliary excretion ratio of kadsurenone on the CsA treated-group was 1.2+/-0.1, which was not significantly different from the group of kadsurenone alone (1.3+/-0.2).",Pharmacokinetics of kadsurenone and its interaction with cyclosporin A in rats using a combined HPLC and microdialysis system. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19111511/),,1.3,219313,DB00091,Cyclosporine
,15932953,CL/F,"The population estimates for CL/F (28.5 l/h), V/F (volume of distribution, 133 l), and interpatient variability (CV%=19.7%) for CL/F were achieved, respectively.",Population pharmacokinetics of cyclosporine in clinical renal transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15932953/),[l] / [h],28.5,219766,DB00091,Cyclosporine
,15932953,V/F (volume of distribution,"The population estimates for CL/F (28.5 l/h), V/F (volume of distribution, 133 l), and interpatient variability (CV%=19.7%) for CL/F were achieved, respectively.",Population pharmacokinetics of cyclosporine in clinical renal transplant patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15932953/),l,133,219767,DB00091,Cyclosporine
,16029064,trough,"If ciclosporin therapy is discontinued, a target trough range of 12-20 microg/L is recommended.",Sirolimus: the evidence for clinical pharmacokinetic monitoring. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16029064/),[μg] / [l],12-20,219893,DB00091,Cyclosporine
,10573065,clearance,"Basiliximab clearance was 36.7+/-15.2 ml/hr, distribution volume 8.0+/-2.4 L, and half life 7.4+/-3.0 days.",Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10573065/),[ml] / [h],36.7,220456,DB00091,Cyclosporine
,10573065,distribution volume,"Basiliximab clearance was 36.7+/-15.2 ml/hr, distribution volume 8.0+/-2.4 L, and half life 7.4+/-3.0 days.",Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10573065/),l,8.0,220457,DB00091,Cyclosporine
,10573065,half life,"Basiliximab clearance was 36.7+/-15.2 ml/hr, distribution volume 8.0+/-2.4 L, and half life 7.4+/-3.0 days.",Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10573065/),d,7.4,220458,DB00091,Cyclosporine
,10684355,plasma concentration of MPA at steady state,The mean plasma concentration of MPA at steady state was 4.7+/-1.3 microg/ml.,Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684355/),[μg] / [ml],4.7,220840,DB00091,Cyclosporine
,10684355,areas under the plasma concentration-time curves (AUCs) over 12 h,"The areas under the plasma concentration-time curves (AUCs) over 12 h (between two administrations) were 57.0+/-15.3 microg.h/ml for MPA and 1,515+/-722 microg.h/ml for MPAG, and the apparent oral clearance was 11.7+/-7.0 and 0.5+/-0.4 l/h for MPA and MPAG, respectively.",Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684355/),[h·μg] / [ml],57.0,220841,DB00091,Cyclosporine
,10684355,areas under the plasma concentration-time curves (AUCs) over 12 h,"The areas under the plasma concentration-time curves (AUCs) over 12 h (between two administrations) were 57.0+/-15.3 microg.h/ml for MPA and 1,515+/-722 microg.h/ml for MPAG, and the apparent oral clearance was 11.7+/-7.0 and 0.5+/-0.4 l/h for MPA and MPAG, respectively.",Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684355/),[h·μg] / [ml],"1,515",220842,DB00091,Cyclosporine
,10684355,apparent oral clearance,"The areas under the plasma concentration-time curves (AUCs) over 12 h (between two administrations) were 57.0+/-15.3 microg.h/ml for MPA and 1,515+/-722 microg.h/ml for MPAG, and the apparent oral clearance was 11.7+/-7.0 and 0.5+/-0.4 l/h for MPA and MPAG, respectively.",Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684355/),[l] / [h],11.7,220843,DB00091,Cyclosporine
,10684355,apparent oral clearance,"The areas under the plasma concentration-time curves (AUCs) over 12 h (between two administrations) were 57.0+/-15.3 microg.h/ml for MPA and 1,515+/-722 microg.h/ml for MPAG, and the apparent oral clearance was 11.7+/-7.0 and 0.5+/-0.4 l/h for MPA and MPAG, respectively.",Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684355/),[l] / [h],0.5,220844,DB00091,Cyclosporine
,10684355,concentration at steady state,"Assuming that the pharmacokinetics of MPA was dose dependent, the mean concentration at steady state and the AUC for MPA were calculated for the recommended dosage schedule of 600 mg/m(2) every 12 h and were 6.3+/-2.7 microg/ml and 75.2+/-32.9 microg.h/ml, respectively.",Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684355/),[μg] / [ml],6.3,220845,DB00091,Cyclosporine
,10684355,AUC,"Assuming that the pharmacokinetics of MPA was dose dependent, the mean concentration at steady state and the AUC for MPA were calculated for the recommended dosage schedule of 600 mg/m(2) every 12 h and were 6.3+/-2.7 microg/ml and 75.2+/-32.9 microg.h/ml, respectively.",Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684355/),[h·μg] / [ml],75.2,220846,DB00091,Cyclosporine
,17038879,Tmax,"At month 6 postsurgery, patients on EC-MPS had a shift to the right in the CsA peak concentration as compared to that in patients given MMF, an effect associated with significant differences in CsA Tmax (1.9 +/- 0.3 h vs. 1.5 +/- 0.6 h, P < 0.05), C2 (988 +/- 259 vs. 720 +/- 214 ng/mL, P < 0.01), and C3 levels (539 +/- 119 vs. 435 +/- 119 ng/mL, P < 0.05).",Mycophenolic acid formulation affects cyclosporine pharmacokinetics in stable kidney transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038879/),h,1.9,221311,DB00091,Cyclosporine
,17038879,Tmax,"At month 6 postsurgery, patients on EC-MPS had a shift to the right in the CsA peak concentration as compared to that in patients given MMF, an effect associated with significant differences in CsA Tmax (1.9 +/- 0.3 h vs. 1.5 +/- 0.6 h, P < 0.05), C2 (988 +/- 259 vs. 720 +/- 214 ng/mL, P < 0.01), and C3 levels (539 +/- 119 vs. 435 +/- 119 ng/mL, P < 0.05).",Mycophenolic acid formulation affects cyclosporine pharmacokinetics in stable kidney transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038879/),h,1.5,221312,DB00091,Cyclosporine
,17038879,C2,"At month 6 postsurgery, patients on EC-MPS had a shift to the right in the CsA peak concentration as compared to that in patients given MMF, an effect associated with significant differences in CsA Tmax (1.9 +/- 0.3 h vs. 1.5 +/- 0.6 h, P < 0.05), C2 (988 +/- 259 vs. 720 +/- 214 ng/mL, P < 0.01), and C3 levels (539 +/- 119 vs. 435 +/- 119 ng/mL, P < 0.05).",Mycophenolic acid formulation affects cyclosporine pharmacokinetics in stable kidney transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038879/),[ng] / [ml],988,221313,DB00091,Cyclosporine
,17038879,C2,"At month 6 postsurgery, patients on EC-MPS had a shift to the right in the CsA peak concentration as compared to that in patients given MMF, an effect associated with significant differences in CsA Tmax (1.9 +/- 0.3 h vs. 1.5 +/- 0.6 h, P < 0.05), C2 (988 +/- 259 vs. 720 +/- 214 ng/mL, P < 0.01), and C3 levels (539 +/- 119 vs. 435 +/- 119 ng/mL, P < 0.05).",Mycophenolic acid formulation affects cyclosporine pharmacokinetics in stable kidney transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038879/),[ng] / [ml],720,221314,DB00091,Cyclosporine
,10090162,bioavailability,The mean bioavailability of CyA from the microemulsion formulation was 23% higher than from conventional CyA.,"Conversion of patients with rheumatoid arthritis from the conventional to a microemulsion formulation of cyclosporine: a double blind comparison to screen for differences in safety, efficacy, and pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10090162/),%,23,221803,DB00091,Cyclosporine
,10440576,area under the blood concentration-time curve from time 0 to time infinity,"At 09:00, the blood concentrations of cyclosporin were higher, the area under the blood concentration-time curve from time 0 to time infinity was significantly greater (9.70 versus 8.42 microg x hr/ml), and the renal clearance was significantly slower (1.14 versus 1.48 ml/min) than those at 22:00.",Circadian changes in pharmacokinetics of cyclosporin in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440576/),[h·μg] / [ml],9.70,222076,DB00091,Cyclosporine
,10440576,area under the blood concentration-time curve from time 0 to time infinity,"At 09:00, the blood concentrations of cyclosporin were higher, the area under the blood concentration-time curve from time 0 to time infinity was significantly greater (9.70 versus 8.42 microg x hr/ml), and the renal clearance was significantly slower (1.14 versus 1.48 ml/min) than those at 22:00.",Circadian changes in pharmacokinetics of cyclosporin in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440576/),[h·μg] / [ml],8.42,222077,DB00091,Cyclosporine
,10440576,renal clearance,"At 09:00, the blood concentrations of cyclosporin were higher, the area under the blood concentration-time curve from time 0 to time infinity was significantly greater (9.70 versus 8.42 microg x hr/ml), and the renal clearance was significantly slower (1.14 versus 1.48 ml/min) than those at 22:00.",Circadian changes in pharmacokinetics of cyclosporin in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440576/),[ml] / [min],1.14,222078,DB00091,Cyclosporine
,10440576,renal clearance,"At 09:00, the blood concentrations of cyclosporin were higher, the area under the blood concentration-time curve from time 0 to time infinity was significantly greater (9.70 versus 8.42 microg x hr/ml), and the renal clearance was significantly slower (1.14 versus 1.48 ml/min) than those at 22:00.",Circadian changes in pharmacokinetics of cyclosporin in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440576/),[ml] / [min],1.48,222079,DB00091,Cyclosporine
,20831533,AUC,"On the contrary, there were no differences in PK parameters after intravenous administration of CyA between HU and control rats; however, AUC, peak level and bioavailability in HU rats (2.01 ± 0.56 μg h/mL, 0.47 ± 0.26 μg/mL and 0.186 ± 0.05, respectively) after oral administration were significantly lower than in the control animals (6.13 ± 0.97 μg h/mL, 0.82 ± 0.17 μg/mL and 0.458 ± 0.07 μg/mL, respectively).",Effect of plasma uric acid on pharmacokinetics of cyclosporine A in living-related renal transplant recipients and pharmacokinetic study in rats with experimental hyperuricaemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20831533/),[h·μg] / [ml],2.01,222176,DB00091,Cyclosporine
,20831533,peak level,"On the contrary, there were no differences in PK parameters after intravenous administration of CyA between HU and control rats; however, AUC, peak level and bioavailability in HU rats (2.01 ± 0.56 μg h/mL, 0.47 ± 0.26 μg/mL and 0.186 ± 0.05, respectively) after oral administration were significantly lower than in the control animals (6.13 ± 0.97 μg h/mL, 0.82 ± 0.17 μg/mL and 0.458 ± 0.07 μg/mL, respectively).",Effect of plasma uric acid on pharmacokinetics of cyclosporine A in living-related renal transplant recipients and pharmacokinetic study in rats with experimental hyperuricaemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20831533/),[μg] / [ml],0.47,222177,DB00091,Cyclosporine
,20831533,peak level,"On the contrary, there were no differences in PK parameters after intravenous administration of CyA between HU and control rats; however, AUC, peak level and bioavailability in HU rats (2.01 ± 0.56 μg h/mL, 0.47 ± 0.26 μg/mL and 0.186 ± 0.05, respectively) after oral administration were significantly lower than in the control animals (6.13 ± 0.97 μg h/mL, 0.82 ± 0.17 μg/mL and 0.458 ± 0.07 μg/mL, respectively).",Effect of plasma uric acid on pharmacokinetics of cyclosporine A in living-related renal transplant recipients and pharmacokinetic study in rats with experimental hyperuricaemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20831533/),[μg] / [ml],0.82,222178,DB00091,Cyclosporine
,20831533,bioavailability,"On the contrary, there were no differences in PK parameters after intravenous administration of CyA between HU and control rats; however, AUC, peak level and bioavailability in HU rats (2.01 ± 0.56 μg h/mL, 0.47 ± 0.26 μg/mL and 0.186 ± 0.05, respectively) after oral administration were significantly lower than in the control animals (6.13 ± 0.97 μg h/mL, 0.82 ± 0.17 μg/mL and 0.458 ± 0.07 μg/mL, respectively).",Effect of plasma uric acid on pharmacokinetics of cyclosporine A in living-related renal transplant recipients and pharmacokinetic study in rats with experimental hyperuricaemia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20831533/),,0.186,222179,DB00091,Cyclosporine
,20831533,bioavailability,"On the contrary, there were no differences in PK parameters after intravenous administration of CyA between HU and control rats; however, AUC, peak level and bioavailability in HU rats (2.01 ± 0.56 μg h/mL, 0.47 ± 0.26 μg/mL and 0.186 ± 0.05, respectively) after oral administration were significantly lower than in the control animals (6.13 ± 0.97 μg h/mL, 0.82 ± 0.17 μg/mL and 0.458 ± 0.07 μg/mL, respectively).",Effect of plasma uric acid on pharmacokinetics of cyclosporine A in living-related renal transplant recipients and pharmacokinetic study in rats with experimental hyperuricaemia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20831533/),[h·μg] / [ml],6.13,222180,DB00091,Cyclosporine
,20831533,bioavailability,"On the contrary, there were no differences in PK parameters after intravenous administration of CyA between HU and control rats; however, AUC, peak level and bioavailability in HU rats (2.01 ± 0.56 μg h/mL, 0.47 ± 0.26 μg/mL and 0.186 ± 0.05, respectively) after oral administration were significantly lower than in the control animals (6.13 ± 0.97 μg h/mL, 0.82 ± 0.17 μg/mL and 0.458 ± 0.07 μg/mL, respectively).",Effect of plasma uric acid on pharmacokinetics of cyclosporine A in living-related renal transplant recipients and pharmacokinetic study in rats with experimental hyperuricaemia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20831533/),[μg] / [ml],0.82,222181,DB00091,Cyclosporine
,20831533,bioavailability,"On the contrary, there were no differences in PK parameters after intravenous administration of CyA between HU and control rats; however, AUC, peak level and bioavailability in HU rats (2.01 ± 0.56 μg h/mL, 0.47 ± 0.26 μg/mL and 0.186 ± 0.05, respectively) after oral administration were significantly lower than in the control animals (6.13 ± 0.97 μg h/mL, 0.82 ± 0.17 μg/mL and 0.458 ± 0.07 μg/mL, respectively).",Effect of plasma uric acid on pharmacokinetics of cyclosporine A in living-related renal transplant recipients and pharmacokinetic study in rats with experimental hyperuricaemia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20831533/),[μg] / [ml],0.458,222182,DB00091,Cyclosporine
,16757288,trough concentration (C(trough)),"Patient 1, who was maintained on 300 mg CsA twice a day with a trough concentration (C(trough)) around 250 ng/mL, restarted HAART 12 days after transplantation with 300 mg APV/r twice a day with corresponding APV C(trough) of 5293 ng/mL and RTV C(trough) of 186 ng/mL.",Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16757288/),[ng] / [ml],250,222392,DB00091,Cyclosporine
,16757288,C(trough),"Patient 1, who was maintained on 300 mg CsA twice a day with a trough concentration (C(trough)) around 250 ng/mL, restarted HAART 12 days after transplantation with 300 mg APV/r twice a day with corresponding APV C(trough) of 5293 ng/mL and RTV C(trough) of 186 ng/mL.",Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16757288/),[ng] / [ml],5293,222393,DB00091,Cyclosporine
,16757288,C(trough),"Patient 1, who was maintained on 300 mg CsA twice a day with a trough concentration (C(trough)) around 250 ng/mL, restarted HAART 12 days after transplantation with 300 mg APV/r twice a day with corresponding APV C(trough) of 5293 ng/mL and RTV C(trough) of 186 ng/mL.",Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16757288/),[ng] / [ml],186,222394,DB00091,Cyclosporine
,16757288,C(trough),"Forty-eight hours after initiation of HAART, C(trough) of CsA was 1200 mg/mL, so it was necessary to reduce the CsA dosage 12-fold (50 mg every day) to achieve a therapeutic effect.",Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16757288/),[mg] / [ml],1200,222395,DB00091,Cyclosporine
,16757288,C(trough),"In Patient 2, who was maintained on 300 mg CsA twice a day and a corresponding C(trough) of 400 ng/mL, HAART was restarted 12 days post-OLT with FosAPV 1400 mg twice a day.",Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16757288/),[ng] / [ml],400,222396,DB00091,Cyclosporine
,16757288,C(trough),"After 48 hours C(trough) of CsA was around 600 ng/mL and C(trough) of FosAPV, 1221 ng/mL.",Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16757288/),[ng] / [ml],600,222397,DB00091,Cyclosporine
,16757288,C(trough),"After 48 hours C(trough) of CsA was around 600 ng/mL and C(trough) of FosAPV, 1221 ng/mL.",Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16757288/),[ng] / [ml],1221,222398,DB00091,Cyclosporine
,15575918,trough levels,"Everolimus trough levels were stable in the first year post-transplant and averaged 5.2 +/- 3.8 and 9.4 +/- 6.3 ng/mL in patients treated with 1.5 and 3 mg/day, respectively.",Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15575918/),[ng] / [ml],5.2,222537,DB00091,Cyclosporine
,15575918,trough levels,"Everolimus trough levels were stable in the first year post-transplant and averaged 5.2 +/- 3.8 and 9.4 +/- 6.3 ng/mL in patients treated with 1.5 and 3 mg/day, respectively.",Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15575918/),[ng] / [ml],9.4,222538,DB00091,Cyclosporine
> or =,15575918,trough levels,Biopsy-proven acute rejection (BPAR) was reduced with everolimus trough levels > or =3 ng/mL.,Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15575918/),[ng] / [ml],3,222539,DB00091,Cyclosporine
,21702368,Cmax,"The Cmax and AUC0-72 increased from 682 to 1073 ng/ml and 34854 to 55322 ng . h/ml, respectively whereas, the relative bioavailability decreased from 120 to 64%.",Nanoparticulate delivery can improve peroral bioavailability of cyclosporine and match Neoral Cmax sparing the kidney from damage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21702368/),[ng] / [ml],682 to 1073,222988,DB00091,Cyclosporine
,21702368,AUC0-72,"The Cmax and AUC0-72 increased from 682 to 1073 ng/ml and 34854 to 55322 ng . h/ml, respectively whereas, the relative bioavailability decreased from 120 to 64%.",Nanoparticulate delivery can improve peroral bioavailability of cyclosporine and match Neoral Cmax sparing the kidney from damage. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21702368/),[h·ng] / [ml],34854 to 55322,222989,DB00091,Cyclosporine
,21702368,relative bioavailability,"The Cmax and AUC0-72 increased from 682 to 1073 ng/ml and 34854 to 55322 ng . h/ml, respectively whereas, the relative bioavailability decreased from 120 to 64%.",Nanoparticulate delivery can improve peroral bioavailability of cyclosporine and match Neoral Cmax sparing the kidney from damage. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21702368/),%,120,222990,DB00091,Cyclosporine
,21702368,relative bioavailability,"The Cmax and AUC0-72 increased from 682 to 1073 ng/ml and 34854 to 55322 ng . h/ml, respectively whereas, the relative bioavailability decreased from 120 to 64%.",Nanoparticulate delivery can improve peroral bioavailability of cyclosporine and match Neoral Cmax sparing the kidney from damage. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21702368/),%,64,222991,DB00091,Cyclosporine
,21702368,Cmax,"On the other hand, the increase in initial CsA loading (10-30% w/w of polymer) recorded a proportional increase in Cmax and AUC0-72, from 494 to 1101 ng/ml and 17774 to 51763 ng . h/ml, respectively.",Nanoparticulate delivery can improve peroral bioavailability of cyclosporine and match Neoral Cmax sparing the kidney from damage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21702368/),[ng] / [ml],494 to 1101,222992,DB00091,Cyclosporine
,21702368,AUC0-72,"On the other hand, the increase in initial CsA loading (10-30% w/w of polymer) recorded a proportional increase in Cmax and AUC0-72, from 494 to 1101 ng/ml and 17774 to 51763 ng . h/ml, respectively.",Nanoparticulate delivery can improve peroral bioavailability of cyclosporine and match Neoral Cmax sparing the kidney from damage. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21702368/),[h·ng] / [ml],17774 to 51763,222993,DB00091,Cyclosporine
,21702368,relative bioavailability,The relative bioavailability also increased from 31 to 89%.,Nanoparticulate delivery can improve peroral bioavailability of cyclosporine and match Neoral Cmax sparing the kidney from damage. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21702368/),%,31,222994,DB00091,Cyclosporine
,21702368,relative bioavailability,The relative bioavailability also increased from 31 to 89%.,Nanoparticulate delivery can improve peroral bioavailability of cyclosporine and match Neoral Cmax sparing the kidney from damage. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21702368/),%,89,222995,DB00091,Cyclosporine
,10984808,clearance,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),[l] / [h·kg],0.407,223254,DB00091,Cyclosporine
,10984808,volume of distribution,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),[l] / [kg],4.0,223255,DB00091,Cyclosporine
,10984808,bioavailability,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),%,31,223256,DB00091,Cyclosporine
,10984808,half-life,"Mean population pharmacokinetic values of 0.407 L/hr/kg for clearance, 4.0 L/kg for volume of distribution, 31% for bioavailability, and 10.6 hours for half-life were determined on the basis of 569 blood cyclosporine levels.",Cyclosporine-drug interactions and the influence of patient age. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10984808/),h,10.6,223257,DB00091,Cyclosporine
,8972562,bioavailability,"The mean bioavailability of cyclosporine from Sandimmun was 8% while it was 34% from the L2-phase, 38% from the predispersed L2-phase and 27% from the dispersed liquid crystalline phase.",Bioavailability of cyclosporine in rats after intragastric administration: a comparative study of the L2-phase and two other lipid-based vehicles. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8972562/),%,8,223541,DB00091,Cyclosporine
,8972562,bioavailability,"The mean bioavailability of cyclosporine from Sandimmun was 8% while it was 34% from the L2-phase, 38% from the predispersed L2-phase and 27% from the dispersed liquid crystalline phase.",Bioavailability of cyclosporine in rats after intragastric administration: a comparative study of the L2-phase and two other lipid-based vehicles. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8972562/),%,34,223542,DB00091,Cyclosporine
,8972562,bioavailability,"The mean bioavailability of cyclosporine from Sandimmun was 8% while it was 34% from the L2-phase, 38% from the predispersed L2-phase and 27% from the dispersed liquid crystalline phase.",Bioavailability of cyclosporine in rats after intragastric administration: a comparative study of the L2-phase and two other lipid-based vehicles. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8972562/),%,38,223543,DB00091,Cyclosporine
,8972562,bioavailability,"The mean bioavailability of cyclosporine from Sandimmun was 8% while it was 34% from the L2-phase, 38% from the predispersed L2-phase and 27% from the dispersed liquid crystalline phase.",Bioavailability of cyclosporine in rats after intragastric administration: a comparative study of the L2-phase and two other lipid-based vehicles. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8972562/),%,27,223544,DB00091,Cyclosporine
,2025515,steady-state,"Our aim was to reach a steady-state cyclosporine blood level of 200-300 micrograms/l, 8 h after a dose in the first days after renal transplantation.",Pharmacokinetically determined cyclosporine dosage in young children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2025515/),,200-300,223810,DB00091,Cyclosporine
,2025515,half-life (t1/2),"The mean terminal cyclosporine half-life (t1/2) was 9.3 h (range 2.8-20.4), blood clearance 10.8 ml/min per kilogram (range 6.8-22.7) and volume of distribution 2.8 l/kg (range 1.4-4.7).",Pharmacokinetically determined cyclosporine dosage in young children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2025515/),h,9.3,223811,DB00091,Cyclosporine
,2025515,blood clearance,"The mean terminal cyclosporine half-life (t1/2) was 9.3 h (range 2.8-20.4), blood clearance 10.8 ml/min per kilogram (range 6.8-22.7) and volume of distribution 2.8 l/kg (range 1.4-4.7).",Pharmacokinetically determined cyclosporine dosage in young children. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2025515/),[ml] / [kg·min],10.8,223812,DB00091,Cyclosporine
,2025515,volume of distribution,"The mean terminal cyclosporine half-life (t1/2) was 9.3 h (range 2.8-20.4), blood clearance 10.8 ml/min per kilogram (range 6.8-22.7) and volume of distribution 2.8 l/kg (range 1.4-4.7).",Pharmacokinetically determined cyclosporine dosage in young children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2025515/),[l] / [kg],2.8,223813,DB00091,Cyclosporine
,2025515,bioavailability,The bioavailability of oral cyclosporine was low; the mean amount absorbed was 21.8% of the administered dose (range 11-35).,Pharmacokinetically determined cyclosporine dosage in young children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2025515/),%,21.8,223814,DB00091,Cyclosporine
,2025515,amount absorbed,The bioavailability of oral cyclosporine was low; the mean amount absorbed was 21.8% of the administered dose (range 11-35).,Pharmacokinetically determined cyclosporine dosage in young children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2025515/),%,21.8,223815,DB00091,Cyclosporine
,12395976,Cmax,"Mean values for Cmax of pravastatin were 384.2 ng/ml, 392.0 ng/ml and 115.1 ng/ml in patients on Days 1, 8 and 29, respectively.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],384.2,223848,DB00091,Cyclosporine
,12395976,Cmax,"Mean values for Cmax of pravastatin were 384.2 ng/ml, 392.0 ng/ml and 115.1 ng/ml in patients on Days 1, 8 and 29, respectively.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],392.0,223849,DB00091,Cyclosporine
,12395976,Cmax,"Mean values for Cmax of pravastatin were 384.2 ng/ml, 392.0 ng/ml and 115.1 ng/ml in patients on Days 1, 8 and 29, respectively.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],115.1,223850,DB00091,Cyclosporine
,12395976,C(max-DN10mg),"After normalization for a dose of 10 mg, the corresponding values of C(max-DN10mg) and Cmax were 96.0 ng/ml, 98.0 ng/ml and 115.1 ng/ml on study Days 1, 8 and 29.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],96.0,223851,DB00091,Cyclosporine
,12395976,C(max-DN10mg),"After normalization for a dose of 10 mg, the corresponding values of C(max-DN10mg) and Cmax were 96.0 ng/ml, 98.0 ng/ml and 115.1 ng/ml on study Days 1, 8 and 29.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],98.0,223852,DB00091,Cyclosporine
,12395976,Cmax,"After normalization for a dose of 10 mg, the corresponding values of C(max-DN10mg) and Cmax were 96.0 ng/ml, 98.0 ng/ml and 115.1 ng/ml on study Days 1, 8 and 29.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],115.1,223853,DB00091,Cyclosporine
,12395976,C(max-DN10mg),These values were 7-8 times higher than the normalized value of C(max-DN10mg) for the control group (13.7 ng/ml).,Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [ml],13.7,223854,DB00091,Cyclosporine
,12395976,AUC(0-24h),"The corresponding values of AUC(0-24h) were 1228.2 ng/ml x h, 1214.1 ng/ml x h and 345.9 ng/ml x h in the patient group on study Days 1, 8 and 29 as well as 157.5 ng/ml x h in the control group prior to normalization.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [h·ml],1228.2,223855,DB00091,Cyclosporine
,12395976,AUC(0-24h),"The corresponding values of AUC(0-24h) were 1228.2 ng/ml x h, 1214.1 ng/ml x h and 345.9 ng/ml x h in the patient group on study Days 1, 8 and 29 as well as 157.5 ng/ml x h in the control group prior to normalization.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [h·ml],1214.1,223856,DB00091,Cyclosporine
,12395976,AUC(0-24h),"The corresponding values of AUC(0-24h) were 1228.2 ng/ml x h, 1214.1 ng/ml x h and 345.9 ng/ml x h in the patient group on study Days 1, 8 and 29 as well as 157.5 ng/ml x h in the control group prior to normalization.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [h·ml],345.9,223857,DB00091,Cyclosporine
,12395976,AUC(0-24h),"The corresponding values of AUC(0-24h) were 1228.2 ng/ml x h, 1214.1 ng/ml x h and 345.9 ng/ml x h in the patient group on study Days 1, 8 and 29 as well as 157.5 ng/ml x h in the control group prior to normalization.",Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395976/),[ng] / [h·ml],157.5,223858,DB00091,Cyclosporine
,12766558,AUC/D,"The mean AUC/D (ng.hr/mL/mg) of CsA were 21.5 +/- 6.0 (A/A), 11.7 +/- 3.2 (G/G) and 19.2 +/- 2.3 (A/G), P = 0.0103 and the mean CL/F (L/hr) were 49.4 +/- 13.9 (A/A), 83.5 +/- 16.0 (G/G), and 52.5 +/- 5.6 (A/G), P = 0.0024.",Association of the CYP3A4*1B 5'-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12766558/),[h·ng] / [mg·ml],21.5,223990,DB00091,Cyclosporine
,12766558,AUC/D,"The mean AUC/D (ng.hr/mL/mg) of CsA were 21.5 +/- 6.0 (A/A), 11.7 +/- 3.2 (G/G) and 19.2 +/- 2.3 (A/G), P = 0.0103 and the mean CL/F (L/hr) were 49.4 +/- 13.9 (A/A), 83.5 +/- 16.0 (G/G), and 52.5 +/- 5.6 (A/G), P = 0.0024.",Association of the CYP3A4*1B 5'-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12766558/),[h·ng] / [mg·ml],11.7,223991,DB00091,Cyclosporine
,12766558,AUC/D,"The mean AUC/D (ng.hr/mL/mg) of CsA were 21.5 +/- 6.0 (A/A), 11.7 +/- 3.2 (G/G) and 19.2 +/- 2.3 (A/G), P = 0.0103 and the mean CL/F (L/hr) were 49.4 +/- 13.9 (A/A), 83.5 +/- 16.0 (G/G), and 52.5 +/- 5.6 (A/G), P = 0.0024.",Association of the CYP3A4*1B 5'-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12766558/),[h·ng] / [mg·ml],19.2,223992,DB00091,Cyclosporine
,12766558,CL/F,"The mean AUC/D (ng.hr/mL/mg) of CsA were 21.5 +/- 6.0 (A/A), 11.7 +/- 3.2 (G/G) and 19.2 +/- 2.3 (A/G), P = 0.0103 and the mean CL/F (L/hr) were 49.4 +/- 13.9 (A/A), 83.5 +/- 16.0 (G/G), and 52.5 +/- 5.6 (A/G), P = 0.0024.",Association of the CYP3A4*1B 5'-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12766558/),[l] / [h],49.4,223993,DB00091,Cyclosporine
,12766558,CL/F,"The mean AUC/D (ng.hr/mL/mg) of CsA were 21.5 +/- 6.0 (A/A), 11.7 +/- 3.2 (G/G) and 19.2 +/- 2.3 (A/G), P = 0.0103 and the mean CL/F (L/hr) were 49.4 +/- 13.9 (A/A), 83.5 +/- 16.0 (G/G), and 52.5 +/- 5.6 (A/G), P = 0.0024.",Association of the CYP3A4*1B 5'-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12766558/),[l] / [h],83.5,223994,DB00091,Cyclosporine
,12766558,CL/F,"The mean AUC/D (ng.hr/mL/mg) of CsA were 21.5 +/- 6.0 (A/A), 11.7 +/- 3.2 (G/G) and 19.2 +/- 2.3 (A/G), P = 0.0103 and the mean CL/F (L/hr) were 49.4 +/- 13.9 (A/A), 83.5 +/- 16.0 (G/G), and 52.5 +/- 5.6 (A/G), P = 0.0024.",Association of the CYP3A4*1B 5'-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12766558/),[l] / [h],52.5,223995,DB00091,Cyclosporine
,20840448,"AUC(0,12h)","Simulations (n= 1000) were conducted to assess the suitability of the MPA dose regimens to maintain total MPA AUC(0,12h) within the range 30 and 60mg l(-1) h associated with optimal outcome.",Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840448/),[h·mg] / [l],30,224060,DB00091,Cyclosporine
,20840448,"AUC(0,12h)","Simulations (n= 1000) were conducted to assess the suitability of the MPA dose regimens to maintain total MPA AUC(0,12h) within the range 30 and 60mg l(-1) h associated with optimal outcome.",Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840448/),[h·mg] / [l],60,224061,DB00091,Cyclosporine
,20840448,clearance,"Population mean estimates of MPA clearance, inter-compartmental clearance, volumes of distribution in the central and peripheral compartments, absorption rate constant and bioavailability were 6.42 l h(-1) , 3.74 l h(-1) , 7.24 l, 16.8l, 0.39h(-1) and 0.48, respectively.",Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840448/),[l] / [h],6.42,224062,DB00091,Cyclosporine
,20840448,bioavailability,"Population mean estimates of MPA clearance, inter-compartmental clearance, volumes of distribution in the central and peripheral compartments, absorption rate constant and bioavailability were 6.42 l h(-1) , 3.74 l h(-1) , 7.24 l, 16.8l, 0.39h(-1) and 0.48, respectively.",Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840448/),,0.48,224063,DB00091,Cyclosporine
,11912269,elimination half-life (t(1/2)),"Pharmacokinetics are characterized by a prolonged absorption phase; the terminal elimination phase started 36 h after the administration, with elimination half-life (t(1/2)) ranging from 89 to 157 h independent of dose.","First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11912269/),h,89 to 157,224099,DB00091,Cyclosporine
,11912269,apparent volume of distribution (V(d)/F),"Maximum plasma concentration and AUC were proportional to dose with low intersubject variability, the apparent volume of distribution (V(d)/F) ranged from 1116 to 1737 L.","First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11912269/),l,1116 to 1737,224100,DB00091,Cyclosporine
,9506007,oral clearance,"In all three patient populations, the pharmacokinetics of BQR were characterized by a lower oral clearance (12-19 mL/min) than that seen in previous studies in patients with cancer (approximately 30 mL/min at similar doses) and a long terminal half life (13-18 hrs).","Phase I safety and pharmacokinetic studies of brequinar sodium after single ascending oral doses in stable renal, hepatic, and cardiac allograft recipients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506007/),[ml] / [min],12-19,224153,DB00091,Cyclosporine
,9506007,oral clearance,"In all three patient populations, the pharmacokinetics of BQR were characterized by a lower oral clearance (12-19 mL/min) than that seen in previous studies in patients with cancer (approximately 30 mL/min at similar doses) and a long terminal half life (13-18 hrs).","Phase I safety and pharmacokinetic studies of brequinar sodium after single ascending oral doses in stable renal, hepatic, and cardiac allograft recipients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506007/),[ml] / [min],30,224154,DB00091,Cyclosporine
,9506007,terminal half life,"In all three patient populations, the pharmacokinetics of BQR were characterized by a lower oral clearance (12-19 mL/min) than that seen in previous studies in patients with cancer (approximately 30 mL/min at similar doses) and a long terminal half life (13-18 hrs).","Phase I safety and pharmacokinetic studies of brequinar sodium after single ascending oral doses in stable renal, hepatic, and cardiac allograft recipients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9506007/),h,13-18,224155,DB00091,Cyclosporine
,2315970,area under the concentration-time curve,"The dose- and protein-corrected area under the concentration-time curve in whole blood; plasma; and HDL, LDL, and VLDL compartments were 44.6 +/- 11.3, 19.2 +/- 2.4; 33.6 +/- 12.3, 49.0 +/- 19.9, and 17.5 +/- 9.0 ng h/ml, respectively.",Single-dose cyclosporine pharmacokinetics in various biological fluids of patients receiving allogeneic marrow transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2315970/),[h·ng] / [ml],44.6,224171,DB00091,Cyclosporine
,2315970,area under the concentration-time curve,"The dose- and protein-corrected area under the concentration-time curve in whole blood; plasma; and HDL, LDL, and VLDL compartments were 44.6 +/- 11.3, 19.2 +/- 2.4; 33.6 +/- 12.3, 49.0 +/- 19.9, and 17.5 +/- 9.0 ng h/ml, respectively.",Single-dose cyclosporine pharmacokinetics in various biological fluids of patients receiving allogeneic marrow transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2315970/),[h·ng] / [ml],19.2,224172,DB00091,Cyclosporine
,2315970,area under the concentration-time curve,"The dose- and protein-corrected area under the concentration-time curve in whole blood; plasma; and HDL, LDL, and VLDL compartments were 44.6 +/- 11.3, 19.2 +/- 2.4; 33.6 +/- 12.3, 49.0 +/- 19.9, and 17.5 +/- 9.0 ng h/ml, respectively.",Single-dose cyclosporine pharmacokinetics in various biological fluids of patients receiving allogeneic marrow transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2315970/),[h·ng] / [ml],33.6,224173,DB00091,Cyclosporine
,2315970,area under the concentration-time curve,"The dose- and protein-corrected area under the concentration-time curve in whole blood; plasma; and HDL, LDL, and VLDL compartments were 44.6 +/- 11.3, 19.2 +/- 2.4; 33.6 +/- 12.3, 49.0 +/- 19.9, and 17.5 +/- 9.0 ng h/ml, respectively.",Single-dose cyclosporine pharmacokinetics in various biological fluids of patients receiving allogeneic marrow transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2315970/),[h·ng] / [ml],49.0,224174,DB00091,Cyclosporine
,2315970,area under the concentration-time curve,"The dose- and protein-corrected area under the concentration-time curve in whole blood; plasma; and HDL, LDL, and VLDL compartments were 44.6 +/- 11.3, 19.2 +/- 2.4; 33.6 +/- 12.3, 49.0 +/- 19.9, and 17.5 +/- 9.0 ng h/ml, respectively.",Single-dose cyclosporine pharmacokinetics in various biological fluids of patients receiving allogeneic marrow transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2315970/),[h·ng] / [ml],17.5,224175,DB00091,Cyclosporine
,9753208,are under the concentration-time curve to infinity (AUC0-infinity),"Mean are under the concentration-time curve to infinity (AUC0-infinity) for Sang-35 was 13,900 microg x hr/L compared with 14,000 microg x hr/L for Neoral, with a 90% confidence interval (CI) of 96% to 103% for the geometric mean ratio of the two formulations.",Comparison of two cyclosporine formulations in healthy volunteers: bioequivalence of the new Sang-35 formulation and Neoral. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9753208/),[h·μg] / [l],"13,900",224393,DB00091,Cyclosporine
,9753208,are under the concentration-time curve to infinity (AUC0-infinity),"Mean are under the concentration-time curve to infinity (AUC0-infinity) for Sang-35 was 13,900 microg x hr/L compared with 14,000 microg x hr/L for Neoral, with a 90% confidence interval (CI) of 96% to 103% for the geometric mean ratio of the two formulations.",Comparison of two cyclosporine formulations in healthy volunteers: bioequivalence of the new Sang-35 formulation and Neoral. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9753208/),[h·μg] / [l],"14,000",224394,DB00091,Cyclosporine
,9753208,maximum concentration (Cmax),"Mean maximum concentration (Cmax) was 1,690 microg/L for Sang-35 and 1,700 microg/L for Neoral, with a 90% CI of 96% to 103%.",Comparison of two cyclosporine formulations in healthy volunteers: bioequivalence of the new Sang-35 formulation and Neoral. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9753208/),[μg] / [l],"1,690",224395,DB00091,Cyclosporine
,9753208,maximum concentration (Cmax),"Mean maximum concentration (Cmax) was 1,690 microg/L for Sang-35 and 1,700 microg/L for Neoral, with a 90% CI of 96% to 103%.",Comparison of two cyclosporine formulations in healthy volunteers: bioequivalence of the new Sang-35 formulation and Neoral. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9753208/),[μg] / [l],"1,700",224396,DB00091,Cyclosporine
<,22466911,AUC,Cardiac rejection was associated with low MPA AUC values with a threshold of <36.2 mg×h/L during the first two post-transplant weeks.,Pharmacokinetic monitoring of mycophenolic acid in heart transplant patients: correlation the side-effects and rejections with pharmacokinetic parameters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22466911/),[h·mg] / [l],36.2,225359,DB00091,Cyclosporine
,22466911,trough level,A threshold of 2-weeks average MPA trough level of 1.43 mg/L provided a sensitivity 82% and a specificity of 60%.<br />,Pharmacokinetic monitoring of mycophenolic acid in heart transplant patients: correlation the side-effects and rejections with pharmacokinetic parameters. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22466911/),[mg] / [l],1.43,225360,DB00091,Cyclosporine
,22466911,trough,"For patients with Cyclosporine co-immunosuppression, we propose an MPA trough of 1.4 mg/L and an MPA AUC of 36 mg × h/L as threshold values for dose adjustments.",Pharmacokinetic monitoring of mycophenolic acid in heart transplant patients: correlation the side-effects and rejections with pharmacokinetic parameters. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22466911/),[mg] / [l],1.4,225361,DB00091,Cyclosporine
,22466911,AUC,"For patients with Cyclosporine co-immunosuppression, we propose an MPA trough of 1.4 mg/L and an MPA AUC of 36 mg × h/L as threshold values for dose adjustments.",Pharmacokinetic monitoring of mycophenolic acid in heart transplant patients: correlation the side-effects and rejections with pharmacokinetic parameters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22466911/),[h·mg] / [l],36,225362,DB00091,Cyclosporine
,31152006,rate,"GFR was calculated using two-compartment PK modeling, determining an average rate of 240 ± 21 μl/min in normal mice, in agreement with published mouse GFR ranges.",Blood Pharmacokinetics Imaging by Noninvasive Heart Fluorescence Tomography and Application to Kidney Glomerular Filtration Rate Assessment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31152006/),[μl] / [min],240,226516,DB00091,Cyclosporine
,18030500,area under the whole-blood concentration versus time curve from 0-12 h (AUC(0-12)),"Administration of CsA with tangerine juice compared with water did not increase significantly the area under the whole-blood concentration versus time curve from 0-12 h (AUC(0-12)) of CsA, (tangerine juice 2,797 +/- 1,361 (P = 0.5); water 3,053 +/- 1,532).",Effect of tangerine juice on cyclosporine levels in renal transplant children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18030500/),,"2,797",226636,DB00091,Cyclosporine
,18030500,area under the whole-blood concentration versus time curve from 0-12 h (AUC(0-12)),"Administration of CsA with tangerine juice compared with water did not increase significantly the area under the whole-blood concentration versus time curve from 0-12 h (AUC(0-12)) of CsA, (tangerine juice 2,797 +/- 1,361 (P = 0.5); water 3,053 +/- 1,532).",Effect of tangerine juice on cyclosporine levels in renal transplant children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18030500/),,"3,053",226637,DB00091,Cyclosporine
,17203553,time after dose,"A total of 31 patients (7 female and 24 male) originally included in a formal clinical trial, contributed 524 sirolimus blood concentrations with the time after dose ranging from 11.08 to 31.83 hours.",Apparent clearance of sirolimus in heart transplant recipients: impact of primary diagnosis and serum lipids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17203553/),h,11.08 to 31.83,226648,DB00091,Cyclosporine
,17203553,CL/F,"Based on the final model, the average values for sirolimus CL/F and apparent volume of distribution were 7.09 and 1350 L/h, respectively.",Apparent clearance of sirolimus in heart transplant recipients: impact of primary diagnosis and serum lipids. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17203553/),[l] / [h],7.09,226649,DB00091,Cyclosporine
,17203553,apparent volume of distribution,"Based on the final model, the average values for sirolimus CL/F and apparent volume of distribution were 7.09 and 1350 L/h, respectively.",Apparent clearance of sirolimus in heart transplant recipients: impact of primary diagnosis and serum lipids. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17203553/),[l] / [h],1350,226650,DB00091,Cyclosporine
,7849332,initial whole blood concentrations,Patients received cyclosporine 3-4 mg/kg by continuous infusion for 5 days followed by cyclosporine 10 mg/kg/d po to maintain initial whole blood concentrations of 300-400 ng/mL.,Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7849332/),[ng] / [ml],300-400,226740,DB00091,Cyclosporine
,7849332,clearance,"The mean clearance of intravenously administered cyclosporine +/- SD in patients receiving no CCB was 5.1 +/- 1.5 mL/min/kg, diltiazem was 3.7 +/- 0.8 mL/min/kg, nifedipine was 6.4 +/- 1.9 mL/min/kg, and verapamil was 5.2 +/- 2.2 mL/min/kg.",Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7849332/),[ml] / [kg·min],5.1,226741,DB00091,Cyclosporine
,7849332,clearance,"The mean clearance of intravenously administered cyclosporine +/- SD in patients receiving no CCB was 5.1 +/- 1.5 mL/min/kg, diltiazem was 3.7 +/- 0.8 mL/min/kg, nifedipine was 6.4 +/- 1.9 mL/min/kg, and verapamil was 5.2 +/- 2.2 mL/min/kg.",Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7849332/),[ml] / [kg·min],3.7,226742,DB00091,Cyclosporine
,7849332,clearance,"The mean clearance of intravenously administered cyclosporine +/- SD in patients receiving no CCB was 5.1 +/- 1.5 mL/min/kg, diltiazem was 3.7 +/- 0.8 mL/min/kg, nifedipine was 6.4 +/- 1.9 mL/min/kg, and verapamil was 5.2 +/- 2.2 mL/min/kg.",Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7849332/),[ml] / [kg·min],6.4,226743,DB00091,Cyclosporine
,7849332,clearance,"The mean clearance of intravenously administered cyclosporine +/- SD in patients receiving no CCB was 5.1 +/- 1.5 mL/min/kg, diltiazem was 3.7 +/- 0.8 mL/min/kg, nifedipine was 6.4 +/- 1.9 mL/min/kg, and verapamil was 5.2 +/- 2.2 mL/min/kg.",Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7849332/),[ml] / [kg·min],5.2,226744,DB00091,Cyclosporine
,15905802,AUC,"The median MPA AUC on day 6 (29.7 mg.h/L) after the first oral dose was slightly lower than the AUCs on the other study days (34.2, 33.8, and 33.8 mg.h/L on days 3, 5, and 10, respectively).",Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15905802/),[h·mg] / [l],29.7,227067,DB00091,Cyclosporine
,15905802,AUCs,"The median MPA AUC on day 6 (29.7 mg.h/L) after the first oral dose was slightly lower than the AUCs on the other study days (34.2, 33.8, and 33.8 mg.h/L on days 3, 5, and 10, respectively).",Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15905802/),[h·mg] / [l],34.2,227068,DB00091,Cyclosporine
,15905802,AUCs,"The median MPA AUC on day 6 (29.7 mg.h/L) after the first oral dose was slightly lower than the AUCs on the other study days (34.2, 33.8, and 33.8 mg.h/L on days 3, 5, and 10, respectively).",Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15905802/),[h·mg] / [l],33.8,227069,DB00091,Cyclosporine
,15905802,bioavailability,"The results of this study show that heart transplant recipients receiving the IV formulation of MMF (1.5 g BID) are not subject to a greater drug exposure than that seen with the oral formulation (1.5 g BID) and that the oral MMF formulation shows excellent, high, and consistent bioavailability (mean 95%) based on comparison with the IV formulation.",Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15905802/),%,95,227070,DB00091,Cyclosporine
,23354298,apparent urinary CsA clearance,"The mean apparent urinary CsA clearance based on a 48-hr collection was 20.4% lower in CYP3A5 expressors compared with CYP3A5 nonexpressors (4.2±1.0 and 5.3±1.3 mL/min, respectively; P=0.037), which is suggestive of CYP3A5-dependent intrarenal CsA metabolism.",CYP3A5 gene variation influences cyclosporine A metabolite formation and renal cyclosporine disposition. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23354298/),[ml] / [min],4.2,227079,DB00091,Cyclosporine
,23354298,apparent urinary CsA clearance,"The mean apparent urinary CsA clearance based on a 48-hr collection was 20.4% lower in CYP3A5 expressors compared with CYP3A5 nonexpressors (4.2±1.0 and 5.3±1.3 mL/min, respectively; P=0.037), which is suggestive of CYP3A5-dependent intrarenal CsA metabolism.",CYP3A5 gene variation influences cyclosporine A metabolite formation and renal cyclosporine disposition. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23354298/),[ml] / [min],5.3,227080,DB00091,Cyclosporine
,21383094,50% effective concentrations [EC50s],"In particular, sanglifehrin B (SfB) was 30- to 50-fold more potent at inhibiting the isomerase activity of all Cyps tested than CsA and was also shown to be a more potent inhibitor of the 1b subgenomic replicon (50% effective concentrations [EC50s] of 0.070 μM and 0.16 μM in Huh 5-2 and Huh 9-13 cells, respectively).",Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21383094/),μM,0.070,227244,DB00091,Cyclosporine
,21383094,50% effective concentrations [EC50s],"In particular, sanglifehrin B (SfB) was 30- to 50-fold more potent at inhibiting the isomerase activity of all Cyps tested than CsA and was also shown to be a more potent inhibitor of the 1b subgenomic replicon (50% effective concentrations [EC50s] of 0.070 μM and 0.16 μM in Huh 5-2 and Huh 9-13 cells, respectively).",Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21383094/),μM,0.16,227245,DB00091,Cyclosporine
<,21383094,oral bioavailability (F,"Physicochemical and mouse pharmacokinetic analyses revealed low oral bioavailability (F<4%) and low solubility (<25 μM), although the half-lives (t1/2) of SfA and SfB in mouse blood after intravenous (i.v.) dosing were long (t1/2>5 h).",Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21383094/),%,4,227246,DB00091,Cyclosporine
<,21383094,so,"Physicochemical and mouse pharmacokinetic analyses revealed low oral bioavailability (F<4%) and low solubility (<25 μM), although the half-lives (t1/2) of SfA and SfB in mouse blood after intravenous (i.v.) dosing were long (t1/2>5 h).",Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21383094/),μ,25,227247,DB00091,Cyclosporine
>,21383094,t1/2,"Physicochemical and mouse pharmacokinetic analyses revealed low oral bioavailability (F<4%) and low solubility (<25 μM), although the half-lives (t1/2) of SfA and SfB in mouse blood after intravenous (i.v.) dosing were long (t1/2>5 h).",Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21383094/),h,5,227248,DB00091,Cyclosporine
,19656203,AUC,"CsA showed circadian variation when comparing a.m. and p.m. administration [AUC: 8066 vs. 6699, P < 0.001 (CI 970.9; 1763.6); C0: 272 vs. 245, P = 0.007 (CI 7.5; 46.1)].",Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19656203/),,8066,227366,DB00091,Cyclosporine
,19656203,AUC,"CsA showed circadian variation when comparing a.m. and p.m. administration [AUC: 8066 vs. 6699, P < 0.001 (CI 970.9; 1763.6); C0: 272 vs. 245, P = 0.007 (CI 7.5; 46.1)].",Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19656203/),,6699,227367,DB00091,Cyclosporine
,19656203,C0,"CsA showed circadian variation when comparing a.m. and p.m. administration [AUC: 8066 vs. 6699, P < 0.001 (CI 970.9; 1763.6); C0: 272 vs. 245, P = 0.007 (CI 7.5; 46.1)].",Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19656203/),,272,227368,DB00091,Cyclosporine
,19656203,C0,"CsA showed circadian variation when comparing a.m. and p.m. administration [AUC: 8066 vs. 6699, P < 0.001 (CI 970.9; 1763.6); C0: 272 vs. 245, P = 0.007 (CI 7.5; 46.1)].",Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19656203/),,245,227369,DB00091,Cyclosporine
,19656203,AUC,A fivefold increase in SRL AUC (from a mean of 130 to 538 ng h/mL) was associated with a 25% increase in mean a.m.,Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19656203/),[h·ng] / [ml],130 to 538,227370,DB00091,Cyclosporine
,19656203,AUC,"CsA AUC [7021 to 8811 ng h/mL, P = 0.037, CI (-3461.2; -118.9)] and with a 42% increase in mean p.m. CsA AUC [5386-7639, P = 0.024, CI (-4164.4; -340.7)].",Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19656203/),[h·ng] / [ml],7021,227371,DB00091,Cyclosporine
,19656203,AUC,"CsA AUC [7021 to 8811 ng h/mL, P = 0.037, CI (-3461.2; -118.9)] and with a 42% increase in mean p.m. CsA AUC [5386-7639, P = 0.024, CI (-4164.4; -340.7)].",Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19656203/),[h·ng] / [ml],8811,227372,DB00091,Cyclosporine
,19656203,AUC,"CsA AUC (from 5860 to 10 974 ng h/mL) was associated with a 70% increase in mean SRL AUC [223 to 380 ng h/mL, P = 0.0026, CI (-291.7; -22.8)].",Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19656203/),[h·ng] / [ml],5860 to 10 974,227373,DB00091,Cyclosporine
,19656203,AUC,"CsA AUC (from 5860 to 10 974 ng h/mL) was associated with a 70% increase in mean SRL AUC [223 to 380 ng h/mL, P = 0.0026, CI (-291.7; -22.8)].",Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19656203/),[h·ng] / [ml],223 to 380,227374,DB00091,Cyclosporine
,19656203,AUC,"A twofold increase in p.m. CsA AUC (from 4573 to 9692 ng h/mL) was associated with a 63% increase in mean SRL AUC [246 to 400 ng h/mL, P = 0.032, CI (-290.7; -16.6)].",Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19656203/),[h·ng] / [ml],4573 to 9692,227375,DB00091,Cyclosporine
,19656203,AUC,"A twofold increase in p.m. CsA AUC (from 4573 to 9692 ng h/mL) was associated with a 63% increase in mean SRL AUC [246 to 400 ng h/mL, P = 0.032, CI (-290.7; -16.6)].",Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19656203/),[h·ng] / [ml],246,227376,DB00091,Cyclosporine
,19656203,AUC,"A twofold increase in p.m. CsA AUC (from 4573 to 9692 ng h/mL) was associated with a 63% increase in mean SRL AUC [246 to 400 ng h/mL, P = 0.032, CI (-290.7; -16.6)].",Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19656203/),[h·ng] / [ml],400,227377,DB00091,Cyclosporine
,11345652,AUC,"The AUC after doses of 2 x 60, 90, 120, and 160 mg/m2 were 3.77 +/- 2.70, 4.57 +/- 2.43, 3.62 +/- 1.58, and 8.58 +/- 7.87 microM.h, respectively.",A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345652/),h·μM,3.77,227478,DB00091,Cyclosporine
,11345652,AUC,"The AUC after doses of 2 x 60, 90, 120, and 160 mg/m2 were 3.77 +/- 2.70, 4.57 +/- 2.43, 3.62 +/- 1.58, and 8.58 +/- 7.87 microM.h, respectively.",A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345652/),h·μM,4.57,227479,DB00091,Cyclosporine
,11345652,AUC,"The AUC after doses of 2 x 60, 90, 120, and 160 mg/m2 were 3.77 +/- 2.70, 4.57 +/- 2.43, 3.62 +/- 1.58, and 8.58 +/- 7.87 microM.h, respectively.",A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345652/),h·μM,3.62,227480,DB00091,Cyclosporine
,11345652,AUC,"The AUC after doses of 2 x 60, 90, 120, and 160 mg/m2 were 3.77 +/- 2.70, 4.57 +/- 2.43, 3.62 +/- 1.58, and 8.58 +/- 7.87 microM.h, respectively.",A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345652/),h·μM,8.58,227481,DB00091,Cyclosporine
,11345652,AUC,The AUC achieved after intravenous administration of paclitaxel 175 mg/m2 was 17.95 +/- 3.94 microM.h.,A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11345652/),h·μM,17.95,227482,DB00091,Cyclosporine
,8351718,initial steady state concentrations,"Our concentration-control strategy assesses CyA exposure by analyzing serial pharmacokinetic profiles, titering drug doses to achieve initial steady state concentrations of 400 ng/mL during continuous i.v. infusion, and to achieve average concentrations, namely AUC divided by dosing interval (in hours), of 550 ng/mL initially with trough levels of 200 ng/mL or above.",Optimization of cyclosporine therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8351718/),[ng] / [ml],400,227612,DB00091,Cyclosporine
,8351718,AUC divided by dosing interval,"Our concentration-control strategy assesses CyA exposure by analyzing serial pharmacokinetic profiles, titering drug doses to achieve initial steady state concentrations of 400 ng/mL during continuous i.v. infusion, and to achieve average concentrations, namely AUC divided by dosing interval (in hours), of 550 ng/mL initially with trough levels of 200 ng/mL or above.",Optimization of cyclosporine therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8351718/),[ng] / [ml],550,227613,DB00091,Cyclosporine
,8351718,trough levels,"Our concentration-control strategy assesses CyA exposure by analyzing serial pharmacokinetic profiles, titering drug doses to achieve initial steady state concentrations of 400 ng/mL during continuous i.v. infusion, and to achieve average concentrations, namely AUC divided by dosing interval (in hours), of 550 ng/mL initially with trough levels of 200 ng/mL or above.",Optimization of cyclosporine therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8351718/),[ng] / [ml],200,227614,DB00091,Cyclosporine
,2859157,half-life of the terminal phase,"The data indicate an increase in the half-life of the terminal phase (255 to 550 min), and in the volume of distribution at steady state (3.16 to 7.82 liters/kg) with increasing dose (5 to 20 mg/kg).",The pharmacokinetics of cyclosporine. I. Single dose and constant rate infusion studies in the rabbit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859157/),min,255 to 550,227710,DB00091,Cyclosporine
,2859157,volume of distribution at steady state,"The data indicate an increase in the half-life of the terminal phase (255 to 550 min), and in the volume of distribution at steady state (3.16 to 7.82 liters/kg) with increasing dose (5 to 20 mg/kg).",The pharmacokinetics of cyclosporine. I. Single dose and constant rate infusion studies in the rabbit. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859157/),[l] / [kg],3.16 to 7.82,227711,DB00091,Cyclosporine
,2859157,Infusion rates,"Infusion rates in two rabbits were increased from 16.8 to 65.4 micrograms/min, and in the third rabbit they were decreased from 65.4 to 16.8 micrograms/min.",The pharmacokinetics of cyclosporine. I. Single dose and constant rate infusion studies in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859157/),[μg] / [min],16.8 to 65.4,227712,DB00091,Cyclosporine
,2859157,Infusion rates,"Infusion rates in two rabbits were increased from 16.8 to 65.4 micrograms/min, and in the third rabbit they were decreased from 65.4 to 16.8 micrograms/min.",The pharmacokinetics of cyclosporine. I. Single dose and constant rate infusion studies in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859157/),[μg] / [min],65.4 to 16.8,227713,DB00091,Cyclosporine
,19370549,AUCs,"The AUCs of DIG with BBR (30 mg/kg, 100 mg/kg) were 133%, 170% (single) and 123%, 169% (2-week) of control, respectively.",Effect of berberine on the pharmacokinetics of substrates of CYP3A and P-gp. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19370549/),%,133,227895,DB00091,Cyclosporine
,19370549,AUCs,"The AUCs of DIG with BBR (30 mg/kg, 100 mg/kg) were 133%, 170% (single) and 123%, 169% (2-week) of control, respectively.",Effect of berberine on the pharmacokinetics of substrates of CYP3A and P-gp. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19370549/),%,170,227896,DB00091,Cyclosporine
,19370549,AUCs,"The AUCs of DIG with BBR (30 mg/kg, 100 mg/kg) were 133%, 170% (single) and 123%, 169% (2-week) of control, respectively.",Effect of berberine on the pharmacokinetics of substrates of CYP3A and P-gp. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19370549/),%,123,227897,DB00091,Cyclosporine
,19370549,AUCs,"The AUCs of DIG with BBR (30 mg/kg, 100 mg/kg) were 133%, 170% (single) and 123%, 169% (2-week) of control, respectively.",Effect of berberine on the pharmacokinetics of substrates of CYP3A and P-gp. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19370549/),%,169,227898,DB00091,Cyclosporine
,7628178,clearance,Administration of ketoconazole caused a significant decrease in intravenous cyclosporine clearance (0.18 +/- 0.05 L/kg/hr versus 0.32 +/- 0.09 L/hr/kg) and a significant increase in cyclosporine oral bioavailability (56.4% +/- 11.7% versus 22.4% +/- 4.8%) compared with values before ketoconazole administration.,The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628178/),[l] / [h·kg],0.18,228240,DB00091,Cyclosporine
,7628178,clearance,Administration of ketoconazole caused a significant decrease in intravenous cyclosporine clearance (0.18 +/- 0.05 L/kg/hr versus 0.32 +/- 0.09 L/hr/kg) and a significant increase in cyclosporine oral bioavailability (56.4% +/- 11.7% versus 22.4% +/- 4.8%) compared with values before ketoconazole administration.,The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628178/),[l] / [h·kg],0.32,228241,DB00091,Cyclosporine
,7628178,oral bioavailability,Administration of ketoconazole caused a significant decrease in intravenous cyclosporine clearance (0.18 +/- 0.05 L/kg/hr versus 0.32 +/- 0.09 L/hr/kg) and a significant increase in cyclosporine oral bioavailability (56.4% +/- 11.7% versus 22.4% +/- 4.8%) compared with values before ketoconazole administration.,The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628178/),%,56.4,228242,DB00091,Cyclosporine
,7628178,oral bioavailability,Administration of ketoconazole caused a significant decrease in intravenous cyclosporine clearance (0.18 +/- 0.05 L/kg/hr versus 0.32 +/- 0.09 L/hr/kg) and a significant increase in cyclosporine oral bioavailability (56.4% +/- 11.7% versus 22.4% +/- 4.8%) compared with values before ketoconazole administration.,The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628178/),%,22.4,228243,DB00091,Cyclosporine
,7628178,Steady-state volume of distribution,Steady-state volume of distribution for intravenously administered cyclosporine was unchanged (1.26 +/- 0.44 L/kg versus 1.10 +/- 0.27 L/kg).,The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628178/),[l] / [kg],1.26,228244,DB00091,Cyclosporine
,7628178,Steady-state volume of distribution,Steady-state volume of distribution for intravenously administered cyclosporine was unchanged (1.26 +/- 0.44 L/kg versus 1.10 +/- 0.27 L/kg).,The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628178/),[l] / [kg],1.10,228245,DB00091,Cyclosporine
,7628178,Hepatic bioavailability (1 - hepatic extraction ratio),"Hepatic bioavailability (1 - hepatic extraction ratio) calculated for intravenous cyclosporine increased by 11% in the presence of ketoconazole (86.3% +/- 3.7% versus 75.2% +/- 6.6% without ketoconazole), which accounts for only one third of the observed increase in cyclosporine oral bioavailability.",The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628178/),%,86.3,228246,DB00091,Cyclosporine
,7628178,Hepatic bioavailability (1 - hepatic extraction ratio),"Hepatic bioavailability (1 - hepatic extraction ratio) calculated for intravenous cyclosporine increased by 11% in the presence of ketoconazole (86.3% +/- 3.7% versus 75.2% +/- 6.6% without ketoconazole), which accounts for only one third of the observed increase in cyclosporine oral bioavailability.",The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7628178/),%,75.2,228247,DB00091,Cyclosporine
,19725595,oral clearance (CL/F),The population pharmacokinetic parameters were oral clearance (CL/F) = 26.9 L/h; central volume of distribution after oral administration (V(1)/F) = 24.4 L; absorption rate constant (k(a)) = 0.544 h-1; lag time = 0.460 h; peripheral volume of distribution = 1119 L and intercompartmental clearance after oral administration (Q/F) = 19.6 L/h.,A population pharmacokinetic model of ciclosporin applicable for assisting dose management of kidney transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19725595/),[l] / [h],26.9,228800,DB00091,Cyclosporine
,19725595,central volume of distribution after oral administration (V(1)/F),The population pharmacokinetic parameters were oral clearance (CL/F) = 26.9 L/h; central volume of distribution after oral administration (V(1)/F) = 24.4 L; absorption rate constant (k(a)) = 0.544 h-1; lag time = 0.460 h; peripheral volume of distribution = 1119 L and intercompartmental clearance after oral administration (Q/F) = 19.6 L/h.,A population pharmacokinetic model of ciclosporin applicable for assisting dose management of kidney transplant recipients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19725595/),l,24.4,228801,DB00091,Cyclosporine
,19725595,absorption rate constant (k(a)),The population pharmacokinetic parameters were oral clearance (CL/F) = 26.9 L/h; central volume of distribution after oral administration (V(1)/F) = 24.4 L; absorption rate constant (k(a)) = 0.544 h-1; lag time = 0.460 h; peripheral volume of distribution = 1119 L and intercompartmental clearance after oral administration (Q/F) = 19.6 L/h.,A population pharmacokinetic model of ciclosporin applicable for assisting dose management of kidney transplant recipients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19725595/),1/[h],0.544,228802,DB00091,Cyclosporine
,19725595,lag time,The population pharmacokinetic parameters were oral clearance (CL/F) = 26.9 L/h; central volume of distribution after oral administration (V(1)/F) = 24.4 L; absorption rate constant (k(a)) = 0.544 h-1; lag time = 0.460 h; peripheral volume of distribution = 1119 L and intercompartmental clearance after oral administration (Q/F) = 19.6 L/h.,A population pharmacokinetic model of ciclosporin applicable for assisting dose management of kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19725595/),h,0.460,228803,DB00091,Cyclosporine
,19725595,peripheral volume of distribution,The population pharmacokinetic parameters were oral clearance (CL/F) = 26.9 L/h; central volume of distribution after oral administration (V(1)/F) = 24.4 L; absorption rate constant (k(a)) = 0.544 h-1; lag time = 0.460 h; peripheral volume of distribution = 1119 L and intercompartmental clearance after oral administration (Q/F) = 19.6 L/h.,A population pharmacokinetic model of ciclosporin applicable for assisting dose management of kidney transplant recipients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19725595/),l,1119,228804,DB00091,Cyclosporine
,19725595,intercompartmental clearance after oral administration (Q/F),The population pharmacokinetic parameters were oral clearance (CL/F) = 26.9 L/h; central volume of distribution after oral administration (V(1)/F) = 24.4 L; absorption rate constant (k(a)) = 0.544 h-1; lag time = 0.460 h; peripheral volume of distribution = 1119 L and intercompartmental clearance after oral administration (Q/F) = 19.6 L/h.,A population pharmacokinetic model of ciclosporin applicable for assisting dose management of kidney transplant recipients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19725595/),[l] / [h],19.6,228805,DB00091,Cyclosporine
,2646782,peak concentrations,"The kinetics of cyclosporine following administration of either oral solution or cyclosporine in olive oil were variable, with peak concentrations ranging from 450 to 1033 ng/ml and 288 to 648 ng/ml, respectively.",Cyclosporine pharmacokinetics in cats following topical ocular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2646782/),[ng] / [ml],450 to 1033,228978,DB00091,Cyclosporine
,2646782,peak concentrations,"The kinetics of cyclosporine following administration of either oral solution or cyclosporine in olive oil were variable, with peak concentrations ranging from 450 to 1033 ng/ml and 288 to 648 ng/ml, respectively.",Cyclosporine pharmacokinetics in cats following topical ocular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2646782/),[ng] / [ml],288 to 648,228979,DB00091,Cyclosporine
,2646782,Absorption lag time,"Absorption lag time ranged from 0 to 1.34 hr for oral solution, and 0.27 to 1.2 hr for cyclosporine in olive oil.",Cyclosporine pharmacokinetics in cats following topical ocular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2646782/),h,0 to 1.34,228980,DB00091,Cyclosporine
,2646782,Absorption lag time,"Absorption lag time ranged from 0 to 1.34 hr for oral solution, and 0.27 to 1.2 hr for cyclosporine in olive oil.",Cyclosporine pharmacokinetics in cats following topical ocular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2646782/),h,0.27 to 1.2,228981,DB00091,Cyclosporine
,2646782,half-life of elimination,"The half-life of elimination ranged from 2.41 to 10.04 hr, and 3.09 to 15.75 hr, respectively.",Cyclosporine pharmacokinetics in cats following topical ocular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2646782/),h,2.41 to 10.04,228982,DB00091,Cyclosporine
,2646782,half-life of elimination,"The half-life of elimination ranged from 2.41 to 10.04 hr, and 3.09 to 15.75 hr, respectively.",Cyclosporine pharmacokinetics in cats following topical ocular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2646782/),h,3.09 to 15.75,228983,DB00091,Cyclosporine
,31468555,Cmin,Caspofungin Cmin in the kidney recipients varied largely compared with healthy volunteers (0.10-12.25 mg/L vs. 1.12-1.78 mg/L).,Factors influencing caspofungin plasma concentrations in kidney transplant patients with high incidence of invasive fungal infections. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31468555/),[mg] / [l],0.10-12.25,229663,DB00091,Cyclosporine
,31468555,Cmin,Caspofungin Cmin in the kidney recipients varied largely compared with healthy volunteers (0.10-12.25 mg/L vs. 1.12-1.78 mg/L).,Factors influencing caspofungin plasma concentrations in kidney transplant patients with high incidence of invasive fungal infections. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31468555/),[mg] / [l],1.12-1.78,229664,DB00091,Cyclosporine
,11498244,clearance,The clearance of CsA decreased from a mean (95% CI) of 9.47 (6.2-12.7)ml/min/kg after a single (first) dose (3mg/kg i.v.) to 1.62 (1.38-1.86)ml/min/kg after 18 days of CsA (3mg/kg i.v. twice daily) co-administration with ketoconazole.,Cyclosporin immunosuppression of sheep: pharmacokinetics and allograft survival. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11498244/),[ml] / [kg·min],9.47,229794,DB00091,Cyclosporine
,11498244,clearance,The clearance of CsA decreased from a mean (95% CI) of 9.47 (6.2-12.7)ml/min/kg after a single (first) dose (3mg/kg i.v.) to 1.62 (1.38-1.86)ml/min/kg after 18 days of CsA (3mg/kg i.v. twice daily) co-administration with ketoconazole.,Cyclosporin immunosuppression of sheep: pharmacokinetics and allograft survival. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11498244/),[ml] / [kg·min],1.62,229795,DB00091,Cyclosporine
,11498244,trough concentration,"Provided that the trough concentration of blood CsA was maintained between 1500-2500 mg/l, long-term healthy skin allografts were maintained on the sheep without significant adverse effects on haematological or biochemical parameters.",Cyclosporin immunosuppression of sheep: pharmacokinetics and allograft survival. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11498244/),[mg] / [l],1500-2500,229796,DB00091,Cyclosporine
,3284095,concentration maximum (Cmax),"The average CsA concentration maximum (Cmax) was 528 ng/mL with an average time to maximum concentration (Tmax) of 4.7 hours, a mean residence time of 7.75 hours, with a Vdss/%F of 9.61 L/kg in the pancreas transplant recipients.",Cyclosporine pharmacokinetics in pancreas transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3284095/),[ng] / [ml],528,229880,DB00091,Cyclosporine
,3284095,time to maximum concentration (Tmax),"The average CsA concentration maximum (Cmax) was 528 ng/mL with an average time to maximum concentration (Tmax) of 4.7 hours, a mean residence time of 7.75 hours, with a Vdss/%F of 9.61 L/kg in the pancreas transplant recipients.",Cyclosporine pharmacokinetics in pancreas transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3284095/),h,4.7,229881,DB00091,Cyclosporine
,3284095,mean residence time,"The average CsA concentration maximum (Cmax) was 528 ng/mL with an average time to maximum concentration (Tmax) of 4.7 hours, a mean residence time of 7.75 hours, with a Vdss/%F of 9.61 L/kg in the pancreas transplant recipients.",Cyclosporine pharmacokinetics in pancreas transplant recipients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3284095/),h,7.75,229882,DB00091,Cyclosporine
,3284095,Vdss/%F,"The average CsA concentration maximum (Cmax) was 528 ng/mL with an average time to maximum concentration (Tmax) of 4.7 hours, a mean residence time of 7.75 hours, with a Vdss/%F of 9.61 L/kg in the pancreas transplant recipients.",Cyclosporine pharmacokinetics in pancreas transplant recipients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3284095/),[l] / [kg],9.61,229883,DB00091,Cyclosporine
,3284095,Cmax,"Additional studies of six patients receiving metoclopramide with CsA revealed an average Cmax of 723 ng/mL, an average Tmax of 2.3 hours, an average MRT of 6.08 hours, and an average Vdss/%F of 5.7% L/kg.",Cyclosporine pharmacokinetics in pancreas transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3284095/),[ng] / [ml],723,229884,DB00091,Cyclosporine
,3284095,Tmax,"Additional studies of six patients receiving metoclopramide with CsA revealed an average Cmax of 723 ng/mL, an average Tmax of 2.3 hours, an average MRT of 6.08 hours, and an average Vdss/%F of 5.7% L/kg.",Cyclosporine pharmacokinetics in pancreas transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3284095/),h,2.3,229885,DB00091,Cyclosporine
,3284095,MRT,"Additional studies of six patients receiving metoclopramide with CsA revealed an average Cmax of 723 ng/mL, an average Tmax of 2.3 hours, an average MRT of 6.08 hours, and an average Vdss/%F of 5.7% L/kg.",Cyclosporine pharmacokinetics in pancreas transplant recipients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3284095/),h,6.08,229886,DB00091,Cyclosporine
,3284095,Vdss/%F,"Additional studies of six patients receiving metoclopramide with CsA revealed an average Cmax of 723 ng/mL, an average Tmax of 2.3 hours, an average MRT of 6.08 hours, and an average Vdss/%F of 5.7% L/kg.",Cyclosporine pharmacokinetics in pancreas transplant recipients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3284095/),[%·l] / [kg],5.7,229887,DB00091,Cyclosporine
,17192496,area under the curve (AUC),"Intravenous dosing resulted in a median area under the curve (AUC) of 28.3 microg x h/mL (range, 9.96-70.4) and an oral AUC of 16.7 microg x h/mL (range, 9.38-35.3).",Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192496/),[h·μg] / [ml],28.3,229900,DB00091,Cyclosporine
,17192496,oral AUC,"Intravenous dosing resulted in a median area under the curve (AUC) of 28.3 microg x h/mL (range, 9.96-70.4) and an oral AUC of 16.7 microg x h/mL (range, 9.38-35.3).",Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192496/),[h·μg] / [ml],16.7,229901,DB00091,Cyclosporine
,17192496,Cmax,"Cmax after intravenous and oral dosing was 12.18 and 5.29 microg/mL, respectively.",Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192496/),[μg] / [ml],12.18,229902,DB00091,Cyclosporine
,17192496,Cmax,"Cmax after intravenous and oral dosing was 12.18 and 5.29 microg/mL, respectively.",Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192496/),[μg] / [ml],5.29,229903,DB00091,Cyclosporine
,17192496,oral bioavailability,"The median oral bioavailability was 72.3% (20.5%-172%), with 8-fold variability.",Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192496/),%,72.3,229904,DB00091,Cyclosporine
< or =,17192496,oral bioavailability,Five patients (28%) had an oral bioavailability < or = 50%.,Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192496/),%,50,229905,DB00091,Cyclosporine
<,17192496,AUC(0-12),"At time of oral pharmacokinetics, 15 patients (83%) had an AUC(0-12) < 30 microg x h/mL.",Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192496/),[h·μg] / [ml],30,229906,DB00091,Cyclosporine
,16647462,AUC0-12,Mean AUC0-12 of 4431 +/- 2400 microg x h/L at week 1 remained stable at week 3 (5119 +/- 1190 microg x h/L).,Pharmacokinetic profiling of cyclosporine microemulsion during the first 3 weeks after simultaneous pancreas-kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16647462/),[h·μg] / [l],4431,229962,DB00091,Cyclosporine
,16647462,AUC0-12,Mean AUC0-12 of 4431 +/- 2400 microg x h/L at week 1 remained stable at week 3 (5119 +/- 1190 microg x h/L).,Pharmacokinetic profiling of cyclosporine microemulsion during the first 3 weeks after simultaneous pancreas-kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16647462/),[h·μg] / [l],5119,229963,DB00091,Cyclosporine
,10653385,Time,Time on i.v. CsA was reduced in the Neoral group (8.4 vs. 11.1 days) and the weight adjusted daily dose of SIM required to achieve target trough levels was about 2-fold more than Neoral from day 22 onward.,NOF-11: a one-year pediatric randomized double-blind comparison of neoral versus sandimmune in orthotopic liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10653385/),,8.4,230003,DB00091,Cyclosporine
,10653385,Time,Time on i.v. CsA was reduced in the Neoral group (8.4 vs. 11.1 days) and the weight adjusted daily dose of SIM required to achieve target trough levels was about 2-fold more than Neoral from day 22 onward.,NOF-11: a one-year pediatric randomized double-blind comparison of neoral versus sandimmune in orthotopic liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10653385/),,11.1,230004,DB00091,Cyclosporine
,24861769,AUC,"Median (range) dose normalized cyclosporin AUC and C2 were 1.15 (mg*h/L)/mg/kg (0.72-3.0) and 265.5 (ng/ml)/mg/kg (120.8-725.7), respectively, on the innovator therapy and 1.05 (mg*h/L)/mg/kg (0.54-2.22) and 317.1 (ng/ml)/mg/kg (116.7-564.7) for the generic drug after the switch.",Therapeutic monitoring of pediatric renal transplant patients with conversion to generic cyclosporin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861769/),,1.15,230168,DB00091,Cyclosporine
,24861769,AUC,"Median (range) dose normalized cyclosporin AUC and C2 were 1.15 (mg*h/L)/mg/kg (0.72-3.0) and 265.5 (ng/ml)/mg/kg (120.8-725.7), respectively, on the innovator therapy and 1.05 (mg*h/L)/mg/kg (0.54-2.22) and 317.1 (ng/ml)/mg/kg (116.7-564.7) for the generic drug after the switch.",Therapeutic monitoring of pediatric renal transplant patients with conversion to generic cyclosporin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861769/),[h·mg] / [l],1.05,230169,DB00091,Cyclosporine
,24861769,C2,"Median (range) dose normalized cyclosporin AUC and C2 were 1.15 (mg*h/L)/mg/kg (0.72-3.0) and 265.5 (ng/ml)/mg/kg (120.8-725.7), respectively, on the innovator therapy and 1.05 (mg*h/L)/mg/kg (0.54-2.22) and 317.1 (ng/ml)/mg/kg (116.7-564.7) for the generic drug after the switch.",Therapeutic monitoring of pediatric renal transplant patients with conversion to generic cyclosporin. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861769/),[ng] / [ml],265.5,230170,DB00091,Cyclosporine
,24861769,C2,"Median (range) dose normalized cyclosporin AUC and C2 were 1.15 (mg*h/L)/mg/kg (0.72-3.0) and 265.5 (ng/ml)/mg/kg (120.8-725.7), respectively, on the innovator therapy and 1.05 (mg*h/L)/mg/kg (0.54-2.22) and 317.1 (ng/ml)/mg/kg (116.7-564.7) for the generic drug after the switch.",Therapeutic monitoring of pediatric renal transplant patients with conversion to generic cyclosporin. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861769/),[h·mg] / [l],1.05,230171,DB00091,Cyclosporine
,24861769,C2,"Median (range) dose normalized cyclosporin AUC and C2 were 1.15 (mg*h/L)/mg/kg (0.72-3.0) and 265.5 (ng/ml)/mg/kg (120.8-725.7), respectively, on the innovator therapy and 1.05 (mg*h/L)/mg/kg (0.54-2.22) and 317.1 (ng/ml)/mg/kg (116.7-564.7) for the generic drug after the switch.",Therapeutic monitoring of pediatric renal transplant patients with conversion to generic cyclosporin. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861769/),[ng] / [ml],317.1,230172,DB00091,Cyclosporine
,31062373,AUC0-12h,Mycophenolic acid AUC0-12h was 1.70-fold greater with tacrolimus (68.9 ± 30.9 mg·h/L) relative to cyclosporine (40.8 ± 17.6 mg·h/L); P < .001.,Influence of Calcineurin Inhibitor and Sex on Mycophenolic Acid Pharmacokinetics and Adverse Effects Post-Renal Transplant. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31062373/),[h·mg] / [l],68.9,230537,DB00091,Cyclosporine
,31062373,AUC0-12h,Mycophenolic acid AUC0-12h was 1.70-fold greater with tacrolimus (68.9 ± 30.9 mg·h/L) relative to cyclosporine (40.8 ± 17.6 mg·h/L); P < .001.,Influence of Calcineurin Inhibitor and Sex on Mycophenolic Acid Pharmacokinetics and Adverse Effects Post-Renal Transplant. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31062373/),[h·mg] / [l],40.8,230538,DB00091,Cyclosporine
,31062373,AUC0-12h,Target mycophenolic acid AUC0-12h of 30-60 mg·h/L was achieved in 56.3% on cyclosporine compared with 34.3% receiving tacrolimus (P < .001).,Influence of Calcineurin Inhibitor and Sex on Mycophenolic Acid Pharmacokinetics and Adverse Effects Post-Renal Transplant. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31062373/),[h·mg] / [l],30-60,230539,DB00091,Cyclosporine
,31062373,clearance,Mycophenolic acid clearance was 48% slower with tacrolimus (10.6 ± 4.7 L/h) relative to cyclosporine (20.5 ± 10.0 L/h); P < .001.,Influence of Calcineurin Inhibitor and Sex on Mycophenolic Acid Pharmacokinetics and Adverse Effects Post-Renal Transplant. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31062373/),[l] / [h],10.6,230540,DB00091,Cyclosporine
,31062373,clearance,Mycophenolic acid clearance was 48% slower with tacrolimus (10.6 ± 4.7 L/h) relative to cyclosporine (20.5 ± 10.0 L/h); P < .001.,Influence of Calcineurin Inhibitor and Sex on Mycophenolic Acid Pharmacokinetics and Adverse Effects Post-Renal Transplant. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31062373/),[l] / [h],20.5,230541,DB00091,Cyclosporine
,17645712,C(2),At conversion the mean C(2) was 969 ng/mL (95% CI: 684-1255; target 1700 ng/mL).,Apparent low absorbers of cyclosporine microemulsion have higher requirements for tacrolimus in renal transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17645712/),[ng] / [ml],969,231081,DB00091,Cyclosporine
,17645712,C(2),At conversion the mean C(2) was 969 ng/mL (95% CI: 684-1255; target 1700 ng/mL).,Apparent low absorbers of cyclosporine microemulsion have higher requirements for tacrolimus in renal transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17645712/),[ng] / [ml],1700,231082,DB00091,Cyclosporine
,17645712,acute,"Although not statistically significant, this group experienced an acute rejection rate of 33%, compared with 21% in the control group.",Apparent low absorbers of cyclosporine microemulsion have higher requirements for tacrolimus in renal transplantation. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17645712/),%,33,231083,DB00091,Cyclosporine
,17645712,acute,"Although not statistically significant, this group experienced an acute rejection rate of 33%, compared with 21% in the control group.",Apparent low absorbers of cyclosporine microemulsion have higher requirements for tacrolimus in renal transplantation. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17645712/),,21,231084,DB00091,Cyclosporine
,10772639,dissociation constant K(D),"In general, blood binding saturation (dissociation constant K(D) = 0. 18 microg/ml) occurred at a lower dose (concentration) than saturation of tissue binding (K(D), 0.005-0.77 microg/g), such that the volume of distribution at steady state first increased as the dose increased from 1.2 to 6 mg/kg, and then decreased as the dose increased to 30 mg/kg.",Dose-dependent pharmacokinetics of cyclosporin A in rats: events in tissues. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10772639/),[μg] / [ml],0. 18,231471,DB00091,Cyclosporine
,8582459,Resting plasma ANF levels,Resting plasma ANF levels were significantly higher in these patients than in 8 healthy subjects (71 vs. 21 ng.l-1).,Raised plasma levels of atrial natriuretic factor in cardiac allograft recipients: evidence of increased cardiac secretion and decreased renal clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8582459/),[ng] / [l],71,231550,DB00091,Cyclosporine
,8582459,Resting plasma ANF levels,Resting plasma ANF levels were significantly higher in these patients than in 8 healthy subjects (71 vs. 21 ng.l-1).,Raised plasma levels of atrial natriuretic factor in cardiac allograft recipients: evidence of increased cardiac secretion and decreased renal clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8582459/),[ng] / [l],21,231551,DB00091,Cyclosporine
,8582459,effective renal plasma flow (ERPF),Both effective renal plasma flow (ERPF) and glomerular filtration rate (GFR) were significantly lower in these patients than in healthy subjects (215 vs. 617 ml.min-1 and 55 vs. 102 ml.min-1 respectively).,Raised plasma levels of atrial natriuretic factor in cardiac allograft recipients: evidence of increased cardiac secretion and decreased renal clearance. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8582459/),[ml] / [min],215,231552,DB00091,Cyclosporine
,8582459,effective renal plasma flow (ERPF),Both effective renal plasma flow (ERPF) and glomerular filtration rate (GFR) were significantly lower in these patients than in healthy subjects (215 vs. 617 ml.min-1 and 55 vs. 102 ml.min-1 respectively).,Raised plasma levels of atrial natriuretic factor in cardiac allograft recipients: evidence of increased cardiac secretion and decreased renal clearance. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8582459/),[ml] / [min],617,231553,DB00091,Cyclosporine
,8582459,glomerular filtration rate (GFR),Both effective renal plasma flow (ERPF) and glomerular filtration rate (GFR) were significantly lower in these patients than in healthy subjects (215 vs. 617 ml.min-1 and 55 vs. 102 ml.min-1 respectively).,Raised plasma levels of atrial natriuretic factor in cardiac allograft recipients: evidence of increased cardiac secretion and decreased renal clearance. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8582459/),[ml] / [min],55,231554,DB00091,Cyclosporine
,8582459,glomerular filtration rate (GFR),Both effective renal plasma flow (ERPF) and glomerular filtration rate (GFR) were significantly lower in these patients than in healthy subjects (215 vs. 617 ml.min-1 and 55 vs. 102 ml.min-1 respectively).,Raised plasma levels of atrial natriuretic factor in cardiac allograft recipients: evidence of increased cardiac secretion and decreased renal clearance. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8582459/),[ml] / [min],102,231555,DB00091,Cyclosporine
,8582459,Total body clearance,Total body clearance of ANF was marginally lower in these patients than in healthy subjects (60 vs.,Raised plasma levels of atrial natriuretic factor in cardiac allograft recipients: evidence of increased cardiac secretion and decreased renal clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8582459/),,60,231556,DB00091,Cyclosporine
,8582459,endogenous secretion rate,Derived endogenous secretion rate of ANF was threefold higher in patients when compared to healthy subjects (633 vs. 208 ng.min-1).,Raised plasma levels of atrial natriuretic factor in cardiac allograft recipients: evidence of increased cardiac secretion and decreased renal clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8582459/),[ng] / [min],633,231557,DB00091,Cyclosporine
,8582459,endogenous secretion rate,Derived endogenous secretion rate of ANF was threefold higher in patients when compared to healthy subjects (633 vs. 208 ng.min-1).,Raised plasma levels of atrial natriuretic factor in cardiac allograft recipients: evidence of increased cardiac secretion and decreased renal clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8582459/),[ng] / [min],208,231558,DB00091,Cyclosporine
,34275856,percentage entrapment efficiencies,The percentage entrapment efficiencies of FTS and FSB were found to be 77.29 and 89.31% for respectively.,Oral bioavailability studies of niosomal formulations of Cyclosporine A in albino rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275856/),%,77.29,231561,DB00091,Cyclosporine
,34275856,percentage entrapment efficiencies,The percentage entrapment efficiencies of FTS and FSB were found to be 77.29 and 89.31% for respectively.,Oral bioavailability studies of niosomal formulations of Cyclosporine A in albino rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275856/),%,89.31,231562,DB00091,Cyclosporine
,34275856,Cmax,In vivo studies demonstrated that the value of Cmax for the FSB formulation was 1968.419 ng/ml and it was 1498.951 ng/ml and 1073.87 ng/ml for FTS and aqueous dispersion of CsA (control) respectively.,Oral bioavailability studies of niosomal formulations of Cyclosporine A in albino rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275856/),[ng] / [ml],1968.419,231563,DB00091,Cyclosporine
,34275856,Cmax,In vivo studies demonstrated that the value of Cmax for the FSB formulation was 1968.419 ng/ml and it was 1498.951 ng/ml and 1073.87 ng/ml for FTS and aqueous dispersion of CsA (control) respectively.,Oral bioavailability studies of niosomal formulations of Cyclosporine A in albino rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275856/),[ng] / [ml],1498.951,231564,DB00091,Cyclosporine
,34275856,Cmax,In vivo studies demonstrated that the value of Cmax for the FSB formulation was 1968.419 ng/ml and it was 1498.951 ng/ml and 1073.87 ng/ml for FTS and aqueous dispersion of CsA (control) respectively.,Oral bioavailability studies of niosomal formulations of Cyclosporine A in albino rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275856/),[ng] / [ml],1073.87,231565,DB00091,Cyclosporine
,1424418,clearances,"For blood and plasma, respectively, clearances of cyclosporine were calculated to be 0.30 and 0.55 L/hr/kg, values for volume of distribution at steady state were 1.31 and 1.68 L/kg, and bioavailabilities were 27% and 33% during the pre-rifampin phase.",Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424418/),[l] / [h·kg],0.30,231598,DB00091,Cyclosporine
,1424418,clearances,"For blood and plasma, respectively, clearances of cyclosporine were calculated to be 0.30 and 0.55 L/hr/kg, values for volume of distribution at steady state were 1.31 and 1.68 L/kg, and bioavailabilities were 27% and 33% during the pre-rifampin phase.",Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424418/),[l] / [h·kg],0.55,231599,DB00091,Cyclosporine
,1424418,volume of distribution at steady state,"For blood and plasma, respectively, clearances of cyclosporine were calculated to be 0.30 and 0.55 L/hr/kg, values for volume of distribution at steady state were 1.31 and 1.68 L/kg, and bioavailabilities were 27% and 33% during the pre-rifampin phase.",Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424418/),[l] / [kg],1.31,231600,DB00091,Cyclosporine
,1424418,volume of distribution at steady state,"For blood and plasma, respectively, clearances of cyclosporine were calculated to be 0.30 and 0.55 L/hr/kg, values for volume of distribution at steady state were 1.31 and 1.68 L/kg, and bioavailabilities were 27% and 33% during the pre-rifampin phase.",Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424418/),[l] / [kg],1.68,231601,DB00091,Cyclosporine
,1424418,bioavailabilities,"For blood and plasma, respectively, clearances of cyclosporine were calculated to be 0.30 and 0.55 L/hr/kg, values for volume of distribution at steady state were 1.31 and 1.68 L/kg, and bioavailabilities were 27% and 33% during the pre-rifampin phase.",Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424418/),%,27,231602,DB00091,Cyclosporine
,1424418,bioavailabilities,"For blood and plasma, respectively, clearances of cyclosporine were calculated to be 0.30 and 0.55 L/hr/kg, values for volume of distribution at steady state were 1.31 and 1.68 L/kg, and bioavailabilities were 27% and 33% during the pre-rifampin phase.",Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424418/),%,33,231603,DB00091,Cyclosporine
,1424418,phase clearances,"Post-rifampin phase clearances of cyclosporine were 0.42 and 0.79 L/hr/kg, values for volume of distribution at steady state were 1.36 and 1.35 L/kg, and bioavailabilities were 10% and 9% for blood and plasma, respectively.",Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424418/),[l] / [h·kg],0.42,231604,DB00091,Cyclosporine
,1424418,phase clearances,"Post-rifampin phase clearances of cyclosporine were 0.42 and 0.79 L/hr/kg, values for volume of distribution at steady state were 1.36 and 1.35 L/kg, and bioavailabilities were 10% and 9% for blood and plasma, respectively.",Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424418/),[l] / [h·kg],0.79,231605,DB00091,Cyclosporine
,1424418,volume of distribution at steady state,"Post-rifampin phase clearances of cyclosporine were 0.42 and 0.79 L/hr/kg, values for volume of distribution at steady state were 1.36 and 1.35 L/kg, and bioavailabilities were 10% and 9% for blood and plasma, respectively.",Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424418/),[l] / [kg],1.36,231606,DB00091,Cyclosporine
,1424418,volume of distribution at steady state,"Post-rifampin phase clearances of cyclosporine were 0.42 and 0.79 L/hr/kg, values for volume of distribution at steady state were 1.36 and 1.35 L/kg, and bioavailabilities were 10% and 9% for blood and plasma, respectively.",Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424418/),[l] / [kg],1.35,231607,DB00091,Cyclosporine
,1424418,bioavailabilities,"Post-rifampin phase clearances of cyclosporine were 0.42 and 0.79 L/hr/kg, values for volume of distribution at steady state were 1.36 and 1.35 L/kg, and bioavailabilities were 10% and 9% for blood and plasma, respectively.",Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424418/),%,10,231608,DB00091,Cyclosporine
,1424418,bioavailabilities,"Post-rifampin phase clearances of cyclosporine were 0.42 and 0.79 L/hr/kg, values for volume of distribution at steady state were 1.36 and 1.35 L/kg, and bioavailabilities were 10% and 9% for blood and plasma, respectively.",Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1424418/),%,9,231609,DB00091,Cyclosporine
,12520626,AUCs,"Pre-tx AUCs (14,540 +/- 5200 micrograms.h/L) were found to be significantly higher than during the post-tx phase (8120 +/- 2870 micrograms.h/L, p = 0.04).",Pharmacokinetics of cyclosporine pre- and post-liver transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520626/),[h·μg] / [l],"14,540",232254,DB00091,Cyclosporine
,12520626,AUCs,"Pre-tx AUCs (14,540 +/- 5200 micrograms.h/L) were found to be significantly higher than during the post-tx phase (8120 +/- 2870 micrograms.h/L, p = 0.04).",Pharmacokinetics of cyclosporine pre- and post-liver transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520626/),[h·μg] / [l],8120,232255,DB00091,Cyclosporine
,12520626,clearance,"CyA clearance values were lower pre-tx as compared to post-tx (0.21 +/- 0.06 L/h/kg vs. 0.38 +/- 0.14 L/h/kg, respectively).",Pharmacokinetics of cyclosporine pre- and post-liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520626/),[l] / [h·kg],0.21,232256,DB00091,Cyclosporine
,12520626,clearance,"CyA clearance values were lower pre-tx as compared to post-tx (0.21 +/- 0.06 L/h/kg vs. 0.38 +/- 0.14 L/h/kg, respectively).",Pharmacokinetics of cyclosporine pre- and post-liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520626/),[l] / [h·kg],0.38,232257,DB00091,Cyclosporine
,10803762,area under the blood CsA concentration-time curve,"In ARF rats, the area under the blood CsA concentration-time curve after oral administration was significantly decreased in comparison with that of control rats; 5.81 +/- 0.55 vs 11.30 +/- 1.59 mg h mL(-1)(mean+/-s.e.m.), respectively, and the relative bioavailabilities in ARF and control rats after oral administration were 15.2% and 43.4%, respectively.",Factors that affect absorption behavior of cyclosporin a in gentamicin-induced acute renal failure in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10803762/),[h·mg] / [ml],5.81,232760,DB00091,Cyclosporine
,10803762,area under the blood CsA concentration-time curve,"In ARF rats, the area under the blood CsA concentration-time curve after oral administration was significantly decreased in comparison with that of control rats; 5.81 +/- 0.55 vs 11.30 +/- 1.59 mg h mL(-1)(mean+/-s.e.m.), respectively, and the relative bioavailabilities in ARF and control rats after oral administration were 15.2% and 43.4%, respectively.",Factors that affect absorption behavior of cyclosporin a in gentamicin-induced acute renal failure in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10803762/),[h·mg] / [ml],11.30,232761,DB00091,Cyclosporine
,10803762,relative bioavailabilities,"In ARF rats, the area under the blood CsA concentration-time curve after oral administration was significantly decreased in comparison with that of control rats; 5.81 +/- 0.55 vs 11.30 +/- 1.59 mg h mL(-1)(mean+/-s.e.m.), respectively, and the relative bioavailabilities in ARF and control rats after oral administration were 15.2% and 43.4%, respectively.",Factors that affect absorption behavior of cyclosporin a in gentamicin-induced acute renal failure in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10803762/),%,15.2,232762,DB00091,Cyclosporine
,10803762,relative bioavailabilities,"In ARF rats, the area under the blood CsA concentration-time curve after oral administration was significantly decreased in comparison with that of control rats; 5.81 +/- 0.55 vs 11.30 +/- 1.59 mg h mL(-1)(mean+/-s.e.m.), respectively, and the relative bioavailabilities in ARF and control rats after oral administration were 15.2% and 43.4%, respectively.",Factors that affect absorption behavior of cyclosporin a in gentamicin-induced acute renal failure in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10803762/),%,43.4,232763,DB00091,Cyclosporine
,12895195,trough concentrations,"Blood tacrolimus trough concentrations were not affected by cerivastatin (mean +/- SD 8.6 +/- 2.1 ng ml(-1) before, and 8.7 +/- 2.4 ng ml(-1) at day 90 of cerivastatin dosing, with a 95% confidence interval on the difference = 0.97, 1.08).",Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12895195/),[ng] / [ml],8.6,232856,DB00091,Cyclosporine
,12895195,trough concentrations,"Blood tacrolimus trough concentrations were not affected by cerivastatin (mean +/- SD 8.6 +/- 2.1 ng ml(-1) before, and 8.7 +/- 2.4 ng ml(-1) at day 90 of cerivastatin dosing, with a 95% confidence interval on the difference = 0.97, 1.08).",Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12895195/),[ng] / [ml],8.7,232857,DB00091,Cyclosporine
,12895195,"area under the blood concentration-time curve to 24 h (AUC(0,24 h))","The mean area under the blood concentration-time curve to 24 h (AUC(0,24 h)) for cerivastatin was 14.5 +/- 2.53 micro g l(-1) h(-1) at day 1 after starting treatment and 19.02 +/- 3.55 micro g l(-1) h(-1) (3 months later), resulting in a 35% higher (AUC(0,24 h)) compared with the first dose.",Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12895195/),[μg] / [h·l],14.5,232858,DB00091,Cyclosporine
,12895195,"area under the blood concentration-time curve to 24 h (AUC(0,24 h))","The mean area under the blood concentration-time curve to 24 h (AUC(0,24 h)) for cerivastatin was 14.5 +/- 2.53 micro g l(-1) h(-1) at day 1 after starting treatment and 19.02 +/- 3.55 micro g l(-1) h(-1) (3 months later), resulting in a 35% higher (AUC(0,24 h)) compared with the first dose.",Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12895195/),[μg] / [h·l],19.02,232859,DB00091,Cyclosporine
,2859158,fp,"In the rabbit, fp was estimated to equal 0.405.",The pharmacokinetics of cyclosporine. Blood plasma distribution and binding studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859158/),,0.405,233089,DB00091,Cyclosporine
,2859158,capacity factor,The capacity factor and the binding affinity constant of the drug for blood cells were estimated to equal 3590 micrograms/liter and 0.00682 liter/microgram in the rabbit.,The pharmacokinetics of cyclosporine. Blood plasma distribution and binding studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859158/),[μg] / [l],3590,233090,DB00091,Cyclosporine
,2859158,binding affinity constant,The capacity factor and the binding affinity constant of the drug for blood cells were estimated to equal 3590 micrograms/liter and 0.00682 liter/microgram in the rabbit.,The pharmacokinetics of cyclosporine. Blood plasma distribution and binding studies. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859158/),[l] / [μg],0.00682,233091,DB00091,Cyclosporine
,9642517,C0,"After the first visit, patients were randomized to Group I (C0: 100-200 ng/ml) or Group II (C2: 200-400 ng/ml).",Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9642517/),[ng] / [ml],100-200,233140,DB00091,Cyclosporine
,9642517,C2,"After the first visit, patients were randomized to Group I (C0: 100-200 ng/ml) or Group II (C2: 200-400 ng/ml).",Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9642517/),[ng] / [ml],200-400,233141,DB00091,Cyclosporine
,9642517,C2 levels,"C2 levels decreased in Group II from 912 +/- 438 to 555 +/- 271 ng/ml (p = 0.01), without evidence of acute rejection on endomyocardial biopsies.",Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9642517/),[ng] / [ml],912,233142,DB00091,Cyclosporine
,9642517,C2 levels,"C2 levels decreased in Group II from 912 +/- 438 to 555 +/- 271 ng/ml (p = 0.01), without evidence of acute rejection on endomyocardial biopsies.",Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9642517/),[ng] / [ml],555,233143,DB00091,Cyclosporine
,28967706,t½,"Letermovir increased CsA and TAC Cmax by 37% and 70%, respectively, and exposure by 70% and 78%, respectively, compared with immunosuppressant alone; t½ was also increased from 10.7 to 17.9 hours for CsA.",Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28967706/),h,10.7,233243,DB00091,Cyclosporine
,28967706,t½,"Letermovir increased CsA and TAC Cmax by 37% and 70%, respectively, and exposure by 70% and 78%, respectively, compared with immunosuppressant alone; t½ was also increased from 10.7 to 17.9 hours for CsA.",Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28967706/),h,17.9,233244,DB00091,Cyclosporine
,28967706,t½,"CsA (50/200 mg) increased letermovir Cmax,ss (109%/167%) and AUCss,τ (126%/237%) and decreased t½ (4.33 to 3.68/3.04 hours) versus letermovir alone.",Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28967706/),h,4.33,233245,DB00091,Cyclosporine
,28967706,t½,"CsA (50/200 mg) increased letermovir Cmax,ss (109%/167%) and AUCss,τ (126%/237%) and decreased t½ (4.33 to 3.68/3.04 hours) versus letermovir alone.",Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28967706/),h,3.68,233246,DB00091,Cyclosporine
,28967706,t½,"CsA (50/200 mg) increased letermovir Cmax,ss (109%/167%) and AUCss,τ (126%/237%) and decreased t½ (4.33 to 3.68/3.04 hours) versus letermovir alone.",Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28967706/),h,3.04,233247,DB00091,Cyclosporine
,25358107,trough concentrations,"On D 14, in the three treated groups, CsA trough concentrations were 687 ± 7, 1200 ± 77 and 2211 ± 1030 ng/ml, respectively; AUC (0-10 h) were 6721 ± 51 ng·h/ml in group 4 mg/kg/d, 13431 ± 988 ng·h/ml in group 8 mg/kg/d and 28264 ± 9430 ng·h/ml in group 12 mg/kg/d.",Oral cyclosporine A in neonatal swines for transplantation studies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25358107/),[ng] / [ml],687,233416,DB00091,Cyclosporine
,25358107,trough concentrations,"On D 14, in the three treated groups, CsA trough concentrations were 687 ± 7, 1200 ± 77 and 2211 ± 1030 ng/ml, respectively; AUC (0-10 h) were 6721 ± 51 ng·h/ml in group 4 mg/kg/d, 13431 ± 988 ng·h/ml in group 8 mg/kg/d and 28264 ± 9430 ng·h/ml in group 12 mg/kg/d.",Oral cyclosporine A in neonatal swines for transplantation studies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25358107/),[ng] / [ml],1200,233417,DB00091,Cyclosporine
,25358107,trough concentrations,"On D 14, in the three treated groups, CsA trough concentrations were 687 ± 7, 1200 ± 77 and 2211 ± 1030 ng/ml, respectively; AUC (0-10 h) were 6721 ± 51 ng·h/ml in group 4 mg/kg/d, 13431 ± 988 ng·h/ml in group 8 mg/kg/d and 28264 ± 9430 ng·h/ml in group 12 mg/kg/d.",Oral cyclosporine A in neonatal swines for transplantation studies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25358107/),[ng] / [ml],2211,233418,DB00091,Cyclosporine
,25358107,AUC (0-10 h),"On D 14, in the three treated groups, CsA trough concentrations were 687 ± 7, 1200 ± 77 and 2211 ± 1030 ng/ml, respectively; AUC (0-10 h) were 6721 ± 51 ng·h/ml in group 4 mg/kg/d, 13431 ± 988 ng·h/ml in group 8 mg/kg/d and 28264 ± 9430 ng·h/ml in group 12 mg/kg/d.",Oral cyclosporine A in neonatal swines for transplantation studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25358107/),[h·ng] / [ml],6721,233419,DB00091,Cyclosporine
,25358107,AUC (0-10 h),"On D 14, in the three treated groups, CsA trough concentrations were 687 ± 7, 1200 ± 77 and 2211 ± 1030 ng/ml, respectively; AUC (0-10 h) were 6721 ± 51 ng·h/ml in group 4 mg/kg/d, 13431 ± 988 ng·h/ml in group 8 mg/kg/d and 28264 ± 9430 ng·h/ml in group 12 mg/kg/d.",Oral cyclosporine A in neonatal swines for transplantation studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25358107/),[h·ng] / [ml],13431,233420,DB00091,Cyclosporine
,25358107,AUC (0-10 h),"On D 14, in the three treated groups, CsA trough concentrations were 687 ± 7, 1200 ± 77 and 2211 ± 1030 ng/ml, respectively; AUC (0-10 h) were 6721 ± 51 ng·h/ml in group 4 mg/kg/d, 13431 ± 988 ng·h/ml in group 8 mg/kg/d and 28264 ± 9430 ng·h/ml in group 12 mg/kg/d.",Oral cyclosporine A in neonatal swines for transplantation studies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25358107/),[h·ng] / [ml],28264,233421,DB00091,Cyclosporine
,25358107,trough blood concentration,"As immunosuppressive therapy in newborn pigs, we recommend a CsA dose of 4 mg/kg/d to achieve a trough blood concentration between 400 and 800 ng/ml.",Oral cyclosporine A in neonatal swines for transplantation studies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25358107/),[ng] / [ml],400 and 800,233422,DB00091,Cyclosporine
,12826141,C0,"The paired values at each point pre- and posttransplant were: C0 = 171 +/- 63 and 215 +/- 112, C1 = 723.86 +/- 345 and 1239.95 +/- 415, C2 = 972 +/- 185 and 1249.95 +/- 336, C3 = 822 +/- 242 and 942.7 +/- 286, and C4 = 601.54 +/- 190 and 670.5 +/- 208 ng/mL respectively.",Pre- and postrenal transplantation pharmacokinetics of cyclosporine microemulsion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12826141/),,171,233655,DB00091,Cyclosporine
,12826141,C0,"The paired values at each point pre- and posttransplant were: C0 = 171 +/- 63 and 215 +/- 112, C1 = 723.86 +/- 345 and 1239.95 +/- 415, C2 = 972 +/- 185 and 1249.95 +/- 336, C3 = 822 +/- 242 and 942.7 +/- 286, and C4 = 601.54 +/- 190 and 670.5 +/- 208 ng/mL respectively.",Pre- and postrenal transplantation pharmacokinetics of cyclosporine microemulsion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12826141/),,215,233656,DB00091,Cyclosporine
,12826141,C1,"The paired values at each point pre- and posttransplant were: C0 = 171 +/- 63 and 215 +/- 112, C1 = 723.86 +/- 345 and 1239.95 +/- 415, C2 = 972 +/- 185 and 1249.95 +/- 336, C3 = 822 +/- 242 and 942.7 +/- 286, and C4 = 601.54 +/- 190 and 670.5 +/- 208 ng/mL respectively.",Pre- and postrenal transplantation pharmacokinetics of cyclosporine microemulsion. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12826141/),,723.86,233657,DB00091,Cyclosporine
,12826141,C1,"The paired values at each point pre- and posttransplant were: C0 = 171 +/- 63 and 215 +/- 112, C1 = 723.86 +/- 345 and 1239.95 +/- 415, C2 = 972 +/- 185 and 1249.95 +/- 336, C3 = 822 +/- 242 and 942.7 +/- 286, and C4 = 601.54 +/- 190 and 670.5 +/- 208 ng/mL respectively.",Pre- and postrenal transplantation pharmacokinetics of cyclosporine microemulsion. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12826141/),,1239.95,233658,DB00091,Cyclosporine
,12826141,C2,"The paired values at each point pre- and posttransplant were: C0 = 171 +/- 63 and 215 +/- 112, C1 = 723.86 +/- 345 and 1239.95 +/- 415, C2 = 972 +/- 185 and 1249.95 +/- 336, C3 = 822 +/- 242 and 942.7 +/- 286, and C4 = 601.54 +/- 190 and 670.5 +/- 208 ng/mL respectively.",Pre- and postrenal transplantation pharmacokinetics of cyclosporine microemulsion. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12826141/),,972,233659,DB00091,Cyclosporine
,12826141,C2,"The paired values at each point pre- and posttransplant were: C0 = 171 +/- 63 and 215 +/- 112, C1 = 723.86 +/- 345 and 1239.95 +/- 415, C2 = 972 +/- 185 and 1249.95 +/- 336, C3 = 822 +/- 242 and 942.7 +/- 286, and C4 = 601.54 +/- 190 and 670.5 +/- 208 ng/mL respectively.",Pre- and postrenal transplantation pharmacokinetics of cyclosporine microemulsion. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12826141/),,1249.95,233660,DB00091,Cyclosporine
,12826141,C3,"The paired values at each point pre- and posttransplant were: C0 = 171 +/- 63 and 215 +/- 112, C1 = 723.86 +/- 345 and 1239.95 +/- 415, C2 = 972 +/- 185 and 1249.95 +/- 336, C3 = 822 +/- 242 and 942.7 +/- 286, and C4 = 601.54 +/- 190 and 670.5 +/- 208 ng/mL respectively.",Pre- and postrenal transplantation pharmacokinetics of cyclosporine microemulsion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12826141/),,822,233661,DB00091,Cyclosporine
,12826141,C3,"The paired values at each point pre- and posttransplant were: C0 = 171 +/- 63 and 215 +/- 112, C1 = 723.86 +/- 345 and 1239.95 +/- 415, C2 = 972 +/- 185 and 1249.95 +/- 336, C3 = 822 +/- 242 and 942.7 +/- 286, and C4 = 601.54 +/- 190 and 670.5 +/- 208 ng/mL respectively.",Pre- and postrenal transplantation pharmacokinetics of cyclosporine microemulsion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12826141/),,942.7,233662,DB00091,Cyclosporine
,12826141,C4,"The paired values at each point pre- and posttransplant were: C0 = 171 +/- 63 and 215 +/- 112, C1 = 723.86 +/- 345 and 1239.95 +/- 415, C2 = 972 +/- 185 and 1249.95 +/- 336, C3 = 822 +/- 242 and 942.7 +/- 286, and C4 = 601.54 +/- 190 and 670.5 +/- 208 ng/mL respectively.",Pre- and postrenal transplantation pharmacokinetics of cyclosporine microemulsion. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12826141/),[ng] / [ml],601.54,233663,DB00091,Cyclosporine
,12826141,C4,"The paired values at each point pre- and posttransplant were: C0 = 171 +/- 63 and 215 +/- 112, C1 = 723.86 +/- 345 and 1239.95 +/- 415, C2 = 972 +/- 185 and 1249.95 +/- 336, C3 = 822 +/- 242 and 942.7 +/- 286, and C4 = 601.54 +/- 190 and 670.5 +/- 208 ng/mL respectively.",Pre- and postrenal transplantation pharmacokinetics of cyclosporine microemulsion. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12826141/),[ng] / [ml],670.5,233664,DB00091,Cyclosporine
,23018254,dose,The mean cyclosporine dose-adjusted trough blood concentrations (ng/ml per mg/kg body weight) in CYP3A4*1/*1B subjects were lower than in the CYP3A4*1/*1 group (37.06±10.38 vs. 44.63±13.99; p<0.218).,Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018254/),[ng] / [kg·mg·ml],37.06,233701,DB00091,Cyclosporine
,23018254,trough blood concentrations,The mean cyclosporine dose-adjusted trough blood concentrations (ng/ml per mg/kg body weight) in CYP3A4*1/*1B subjects were lower than in the CYP3A4*1/*1 group (37.06±10.38 vs. 44.63±13.99; p<0.218).,Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018254/),[ng] / [kg·mg·ml],37.06,233702,DB00091,Cyclosporine
,23018254,trough blood concentrations,The mean cyclosporine dose-adjusted trough blood concentrations (ng/ml per mg/kg body weight) in CYP3A4*1/*1B subjects were lower than in the CYP3A4*1/*1 group (37.06±10.38 vs. 44.63±13.99; p<0.218).,Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018254/),[ng] / [kg·mg·ml],44.63,233703,DB00091,Cyclosporine
,32393425,IC50,"In the liver microsome incubation system, the IC50 of CsA for UGT1A1 enzyme was 9.4 μM.",Effects of cyclosporin A on the pharmacokinetics and toxicities of irinotecan mediated by UGT1A1 in vitro and in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32393425/),μM,9.4,235530,DB00091,Cyclosporine
,17889129,C0,"Mean predose levels of AcMPAG-C0 and AcMPAG-AUC(0-12h) were much higher in group II than in group I (0.5 +/- 2 vs 1.6 +/- 1 microg/mL and 12 +/- 2 vs. 32 +/- 19 microg*h/mL respectively, P < .005).",Influence of renal insufficiency on pharmacokinetics of ACYL-glucuronide metabolite of mycophenolic acid in renal transplant patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17889129/),[μg] / [ml],0.5,235561,DB00091,Cyclosporine
,17889129,C0,"Mean predose levels of AcMPAG-C0 and AcMPAG-AUC(0-12h) were much higher in group II than in group I (0.5 +/- 2 vs 1.6 +/- 1 microg/mL and 12 +/- 2 vs. 32 +/- 19 microg*h/mL respectively, P < .005).",Influence of renal insufficiency on pharmacokinetics of ACYL-glucuronide metabolite of mycophenolic acid in renal transplant patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17889129/),[μg] / [ml],1.6,235562,DB00091,Cyclosporine
,17889129,AUC(0-12h),"Mean predose levels of AcMPAG-C0 and AcMPAG-AUC(0-12h) were much higher in group II than in group I (0.5 +/- 2 vs 1.6 +/- 1 microg/mL and 12 +/- 2 vs. 32 +/- 19 microg*h/mL respectively, P < .005).",Influence of renal insufficiency on pharmacokinetics of ACYL-glucuronide metabolite of mycophenolic acid in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17889129/),[h·μg] / [ml],12,235563,DB00091,Cyclosporine
,17889129,AUC(0-12h),"Mean predose levels of AcMPAG-C0 and AcMPAG-AUC(0-12h) were much higher in group II than in group I (0.5 +/- 2 vs 1.6 +/- 1 microg/mL and 12 +/- 2 vs. 32 +/- 19 microg*h/mL respectively, P < .005).",Influence of renal insufficiency on pharmacokinetics of ACYL-glucuronide metabolite of mycophenolic acid in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17889129/),[h·μg] / [ml],32,235564,DB00091,Cyclosporine
,25488594,Absolute bioavailability,"Absolute bioavailability of danoprevir 100 mg was low (1.15%), but increased more than threefold (3.86%) when co-administered with ritonavir.",Characterization of the transmembrane transport and absolute bioavailability of the HCV protease inhibitor danoprevir. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25488594/),%,1.15,235618,DB00091,Cyclosporine
,25488594,Absolute bioavailability,"Absolute bioavailability of danoprevir 100 mg was low (1.15%), but increased more than threefold (3.86%) when co-administered with ritonavir.",Characterization of the transmembrane transport and absolute bioavailability of the HCV protease inhibitor danoprevir. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25488594/),%,3.86,235619,DB00091,Cyclosporine
>,16998264,C2,"Mean C2 values >1,000 ng/ml were obtained in patients with no rejection at 1 month and 12 months after transplantation; however, renal impairment may occur.",Pharmacokinetic study and limited sampling strategy of cyclosporine in Japanese heart transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16998264/),[ng] / [ml],"1,000",235759,DB00091,Cyclosporine
,24783515,polydispersity index,"The results showed that the obtained formulation has a small particle size (mean diameter of 100.2 +/- 15.2 nm), a homogeneous distribution [the polydispersity index was (0.251 +/- 0.018)] and high encapsulation efficiency (90.15 +/- 2.47) % and (80.64 +/- 3.52) % for paclitaxel and cyclosporine respectively with a mild and easy preparation process.",[Co-delivery of paclitaxel and cyclosporine by a novel liposome-silica hybrid nano-carrier for anti-tumor therapy via oral route]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24783515/),,0.251,236571,DB00091,Cyclosporine
,24783515,encapsulation efficiency,"The results showed that the obtained formulation has a small particle size (mean diameter of 100.2 +/- 15.2 nm), a homogeneous distribution [the polydispersity index was (0.251 +/- 0.018)] and high encapsulation efficiency (90.15 +/- 2.47) % and (80.64 +/- 3.52) % for paclitaxel and cyclosporine respectively with a mild and easy preparation process.",[Co-delivery of paclitaxel and cyclosporine by a novel liposome-silica hybrid nano-carrier for anti-tumor therapy via oral route]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24783515/),%,90.15,236572,DB00091,Cyclosporine
,24783515,encapsulation efficiency,"The results showed that the obtained formulation has a small particle size (mean diameter of 100.2 +/- 15.2 nm), a homogeneous distribution [the polydispersity index was (0.251 +/- 0.018)] and high encapsulation efficiency (90.15 +/- 2.47) % and (80.64 +/- 3.52) % for paclitaxel and cyclosporine respectively with a mild and easy preparation process.",[Co-delivery of paclitaxel and cyclosporine by a novel liposome-silica hybrid nano-carrier for anti-tumor therapy via oral route]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24783515/),%,80.64,236573,DB00091,Cyclosporine
,12913261,cumulative,The parameters of renal function tests reached peak levels at the cumulative dose of 4000 to 10000 mg and at the cumulative AUC of 280000 to 660000 ng/ml.h.,Relationship between development of nephrotoxicity and blood concentration of cyclosporine A in bone-marrow transplanted recipients who received the continuous intravenous infusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12913261/),[ng] / [h·ml],280000 to 660000,236725,DB00091,Cyclosporine
,12913261,AUC,The parameters of renal function tests reached peak levels at the cumulative dose of 4000 to 10000 mg and at the cumulative AUC of 280000 to 660000 ng/ml.h.,Relationship between development of nephrotoxicity and blood concentration of cyclosporine A in bone-marrow transplanted recipients who received the continuous intravenous infusion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12913261/),[ng] / [h·ml],280000 to 660000,236726,DB00091,Cyclosporine
less,16321615,area under the curve (AUC) from 0 to 6 hours,Subjects with an unbound MPA area under the curve (AUC) from 0 to 6 hours of less than 150 ng .,Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16321615/),ng,150,237129,DB00091,Cyclosporine
less,16321615,unbound AUC from 0 to 12 hours,"An unbound AUC from 0 to 12 hours of less than 300 ng . h/mL was also associated with more frequent acute graft versus host disease (58% versus 35%, P = .05).",Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16321615/),[h·ng] / [ml],300,237130,DB00091,Cyclosporine
,16321615,unbound AUC from 0 to 12 hours,"An unbound AUC from 0 to 12 hours of less than 300 ng . h/mL was also associated with more frequent acute graft versus host disease (58% versus 35%, P = .05).",Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16321615/),,35,237131,DB00091,Cyclosporine
greater,16321615,trough concentrations,A higher cumulative incidence of engraftment was associated with total MPA trough concentrations greater than 1 microg/mL (P < .01).,Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16321615/),[μg] / [ml],1,237132,DB00091,Cyclosporine
,20683390,steady-state predose blood concentrations,"Using a validated liquid chromatography method with tandem mass spectrometry, steady-state predose blood concentrations averaged approximately 600 and 900 ng/mL at these dose levels, respectively.",Overview of sotrastaurin clinical pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20683390/),[ng] / [ml],600,237179,DB00091,Cyclosporine
,20683390,steady-state predose blood concentrations,"Using a validated liquid chromatography method with tandem mass spectrometry, steady-state predose blood concentrations averaged approximately 600 and 900 ng/mL at these dose levels, respectively.",Overview of sotrastaurin clinical pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20683390/),[ng] / [ml],900,237180,DB00091,Cyclosporine
,20683390,elimination half-life,The elimination half-life of sotrastaurin averages 6 hours.,Overview of sotrastaurin clinical pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20683390/),h,6,237181,DB00091,Cyclosporine
,10440386,AUC,"In the whole lung, the AUC was greater for the aerosol route at 25 mg/kg doses (588 ng x hr/mg) than for the low-dose (200 ng x hr/mg) or IM administration (200 ng x hr/mg).",Nebulized cyclosporine in the rat: assessment of regional lung and extrapulmonary deposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440386/),[h·ng] / [mg],588,237248,DB00091,Cyclosporine
,10440386,AUC,"In the whole lung, the AUC was greater for the aerosol route at 25 mg/kg doses (588 ng x hr/mg) than for the low-dose (200 ng x hr/mg) or IM administration (200 ng x hr/mg).",Nebulized cyclosporine in the rat: assessment of regional lung and extrapulmonary deposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440386/),,200,237249,DB00091,Cyclosporine
,17399839,relative bioavailability,The relative bioavailability of nanoparticulate formulation was found to be 119.2% as compared to Sandimmune Neoral.,PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17399839/),%,119.2,237537,DB00091,Cyclosporine
,16513536,blood trough level,The CsA dose was adjusted to maintain the blood trough level between 150 and 200 ng/mL.,"Single-dose daily infusion of cyclosporine for prevention of Graft-versus-host disease after allogeneic bone marrow transplantation from HLA allele-matched, unrelated donors. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16513536/),[ng] / [ml],150 and 200,237577,DB00091,Cyclosporine
,16513536,trough concentration,"The mean trough concentration, mean peak concentration, mean time to peak concentration, and area under the curve (24 hours) were 161 +/- 43 ng/mL, 1498 +/- 387 ng/mL, 3.2 +/- 1.0 hours, and 10,848 +/- 1,991 ng +/- h/mL, respectively.","Single-dose daily infusion of cyclosporine for prevention of Graft-versus-host disease after allogeneic bone marrow transplantation from HLA allele-matched, unrelated donors. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16513536/),[ng] / [ml],161,237578,DB00091,Cyclosporine
,16513536,peak concentration,"The mean trough concentration, mean peak concentration, mean time to peak concentration, and area under the curve (24 hours) were 161 +/- 43 ng/mL, 1498 +/- 387 ng/mL, 3.2 +/- 1.0 hours, and 10,848 +/- 1,991 ng +/- h/mL, respectively.","Single-dose daily infusion of cyclosporine for prevention of Graft-versus-host disease after allogeneic bone marrow transplantation from HLA allele-matched, unrelated donors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16513536/),[ng] / [ml],1498,237579,DB00091,Cyclosporine
,16513536,peak concentration,"The mean trough concentration, mean peak concentration, mean time to peak concentration, and area under the curve (24 hours) were 161 +/- 43 ng/mL, 1498 +/- 387 ng/mL, 3.2 +/- 1.0 hours, and 10,848 +/- 1,991 ng +/- h/mL, respectively.","Single-dose daily infusion of cyclosporine for prevention of Graft-versus-host disease after allogeneic bone marrow transplantation from HLA allele-matched, unrelated donors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16513536/),h,3.2,237580,DB00091,Cyclosporine
,16513536,area under the curve (24 hours),"The mean trough concentration, mean peak concentration, mean time to peak concentration, and area under the curve (24 hours) were 161 +/- 43 ng/mL, 1498 +/- 387 ng/mL, 3.2 +/- 1.0 hours, and 10,848 +/- 1,991 ng +/- h/mL, respectively.","Single-dose daily infusion of cyclosporine for prevention of Graft-versus-host disease after allogeneic bone marrow transplantation from HLA allele-matched, unrelated donors. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16513536/),[+·ng] / [-·h·ml],"10,848",237581,DB00091,Cyclosporine
,27085046,Entrapment efficiency,"Entrapment efficiency of pro-G-BLs remains as high as 83.7%, in sharp contrast with 66.7% for pro-BLs.",Readily restoring freeze-dried probilosomes as potential nanocarriers for enhancing oral delivery of cyclosporine A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27085046/),%,83.7,237751,DB00091,Cyclosporine
,27085046,Entrapment efficiency,"Entrapment efficiency of pro-G-BLs remains as high as 83.7%, in sharp contrast with 66.7% for pro-BLs.",Readily restoring freeze-dried probilosomes as potential nanocarriers for enhancing oral delivery of cyclosporine A. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27085046/),%,66.7,237752,DB00091,Cyclosporine
,27085046,relative oral bioavailability,"The relative oral bioavailability of CyA-loaded pro-G-BLs, pro-BLs and G-BLs was 165.2%, 123.5% and 130.1%, respectively, with Neoral(®) as the reference.",Readily restoring freeze-dried probilosomes as potential nanocarriers for enhancing oral delivery of cyclosporine A. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27085046/),%,165.2,237753,DB00091,Cyclosporine
,27085046,relative oral bioavailability,"The relative oral bioavailability of CyA-loaded pro-G-BLs, pro-BLs and G-BLs was 165.2%, 123.5% and 130.1%, respectively, with Neoral(®) as the reference.",Readily restoring freeze-dried probilosomes as potential nanocarriers for enhancing oral delivery of cyclosporine A. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27085046/),%,123.5,237754,DB00091,Cyclosporine
,27085046,relative oral bioavailability,"The relative oral bioavailability of CyA-loaded pro-G-BLs, pro-BLs and G-BLs was 165.2%, 123.5% and 130.1%, respectively, with Neoral(®) as the reference.",Readily restoring freeze-dried probilosomes as potential nanocarriers for enhancing oral delivery of cyclosporine A. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27085046/),%,130.1,237755,DB00091,Cyclosporine
,10220493,systemic clearance,"After i.v. administration of 1 mg/kg SDZ-RAD or rapamycin, the area under the concentration curve (AUC) for rapamycin was twice that of SDZ-RAD, resulting in a systemic clearance of 6.2 ml/min and 3.0 ml/min for SDZ-RAD and rapamycin, respectively.",Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10220493/),[ml] / [min],6.2,238419,DB00091,Cyclosporine
,10220493,systemic clearance,"After i.v. administration of 1 mg/kg SDZ-RAD or rapamycin, the area under the concentration curve (AUC) for rapamycin was twice that of SDZ-RAD, resulting in a systemic clearance of 6.2 ml/min and 3.0 ml/min for SDZ-RAD and rapamycin, respectively.",Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10220493/),[ml] / [min],3.0,238420,DB00091,Cyclosporine
,10220493,AUC for oral absorption,"However, the AUC for oral absorption was similar for the two compounds: 140 and 172 ng*h/ml for SDZ-RAD and rapamycin, respectively.",Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10220493/),[h·ng] / [ml],140,238421,DB00091,Cyclosporine
,10220493,AUC for oral absorption,"However, the AUC for oral absorption was similar for the two compounds: 140 and 172 ng*h/ml for SDZ-RAD and rapamycin, respectively.",Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10220493/),[h·ng] / [ml],172,238422,DB00091,Cyclosporine
,10220493,absolute oral bioavailability,"Because blood clearance was faster for SDZ-RAD after i.v. administration, the absolute oral bioavailability for SDZ-RAD was 16% compared with 10% for rapamycin.",Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10220493/),%,16,238423,DB00091,Cyclosporine
,10220493,absolute oral bioavailability,"Because blood clearance was faster for SDZ-RAD after i.v. administration, the absolute oral bioavailability for SDZ-RAD was 16% compared with 10% for rapamycin.",Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10220493/),%,10,238424,DB00091,Cyclosporine
,16359376,C2,"The acute rejection rate was lower (19% vs. 43%; P < 0.05) in patients achieving CsA C2 target range during the first week (1600-2000 microg/l), n = 26, compared with those who did not, n = 42.",Mycophenolic acid clinical pharmacokinetics influenced by a cyclosporine C2 based immunosuppressive regimen in renal allograft recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16359376/),[μg] / [l],1600-2000,239046,DB00091,Cyclosporine
,16364860,C2,"Based on their average C2 levels in the first post-transplant month, patients were stratified retrospectively into Low C2 (<1,000 microg/liter, n = 18), Intermediate C2 (1,000-1,500 microg/liter, n = 16) and High C2 (>1,500 microg/liter, n = 14) Groups.",Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16364860/),[μg] / [l],"1,000-1,500",239786,DB00091,Cyclosporine
,16364860,C2,"The mean +/- SD values of CsA C2 and AUC(0 to 6 hours) in the first year post-transplant were significantly lower in patients with >2 rejection episodes compared with those with < or =2 rejection episodes (C2: 875 +/- 546 microg/liter vs 1,114 +/- 633 microg/liter, p = 0.01; AUC(0-6 hours): 4,036 +/- 1,904 microg x hour/liter vs 4,870 +/- 2,182 microg x hour/liter; p = 0.01) whereas C0 and C6 did not differ.",Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16364860/),[μg] / [l],875,239787,DB00091,Cyclosporine
,16364860,C2,"The mean +/- SD values of CsA C2 and AUC(0 to 6 hours) in the first year post-transplant were significantly lower in patients with >2 rejection episodes compared with those with < or =2 rejection episodes (C2: 875 +/- 546 microg/liter vs 1,114 +/- 633 microg/liter, p = 0.01; AUC(0-6 hours): 4,036 +/- 1,904 microg x hour/liter vs 4,870 +/- 2,182 microg x hour/liter; p = 0.01) whereas C0 and C6 did not differ.",Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16364860/),[μg] / [l],"1,114",239788,DB00091,Cyclosporine
,16364860,AUC(0-6 hours),"The mean +/- SD values of CsA C2 and AUC(0 to 6 hours) in the first year post-transplant were significantly lower in patients with >2 rejection episodes compared with those with < or =2 rejection episodes (C2: 875 +/- 546 microg/liter vs 1,114 +/- 633 microg/liter, p = 0.01; AUC(0-6 hours): 4,036 +/- 1,904 microg x hour/liter vs 4,870 +/- 2,182 microg x hour/liter; p = 0.01) whereas C0 and C6 did not differ.",Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16364860/),[h·μg] / [l],"4,036",239789,DB00091,Cyclosporine
,16364860,AUC(0-6 hours),"The mean +/- SD values of CsA C2 and AUC(0 to 6 hours) in the first year post-transplant were significantly lower in patients with >2 rejection episodes compared with those with < or =2 rejection episodes (C2: 875 +/- 546 microg/liter vs 1,114 +/- 633 microg/liter, p = 0.01; AUC(0-6 hours): 4,036 +/- 1,904 microg x hour/liter vs 4,870 +/- 2,182 microg x hour/liter; p = 0.01) whereas C0 and C6 did not differ.",Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16364860/),[h·μg] / [l],"4,870",239790,DB00091,Cyclosporine
,16364860,C2 concentrations,"C2 concentrations between 1,000 and 1,500 microg/liter within the first post-operative month may be associated with better graft outcomes and improved pulmonary function and worsened renal function.",Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16364860/),[μg] / [l],"1,000 and 1,500",239791,DB00091,Cyclosporine
,11264639,clearance,Basiliximab clearance was 29+/-14 mL/h when coadministered with azathioprine and 18+/-8 mL/h with mycophenolate mofetil.,Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),[ml] / [h],29,239826,DB00091,Cyclosporine
,11264639,clearance,Basiliximab clearance was 29+/-14 mL/h when coadministered with azathioprine and 18+/-8 mL/h with mycophenolate mofetil.,Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),[ml] / [h],18,239827,DB00091,Cyclosporine
,11264639,clearance,Both were significantly lower compared with a clearance of 37+/-15 mL/h from a previous study of basiliximab with dual therapy (p<0.001).,Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),[ml] / [h],37,239828,DB00091,Cyclosporine
,11264639,durations,"As a consequence of the lower clearance of basiliximab, the durations of CD25 saturation were prolonged in the presence of azathioprine (50+/-20 d; range, 13--84) and mycophenolate mofetil (59+/-17 d; range, 28--94) compared with dual therapy (36+/-14 d; range, 12--91).",Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),d,50,239829,DB00091,Cyclosporine
,11264639,durations,"As a consequence of the lower clearance of basiliximab, the durations of CD25 saturation were prolonged in the presence of azathioprine (50+/-20 d; range, 13--84) and mycophenolate mofetil (59+/-17 d; range, 28--94) compared with dual therapy (36+/-14 d; range, 12--91).",Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),d,59,239830,DB00091,Cyclosporine
,11264639,durations,"As a consequence of the lower clearance of basiliximab, the durations of CD25 saturation were prolonged in the presence of azathioprine (50+/-20 d; range, 13--84) and mycophenolate mofetil (59+/-17 d; range, 28--94) compared with dual therapy (36+/-14 d; range, 12--91).",Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),d,36,239831,DB00091,Cyclosporine
,11264639,saturation,"As a consequence of the lower clearance of basiliximab, the durations of CD25 saturation were prolonged in the presence of azathioprine (50+/-20 d; range, 13--84) and mycophenolate mofetil (59+/-17 d; range, 28--94) compared with dual therapy (36+/-14 d; range, 12--91).",Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),d,50,239832,DB00091,Cyclosporine
,11264639,saturation,"As a consequence of the lower clearance of basiliximab, the durations of CD25 saturation were prolonged in the presence of azathioprine (50+/-20 d; range, 13--84) and mycophenolate mofetil (59+/-17 d; range, 28--94) compared with dual therapy (36+/-14 d; range, 12--91).",Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),d,59,239833,DB00091,Cyclosporine
,11264639,saturation,"As a consequence of the lower clearance of basiliximab, the durations of CD25 saturation were prolonged in the presence of azathioprine (50+/-20 d; range, 13--84) and mycophenolate mofetil (59+/-17 d; range, 28--94) compared with dual therapy (36+/-14 d; range, 12--91).",Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),d,36,239834,DB00091,Cyclosporine
,14561988,Trough blood concentration (TBC),"Trough blood concentration (TBC) during the first 2 weeks post transplantation was lower in children who developed grade II-IV aGVHD than those developing no GVHD or only grade I (57+/-9 vs 94+/-8 ng/ml, P=0.007), whereas peak blood concentration and area under concentration curve vs time were similar in both groups.",Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14561988/),[ng] / [ml],57,240082,DB00091,Cyclosporine
,14561988,Trough blood concentration (TBC),"Trough blood concentration (TBC) during the first 2 weeks post transplantation was lower in children who developed grade II-IV aGVHD than those developing no GVHD or only grade I (57+/-9 vs 94+/-8 ng/ml, P=0.007), whereas peak blood concentration and area under concentration curve vs time were similar in both groups.",Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14561988/),[ng] / [ml],94,240083,DB00091,Cyclosporine
,14629289,Cmin,Everolimus Cmin averaged 9-11 ng/mL in the immediate cyclosporine group over the first 3 months.,Influence of delayed initiation of cyclosporine on everolimus pharmacokinetics in de novo renal transplant patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14629289/),[ng] / [ml],9-11,240928,DB00091,Cyclosporine
,14629289,Cmins,"In the delayed cyclosporine group, average everolimus Cmins were significantly lower by 2.9-fold in the absence vs. presence of cyclosporine: 2.9 +/- 2.8 vs. 8.3 +/- 3.7 ng/mL (p < 0.001).",Influence of delayed initiation of cyclosporine on everolimus pharmacokinetics in de novo renal transplant patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14629289/),[ng] / [ml],2.9,240929,DB00091,Cyclosporine
,14629289,Cmins,"In the delayed cyclosporine group, average everolimus Cmins were significantly lower by 2.9-fold in the absence vs. presence of cyclosporine: 2.9 +/- 2.8 vs. 8.3 +/- 3.7 ng/mL (p < 0.001).",Influence of delayed initiation of cyclosporine on everolimus pharmacokinetics in de novo renal transplant patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14629289/),[ng] / [ml],8.3,240930,DB00091,Cyclosporine
,12595513,trough,Lowering CsA to low target CsA trough (30 to 70 ng/ml) never led to acute rejection or major renal function deterioration.,Renal transplantation: can we reduce calcineurin inhibitor/stop steroids? Evidence based on protocol biopsy findings. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12595513/),[ng] / [ml],30 to 70,240980,DB00091,Cyclosporine
,16198658,IC50,"In vitro, cyclosporine inhibited the formation of M1 (IC50 [concentration of inhibitor to cause 50% inhibition of original enzyme activity], 0.2 micromol/L) and M2 (IC50, 4.3 micromol/L) but had no effect on M4.",Cyclosporine markedly raises the plasma concentrations of repaglinide. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16198658/),[μM] / [l],0.2,241315,DB00091,Cyclosporine
,16198658,IC50,"In vitro, cyclosporine inhibited the formation of M1 (IC50 [concentration of inhibitor to cause 50% inhibition of original enzyme activity], 0.2 micromol/L) and M2 (IC50, 4.3 micromol/L) but had no effect on M4.",Cyclosporine markedly raises the plasma concentrations of repaglinide. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16198658/),[μM] / [l],4.3,241316,DB00091,Cyclosporine
,11148182,trough concentrations (C(min)),"For groups 1 and 2, the MPA trough concentrations (C(min)) were 1.63 +/- 1.07 and 2.29 +/- 1.16 mg/L, respectively (P = 0.06), and the areas under the curve (AUCs) for MPA from t(0) to t(12 h) (MPA-AUC(0-12h)) were 39.80 +/- 15.29 and 62.10 +/- 21.07 mg.",Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),[mg] / [l],1.63,241348,DB00091,Cyclosporine
,11148182,trough concentrations (C(min)),"For groups 1 and 2, the MPA trough concentrations (C(min)) were 1.63 +/- 1.07 and 2.29 +/- 1.16 mg/L, respectively (P = 0.06), and the areas under the curve (AUCs) for MPA from t(0) to t(12 h) (MPA-AUC(0-12h)) were 39.80 +/- 15.29 and 62.10 +/- 21.07 mg.",Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),[mg] / [l],2.29,241349,DB00091,Cyclosporine
,11148182,areas under the curve (AUCs) for,"For groups 1 and 2, the MPA trough concentrations (C(min)) were 1.63 +/- 1.07 and 2.29 +/- 1.16 mg/L, respectively (P = 0.06), and the areas under the curve (AUCs) for MPA from t(0) to t(12 h) (MPA-AUC(0-12h)) were 39.80 +/- 15.29 and 62.10 +/- 21.07 mg.",Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),mg,39.80,241350,DB00091,Cyclosporine
,11148182,areas under the curve (AUCs) for,"For groups 1 and 2, the MPA trough concentrations (C(min)) were 1.63 +/- 1.07 and 2.29 +/- 1.16 mg/L, respectively (P = 0.06), and the areas under the curve (AUCs) for MPA from t(0) to t(12 h) (MPA-AUC(0-12h)) were 39.80 +/- 15.29 and 62.10 +/- 21.07 mg.",Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),mg,62.10,241351,DB00091,Cyclosporine
,11148182,C(min),"In this group, the MPA-C(min) and MPA-AUC were significantly lower by the time acute rejection occurred (1.00 +/- 0.45 mg/L and 25.00 +/- 6.20 mg.",Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),,1.,241352,DB00091,Cyclosporine
,11148182,AUC,"In this group, the MPA-C(min) and MPA-AUC were significantly lower by the time acute rejection occurred (1.00 +/- 0.45 mg/L and 25.00 +/- 6.20 mg.",Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),mg,25.00,241353,DB00091,Cyclosporine
,11148182,C(min),C:(min) and AUC did not differ between the two groups [C(min) = 2.22 +/- 1.13 vs 2.17 +/- 1.13 mg/L (P = 0.9); AUC = 66.82 +/- 29.87 vs 55.70 +/- 11.74 mg.,Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),[mg] / [l],2.22,241354,DB00091,Cyclosporine
,11148182,C(min),C:(min) and AUC did not differ between the two groups [C(min) = 2.22 +/- 1.13 vs 2.17 +/- 1.13 mg/L (P = 0.9); AUC = 66.82 +/- 29.87 vs 55.70 +/- 11.74 mg.,Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),[mg] / [l],2.17,241355,DB00091,Cyclosporine
,11148182,AUC,C:(min) and AUC did not differ between the two groups [C(min) = 2.22 +/- 1.13 vs 2.17 +/- 1.13 mg/L (P = 0.9); AUC = 66.82 +/- 29.87 vs 55.70 +/- 11.74 mg.,Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),mg,66.82,241356,DB00091,Cyclosporine
,11148182,AUC,C:(min) and AUC did not differ between the two groups [C(min) = 2.22 +/- 1.13 vs 2.17 +/- 1.13 mg/L (P = 0.9); AUC = 66.82 +/- 29.87 vs 55.70 +/- 11.74 mg.,Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),mg,55.70,241357,DB00091,Cyclosporine
,11148182,C(30),h/L (P = 0.11)]; and C(30) was significantly higher in group 2 than in group 1 (C(30) = 32.99 +/- 12.59 vs 7.45 +/- 5.40 mg/L; P <0.0001).,Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),[mg] / [l],32.99,241358,DB00091,Cyclosporine
,11148182,C(30),h/L (P = 0.11)]; and C(30) was significantly higher in group 2 than in group 1 (C(30) = 32.99 +/- 12.59 vs 7.45 +/- 5.40 mg/L; P <0.0001).,Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),[mg] / [l],7.45,241359,DB00091,Cyclosporine
,3097895,absolute bioavailability,Pharmacokinetic studies performed in toxicological studies indicate that CsA is well absorbed in rats and dogs with absolute bioavailability in the range of 10% to 30% when administered by gavage (olive oil).,Pharmacokinetics of cyclosporine in toxicological studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3097895/),%,10,241510,DB00091,Cyclosporine
,3097895,absolute bioavailability,Pharmacokinetic studies performed in toxicological studies indicate that CsA is well absorbed in rats and dogs with absolute bioavailability in the range of 10% to 30% when administered by gavage (olive oil).,Pharmacokinetics of cyclosporine in toxicological studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3097895/),%,30,241511,DB00091,Cyclosporine
less,3097895,bioavailability,"Exceptions are the guinea pig, the rabbit and marmoset with low bioavailability (less than 5%).",Pharmacokinetics of cyclosporine in toxicological studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3097895/),%,5,241512,DB00091,Cyclosporine
,16014572,EC50,Concanavalin A-stimulated IL-2 production in whole blood is inhibited by A-770041 with an EC50 of approximately 80 nM.,"A-770041, a novel and selective small-molecule inhibitor of Lck, prevents heart allograft rejection. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16014572/),nM,80,241682,DB00091,Cyclosporine
,16014572,F,A-770041 is orally bioavailable (F = 34.1 +/- 7.2% at 10 mg/kg) and has a t(1/2) of 4.1 +/- 0.1 h.,"A-770041, a novel and selective small-molecule inhibitor of Lck, prevents heart allograft rejection. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16014572/),%,34.1,241683,DB00091,Cyclosporine
,16014572,t(1/2),A-770041 is orally bioavailable (F = 34.1 +/- 7.2% at 10 mg/kg) and has a t(1/2) of 4.1 +/- 0.1 h.,"A-770041, a novel and selective small-molecule inhibitor of Lck, prevents heart allograft rejection. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16014572/),h,4.1,241684,DB00091,Cyclosporine
,16014572,EC50,Concanavalin A-induced IL-2 production in vivo is inhibited by oral administration of A-770041 (in vivo EC50 = 78 +/- 28 nM).,"A-770041, a novel and selective small-molecule inhibitor of Lck, prevents heart allograft rejection. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16014572/),nM,78,241685,DB00091,Cyclosporine
,23084335,trough level,We evaluated a patient with cutaneous and pulmonary aspergillosis who was successfully treated with voriconazole and a low cyclosporine trough level (3.2 - 27.9 ng/ml) for 3 months.,Pharmacokinetic effect of voriconazole on cyclosporine in the treatment of aspergillosis after renal transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23084335/),[ng] / [ml],3.2 - 27.9,241693,DB00091,Cyclosporine
,9164206,fluid-to-blood AUC ratio,"Pharmacokinetic analysis confirmed that at 20 mg CsA/kg, there was an IP fluid-to-blood AUC ratio of 600:1 in favor of peritoneal exposure.",Pharmacokinetic and phase I trial of intraperitoneal carboplatin and cyclosporine in refractory ovarian cancer patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164206/),,600:1,241860,DB00091,Cyclosporine
,9164206,fluid-to-blood ratio,"At the highest dose delivered, 34.6 mg CsA/kg, the mean IP CsA levels of 1,110 micrograms/ mL were tolerated moderately well and the IP fluid-to-blood ratio of 1,000:1 was maintained.",Pharmacokinetic and phase I trial of intraperitoneal carboplatin and cyclosporine in refractory ovarian cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164206/),,"1,000:1",241861,DB00091,Cyclosporine
,9164206,fluid to blood ratios,"We have established the feasibility of delivering IP CsA up to doses of 34.6 mg/kg in conjunction with carboplatin, and the sustaining of IP fluid to blood ratios of 1,000:1.",Pharmacokinetic and phase I trial of intraperitoneal carboplatin and cyclosporine in refractory ovarian cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9164206/),,"1,000:1",241862,DB00091,Cyclosporine
,10710823,Tmax,"Tmax was 1.60 +/- 0.44 hours after test drug and 1.67 +/- 0.48 after reference drug (p = 0.27, Wilcoxon test).",Comparison of two microemulsion of cyclosporine A in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10710823/),h,1.60,242237,DB00091,Cyclosporine
,10710823,Tmax,"Tmax was 1.60 +/- 0.44 hours after test drug and 1.67 +/- 0.48 after reference drug (p = 0.27, Wilcoxon test).",Comparison of two microemulsion of cyclosporine A in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10710823/),,1.67,242238,DB00091,Cyclosporine
,10221478,trough levels,"Simultaneous treatment caused poor tolerability (poor grooming, lethargy) and significantly higher day-14 RAD and cyclosporine (CsA) trough levels (49+/-5 and 638+/-106 ng/ml; P<0.04) than in the staggered group (28+/-3 and 318+/-25 ng/ml) in which all animals were clinically normal.","Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10221478/),[ng] / [ml],49,242441,DB00091,Cyclosporine
,10221478,trough levels,"Simultaneous treatment caused poor tolerability (poor grooming, lethargy) and significantly higher day-14 RAD and cyclosporine (CsA) trough levels (49+/-5 and 638+/-106 ng/ml; P<0.04) than in the staggered group (28+/-3 and 318+/-25 ng/ml) in which all animals were clinically normal.","Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10221478/),[ng] / [ml],638,242442,DB00091,Cyclosporine
,10221478,trough levels,"Simultaneous treatment caused poor tolerability (poor grooming, lethargy) and significantly higher day-14 RAD and cyclosporine (CsA) trough levels (49+/-5 and 638+/-106 ng/ml; P<0.04) than in the staggered group (28+/-3 and 318+/-25 ng/ml) in which all animals were clinically normal.","Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10221478/),[ng] / [ml],28,242443,DB00091,Cyclosporine
,10221478,trough levels,"Simultaneous treatment caused poor tolerability (poor grooming, lethargy) and significantly higher day-14 RAD and cyclosporine (CsA) trough levels (49+/-5 and 638+/-106 ng/ml; P<0.04) than in the staggered group (28+/-3 and 318+/-25 ng/ml) in which all animals were clinically normal.","Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10221478/),[ng] / [ml],318,242444,DB00091,Cyclosporine
,10221478,trough levels,RAD and CsA day-14 trough levels in the staggered group were the same or lower than trough levels in animals treated with either drug alone (RAD 27+/-3/Neoral 815+/-67 ng/ml).,"Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10221478/),[ng] / [ml],27,242445,DB00091,Cyclosporine
,10221478,trough levels,RAD and CsA day-14 trough levels in the staggered group were the same or lower than trough levels in animals treated with either drug alone (RAD 27+/-3/Neoral 815+/-67 ng/ml).,"Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10221478/),[ng] / [ml],815,242446,DB00091,Cyclosporine
,31873806,clearance (CL),"The population estimate of the clearance (CL) was 30.4 L/h, the volume of distribution (V) was 874.0 L and the bioavailability (F) was 81.1%.",Multicenter-Based Population Pharmacokinetic Analysis of Ciclosporin in Hematopoietic Stem Cell Transplantation Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31873806/),[l] / [h],30.4,242781,DB00091,Cyclosporine
,31873806,volume of distribution (V),"The population estimate of the clearance (CL) was 30.4 L/h, the volume of distribution (V) was 874.0 L and the bioavailability (F) was 81.1%.",Multicenter-Based Population Pharmacokinetic Analysis of Ciclosporin in Hematopoietic Stem Cell Transplantation Patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31873806/),l,874.0,242782,DB00091,Cyclosporine
,31873806,bioavailability (F),"The population estimate of the clearance (CL) was 30.4 L/h, the volume of distribution (V) was 874.0 L and the bioavailability (F) was 81.1%.",Multicenter-Based Population Pharmacokinetic Analysis of Ciclosporin in Hematopoietic Stem Cell Transplantation Patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31873806/),%,81.1,242783,DB00091,Cyclosporine
,12766573,protein bindings,Reported protein bindings are 97% for mycophenolic acid and 82% for mycophenolic acid glucuronide.,Automated determination of free mycophenolic acid and its glucuronide in plasma from renal allograft recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12766573/),%,97,242825,DB00091,Cyclosporine
,12766573,protein bindings,Reported protein bindings are 97% for mycophenolic acid and 82% for mycophenolic acid glucuronide.,Automated determination of free mycophenolic acid and its glucuronide in plasma from renal allograft recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12766573/),%,82,242826,DB00091,Cyclosporine
,12766573,Total concentrations,Total concentrations ranged from 0.57 to 16.2 microg/mL mycophenolic acid and 36 to 199 microg/mL mycophenolic acid glucuronide.,Automated determination of free mycophenolic acid and its glucuronide in plasma from renal allograft recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12766573/),[μg] / [ml],0.57 to 16.2,242827,DB00091,Cyclosporine
,12766573,Total concentrations,Total concentrations ranged from 0.57 to 16.2 microg/mL mycophenolic acid and 36 to 199 microg/mL mycophenolic acid glucuronide.,Automated determination of free mycophenolic acid and its glucuronide in plasma from renal allograft recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12766573/),[μg] / [ml],36 to 199,242828,DB00091,Cyclosporine
,12766573,Free concentrations,Free concentrations ranged from 13 to 210 ng/mL mycophenolic acid and 8 to 58 microg/mL mycophenolic acid glucuronide.,Automated determination of free mycophenolic acid and its glucuronide in plasma from renal allograft recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12766573/),[ng] / [ml],13 to 210,242829,DB00091,Cyclosporine
,12766573,Free concentrations,Free concentrations ranged from 13 to 210 ng/mL mycophenolic acid and 8 to 58 microg/mL mycophenolic acid glucuronide.,Automated determination of free mycophenolic acid and its glucuronide in plasma from renal allograft recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12766573/),[μg] / [ml],8 to 58,242830,DB00091,Cyclosporine
,8545871,Clt,Clearance (Clt) and volume of distribution (Vss) values (mean +/- s.d.) calculated from the i.v. dose were similar to that previously reported for pediatric patients (Clt = 12.0 +/- 1.3 ml/min/kg; Vss = 2.2 +/- 0.2 L/kg).,Absorption characteristics of a microemulsion formulation of cyclosporine in de novo pediatric liver transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8545871/),[ml] / [kg·min],12.0,243541,DB00091,Cyclosporine
,8545871,Vss,Clearance (Clt) and volume of distribution (Vss) values (mean +/- s.d.) calculated from the i.v. dose were similar to that previously reported for pediatric patients (Clt = 12.0 +/- 1.3 ml/min/kg; Vss = 2.2 +/- 0.2 L/kg).,Absorption characteristics of a microemulsion formulation of cyclosporine in de novo pediatric liver transplant recipients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8545871/),[l] / [kg],2.2,243542,DB00091,Cyclosporine
,15005638,maximal plasma concentration,Single-dose administration of 7.5 mg/kg produced a maximal plasma concentration of 2.3-2.7 mg/L for quinupristin and 6.1-8.2 mg/L for dalfopristin.,Clinical pharmacokinetics of quinupristin/dalfopristin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005638/),[mg] / [l],2.3-2.7,243865,DB00091,Cyclosporine
,15005638,maximal plasma concentration,Single-dose administration of 7.5 mg/kg produced a maximal plasma concentration of 2.3-2.7 mg/L for quinupristin and 6.1-8.2 mg/L for dalfopristin.,Clinical pharmacokinetics of quinupristin/dalfopristin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005638/),[mg] / [l],6.1-8.2,243866,DB00091,Cyclosporine
,15005638,area under the concentration-time curve (AUC),The area under the concentration-time curve (AUC) obtained with the same dose was 2.7-3.3 and 6.5-7.7 mg.,Clinical pharmacokinetics of quinupristin/dalfopristin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005638/),mg,2.7-3.3,243867,DB00091,Cyclosporine
,15005638,area under the concentration-time curve (AUC),The area under the concentration-time curve (AUC) obtained with the same dose was 2.7-3.3 and 6.5-7.7 mg.,Clinical pharmacokinetics of quinupristin/dalfopristin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005638/),mg,6.5-7.7,243868,DB00091,Cyclosporine
,15005638,steady-state volumes of distribution,"Quinupristin and dalfopristin exhibit steady-state volumes of distribution of 0.46-0.54 and 0.24-0.30 L/kg, respectively.",Clinical pharmacokinetics of quinupristin/dalfopristin. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005638/),[l] / [kg],0.46-0.54,243869,DB00091,Cyclosporine
,15005638,steady-state volumes of distribution,"Quinupristin and dalfopristin exhibit steady-state volumes of distribution of 0.46-0.54 and 0.24-0.30 L/kg, respectively.",Clinical pharmacokinetics of quinupristin/dalfopristin. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005638/),[l] / [kg],0.24-0.30,243870,DB00091,Cyclosporine
,15005638,protein binding,"Quinupristin exhibits higher protein binding (55-78%) than dalfopristin (11-26%), though both entities distribute well into tissues.",Clinical pharmacokinetics of quinupristin/dalfopristin. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005638/),%,55-78,243871,DB00091,Cyclosporine
,15005638,protein binding,"Quinupristin exhibits higher protein binding (55-78%) than dalfopristin (11-26%), though both entities distribute well into tissues.",Clinical pharmacokinetics of quinupristin/dalfopristin. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005638/),%,11-26,243872,DB00091,Cyclosporine
,15005638,Extravascular penetration,"Extravascular penetration, as measured in blister fluid, is 40-80%.",Clinical pharmacokinetics of quinupristin/dalfopristin. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005638/),%,40-80,243873,DB00091,Cyclosporine
,15005638,elimination half-lives,"The elimination half-lives of quinupristin and dalfopristin are similar, and are 0.7-1.3 hours after single doses.",Clinical pharmacokinetics of quinupristin/dalfopristin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005638/),h,0.7-1.3,243874,DB00091,Cyclosporine
,15005638,half-lives,"The metabolites have slightly longer half-lives, ranging from 1.2 to 1.8 hours.",Clinical pharmacokinetics of quinupristin/dalfopristin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005638/),h,1.2 to 1.8,243875,DB00091,Cyclosporine
,15005638,clearances,"With repeated doses, plasma clearance of quinupristin and dalfopristin is reduced by approximately 20% compared with single doses, resulting in clearances of 0.7-0.8 L/h/kg.",Clinical pharmacokinetics of quinupristin/dalfopristin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005638/),[l] / [h·kg],0.7-0.8,243876,DB00091,Cyclosporine
,17624028,Cmax,"We found that the mean Cmax (95% confidence intervals) of cyclosporine were 2237 (2905, 1859) (*1/*1), 2247 (2916, 1869) (*1/*18B), and 905 (1192, 506) ng ml(-1) (*18B/*18B)(p = 0.037) and the mean AUCO-4 were 5026 (6181, 4372) (*1/*1), 4434 (5481, 3841) (*1/*18B) and 2561 (3155, 1736) ng ml(-1) h (*18B/*18B) (p=0.021).",Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17624028/),[ng] / [ml],2237,244598,DB00091,Cyclosporine
,17624028,Cmax,"We found that the mean Cmax (95% confidence intervals) of cyclosporine were 2237 (2905, 1859) (*1/*1), 2247 (2916, 1869) (*1/*18B), and 905 (1192, 506) ng ml(-1) (*18B/*18B)(p = 0.037) and the mean AUCO-4 were 5026 (6181, 4372) (*1/*1), 4434 (5481, 3841) (*1/*18B) and 2561 (3155, 1736) ng ml(-1) h (*18B/*18B) (p=0.021).",Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17624028/),[ng] / [ml],2247,244599,DB00091,Cyclosporine
,17624028,Cmax,"We found that the mean Cmax (95% confidence intervals) of cyclosporine were 2237 (2905, 1859) (*1/*1), 2247 (2916, 1869) (*1/*18B), and 905 (1192, 506) ng ml(-1) (*18B/*18B)(p = 0.037) and the mean AUCO-4 were 5026 (6181, 4372) (*1/*1), 4434 (5481, 3841) (*1/*18B) and 2561 (3155, 1736) ng ml(-1) h (*18B/*18B) (p=0.021).",Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17624028/),[ng] / [ml],905,244600,DB00091,Cyclosporine
,17624028,AUCO-4,"We found that the mean Cmax (95% confidence intervals) of cyclosporine were 2237 (2905, 1859) (*1/*1), 2247 (2916, 1869) (*1/*18B), and 905 (1192, 506) ng ml(-1) (*18B/*18B)(p = 0.037) and the mean AUCO-4 were 5026 (6181, 4372) (*1/*1), 4434 (5481, 3841) (*1/*18B) and 2561 (3155, 1736) ng ml(-1) h (*18B/*18B) (p=0.021).",Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17624028/),[h·ng] / [ml],5026,244601,DB00091,Cyclosporine
,17624028,AUCO-4,"We found that the mean Cmax (95% confidence intervals) of cyclosporine were 2237 (2905, 1859) (*1/*1), 2247 (2916, 1869) (*1/*18B), and 905 (1192, 506) ng ml(-1) (*18B/*18B)(p = 0.037) and the mean AUCO-4 were 5026 (6181, 4372) (*1/*1), 4434 (5481, 3841) (*1/*18B) and 2561 (3155, 1736) ng ml(-1) h (*18B/*18B) (p=0.021).",Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17624028/),[h·ng] / [ml],4434,244602,DB00091,Cyclosporine
,17624028,AUCO-4,"We found that the mean Cmax (95% confidence intervals) of cyclosporine were 2237 (2905, 1859) (*1/*1), 2247 (2916, 1869) (*1/*18B), and 905 (1192, 506) ng ml(-1) (*18B/*18B)(p = 0.037) and the mean AUCO-4 were 5026 (6181, 4372) (*1/*1), 4434 (5481, 3841) (*1/*18B) and 2561 (3155, 1736) ng ml(-1) h (*18B/*18B) (p=0.021).",Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17624028/),[h·ng] / [ml],2561,244603,DB00091,Cyclosporine
,17555465,trough concentrations,"Patients (n = 45) were randomized 2 : 1 to receive treatment with sirolimus (n = 30; dosed to maintain trough concentrations of 10-25 ng ml(-1) until week 8, and then 8-15 ng ml(-1) thereafter) or CsA (n = 15; administered as per centre practice) both in combination with daclizumab, oral MMF and corticosteroids.","Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555465/),[ng] / [ml],10-25,244711,DB00091,Cyclosporine
,17555465,trough concentrations,"Patients (n = 45) were randomized 2 : 1 to receive treatment with sirolimus (n = 30; dosed to maintain trough concentrations of 10-25 ng ml(-1) until week 8, and then 8-15 ng ml(-1) thereafter) or CsA (n = 15; administered as per centre practice) both in combination with daclizumab, oral MMF and corticosteroids.","Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555465/),[ng] / [ml],8-15,244712,DB00091,Cyclosporine
,17555465,"AUC(0,12 h)","MPA exposure was 39-50% lower (month 6 mean AUC(0,12 h) (95%CI): 40.4 (33.8, 47.0) vs. 68.5 (54.9, 82.0) microg ml(-1) h) and MPAG exposure was 25-52% higher (722 (607, 838) vs. 485 (402, 569) microg ml(-1) h at month 6) in the presence of CsA compared with sirolimus across visits.","Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555465/),[h·μg] / [ml],40.4,244713,DB00091,Cyclosporine
,17555465,"AUC(0,12 h)","MPA exposure was 39-50% lower (month 6 mean AUC(0,12 h) (95%CI): 40.4 (33.8, 47.0) vs. 68.5 (54.9, 82.0) microg ml(-1) h) and MPAG exposure was 25-52% higher (722 (607, 838) vs. 485 (402, 569) microg ml(-1) h at month 6) in the presence of CsA compared with sirolimus across visits.","Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555465/),[h·μg] / [ml],68.5,244714,DB00091,Cyclosporine
,17555465,"AUC(0,12 h)","MPA exposure was 39-50% lower (month 6 mean AUC(0,12 h) (95%CI): 40.4 (33.8, 47.0) vs. 68.5 (54.9, 82.0) microg ml(-1) h) and MPAG exposure was 25-52% higher (722 (607, 838) vs. 485 (402, 569) microg ml(-1) h at month 6) in the presence of CsA compared with sirolimus across visits.","Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555465/),[h·μg] / [ml],722,244715,DB00091,Cyclosporine
,17555465,"AUC(0,12 h)","MPA exposure was 39-50% lower (month 6 mean AUC(0,12 h) (95%CI): 40.4 (33.8, 47.0) vs. 68.5 (54.9, 82.0) microg ml(-1) h) and MPAG exposure was 25-52% higher (722 (607, 838) vs. 485 (402, 569) microg ml(-1) h at month 6) in the presence of CsA compared with sirolimus across visits.","Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555465/),[h·μg] / [ml],485,244716,DB00091,Cyclosporine
,17555465,exposure,"MPA exposure was 39-50% lower (month 6 mean AUC(0,12 h) (95%CI): 40.4 (33.8, 47.0) vs. 68.5 (54.9, 82.0) microg ml(-1) h) and MPAG exposure was 25-52% higher (722 (607, 838) vs. 485 (402, 569) microg ml(-1) h at month 6) in the presence of CsA compared with sirolimus across visits.","Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555465/),[h·μg] / [ml],722,244717,DB00091,Cyclosporine
,17555465,exposure,"MPA exposure was 39-50% lower (month 6 mean AUC(0,12 h) (95%CI): 40.4 (33.8, 47.0) vs. 68.5 (54.9, 82.0) microg ml(-1) h) and MPAG exposure was 25-52% higher (722 (607, 838) vs. 485 (402, 569) microg ml(-1) h at month 6) in the presence of CsA compared with sirolimus across visits.","Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555465/),[h·μg] / [ml],485,244718,DB00091,Cyclosporine
,15866679,AUC/dose,"The cyclosporine daily dose was lower with diltiazem (173 +/- 4 mg vs 213 +/- 4 mg, P = .002), but despite a dose reduction of only 19% +/- 1.5%, there was a trend to a larger AUC/dose (28 +/- 5 ng x h/mL x mg vs 17 +/- 2 ng x h/mL x mg, P = .1) and a trend to an increased C2 when treatment included diltiazem (1035 +/- 156 ng/mL vs 652 +/- 126 ng/mL, P = NS).",Correlation Between C2 and AUC(0-4) in Renal Transplant Patients Treated With Diltiazem. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866679/),[h·ng] / [mg·ml],28,245091,DB00091,Cyclosporine
,15866679,AUC/dose,"The cyclosporine daily dose was lower with diltiazem (173 +/- 4 mg vs 213 +/- 4 mg, P = .002), but despite a dose reduction of only 19% +/- 1.5%, there was a trend to a larger AUC/dose (28 +/- 5 ng x h/mL x mg vs 17 +/- 2 ng x h/mL x mg, P = .1) and a trend to an increased C2 when treatment included diltiazem (1035 +/- 156 ng/mL vs 652 +/- 126 ng/mL, P = NS).",Correlation Between C2 and AUC(0-4) in Renal Transplant Patients Treated With Diltiazem. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866679/),[h·ng] / [mg·ml],17,245092,DB00091,Cyclosporine
,15866679,C2,"The cyclosporine daily dose was lower with diltiazem (173 +/- 4 mg vs 213 +/- 4 mg, P = .002), but despite a dose reduction of only 19% +/- 1.5%, there was a trend to a larger AUC/dose (28 +/- 5 ng x h/mL x mg vs 17 +/- 2 ng x h/mL x mg, P = .1) and a trend to an increased C2 when treatment included diltiazem (1035 +/- 156 ng/mL vs 652 +/- 126 ng/mL, P = NS).",Correlation Between C2 and AUC(0-4) in Renal Transplant Patients Treated With Diltiazem. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866679/),[ng] / [ml],1035,245093,DB00091,Cyclosporine
,15866679,C2,"The cyclosporine daily dose was lower with diltiazem (173 +/- 4 mg vs 213 +/- 4 mg, P = .002), but despite a dose reduction of only 19% +/- 1.5%, there was a trend to a larger AUC/dose (28 +/- 5 ng x h/mL x mg vs 17 +/- 2 ng x h/mL x mg, P = .1) and a trend to an increased C2 when treatment included diltiazem (1035 +/- 156 ng/mL vs 652 +/- 126 ng/mL, P = NS).",Correlation Between C2 and AUC(0-4) in Renal Transplant Patients Treated With Diltiazem. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866679/),[ng] / [ml],652,245094,DB00091,Cyclosporine
,11127945,clearance,"The median clearance of VP-16 was 0.96 l/h per m2 (range 0.8-1.5 l/h per m2), which is lower than for VP-16 alone and similar to previously reported effects of CSA on VP-16 elimination.","A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127945/),[l] / [h·m2],0.96,245132,DB00091,Cyclosporine
,11127945,AUC,The median measured CBDCA AUC was 3.0 mg/ml x min (range 2.4-4.8 mg/ml x min).,"A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127945/),[mg] / [min·ml],3.0,245133,DB00091,Cyclosporine
,11127945,plasma concentrations,"The median end of infusion PCZ and total DP plasma concentrations were 1.2 microM (range 0.5-2.2 microM) and 4.4 microM (range 1.3-5.9 microM), respectively, consistent with in vitro resistance modulatory levels.","A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127945/),μM,4.4,245134,DB00091,Cyclosporine
,11127945,free,"However, free DP was only 0.02 microM (range 0.004-0.04 microM).","A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127945/),μM,0.02,245135,DB00091,Cyclosporine
,12088832,areas under the curve,"CsA areas under the curve between normal and stroke-induced rats were not significantly different in blood (18355 vs. 19405 ng x h/ml, NS) or in brain tissue (15664 vs. 14931 ng x h/g, NS).",Cyclosporin A in blood and brain tissue following intra-carotid injections in normal and stroke-induced rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12088832/),[h·ng] / [ml],18355,245367,DB00091,Cyclosporine
,12088832,areas under the curve,"CsA areas under the curve between normal and stroke-induced rats were not significantly different in blood (18355 vs. 19405 ng x h/ml, NS) or in brain tissue (15664 vs. 14931 ng x h/g, NS).",Cyclosporin A in blood and brain tissue following intra-carotid injections in normal and stroke-induced rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12088832/),[h·ng] / [ml],19405,245368,DB00091,Cyclosporine
,12088832,areas under the curve,"CsA areas under the curve between normal and stroke-induced rats were not significantly different in blood (18355 vs. 19405 ng x h/ml, NS) or in brain tissue (15664 vs. 14931 ng x h/g, NS).",Cyclosporin A in blood and brain tissue following intra-carotid injections in normal and stroke-induced rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12088832/),[h·ng] / [g],15664,245369,DB00091,Cyclosporine
,12088832,areas under the curve,"CsA areas under the curve between normal and stroke-induced rats were not significantly different in blood (18355 vs. 19405 ng x h/ml, NS) or in brain tissue (15664 vs. 14931 ng x h/g, NS).",Cyclosporin A in blood and brain tissue following intra-carotid injections in normal and stroke-induced rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12088832/),[h·ng] / [g],14931,245370,DB00091,Cyclosporine
,12088832,brain-blood ratio,These results demonstrate that intra-carotid injection of CsA results in high levels in brain (brain-blood ratio from 0.5 to 1).,Cyclosporin A in blood and brain tissue following intra-carotid injections in normal and stroke-induced rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12088832/),,0.,245371,DB00091,Cyclosporine
,15848558,AUC0-12,"While patients on SRL were receiving 0.75 g MMF twice a day, mean AUC0-12 and C0 values of MPA were comparable to those of patients receiving CsA and 1 g MMF twice a day (54.1 +/- 17.6 and 3 +/- 1.87 vs 51.7 +/- 16.7 mg.h/L and 2.76 +/- 1.57 mg/L, respectively).",Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848558/),[h·mg] / [l],54.1,245397,DB00091,Cyclosporine
,15848558,AUC0-12,"While patients on SRL were receiving 0.75 g MMF twice a day, mean AUC0-12 and C0 values of MPA were comparable to those of patients receiving CsA and 1 g MMF twice a day (54.1 +/- 17.6 and 3 +/- 1.87 vs 51.7 +/- 16.7 mg.h/L and 2.76 +/- 1.57 mg/L, respectively).",Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848558/),[h·mg] / [l],51.7,245398,DB00091,Cyclosporine
,15848558,C0,"While patients on SRL were receiving 0.75 g MMF twice a day, mean AUC0-12 and C0 values of MPA were comparable to those of patients receiving CsA and 1 g MMF twice a day (54.1 +/- 17.6 and 3 +/- 1.87 vs 51.7 +/- 16.7 mg.h/L and 2.76 +/- 1.57 mg/L, respectively).",Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848558/),[h·mg] / [l],3,245399,DB00091,Cyclosporine
,15848558,C0,"While patients on SRL were receiving 0.75 g MMF twice a day, mean AUC0-12 and C0 values of MPA were comparable to those of patients receiving CsA and 1 g MMF twice a day (54.1 +/- 17.6 and 3 +/- 1.87 vs 51.7 +/- 16.7 mg.h/L and 2.76 +/- 1.57 mg/L, respectively).",Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848558/),[mg] / [l],2.76,245400,DB00091,Cyclosporine
,15848558,AUC0-12,"On the other hand, 0.5 g MMF twice a day with SRL therapy resulted in AUC0-12 and C0 values of MPA of 32.3 +/- 12.6 mg.h/L and 2.32 +/- 1.72 mg/L, respectively, whereas, 1 g MMF twice a day with SRL resulted in AUC0-12 and C0 values of MPA of 70.9 +/- 19.3 mg.h/L and 4.7 +/- 2.44 mg/L, respectively.",Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848558/),[h·mg] / [l],32.3,245401,DB00091,Cyclosporine
,15848558,C0,"On the other hand, 0.5 g MMF twice a day with SRL therapy resulted in AUC0-12 and C0 values of MPA of 32.3 +/- 12.6 mg.h/L and 2.32 +/- 1.72 mg/L, respectively, whereas, 1 g MMF twice a day with SRL resulted in AUC0-12 and C0 values of MPA of 70.9 +/- 19.3 mg.h/L and 4.7 +/- 2.44 mg/L, respectively.",Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848558/),[mg] / [l],2.32,245402,DB00091,Cyclosporine
,15848558,AUC0-12,"On the other hand, 0.5 g MMF twice a day with SRL therapy resulted in AUC0-12 and C0 values of MPA of 32.3 +/- 12.6 mg.h/L and 2.32 +/- 1.72 mg/L, respectively, whereas, 1 g MMF twice a day with SRL resulted in AUC0-12 and C0 values of MPA of 70.9 +/- 19.3 mg.h/L and 4.7 +/- 2.44 mg/L, respectively.",Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848558/),[h·mg] / [l],70.9,245403,DB00091,Cyclosporine
,15848558,C0,"On the other hand, 0.5 g MMF twice a day with SRL therapy resulted in AUC0-12 and C0 values of MPA of 32.3 +/- 12.6 mg.h/L and 2.32 +/- 1.72 mg/L, respectively, whereas, 1 g MMF twice a day with SRL resulted in AUC0-12 and C0 values of MPA of 70.9 +/- 19.3 mg.h/L and 4.7 +/- 2.44 mg/L, respectively.",Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848558/),[mg] / [l],4.7,245404,DB00091,Cyclosporine
,34082013,penetration ratio,"The pharmacokinetic results demonstrated that the VPA penetration ratio of the BBB, determined by the area under the concentration curve (AUC) ratio of VPA (AUCbrain/AUCblood), was approximately 0.36.",Modulation of the transport of valproic acid through the blood-brain barrier in rats by the Gastrodia elata extracts. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34082013/),,0.36,245826,DB00091,Cyclosporine
,34082013,area under the concentration curve (AUC) ratio,"The pharmacokinetic results demonstrated that the VPA penetration ratio of the BBB, determined by the area under the concentration curve (AUC) ratio of VPA (AUCbrain/AUCblood), was approximately 0.36.",Modulation of the transport of valproic acid through the blood-brain barrier in rats by the Gastrodia elata extracts. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34082013/),,0.36,245827,DB00091,Cyclosporine
,34082013,penetration ratios,"After treatment with the G. elata extract (1 and 3 g/kg, p.o. for 5 consecutive days), the VPA penetration ratios were significantly enhanced to 1.47 and 1.02, respectively.",Modulation of the transport of valproic acid through the blood-brain barrier in rats by the Gastrodia elata extracts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34082013/),,1.47,245828,DB00091,Cyclosporine
,34082013,penetration ratios,"After treatment with the G. elata extract (1 and 3 g/kg, p.o. for 5 consecutive days), the VPA penetration ratios were significantly enhanced to 1.47 and 1.02, respectively.",Modulation of the transport of valproic acid through the blood-brain barrier in rats by the Gastrodia elata extracts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34082013/),,1.02,245829,DB00091,Cyclosporine
,34082013,penetration ratio,"Instead, the VPA penetration ratio in the brain was suppressed back to 0.38.",Modulation of the transport of valproic acid through the blood-brain barrier in rats by the Gastrodia elata extracts. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34082013/),,0.38,245830,DB00091,Cyclosporine
,10564835,solubilization,The solubilization of CsA was 2-fold greater in mixed micellar solution than in liposomes (0.06 vs 0.03 mg of CsA/mg of lipid).,Pharmacokinetics and organ distribution of cyclosporin A incorporated in liposomes and mixed micelles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10564835/),mg,0.06,245959,DB00091,Cyclosporine
,10564835,solubilization,The solubilization of CsA was 2-fold greater in mixed micellar solution than in liposomes (0.06 vs 0.03 mg of CsA/mg of lipid).,Pharmacokinetics and organ distribution of cyclosporin A incorporated in liposomes and mixed micelles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10564835/),mg,0.03,245960,DB00091,Cyclosporine
,8334815,AUC,"3. Cyclosporin A absorption in SI (AUC, 991 micrograms l-1 h) was nearly double that in more distal segments and decreased progressively (SII, 533 micrograms l-1 h; SIII, 470 micrograms l-1 h; SIV, 419 micrograms l-1 h).",Localization of cyclosporin A absorption in rat small bowel and the effect of bile. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8334815/),[h·μg] / [l],991,246306,DB00091,Cyclosporine
,8334815,AUC,"3. Cyclosporin A absorption in SI (AUC, 991 micrograms l-1 h) was nearly double that in more distal segments and decreased progressively (SII, 533 micrograms l-1 h; SIII, 470 micrograms l-1 h; SIV, 419 micrograms l-1 h).",Localization of cyclosporin A absorption in rat small bowel and the effect of bile. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8334815/),[h·μg] / [l],533,246307,DB00091,Cyclosporine
,8334815,AUC,"3. Cyclosporin A absorption in SI (AUC, 991 micrograms l-1 h) was nearly double that in more distal segments and decreased progressively (SII, 533 micrograms l-1 h; SIII, 470 micrograms l-1 h; SIV, 419 micrograms l-1 h).",Localization of cyclosporin A absorption in rat small bowel and the effect of bile. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8334815/),[h·μg] / [l],470,246308,DB00091,Cyclosporine
,8334815,AUC,"3. Cyclosporin A absorption in SI (AUC, 991 micrograms l-1 h) was nearly double that in more distal segments and decreased progressively (SII, 533 micrograms l-1 h; SIII, 470 micrograms l-1 h; SIV, 419 micrograms l-1 h).",Localization of cyclosporin A absorption in rat small bowel and the effect of bile. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8334815/),[h·μg] / [l],419,246309,DB00091,Cyclosporine
,8334815,Cmax.,"There were corresponding differences in Cmax.: 327 micrograms/l in SI and 201 micrograms/l, 169 micrograms/l and 151 micrograms/l in SII, SIII and SIV, respectively.",Localization of cyclosporin A absorption in rat small bowel and the effect of bile. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8334815/),[μg] / [l],327,246310,DB00091,Cyclosporine
,8334815,Cmax.,"There were corresponding differences in Cmax.: 327 micrograms/l in SI and 201 micrograms/l, 169 micrograms/l and 151 micrograms/l in SII, SIII and SIV, respectively.",Localization of cyclosporin A absorption in rat small bowel and the effect of bile. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8334815/),[μg] / [l],201,246311,DB00091,Cyclosporine
,8334815,Cmax.,"There were corresponding differences in Cmax.: 327 micrograms/l in SI and 201 micrograms/l, 169 micrograms/l and 151 micrograms/l in SII, SIII and SIV, respectively.",Localization of cyclosporin A absorption in rat small bowel and the effect of bile. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8334815/),[μg] / [l],169,246312,DB00091,Cyclosporine
,8334815,Cmax.,"There were corresponding differences in Cmax.: 327 micrograms/l in SI and 201 micrograms/l, 169 micrograms/l and 151 micrograms/l in SII, SIII and SIV, respectively.",Localization of cyclosporin A absorption in rat small bowel and the effect of bile. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8334815/),[μg] / [l],151,246313,DB00091,Cyclosporine
,8334815,Tmax.,"Tmax. was shorter in SIV (0.9 h) than in other segments (1.3-1.5 h), but there were no significant differences between the segments for t1/2a, t1/2 lambda or MRT.",Localization of cyclosporin A absorption in rat small bowel and the effect of bile. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8334815/),h,0.9,246314,DB00091,Cyclosporine
,8334815,Tmax.,"Tmax. was shorter in SIV (0.9 h) than in other segments (1.3-1.5 h), but there were no significant differences between the segments for t1/2a, t1/2 lambda or MRT.",Localization of cyclosporin A absorption in rat small bowel and the effect of bile. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8334815/),h,1.3-1.5,246315,DB00091,Cyclosporine
,1458769,steady-state plasma level,Plasma concentrations reached a mean steady-state plasma level of 1798 +/- 481 ng/ml.,"Pharmacokinetics and biochemical efficacy of pirmagrel, a thromboxane synthase inhibitor, in renal allograft recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458769/),[ng] / [ml],1798,246409,DB00091,Cyclosporine
,1458769,distribution half-life,"Biphasic, rapid elimination of pirmagrel was observed with a distribution half-life of 6.7 minutes and a terminal half-life of 73 minutes.","Pharmacokinetics and biochemical efficacy of pirmagrel, a thromboxane synthase inhibitor, in renal allograft recipients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458769/),min,6.7,246410,DB00091,Cyclosporine
,1458769,terminal half-life,"Biphasic, rapid elimination of pirmagrel was observed with a distribution half-life of 6.7 minutes and a terminal half-life of 73 minutes.","Pharmacokinetics and biochemical efficacy of pirmagrel, a thromboxane synthase inhibitor, in renal allograft recipients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458769/),min,73,246411,DB00091,Cyclosporine
,1458769,Plasma clearance,"Plasma clearance and the volume of distribution of the drug were 300 +/- 87 ml/hr/kg and 497 +/- 232 ml/kg, respectively.","Pharmacokinetics and biochemical efficacy of pirmagrel, a thromboxane synthase inhibitor, in renal allograft recipients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458769/),[ml] / [h·kg],300,246412,DB00091,Cyclosporine
,1458769,volume of distribution,"Plasma clearance and the volume of distribution of the drug were 300 +/- 87 ml/hr/kg and 497 +/- 232 ml/kg, respectively.","Pharmacokinetics and biochemical efficacy of pirmagrel, a thromboxane synthase inhibitor, in renal allograft recipients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458769/),[ml] / [kg],497,246413,DB00091,Cyclosporine
,16126736,MTD,The MTD of DP was 40/150.,"A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16126736/),-1,40,246850,DB00091,Cyclosporine
,7794718,area under the concentration-time curve,"Compared with equal doses of Sandimmun, the 8-h area under the concentration-time curve increased from 1,422 to 2,657 ng x h/ml and the peak concentration rose from 319 to 824 ng/ml (P < 0.01).",Improved absorption of cyclosporin A from a new microemulsion formulation: implications for dosage and monitoring. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7794718/),[h·ng] / [ml],1,247172,DB00091,Cyclosporine
,7794718,peak concentration,"Compared with equal doses of Sandimmun, the 8-h area under the concentration-time curve increased from 1,422 to 2,657 ng x h/ml and the peak concentration rose from 319 to 824 ng/ml (P < 0.01).",Improved absorption of cyclosporin A from a new microemulsion formulation: implications for dosage and monitoring. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7794718/),[ng] / [ml],319 to 824,247173,DB00091,Cyclosporine
,11793083,area under concentration-time curve (AUC0-12),The dosing regimen of MMF 600 mg/m2 b.i.d. achieved the targeted early post-transplantation MPA 12-h area under concentration-time curve (AUC0-12) of 27.2 microg h per ml.,The use of mycophenolate mofetil suspension in pediatric renal allograft recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11793083/),[h·μg] / [ml],27.2,247467,DB00091,Cyclosporine
,10594869,Area under the concentration-time curve (AUC),"Area under the concentration-time curve (AUC) values for the liquid formulation and for the solid tablet at 2, 4, and 8 weeks postconversion were 256.5, 205.8, 226.1, and 224.4 ng.h/mL, respectively (p=NS).",Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594869/),[h·ng] / [ml],256.5,247917,DB00091,Cyclosporine
,10594869,Area under the concentration-time curve (AUC),"Area under the concentration-time curve (AUC) values for the liquid formulation and for the solid tablet at 2, 4, and 8 weeks postconversion were 256.5, 205.8, 226.1, and 224.4 ng.h/mL, respectively (p=NS).",Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594869/),[h·ng] / [ml],205.8,247918,DB00091,Cyclosporine
,10594869,Area under the concentration-time curve (AUC),"Area under the concentration-time curve (AUC) values for the liquid formulation and for the solid tablet at 2, 4, and 8 weeks postconversion were 256.5, 205.8, 226.1, and 224.4 ng.h/mL, respectively (p=NS).",Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594869/),[h·ng] / [ml],226.1,247919,DB00091,Cyclosporine
,10594869,Area under the concentration-time curve (AUC),"Area under the concentration-time curve (AUC) values for the liquid formulation and for the solid tablet at 2, 4, and 8 weeks postconversion were 256.5, 205.8, 226.1, and 224.4 ng.h/mL, respectively (p=NS).",Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594869/),[h·ng] / [ml],224.4,247920,DB00091,Cyclosporine
,10594869,C(max),"The only significant differences observed among the PK parameters of the solid tablet versus those of the liquid formulation were the lower C(max) values of the solid, namely 25.3, 24.9, and 26.7 ng/mL versus 37.1 ng/mL (p<0.05).",Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594869/),[ng] / [ml],25.3,247921,DB00091,Cyclosporine
,10594869,C(max),"The only significant differences observed among the PK parameters of the solid tablet versus those of the liquid formulation were the lower C(max) values of the solid, namely 25.3, 24.9, and 26.7 ng/mL versus 37.1 ng/mL (p<0.05).",Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594869/),[ng] / [ml],24.9,247922,DB00091,Cyclosporine
,10594869,C(max),"The only significant differences observed among the PK parameters of the solid tablet versus those of the liquid formulation were the lower C(max) values of the solid, namely 25.3, 24.9, and 26.7 ng/mL versus 37.1 ng/mL (p<0.05).",Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594869/),[ng] / [ml],26.7,247923,DB00091,Cyclosporine
,10594869,C(max),"The only significant differences observed among the PK parameters of the solid tablet versus those of the liquid formulation were the lower C(max) values of the solid, namely 25.3, 24.9, and 26.7 ng/mL versus 37.1 ng/mL (p<0.05).",Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594869/),[ng] / [ml],37.1,247924,DB00091,Cyclosporine
,10594869,dose corrected C(max),"In addition, the dose corrected C(max) was lower in the solid tablet PK profiles compared with the prior PK profiles for the liquid (7.7 versus 10.2 ng/mL, p<0.02).",Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594869/),[ng] / [ml],7.7,247925,DB00091,Cyclosporine
,10594869,dose corrected C(max),"In addition, the dose corrected C(max) was lower in the solid tablet PK profiles compared with the prior PK profiles for the liquid (7.7 versus 10.2 ng/mL, p<0.02).",Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10594869/),[ng] / [ml],10.2,247926,DB00091,Cyclosporine
<,9664953,%CVAUC,%CVAUC values of < or = 20% were seen in a significantly greater proportion of CsA-ME patients than CsA patients.,Improved cyclosporine pharmacokinetics in maintenance renal transplant recipients converted to cyclosporine for microemulsion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9664953/),%,20,248438,DB00091,Cyclosporine
,18377332,C(max),"Overall, no significant difference was found between both groups for their 0 - 12 h and 0 - 24 h areas under the concentration-time curve, C(max), T(max), C(0 h), C(12 h) and C(24 h), although the mean C(max) was numerically higher by 39% in the autoimmune disease patients (autoimmune disease 27.3 +/- 17.4 mg/l and renal transplant 19.6 +/- 15.7 mg/l).",Pharmacokinetics of enteric-coated mycophenolate sodium: comparative study in patients with autoimmune disease and renal allograft. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18377332/),[mg] / [l],27.3,248554,DB00091,Cyclosporine
,18377332,C(max),"Overall, no significant difference was found between both groups for their 0 - 12 h and 0 - 24 h areas under the concentration-time curve, C(max), T(max), C(0 h), C(12 h) and C(24 h), although the mean C(max) was numerically higher by 39% in the autoimmune disease patients (autoimmune disease 27.3 +/- 17.4 mg/l and renal transplant 19.6 +/- 15.7 mg/l).",Pharmacokinetics of enteric-coated mycophenolate sodium: comparative study in patients with autoimmune disease and renal allograft. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18377332/),[mg] / [l],19.6,248555,DB00091,Cyclosporine
,18377332,C,The mycophenolic acid trough levels did not reflect the systemic exposure to mycophenolic acid adequately; a limited sampling strategy for estimating mycophenolic acid exposure in autoimmune disease patients should include times around C(1.5 h) and/or C(2 h) reflecting T(max) if further studies confirm its usefulness.,Pharmacokinetics of enteric-coated mycophenolate sodium: comparative study in patients with autoimmune disease and renal allograft. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18377332/),h,1.5,248556,DB00091,Cyclosporine
,10375806,Cmax,"The blood concentration-time curve was fitted to open 2-compartment model, and the pharmacokinetic parameters of Cic alone and Cic + Sim were: Cmax (646 +/- 94) and (698 +/- 340) micrograms.",Delay of metabolism rate of ciclosporin by simvastatin in 7 Chinese healthy men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10375806/),μg,646,248572,DB00091,Cyclosporine
,10375806,Cmax,"The blood concentration-time curve was fitted to open 2-compartment model, and the pharmacokinetic parameters of Cic alone and Cic + Sim were: Cmax (646 +/- 94) and (698 +/- 340) micrograms.",Delay of metabolism rate of ciclosporin by simvastatin in 7 Chinese healthy men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10375806/),μg,698,248573,DB00091,Cyclosporine
,10375806,Tmax,L-1; Tmax (1.12 +/- 0.13) and (1.13 +/- 0.21) h; AUC (2.3 +/- 0.4) and (2.6 +/- 1.2) mg.h.L-1; T1/2 beta (12 +/- 6) and (23 +/- 8) h (P < 0.05).,Delay of metabolism rate of ciclosporin by simvastatin in 7 Chinese healthy men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10375806/),h,1.12,248574,DB00091,Cyclosporine
,10375806,Tmax,L-1; Tmax (1.12 +/- 0.13) and (1.13 +/- 0.21) h; AUC (2.3 +/- 0.4) and (2.6 +/- 1.2) mg.h.L-1; T1/2 beta (12 +/- 6) and (23 +/- 8) h (P < 0.05).,Delay of metabolism rate of ciclosporin by simvastatin in 7 Chinese healthy men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10375806/),h,1.13,248575,DB00091,Cyclosporine
,10375806,AUC,L-1; Tmax (1.12 +/- 0.13) and (1.13 +/- 0.21) h; AUC (2.3 +/- 0.4) and (2.6 +/- 1.2) mg.h.L-1; T1/2 beta (12 +/- 6) and (23 +/- 8) h (P < 0.05).,Delay of metabolism rate of ciclosporin by simvastatin in 7 Chinese healthy men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10375806/),[h·mg] / [l],2.3,248576,DB00091,Cyclosporine
,10375806,AUC,L-1; Tmax (1.12 +/- 0.13) and (1.13 +/- 0.21) h; AUC (2.3 +/- 0.4) and (2.6 +/- 1.2) mg.h.L-1; T1/2 beta (12 +/- 6) and (23 +/- 8) h (P < 0.05).,Delay of metabolism rate of ciclosporin by simvastatin in 7 Chinese healthy men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10375806/),[h·mg] / [l],2.6,248577,DB00091,Cyclosporine
,10375806,T1/2 beta,L-1; Tmax (1.12 +/- 0.13) and (1.13 +/- 0.21) h; AUC (2.3 +/- 0.4) and (2.6 +/- 1.2) mg.h.L-1; T1/2 beta (12 +/- 6) and (23 +/- 8) h (P < 0.05).,Delay of metabolism rate of ciclosporin by simvastatin in 7 Chinese healthy men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10375806/),h,12,248578,DB00091,Cyclosporine
,10375806,T1/2 beta,L-1; Tmax (1.12 +/- 0.13) and (1.13 +/- 0.21) h; AUC (2.3 +/- 0.4) and (2.6 +/- 1.2) mg.h.L-1; T1/2 beta (12 +/- 6) and (23 +/- 8) h (P < 0.05).,Delay of metabolism rate of ciclosporin by simvastatin in 7 Chinese healthy men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10375806/),h,23,248579,DB00091,Cyclosporine
,8633383,trough CsA blood levels,"We first documented that in PBMC from these patients complete inhibition of calcineurin phosphatase activity by in vitro addition of CsA occurs at concentrations that are easily achieved in vivo for a dose as low as 3 mg/kg/day orally, which corresponds to trough CsA blood levels of 100-150 ng/ml.",Recovery of blood mononuclear cell calcineurin activity segregates two populations of renal transplant patients with different sensitivities to cyclosporine inhibition. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8633383/),[ng] / [ml],100-150,248871,DB00091,Cyclosporine
,8633383,trough level,"However, ex vivo, at a blood CsA trough level of 250 ng/ml, calcineurin activity in PBMC was only inhibited from 40% to 70% as compared with controls.",Recovery of blood mononuclear cell calcineurin activity segregates two populations of renal transplant patients with different sensitivities to cyclosporine inhibition. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8633383/),[ng] / [ml],250,248872,DB00091,Cyclosporine
,10856107,AUC,"The mean AUC values +/- SD after 60, 180, and 300 mg/m(2) of oral paclitaxel were 1.65 +/- 0.93, 3.33 +/- 2.39, and 3.46 +/- 1.37 micromol/L.h, respectively.",Phase I and pharmacokinetic study of oral paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10856107/),[μM] / [h·l],1.65,248902,DB00091,Cyclosporine
,10856107,AUC,"The mean AUC values +/- SD after 60, 180, and 300 mg/m(2) of oral paclitaxel were 1.65 +/- 0.93, 3.33 +/- 2.39, and 3.46 +/- 1.37 micromol/L.h, respectively.",Phase I and pharmacokinetic study of oral paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10856107/),[μM] / [h·l],3.33,248903,DB00091,Cyclosporine
,10856107,AUC,"The mean AUC values +/- SD after 60, 180, and 300 mg/m(2) of oral paclitaxel were 1.65 +/- 0.93, 3.33 +/- 2.39, and 3.46 +/- 1.37 micromol/L.h, respectively.",Phase I and pharmacokinetic study of oral paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10856107/),[μM] / [h·l],3.46,248904,DB00091,Cyclosporine
,10856107,AUC,The AUC of intravenous paclitaxel was 15.39 +/- 3.26 micromol/L.h.,Phase I and pharmacokinetic study of oral paclitaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10856107/),[μM] / [h·l],15.39,248905,DB00091,Cyclosporine
,10856107,MTD,The MTD of oral paclitaxel was 300 mg/m(2).,Phase I and pharmacokinetic study of oral paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10856107/),[mg] / [m],300,248906,DB00091,Cyclosporine
,8899852,ECF,"The liver ECF-to-plasma AUC ratios of VP-16 were 32-39 and 0.17 with local CS application and iv administration, respectively, indicating a remarkable advantage of the local drug delivery system.","Microdialysis assessment of microfibrous collagen containing a P-glycoprotein-mediated transport inhibitor, cyclosporine A, for local delivery of etoposide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8899852/),,32,248930,DB00091,Cyclosporine
,8899852,ECF,"The liver ECF-to-plasma AUC ratios of VP-16 were 32-39 and 0.17 with local CS application and iv administration, respectively, indicating a remarkable advantage of the local drug delivery system.","Microdialysis assessment of microfibrous collagen containing a P-glycoprotein-mediated transport inhibitor, cyclosporine A, for local delivery of etoposide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8899852/),,0.17,248931,DB00091,Cyclosporine
,8899852,-to-plasma AUC ratios,"The liver ECF-to-plasma AUC ratios of VP-16 were 32-39 and 0.17 with local CS application and iv administration, respectively, indicating a remarkable advantage of the local drug delivery system.","Microdialysis assessment of microfibrous collagen containing a P-glycoprotein-mediated transport inhibitor, cyclosporine A, for local delivery of etoposide. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8899852/),,32,248932,DB00091,Cyclosporine
,8899852,-to-plasma AUC ratios,"The liver ECF-to-plasma AUC ratios of VP-16 were 32-39 and 0.17 with local CS application and iv administration, respectively, indicating a remarkable advantage of the local drug delivery system.","Microdialysis assessment of microfibrous collagen containing a P-glycoprotein-mediated transport inhibitor, cyclosporine A, for local delivery of etoposide. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8899852/),,0.17,248933,DB00091,Cyclosporine
,28923619,trough level,Target trough level of EVL was 3-8 ng/mL.,Ten-Year Follow-up of Pharmacokinetics-Guided Very Early Cyclosporine Minimization Synchronized With Everolimus Initiation in De Novo Kidney Transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28923619/),[ng] / [ml],3-8,249097,DB00091,Cyclosporine
,28923619,Cmax,"Pharmacokinetics study found that Cmax of CsA ranged from 309 to 1,896 ng/mL, mean area under the receiver operating characteristic curve (AUC) of CsA was 3,449 ± 1,402 ng·h/mL, C0 of EVL was 5.2 ± 1.5 ng/mL, Cmax of EVL was 15.4 ± 4.6 ng/mL, and AUC of EVL was 99.7 ± 26.1 ng·h/mL.",Ten-Year Follow-up of Pharmacokinetics-Guided Very Early Cyclosporine Minimization Synchronized With Everolimus Initiation in De Novo Kidney Transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28923619/),[ng] / [ml],"309 to 1,896",249098,DB00091,Cyclosporine
,28923619,area under the receiver operating characteristic curve (AUC),"Pharmacokinetics study found that Cmax of CsA ranged from 309 to 1,896 ng/mL, mean area under the receiver operating characteristic curve (AUC) of CsA was 3,449 ± 1,402 ng·h/mL, C0 of EVL was 5.2 ± 1.5 ng/mL, Cmax of EVL was 15.4 ± 4.6 ng/mL, and AUC of EVL was 99.7 ± 26.1 ng·h/mL.",Ten-Year Follow-up of Pharmacokinetics-Guided Very Early Cyclosporine Minimization Synchronized With Everolimus Initiation in De Novo Kidney Transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28923619/),[h·ng] / [ml],"3,449",249099,DB00091,Cyclosporine
,28923619,C0,"Pharmacokinetics study found that Cmax of CsA ranged from 309 to 1,896 ng/mL, mean area under the receiver operating characteristic curve (AUC) of CsA was 3,449 ± 1,402 ng·h/mL, C0 of EVL was 5.2 ± 1.5 ng/mL, Cmax of EVL was 15.4 ± 4.6 ng/mL, and AUC of EVL was 99.7 ± 26.1 ng·h/mL.",Ten-Year Follow-up of Pharmacokinetics-Guided Very Early Cyclosporine Minimization Synchronized With Everolimus Initiation in De Novo Kidney Transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28923619/),[ng] / [ml],5.2,249100,DB00091,Cyclosporine
,28923619,Cmax,"Pharmacokinetics study found that Cmax of CsA ranged from 309 to 1,896 ng/mL, mean area under the receiver operating characteristic curve (AUC) of CsA was 3,449 ± 1,402 ng·h/mL, C0 of EVL was 5.2 ± 1.5 ng/mL, Cmax of EVL was 15.4 ± 4.6 ng/mL, and AUC of EVL was 99.7 ± 26.1 ng·h/mL.",Ten-Year Follow-up of Pharmacokinetics-Guided Very Early Cyclosporine Minimization Synchronized With Everolimus Initiation in De Novo Kidney Transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28923619/),[ng] / [ml],15.4,249101,DB00091,Cyclosporine
,28923619,AUC,"Pharmacokinetics study found that Cmax of CsA ranged from 309 to 1,896 ng/mL, mean area under the receiver operating characteristic curve (AUC) of CsA was 3,449 ± 1,402 ng·h/mL, C0 of EVL was 5.2 ± 1.5 ng/mL, Cmax of EVL was 15.4 ± 4.6 ng/mL, and AUC of EVL was 99.7 ± 26.1 ng·h/mL.",Ten-Year Follow-up of Pharmacokinetics-Guided Very Early Cyclosporine Minimization Synchronized With Everolimus Initiation in De Novo Kidney Transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28923619/),[h·ng] / [ml],99.7,249102,DB00091,Cyclosporine
,24385281,AUC from 0 to 6 h,"No significant difference in mean dose-adjusted total prednisolone AUC from 0 to 6 h post-dose or mean dose-adjusted free prednisolone AUC from 0 to 12 h was observed between the cyclosporine and tacrolimus groups (449 versus 428 nmol·h/L/mg, p = 0.43, and 32 versus 30 nmol·h/L/mg, p = 0.51, respectively).",Comparison of the influence of cyclosporine and tacrolimus on the pharmacokinetics of prednisolone in adult male kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24385281/),[h·nM] / [l·mg],449,249174,DB00091,Cyclosporine
,24385281,AUC from 0 to 6 h,"No significant difference in mean dose-adjusted total prednisolone AUC from 0 to 6 h post-dose or mean dose-adjusted free prednisolone AUC from 0 to 12 h was observed between the cyclosporine and tacrolimus groups (449 versus 428 nmol·h/L/mg, p = 0.43, and 32 versus 30 nmol·h/L/mg, p = 0.51, respectively).",Comparison of the influence of cyclosporine and tacrolimus on the pharmacokinetics of prednisolone in adult male kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24385281/),[h·nM] / [l·mg],428,249175,DB00091,Cyclosporine
,24385281,AUC from 0 to 12 h,"No significant difference in mean dose-adjusted total prednisolone AUC from 0 to 6 h post-dose or mean dose-adjusted free prednisolone AUC from 0 to 12 h was observed between the cyclosporine and tacrolimus groups (449 versus 428 nmol·h/L/mg, p = 0.43, and 32 versus 30 nmol·h/L/mg, p = 0.51, respectively).",Comparison of the influence of cyclosporine and tacrolimus on the pharmacokinetics of prednisolone in adult male kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24385281/),[h·nM] / [l·mg],32,249176,DB00091,Cyclosporine
,24385281,AUC from 0 to 12 h,"No significant difference in mean dose-adjusted total prednisolone AUC from 0 to 6 h post-dose or mean dose-adjusted free prednisolone AUC from 0 to 12 h was observed between the cyclosporine and tacrolimus groups (449 versus 428 nmol·h/L/mg, p = 0.43, and 32 versus 30 nmol·h/L/mg, p = 0.51, respectively).",Comparison of the influence of cyclosporine and tacrolimus on the pharmacokinetics of prednisolone in adult male kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24385281/),[h·nM] / [l·mg],30,249177,DB00091,Cyclosporine
,14531725,oral bioavailability,"However, atorvastatin acid is subject to extensive first-pass metabolism in the gut wall as well as in the liver, as oral bioavailability is 14%.",Clinical pharmacokinetics of atorvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14531725/),%,14,249256,DB00091,Cyclosporine
,14531725,volume of distribution,"The volume of distribution of atorvastatin acid is 381L, and plasma protein binding exceeds 98%.",Clinical pharmacokinetics of atorvastatin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14531725/),l,381,249257,DB00091,Cyclosporine
exceeds,14531725,plasma protein binding,"The volume of distribution of atorvastatin acid is 381L, and plasma protein binding exceeds 98%.",Clinical pharmacokinetics of atorvastatin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14531725/),%,98,249258,DB00091,Cyclosporine
,14531725,total plasma clearance,The total plasma clearance of atorvastatin acid is 625 mL/min and the half-life is about 7 hours.,Clinical pharmacokinetics of atorvastatin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14531725/),[ml] / [min],625,249259,DB00091,Cyclosporine
,14531725,half-life,The total plasma clearance of atorvastatin acid is 625 mL/min and the half-life is about 7 hours.,Clinical pharmacokinetics of atorvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14531725/),h,7,249260,DB00091,Cyclosporine
,9422405,terminal half-life,Postinfusion concentrations declined in a biphasic manner with a terminal half-life of 6.5+/-2.1 days.,"Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422405/),d,6.5,249622,DB00091,Cyclosporine
,15848720,C0h,"Evening doses of CsA (25/50/75 or 100 mg) and MMF (250/500 or 1000 mg) produced C0h levels as follows: CsA, 162 +/- 12 ng/mL; MPA, 1.7 +/- 0.2 mg/L.",C0h/C2h monitoring of the pharmacodynamics of cyclosporin plus mycophenolate mofetil in human heart transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848720/),[ng] / [ml],162,249927,DB00091,Cyclosporine
,15848720,C0h,"Evening doses of CsA (25/50/75 or 100 mg) and MMF (250/500 or 1000 mg) produced C0h levels as follows: CsA, 162 +/- 12 ng/mL; MPA, 1.7 +/- 0.2 mg/L.",C0h/C2h monitoring of the pharmacodynamics of cyclosporin plus mycophenolate mofetil in human heart transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848720/),[mg] / [l],1.7,249928,DB00091,Cyclosporine
,15848720,C2h,"Morning doses of CsA (50/75 or 100 mg) and MMF (250/500/1000 or 1500 mg) produced C2h-levels as follows: CsA, 589 +/- 56 ng/mL and MPA, 7.4 +/- 1.3 mg/L.",C0h/C2h monitoring of the pharmacodynamics of cyclosporin plus mycophenolate mofetil in human heart transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848720/),[ng] / [ml],589,249929,DB00091,Cyclosporine
,15848720,C2h,"Morning doses of CsA (50/75 or 100 mg) and MMF (250/500/1000 or 1500 mg) produced C2h-levels as follows: CsA, 589 +/- 56 ng/mL and MPA, 7.4 +/- 1.3 mg/L.",C0h/C2h monitoring of the pharmacodynamics of cyclosporin plus mycophenolate mofetil in human heart transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848720/),[mg] / [l],7.4,249930,DB00091,Cyclosporine
,11914912,apparent K(i),"The transport of [(3)H]paclitaxel across the Caco-2 monolayer was markedly inhibited in the presence of MS-209, and the apparent K(i)of MS-209 for the active transport of [(3)H]paclitaxel was 0.4 microM.",P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11914912/),μM,0.4,250282,DB00091,Cyclosporine
,17362315,AUC,"CBDCA pharmacokinetics revealed a measured AUC of 3.61 versus a targeted AUC of 3, suggesting a possible effect of IFN on CBDCA levels versus errors in the estimation of CBDCA clearance using measured creatinine clearance.",Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: a California Cancer Consortium Trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17362315/),,3.61,250286,DB00091,Cyclosporine
,17362315,AUC,"CBDCA pharmacokinetics revealed a measured AUC of 3.61 versus a targeted AUC of 3, suggesting a possible effect of IFN on CBDCA levels versus errors in the estimation of CBDCA clearance using measured creatinine clearance.",Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: a California Cancer Consortium Trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17362315/),,3,250287,DB00091,Cyclosporine
,1493564,trough concentrations,The recommend trough concentrations are 150-200 ng/ml during the first three months.,[Pharmacokinetics and therapeutic monitoring of cyclosporine in liver transplant recipients]. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1493564/),[ng] / [ml],150-200,250361,DB00091,Cyclosporine
,8653992,area under the blood concentration-time curve (AUC,A significant increase was observed in area under the blood concentration-time curve (AUC;mean +/ SD) with concomitant TPGS administration (3908 +/- 2601 versus 6296 +/- 5102 ng x hr/ml).,The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8653992/),[h·ng] / [ml],3908,250873,DB00091,Cyclosporine
,8653992,area under the blood concentration-time curve (AUC,A significant increase was observed in area under the blood concentration-time curve (AUC;mean +/ SD) with concomitant TPGS administration (3908 +/- 2601 versus 6296 +/- 5102 ng x hr/ml).,The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8653992/),[h·ng] / [ml],6296,250874,DB00091,Cyclosporine
,8653992,apparent oral clearance,Significant decreases were observed in apparent oral clearance (0.24 +/- 0.14 versus 0.15 +/- 0.08 L/hr/kg) and apparent oral steady-state volume of distribution (1.57 +/- 0.95 versus 1.07 +/- 0.73 L/kg).,The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8653992/),[l] / [h·kg],0.24,250875,DB00091,Cyclosporine
,8653992,apparent oral clearance,Significant decreases were observed in apparent oral clearance (0.24 +/- 0.14 versus 0.15 +/- 0.08 L/hr/kg) and apparent oral steady-state volume of distribution (1.57 +/- 0.95 versus 1.07 +/- 0.73 L/kg).,The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8653992/),[l] / [h·kg],0.15,250876,DB00091,Cyclosporine
,8653992,apparent oral steady-state volume of distribution,Significant decreases were observed in apparent oral clearance (0.24 +/- 0.14 versus 0.15 +/- 0.08 L/hr/kg) and apparent oral steady-state volume of distribution (1.57 +/- 0.95 versus 1.07 +/- 0.73 L/kg).,The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8653992/),[l] / [kg],1.57,250877,DB00091,Cyclosporine
,8653992,apparent oral steady-state volume of distribution,Significant decreases were observed in apparent oral clearance (0.24 +/- 0.14 versus 0.15 +/- 0.08 L/hr/kg) and apparent oral steady-state volume of distribution (1.57 +/- 0.95 versus 1.07 +/- 0.73 L/kg).,The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8653992/),[l] / [kg],1.07,250878,DB00091,Cyclosporine
,34008179,half-life,Oral tofacitinib undergoes extensive hepatic metabolism and has numerous drug interactions and a half-life of 3 hours necessitating twice daily dosing.,Sublingual tofacitinib for alopecia areata: a roll-over pilot clinical trial and analysis of pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34008179/),h,3,250883,DB00091,Cyclosporine
,34008179,Total treatment response,Total treatment response to tofacitinib was 37.5%.,Sublingual tofacitinib for alopecia areata: a roll-over pilot clinical trial and analysis of pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34008179/),%,37.5,250884,DB00091,Cyclosporine
,34008179,maximum plasma concentration,Mean maximum plasma concentration was 43.18 ng/ml occurring after 1 hour.,Sublingual tofacitinib for alopecia areata: a roll-over pilot clinical trial and analysis of pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34008179/),[ng] / [ml],43.18,250885,DB00091,Cyclosporine
up to,34008179,Elimination half-life,Elimination half-life is estimated to be up to 11 hours.,Sublingual tofacitinib for alopecia areata: a roll-over pilot clinical trial and analysis of pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34008179/),h,11,250886,DB00091,Cyclosporine
up to,34008179,half-life,"An estimated half-life of up to 11 hours may be achieved with sublingual tofacitinib, which is significantly longer than the oral form and may facilitate daily dosing.",Sublingual tofacitinib for alopecia areata: a roll-over pilot clinical trial and analysis of pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34008179/),h,11,250887,DB00091,Cyclosporine
,17587705,AUC(0-12 h) h,The MPA AUC(0-12 h) h values in the cyclosporine (CsA) and tacrolimus (FK) groups ranged from 13.11 to 50.98 mug .,Limited sampling strategy for mycophenolic acid in Japanese heart transplant recipients: comparison of cyclosporin and tacrolimus treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17587705/),μg,13.11 to 50.98,251342,DB00091,Cyclosporine
,11295581,morning trough concentration,The mean morning trough concentration of cyclosporine was not significantly different after administration of Neoral compared with Sandimmune in any of the groups studied (179 vs. 167 microg/liter for Group A; 171 vs. 147 microg/liter for Group B; 189 vs. 194 microg/liter for Group C; and 181 vs 201 microg/liter for Group D).,Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),[μg] / [l],179,251609,DB00091,Cyclosporine
,11295581,morning trough concentration,The mean morning trough concentration of cyclosporine was not significantly different after administration of Neoral compared with Sandimmune in any of the groups studied (179 vs. 167 microg/liter for Group A; 171 vs. 147 microg/liter for Group B; 189 vs. 194 microg/liter for Group C; and 181 vs 201 microg/liter for Group D).,Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),[μg] / [l],167,251610,DB00091,Cyclosporine
,11295581,morning trough concentration,The mean morning trough concentration of cyclosporine was not significantly different after administration of Neoral compared with Sandimmune in any of the groups studied (179 vs. 167 microg/liter for Group A; 171 vs. 147 microg/liter for Group B; 189 vs. 194 microg/liter for Group C; and 181 vs 201 microg/liter for Group D).,Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),[μg] / [l],171,251611,DB00091,Cyclosporine
,11295581,morning trough concentration,The mean morning trough concentration of cyclosporine was not significantly different after administration of Neoral compared with Sandimmune in any of the groups studied (179 vs. 167 microg/liter for Group A; 171 vs. 147 microg/liter for Group B; 189 vs. 194 microg/liter for Group C; and 181 vs 201 microg/liter for Group D).,Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),[μg] / [l],147,251612,DB00091,Cyclosporine
,11295581,morning trough concentration,The mean morning trough concentration of cyclosporine was not significantly different after administration of Neoral compared with Sandimmune in any of the groups studied (179 vs. 167 microg/liter for Group A; 171 vs. 147 microg/liter for Group B; 189 vs. 194 microg/liter for Group C; and 181 vs 201 microg/liter for Group D).,Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),[μg] / [l],189,251613,DB00091,Cyclosporine
,11295581,morning trough concentration,The mean morning trough concentration of cyclosporine was not significantly different after administration of Neoral compared with Sandimmune in any of the groups studied (179 vs. 167 microg/liter for Group A; 171 vs. 147 microg/liter for Group B; 189 vs. 194 microg/liter for Group C; and 181 vs 201 microg/liter for Group D).,Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),[μg] / [l],194,251614,DB00091,Cyclosporine
,11295581,morning trough concentration,The mean morning trough concentration of cyclosporine was not significantly different after administration of Neoral compared with Sandimmune in any of the groups studied (179 vs. 167 microg/liter for Group A; 171 vs. 147 microg/liter for Group B; 189 vs. 194 microg/liter for Group C; and 181 vs 201 microg/liter for Group D).,Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),[μg] / [l],181,251615,DB00091,Cyclosporine
,11295581,morning trough concentration,The mean morning trough concentration of cyclosporine was not significantly different after administration of Neoral compared with Sandimmune in any of the groups studied (179 vs. 167 microg/liter for Group A; 171 vs. 147 microg/liter for Group B; 189 vs. 194 microg/liter for Group C; and 181 vs 201 microg/liter for Group D).,Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),[μg] / [l],201,251616,DB00091,Cyclosporine
,11295581,bioavailability,"The faster absorption and improved bioavailability of cyclosporine (around 40%) with Neoral compared with Sandimmune was not seen in patients receiving ketoconazole, where in fact cyclosporine bioavailability was already maximal.",Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11295581/),%,40,251617,DB00091,Cyclosporine
,8781610,maximal CsA plasma level,The average maximal CsA plasma level after the microemulsion was 396 ng/ml (95% CI: 71-722 ng/ml) higher than after the standard formulation.,Pharmacokinetics of the conventional and microemulsion formulations of cyclosporine in pancreas-kidney transplant recipients with gastroparesis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8781610/),[ng] / [ml],396,252115,DB00091,Cyclosporine
,18466432,trough daclizumab levels,"Median (range) estimated trough daclizumab levels achieved on day 56 (before dose 5) were 3.88 microg/mL (2.48-8.78), 4.54 microg/mL (1.79-18.7), and 4.94 microg/mL (0.05-10.6) in the less than or equal to five yr (n = 15), 6-12 yr (n = 17), and 13-17 yr (n = 22) age groups, respectively.",Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18466432/),[μg] / [ml],3.88,252560,DB00091,Cyclosporine
,18466432,trough daclizumab levels,"Median (range) estimated trough daclizumab levels achieved on day 56 (before dose 5) were 3.88 microg/mL (2.48-8.78), 4.54 microg/mL (1.79-18.7), and 4.94 microg/mL (0.05-10.6) in the less than or equal to five yr (n = 15), 6-12 yr (n = 17), and 13-17 yr (n = 22) age groups, respectively.",Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18466432/),[μg] / [ml],4.54,252561,DB00091,Cyclosporine
,18466432,trough daclizumab levels,"Median (range) estimated trough daclizumab levels achieved on day 56 (before dose 5) were 3.88 microg/mL (2.48-8.78), 4.54 microg/mL (1.79-18.7), and 4.94 microg/mL (0.05-10.6) in the less than or equal to five yr (n = 15), 6-12 yr (n = 17), and 13-17 yr (n = 22) age groups, respectively.",Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18466432/),[μg] / [ml],4.94,252562,DB00091,Cyclosporine
,18466432,exposure,"Steady-state median (range) daclizumab exposures were 2040 mg x h/mL (1585-3778), 2757 mg x h/mL (1873-3494) and 3297 mg x h/mL (1705-6453), respectively.",Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18466432/),[h·mg] / [ml],2040,252563,DB00091,Cyclosporine
,18466432,exposure,"Steady-state median (range) daclizumab exposures were 2040 mg x h/mL (1585-3778), 2757 mg x h/mL (1873-3494) and 3297 mg x h/mL (1705-6453), respectively.",Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18466432/),[h·mg] / [ml],2757,252564,DB00091,Cyclosporine
,18466432,exposure,"Steady-state median (range) daclizumab exposures were 2040 mg x h/mL (1585-3778), 2757 mg x h/mL (1873-3494) and 3297 mg x h/mL (1705-6453), respectively.",Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18466432/),[h·mg] / [ml],3297,252565,DB00091,Cyclosporine
,33527141,Cmax,"In 24 patients, MPA exposure (Cmax and AUC0-12) was similar in the presence and absence of voclosporin, with treatment ratios of 0.94 and 1.09, respectively (Cmax: 16.5 μg/mL [Day 1] vs.15.8 μg/mL [Day 7], AUC0-12: 39.1 μg.h/mL [Day 1] vs. 40.8 μg.h/mL [Day 7].",Voclosporin: a novel calcineurin inhibitor without impact on mycophenolic acid in patients with SLE. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33527141/),[μg] / [ml],16.5,253015,DB00091,Cyclosporine
,33527141,Cmax,"In 24 patients, MPA exposure (Cmax and AUC0-12) was similar in the presence and absence of voclosporin, with treatment ratios of 0.94 and 1.09, respectively (Cmax: 16.5 μg/mL [Day 1] vs.15.8 μg/mL [Day 7], AUC0-12: 39.1 μg.h/mL [Day 1] vs. 40.8 μg.h/mL [Day 7].",Voclosporin: a novel calcineurin inhibitor without impact on mycophenolic acid in patients with SLE. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33527141/),[μg] / [ml],15.8,253016,DB00091,Cyclosporine
,33527141,AUC0-12,"In 24 patients, MPA exposure (Cmax and AUC0-12) was similar in the presence and absence of voclosporin, with treatment ratios of 0.94 and 1.09, respectively (Cmax: 16.5 μg/mL [Day 1] vs.15.8 μg/mL [Day 7], AUC0-12: 39.1 μg.h/mL [Day 1] vs. 40.8 μg.h/mL [Day 7].",Voclosporin: a novel calcineurin inhibitor without impact on mycophenolic acid in patients with SLE. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33527141/),[h·μg] / [ml],39.1,253017,DB00091,Cyclosporine
,33527141,AUC0-12,"In 24 patients, MPA exposure (Cmax and AUC0-12) was similar in the presence and absence of voclosporin, with treatment ratios of 0.94 and 1.09, respectively (Cmax: 16.5 μg/mL [Day 1] vs.15.8 μg/mL [Day 7], AUC0-12: 39.1 μg.h/mL [Day 1] vs. 40.8 μg.h/mL [Day 7].",Voclosporin: a novel calcineurin inhibitor without impact on mycophenolic acid in patients with SLE. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33527141/),[h·μg] / [ml],40.8,253018,DB00091,Cyclosporine
,18296555,area under the concentration-time curve (AUC)(0-8),"The median (range) total mycophenolic acid area under the concentration-time curve (AUC)(0-8) was 12.6 mcg.h/mL (4.9-49.2), and unbound mycophenolic acid AUC(0-8) was 0.274 mcg.h/mL (0.037-1.4).",Higher mycophenolate dose requirements in children undergoing hematopoietic cell transplant (HCT). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18296555/),[h·mcg] / [ml],12.6,253071,DB00091,Cyclosporine
,18296555,AUC(0-8),"The median (range) total mycophenolic acid area under the concentration-time curve (AUC)(0-8) was 12.6 mcg.h/mL (4.9-49.2), and unbound mycophenolic acid AUC(0-8) was 0.274 mcg.h/mL (0.037-1.4).",Higher mycophenolate dose requirements in children undergoing hematopoietic cell transplant (HCT). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18296555/),[h·mcg] / [ml],0.274,253072,DB00091,Cyclosporine
,18296555,Total,"Total and unbound mycophenolic acid trough concentrations were 0.27 (0.03-2.9) and 0.005 (0-0.034) mcg/mL, respectively.",Higher mycophenolate dose requirements in children undergoing hematopoietic cell transplant (HCT). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18296555/),[mcg] / [ml],0.27,253073,DB00091,Cyclosporine
,18296555,unbound,"Total and unbound mycophenolic acid trough concentrations were 0.27 (0.03-2.9) and 0.005 (0-0.034) mcg/mL, respectively.",Higher mycophenolate dose requirements in children undergoing hematopoietic cell transplant (HCT). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18296555/),[mcg] / [ml],0.27,253074,DB00091,Cyclosporine
,18296555,trough concentrations,"Total and unbound mycophenolic acid trough concentrations were 0.27 (0.03-2.9) and 0.005 (0-0.034) mcg/mL, respectively.",Higher mycophenolate dose requirements in children undergoing hematopoietic cell transplant (HCT). ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18296555/),[mcg] / [ml],0.005,253075,DB00091,Cyclosporine
> or =,10665942,AUC,An AUC > or = 4158 ng/ml per h was the best predictor for the presence of hypertrichosis.,Impact of cyclosporin A pharmacokinetics on the presence of side effects in pediatric renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10665942/),[ng] / [h·ml],4158,253196,DB00091,Cyclosporine
> or =,10665942,Cmax,A Cmax > or = 878 ng/ml was the best predictor for the appearance of tremor.,Impact of cyclosporin A pharmacokinetics on the presence of side effects in pediatric renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10665942/),[ng] / [ml],878,253197,DB00091,Cyclosporine
,16509024,maximum concentrations,"Mean +/- SD maximum concentrations were significantly higher after administration of the modified form than after administration of the original form (594.9 +/- 349.7 vs 483.0 +/- 363.0 microg/L, p=0.003), as was the area under the concentration-time curve from 0-12 hours (AUC0-12; 3432 +/- 1563 vs 3144 +/- 1780 microg/L x hr, p=0.022).",Disposition of two oral formulations of cyclosporine in pediatric patients receiving hematopoietic stem cell transplants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16509024/),[μg] / [l],594.9,253833,DB00091,Cyclosporine
,16509024,maximum concentrations,"Mean +/- SD maximum concentrations were significantly higher after administration of the modified form than after administration of the original form (594.9 +/- 349.7 vs 483.0 +/- 363.0 microg/L, p=0.003), as was the area under the concentration-time curve from 0-12 hours (AUC0-12; 3432 +/- 1563 vs 3144 +/- 1780 microg/L x hr, p=0.022).",Disposition of two oral formulations of cyclosporine in pediatric patients receiving hematopoietic stem cell transplants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16509024/),[μg] / [l],483.0,253834,DB00091,Cyclosporine
,16509024,area under the concentration-time curve from 0-12 hours (AUC0-12,"Mean +/- SD maximum concentrations were significantly higher after administration of the modified form than after administration of the original form (594.9 +/- 349.7 vs 483.0 +/- 363.0 microg/L, p=0.003), as was the area under the concentration-time curve from 0-12 hours (AUC0-12; 3432 +/- 1563 vs 3144 +/- 1780 microg/L x hr, p=0.022).",Disposition of two oral formulations of cyclosporine in pediatric patients receiving hematopoietic stem cell transplants. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16509024/),[μg] / [h·l],3432,253835,DB00091,Cyclosporine
,16509024,area under the concentration-time curve from 0-12 hours (AUC0-12,"Mean +/- SD maximum concentrations were significantly higher after administration of the modified form than after administration of the original form (594.9 +/- 349.7 vs 483.0 +/- 363.0 microg/L, p=0.003), as was the area under the concentration-time curve from 0-12 hours (AUC0-12; 3432 +/- 1563 vs 3144 +/- 1780 microg/L x hr, p=0.022).",Disposition of two oral formulations of cyclosporine in pediatric patients receiving hematopoietic stem cell transplants. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16509024/),[μg] / [h·l],3144,253836,DB00091,Cyclosporine
,9712463,dose-rate-Css(trough) ratio,"The mean (and 95% confidence interval) dose-rate-Css(trough) ratio for cyclosporine generated from concentrations measured using EMIT was 94 (82.5-105.5) Lh(-1) for patients administered cyclosporine alone, 66.7 (58.1-75.3) Lh(-1) for patients administered concomitant diltiazem, 47.9 (15.4 -80.4) Lh(-1) for patients administered concomitant itraconazole, 21.7 (14.8-28.5) Lh(-1) for patients administered concomitant ketoconazole, and 14.9 (11.8-18.1) Lh(-1) for patients concomitantly administered diltiazem and ketoconazole.",Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712463/),1/[lh],94,253963,DB00091,Cyclosporine
,9712463,dose-rate-Css(trough) ratio,"The mean (and 95% confidence interval) dose-rate-Css(trough) ratio for cyclosporine generated from concentrations measured using EMIT was 94 (82.5-105.5) Lh(-1) for patients administered cyclosporine alone, 66.7 (58.1-75.3) Lh(-1) for patients administered concomitant diltiazem, 47.9 (15.4 -80.4) Lh(-1) for patients administered concomitant itraconazole, 21.7 (14.8-28.5) Lh(-1) for patients administered concomitant ketoconazole, and 14.9 (11.8-18.1) Lh(-1) for patients concomitantly administered diltiazem and ketoconazole.",Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712463/),1/[lh],66.7,253964,DB00091,Cyclosporine
,9712463,dose-rate-Css(trough) ratio,"The mean (and 95% confidence interval) dose-rate-Css(trough) ratio for cyclosporine generated from concentrations measured using EMIT was 94 (82.5-105.5) Lh(-1) for patients administered cyclosporine alone, 66.7 (58.1-75.3) Lh(-1) for patients administered concomitant diltiazem, 47.9 (15.4 -80.4) Lh(-1) for patients administered concomitant itraconazole, 21.7 (14.8-28.5) Lh(-1) for patients administered concomitant ketoconazole, and 14.9 (11.8-18.1) Lh(-1) for patients concomitantly administered diltiazem and ketoconazole.",Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712463/),1/[lh],47.9,253965,DB00091,Cyclosporine
,9712463,dose-rate-Css(trough) ratio,"The mean (and 95% confidence interval) dose-rate-Css(trough) ratio for cyclosporine generated from concentrations measured using EMIT was 94 (82.5-105.5) Lh(-1) for patients administered cyclosporine alone, 66.7 (58.1-75.3) Lh(-1) for patients administered concomitant diltiazem, 47.9 (15.4 -80.4) Lh(-1) for patients administered concomitant itraconazole, 21.7 (14.8-28.5) Lh(-1) for patients administered concomitant ketoconazole, and 14.9 (11.8-18.1) Lh(-1) for patients concomitantly administered diltiazem and ketoconazole.",Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712463/),1/[lh],21.7,253966,DB00091,Cyclosporine
,9712463,dose-rate-Css(trough) ratio,"The mean (and 95% confidence interval) dose-rate-Css(trough) ratio for cyclosporine generated from concentrations measured using EMIT was 94 (82.5-105.5) Lh(-1) for patients administered cyclosporine alone, 66.7 (58.1-75.3) Lh(-1) for patients administered concomitant diltiazem, 47.9 (15.4 -80.4) Lh(-1) for patients administered concomitant itraconazole, 21.7 (14.8-28.5) Lh(-1) for patients administered concomitant ketoconazole, and 14.9 (11.8-18.1) Lh(-1) for patients concomitantly administered diltiazem and ketoconazole.",Effect of metabolic inhibitors on cyclosporine pharmacokinetics using a population approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9712463/),1/[lh],14.9,253967,DB00091,Cyclosporine
,32745564,emulsification time,"The optimized PTX-SMEDDS showed emulsification time of 31 ± 4 s, droplet size of 19.4 ± 0.5 nm, poly-dispersibility index of 0.35 ± 0.08, percentage transmittance after dilution of 99 ± 0.02%, zeta potential of 36.82 ± 1.8 mv, cloud point of 78 ± 0.5 °C and infinite dilution capability.",Dual Formulation and Interaction Strategies to Enhance the Oral Bioavailability of Paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32745564/),s,31,254069,DB00091,Cyclosporine
,32745564,poly-dispersibility index,"The optimized PTX-SMEDDS showed emulsification time of 31 ± 4 s, droplet size of 19.4 ± 0.5 nm, poly-dispersibility index of 0.35 ± 0.08, percentage transmittance after dilution of 99 ± 0.02%, zeta potential of 36.82 ± 1.8 mv, cloud point of 78 ± 0.5 °C and infinite dilution capability.",Dual Formulation and Interaction Strategies to Enhance the Oral Bioavailability of Paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32745564/),,0.35,254070,DB00091,Cyclosporine
,32745564,percentage transmittance,"The optimized PTX-SMEDDS showed emulsification time of 31 ± 4 s, droplet size of 19.4 ± 0.5 nm, poly-dispersibility index of 0.35 ± 0.08, percentage transmittance after dilution of 99 ± 0.02%, zeta potential of 36.82 ± 1.8 mv, cloud point of 78 ± 0.5 °C and infinite dilution capability.",Dual Formulation and Interaction Strategies to Enhance the Oral Bioavailability of Paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32745564/),%,99,254071,DB00091,Cyclosporine
,32745564,zeta potential,"The optimized PTX-SMEDDS showed emulsification time of 31 ± 4 s, droplet size of 19.4 ± 0.5 nm, poly-dispersibility index of 0.35 ± 0.08, percentage transmittance after dilution of 99 ± 0.02%, zeta potential of 36.82 ± 1.8 mv, cloud point of 78 ± 0.5 °C and infinite dilution capability.",Dual Formulation and Interaction Strategies to Enhance the Oral Bioavailability of Paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32745564/),mv,36.82,254072,DB00091,Cyclosporine
,21618566,terminal elimination half-life (t(½)),Coadministration with telaprevir increased the terminal elimination half-life (t(½)) of cyclosporine from a mean (standard deviation [SD]) of 12 (1.67) hours to 42.1 (11.3) hours and t(½) of tacrolimus from a mean (SD) of 40.7 (5.85) hours to 196 (159) hours.,Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21618566/),h,12,254143,DB00091,Cyclosporine
,21618566,terminal elimination half-life (t(½)),Coadministration with telaprevir increased the terminal elimination half-life (t(½)) of cyclosporine from a mean (standard deviation [SD]) of 12 (1.67) hours to 42.1 (11.3) hours and t(½) of tacrolimus from a mean (SD) of 40.7 (5.85) hours to 196 (159) hours.,Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21618566/),h,42.1,254144,DB00091,Cyclosporine
,21618566,t(½),Coadministration with telaprevir increased the terminal elimination half-life (t(½)) of cyclosporine from a mean (standard deviation [SD]) of 12 (1.67) hours to 42.1 (11.3) hours and t(½) of tacrolimus from a mean (SD) of 40.7 (5.85) hours to 196 (159) hours.,Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21618566/),h,40.7,254145,DB00091,Cyclosporine
,21618566,t(½),Coadministration with telaprevir increased the terminal elimination half-life (t(½)) of cyclosporine from a mean (standard deviation [SD]) of 12 (1.67) hours to 42.1 (11.3) hours and t(½) of tacrolimus from a mean (SD) of 40.7 (5.85) hours to 196 (159) hours.,Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21618566/),h,196,254146,DB00091,Cyclosporine
,15049795,weight,"Based on an inter-study analysis, weight-normalized CL/F in the current population of younger pediatric dialysis patients (5-11 yr, 544 +/- 463 mL/h/kg, n = 7) was increased by 90% (p < or = 0.05) compared with healthy adults (19-36 yr, 287 +/- 111 mL/h/kg, n = 25).","Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049795/),[ml] / [h·kg],544,254238,DB00091,Cyclosporine
,15049795,weight,"Based on an inter-study analysis, weight-normalized CL/F in the current population of younger pediatric dialysis patients (5-11 yr, 544 +/- 463 mL/h/kg, n = 7) was increased by 90% (p < or = 0.05) compared with healthy adults (19-36 yr, 287 +/- 111 mL/h/kg, n = 25).","Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049795/),[ml] / [h·kg],287,254239,DB00091,Cyclosporine
,17038875,time after dose,"A total of 31 patients (7 female and 24 male) originally included in a formal clinical trial, contributed 524 sirolimus blood concentrations with the time after dose ranging from 11.08 to 31.83 hours.",Apparent clearance of sirolimus in heart transplant recipients: impact of primary diagnosis and serum lipids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038875/),h,11.08 to 31.83,254362,DB00091,Cyclosporine
,17038875,CL/F,"Based on the final model, the average values for sirolimus CL/F and apparent volume of distribution were 7.09 and 1,350 L/h, respectively.",Apparent clearance of sirolimus in heart transplant recipients: impact of primary diagnosis and serum lipids. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038875/),[l] / [h],7.09,254363,DB00091,Cyclosporine
,17038875,apparent volume of distribution,"Based on the final model, the average values for sirolimus CL/F and apparent volume of distribution were 7.09 and 1,350 L/h, respectively.",Apparent clearance of sirolimus in heart transplant recipients: impact of primary diagnosis and serum lipids. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038875/),[l] / [h],"1,350",254364,DB00091,Cyclosporine
,11903387,area under the concentration curve (AUC),"Morning doses were adjusted to reach a day-time area under the concentration curve (AUC) of 7,800 ng hour/ml (utilizing 2 hour and 6 hour levels) and evening doses were adjusted to a morning trough of 300 ng/ml.",Diurnal cyclosporine dosing optimizes exposure and reduces the risk of acute rejection after kidney transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903387/),[h·ng] / [ml],"7,800",254508,DB00091,Cyclosporine
,11903387,trough,"Morning doses were adjusted to reach a day-time area under the concentration curve (AUC) of 7,800 ng hour/ml (utilizing 2 hour and 6 hour levels) and evening doses were adjusted to a morning trough of 300 ng/ml.",Diurnal cyclosporine dosing optimizes exposure and reduces the risk of acute rejection after kidney transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903387/),[ng] / [ml],300,254509,DB00091,Cyclosporine
,14743973,T(1/2),The brain T(1/2) in rat treated with ery(75.0 min) and CsA(79.0 min) were larger than that (44.2 min) in rats NMD alone.,Effect of P-glycoprotein inhibitors erythromycin and cyclosporin A on brain pharmacokinetics of nimodipine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14743973/),min,75.0,254714,DB00091,Cyclosporine
,14743973,T(1/2),The brain T(1/2) in rat treated with ery(75.0 min) and CsA(79.0 min) were larger than that (44.2 min) in rats NMD alone.,Effect of P-glycoprotein inhibitors erythromycin and cyclosporin A on brain pharmacokinetics of nimodipine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14743973/),min,79.0,254715,DB00091,Cyclosporine
,14743973,T(1/2),The brain T(1/2) in rat treated with ery(75.0 min) and CsA(79.0 min) were larger than that (44.2 min) in rats NMD alone.,Effect of P-glycoprotein inhibitors erythromycin and cyclosporin A on brain pharmacokinetics of nimodipine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14743973/),min,44.2,254716,DB00091,Cyclosporine
,10074590,bio,"The patient exhibited very high bioavailability, F = 95%, and an oral elimination T1/2 of over 21 hours.",Cyclosporine disposition and long-term renal function in a 500-pound kidney transplant recipient. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10074590/),%,95,255171,DB00091,Cyclosporine
over,10074590,oral elimination T1/2,"The patient exhibited very high bioavailability, F = 95%, and an oral elimination T1/2 of over 21 hours.",Cyclosporine disposition and long-term renal function in a 500-pound kidney transplant recipient. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10074590/),h,21,255172,DB00091,Cyclosporine
,6718808,t 1/2,"The t 1/2 values for the alpha-distribution and beta-elimination phases were about 6 min and 16.5 h, respectively.",Evidence for a possible dose-dependent pharmacokinetics of Cyclosporin-A in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6718808/),min,6,255624,DB00091,Cyclosporine
,6718808,t 1/2,"The t 1/2 values for the alpha-distribution and beta-elimination phases were about 6 min and 16.5 h, respectively.",Evidence for a possible dose-dependent pharmacokinetics of Cyclosporin-A in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6718808/),h,16.5,255625,DB00091,Cyclosporine
,6718808,normalized areas under the plasma concentration/time curves,"The values for the normalized areas under the plasma concentration/time curves obtained at different Cy-A doses (20, 40 and 80 mg/kg) were about 1, 3 and 25, respectively.",Evidence for a possible dose-dependent pharmacokinetics of Cyclosporin-A in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6718808/),,1,255626,DB00091,Cyclosporine
,6718808,normalized areas under the plasma concentration/time curves,"The values for the normalized areas under the plasma concentration/time curves obtained at different Cy-A doses (20, 40 and 80 mg/kg) were about 1, 3 and 25, respectively.",Evidence for a possible dose-dependent pharmacokinetics of Cyclosporin-A in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6718808/),,3,255627,DB00091,Cyclosporine
,6718808,normalized areas under the plasma concentration/time curves,"The values for the normalized areas under the plasma concentration/time curves obtained at different Cy-A doses (20, 40 and 80 mg/kg) were about 1, 3 and 25, respectively.",Evidence for a possible dose-dependent pharmacokinetics of Cyclosporin-A in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6718808/),,25,255628,DB00091,Cyclosporine
,7697949,peak concentration,"Grapefruit juice increased the peak concentration of cyclosporine by 185 ng/ml (95% confidence interval, 60 to 310; p = 0.008).",The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7697949/),[ng] / [ml],185,255923,DB00091,Cyclosporine
,9505993,Absolute bioavailability,Absolute bioavailability from the microemulsion formulation was 60%.,"Optimizing the absorption of valspodar, a P-glycoprotein modulator, Part II: Quantifying its pharmacokinetic variability and refining the bioavailability estimate. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9505993/),%,60,255985,DB00091,Cyclosporine
,7988626,bioavailability,"The mean bioavailability was 39%, blood clearance was 0.55 l.h-1.kg-1 and volume of distribution at steady-state was 2.77 l.kg-1.",Cyclosporine pharmacokinetics in nephrotic and kidney-transplanted children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988626/),%,39,256088,DB00091,Cyclosporine
,7988626,blood clearance,"The mean bioavailability was 39%, blood clearance was 0.55 l.h-1.kg-1 and volume of distribution at steady-state was 2.77 l.kg-1.",Cyclosporine pharmacokinetics in nephrotic and kidney-transplanted children. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988626/),[l] / [h·kg],0.55,256089,DB00091,Cyclosporine
,7988626,volume of distribution at steady-state,"The mean bioavailability was 39%, blood clearance was 0.55 l.h-1.kg-1 and volume of distribution at steady-state was 2.77 l.kg-1.",Cyclosporine pharmacokinetics in nephrotic and kidney-transplanted children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988626/),[l] / [kg],2.77,256090,DB00091,Cyclosporine
,7988626,maximum blood concentration,The maximum blood concentration of CsA was significantly higher in children with a monophasic profile than in children with a biphasic profile (550 vs 380 ng.ml-1).,Cyclosporine pharmacokinetics in nephrotic and kidney-transplanted children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988626/),[ng] / [ml],550,256091,DB00091,Cyclosporine
,7988626,maximum blood concentration,The maximum blood concentration of CsA was significantly higher in children with a monophasic profile than in children with a biphasic profile (550 vs 380 ng.ml-1).,Cyclosporine pharmacokinetics in nephrotic and kidney-transplanted children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988626/),[ng] / [ml],380,256092,DB00091,Cyclosporine
,7988626,Blood clearance,Blood clearance was significantly higher in the transplant recipients than in the patients with nephrotic syndrome (0.65 vs 0.43 l.h-1.kg-1.,Cyclosporine pharmacokinetics in nephrotic and kidney-transplanted children. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988626/),[l] / [h·kg],0.65,256093,DB00091,Cyclosporine
,7988626,Blood clearance,Blood clearance was significantly higher in the transplant recipients than in the patients with nephrotic syndrome (0.65 vs 0.43 l.h-1.kg-1.,Cyclosporine pharmacokinetics in nephrotic and kidney-transplanted children. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988626/),[l] / [h·kg],0.43,256094,DB00091,Cyclosporine
,15909533,flow rate,"Samples were eluted with a mobile phase containing acetonitrile-methanol-tetrahydrofuran-20 mM K2HPO4 (pH 7.0) (24:20:10:946, v/v), and the flow rate of the mobile phase was 1 ml/min.",Measurement of unbound ranitidine in blood and bile of anesthetized rats using microdialysis coupled to liquid chromatography and its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15909533/),[ml] / [min],1,256164,DB00091,Cyclosporine
,15909533,bile-to-blood distribution ratio (AUC(bile)/AUC(blood)),"The bile-to-blood distribution ratio (AUC(bile)/AUC(blood)) was 9.8 +/- 1.9 and 13.9 +/- 3.8 at the dosages of 10 and 30 mg/kg, respectively.",Measurement of unbound ranitidine in blood and bile of anesthetized rats using microdialysis coupled to liquid chromatography and its pharmacokinetic application. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15909533/),,9.8,256165,DB00091,Cyclosporine
,15909533,bile-to-blood distribution ratio (AUC(bile)/AUC(blood)),"The bile-to-blood distribution ratio (AUC(bile)/AUC(blood)) was 9.8 +/- 1.9 and 13.9 +/- 3.8 at the dosages of 10 and 30 mg/kg, respectively.",Measurement of unbound ranitidine in blood and bile of anesthetized rats using microdialysis coupled to liquid chromatography and its pharmacokinetic application. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15909533/),,13.9,256166,DB00091,Cyclosporine
,16176120,absorption rate constant (k(a)),"The following population parameters were estimated: absorption rate constant (k(a)) 4.1h(-1), central volume of distribution (V1) 91 L, peripheral volume of distribution (V2) 237 L, clearance (CL) 33 L/h, intercompartment clearance (Q) 35 L/h and absorption lag time 0.21 h.",Population pharmacokinetics of mycophenolic acid in renal transplant recipients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16176120/),1/[h],4.1,256210,DB00091,Cyclosporine
,16176120,central volume of distribution (V1),"The following population parameters were estimated: absorption rate constant (k(a)) 4.1h(-1), central volume of distribution (V1) 91 L, peripheral volume of distribution (V2) 237 L, clearance (CL) 33 L/h, intercompartment clearance (Q) 35 L/h and absorption lag time 0.21 h.",Population pharmacokinetics of mycophenolic acid in renal transplant recipients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16176120/),l,91,256211,DB00091,Cyclosporine
,16176120,peripheral volume of distribution (V2),"The following population parameters were estimated: absorption rate constant (k(a)) 4.1h(-1), central volume of distribution (V1) 91 L, peripheral volume of distribution (V2) 237 L, clearance (CL) 33 L/h, intercompartment clearance (Q) 35 L/h and absorption lag time 0.21 h.",Population pharmacokinetics of mycophenolic acid in renal transplant recipients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16176120/),l,237,256212,DB00091,Cyclosporine
,16176120,clearance (CL),"The following population parameters were estimated: absorption rate constant (k(a)) 4.1h(-1), central volume of distribution (V1) 91 L, peripheral volume of distribution (V2) 237 L, clearance (CL) 33 L/h, intercompartment clearance (Q) 35 L/h and absorption lag time 0.21 h.",Population pharmacokinetics of mycophenolic acid in renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16176120/),[l] / [h],33,256213,DB00091,Cyclosporine
,16176120,intercompartment clearance (Q),"The following population parameters were estimated: absorption rate constant (k(a)) 4.1h(-1), central volume of distribution (V1) 91 L, peripheral volume of distribution (V2) 237 L, clearance (CL) 33 L/h, intercompartment clearance (Q) 35 L/h and absorption lag time 0.21 h.",Population pharmacokinetics of mycophenolic acid in renal transplant recipients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16176120/),[l] / [h],35,256214,DB00091,Cyclosporine
,16176120,absorption lag time,"The following population parameters were estimated: absorption rate constant (k(a)) 4.1h(-1), central volume of distribution (V1) 91 L, peripheral volume of distribution (V2) 237 L, clearance (CL) 33 L/h, intercompartment clearance (Q) 35 L/h and absorption lag time 0.21 h.",Population pharmacokinetics of mycophenolic acid in renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16176120/),h,0.21,256215,DB00091,Cyclosporine
,14517192,AUC0-12,"Carriers of haplotype 12 (2677G and 3435T), which has previously been associated with increased digoxin AUC values, had a median AUC0-12 of 18.9 micro g*h*L-1 (range: 9.0-35.2) compared to 17.5 micro g*h*L-1 (range: 7.5-37.1) in the noncarrier group.",MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14517192/),[h·μg] / [l],18.9,256400,DB00091,Cyclosporine
,14517192,AUC0-12,"Carriers of haplotype 12 (2677G and 3435T), which has previously been associated with increased digoxin AUC values, had a median AUC0-12 of 18.9 micro g*h*L-1 (range: 9.0-35.2) compared to 17.5 micro g*h*L-1 (range: 7.5-37.1) in the noncarrier group.",MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14517192/),[h·μg] / [l],17.5,256401,DB00091,Cyclosporine
,15795646,AUC level,"In the CC group, MMF doses were adjusted based on the calculated AUC, targeting at an AUC level of 45 mg.h/L.",Predicting the usefulness of therapeutic drug monitoring of mycophenolic acid: a computer simulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795646/),[h·mg] / [l],45,256570,DB00091,Cyclosporine
,15795646,AUC,"On day 7 after transplantation, significantly more AUC values were on target (AUC range 30-60 mg.h/L) in the CC group than in the FD group: 76% versus 13%, respectively, P < 0.001.",Predicting the usefulness of therapeutic drug monitoring of mycophenolic acid: a computer simulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795646/),[h·mg] / [l],30-60,256571,DB00091,Cyclosporine
,12021631,AUC(12h),"Values (median [range]) of AcMPAG-AUC(12h) (10.1 [3.30-30.1] mg.h/L), AcMPAG-C(0) (0.48 [0.08-1.43] mg/L), and AcMPAG-C(max) (1.95 [0.88-5.35] mg/L) were significantly (p < 0.05) higher in the stable phase than in the initial phase: 3.54 [2.07-20.0] mg.h/L for AUC(12h); 0.25 [<0.04-0.97] mg/L for C(0), and 1.12 [0.32-2.44] mg/L for C(max).",Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021631/),[h·mg] / [l],10.1,257284,DB00091,Cyclosporine
,12021631,C(0),"Values (median [range]) of AcMPAG-AUC(12h) (10.1 [3.30-30.1] mg.h/L), AcMPAG-C(0) (0.48 [0.08-1.43] mg/L), and AcMPAG-C(max) (1.95 [0.88-5.35] mg/L) were significantly (p < 0.05) higher in the stable phase than in the initial phase: 3.54 [2.07-20.0] mg.h/L for AUC(12h); 0.25 [<0.04-0.97] mg/L for C(0), and 1.12 [0.32-2.44] mg/L for C(max).",Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021631/),[mg] / [l],0.48,257285,DB00091,Cyclosporine
,12021631,C(max),"Values (median [range]) of AcMPAG-AUC(12h) (10.1 [3.30-30.1] mg.h/L), AcMPAG-C(0) (0.48 [0.08-1.43] mg/L), and AcMPAG-C(max) (1.95 [0.88-5.35] mg/L) were significantly (p < 0.05) higher in the stable phase than in the initial phase: 3.54 [2.07-20.0] mg.h/L for AUC(12h); 0.25 [<0.04-0.97] mg/L for C(0), and 1.12 [0.32-2.44] mg/L for C(max).",Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021631/),[mg] / [l],1.95,257286,DB00091,Cyclosporine
,12021631,AUC(12h),"Values (median [range]) of AcMPAG-AUC(12h) (10.1 [3.30-30.1] mg.h/L), AcMPAG-C(0) (0.48 [0.08-1.43] mg/L), and AcMPAG-C(max) (1.95 [0.88-5.35] mg/L) were significantly (p < 0.05) higher in the stable phase than in the initial phase: 3.54 [2.07-20.0] mg.h/L for AUC(12h); 0.25 [<0.04-0.97] mg/L for C(0), and 1.12 [0.32-2.44] mg/L for C(max).",Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021631/),[h·mg] / [l],3.54,257287,DB00091,Cyclosporine
,12021631,C(0),"Values (median [range]) of AcMPAG-AUC(12h) (10.1 [3.30-30.1] mg.h/L), AcMPAG-C(0) (0.48 [0.08-1.43] mg/L), and AcMPAG-C(max) (1.95 [0.88-5.35] mg/L) were significantly (p < 0.05) higher in the stable phase than in the initial phase: 3.54 [2.07-20.0] mg.h/L for AUC(12h); 0.25 [<0.04-0.97] mg/L for C(0), and 1.12 [0.32-2.44] mg/L for C(max).",Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021631/),[mg] / [l],0.25,257288,DB00091,Cyclosporine
,12021631,C(max),"Values (median [range]) of AcMPAG-AUC(12h) (10.1 [3.30-30.1] mg.h/L), AcMPAG-C(0) (0.48 [0.08-1.43] mg/L), and AcMPAG-C(max) (1.95 [0.88-5.35] mg/L) were significantly (p < 0.05) higher in the stable phase than in the initial phase: 3.54 [2.07-20.0] mg.h/L for AUC(12h); 0.25 [<0.04-0.97] mg/L for C(0), and 1.12 [0.32-2.44] mg/L for C(max).",Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021631/),[mg] / [l],1.12,257289,DB00091,Cyclosporine
,17460256,cumulative release,"The cumulative release over the 400-day assay period from implants A and B was 3.8 +/- 0.3 and 2.3 +/- 0.3 mg, respectively.",A pharmacokinetic and safety evaluation of an episcleral cyclosporine implant for potential use in high-risk keratoplasty rejection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17460256/),mg,3.8,257370,DB00091,Cyclosporine
,17460256,cumulative release,"The cumulative release over the 400-day assay period from implants A and B was 3.8 +/- 0.3 and 2.3 +/- 0.3 mg, respectively.",A pharmacokinetic and safety evaluation of an episcleral cyclosporine implant for potential use in high-risk keratoplasty rejection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17460256/),mg,2.3,257371,DB00091,Cyclosporine
less,3514043,bioavailability,The bioavailability of cyclosporin ranges from less than 5% to 89% in transplant patients; poor absorption has frequently been observed in liver and kidney transplant patients and in bone marrow recipients.,Clinical pharmacokinetics of cyclosporin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3514043/),%,5,257444,DB00091,Cyclosporine
,3514043,bioavailability,The bioavailability of cyclosporin ranges from less than 5% to 89% in transplant patients; poor absorption has frequently been observed in liver and kidney transplant patients and in bone marrow recipients.,Clinical pharmacokinetics of cyclosporin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3514043/),%,89,257445,DB00091,Cyclosporine
,3514043,volume of distribution,The volume of distribution (whole blood; HPLC) ranges from 0.9 to 4.8 L/kg.,Clinical pharmacokinetics of cyclosporin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3514043/),[l] / [kg],0.9 to 4.8,257446,DB00091,Cyclosporine
,3514043,blood to plasma ratio,Cyclosporin is highly bound to erythrocytes and plasma proteins and has a blood to plasma ratio of approximately 2.,Clinical pharmacokinetics of cyclosporin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3514043/),,2,257447,DB00091,Cyclosporine
,15041382,C2,"There were no significant differences in median CsA C2 values and CNa between the CsA alone and the CsA+MMF groups (388 microg/L and 497.5 microg/L and CNa 2h; 3.92% alkaline phosphatase [AP]; 3.94% AP, respectively).",New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041382/),[μg] / [l],388,257636,DB00091,Cyclosporine
,15041382,CNa,"There were no significant differences in median CsA C2 values and CNa between the CsA alone and the CsA+MMF groups (388 microg/L and 497.5 microg/L and CNa 2h; 3.92% alkaline phosphatase [AP]; 3.94% AP, respectively).",New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041382/),[μg] / [l],497.5,257637,DB00091,Cyclosporine
,15041382,CNa,"There were no significant differences in median CsA C2 values and CNa between the CsA alone and the CsA+MMF groups (388 microg/L and 497.5 microg/L and CNa 2h; 3.92% alkaline phosphatase [AP]; 3.94% AP, respectively).",New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041382/),h,2,257638,DB00091,Cyclosporine
,15041382,CNa,"There were no significant differences in median CsA C2 values and CNa between the CsA alone and the CsA+MMF groups (388 microg/L and 497.5 microg/L and CNa 2h; 3.92% alkaline phosphatase [AP]; 3.94% AP, respectively).",New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041382/),%,3.92,257639,DB00091,Cyclosporine
,15041382,CNa,"There were no significant differences in median CsA C2 values and CNa between the CsA alone and the CsA+MMF groups (388 microg/L and 497.5 microg/L and CNa 2h; 3.92% alkaline phosphatase [AP]; 3.94% AP, respectively).",New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041382/),%,3.94,257640,DB00091,Cyclosporine
,15041382,IL-2,"In vitro production of IL-2 was significantly lower in the CsA+MMF group than in the CsA group (median IL-2 2h: 280.52 ng/L, 169.48 ng/L, P<.001).",New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041382/),[ng] / [l],280.52,257641,DB00091,Cyclosporine
,15041382,IL-2,"In vitro production of IL-2 was significantly lower in the CsA+MMF group than in the CsA group (median IL-2 2h: 280.52 ng/L, 169.48 ng/L, P<.001).",New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041382/),[ng] / [l],169.48,257642,DB00091,Cyclosporine
,15041382,2h,"In vitro production of IL-2 was significantly lower in the CsA+MMF group than in the CsA group (median IL-2 2h: 280.52 ng/L, 169.48 ng/L, P<.001).",New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041382/),[ng] / [l],280.52,257643,DB00091,Cyclosporine
,15041382,2h,"In vitro production of IL-2 was significantly lower in the CsA+MMF group than in the CsA group (median IL-2 2h: 280.52 ng/L, 169.48 ng/L, P<.001).",New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041382/),[ng] / [l],169.48,257644,DB00091,Cyclosporine
below,15041382,C2,"In stable renal transplant patients, median CsA C2 values below 500 microg/L were associated with inhibition of CNa and IL-2 synthesis.",New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041382/),[μg] / [l],500,257645,DB00091,Cyclosporine
,11350887,MTD,The MTD of DP without PSC 833 was 35 mg/m(2) doxorubicin and 150 mg/m(2) paclitaxel.,"A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11350887/),mg,35,257766,DB00091,Cyclosporine
,11350887,MTD,The MTD of DPV without G-CSF was 12.5 mg/m(2) doxorubicin and 70 mg/m(2) paclitaxel.,"A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11350887/),mg,12.5,257767,DB00091,Cyclosporine
,27128614,maximum concentration (Cmax ),"Mean (±SD) sirolimus maximum concentration (Cmax ), area under the concentration-time curve within a dosing interval of τ (AUCτ ), oral clearance (CL/F), and trough concentration (Ctrough ) at steady state were: 14.1 ± 13.4 ng/mL, 199 ± 210 ng · h/mL, 10.1 ± 4.4 L/h, and 5.9 ± 6.3 ng/mL, respectively.",Steady-state pharmacokinetics of sirolimus in stable adult Chinese renal transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128614/),[ng] / [ml],14.1,258131,DB00091,Cyclosporine
,27128614,area under the concentration-time curve within a dosing interval of τ (AUCτ ),"Mean (±SD) sirolimus maximum concentration (Cmax ), area under the concentration-time curve within a dosing interval of τ (AUCτ ), oral clearance (CL/F), and trough concentration (Ctrough ) at steady state were: 14.1 ± 13.4 ng/mL, 199 ± 210 ng · h/mL, 10.1 ± 4.4 L/h, and 5.9 ± 6.3 ng/mL, respectively.",Steady-state pharmacokinetics of sirolimus in stable adult Chinese renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128614/),[h·ng] / [ml],199,258132,DB00091,Cyclosporine
,27128614,area under the concentration-time curve within a dosing interval of τ (AUCτ ),"Mean (±SD) sirolimus maximum concentration (Cmax ), area under the concentration-time curve within a dosing interval of τ (AUCτ ), oral clearance (CL/F), and trough concentration (Ctrough ) at steady state were: 14.1 ± 13.4 ng/mL, 199 ± 210 ng · h/mL, 10.1 ± 4.4 L/h, and 5.9 ± 6.3 ng/mL, respectively.",Steady-state pharmacokinetics of sirolimus in stable adult Chinese renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128614/),[l] / [h],10.1,258133,DB00091,Cyclosporine
,27128614,oral clearance (CL/F),"Mean (±SD) sirolimus maximum concentration (Cmax ), area under the concentration-time curve within a dosing interval of τ (AUCτ ), oral clearance (CL/F), and trough concentration (Ctrough ) at steady state were: 14.1 ± 13.4 ng/mL, 199 ± 210 ng · h/mL, 10.1 ± 4.4 L/h, and 5.9 ± 6.3 ng/mL, respectively.",Steady-state pharmacokinetics of sirolimus in stable adult Chinese renal transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128614/),[h·ng] / [ml],199,258134,DB00091,Cyclosporine
,27128614,oral clearance (CL/F),"Mean (±SD) sirolimus maximum concentration (Cmax ), area under the concentration-time curve within a dosing interval of τ (AUCτ ), oral clearance (CL/F), and trough concentration (Ctrough ) at steady state were: 14.1 ± 13.4 ng/mL, 199 ± 210 ng · h/mL, 10.1 ± 4.4 L/h, and 5.9 ± 6.3 ng/mL, respectively.",Steady-state pharmacokinetics of sirolimus in stable adult Chinese renal transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128614/),[l] / [h],10.1,258135,DB00091,Cyclosporine
,27128614,trough concentration (Ctrough ) at steady state,"Mean (±SD) sirolimus maximum concentration (Cmax ), area under the concentration-time curve within a dosing interval of τ (AUCτ ), oral clearance (CL/F), and trough concentration (Ctrough ) at steady state were: 14.1 ± 13.4 ng/mL, 199 ± 210 ng · h/mL, 10.1 ± 4.4 L/h, and 5.9 ± 6.3 ng/mL, respectively.",Steady-state pharmacokinetics of sirolimus in stable adult Chinese renal transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128614/),[ng] / [ml],5.9,258136,DB00091,Cyclosporine
,27128614,tmax,Median tmax (range) was 2.49 hours (1-12 hours).,Steady-state pharmacokinetics of sirolimus in stable adult Chinese renal transplant patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128614/),h,2.49,258137,DB00091,Cyclosporine
,17201457,Oral bioavailability,"Oral bioavailability of MPA, subsequent to mycophenolate mofetil administration, ranges from 80.7% to 94%.",Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201457/),%,80.7,258222,DB00091,Cyclosporine
,17201457,Oral bioavailability,"Oral bioavailability of MPA, subsequent to mycophenolate mofetil administration, ranges from 80.7% to 94%.",Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201457/),%,94,258223,DB00091,Cyclosporine
,17201457,absolute bioavailability,EC-mycophenolate sodium has an absolute bioavailability of MPA of approximately 72%.,Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201457/),%,72,258224,DB00091,Cyclosporine
,17201457,lag time in absorption,EC-mycophenolate sodium exhibits a median lag time in absorption of MPA from 0.25 to 1.25 hours.,Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201457/),h,0.25 to 1.25,258225,DB00091,Cyclosporine
,17201457,elimination half-life,The mean elimination half-life of MPA ranges from 9 to 17 hours.,Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201457/),h,9 to 17,258226,DB00091,Cyclosporine
,17201457,CL/F,"In population pharmacokinetic studies, MPA CL/F in adults ranges from 14.1 to 34.9 L/h (ciclosporin co-therapy) and from 11.9 to 25.4 L/h (tacrolimus co-therapy).",Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201457/),[l] / [h],14.1 to 34.9,258227,DB00091,Cyclosporine
,17201457,CL/F,"In population pharmacokinetic studies, MPA CL/F in adults ranges from 14.1 to 34.9 L/h (ciclosporin co-therapy) and from 11.9 to 25.4 L/h (tacrolimus co-therapy).",Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201457/),[l] / [h],11.9 to 25.4,258228,DB00091,Cyclosporine
,17201457,AUC from 0 to 12 hours (AUC12),Targeting a total MPA AUC from 0 to 12 hours (AUC12) of 30-60 mg.,Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201457/),mg,30-60,258229,DB00091,Cyclosporine
,25072223,Peak miosis,"Peak miosis was similar in controls and cyclosporine-treated subjects after oral methadone (1.4±0.4 and 1.3±0.5 mm/mg, respectively) and IV methadone (3.1±1.0 and 3.2±0.8 mm, respectively).",Cyclosporine-inhibitable cerebral drug transport does not influence clinical methadone pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25072223/),[mm] / [mg],1.4,258605,DB00091,Cyclosporine
,25072223,Peak miosis,"Peak miosis was similar in controls and cyclosporine-treated subjects after oral methadone (1.4±0.4 and 1.3±0.5 mm/mg, respectively) and IV methadone (3.1±1.0 and 3.2±0.8 mm, respectively).",Cyclosporine-inhibitable cerebral drug transport does not influence clinical methadone pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25072223/),[mm] / [mg],1.3,258606,DB00091,Cyclosporine
,25072223,Peak miosis,"Peak miosis was similar in controls and cyclosporine-treated subjects after oral methadone (1.4±0.4 and 1.3±0.5 mm/mg, respectively) and IV methadone (3.1±1.0 and 3.2±0.8 mm, respectively).",Cyclosporine-inhibitable cerebral drug transport does not influence clinical methadone pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25072223/),mm,3.1,258607,DB00091,Cyclosporine
,25072223,Peak miosis,"Peak miosis was similar in controls and cyclosporine-treated subjects after oral methadone (1.4±0.4 and 1.3±0.5 mm/mg, respectively) and IV methadone (3.1±1.0 and 3.2±0.8 mm, respectively).",Cyclosporine-inhibitable cerebral drug transport does not influence clinical methadone pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25072223/),mm,3.2,258608,DB00091,Cyclosporine
,22054177,bioavailability,"In lung transplant recipients, the bioavailability was, on average, 31% lower in patients with cystic fibrosis than in patients without cystic fibrosis (p < 0.001).","Bayesian estimation of mycophenolate mofetil in lung transplantation, using a population pharmacokinetic model developed in kidney and lung transplant recipients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22054177/),%,31,259227,DB00091,Cyclosporine
,9791160,Cmax,"After the introduction of enteral feeding, the peak levels increased (Cmax, 655 ng/mL) and were achieved significantly sooner (Tmax, 2 hours).",Efficacy of Neoral in the immediate postoperative period in children post-liver transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9791160/),[ng] / [ml],655,259389,DB00091,Cyclosporine
,9791160,Tmax,"After the introduction of enteral feeding, the peak levels increased (Cmax, 655 ng/mL) and were achieved significantly sooner (Tmax, 2 hours).",Efficacy of Neoral in the immediate postoperative period in children post-liver transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9791160/),h,2,259390,DB00091,Cyclosporine
,16573602,C0,Mean C0 and C2 were 96.2 +/- 59.5 and 504 +/- 305.4 ng/mL respectively.,Cyclosporine drug monitoring with C0 and C2 concentrations in children with stable renal allograft function. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16573602/),[ng] / [ml],96.2,259396,DB00091,Cyclosporine
,16573602,C2,Mean C0 and C2 were 96.2 +/- 59.5 and 504 +/- 305.4 ng/mL respectively.,Cyclosporine drug monitoring with C0 and C2 concentrations in children with stable renal allograft function. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16573602/),[ng] / [ml],504,259397,DB00091,Cyclosporine
,15167630,absorption rate constant (k(a)),"Typical values for the absorption rate constant (k(a)), elimination rate constant (k(el)), apparent volume of distribution for the central compartment (Vd/F), and oral clearance (CL/F) calculated by population pharmacokinetic analysis were 2.16 hours(-1), 0.547 hours(-1), 43.3 L, and 23.7 L/h, respectively.",Dose adjustment strategy for oral microemulsion formulation of cyclosporine: population pharmacokinetics-based analysis in kidney transplant patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15167630/),1/[hours],2.16,259664,DB00091,Cyclosporine
,15167630,elimination rate constant (k(el)),"Typical values for the absorption rate constant (k(a)), elimination rate constant (k(el)), apparent volume of distribution for the central compartment (Vd/F), and oral clearance (CL/F) calculated by population pharmacokinetic analysis were 2.16 hours(-1), 0.547 hours(-1), 43.3 L, and 23.7 L/h, respectively.",Dose adjustment strategy for oral microemulsion formulation of cyclosporine: population pharmacokinetics-based analysis in kidney transplant patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15167630/),1/[hours],0.547,259665,DB00091,Cyclosporine
,15167630,elimination rate constant (k(el)),"Typical values for the absorption rate constant (k(a)), elimination rate constant (k(el)), apparent volume of distribution for the central compartment (Vd/F), and oral clearance (CL/F) calculated by population pharmacokinetic analysis were 2.16 hours(-1), 0.547 hours(-1), 43.3 L, and 23.7 L/h, respectively.",Dose adjustment strategy for oral microemulsion formulation of cyclosporine: population pharmacokinetics-based analysis in kidney transplant patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15167630/),l,43.3,259666,DB00091,Cyclosporine
,15167630,apparent volume of distribution for the central compartment (Vd/F),"Typical values for the absorption rate constant (k(a)), elimination rate constant (k(el)), apparent volume of distribution for the central compartment (Vd/F), and oral clearance (CL/F) calculated by population pharmacokinetic analysis were 2.16 hours(-1), 0.547 hours(-1), 43.3 L, and 23.7 L/h, respectively.",Dose adjustment strategy for oral microemulsion formulation of cyclosporine: population pharmacokinetics-based analysis in kidney transplant patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15167630/),1/[hours],0.547,259667,DB00091,Cyclosporine
,15167630,apparent volume of distribution for the central compartment (Vd/F),"Typical values for the absorption rate constant (k(a)), elimination rate constant (k(el)), apparent volume of distribution for the central compartment (Vd/F), and oral clearance (CL/F) calculated by population pharmacokinetic analysis were 2.16 hours(-1), 0.547 hours(-1), 43.3 L, and 23.7 L/h, respectively.",Dose adjustment strategy for oral microemulsion formulation of cyclosporine: population pharmacokinetics-based analysis in kidney transplant patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15167630/),l,43.3,259668,DB00091,Cyclosporine
,15167630,oral clearance (CL/F),"Typical values for the absorption rate constant (k(a)), elimination rate constant (k(el)), apparent volume of distribution for the central compartment (Vd/F), and oral clearance (CL/F) calculated by population pharmacokinetic analysis were 2.16 hours(-1), 0.547 hours(-1), 43.3 L, and 23.7 L/h, respectively.",Dose adjustment strategy for oral microemulsion formulation of cyclosporine: population pharmacokinetics-based analysis in kidney transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15167630/),[l] / [h],23.7,259669,DB00091,Cyclosporine
,21406600,half-life,Mean half-life increased from 25 to 45 hours.,Effect of cyclosporine on the pharmacokinetics of aliskiren in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21406600/),h,25 to 45,259687,DB00091,Cyclosporine
,1352812,disposition half-lives,"Following i.v. infusion, cyclosporin exhibited triphasic behaviour with mean +/- s.e.m. disposition half-lives of 9.0 +/- 1.3 min, 4.0 +/- 0.5 h and 16.0 +/- 1.7 h.",Absorption kinetics of cyclosporin in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352812/),min,9.0,259748,DB00091,Cyclosporine
,1352812,disposition half-lives,"Following i.v. infusion, cyclosporin exhibited triphasic behaviour with mean +/- s.e.m. disposition half-lives of 9.0 +/- 1.3 min, 4.0 +/- 0.5 h and 16.0 +/- 1.7 h.",Absorption kinetics of cyclosporin in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352812/),h,4.0,259749,DB00091,Cyclosporine
,1352812,disposition half-lives,"Following i.v. infusion, cyclosporin exhibited triphasic behaviour with mean +/- s.e.m. disposition half-lives of 9.0 +/- 1.3 min, 4.0 +/- 0.5 h and 16.0 +/- 1.7 h.",Absorption kinetics of cyclosporin in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352812/),h,16.0,259750,DB00091,Cyclosporine
,1352812,peak blood concentration (Cmax),"Following oral administration, peak blood concentration (Cmax) of 1290 +/- 93 ng mL-1 was reached after 5 h, when cyclosporin absorption essentially ceased.",Absorption kinetics of cyclosporin in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352812/),[ng] / [ml],1290,259751,DB00091,Cyclosporine
,1352812,absolute bioavailability (F),The absolute bioavailability (F) of cyclosporin was 24.0%.,Absorption kinetics of cyclosporin in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352812/),%,24.0,259752,DB00091,Cyclosporine
,24935294,C0,"In this phase 3, multicenter, randomized, open-label study, patients were randomized (1:1) to 1 of the 2 groups: everolimus 1.5 mg (targeted C0 of 3-8 ng/mL) plus reduced-dose cyclosporine or mycophenolate mofetil 2 g/d plus standard-dose cyclosporine.",Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24935294/),[ng] / [ml],3-8,259795,DB00091,Cyclosporine
,24935294,trough concentration,"Everolimus mean trough concentration was 4.307 ± 1.2459 ng/mL and mean peak concentration was 13.539 ± 3.5330 ng/mL, which peaked at 1 to 2 hours postdose.",Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24935294/),[ng] / [ml],4.307,259796,DB00091,Cyclosporine
,24935294,peak concentration,"Everolimus mean trough concentration was 4.307 ± 1.2459 ng/mL and mean peak concentration was 13.539 ± 3.5330 ng/mL, which peaked at 1 to 2 hours postdose.",Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24935294/),[ng] / [ml],13.539,259797,DB00091,Cyclosporine
,24935294,area under the concentration-time curve,"The average concentration was 7.558 ± 1.4723 ng/mL, area under the concentration-time curve was 90.70 ± 17.667 ng·h/mL, and peak-trough fluctuation was 122.6%.",Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24935294/),[h·ng] / [ml],90.70,259798,DB00091,Cyclosporine
,24935294,trough levels,"The mean everolimus trough levels were within the target ranges at all time points ranging from 3.4 to 5.5 ng/mL (everolimus 0.75 mg twice a day, safety population).",Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24935294/),[ng] / [ml],3.4 to 5.5,259799,DB00091,Cyclosporine
,15127586,relative bioavailability,"The relative bioavailability in rats was 101.6%, with a smaller absorption rate (P < 0.05) and a smaller elimination rate (P < 0.1).",[Study on preparation conditions for polylactide nanoparticles loaded cyclosporine A and its oral bioavailability in rats]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15127586/),%,101.6,260189,DB00091,Cyclosporine
,24548445,AUC0-12 h,There were variable MPA AUC0-12 h levels between 14 and 67 mg×h/L (mean: 37 ± 14).,[Use of limited sampling strategy for estimating area under concentration-versus-time curve of mycophenolate sodium in renal allograft recipients]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24548445/),,37,260384,DB00091,Cyclosporine
,17640939,"AUC(ss, 0-12)","An AUC(ss, 0-12) of 45 mg h/l could be attained with an MMF dose of 12 mg/kg BD.",Is a standard fixed dose of mycophenolate mofetil ideal for all patients? ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17640939/),[h·mg] / [l],45,260907,DB00091,Cyclosporine
,21168621,C(0),We enrolled 10 de novo kidney transplant recipients to receive CsA (target C(0) 250-350 ng/mL) and prednisolone as initial therapy.,Long-term outcome of very early cyclosporine minimization and de novo everolimus therapy in kidney transplant recipients: a pharmacokinetic guided approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168621/),[ng] / [ml],250-350,260925,DB00091,Cyclosporine
,21168621,target,"Everolimus (target trough level, 3-8 ng/mL) was concomitantly started at the day of CsA reduction.",Long-term outcome of very early cyclosporine minimization and de novo everolimus therapy in kidney transplant recipients: a pharmacokinetic guided approach. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168621/),[ng] / [ml],3-8,260926,DB00091,Cyclosporine
,21168621,trough level,"Everolimus (target trough level, 3-8 ng/mL) was concomitantly started at the day of CsA reduction.",Long-term outcome of very early cyclosporine minimization and de novo everolimus therapy in kidney transplant recipients: a pharmacokinetic guided approach. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168621/),[ng] / [ml],3-8,260927,DB00091,Cyclosporine
,21168621,trough level,CsA was then gradually reduced to maintain a trough level of 50-100 ng/mL and/or C(max) <600 ng/mL.,Long-term outcome of very early cyclosporine minimization and de novo everolimus therapy in kidney transplant recipients: a pharmacokinetic guided approach. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168621/),[ng] / [ml],50-100,260928,DB00091,Cyclosporine
<,21168621,C(max),CsA was then gradually reduced to maintain a trough level of 50-100 ng/mL and/or C(max) <600 ng/mL.,Long-term outcome of very early cyclosporine minimization and de novo everolimus therapy in kidney transplant recipients: a pharmacokinetic guided approach. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168621/),[ng] / [ml],600,260929,DB00091,Cyclosporine
,21168621,initial trough everolimus,The mean initial trough everolimus was 5.2 ± 1.5 ng/mL.,Long-term outcome of very early cyclosporine minimization and de novo everolimus therapy in kidney transplant recipients: a pharmacokinetic guided approach. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168621/),[ng] / [ml],5.2,260930,DB00091,Cyclosporine
,2716940,Absolute bioavailability,Absolute bioavailability (18%) was also diminished.,[Pharmacokinetics of cyclosporin A in patients with nephrotic syndrome]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2716940/),%,18,261594,DB00091,Cyclosporine
,16534473,AUC(0-12),"The main pharmacokinetic features were: AUC(0-12): Cysporin 3495+/-1319, Neoral 3853+/-1378 (P<0.05); C(max): Cysporin 755+/-301, Neoral 881+/-368 (P<0.05); C(2): Cysporin 613+/-235, Neoral 672+/-255 (P>0.05); T(max): Cysporin 1.9+/-0.8, Neoral 1.4+/-0.6 (P<0.005); and T1/2: Cysporin 8.8+/-4.3, Neoral 8.7+/-6.2 (P>0.05).",Assessment of the bioequivalence of a generic cyclosporine A by a randomized controlled trial in stable renal recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16534473/),,3495,261618,DB00091,Cyclosporine
,16534473,AUC(0-12),"The main pharmacokinetic features were: AUC(0-12): Cysporin 3495+/-1319, Neoral 3853+/-1378 (P<0.05); C(max): Cysporin 755+/-301, Neoral 881+/-368 (P<0.05); C(2): Cysporin 613+/-235, Neoral 672+/-255 (P>0.05); T(max): Cysporin 1.9+/-0.8, Neoral 1.4+/-0.6 (P<0.005); and T1/2: Cysporin 8.8+/-4.3, Neoral 8.7+/-6.2 (P>0.05).",Assessment of the bioequivalence of a generic cyclosporine A by a randomized controlled trial in stable renal recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16534473/),,3853,261619,DB00091,Cyclosporine
,16534473,C(max),"The main pharmacokinetic features were: AUC(0-12): Cysporin 3495+/-1319, Neoral 3853+/-1378 (P<0.05); C(max): Cysporin 755+/-301, Neoral 881+/-368 (P<0.05); C(2): Cysporin 613+/-235, Neoral 672+/-255 (P>0.05); T(max): Cysporin 1.9+/-0.8, Neoral 1.4+/-0.6 (P<0.005); and T1/2: Cysporin 8.8+/-4.3, Neoral 8.7+/-6.2 (P>0.05).",Assessment of the bioequivalence of a generic cyclosporine A by a randomized controlled trial in stable renal recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16534473/),,755,261620,DB00091,Cyclosporine
,16534473,C(max),"The main pharmacokinetic features were: AUC(0-12): Cysporin 3495+/-1319, Neoral 3853+/-1378 (P<0.05); C(max): Cysporin 755+/-301, Neoral 881+/-368 (P<0.05); C(2): Cysporin 613+/-235, Neoral 672+/-255 (P>0.05); T(max): Cysporin 1.9+/-0.8, Neoral 1.4+/-0.6 (P<0.005); and T1/2: Cysporin 8.8+/-4.3, Neoral 8.7+/-6.2 (P>0.05).",Assessment of the bioequivalence of a generic cyclosporine A by a randomized controlled trial in stable renal recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16534473/),,881,261621,DB00091,Cyclosporine
,16534473,C(2),"The main pharmacokinetic features were: AUC(0-12): Cysporin 3495+/-1319, Neoral 3853+/-1378 (P<0.05); C(max): Cysporin 755+/-301, Neoral 881+/-368 (P<0.05); C(2): Cysporin 613+/-235, Neoral 672+/-255 (P>0.05); T(max): Cysporin 1.9+/-0.8, Neoral 1.4+/-0.6 (P<0.005); and T1/2: Cysporin 8.8+/-4.3, Neoral 8.7+/-6.2 (P>0.05).",Assessment of the bioequivalence of a generic cyclosporine A by a randomized controlled trial in stable renal recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16534473/),,613,261622,DB00091,Cyclosporine
,16534473,C(2),"The main pharmacokinetic features were: AUC(0-12): Cysporin 3495+/-1319, Neoral 3853+/-1378 (P<0.05); C(max): Cysporin 755+/-301, Neoral 881+/-368 (P<0.05); C(2): Cysporin 613+/-235, Neoral 672+/-255 (P>0.05); T(max): Cysporin 1.9+/-0.8, Neoral 1.4+/-0.6 (P<0.005); and T1/2: Cysporin 8.8+/-4.3, Neoral 8.7+/-6.2 (P>0.05).",Assessment of the bioequivalence of a generic cyclosporine A by a randomized controlled trial in stable renal recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16534473/),,672,261623,DB00091,Cyclosporine
,16534473,T(max),"The main pharmacokinetic features were: AUC(0-12): Cysporin 3495+/-1319, Neoral 3853+/-1378 (P<0.05); C(max): Cysporin 755+/-301, Neoral 881+/-368 (P<0.05); C(2): Cysporin 613+/-235, Neoral 672+/-255 (P>0.05); T(max): Cysporin 1.9+/-0.8, Neoral 1.4+/-0.6 (P<0.005); and T1/2: Cysporin 8.8+/-4.3, Neoral 8.7+/-6.2 (P>0.05).",Assessment of the bioequivalence of a generic cyclosporine A by a randomized controlled trial in stable renal recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16534473/),,1.9,261624,DB00091,Cyclosporine
,16534473,T(max),"The main pharmacokinetic features were: AUC(0-12): Cysporin 3495+/-1319, Neoral 3853+/-1378 (P<0.05); C(max): Cysporin 755+/-301, Neoral 881+/-368 (P<0.05); C(2): Cysporin 613+/-235, Neoral 672+/-255 (P>0.05); T(max): Cysporin 1.9+/-0.8, Neoral 1.4+/-0.6 (P<0.005); and T1/2: Cysporin 8.8+/-4.3, Neoral 8.7+/-6.2 (P>0.05).",Assessment of the bioequivalence of a generic cyclosporine A by a randomized controlled trial in stable renal recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16534473/),,1.4,261625,DB00091,Cyclosporine
,16534473,T1/2,"The main pharmacokinetic features were: AUC(0-12): Cysporin 3495+/-1319, Neoral 3853+/-1378 (P<0.05); C(max): Cysporin 755+/-301, Neoral 881+/-368 (P<0.05); C(2): Cysporin 613+/-235, Neoral 672+/-255 (P>0.05); T(max): Cysporin 1.9+/-0.8, Neoral 1.4+/-0.6 (P<0.005); and T1/2: Cysporin 8.8+/-4.3, Neoral 8.7+/-6.2 (P>0.05).",Assessment of the bioequivalence of a generic cyclosporine A by a randomized controlled trial in stable renal recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16534473/),,8.8,261626,DB00091,Cyclosporine
,16534473,T1/2,"The main pharmacokinetic features were: AUC(0-12): Cysporin 3495+/-1319, Neoral 3853+/-1378 (P<0.05); C(max): Cysporin 755+/-301, Neoral 881+/-368 (P<0.05); C(2): Cysporin 613+/-235, Neoral 672+/-255 (P>0.05); T(max): Cysporin 1.9+/-0.8, Neoral 1.4+/-0.6 (P<0.005); and T1/2: Cysporin 8.8+/-4.3, Neoral 8.7+/-6.2 (P>0.05).",Assessment of the bioequivalence of a generic cyclosporine A by a randomized controlled trial in stable renal recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16534473/),,8.7,261627,DB00091,Cyclosporine
,12021632,t(max),"According to their genotypes, mean t(max) 1.6 +/- 0.3 hours, mean C(max) 1337 +/- 329 ng/mL, mean Cl/F 66.5 +/- 18.3 L/h, and mean AUC 5642 +/- 1577 ng.h/mL in C/C group and mean t(max) 2.0 +/- 0.6 hours, mean C(max) 1540 +/- 721 ng/mL, mean Cl/F 55.2 +/- 18.9 L/h, and mean AUC 6902 +/- 1405 ng.h/mL in C/T+T/T group.",C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021632/),h,1.6,261930,DB00091,Cyclosporine
,12021632,C(max),"According to their genotypes, mean t(max) 1.6 +/- 0.3 hours, mean C(max) 1337 +/- 329 ng/mL, mean Cl/F 66.5 +/- 18.3 L/h, and mean AUC 5642 +/- 1577 ng.h/mL in C/C group and mean t(max) 2.0 +/- 0.6 hours, mean C(max) 1540 +/- 721 ng/mL, mean Cl/F 55.2 +/- 18.9 L/h, and mean AUC 6902 +/- 1405 ng.h/mL in C/T+T/T group.",C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021632/),[ng] / [ml],1337,261931,DB00091,Cyclosporine
,12021632,Cl/F,"According to their genotypes, mean t(max) 1.6 +/- 0.3 hours, mean C(max) 1337 +/- 329 ng/mL, mean Cl/F 66.5 +/- 18.3 L/h, and mean AUC 5642 +/- 1577 ng.h/mL in C/C group and mean t(max) 2.0 +/- 0.6 hours, mean C(max) 1540 +/- 721 ng/mL, mean Cl/F 55.2 +/- 18.9 L/h, and mean AUC 6902 +/- 1405 ng.h/mL in C/T+T/T group.",C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021632/),[l] / [h],66.5,261932,DB00091,Cyclosporine
,12021632,AUC,"According to their genotypes, mean t(max) 1.6 +/- 0.3 hours, mean C(max) 1337 +/- 329 ng/mL, mean Cl/F 66.5 +/- 18.3 L/h, and mean AUC 5642 +/- 1577 ng.h/mL in C/C group and mean t(max) 2.0 +/- 0.6 hours, mean C(max) 1540 +/- 721 ng/mL, mean Cl/F 55.2 +/- 18.9 L/h, and mean AUC 6902 +/- 1405 ng.h/mL in C/T+T/T group.",C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021632/),[h·ng] / [ml],5642,261933,DB00091,Cyclosporine
,12021632,t(max),"According to their genotypes, mean t(max) 1.6 +/- 0.3 hours, mean C(max) 1337 +/- 329 ng/mL, mean Cl/F 66.5 +/- 18.3 L/h, and mean AUC 5642 +/- 1577 ng.h/mL in C/C group and mean t(max) 2.0 +/- 0.6 hours, mean C(max) 1540 +/- 721 ng/mL, mean Cl/F 55.2 +/- 18.9 L/h, and mean AUC 6902 +/- 1405 ng.h/mL in C/T+T/T group.",C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021632/),h,2.0,261934,DB00091,Cyclosporine
,12021632,C(max),"According to their genotypes, mean t(max) 1.6 +/- 0.3 hours, mean C(max) 1337 +/- 329 ng/mL, mean Cl/F 66.5 +/- 18.3 L/h, and mean AUC 5642 +/- 1577 ng.h/mL in C/C group and mean t(max) 2.0 +/- 0.6 hours, mean C(max) 1540 +/- 721 ng/mL, mean Cl/F 55.2 +/- 18.9 L/h, and mean AUC 6902 +/- 1405 ng.h/mL in C/T+T/T group.",C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021632/),[ng] / [ml],1540,261935,DB00091,Cyclosporine
,12021632,Cl/F,"According to their genotypes, mean t(max) 1.6 +/- 0.3 hours, mean C(max) 1337 +/- 329 ng/mL, mean Cl/F 66.5 +/- 18.3 L/h, and mean AUC 5642 +/- 1577 ng.h/mL in C/C group and mean t(max) 2.0 +/- 0.6 hours, mean C(max) 1540 +/- 721 ng/mL, mean Cl/F 55.2 +/- 18.9 L/h, and mean AUC 6902 +/- 1405 ng.h/mL in C/T+T/T group.",C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021632/),[l] / [h],55.2,261936,DB00091,Cyclosporine
,12021632,AUC,"According to their genotypes, mean t(max) 1.6 +/- 0.3 hours, mean C(max) 1337 +/- 329 ng/mL, mean Cl/F 66.5 +/- 18.3 L/h, and mean AUC 5642 +/- 1577 ng.h/mL in C/C group and mean t(max) 2.0 +/- 0.6 hours, mean C(max) 1540 +/- 721 ng/mL, mean Cl/F 55.2 +/- 18.9 L/h, and mean AUC 6902 +/- 1405 ng.h/mL in C/T+T/T group.",C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021632/),[h·ng] / [ml],6902,261937,DB00091,Cyclosporine
,18217908,C2,"In the study observation period in weeks 4-15, the median (25-75 percentile) C2 was 568 (469-750) ng/mL for group A; 1055 (840-1224) ng/mL for group B; and 764 (575-959) ng/mL for group C.",Cyclosporine pharmacokinetics and blood pressure responses after conversion to once-daily dosing in maintenance liver transplant patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18217908/),[ng] / [ml],568,262008,DB00091,Cyclosporine
,18217908,C2,"In the study observation period in weeks 4-15, the median (25-75 percentile) C2 was 568 (469-750) ng/mL for group A; 1055 (840-1224) ng/mL for group B; and 764 (575-959) ng/mL for group C.",Cyclosporine pharmacokinetics and blood pressure responses after conversion to once-daily dosing in maintenance liver transplant patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18217908/),[ng] / [ml],1055,262009,DB00091,Cyclosporine
,18217908,C2,"In the study observation period in weeks 4-15, the median (25-75 percentile) C2 was 568 (469-750) ng/mL for group A; 1055 (840-1224) ng/mL for group B; and 764 (575-959) ng/mL for group C.",Cyclosporine pharmacokinetics and blood pressure responses after conversion to once-daily dosing in maintenance liver transplant patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18217908/),[ng] / [ml],764,262010,DB00091,Cyclosporine
,1971578,half-life (t1/2B),"The isolated metabolite was administered iv to three rabbits at a dose of 1.0 mg/kg with the following mean pharmacokinetic parameters being determined: half-life (t1/2B) 2.22 hr, volume of distribution (Vss) 1.44 liters/kg, and clearance 11.07 ml/min/kg.",Pharmacokinetics and biotransformation of the cyclosporine metabolite M-17 in the rabbit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971578/),h,2.22,262421,DB00091,Cyclosporine
,1971578,volume of distribution (Vss),"The isolated metabolite was administered iv to three rabbits at a dose of 1.0 mg/kg with the following mean pharmacokinetic parameters being determined: half-life (t1/2B) 2.22 hr, volume of distribution (Vss) 1.44 liters/kg, and clearance 11.07 ml/min/kg.",Pharmacokinetics and biotransformation of the cyclosporine metabolite M-17 in the rabbit. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971578/),[l] / [kg],1.44,262422,DB00091,Cyclosporine
,1971578,clearance,"The isolated metabolite was administered iv to three rabbits at a dose of 1.0 mg/kg with the following mean pharmacokinetic parameters being determined: half-life (t1/2B) 2.22 hr, volume of distribution (Vss) 1.44 liters/kg, and clearance 11.07 ml/min/kg.",Pharmacokinetics and biotransformation of the cyclosporine metabolite M-17 in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971578/),[ml] / [kg·min],11.07,262423,DB00091,Cyclosporine
,22764422,oral bioavailability,The oral bioavailability of the coated solid CsA SNEDDS pellets was (74.89 +/- 25.34) % and (81.44 +/- 27.96) % that of its liquid counterpart (the liquid CsA SNEDDS) and Neoral respectively The liquid CsA SNEDDS was bioequivalent to Neoral.,Solid self-nanoemulsifying cyclosporine A pellets prepared by fluid-bed coating: stability and bioavailability study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22764422/),%,74.89,262483,DB00091,Cyclosporine
,22764422,oral bioavailability,The oral bioavailability of the coated solid CsA SNEDDS pellets was (74.89 +/- 25.34) % and (81.44 +/- 27.96) % that of its liquid counterpart (the liquid CsA SNEDDS) and Neoral respectively The liquid CsA SNEDDS was bioequivalent to Neoral.,Solid self-nanoemulsifying cyclosporine A pellets prepared by fluid-bed coating: stability and bioavailability study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22764422/),%,81.44,262484,DB00091,Cyclosporine
,9776421,Elimination half-life,Elimination half-life was longer in the 9 cyclosporine-treated subjects (108.0+/-13.6 min) than in the other nine (71.2+/-8.3 min; p <0.02).,Pharmacokinetics of deflazacort in renal transplanted and hemodialyzed children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9776421/),min,108.0,262698,DB00091,Cyclosporine
,9776421,Elimination half-life,Elimination half-life was longer in the 9 cyclosporine-treated subjects (108.0+/-13.6 min) than in the other nine (71.2+/-8.3 min; p <0.02).,Pharmacokinetics of deflazacort in renal transplanted and hemodialyzed children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9776421/),min,71.2,262699,DB00091,Cyclosporine
,25747979,Absolute bioavailability,Absolute bioavailability of morin was dramatically increased by the oral administration of morin-loaded PluronicF127 and Tween80 mixed micelle from 0.4% to 11.2% without changing the systemic clearance and half-life.,Enhanced oral bioavailability of morin administered in mixed micelle formulation with PluronicF127 and Tween80 in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25747979/),%,0.4,262729,DB00091,Cyclosporine
,25747979,Absolute bioavailability,Absolute bioavailability of morin was dramatically increased by the oral administration of morin-loaded PluronicF127 and Tween80 mixed micelle from 0.4% to 11.2% without changing the systemic clearance and half-life.,Enhanced oral bioavailability of morin administered in mixed micelle formulation with PluronicF127 and Tween80 in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25747979/),%,11.2,262730,DB00091,Cyclosporine
,2045532,Bioavailability,Bioavailability was 18 +/- 7% (mean +/- SD) for the oral dose and was unmeasurable for the oil and water enemas.,"The pharmacokinetics and colonic tissue concentrations of cyclosporine after i.v., oral, and enema administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2045532/),%,18,262998,DB00091,Cyclosporine
,18197560,apparent plasma clearance (CL),"During initial screening, 1 exhibited an apparent plasma clearance (CL) of 227 ml min(-1) kg(-1) in Sprague-Dawley rats following an intravenous bolus dose formulated in an aqueous solution containing 40% polyethylene glycol.",Importance of mechanistic drug metabolism studies in support of drug discovery: A case study with an N -sulfonylated dipeptide VLA-4 antagonist in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18197560/),[ml] / [kg·min],227,263246,DB00091,Cyclosporine
,18197560,apparent plasma CL,"However, the apparent plasma CL was reduced to 97 ml in(-1) kg(-1) when a 2-min time point was added to sample collections, and further decreased to 48 ml min(-1) kg(-1) after the dose was formulated in rat plasma.",Importance of mechanistic drug metabolism studies in support of drug discovery: A case study with an N -sulfonylated dipeptide VLA-4 antagonist in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18197560/),[ml] / [in·kg],97,263247,DB00091,Cyclosporine
,18197560,apparent plasma CL,"However, the apparent plasma CL was reduced to 97 ml in(-1) kg(-1) when a 2-min time point was added to sample collections, and further decreased to 48 ml min(-1) kg(-1) after the dose was formulated in rat plasma.",Importance of mechanistic drug metabolism studies in support of drug discovery: A case study with an N -sulfonylated dipeptide VLA-4 antagonist in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18197560/),[ml] / [kg·min],48,263248,DB00091,Cyclosporine
>,18197560,hepatic extraction,"The lung extraction of 1 in rats was negligible whereas the hepatic extraction was > or =90%, based on comparison of area under the curve (AUC) values derived from intra-artery, intravenous, and portal vein administration.",Importance of mechanistic drug metabolism studies in support of drug discovery: A case study with an N -sulfonylated dipeptide VLA-4 antagonist in rats. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18197560/),%,90,263249,DB00091,Cyclosporine
,21161198,clearance (CL/F),"The estimated clearance (CL/F) was 49.5 l·h(-1), the volume of distribution (Vd/F) was 226 l.",Population pharmacokinetic study of cyclosporine in Chinese renal transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21161198/),[l] / [h],49.5,263548,DB00091,Cyclosporine
,21161198,volume of distribution (Vd/F),"The estimated clearance (CL/F) was 49.5 l·h(-1), the volume of distribution (Vd/F) was 226 l.",Population pharmacokinetic study of cyclosporine in Chinese renal transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21161198/),l,226,263549,DB00091,Cyclosporine
,21161198,K(a),K(a) was fixed as 1.25 h(-1).,Population pharmacokinetic study of cyclosporine in Chinese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21161198/),1/[h],1.25,263550,DB00091,Cyclosporine
,21161198,AUC,"The AUC estimated based on the Bayesian method was 7,465 ± 1,708 ng·h·ml(-1) (2,946 ∼13,926 ng·h·ml(-1)).",Population pharmacokinetic study of cyclosporine in Chinese renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21161198/),[h·ng] / [ml],"7,465",263551,DB00091,Cyclosporine
,21161198,AUC,"The AUC estimated based on the Bayesian method was 7,465 ± 1,708 ng·h·ml(-1) (2,946 ∼13,926 ng·h·ml(-1)).",Population pharmacokinetic study of cyclosporine in Chinese renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21161198/),∼13,"2,946",263552,DB00091,Cyclosporine
,21161198,AUC,"The AUC estimated based on the Bayesian method was 7,465 ± 1,708 ng·h·ml(-1) (2,946 ∼13,926 ng·h·ml(-1)).",Population pharmacokinetic study of cyclosporine in Chinese renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21161198/),[h·ng] / [ml],926,263553,DB00091,Cyclosporine
,11419964,C(max)(ss),"After switching from standard formulation CsA-SCG to CsA-ME, significant changes were observed in C(max)(ss)( 732 +/- 178 vs 935 +/- 250 ng ml(-1), P< 0.001) and t(max)( 2.63 +/- 1.21 vs 1.36 +/- 0.49 h, P< 0.001).",Pharmacokinetics of two oral cyclosporin a formulations in clinically stable heart-transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11419964/),[ng] / [ml],732,264167,DB00091,Cyclosporine
,11419964,C(max)(ss),"After switching from standard formulation CsA-SCG to CsA-ME, significant changes were observed in C(max)(ss)( 732 +/- 178 vs 935 +/- 250 ng ml(-1), P< 0.001) and t(max)( 2.63 +/- 1.21 vs 1.36 +/- 0.49 h, P< 0.001).",Pharmacokinetics of two oral cyclosporin a formulations in clinically stable heart-transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11419964/),[ng] / [ml],935,264168,DB00091,Cyclosporine
,11419964,t(max),"After switching from standard formulation CsA-SCG to CsA-ME, significant changes were observed in C(max)(ss)( 732 +/- 178 vs 935 +/- 250 ng ml(-1), P< 0.001) and t(max)( 2.63 +/- 1.21 vs 1.36 +/- 0.49 h, P< 0.001).",Pharmacokinetics of two oral cyclosporin a formulations in clinically stable heart-transplant patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11419964/),h,2.63,264169,DB00091,Cyclosporine
,11419964,t(max),"After switching from standard formulation CsA-SCG to CsA-ME, significant changes were observed in C(max)(ss)( 732 +/- 178 vs 935 +/- 250 ng ml(-1), P< 0.001) and t(max)( 2.63 +/- 1.21 vs 1.36 +/- 0.49 h, P< 0.001).",Pharmacokinetics of two oral cyclosporin a formulations in clinically stable heart-transplant patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11419964/),h,1.36,264170,DB00091,Cyclosporine
,11419964,bioavailability,The CsA-ME mean bioavailability was higher than CsA-SCG ( 75 +/- 19 vs 66 +/- 16%;P< 0.001).,Pharmacokinetics of two oral cyclosporin a formulations in clinically stable heart-transplant patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11419964/),%,75,264171,DB00091,Cyclosporine
,11419964,bioavailability,The CsA-ME mean bioavailability was higher than CsA-SCG ( 75 +/- 19 vs 66 +/- 16%;P< 0.001).,Pharmacokinetics of two oral cyclosporin a formulations in clinically stable heart-transplant patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11419964/),%,66,264172,DB00091,Cyclosporine
,21757611,efflux ratio,"Two P-glycoprotein (P-gp) inhibitors, verapamil and cyclosporine A, substantially decreased the efflux ratio of Rh2s from 28.5 to 1.0 and 1.2, respectively, in Caco-2 cells.",Enhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21757611/),,28.5,264320,DB00091,Cyclosporine
,21757611,efflux ratio,"Two P-glycoprotein (P-gp) inhibitors, verapamil and cyclosporine A, substantially decreased the efflux ratio of Rh2s from 28.5 to 1.0 and 1.2, respectively, in Caco-2 cells.",Enhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21757611/),,1.0,264321,DB00091,Cyclosporine
,21757611,efflux ratio,"Two P-glycoprotein (P-gp) inhibitors, verapamil and cyclosporine A, substantially decreased the efflux ratio of Rh2s from 28.5 to 1.0 and 1.2, respectively, in Caco-2 cells.",Enhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21757611/),,1.2,264322,DB00091,Cyclosporine
,21757611,oral bioavailability,"In the A/J mice, the oral bioavailability of Rh2s (0.94% at 5 mg/kg and 0.52% at 20 mg/kg) was substantially increased by P-gp inhibitor to 33.18 and 27.14%, respectively.",Enhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21757611/),%,0.94,264323,DB00091,Cyclosporine
,21757611,oral bioavailability,"In the A/J mice, the oral bioavailability of Rh2s (0.94% at 5 mg/kg and 0.52% at 20 mg/kg) was substantially increased by P-gp inhibitor to 33.18 and 27.14%, respectively.",Enhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21757611/),%,0.52,264324,DB00091,Cyclosporine
,21757611,oral bioavailability,"In the A/J mice, the oral bioavailability of Rh2s (0.94% at 5 mg/kg and 0.52% at 20 mg/kg) was substantially increased by P-gp inhibitor to 33.18 and 27.14%, respectively.",Enhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21757611/),%,33.18,264325,DB00091,Cyclosporine
,21757611,oral bioavailability,"In the A/J mice, the oral bioavailability of Rh2s (0.94% at 5 mg/kg and 0.52% at 20 mg/kg) was substantially increased by P-gp inhibitor to 33.18 and 27.14%, respectively.",Enhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21757611/),%,27.14,264326,DB00091,Cyclosporine
,16269051,t(max),"After a brief lag phase (t(lag) 0.75 h), MPA was rapidly absorbed (t(max) 2.5 h) and rapidly converted to MPAG (t(max) 3.25 h), with relatively high plasma concentrations of MPAG (C(max) 67.7 microg/mL) compared with MPA (C(max) 36.3 microg/mL).",Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269051/),h,2.5,264550,DB00091,Cyclosporine
,16269051,t(max),"After a brief lag phase (t(lag) 0.75 h), MPA was rapidly absorbed (t(max) 2.5 h) and rapidly converted to MPAG (t(max) 3.25 h), with relatively high plasma concentrations of MPAG (C(max) 67.7 microg/mL) compared with MPA (C(max) 36.3 microg/mL).",Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269051/),h,3.25,264551,DB00091,Cyclosporine
,16269051,C(max),"After a brief lag phase (t(lag) 0.75 h), MPA was rapidly absorbed (t(max) 2.5 h) and rapidly converted to MPAG (t(max) 3.25 h), with relatively high plasma concentrations of MPAG (C(max) 67.7 microg/mL) compared with MPA (C(max) 36.3 microg/mL).",Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269051/),[μg] / [ml],67.7,264552,DB00091,Cyclosporine
,16269051,C(max),"After a brief lag phase (t(lag) 0.75 h), MPA was rapidly absorbed (t(max) 2.5 h) and rapidly converted to MPAG (t(max) 3.25 h), with relatively high plasma concentrations of MPAG (C(max) 67.7 microg/mL) compared with MPA (C(max) 36.3 microg/mL).",Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269051/),[μg] / [ml],36.3,264553,DB00091,Cyclosporine
,16269051,elimination half-life,"The elimination half-life for MPAG was slightly longer than for MPA (approximately 13 h vs. 8.5 h), and the apparent oral clearance of MPA was approximately 0.2 L/h/kg.",Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269051/),h,13,264554,DB00091,Cyclosporine
,16269051,elimination half-life,"The elimination half-life for MPAG was slightly longer than for MPA (approximately 13 h vs. 8.5 h), and the apparent oral clearance of MPA was approximately 0.2 L/h/kg.",Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269051/),h,8.5,264555,DB00091,Cyclosporine
,16269051,apparent oral clearance,"The elimination half-life for MPAG was slightly longer than for MPA (approximately 13 h vs. 8.5 h), and the apparent oral clearance of MPA was approximately 0.2 L/h/kg.",Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269051/),[l] / [h·kg],0.2,264556,DB00091,Cyclosporine
,30359668,Kd,"The resultant fusion protein, termed CA192, which assembles into a dimeric species in solution, effectively binds and solubilizes CsA with a Kd of 189 nM, comparable to that of endogenous CypA with a Kd of 35.5 nM.",A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30359668/),nM,189,265008,DB00091,Cyclosporine
,30359668,Kd,"The resultant fusion protein, termed CA192, which assembles into a dimeric species in solution, effectively binds and solubilizes CsA with a Kd of 189 nM, comparable to that of endogenous CypA with a Kd of 35.5 nM.",A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30359668/),nM,35.5,265009,DB00091,Cyclosporine
,30359668,half-life,The release profile of CsA from CA192 follows a one phase decay model with a half-life of 957.3 h without a burst release stage.,A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30359668/),h,957.3,265010,DB00091,Cyclosporine
,30359668,IC50,"Moreover, CA192-CsA inhibited IL-2 expression induced in Jurkat cells through the calcineurin-NFAT signaling pathway with an IC50 of 1.2 nM, comparable to that of free CsA with an IC50 of 0.5 nM.",A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30359668/),nM,1.2,265011,DB00091,Cyclosporine
,30359668,IC50,"Moreover, CA192-CsA inhibited IL-2 expression induced in Jurkat cells through the calcineurin-NFAT signaling pathway with an IC50 of 1.2 nM, comparable to that of free CsA with an IC50 of 0.5 nM.",A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30359668/),nM,0.5,265012,DB00091,Cyclosporine
,30359668,mean residence time,The intravenous pharmacokinetics of CA192 followed a two-compartment model with a mean residence time of 7.3 h.,A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30359668/),h,7.3,265013,DB00091,Cyclosporine
,30359668,bioavailability,Subcutaneous administration revealed a bioavailability of 30% and a mean residence time of 15.9 h.,A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30359668/),%,30,265014,DB00091,Cyclosporine
,30359668,mean residence time,Subcutaneous administration revealed a bioavailability of 30% and a mean residence time of 15.9 h.,A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30359668/),h,15.9,265015,DB00091,Cyclosporine
,14749696,peak plasma concentration (C(max)),"The mean peak plasma concentration (C(max)) of pravastatin was 122.2 +/- 88.2 ng/mL (range, 11.4-305.0 ng/mL), and the area under the plasma concentration-time curve of pravastatin from 0 to 10 hours [AUC(0-10)] was 264.1 +/- 192.4 ng.h/mL (range, 30.8-701.6 ng.h/mL).",Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749696/),[ng] / [ml],122.2,265126,DB00091,Cyclosporine
,14749696,area under the plasma concentration-time curve of pravastatin from 0 to 10 hours [AUC(0-10)],"The mean peak plasma concentration (C(max)) of pravastatin was 122.2 +/- 88.2 ng/mL (range, 11.4-305.0 ng/mL), and the area under the plasma concentration-time curve of pravastatin from 0 to 10 hours [AUC(0-10)] was 264.1 +/- 192.4 ng.h/mL (range, 30.8-701.6 ng.h/mL).",Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749696/),[h·ng] / [ml],264.1,265127,DB00091,Cyclosporine
,14749696,time of peak concentration (t(max)),"The time of peak concentration (t(max)) of pravastatin was 1.1 +/- 0.4 hours (range, 0.5-2 hours), and the mean elimination half-life (t(1/2)) was 1.2 +/- 0.3 hours (range, 0.7-2.2 hours); these parameters were similar to those in the hypercholesterolemic children.",Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749696/),h,1.1,265128,DB00091,Cyclosporine
,14749696,elimination half-life (t(1/2)),"The time of peak concentration (t(max)) of pravastatin was 1.1 +/- 0.4 hours (range, 0.5-2 hours), and the mean elimination half-life (t(1/2)) was 1.2 +/- 0.3 hours (range, 0.7-2.2 hours); these parameters were similar to those in the hypercholesterolemic children.",Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749696/),h,1.2,265129,DB00091,Cyclosporine
,11437692,area under the concentration-time curve over the first 4 hours postdose (AUC(0-4h)),"In a prospective trial in de novo renal transplant recipients, patients who achieved target concentrations for area under the concentration-time curve over the first 4 hours postdose (AUC(0-4h)) of 4500 to 5500 ng.",C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11437692/),ng,4500 to 5500,265149,DB00091,Cyclosporine
,24673717,AUC,"The mean (range) MPA AUC was 42 ± 14.67 (29.29-75.95) mg/l h after the first dose, and 44.72 ± 14.57 (32.06-80.79) mg/l h on day 4 after operation.",Lower dosing of enteric-coated mycophenolate sodium (Myfortic) can achieve target mycophenolic acid exposure rapidly in most Chinese renal transplant patients: a pilot study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673717/),[mg] / [h·l],42,265447,DB00091,Cyclosporine
,24673717,AUC,"The mean (range) MPA AUC was 42 ± 14.67 (29.29-75.95) mg/l h after the first dose, and 44.72 ± 14.57 (32.06-80.79) mg/l h on day 4 after operation.",Lower dosing of enteric-coated mycophenolate sodium (Myfortic) can achieve target mycophenolic acid exposure rapidly in most Chinese renal transplant patients: a pilot study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673717/),[mg] / [h·l],44.72,265448,DB00091,Cyclosporine
,2338370,Vm,"Only in 3 cases were saturable Michaelis-Menten kinetics observed (Vm = 23 ng/ml h-1, Km = 636 ng/ml).",Slow accumulation of cyclosporin metabolites as measured by specific and nonspecific cyclosporin RIA. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338370/),[ng] / [h·ml],23,265500,DB00091,Cyclosporine
,2338370,Km,"Only in 3 cases were saturable Michaelis-Menten kinetics observed (Vm = 23 ng/ml h-1, Km = 636 ng/ml).",Slow accumulation of cyclosporin metabolites as measured by specific and nonspecific cyclosporin RIA. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338370/),[ng] / [ml],636,265501,DB00091,Cyclosporine
,2338370,Bioavailability,Bioavailability was 0.72 as estimated from first-pass extraction.,Slow accumulation of cyclosporin metabolites as measured by specific and nonspecific cyclosporin RIA. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338370/),,0.72,265502,DB00091,Cyclosporine
,2338370,elimination half-life,The median values (5-95% CI) for the elimination half-life of nonspecific RIA concentrations increased from 5 h (2.5-6.2) on day 2 after transplantation to 10 h (9.2-11) after long-term dosage.,Slow accumulation of cyclosporin metabolites as measured by specific and nonspecific cyclosporin RIA. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338370/),h,5,265503,DB00091,Cyclosporine
,2338370,elimination half-life,The median values (5-95% CI) for the elimination half-life of nonspecific RIA concentrations increased from 5 h (2.5-6.2) on day 2 after transplantation to 10 h (9.2-11) after long-term dosage.,Slow accumulation of cyclosporin metabolites as measured by specific and nonspecific cyclosporin RIA. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338370/),h,10,265504,DB00091,Cyclosporine
,2338370,elimination half-life,"The specific monoclonal antibody data revealed an elimination half-life of 6.4 h (5.6-7.7) for parent cyclosporin, which was unchanged after multiple dosing.",Slow accumulation of cyclosporin metabolites as measured by specific and nonspecific cyclosporin RIA. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338370/),h,6.4,265505,DB00091,Cyclosporine
,2338370,elimination half-life,"After month 6, the elimination half-life of specific monoclonal antibody data was significantly shorter (p = 0.03) than elimination half-life of nonspecific RIA concentrations (6.6 vs 9.1 h).",Slow accumulation of cyclosporin metabolites as measured by specific and nonspecific cyclosporin RIA. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338370/),h,6.6,265506,DB00091,Cyclosporine
,2338370,elimination half-life,"After month 6, the elimination half-life of specific monoclonal antibody data was significantly shorter (p = 0.03) than elimination half-life of nonspecific RIA concentrations (6.6 vs 9.1 h).",Slow accumulation of cyclosporin metabolites as measured by specific and nonspecific cyclosporin RIA. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338370/),h,9.1,265507,DB00091,Cyclosporine
above,10228992,AUC,"By analysis of rejection episodes and toxicity, we estimated a target AUC above 5,000 ng x h/ml in the early post-transplant period and 3,900 ng x h/ml beyond 100 days.",Abbreviated cyclosporine AUCs on Neoral--the search continues! ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10228992/),[h·ng] / [ml],"5,000",265572,DB00091,Cyclosporine
,10228992,AUC,"By analysis of rejection episodes and toxicity, we estimated a target AUC above 5,000 ng x h/ml in the early post-transplant period and 3,900 ng x h/ml beyond 100 days.",Abbreviated cyclosporine AUCs on Neoral--the search continues! ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10228992/),[h·ng] / [ml],"3,900",265573,DB00091,Cyclosporine
,10228992,C3,"From our data, we recommend a target C3 at approximately 800 ng/ml early after transplantation and 450-550 ng/ml beyond 100 days.",Abbreviated cyclosporine AUCs on Neoral--the search continues! ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10228992/),[ng] / [ml],800,265574,DB00091,Cyclosporine
,10228992,C3,"From our data, we recommend a target C3 at approximately 800 ng/ml early after transplantation and 450-550 ng/ml beyond 100 days.",Abbreviated cyclosporine AUCs on Neoral--the search continues! ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10228992/),[ng] / [ml],450-550,265575,DB00091,Cyclosporine
,20735037,k,"The k values were 19.0±5.9 and 18.8±3.8 at the doses of 10 and 20 mg/kg, respectively.",Analysis of biliary excretion of icariin in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20735037/),,19.0,265933,DB00091,Cyclosporine
,20735037,k,"The k values were 19.0±5.9 and 18.8±3.8 at the doses of 10 and 20 mg/kg, respectively.",Analysis of biliary excretion of icariin in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20735037/),,18.8,265934,DB00091,Cyclosporine
,20735037,k,"The decreased biliary excretion of icariin due to pretreatment with CsA was evidenced by the reduced k values (18.8±3.8 vs 9.9±1.9, p=0.005).",Analysis of biliary excretion of icariin in rats. ,Km-Q52,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20735037/),,18.8,265935,DB00091,Cyclosporine
,20735037,k,"The decreased biliary excretion of icariin due to pretreatment with CsA was evidenced by the reduced k values (18.8±3.8 vs 9.9±1.9, p=0.005).",Analysis of biliary excretion of icariin in rats. ,Km-Q52,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20735037/),,9.9,265936,DB00091,Cyclosporine
,9431828,trough concentrations,Mean trough concentrations of cyclosporine in whole blood were 349 microg l-1 before and 242 microg l-1 after simvastatin administration (P < 0.0001).,Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431828/),[μg] / [l],349,265958,DB00091,Cyclosporine
,9431828,trough concentrations,Mean trough concentrations of cyclosporine in whole blood were 349 microg l-1 before and 242 microg l-1 after simvastatin administration (P < 0.0001).,Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431828/),[μg] / [l],242,265959,DB00091,Cyclosporine
,9431828,DR/C(SS trough),The average cyclosporine DR/C(SS trough) was significantly increased from 24.5 l h-1 before to 28.9 l h-1 after simvastatin administration (P < 0.05).,Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431828/),[l] / [h],24.5,265960,DB00091,Cyclosporine
,9431828,DR/C(SS trough),The average cyclosporine DR/C(SS trough) was significantly increased from 24.5 l h-1 before to 28.9 l h-1 after simvastatin administration (P < 0.05).,Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431828/),[l] / [h],28.9,265961,DB00091,Cyclosporine
,17631021,C0,"Baseline CSA dose was 5.39 +/- 2.05 mg/kg/day (mean +/- s.d.), with mean C0 = 267 +/- 112, C2 = 1065 +/- 565, and AUC(0-5) = 3817 +/- 1435.",Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17631021/),,267,267103,DB00091,Cyclosporine
,17631021,C2,"Baseline CSA dose was 5.39 +/- 2.05 mg/kg/day (mean +/- s.d.), with mean C0 = 267 +/- 112, C2 = 1065 +/- 565, and AUC(0-5) = 3817 +/- 1435.",Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17631021/),,1065,267104,DB00091,Cyclosporine
,17631021,AUC(0-5),"Baseline CSA dose was 5.39 +/- 2.05 mg/kg/day (mean +/- s.d.), with mean C0 = 267 +/- 112, C2 = 1065 +/- 565, and AUC(0-5) = 3817 +/- 1435.",Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17631021/),,3817,267105,DB00091,Cyclosporine
,17631021,C2,"These seven participants completed 48 wk of study, with mean CSA dose decreasing to 4.55 +/- 3.61 mg/kg/day, maintaining mean C2 599 +/- 211 (vs. target C2 = 800).",Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17631021/),,599,267106,DB00091,Cyclosporine
,17631021,C2,"These seven participants completed 48 wk of study, with mean CSA dose decreasing to 4.55 +/- 3.61 mg/kg/day, maintaining mean C2 599 +/- 211 (vs. target C2 = 800).",Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17631021/),,800,267107,DB00091,Cyclosporine
>,17631021,C2 levels,"Five patients failed to achieve target C2 levels (>800) during the first four wk, despite comparable AUC values, and were maintained on trough monitoring (C0).",Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17631021/),,800,267108,DB00091,Cyclosporine
,11181682,area under the concentration-time curve (AUC),The mean (+/- SD) area under the concentration-time curve (AUC) in patients who received oral docetaxel 75 mg/m(2) without CsA was 0.37 +/- 0.33 mg.h/L and 2.71 +/- 1.81 mg.h/L for the same oral docetaxel dose with CsA.,Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11181682/),[h·mg] / [l],0.37,267598,DB00091,Cyclosporine
,11181682,area under the concentration-time curve (AUC),The mean (+/- SD) area under the concentration-time curve (AUC) in patients who received oral docetaxel 75 mg/m(2) without CsA was 0.37 +/- 0.33 mg.h/L and 2.71 +/- 1.81 mg.h/L for the same oral docetaxel dose with CsA.,Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11181682/),[h·mg] / [l],2.71,267599,DB00091,Cyclosporine
,11181682,AUC,The mean AUC of IV docetaxel 100 mg/m(2) was 4.41 +/- 2.10 mg.h/L.,Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11181682/),[h·mg] / [l],4.41,267600,DB00091,Cyclosporine
,11181682,absolute bioavailability,The absolute bioavailability of oral docetaxel was 8% +/- 6% without and 90% +/- 44% with CsA.,Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11181682/),%,8,267601,DB00091,Cyclosporine
,11181682,absolute bioavailability,The absolute bioavailability of oral docetaxel was 8% +/- 6% without and 90% +/- 44% with CsA.,Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11181682/),%,90,267602,DB00091,Cyclosporine
,32557653,clearance (CL/F),"Cyclosporine clearance (CL/F) was estimated as 15.1 L/h, and volume of distribution (V/F) was 108 L.",Population Pharmacokinetic Modeling of Cyclosporine Among Malaysian Renal Transplant Patients: An Evaluation of Methods to Handle Missing Doses in Conventional Drug-Monitoring Data. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32557653/),[l] / [h],15.1,267789,DB00091,Cyclosporine
,32557653,volume of distribution (V/F),"Cyclosporine clearance (CL/F) was estimated as 15.1 L/h, and volume of distribution (V/F) was 108 L.",Population Pharmacokinetic Modeling of Cyclosporine Among Malaysian Renal Transplant Patients: An Evaluation of Methods to Handle Missing Doses in Conventional Drug-Monitoring Data. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32557653/),l,108,267790,DB00091,Cyclosporine
,22105585,C₀ concentration,"Median daily CsA dosage was 150 mg (50-250), CsA C₀ concentration 102 mcg/L (range 33-157), and CsA C₂ concentration 551 mcg/L (range 254-1228).",Pharmacodynamic monitoring of cyclosporin A reveals risk of opportunistic infections and malignancies in renal transplant recipients 65 years and older. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22105585/),[mcg] / [l],102,268814,DB00091,Cyclosporine
,22105585,C₂ concentration,"Median daily CsA dosage was 150 mg (50-250), CsA C₀ concentration 102 mcg/L (range 33-157), and CsA C₂ concentration 551 mcg/L (range 254-1228).",Pharmacodynamic monitoring of cyclosporin A reveals risk of opportunistic infections and malignancies in renal transplant recipients 65 years and older. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22105585/),[mcg] / [l],551,268815,DB00091,Cyclosporine
,22446981,V,"The final model formula was: CL = 28.2 × [1 - 0.0263 × (HCT - 26.62)] × [1 - 0.0289 × (ALB - 37.63)] × [1 - 0.146 × ITR] (L/h); V = 1,080 (L); K (a) = 1.28 (h⁻¹); F = 0.711.",Population pharmacokinetics of cyclosporine A based on NONMEM in Chinese allogeneic hematopoietic stem cell transplantation recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22446981/),l,"1,080",270121,DB00091,Cyclosporine
,22446981,K (a),"The final model formula was: CL = 28.2 × [1 - 0.0263 × (HCT - 26.62)] × [1 - 0.0289 × (ALB - 37.63)] × [1 - 0.146 × ITR] (L/h); V = 1,080 (L); K (a) = 1.28 (h⁻¹); F = 0.711.",Population pharmacokinetics of cyclosporine A based on NONMEM in Chinese allogeneic hematopoietic stem cell transplantation recipients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22446981/),h⁻¹,1.28,270122,DB00091,Cyclosporine
,15020609,disease-free survival,The median disease-free survival in those achieving CR was similar in the two arms (10 versus 9.3 months) as was the patients' overall survival (4.6 versus 5.4 months).,"Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15020609/),month,10,270463,DB00091,Cyclosporine
,15020609,disease-free survival,The median disease-free survival in those achieving CR was similar in the two arms (10 versus 9.3 months) as was the patients' overall survival (4.6 versus 5.4 months).,"Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15020609/),month,9.3,270464,DB00091,Cyclosporine
,15020609,overall survival,The median disease-free survival in those achieving CR was similar in the two arms (10 versus 9.3 months) as was the patients' overall survival (4.6 versus 5.4 months).,"Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15020609/),month,4.6,270465,DB00091,Cyclosporine
,15020609,overall survival,The median disease-free survival in those achieving CR was similar in the two arms (10 versus 9.3 months) as was the patients' overall survival (4.6 versus 5.4 months).,"Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15020609/),month,5.4,270466,DB00091,Cyclosporine
,15020609,CR rates,The CR rates in MDR+ (69% of patients) versus MDR- patients were similar for those receiving either chemotherapy regimen (16% versus 24%).,"Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15020609/),%,16,270467,DB00091,Cyclosporine
,15020609,CR rates,The CR rates in MDR+ (69% of patients) versus MDR- patients were similar for those receiving either chemotherapy regimen (16% versus 24%).,"Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15020609/),,24,270468,DB00091,Cyclosporine
,15020609,CR rate,"The CR rate for unfavorable cytogenetic patients (45% of patients) was 13% compared to the remainder, 28% (P=.09).","Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15020609/),%,13,270469,DB00091,Cyclosporine
up to,7902206,steady-state levels,Conclusions from the initial phase I trial with the use of CsA as a modulator of etoposide are: (1) Serum CsA steady-state levels of up to 4800 ng/ml (4 microM) could be achieved with acceptable toxicity.,Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902206/),[ng] / [ml],4800,270936,DB00091,Cyclosporine
above,7902206,steady-state plasma CsA levels,"Renal toxicity was uncommon, but severe in two patients with steady-state plasma CsA levels above 6000 ng/ml.",Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902206/),[ng] / [ml],6000,270937,DB00091,Cyclosporine
,7902206,steady-state serum levels,(4) The recommended dose of CsA is a 6-7 mg/kg loading dose administered as a 2-hour intravenous infusion followed by a continuous infusion of 18-21 mg/kg/day for 60 hours with adjustments in the infusion rate to maintain steady-state serum levels of 3000-4800 ng/ml (2.5-4.0 M).,Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902206/),[ng] / [ml],3000-4800,270938,DB00091,Cyclosporine
,2266495,clearance,"When compared with Wistar rats (n = 10), dark Agouti rats (n = 10) had a higher mean clearance (4.8 ml/min per kg vs. 3.3 ml/min per kg) and a lower mean residence time (606 min vs. 1361 min) after intravenous dosing of CsA.",Pharmacokinetics and chronic toxicity of cyclosporine A in genetic hydroxylation-deficient dark Agouti rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2266495/),[ml] / [kg·min],4.8,272317,DB00091,Cyclosporine
,2266495,clearance,"When compared with Wistar rats (n = 10), dark Agouti rats (n = 10) had a higher mean clearance (4.8 ml/min per kg vs. 3.3 ml/min per kg) and a lower mean residence time (606 min vs. 1361 min) after intravenous dosing of CsA.",Pharmacokinetics and chronic toxicity of cyclosporine A in genetic hydroxylation-deficient dark Agouti rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2266495/),[ml] / [kg·min],3.3,272318,DB00091,Cyclosporine
,2266495,mean residence time,"When compared with Wistar rats (n = 10), dark Agouti rats (n = 10) had a higher mean clearance (4.8 ml/min per kg vs. 3.3 ml/min per kg) and a lower mean residence time (606 min vs. 1361 min) after intravenous dosing of CsA.",Pharmacokinetics and chronic toxicity of cyclosporine A in genetic hydroxylation-deficient dark Agouti rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2266495/),min,606,272319,DB00091,Cyclosporine
,2266495,mean residence time,"When compared with Wistar rats (n = 10), dark Agouti rats (n = 10) had a higher mean clearance (4.8 ml/min per kg vs. 3.3 ml/min per kg) and a lower mean residence time (606 min vs. 1361 min) after intravenous dosing of CsA.",Pharmacokinetics and chronic toxicity of cyclosporine A in genetic hydroxylation-deficient dark Agouti rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2266495/),min,1361,272320,DB00091,Cyclosporine
,2266495,systemic availability,The systemic availability of subcutaneous CsA was close to 100%.,Pharmacokinetics and chronic toxicity of cyclosporine A in genetic hydroxylation-deficient dark Agouti rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2266495/),%,100,272321,DB00091,Cyclosporine
,2266495,steady state CsA concentrations,The steady state CsA concentrations assessed by HPLC in whole blood after subcutaneous dosing of 20 mg/kg per day for 23 days (n = 10) were about 1000 ng/ml in dark Agouti rats.,Pharmacokinetics and chronic toxicity of cyclosporine A in genetic hydroxylation-deficient dark Agouti rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2266495/),[ng] / [ml],1000,272322,DB00091,Cyclosporine
,8652269,half-life,"In a preliminary pharmacokinetic investigation, Ro 44-5912 appeared to have a longer half-life in mice than did its (R) enantiomer Ro 44-5911 (3.15 +/- 0.02 h versus 2.15 +/- 0.14 h) as measured by total radiolabel in plasma.",The dithiane Ro 44-5912 enhances vinblastine sensitivity of drug resistant and parental KB lines in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8652269/),h,3.15,272928,DB00091,Cyclosporine
,8652269,half-life,"In a preliminary pharmacokinetic investigation, Ro 44-5912 appeared to have a longer half-life in mice than did its (R) enantiomer Ro 44-5911 (3.15 +/- 0.02 h versus 2.15 +/- 0.14 h) as measured by total radiolabel in plasma.",The dithiane Ro 44-5912 enhances vinblastine sensitivity of drug resistant and parental KB lines in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8652269/),h,2.15,272929,DB00091,Cyclosporine
,34096287,oral bioavailability (F,"CsO exhibited a higher plasma concentration than CsA, which resulted from minimal CypA binding and lower accumulation in red blood cells and moderate oral bioavailability (F = 12%).","Interplay among Conformation, Intramolecular Hydrogen Bonds, and Chameleonicity in the Membrane Permeability and Cyclophilin A Binding of Macrocyclic Peptide Cyclosporin O Derivatives. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34096287/),%,12,273026,DB00091,Cyclosporine
,27117038,absorption rate constant (Ka),"The estimates of absorption rate constant (Ka), clearance (CL/F), and central volume of distribution (V2/F) were 0.24 h(-1), 8.81 L/h, and 676 L, respectively.",Population pharmacokinetic characteristics of sirolimus in healthy Chinese subjects and renal transplant patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27117038/),1/[h],0.24,273202,DB00091,Cyclosporine
,27117038,clearance (CL/F),"The estimates of absorption rate constant (Ka), clearance (CL/F), and central volume of distribution (V2/F) were 0.24 h(-1), 8.81 L/h, and 676 L, respectively.",Population pharmacokinetic characteristics of sirolimus in healthy Chinese subjects and renal transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27117038/),[l] / [h],8.81,273203,DB00091,Cyclosporine
,27117038,central volume of distribution (V2/F),"The estimates of absorption rate constant (Ka), clearance (CL/F), and central volume of distribution (V2/F) were 0.24 h(-1), 8.81 L/h, and 676 L, respectively.",Population pharmacokinetic characteristics of sirolimus in healthy Chinese subjects and renal transplant patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27117038/),l,676,273204,DB00091,Cyclosporine
,19005405,saturation duration,A cross-study comparison revealed that MMF reduced basiliximab clearance and prolonged CD25 saturation duration from approximately 5 weeks in the absence of MMF to 10 weeks in the presence of MMF.,Pharmacokinetics and immunodynamics of basiliximab in pediatric renal transplant recipients on mycophenolate mofetil comedication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19005405/),weeks,5,273332,DB00091,Cyclosporine
,19005405,saturation duration,A cross-study comparison revealed that MMF reduced basiliximab clearance and prolonged CD25 saturation duration from approximately 5 weeks in the absence of MMF to 10 weeks in the presence of MMF.,Pharmacokinetics and immunodynamics of basiliximab in pediatric renal transplant recipients on mycophenolate mofetil comedication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19005405/),weeks,10,273333,DB00091,Cyclosporine
,9068926,peak drug plasma concentration (Cmax),"Plasma concentrations in healthy volunteers reach a mean peak drug plasma concentration (Cmax) of approximately 2.8 and 5.2 mg/L within 1 to 2 hours after oral administration of levofloxacin 250 and 500mg tablets, respectively.",The clinical pharmacokinetics of levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[mg] / [l],2.8,273446,DB00091,Cyclosporine
,9068926,peak drug plasma concentration (Cmax),"Plasma concentrations in healthy volunteers reach a mean peak drug plasma concentration (Cmax) of approximately 2.8 and 5.2 mg/L within 1 to 2 hours after oral administration of levofloxacin 250 and 500mg tablets, respectively.",The clinical pharmacokinetics of levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[mg] / [l],5.2,273447,DB00091,Cyclosporine
,9068926,bioavailability,The bioavailability of oral levofloxacin approaches 100% and is little affected by the administration with food.,The clinical pharmacokinetics of levofloxacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),%,100,273448,DB00091,Cyclosporine
,9068926,Cmax,"Single oral doses of levofloxacin 50 to 1000mg produce a mean Cmax and area under the concentration-time curve (AUC) ranging from approximately 0.6 to 9.4 mg/L and 4.7 to 108 mg.h/L, respectively, both increasing linearly in a dose-proportional fashion.",The clinical pharmacokinetics of levofloxacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[mg] / [l],0.6 to 9.4,273449,DB00091,Cyclosporine
,9068926,area under the concentration-time curve (AUC),"Single oral doses of levofloxacin 50 to 1000mg produce a mean Cmax and area under the concentration-time curve (AUC) ranging from approximately 0.6 to 9.4 mg/L and 4.7 to 108 mg.h/L, respectively, both increasing linearly in a dose-proportional fashion.",The clinical pharmacokinetics of levofloxacin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[h·mg] / [l],4.7 to 108,273450,DB00091,Cyclosporine
,9068926,volume of distribution,"Levofloxacin is widely distributed throughout the body, with a mean volume of distribution of 1.1 L/kg, and penetrates well into most body tissues and fluids.",The clinical pharmacokinetics of levofloxacin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),[l] / [kg],1.1,273451,DB00091,Cyclosporine
,9068926,plasma elimination half-life (t1/2 beta),The plasma elimination half-life (t1/2 beta) ranges from 6 to 8 hours in individuals with normal renal function.,The clinical pharmacokinetics of levofloxacin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9068926/),h,6 to 8,273452,DB00091,Cyclosporine
,14578679,apparent clearance,"The apparent clearance of Cu was not significantly different between the two groups, with mean +/- standard deviation (+/- SD) values of 230 +/- 56.0 and 202 +/- 49.9 L/h/m2 in the absence and presence of valspodar, respectively (P = 0.17).",Effect of valspodar on the pharmacokinetics of unbound paclitaxel. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14578679/),[l] / [h·m2],230,273540,DB00091,Cyclosporine
,14578679,apparent clearance,"The apparent clearance of Cu was not significantly different between the two groups, with mean +/- standard deviation (+/- SD) values of 230 +/- 56.0 and 202 +/- 49.9 L/h/m2 in the absence and presence of valspodar, respectively (P = 0.17).",Effect of valspodar on the pharmacokinetics of unbound paclitaxel. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14578679/),[l] / [h·m2],202,273541,DB00091,Cyclosporine
,14578679,volume of Cu distribution,"The volume of Cu distribution was slightly larger in the presence of valspodar (1160 +/- 474 vs. 1620 +/- 552 L/m2; P = 0.025), which contributed to a minor difference in the terminal disposition half-life (6.12 +/- 3.42 vs. 8.50 +/- 2.06 h; P = 0.028).",Effect of valspodar on the pharmacokinetics of unbound paclitaxel. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14578679/),[l] / [m2],1160,273542,DB00091,Cyclosporine
,14578679,volume of Cu distribution,"The volume of Cu distribution was slightly larger in the presence of valspodar (1160 +/- 474 vs. 1620 +/- 552 L/m2; P = 0.025), which contributed to a minor difference in the terminal disposition half-life (6.12 +/- 3.42 vs. 8.50 +/- 2.06 h; P = 0.028).",Effect of valspodar on the pharmacokinetics of unbound paclitaxel. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14578679/),[l] / [m2],1620,273543,DB00091,Cyclosporine
,14578679,terminal disposition half-life,"The volume of Cu distribution was slightly larger in the presence of valspodar (1160 +/- 474 vs. 1620 +/- 552 L/m2; P = 0.025), which contributed to a minor difference in the terminal disposition half-life (6.12 +/- 3.42 vs. 8.50 +/- 2.06 h; P = 0.028).",Effect of valspodar on the pharmacokinetics of unbound paclitaxel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14578679/),h,6.12,273544,DB00091,Cyclosporine
,14578679,terminal disposition half-life,"The volume of Cu distribution was slightly larger in the presence of valspodar (1160 +/- 474 vs. 1620 +/- 552 L/m2; P = 0.025), which contributed to a minor difference in the terminal disposition half-life (6.12 +/- 3.42 vs. 8.50 +/- 2.06 h; P = 0.028).",Effect of valspodar on the pharmacokinetics of unbound paclitaxel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14578679/),h,8.50,273545,DB00091,Cyclosporine
,15686736,bioavailability,"The mean bioavailability of Cicloral compared with Neoral amounted to 83% (AUC) and 78% (Cmax), respectively.",Cicloral versus neoral: a bioequivalence study in healthy volunteers on the influence of a fat-rich meal on the bioavailability of cicloral. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15686736/),%,83,274254,DB00091,Cyclosporine
,15686736,bioavailability,"The mean bioavailability of Cicloral compared with Neoral amounted to 83% (AUC) and 78% (Cmax), respectively.",Cicloral versus neoral: a bioequivalence study in healthy volunteers on the influence of a fat-rich meal on the bioavailability of cicloral. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15686736/),%,78,274255,DB00091,Cyclosporine
,15686736,bioavailability,"When administered after a fat-rich meal, the bioavailability of Cicloral was 121% (AUC) and 132% (Cmax) compared with fasting administration.",Cicloral versus neoral: a bioequivalence study in healthy volunteers on the influence of a fat-rich meal on the bioavailability of cicloral. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15686736/),%,121,274256,DB00091,Cyclosporine
,15686736,bioavailability,"When administered after a fat-rich meal, the bioavailability of Cicloral was 121% (AUC) and 132% (Cmax) compared with fasting administration.",Cicloral versus neoral: a bioequivalence study in healthy volunteers on the influence of a fat-rich meal on the bioavailability of cicloral. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15686736/),%,132,274257,DB00091,Cyclosporine
,15686736,Time to Cmax,Time to Cmax was 1.3 to 1.4 hours for both medications and modes of administration.,Cicloral versus neoral: a bioequivalence study in healthy volunteers on the influence of a fat-rich meal on the bioavailability of cicloral. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15686736/),h,1.3 to 1.4,274258,DB00091,Cyclosporine
